The O +
TGF O -
- O -
beta O +
type O +
II O +
receptor O +
in O +
chronic O +
myeloid O +
leukemia O -
: O +
analysis O +
of O +
microsatellite O +
regions O +
and O +
gene O +
expression O -
. O +

Genomic O +
instability O +
is O +
one O +
mechanism O +
proposed O +
to O +
play O +
a O +
role O +
in O +
the O +
disease O +
progression O +
of O +
chronic O +
myeloid O +
leukemia O +
( O -
CML O -
) O -
. O +

Microsatellite O +
regions O +
in O +
the O +
type O +
II O +
transforming O +
growth O +
factor O -
- O -
beta O +
receptor O +
( O -
TGF O -
- O -
beta O +
RII O -
) O +
gene O +
appear O +
to O +
be O +
targets O +
for O +
mutation O +
in O +
some O +
cancers O +
displaying O +
microsatellite O +
instability O +
( O -
replication O +
error O +
phenotype O -
, O +
RER+ O -
) O -
. O +

Furthermore O -
, O +
TGF O -
- O -
beta O +
RII O +
mutations O +
in O +
RER+ O +
tumors O +
have O +
been O +
associated O +
with O +
decreased O +
TGF O -
- O -
beta O +
RII O +
mRNA O +
levels O -
. O +

As O +
TGF O -
- O -
beta O +
is O +
a O +
potent O +
negative O +
growth O +
regulator O +
of O +
hematopoietic O +
cells O -
, O +
investigations O +
were O +
undertaken O +
to O +
determine O +
whether O +
inactivation O +
of O +
the O +
receptor O +
by O +
microsatellite O +
alteration O +
might O +
be O +
involved O +
in O +
the O +
progression O +
of O +
CML O -
. O +

Analysis O +
of O +
TGF O -
- O -
beta O +
RII O +
mRNA O +
expression O +
by O +
RNase O +
protection O -
, O +
with O +
comparison O +
of O +
cells O +
from O +
the O +
chronic O -
, O +
accelerated O +
and O +
blast O +
phases O +
of O +
CML O -
, O +
showed O +
no O +
change O +
in O +
TGF O -
- O -
beta O +
RII O +
transcript O +
levels O +
during O +
disease O +
progression O -
. O +

However O -
, O +
during O +
each O +
phase O +
of O +
the O +
disease O -
, O +
low O +
levels O +
of O +
TGF O -
- O -
beta O +
RII O +
were O +
detected O +
when O +
compared O +
with O +
the O +
hematopoietic O +
cells O +
of O +
normal O +
donors O -
. O +

Furthermore O -
, O +
this O +
decreased O +
expression O +
was O +
also O +
observed O +
in O +
the O +
other O +
myeloproliferative O +
disorders O -
, O +
polycythemia O +
rubra O +
vera O +
( O -
PRV O -
) O +
and O +
essential O +
thrombocythemia O +
( O -
ET O -
) O -
. O +

The O +
leukemia O +
cell O +
lines O +
K562 O +
and O +
HL-60 O +
had O +
no O +
detectable O +
TGF O -
- O -
beta O +
RII O +
mRNA O -
. O +

Two O +
microsatellite O +
regions O +
found O +
altered O +
in O +
RER+ O +
colon O +
cancers O +
were O +
analyzed O +
to O +
establish O +
if O +
these O +
sequences O +
were O +
aberrant O +
in O +
CML O -
. O +

No O +
alteration O +
was O +
detected O +
in O +
either O +
of O +
these O +
regions O +
in O +
any O +
phase O +
of O +
the O +
disease O -
. O +

These O +
results O +
suggest O +
that O +
alterations O +
of O +
the O +
microsatellite O +
regions O +
in O +
the O +
TGF O -
- O -
beta O +
RII O +
gene O +
are O +
not O +
involved O +
in O +
the O +
progression O +
of O +
CML O -
. O +

Decreased O +
expression O +
of O +
TGF O -
- O -
beta O +
RII O +
in O +
CML O +
cells O +
and O +
leukemia O +
cell O +
lines O +
raises O +
the O +
possibility O +
that O +
altered O +
expression O +
of O +
the O +
receptor O +
may O +
play O +
a O +
role O +
in O +
the O +
initiation O +
and/or O +
maintenance O +
of O +
the O +
disease O +
state O -
. O +

N O -
- O -
glycosylation O +
of O +
glucose O +
transporter-1 O +
( O -
Glut-1 O -
) O +
is O +
associated O +
with O +
increased O +
transporter O +
affinity O +
for O +
glucose B-Chemical +
in O +
human O +
leukemic O +
cells O -
. O +

To O +
elucidate O +
the O +
role O +
of O +
N O -
- O -
glycosylation O +
in O +
the O +
functional O +
activity O +
of O +
the O +
universal O +
glucose B-Chemical +
transporter O -
, O +
Glut-1 O -
, O +
we O +
investigated O +
effects O +
of O +
the O +
N O -
- O -
glycosylation O +
inhibitor O -
, O +
tunicamycin B-Chemical -
, O +
on O +
glucose B-Chemical +
transport O +
by O +
human O +
leukemic O +
cell O +
lines O +
K562 O -
, O +
U937 O +
and O +
HL60 O -
. O +

Treatment O +
with O +
tunicamycin B-Chemical +
produced O +
a O +
40 O -
- O -
50 O -
% O +
inhibition O +
of O +
2-deoxyglucose B-Chemical +
uptake O +
and O +
this O +
was O +
associated O +
with O +
a O +
2 O -
- O -
2.5-fold O +
decrease O +
in O +
transporter O +
affinity O +
for O +
glucose B-Chemical +
( O -
Km O -
) O +
without O +
a O +
change O +
in O +
Vmax O -
. O +

Leukemic O +
K562 O -
, O +
U937 O +
and O +
HL60 O +
cells O +
expressed O +
Glut-1 O +
transporter O +
protein O -
. O +

With O +
K562 O +
cells O +
Glut-1 O +
appeared O +
as O +
a O +
broad O +
band O +
of O +
50 O -
- O -
60 O +
kDa O -
, O +
whereas O +
with O +
U937 O +
and O +
HL60 O +
cells O +
a O +
diffuse O +
band O +
was O +
observed O +
at O +
approximately O +
55 O +
kDa O -
. O +

Treatment O +
of O +
K562 O +
cells O +
with O +
tunicamycin B-Chemical +
for O +
18 O +
h O -
, O +
resulted O +
in O +
extensive O +
loss O +
of O +
the O +
50 O -
- O -
60 O +
kDa O +
glycoprotein O -
, O +
appearance O +
of O +
a O +
30 O -
- O -
40 O +
kDa O +
band O +
and O +
increased O +
staining O +
of O +
a O +
45 O +
kDa O +
band O -
. O +

With O +
U937 O +
cells O -
, O +
tunicamycin B-Chemical +
treatment O +
resulted O +
in O +
the O +
appearance O +
of O +
a O +
30 O -
- O -
40 O +
kDa O +
band O +
and O +
increased O +
staining O +
of O +
a O +
45 O +
kDa O +
band O -
. O +

With O +
HL60 O +
cells O +
loss O +
of O +
the O +
55 O +
kDa O +
Glut-1 O +
band O +
was O +
observed O +
and O +
a O +
band O +
of O +
45 O +
kDa O +
appeared O -
. O +

Tunicamycin B-Chemical -
- O -
treatment O +
resulted O +
in O +
75 O -
- O -
90 O -
% O +
inhibition O +
in O +
[ B-Chemical -
3H I-Chemical -
] I-Chemical -
mannose I-Chemical +
incorporation O +
but O +
only O +
20 O -
- O -
25 O -
% O +
inhibition O +
in O +
[ B-Chemical -
3H I-Chemical -
] I-Chemical -
thymidine I-Chemical +
and O +
[ B-Chemical -
3H I-Chemical -
] I-Chemical -
leucine I-Chemical +
incorporation O -
. O +

In O +
contrast O -
, O +
tunicamycin B-Chemical +
had O +
little O +
effect O +
on O +
the O +
viability O +
and O +
MTT B-Chemical +
responses O +
of O +
the O +
cells O +
used O -
. O +

These O +
results O +
suggest O +
that O +
in O +
leukemic O +
cells O +
N O -
- O -
glycosylation O +
of O +
Glut-1 O +
plays O +
an O +
important O +
role O +
in O +
maintaining O +
its O +
structure O +
and O +
functional O +
integration O -
. O +

Thyrotropin O +
receptor O -
: O +
a O +
role O +
for O +
thyroid O +
tumourigenesis O -
? O +

Human O +
thyroid O +
tumours O +
represent O +
an O +
example O +
of O +
the O +
interplay O +
of O +
genetic O +
and O +
non O +
genetic O +
carcinogenesis O -
. O +

Recently O -
, O +
genetic O +
abnormalities O +
in O +
the O +
elements O +
of O +
the O +
Thyrotropin O +
receptor O +
( O -
TSH O -
- O -
R O -
) O +
dependent O +
cAMP B-Chemical +
regulatory O +
cascade O +
have O +
been O +
found O +
to O +
be O +
involved O +
both O +
in O +
benign O +
and O +
malignant O +
thyroid O +
tumours O -
. O +

The O +
presence O +
of O +
activating O +
mutations O +
has O +
been O +
demonstrated O +
in O +
the O +
TSH O -
- O -
R O +
gene O +
as O +
well O +
as O +
in O +
the O +
Gs O +
alpha O +
protein O +
gene O +
in O +
thyroid O +
toxic O +
adenoma O +
resulting O +
in O +
the O +
constitutive O +
activation O +
of O +
the O +
cAMP B-Chemical +
pathway O +
and O +
it O +
has O +
been O +
hypothesised O +
that O +
these O +
genetic O +
alterations O +
may O +
play O +
a O +
causative O +
role O +
in O +
the O +
disease O -
. O +

However O -
, O +
recent O +
observations O +
suggest O +
more O +
caution O +
in O +
accepting O +
such O +
a O +
hypothesis O -
. O +

The O +
presence O +
of O +
activating O +
TSH O -
- O -
R O +
mutations O +
has O +
also O +
been O +
demonstrated O +
in O +
differentiated O +
thyroid O +
carcinomas O -
. O +

At O +
present O -
, O +
the O +
percentage O +
of O +
such O +
a O +
modification O +
is O +
low O -
, O +
unless O +
referred O +
to O +
selected O +
series O +
of O +
tumours O -
. O +

Activating O +
mutations O +
of O +
the O +
TSH O -
- O -
R O +
gene O +
have O +
been O +
detected O +
in O +
a O +
group O +
of O +
differentiated O +
carcinomas O +
with O +
high O +
basal O +
adenylyl O +
cyclase O +
activity O -
, O +
and O +
in O +
a O +
few O +
cases O +
of O +
hyperfunctioning O +
thyroid O +
carcinoma O -
. O +

However O -
, O +
the O +
role O +
of O +
the O +
TSH O -
- O -
R O -
- O -
related O +
cAMP B-Chemical +
pathway O +
alterations O +
in O +
thyroid O +
transformation O +
remains O +
to O +
be O +
elucidated O -
. O +

In O +
this O +
review O -
, O +
the O +
role O +
of O +
TSH O -
- O -
R O +
gene O +
alterations O +
in O +
benign O +
and O +
malignant O +
thyroid O +
neoplasia O +
is O +
examined O -
. O +

Immunohistochemical O +
analysis O +
of O +
nm23-H1 O +
gene O +
product O +
in O +
node O -
- O -
positive O +
lung O +
cancer O +
and O +
lymph O +
nodes O -
. O +

The O +
nm23-H1 O +
gene O +
product O +
has O +
been O +
considered O +
as O +
an O +
anti O -
- O -
metastatic O +
protein O +
and O +
the O +
level O +
of O +
its O +
expression O +
has O +
been O +
reported O +
to O +
correlate O +
inversely O +
with O +
metastatic O +
potential O +
in O +
some O +
cancers O -
. O +

However O -
, O +
the O +
expression O +
of O +
nm23-H1 O +
gene O +
product O +
in O +
the O +
metastatic O +
sites O +
have O +
not O +
been O +
studied O +
in O +
detail O -
. O +

We O +
examined O +
the O +
expression O +
of O +
nm23-H1 O +
gene O +
product O +
in O +
surgically O +
resected O +
46 O +
pairs O +
of O +
primary O +
lung O +
cancers O +
and O +
metastatic O +
lymph O +
nodes O +
by O +
immunohistochemistry O -
. O +

The O +
positive O +
staining O +
of O +
nm23-H1 O +
gene O +
product O +
in O +
primary O +
cancers O +
and O +
metastatic O +
lymph O +
nodes O +
were O +
observed O +
in O +
56.5 O +
and O +
67.4 O -
% O -
, O +
respectively O -
. O +

The O +
heterogeneity O +
of O +
nm23-H1 O +
gene O +
product O +
expression O +
between O +
primary O +
cancers O +
and O +
metastatic O +
lymph O +
nodes O +
was O +
observed O +
in O +
41.3 O -
% O -
. O +

No O +
correlations O +
were O +
found O +
between O +
the O +
nm23-H1 O +
gene O +
product O +
expression O +
in O +
lung O +
cancers O +
and O +
the O +
patients O +
survival O -
. O +

No O +
significant O +
association O +
was O +
also O +
observed O +
between O +
nm23-H1 O +
gene O +
product O +
expression O +
in O +
lymph O +
nodes O +
and O +
the O +
patients O +
survival O -
. O +

There O +
was O -
, O +
furthermore O -
, O +
no O +
correlation O +
between O +
the O +
heterogeneity O +
of O +
nm23-H1 O +
gene O +
product O +
expression O +
and O +
the O +
patients O +
survival O -
. O +

In O +
conclusion O -
, O +
the O +
level O +
of O +
nm23-H1 O +
gene O +
product O +
expression O +
does O +
not O +
significantly O +
reveal O +
prognostic O +
value O +
in O +
node O -
- O -
positive O +
lung O +
cancers O -
. O +

Expression O +
of O +
nm23-H1 O +
gene O +
product O +
in O +
metastatic O +
lymph O +
nodes O +
was O +
also O +
unrelated O +
to O +
patients O +
survival O -
. O +

Cooccurrence O +
of O +
reduced O +
expression O +
of O +
alpha O -
- O -
catenin O +
and O +
overexpression O +
of O +
p53 O +
is O +
a O +
predictor O +
of O +
lymph O +
node O +
metastasis O +
in O +
early O +
gastric O +
cancer O -
. O +

BACKGROUND O +
AND O +
OBJECTIVES O -
: O +
Even O +
though O +
the O +
pathological O +
background O +
contributes O +
to O +
lymph O +
node O +
metastasis O -
, O +
the O +
biological O +
characteristics O +
of O +
tumors O +
have O +
also O +
gained O +
wide O +
attention O -
. O +

In O +
this O +
study O -
, O +
the O +
expression O +
of O +
the O +
cadherin O -
- O -
catenin O +
complex O +
and O +
p53 O +
was O +
studied O +
in O +
early O +
gastric O +
cancer O -
. O +

Their O +
correlation O +
with O +
lymph O +
node O +
metastasis O +
and O +
the O +
predictability O +
of O +
lymph O +
node O +
metastases O -
, O +
by O +
combining O +
these O +
factors O -
, O +
were O +
also O +
discussed O -
. O +

METHODS O -
: O +
One O +
hundred O +
and O +
one O +
specimens O +
obtained O +
from O +
surgery O +
were O +
studied O +
by O +
immunohistochemistry O +
using O +
monoclonal O +
anti O -
- O -
E O -
- O -
cadherin O -
, O +
anti O -
- O -
alpha O -
- O -
catenin O +
and O +
anti O -
- O -
p53 O +
antibodies O -
. O +

RESULTS O -
: O +
Expression O +
of O +
E O -
- O -
cadherin O +
and O +
alpha O -
- O -
catenin O +
was O +
reduced O +
in O +
50.5 O +
and O +
64.4 O -
% O -
, O +
respectively O -
. O +

p53 O +
protein O +
staining O +
was O +
positive O +
in O +
29.7 O -
% O -
. O +

There O +
was O +
a O +
significant O +
correlation O +
between O +
E O -
- O -
cadherin O +
and O +
alpha O -
- O -
catenin O +
expression O -
, O +
but O +
no O +
correlation O +
was O +
found O +
between O +
p53 O +
expression O +
and O +
E O -
- O -
cadherin O +
or O +
alpha O -
- O -
catenin O +
expression O -
. O +

A O +
reduction O +
in O +
alpha O -
- O -
catenin O +
expression O +
and O +
p53 O +
overexpression O +
correlated O +
to O +
lymph O +
node O +
metastases O -
, O +
respectively O -
. O +

Multivariate O +
analysis O +
showed O +
that O +
cooccurrence O +
of O +
reduced O +
expression O +
of O +
alpha O -
- O -
catenin O +
and O +
overexpression O +
of O +
p53 O +
was O +
an O +
independent O +
factor O +
indicating O +
lymph O +
node O +
metastases O -
. O +

CONCLUSION O -
: O +
A O +
study O +
of O +
both O +
alpha O -
- O -
catenin O +
and O +
p53 O +
expression O +
may O +
be O +
helpful O +
to O +
predict O +
lymph O +
node O +
metastases O +
in O +
early O +
gastric O +
cancer O -
. O +

Proto O -
- O -
oncogene O +
N O -
- O -
myc O +
promoter O +
is O +
down O +
regulated O +
by O +
the O +
Wilms O -
' O +
tumor O +
suppressor O +
gene O +
WT1 O -
. O +

The O +
Wilms O -
' O +
tumor O +
1 O +
( O -
WT1 O -
) O +
gene O +
is O +
a O +
tumor O +
suppressor O +
gene O +
that O +
encodes O +
a O +
zinc B-Chemical -
- O -
finger O +
transcription O +
factor O -
. O +

WT1 O +
represses O +
transcription O +
of O +
several O +
growth O +
factors O +
and O +
growth O +
factor O +
receptors O -
. O +

The O +
N O -
- O -
myc O +
proto O -
- O -
oncogene O +
encodes O +
a O +
transcription O +
factor O +
which O +
regulates O +
cell O +
growth O +
and O +
differentiation O -
. O +

N O -
- O -
myc O +
is O +
coexpressed O +
with O +
WT1 O +
in O +
the O +
developing O +
kidney O +
and O +
is O +
overexpressed O +
in O +
many O +
Wilms O -
' O +
tumors O -
. O +

Here O -
, O +
we O +
show O +
that O +
the O +
proto O -
- O -
oncogene O +
N O -
- O -
myc O +
promoter O +
was O +
down O -
- O -
regulated O +
by O +
WT1 O +
in O +
transient O +
transfection O +
assays O -
. O +

However O -
, O +
mutant O +
WT1 O +
( O -
R394W O -
) O +
which O +
has O +
a O +
mutation O +
in O +
the O +
DNA O +
binding O +
domain O +
could O +
not O +
repress O +
the O +
N O -
- O -
myc O +
promoter O -
. O +

Electrophoretic O +
mobility O +
shift O +
assays O +
showed O +
that O +
the O +
oligonucleotides O +
containing O +
the O +
WT1 O +
motifs O +
could O +
bind O +
recombinant O +
WT1 O +
proteins O -
. O +

This O +
suggests O +
that O +
the O +
repression O +
of O +
the O +
N O -
- O -
myc O +
promoter O +
is O +
mediated O +
through O +
the O +
WT1 O +
binding O +
sites O -
. O +

This O +
finding O +
may O +
help O +
to O +
elucidate O +
the O +
relationship O +
of O +
WT1 O +
and O +
N O -
- O -
myc O +
in O +
tumorigenesis O +
and O +
renal O +
development O -
. O +

External O +
beam O +
radiotherapy O +
for O +
subretinal O +
neovascularization O +
in O +
age O -
- O -
related O +
macular O +
degeneration O -
: O +
is O +
this O +
treatment O +
efficient O -
? O +

PURPOSE O -
: O +
Control O +
of O +
the O +
natural O +
course O +
of O +
subretinal O +
neovascularization O +
( O -
SRNV O -
) O +
in O +
age O -
- O -
related O +
macular O +
degeneration O +
( O -
AMD O -
) O +
is O +
difficult O -
. O +

Only O +
a O +
subset O +
of O +
patients O +
is O +
suitable O +
for O +
laser O +
coagulation O -
. O +

This O +
prospective O +
study O +
aimed O +
to O +
determine O +
the O +
efficacy O +
and O +
individual O +
benefit O +
of O +
external O +
beam O +
radiotherapy O +
( O -
EBRT O -
) O -
. O +

METHODS O +
AND O +
MATERIALS O -
: O +
The O +
prospective O +
trial O +
included O +
287 O +
patients O +
with O +
subfoveal O +
neovascularization O +
due O +
to O +
AMD O +
which O +
was O +
verified O +
by O +
fluorescein B-Chemical +
angiography O -
. O +

Patients O +
have O +
been O +
treated O +
between O +
January O +
1996 O +
and O +
October O +
1997 O -
. O +

All O +
patients O +
received O +
a O +
total O +
dose O +
of O +
16 O +
Gy O +
in O +
2-Gy O +
daily O +
fractions O +
with O +
5 O -
- O -
6 O +
MeV O +
photons O +
based O +
on O +
computerized O +
treatment O +
planning O +
in O +
individual O +
head O +
mask O +
fixation O -
. O +

This O +
first O +
analysis O +
is O +
based O +
on O +
73 O +
patients O +
( O -
50 O +
women O -
, O +
23 O +
men O -
, O +
median O +
age O +
74.3 O +
years O -
) O -
, O +
with O +
a O +
median O +
follow O -
- O -
up O +
of O +
13.3 O +
months O +
and O +
a O +
minimum O +
follow O -
- O -
up O +
of O +
11 O +
months O -
. O +

RESULTS O -
: O +
All O +
patients O +
completed O +
therapy O +
and O +
tolerability O +
was O +
good O -
. O +

First O +
clinical O +
control O +
with O +
second O +
angiography O +
was O +
performed O +
6 O +
weeks O +
after O +
irradiation O -
, O +
then O +
in O +
3-month O +
intervals O -
. O +

Eighteen O +
patients O +
with O +
SRNV O +
refusing O +
radiotherapy O +
served O +
as O +
a O +
control O +
group O +
and O +
were O +
matched O +
with O +
18 O +
irradiated O +
patients O -
. O +

After O +
7 O +
months O +
median O +
visual O +
acuity O +
( O -
VA O -
) O +
was O +
20 O -
/ O -
160 O +
for O +
the O +
irradiated O +
and O +
20 O -
/ O -
400 O +
for O +
the O +
untreated O +
patients O -
. O +

One O +
year O +
after O +
radiotherapy O +
final O +
median O +
VA O +
was O +
20 O -
/ O -
400 O +
in O +
both O +
groups O -
. O +

CONCLUSION O -
: O +
These O +
results O +
suggest O +
that O +
16 O +
Gy O +
of O +
conventionally O +
fractionated O +
external O +
beam O +
irradiation O +
slows O +
down O +
the O +
visual O +
loss O +
in O +
exudative O +
AMD O +
for O +
only O +
a O +
few O +
months O -
. O +

Patients O -
' O +
reading O +
vision O +
could O +
not O +
be O +
saved O +
for O +
a O +
long O -
- O -
term O +
run O -
. O +

LMP1 O +
of O +
Epstein O -
- O -
Barr O +
virus O +
induces O +
proliferation O +
of O +
primary O +
mouse O +
embryonic O +
fibroblasts O +
and O +
cooperatively O +
transforms O +
the O +
cells O +
with O +
a O +
p16-insensitive O +
CDK4 O +
oncogene O -
. O +

The O +
latent O +
membrane O +
protein O +
LMP1 O +
of O +
Epstein O -
- O -
Barr O +
virus O +
( O -
EBV O -
) O +
is O +
often O +
present O +
in O +
EBV O -
- O -
associated O +
malignancies O +
including O +
nasopharyngeal O +
carcinoma O +
and O +
Hodgkin O -
's O +
lymphoma O -
. O +

Previous O +
work O +
demonstrates O +
that O +
the O +
LMP1 O +
gene O +
of O +
EBV O +
is O +
sufficient O +
to O +
transform O +
certain O +
established O +
rodent O +
fibroblast O +
cell O +
lines O +
and O +
to O +
induce O +
the O +
tumorigenicity O +
of O +
some O +
human O +
epithelial O +
cell O +
lines O -
. O +

In O +
addition O -
, O +
LMP1 O +
plays O +
pleiotropic O +
roles O +
in O +
cell O +
growth O +
arrest O -
, O +
differentiation O -
, O +
and O +
apoptosis O -
, O +
depending O +
on O +
the O +
background O +
of O +
the O +
target O +
cells O -
. O +

To O +
examine O +
the O +
roles O +
of O +
LMP1 O +
in O +
cell O +
proliferation O +
and O +
growth O +
regulation O +
in O +
primary O +
culture O +
cells O -
, O +
we O +
constructed O +
a O +
recombinant O +
retrovirus O +
containing O +
an O +
LMP1 O +
gene O -
. O +

With O +
this O +
retrovirus O -
, O +
LMP1 O +
was O +
shown O +
to O +
stimulate O +
the O +
proliferation O +
of O +
primary O +
mouse O +
embryonic O +
fibroblasts O +
( O -
MEF O +
cells O -
) O -
. O +

It O +
has O +
a O +
mitogenic O +
activity O +
for O +
MEF O +
cells O -
, O +
as O +
demonstrated O +
by O +
an O +
immediate O +
induction O +
of O +
cell O +
doubling O +
time O -
. O +

In O +
addition O -
, O +
it O +
significantly O +
extends O +
the O +
passage O +
number O +
of O +
MEF O +
cells O +
to O +
more O +
than O +
30 O +
after O +
retroviral O +
infection O -
, O +
compared O +
with O +
less O +
than O +
5 O +
for O +
uninfected O +
MEF O +
cells O -
. O +

Furthermore O -
, O +
LMP1 O +
cooperates O +
with O +
a O +
p16-insensitive O +
CDK4 O -
( O -
R24C O -
) O +
oncogene O +
in O +
transforming O +
MEF O +
cells O -
. O +

Our O +
results O +
provide O +
the O +
first O +
evidence O +
of O +
the O +
abilities O +
of O +
the O +
LMP1 O +
gene O -
, O +
acting O +
alone O -
, O +
to O +
effectively O +
induce O +
the O +
proliferation O +
of O +
primary O +
MEF O +
cells O +
and O +
of O +
its O +
cooperativity O +
with O +
another O +
cellular O +
oncogene O +
in O +
transforming O +
primary O +
cells O -
. O +

Autotaxin O +
( O -
ATX O -
) O -
, O +
a O +
potent O +
tumor O +
motogen O -
, O +
augments O +
invasive O +
and O +
metastatic O +
potential O +
of O +
ras O -
- O -
transformed O +
cells O -
. O +

Autotaxin O +
( O -
ATX O -
) O -
, O +
an O +
exo O -
- O -
nucleotide O +
pyrophosphatase O +
and O +
phosphodiesterase O -
, O +
was O +
originally O +
isolated O +
as O +
a O +
potent O +
stimulator O +
of O +
tumor O +
cell O +
motility O -
. O +

In O +
order O +
to O +
study O +
whether O +
ATX O +
expression O +
affects O +
motility O -
- O -
dependent O +
processes O +
such O +
as O +
invasion O +
and O +
metastasis O -
, O +
we O +
stably O +
transfected O +
full O -
- O -
length O +
ATX O +
cDNA O +
into O +
two O +
non O -
- O -
expressing O +
cell O +
lines O -
, O +
parental O +
and O +
ras O -
- O -
transformed O +
NIH3T3 O +
( O -
clone7 O -
) O +
cells O -
. O +

The O +
effect O +
of O +
ATX O +
secretion O +
on O +
in O +
vitro O +
cell O +
motility O +
was O +
variable O -
. O +

The O +
ras O -
- O -
transformed O -
, O +
ATX O -
- O -
secreting O +
subclones O +
had O +
enhanced O +
motility O +
to O +
ATX O +
as O +
chemoattractant O -
, O +
but O +
there O +
was O +
little O +
difference O +
in O +
the O +
motility O +
responses O +
of O +
NIH3T3 O +
cells O +
transfected O +
with O +
atx O -
, O +
an O +
inactive O +
mutant O +
gene O -
, O +
or O +
empty O +
vector O -
. O +

In O +
MatrigelTM O +
invasion O +
assays O -
, O +
all O +
subclones O -
, O +
which O +
secreted O +
enzymatically O +
active O +
ATX O -
, O +
demonstrated O +
greater O +
spontaneous O +
and O +
ATX O -
- O -
stimulated O +
invasion O +
than O +
appropriate O +
controls O -
. O +

This O +
difference O +
in O +
invasiveness O +
was O +
not O +
caused O +
by O +
differences O +
in O +
gelatinase O +
production O -
, O +
which O +
was O +
constant O +
within O +
each O +
group O +
of O +
transfectants O -
. O +

In O +
vivo O +
studies O +
with O +
athymic O +
nude O +
mice O +
demonstrated O +
that O +
injection O +
of O +
atx O -
- O -
transfected O +
NIH3T3 O +
cells O +
resulted O +
in O +
a O +
weak O +
tumorigenic O +
capacity O +
with O +
few O +
experimental O +
metastases O -
. O +

Combination O +
of O +
ATX O +
expression O +
with O +
ras O +
transformation O +
produced O +
cells O +
with O +
greatly O +
amplified O +
tumorigenesis O +
and O +
metastatic O +
potential O +
compared O +
to O +
ras O -
- O -
transformed O +
controls O -
. O +

Thus O -
, O +
ATX O +
appears O +
to O +
augment O +
cellular O +
characteristics O +
necessary O +
for O +
tumor O +
aggressiveness O -
. O +

Tumour O -
- O -
specific O +
distribution O +
of O +
BRCA1 O +
promoter O +
region O +
methylation O +
supports O +
a O +
pathogenetic O +
role O +
in O +
breast O +
and O +
ovarian O +
cancer O -
. O +

The O +
role O +
of O +
BRCA1 O +
in O +
sporadic O +
breast O +
and O +
ovarian O +
cancers O +
remains O +
elusive O -
. O +

Direct O +
involvement O +
of O +
BRCA1 O +
in O +
the O +
development O +
of O +
breast O +
and O +
ovarian O +
cancer O +
is O +
suggested O +
by O +
the O +
finding O +
that O +
the O +
BRCA1 O +
promoter O +
region O +
CpG O +
island O +
is O +
methylated O +
in O +
a O +
proportion O +
of O +
breast O +
and O +
ovarian O +
cancers O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
compare O +
the O +
incidence O +
of O +
BRCA1 O +
promoter O +
region O +
methylation O +
in O +
tumours O +
in O +
which O +
loss O +
of O +
BRCA1 O +
has O +
been O +
shown O +
to O +
play O +
a O +
role O +
in O +
pathogenesis O +
( O -
breast O +
and O +
ovarian O +
carcinomas O -
) O +
with O +
the O +
incidence O +
in O +
tumours O +
in O +
which O +
BRCA1 O +
is O +
unlikely O +
to O +
play O +
a O +
role O +
in O +
pathogenesis O -
. O +

Promoter O +
region O +
hypermethylation O +
was O +
significantly O +
more O +
common O +
( O -
P O +
< O +
0.008 O -
) O +
in O +
breast O +
and O +
ovarian O +
cancer O +
( O -
6 O -
/ O -
38 O +
tumours O +
methylated O -
) O +
than O +
in O +
colon O +
cancer O +
( O -
0 O -
/ O -
35 O +
tumours O +
methylated O -
) O +
or O +
in O +
leukaemias O +
( O -
0 O -
/ O -
19 O +
samples O +
methylated O -
) O -
. O +

The O +
restriction O +
of O +
BRCA1 O +
promoter O +
region O +
hypermethylation O +
to O +
breast O +
and O +
ovarian O +
cancer O +
is O +
consistent O +
with O +
a O +
pathogenetic O +
role O +
of O +
BRCA1 O +
promoter O +
methylation O +
in O +
these O +
tumours O -
. O +

We O +
suggest O +
that O +
the O +
rarity O +
of O +
observed O +
BRCA1 O +
mutations O +
in O +
sporadic O +
breast O +
and O +
ovarian O +
cancer O +
is O +
due O +
to O +
the O +
greater O +
likelihood O +
of O +
BRCA1 O +
inactivation O +
by O +
non O -
- O -
mutational O +
mechanisms O +
such O +
as O +
methylation O -
. O +

Oncogenic O +
epidermal O +
growth O +
factor O +
receptor O +
mutants O +
with O +
tandem O +
duplication O -
: O +
gene O +
structure O +
and O +
effects O +
on O +
receptor O +
function O -
. O +

A O +
number O +
of O +
epidermal O +
growth O +
factor O +
receptor O +
( O -
EGFR O -
) O +
deletion O +
mutants O +
have O +
been O +
identified O +
in O +
gliomas O -
, O +
in O +
which O +
the O +
EGFR O +
gene O +
is O +
frequently O +
amplified O +
and O +
rearranged O -
. O +

We O +
have O +
previously O +
characterized O +
the O +
structure O +
of O +
a O +
gene O +
in O +
A-172 O +
human O +
glioma O +
cells O +
that O +
encodes O +
a O +
190-kDa O +
EGFR O +
mutant O +
with O +
tandem O +
duplication O +
of O +
the O +
tyrosine O +
kinase O +
( O -
TK O -
) O +
and O +
calcium B-Chemical -
- O -
mediated O +
internalization O +
( O -
CAIN O -
) O +
domains O -
. O +

Here O +
we O +
describe O +
a O +
185-kDa O +
tandem O +
duplication O +
mutant O +
( O -
TDM O -
) O +
that O +
is O +
expressed O +
in O +
KE O +
and O +
A-1235 O +
glioma O +
cells O -
, O +
along O +
with O +
certain O +
functional O +
characteristics O +
of O +
the O +
mutants O -
. O +

The O +
corresponding O +
transcripts O +
in O +
KE O +
and O +
A-1235 O +
cells O +
contain O +
1053 O +
additional O +
nucleotides O +
representing O +
an O +
in O -
- O -
frame O +
duplication O +
of O +
exons O +
18 O +
through O +
25 O +
which O +
encode O +
the O +
entire O +
TK O +
region O +
and O +
a O +
portion O +
of O +
the O +
CAIN O +
domain O -
. O +

As O +
with O +
duplication O +
of O +
the O +
entire O +
TK O -
/ O -
CAIN O +
region O +
( O -
exons O +
18 O -
- O -
26 O -
) O +
in O +
A-172 O +
cells O -
, O +
duplication O +
of O +
exons O +
18 O -
- O -
25 O +
is O +
associated O +
with O +
a O +
specific O +
genomic O +
rearrangement O +
between O +
flanking O +
introns O -
. O +

Involved O +
introns O +
contain O +
homology O +
to O +
recombination O +
signal O +
sequence O +
( O -
RSS O -
) O +
heptamers O +
present O +
in O +
the O +
V O -
( O -
D O -
) O -
J O +
region O +
of O +
the O +
T O +
lymphocyte O +
receptor O +
gene O -
. O +

In O +
defined O +
medium O -
, O +
both O +
oncogenic O +
TDM O +
are O +
constitutively O +
autophosphorylated O +
and O +
inefficiently O +
downregulated O -
. O +

High O -
- O -
affinity O +
binding O +
is O +
reduced O +
in O +
EGFR.TDM O -
/ O -
18 O -
- O -
26 O -
, O +
although O +
the O +
t1 O -
/ O -
2 O +
of O +
receptor O +
internalization O +
is O +
not O +
prolonged O -
. O +

Ciprofloxacin B-Chemical +
mediated O +
cell O +
growth O +
inhibition O -
, O +
S O -
/ O -
G2-M O +
cell O +
cycle O +
arrest O -
, O +
and O +
apoptosis O +
in O +
a O +
human O +
transitional O +
cell O +
carcinoma O +
of O +
the O +
bladder O +
cell O +
line O -
. O +

The O +
second O +
most O +
prevalent O +
urological O +
malignancy O +
in O +
middle O +
aged O +
and O +
elderly O +
men O +
is O +
bladder O +
cancer O -
, O +
with O +
90 O -
% O +
of O +
the O +
cases O +
being O +
transitional O +
cell O +
carcinomas O -
. O +

The O +
success O +
of O +
current O +
systemic O +
and O +
intravesical O +
therapeutic O +
agents O -
, O +
such O +
as O +
cisplatin B-Chemical -
, O +
thiotepa B-Chemical -
, O +
Adriamycin B-Chemical -
, O +
mitomycin B-Chemical +
C I-Chemical -
, O +
and O +
bacillus O +
Calmette O -
- O -
Guerin O -
, O +
is O +
limited O +
with O +
recurrence O +
rates O +
reduced O +
to O +
17 O -
- O -
44 O -
% O -
. O +

In O +
addition O -
, O +
most O +
of O +
these O +
agents O +
require O +
instrumentation O +
of O +
the O +
urinary O +
tract O +
and O +
are O +
delivered O +
at O +
a O +
significant O +
cost O +
and O +
potential O +
morbidity O +
to O +
the O +
patient O -
. O +

Fluroquinolone B-Chemical +
antibiotics O +
such O +
as O +
ciprofloxacin B-Chemical -
, O +
which O +
can O +
be O +
administered O +
p.o O -
. O -
, O +
may O +
have O +
a O +
profound O +
effect O +
in O +
bladder O +
cancer O +
management O -
. O +

This O +
is O +
primarily O +
based O +
on O +
limited O +
in O +
vitro O +
studies O +
on O +
tumor O +
cells O +
derived O +
from O +
transitional O +
cell O +
carcinoma O +
of O +
the O +
bladder O +
that O +
revealed O +
a O +
dose- O +
and O +
time O -
- O -
dependent O +
inhibition O +
of O +
cell O +
growth O +
by O +
ciprofloxacin B-Chemical +
at O +
concentrations O +
that O +
are O +
easily O +
attainable O +
in O +
the O +
urine O +
of O +
patients O -
. O +

However O -
, O +
the O +
mechanism O -
( O -
s O -
) O +
by O +
which O +
ciprofloxacin B-Chemical +
elicits O +
its O +
biological O +
effects O +
on O +
bladder O +
cancer O +
cells O +
is O +
not O +
well O +
documented O -
. O +

Our O +
experimental O +
data O +
confirm O +
previous O +
studies O +
showing O +
the O +
in O +
vitro O +
cell O +
growth O +
inhibition O +
of O +
the O +
transitional O +
cell O +
carcinoma O +
of O +
the O +
bladder O +
cell O +
line O +
HTB9 O +
and O +
further O +
showed O +
the O +
induction O +
of O +
cell O +
cycle O +
arrest O +
at O +
the O +
S O -
/ O -
G2-M O +
checkpoints O -
. O +

In O +
addition O -
, O +
we O +
found O +
down O -
- O -
regulation O +
of O +
cyclin O +
B O -
, O +
cyclin O +
E O -
, O +
and O +
dephosphorylation O +
of O +
cdk2 O +
in O +
ciprofloxacin B-Chemical -
- O -
treated O +
bladder O +
tumor O +
cells O -
. O +

There O +
was O +
also O +
an O +
up O -
- O -
regulation O +
of O +
Bax O -
, O +
which O +
altered O +
the O +
Bax O -
: O -
Bcl-2 O +
ratio O -
, O +
which O +
may O +
be O +
responsible O +
for O +
mitochondrial O +
depolarization O +
reported O +
to O +
be O +
involved O +
prior O +
to O +
the O +
induction O +
of O +
apoptosis O -
. O +

The O +
cyclin O -
- O -
dependent O +
kinase O +
inhibitor O +
p21WAF1 O +
level O +
was O +
found O +
to O +
be O +
decreased O +
within O +
12 O +
h O +
of O +
ciprofloxacin B-Chemical +
treatment O +
and O +
disappeared O +
completely O +
when O +
HTB9 O +
cells O +
were O +
treated O +
with O +
200 O +
microg O -
/ O -
ml O +
ciprofloxacin B-Chemical +
for O +
24 O +
h. O +
The O +
down O -
- O -
regulation O +
of O +
p21WAF1 O +
closely O +
correlated O +
with O +
poly O -
( O -
ADP O -
- O -
ribose O -
) O +
polymerase O +
cleavage O +
and O +
CPP32 O +
activation O -
. O +

Recent O +
studies O +
revealed O +
that O +
p21WAF1 O +
protects O +
cells O +
from O +
apoptosis O +
by O +
arresting O +
them O +
in O +
G1 O +
and O +
further O +
binds O +
to O +
pro O -
- O -
caspase-3 O -
, O +
preventing O +
its O +
activation O +
and O +
thus O -
, O +
inhibiting O +
the O +
apoptotic O +
cascade O -
. O +

Hence O -
, O +
the O +
down O -
- O -
regulation O +
of O +
p21WAF1 O -
, O +
together O +
with O +
the O +
alterations O +
in O +
Bax O +
and O +
cdk2 O +
as O +
observed O +
in O +
our O +
studies O -
, O +
may O +
define O +
a O +
novel O +
mechanism O +
by O +
which O +
ciprofloxacin B-Chemical +
inhibits O +
tumor O +
cell O +
growth O +
and O +
induces O +
apoptotic O +
cell O +
death O -
. O +

The O +
results O +
of O +
our O +
current O +
studies O +
provide O +
strong O +
experimental O +
evidence O +
for O +
the O +
use O +
of O +
ciprofloxacin B-Chemical +
as O +
a O +
potential O +
preventive O +
and/or O +
therapeutic O +
agent O +
for O +
the O +
management O +
of O +
transitional O +
cell O +
carcinoma O +
of O +
the O +
bladder O -
. O +

Adenovirus O -
- O -
mediated O +
gene O +
transfer O +
of O +
endostatin O +
in O +
vivo O +
results O +
in O +
high O +
level O +
of O +
transgene O +
expression O +
and O +
inhibition O +
of O +
tumor O +
growth O +
and O +
metastases O -
. O +

Inhibition O +
of O +
angiogenesis O +
has O +
been O +
shown O +
to O +
be O +
an O +
effective O +
strategy O +
in O +
cancer O +
therapy O +
in O +
mice O -
. O +

However O -
, O +
its O +
widespread O +
application O +
has O +
been O +
hampered O +
by O +
difficulties O +
in O +
the O +
large O -
- O -
scale O +
production O +
of O +
the O +
antiangiogenic O +
proteins O -
. O +

This O +
limitation O +
may O +
be O +
resolved O +
by O +
in O +
vivo O +
delivery O +
and O +
expression O +
of O +
the O +
antiangiogenic O +
genes O -
. O +

We O +
have O +
constructed O +
a O +
recombinant O +
adenovirus O +
that O +
expresses O +
murine O +
endostatin O +
that O +
is O +
biologically O +
active O +
both O +
in O +
vitro O -
, O +
as O +
determined O +
in O +
endothelial O +
cell O +
proliferation O +
assays O -
, O +
and O +
in O +
vivo O -
, O +
by O +
suppression O +
of O +
angiogenesis O +
induced O +
by O +
vascular O +
endothelial O +
growth O +
factor O +
165 O -
. O +

Persistent O +
high O +
serum O +
levels O +
of O +
endostatin O +
( O -
605 O -
- O -
1740 O +
ng O -
/ O -
ml O -
; O +
mean O -
, O +
936 O +
ng O -
/ O -
ml O -
) O +
were O +
achieved O +
after O +
systemic O +
administration O +
of O +
the O +
vector O +
to O +
nude O +
mice O -
, O +
which O +
resulted O +
in O +
significant O +
reduction O +
of O +
the O +
growth O +
rates O +
and O +
the O +
volumes O +
of O +
JC O +
breast O +
carcinoma O +
and O +
Lewis O +
lung O +
carcinoma O +
( O -
P O +
less O +
than O +
0.001 O +
and O +
P O +
less O +
than O +
0.05 O -
, O +
respectively O -
) O -
. O +

In O +
addition O -
, O +
the O +
endostatin O +
vector O +
treatment O +
completely O +
prevented O +
the O +
formation O +
of O +
pulmonary O +
micrometastases O +
in O +
Lewis O +
lung O +
carcinoma O +
( O -
P O +
= O +
0.0001 O -
) O -
. O +

Immunohistochemical O +
staining O +
of O +
the O +
tumors O +
demonstrated O +
a O +
decreased O +
number O +
of O +
blood O +
vessels O +
in O +
the O +
treatment O +
group O +
versus O +
the O +
controls O -
. O +

In O +
conclusion O -
, O +
the O +
present O +
study O +
clearly O +
demonstrates O +
the O +
potential O +
of O +
vector O -
- O -
mediated O +
antiangiogenic O +
gene O +
therapy O +
as O +
a O +
component O +
in O +
cancer O +
therapy O -
. O +

Neuroblastoma O +
and O +
hepatocyte O +
coculture O +
conditioned O +
media O +
alter O +
apoptosis O -
. O +

BACKGROUND O -
: O +
Neuroblastoma O +
is O +
a O +
childhood O +
tumor O +
that O +
often O +
displays O +
unusual O +
biological O +
behavior O -
. O +

The O +
tumor O +
may O +
present O +
with O +
widespread O +
metastases O +
that O +
are O +
unresponsive O +
to O +
aggressive O +
treatment O -
. O +

At O +
other O +
times O -
, O +
both O +
the O +
metastases O +
and O +
the O +
primary O +
tumor O +
may O +
spontaneously O +
regress O +
without O +
treatment O -
. O +

Apoptosis O -
, O +
or O +
programmed O +
cell O +
death O -
, O +
is O +
thought O +
to O +
play O +
a O +
role O +
in O +
the O +
dichotomous O +
behavior O +
of O +
neuroblastoma O -
. O +

We O +
hypothesize O +
that O +
neuroblastoma O +
cells O +
will O +
interact O +
with O +
host O +
tissues O +
to O +
release O +
mediators O +
that O +
affect O +
apoptosis O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
Human O +
neuroblastoma O +
cells O +
and O +
human O +
Chang O +
hepatocytes O +
are O +
grown O +
in O +
a O +
noncontact O -
, O +
coculture O +
system O -
. O +

After O +
incubation O +
for O +
4 O +
days O -
, O +
the O +
medium O +
from O +
the O +
coculture O +
system O +
is O +
collected O -
. O +

Neuroblastoma O +
cells O +
and O +
Chang O +
hepatocytes O +
are O +
then O +
plated O +
separately O +
with O +
the O +
conditioned O +
medium O +
and O +
their O +
own O +
standard O +
growth O +
medium O +
as O +
controls O -
. O +

After O +
4 O +
days O -
, O +
these O +
cells O +
are O +
harvested O +
and O +
cytospins O +
made O +
for O +
immunostaining O -
. O +

Tumor O +
necrosis O +
factor O +
alpha O +
( O -
TNF O -
- O -
alpha O -
) O -
, O +
Fas O +
ligand O -
, O +
and O +
Bcl-2 O -
, O +
are O +
measured O +
with O +
immunohistochemistry O -
. O +

Apoptosis O +
is O +
detected O +
with O +
the O +
TUNEL O +
method O -
. O +

Immunostaining O +
data O +
are O +
interpreted O +
with O +
computer O +
image O +
analysis O +
and O +
reported O +
as O +
stain O +
index O -
. O +

TUNEL O +
data O +
are O +
reported O +
as O +
percentage O +
apoptotic O +
cells O -
. O +

All O +
data O +
are O +
reported O +
as O +
means O +
+ O -
/- O +

SEM O -
. O +

Statistical O +
analysis O +
is O +
performed O +
and O +
P O +
< O +
0.05 O +
considered O +
significant O -
. O +

RESULTS O -
: O +
Chang O +
hepatocytes O +
grown O +
in O +
the O +
coculture O +
conditioned O +
media O +
have O +
an O +
increase O +
in O +
TNF O -
- O -
alpha O +
and O +
Fas O +
ligand O -
. O +

The O +
neuroblastoma O +
cells O +
have O +
a O +
significant O +
decrease O +
in O +
Fas O +
ligand O -
. O +

There O +
is O +
a O +
significant O +
increase O +
in O +
the O +
number O +
of O +
apoptotic O +
hepatocytes O +
when O +
they O +
are O +
cultured O +
in O +
the O +
conditioned O +
media O -
. O +

In O +
contrast O -
, O +
the O +
neuroblastoma O +
cells O +
grown O +
in O +
the O +
coculture O +
conditioned O +
media O +
show O +
no O +
increase O +
in O +
apoptosis O -
. O +

Finally O -
, O +
Bcl-2 O +
is O +
significantly O +
increased O +
in O +
the O +
neuroblastoma O +
cells O +
cultured O +
in O +
the O +
conditioned O +
media O -
. O +

CONCLUSIONS O -
: O +
Neuroblastoma O +
cells O +
grown O +
in O +
coculture O +
conditioned O +
media O +
show O +
increased O +
expression O +
of O +
Bcl-2 O +
and O +
decreased O +
Fas O +
ligand O +
levels O -
. O +

These O +
changes O +
should O +
diminish O +
apoptosis O +
activity O +
in O +
the O +
tumor O +
cells O -
. O +

In O +
contrast O -
, O +
the O +
conditioned O +
media O +
induce O +
elevated O +
levels O +
of O +
proapoptotic O +
mediators O +
in O +
the O +
Chang O +
hepatocytes O -
. O +

A O +
tumor O -
's O +
ability O +
to O +
successfully O +
metastasize O +
may O +
be O +
dependent O +
on O +
mediators O +
generated O +
in O +
the O +
tumor O -
- O -
host O +
interaction O -
, O +
and O +
may O +
not O +
be O +
just O +
an O +
independent O +
characteristic O +
of O +
the O +
tumor O +
itself O -
. O +

Neoplastic O +
transformation O +
by O +
Notch O +
requires O +
nuclear O +
localization O -
. O +

Notch O +
proteins O +
are O +
plasma O +
membrane O -
- O -
spanning O +
receptors O +
that O +
mediate O +
important O +
cell O +
fate O +
decisions O +
such O +
as O +
differentiation O -
, O +
proliferation O -
, O +
and O +
apoptosis O -
. O +

The O +
mechanism O +
of O +
Notch O +
signaling O +
remains O +
poorly O +
understood O -
. O +

However O -
, O +
it O +
is O +
clear O +
that O +
the O +
Notch O +
signaling O +
pathway O +
mediates O +
its O +
effects O +
through O +
intercellular O +
contact O +
between O +
neighboring O +
cells O -
. O +

The O +
prevailing O +
model O +
for O +
Notch O +
signaling O +
suggests O +
that O +
ligand O -
, O +
presented O +
on O +
a O +
neighboring O +
cell O -
, O +
triggers O +
proteolytic O +
processing O +
of O +
Notch O -
. O +

Following O +
proteolysis O -
, O +
it O +
is O +
thought O +
that O +
the O +
intracellular O +
portion O +
of O +
Notch O +
( O -
N O -
( O -
ic O -
) O -
) O +
translocates O +
to O +
the O +
nucleus O -
, O +
where O +
it O +
is O +
involved O +
in O +
regulating O +
gene O +
expression O -
. O +

There O +
is O +
considerable O +
debate O +
concerning O +
where O +
in O +
the O +
cell O +
Notch O +
functions O +
and O +
what O +
proteins O +
serve O +
as O +
effectors O +
of O +
the O +
Notch O +
signal O -
. O +

Several O +
Notch O +
genes O +
have O +
clearly O +
been O +
shown O +
to O +
be O +
proto O -
- O -
oncogenes O +
in O +
mammalian O +
cells O -
. O +

Activation O +
of O +
Notch O +
proto O -
- O -
oncogenes O +
has O +
been O +
associated O +
with O +
tumorigenesis O +
in O +
several O +
human O +
and O +
other O +
mammalian O +
cancers O -
. O +

Transforming O +
alleles O +
of O +
Notch O +
direct O +
the O +
expression O +
of O +
truncated O +
proteins O +
that O +
primarily O +
consist O +
of O +
N O -
( O -
ic O -
) O +
and O +
are O +
not O +
tethered O +
to O +
the O +
plasma O +
membrane O -
. O +

However O -
, O +
the O +
mechanism O +
by O +
which O +
Notch O +
oncoproteins O +
( O -
generically O +
termed O +
here O +
as O +
N O -
( O -
ic O -
) O -
) O +
induce O +
neoplastic O +
transformation O +
is O +
not O +
known O -
. O +

Previously O +
we O +
demonstrated O +
that O +
N1 O -
( O -
ic O -
) O +
and O +
N2 O -
( O -
ic O -
) O +
could O +
transform O +
E1A O +
immortalized O +
baby O +
rat O +
kidney O +
cells O +
( O -
RKE O -
) O +
in O +
vitro O -
. O +

We O +
now O +
report O +
direct O +
evidence O +
that O +
N1 O -
( O -
ic O -
) O +
must O +
accumulate O +
in O +
the O +
nucleus O +
to O +
induce O +
transformation O +
of O +
RKE O +
cells O -
. O +

In O +
addition O -
, O +
we O +
define O +
the O +
minimal O +
domain O +
of O +
N1 O -
( O -
ic O -
) O +
required O +
to O +
induce O +
transformation O +
and O +
present O +
evidence O +
that O +
transformation O +
of O +
RKE O +
cells O +
by O +
N1 O -
( O -
ic O -
) O +
is O +
likely O +
to O +
be O +
through O +
a O +
CBF1-independent O +
pathway O -
. O +

TEL O -
, O +
a O +
putative O +
tumor O +
suppressor O -
, O +
modulates O +
cell O +
growth O +
and O +
cell O +
morphology O +
of O +
ras O -
- O -
transformed O +
cells O +
while O +
repressing O +
the O +
transcription O +
of O +
stromelysin-1 O -
. O +

TEL O +
is O +
a O +
member O +
of O +
the O +
ETS O +
family O +
of O +
transcription O +
factors O +
that O +
interacts O +
with O +
the O +
mSin3 O +
and O +
SMRT O +
corepressors O +
to O +
regulate O +
transcription O -
. O +

TEL O +
is O +
biallelically O +
disrupted O +
in O +
acute O +
leukemia O -
, O +
and O +
loss O +
of O +
heterozygosity O +
at O +
the O +
TEL O +
locus O +
has O +
been O +
observed O +
in O +
various O +
cancers O -
. O +

Here O +
we O +
show O +
that O +
expression O +
of O +
TEL O +
in O +
Ras O -
- O -
transformed O +
NIH O +
3T3 O +
cells O +
inhibits O +
cell O +
growth O +
in O +
soft O +
agar O +
and O +
in O +
normal O +
cultures O -
. O +

Unexpectedly O -
, O +
cells O +
expressing O +
both O +
Ras O +
and O +
TEL O +
grew O +
as O +
aggregates O -
. O +

To O +
begin O +
to O +
explain O +
the O +
morphology O +
of O +
Ras O -
- O -
plus O +
TEL O -
- O -
expressing O +
cells O -
, O +
we O +
demonstrated O +
that O +
the O +
endogenous O +
matrix O +
metalloproteinase O +
stromelysin-1 O +
was O +
repressed O +
by O +
TEL O -
. O +

TEL O +
bound O +
sequences O +
in O +
the O +
stromelysin-1 O +
promoter O +
and O +
repressed O +
the O +
promoter O +
in O +
transient O -
- O -
expression O +
assays O -
, O +
suggesting O +
that O +
it O +
is O +
a O +
direct O +
target O +
for O +
TEL O -
- O -
mediated O +
regulation O -
. O +

Mutants O +
of O +
TEL O +
that O +
removed O +
a O +
binding O +
site O +
for O +
the O +
mSin3A O +
corepressor O +
but O +
retained O +
the O +
ETS O +
domain O +
failed O +
to O +
repress O +
stromelysin-1 O -
. O +

When O +
BB-94 B-Chemical -
, O +
a O +
matrix O +
metalloproteinase O +
inhibitor O -
, O +
was O +
added O +
to O +
the O +
culture O +
medium O +
of O +
Ras O -
- O -
expressing O +
cells O -
, O +
it O +
caused O +
a O +
cell O +
aggregation O +
phenotype O +
similar O +
to O +
that O +
caused O +
by O +
TEL O +
expression O -
. O +

In O +
addition O -
, O +
TEL O +
inhibited O +
the O +
invasiveness O +
of O +
Ras O -
- O -
transformed O +
cells O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Our O +
results O +
suggest O +
that O +
TEL O +
acts O +
as O +
a O +
tumor O +
suppressor O -
, O +
in O +
part O -
, O +
by O +
transcriptional O +
repression O +
of O +
stromelysin-1 O -
. O +

Caspase-3 O +
is O +
essential O +
for O +
procaspase-9 O +
processing O +
and O +
cisplatin B-Chemical -
- O -
induced O +
apoptosis O +
of O +
MCF-7 O +
breast O +
cancer O +
cells O -
. O +

In O +
this O +
study O -
, O +
we O +
sought O +
to O +
investigate O +
in O +
more O +
detail O +
the O +
role O +
of O +
caspase-3 O +
in O +
apoptotic O +
processes O +
in O +
cultured O +
cells O +
and O +
in O +
cell O -
- O -
free O +
extracts O +
of O +
breast O +
cancer O +
cells O -
. O +

We O +
present O +
evidence O +
that O +
apoptosis O +
of O +
caspase-3-deficient O +
MCF-7 O +
breast O +
cancer O +
cells O +
is O +
defective O +
in O +
response O +
to O +
cisplatin B-Chemical +
treatment O -
, O +
as O +
determined O +
by O +
chromatin O +
condensation O -
, O +
nuclear O +
fragmentation O -
, O +
DNA O +
fragmentation O -
, O +
and O +
release O +
of O +
cytochrome O +
c O +
from O +
the O +
mitochondria O -
. O +

Reconstitution O +
of O +
MCF-7 O +
cells O +
by O +
stable O +
transfection O +
of O +
CASP-3 O +
cDNA O +
restores O +
all O +
these O +
defects O +
and O +
results O +
in O +
an O +
extensive O +
apoptosis O +
after O +
cisplatin B-Chemical +
treatment O -
. O +

We O +
further O +
show O +
that O +
in O +
extracts O +
from O +
caspase-3-deficient O +
MCF-7 O +
cells O -
, O +
procaspase-9 O +
processing O +
is O +
strongly O +
impaired O +
after O +
stimulation O +
with O +
either O +
cytochrome O +
c O +
or O +
recombinant O +
caspase-8 O -
. O +

Reconstitution O +
of O +
MCF-7 O +
cell O +
extracts O +
with O +
procaspase-3 O +
corrects O +
this O +
defect O -
, O +
resulting O +
in O +
an O +
efficient O +
and O +
complete O +
processing O +
of O +
procaspase-9 O -
. O +

Together O -
, O +
our O +
data O +
define O +
caspase-3 O +
as O +
an O +
important O +
integrator O +
of O +
the O +
apoptotic O +
process O +
in O +
MCF-7 O +
breast O +
cancer O +
cells O +
and O +
reveal O +
an O +
essential O +
function O +
of O +
caspase-3 O +
for O +
procaspase-9 O +
processing O -
. O +

Vasodilator O -
- O -
stimulated O +
phosphoprotein O +
is O +
involved O +
in O +
stress O -
- O -
fiber O +
and O +
membrane O +
ruffle O +
formation O +
in O +
endothelial O +
cells O -
. O +

Vasodilator O -
- O -
stimulated O +
phosphoprotein O +
( O -
VASP O -
) O +
is O +
highly O +
expressed O +
in O +
vascular O +
endothelial O +
cells O -
, O +
where O +
it O +
has O +
been O +
implicated O +
in O +
cellular O +
reorganization O +
during O +
angiogenesis O -
, O +
as O +
well O +
as O +
in O +
endothelial O +
retraction O +
and O +
changes O +
in O +
vessel O +
permeability O -
. O +

However O -
, O +
the O +
cellular O +
functions O +
of O +
VASP O +
are O +
not O +
known O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
expressed O +
wild O -
- O -
type O +
and O +
mutant O +
forms O +
of O +
VASP O +
in O +
endothelial O +
cells O +
to O +
determine O +
in O +
what O +
aspects O +
of O +
cytoskeletal O +
behavior O +
this O +
protein O +
participates O -
. O +

Expression O +
of O +
wild O -
- O -
type O +
VASP O +
induces O +
marked O +
membrane O +
ruffling O +
and O +
formation O +
of O +
prominent O +
stress O +
fibers O +
in O +
bovine O +
aortic O +
endothelial O +
cells O -
. O +

Deletion O +
of O +
the O +
proline O -
- O -
rich O +
domain O +
of O +
VASP O +
abolishes O +
its O +
ability O +
to O +
bind O +
profilin O +
but O +
does O +
not O +
affect O +
ruffling O +
or O +
stress O +
fiber O +
formation O -
. O +

Further O +
deletions O +
reveal O +
a O +
sequence O +
within O +
the O +
carboxy O -
- O -
terminal O +
domain O +
that O +
is O +
responsible O +
for O +
in O +
vivo O +
bundle O +
formation O -
. O +

Ruffling O +
occurs O +
only O +
on O +
the O +
expression O +
of O +
forms O +
of O +
VASP O +
that O +
possess O +
bundling O +
activity O +
and O +
the O +
capacity O +
to O +
bind O +
zyxin O -
/ O -
vinculin O -
- O -
derived O +
peptide O -
. O +

The O +
ability O +
of O +
distinct O +
subdomains O +
within O +
VASP O +
to O +
bind O +
adhesion O +
proteins O +
and O +
induce O +
F O -
- O -
actin O +
bundling O +
in O +
vivo O +
suggests O +
that O +
this O +
protein O +
could O +
function O +
in O +
the O +
aggregation O +
and O +
tethering O +
of O +
actin O +
filaments O +
during O +
the O +
formation O +
of O +
endothelial O +
cell O -
- O -
substrate O +
and O +
cell O -
- O -
cell O +
contacts O -
. O +

These O +
data O +
provide O +
a O +
mechanism O +
whereby O +
VASP O +
can O +
influence O +
endothelial O +
migration O +
and O +
organization O +
during O +
capillary O +
formation O +
and O +
modulate O +
vascular O +
permeability O +
via O +
effects O +
on O +
endothelial O +
cell O +
contractility O -
. O +

Reduced O +
oncogenicity O +
of O +
p190 O +
Bcr O -
/ O -
Abl O +
F O -
- O -
actin O -
- O -
binding O +
domain O +
mutants O -
. O +

The O +
deregulated O +
Bcr O -
/ O -
Abl O +
tyrosine O +
kinase O +
is O +
responsible O +
for O +
the O +
development O +
of O +
Philadelphia O +
( O -
Ph O -
) O -
-positive O +
leukemia O +
in O +
humans O -
. O +

To O +
investigate O +
the O +
significance O +
of O +
the O +
C O -
- O -
terminal O +
Abl O +
actin O -
- O -
binding O +
domain O +
within O +
Bcr O -
/ O -
Abl O +
p190 O +
in O +
the O +
development O +
of O +
leukemia O -
/ O -
lymphoma O +
in O +
vivo O -
, O +
mutant O +
p190 O +
DNA O +
constructs O +
were O +
used O +
to O +
generate O +
transgenic O +
mice O -
. O +

Eight O +
founder O +
and O +
progeny O +
mice O +
of O +
5 O +
different O +
lines O +
were O +
monitored O +
for O +
leukemogenesis O -
. O +

Latency O +
was O +
markedly O +
increased O +
and O +
occurrence O +
decreased O +
in O +
the O +
p190 O +
del O +
C O +
lines O +
as O +
compared O +
with O +
nonmutated O +
p190 O +
BCR O -
/ O -
ABL O +
transgenics O -
. O +

Western O +
blot O +
analysis O +
of O +
involved O +
hematologic O +
tissues O +
of O +
the O +
p190 O +
del O +
C O +
transgenics O +
with O +
end O -
- O -
stage O +
disease O +
showed O +
high O -
- O -
level O +
expression O +
of O +
the O +
transgene O +
and O +
tyrosine O +
phosphorylation O +
of O +
Cbl O +
and O +
Hef1 O -
/ O -
Cas O -
, O +
proteins O +
previously O +
shown O +
to O +
be O +
affected O +
by O +
Bcr O -
/ O -
Abl O -
. O +

These O +
results O +
show O +
that O +
the O +
actin O -
- O -
binding O +
domain O +
of O +
Abl O +
enhances O +
leukemia O +
development O +
but O +
does O +
not O +
appear O +
to O +
be O +
an O +
absolute O +
requirement O +
for O +
leukemogenesis O -
. O +

Building O +
the O +
vertebrate O +
vasculature O -
: O +
research O +
is O +
going O +
swimmingly O -
. O +

The O +
vertebrate O +
vasculature O +
develops O +
in O +
remarkably O +
similar O +
fashion O +
in O +
all O +
vertebrates O -
. O +

A O +
cohort O +
of O +
unspecified O +
mesodermal O +
cells O +
differentiates O +
into O +
primitive O +
endothelial O +
cells O -
, O +
which O +
migrate O +
to O +
and O +
occupy O +
positions O +
within O +
the O +
stereotypical O +
blueprint O +
of O +
the O +
primitive O +
vasculature O -
. O +

Once O +
in O +
position O -
, O +
these O +
cells O +
coalesce O +
and O +
form O +
cords O -
, O +
which O +
lumenize O +
and O +
become O +
ensheathed O +
by O +
supporting O +
pericytes O +
and O +
smooth O +
muscle O +
cells O -
. O +

This O +
primitive O +
vascular O +
network O +
is O +
extensively O +
remodeled O +
in O +
some O +
places O -
, O +
and O +
expanded O +
by O +
sprouting O +
in O +
others O -
. O +

Various O +
studies O +
using O +
the O +
mouse O -
, O +
quail O -
/ O -
chick O -
, O +
and O +
frog O +
have O +
uncovered O +
a O +
number O +
of O +
signals O +
that O +
guide O +
these O +
complex O +
processes O +
but O +
many O +
gaps O +
still O +
exist O +
in O +
our O +
understanding O +
of O +
the O +
mechanisms O +
by O +
which O +
the O +
embryonic O +
vasculature O +
is O +
built O -
. O +

Because O +
many O +
questions O +
will O +
require O +
in O +
vivo O +
studies O +
to O +
be O +
properly O +
addressed O -
, O +
the O +
zebrafish O -
, O +
with O +
its O +
unique O +
accessibility O +
to O +
analysis O +
by O +
combined O +
embryological O -
, O +
molecular O -
, O +
and O +
genetic O +
methods O -
, O +
should O +
prove O +
invaluable O +
in O +
identifying O +
new O +
molecules O +
involved O +
in O +
blood O +
vessel O +
development O +
and O +
integrating O +
pathways O +
that O +
influence O +
embryonic O +
blood O +
vessel O +
formation O -
. O +

Nitric O +
oxide O +
synthase O +
inhibition O +
results O +
in O +
synergistic O +
anti O -
- O -
tumour O +
activity O +
with O +
melphalan B-Chemical +
and O +
tumour O +
necrosis O +
factor O +
alpha O -
- O -
based O +
isolated O +
limb O +
perfusions O -
. O +

Nitric B-Chemical +
oxide I-Chemical +
( O -
NO B-Chemical -
) O +
is O +
an O +
important O +
molecule O +
in O +
regulating O +
tumour O +
blood O +
flow O +
and O +
stimulating O +
tumour O +
angiogenesis O -
. O +

Inhibition O +
of O +
NO O +
synthase O +
by O +
L B-Chemical -
- I-Chemical -
NAME I-Chemical +
might O +
induce O +
an O +
anti O -
- O -
tumour O +
effect O +
by O +
limiting O +
nutrients O +
and O +
oxygen B-Chemical +
to O +
reach O +
tumour O +
tissue O +
or O +
affecting O +
vascular O +
growth O -
. O +

The O +
anti O -
- O -
tumour O +
effect O +
of O +
L B-Chemical -
- I-Chemical -
NAME I-Chemical +
after O +
systemic O +
administration O +
was O +
studied O +
in O +
a O +
renal O +
subcapsular O +
CC531 O +
adenocarcinoma O +
model O +
in O +
rats O -
. O +

Moreover O -
, O +
regional O +
administration O +
of O +
L B-Chemical -
- I-Chemical -
NAME I-Chemical -
, O +
in O +
combination O +
with O +
TNF O +
and O +
melphalan B-Chemical -
, O +
was O +
studied O +
in O +
an O +
isolated O +
limb O +
perfusion O +
( O -
ILP O -
) O +
model O +
using O +
BN175 O +
soft O -
- O -
tissue O +
sarcomas O -
. O +

Systemic O +
treatment O +
with O +
L B-Chemical -
- I-Chemical -
NAME I-Chemical +
inhibited O +
growth O +
of O +
adenocarcinoma O +
significantly O +
but O +
was O +
accompanied O +
by O +
impaired O +
renal O +
function O -
. O +

In O +
ILP O -
, O +
reduced O +
tumour O +
growth O +
was O +
observed O +
when O +
L B-Chemical -
- I-Chemical -
NAME I-Chemical +
was O +
used O +
alone O -
. O +

In O +
combination O +
with O +
TNF O +
or O +
melphalan B-Chemical -
, O +
L B-Chemical -
- I-Chemical -
NAME I-Chemical +
increased O +
response O +
rates O +
significantly O +
compared O +
to O +
perfusions O +
without O +
L B-Chemical -
- I-Chemical -
NAME I-Chemical +
( O -
0 O -
- O -
64 O -
% O +
and O +
0 O -
- O -
63 O -
% O +
respectively O -
) O -
. O +

An O +
additional O +
anti O -
- O -
tumour O +
effect O +
was O +
demonstrated O +
when O +
L B-Chemical -
- I-Chemical -
NAME I-Chemical +
was O +
added O +
to O +
the O +
synergistic O +
combination O +
of O +
melphalan B-Chemical +
and O +
TNF O +
( O -
responses O +
increased O +
from O +
70 O +
to O +
100 O -
% O -
) O -
. O +

Inhibition O +
of O +
NO O +
synthase O +
reduces O +
tumour O +
growth O +
both O +
after O +
systemic O +
and O +
regional O +
( O -
ILP O -
) O +
treatment O -
. O +

A O +
synergistic O +
anti O -
- O -
tumour O +
effect O +
of O +
L B-Chemical -
- I-Chemical -
NAME I-Chemical +
is O +
observed O +
in O +
combination O +
with O +
melphalan B-Chemical +
and/or O +
TNF O +
using O +
ILP O -
. O +

These O +
results O +
indicate O +
a O +
possible O +
role O +
of O +
L B-Chemical -
- I-Chemical -
NAME I-Chemical +
for O +
the O +
treatment O +
of O +
solid O +
tumours O +
in O +
a O +
systemic O +
or O +
regional O +
setting O -
. O +

[ O -
Interleukin-18 O +
and O +
new O +
drugs O -
. O +

Protective O +
effect O +
against O +
tumor O +
growth O +
and O +
infections O -
] O -
. O +

IL-18 O -
, O +
originally O +
identified O +
as O +
interferon O -
- O -
gamma O +
inducing O +
factor O +
( O -
IGIF O -
) O -
, O +
is O +
related O +
to O +
the O +
IL-1 O +
family O +
in O +
terms O +
of O +
its O +
structure O +
as O +
well O +
as O +
its O +
processing O -
, O +
receptor O -
, O +
signal O +
transduction O +
pathway O +
and O +
pro O -
- O -
inflammatory O +
properties O -
. O +

IL-18 O +
is O +
also O +
functionally O +
related O +
to O +
IL-12 O -
, O +
as O +
it O +
induces O +
the O +
production O +
of O +
Th1 O +
cytokines O +
and O +
participates O +
in O +
cell O -
- O -
mediated O +
immune O +
cytotoxicity O -
. O +

A O +
summary O +
is O +
made O +
of O +
recent O +
advances O +
in O +
the O +
understanding O +
of O +
IL-18 O +
structure O -
, O +
processing O -
, O +
receptor O +
expression O +
and O +
immunoregulatory O +
functions O -
. O +

It O +
focuses O +
on O +
the O +
role O +
of O +
IL-18 O +
modulation O +
in O +
tumours O -
, O +
infections O +
and O +
autoimmune O +
and O +
inflammatory O +
diseases O -
. O +

Apoptosis O +
induced O +
by O +
1'-acetoxychavicol B-Chemical +
acetate I-Chemical +
in O +
Ehrlich O +
ascites O +
tumor O +
cells O +
is O +
associated O +
with O +
modulation O +
of O +
polyamine O +
metabolism O +
and O +
caspase-3 O +
activation O -
. O +

The O +
efficacy O +
of O +
the O +
antitumor O +
activity O +
of O +
1'-acetoxychavicol B-Chemical +
acetate I-Chemical +
( O -
ACA B-Chemical -
) O -
, O +
reported O +
to O +
be O +
a O +
suppressor O +
of O +
chemically O +
induced O +
carcinogenesis O -
, O +
was O +
evaluated O +
in O +
Ehrlich O +
ascites O +
tumor O +
cells O -
. O +

ACA B-Chemical +
treatment O +
resulted O +
in O +
changes O +
in O +
morphology O +
and O +
a O +
dose O -
- O -
dependent O +
suppression O +
of O +
cell O +
viability O -
. O +

Apoptosis O -
, O +
characterized O +
by O +
nuclear O +
condensation O -
, O +
membrane O +
blebbing O -
, O +
cell O +
shrinkage O +
and O +
a O +
significant O +
induction O +
of O +
caspase-3-like O +
protease O +
activity O +
at O +
8 O +
h O +
in O +
a O +
time O -
- O -
course O +
study O +
were O +
observed O -
. O +

Formation O +
of O +
apoptotic O +
bodies O +
was O +
preceded O +
by O +
lowering O +
of O +
intracellular O +
polyamines O -
, O +
particularly O +
putrescine B-Chemical -
, O +
and O +
both O +
dose- O +
and O +
time O -
- O -
dependent O +
inhibitory O +
and O +
activation O +
effect O +
by O +
ACA B-Chemical +
on O +
ornithine O +
decarboxylase O +
( O -
ODC O -
) O +
and O +
spermidine O -
/ O -
spermine O +
N O -
( O -
1 O -
) O -
-acetyltransferase O +
( O -
SSAT O -
) O -
, O +
respectively O -
. O +

Administration O +
of O +
exogenous O +
polyamines O +
prevented O +
ACA B-Chemical -
- O -
induced O +
apoptosis O +
represented O +
by O +
a O +
reduction O +
in O +
the O +
number O +
of O +
apoptotic O +
bodies O +
and O +
also O +
caused O +
reduction O +
in O +
the O +
induced O +
caspase-3-like O +
protease O +
activity O +
at O +
8 O +
h. O +
These O +
findings O +
suggest O +
that O +
the O +
anticarcinogenic O +
effects O +
of O +
ACA B-Chemical +
might O +
be O +
partly O +
due O +
to O +
perturbation O +
of O +
the O +
polyamine O +
metabolic O +
pathway O +
and O +
triggering O +
of O +
caspase-3-like O +
activity O -
, O +
which O +
result O +
in O +
apoptosis O -
. O +

TRADD O +
domain O +
of O +
Epstein O -
- O -
Barr O +
virus O +
transforming O +
protein O +
LMP1 O +
is O +
essential O +
for O +
inducing O +
immortalization O +
and O +
suppressing O +
senescence O +
of O +
primary O +
rodent O +
fibroblasts O -
. O +

Mutation O +
analysis O +
of O +
latent O +
membrane O +
protein O +
1 O +
( O -
LMP1 O -
) O +
in O +
Epstein O -
- O -
Barr O +
virus O +
( O -
EBV O -
) O -
-induced O +
B O -
- O -
cell O +
immortalization O +
revealed O +
two O +
transformation O +
effector O +
sites O -
, O +
TES1 O +
and O +
TES2 O -
. O +

TES2 O +
mediates O +
the O +
interaction O +
with O +
tumor O +
necrosis O +
factor O +
receptor O -
- O -
associated O +
death O +
domain O +
protein O +
( O -
TRADD O -
) O +
and O +
plays O +
a O +
key O +
role O +
in O +
transactivating O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O -
. O +

Recombinant O +
EBV O +
containing O +
LMP1 O +
with O +
TES2 O +
deleted O +
induces O +
a O +
limited O +
proliferation O +
of O +
B O +
cells O -
. O +

The O +
present O +
study O +
shows O +
that O +
a O +
mutant O +
with O +
an O +
LMP1 O +
site O -
- O -
specific O +
mutation O +
at O +
TES2 O -
, O +
LMP1 O -
( O -
TRADD O -
) O -
, O +
initially O +
stimulates O +
cell O +
growth O +
and O +
significantly O +
extends O +
the O +
life O +
span O +
of O +
MEF O -
. O +

However O -
, O +
it O +
is O +
not O +
sufficient O +
for O +
the O +
immortalization O +
of O +
MEF O -
, O +
and O +
MEF O -
- O -
LMP1 O -
( O -
TRADD O -
) O +
cells O +
eventually O +
enter O +
growth O +
arrest O -
. O +

Further O +
analysis O +
reveals O +
that O +
although O +
LMP1 O -
( O -
TRADD O -
) O +
promotes O +
cell O +
growth O -
, O +
it O +
does O +
not O +
prevent O +
the O +
eventual O +
onset O +
of O +
senescence O +
and O +
the O +
expression O +
of O +
tumor O +
suppressor O +
p16 O -
( O -
Ink4a O -
) O -
. O +

IL-12 O +
inhibition O +
of O +
endothelial O +
cell O +
functions O +
and O +
angiogenesis O +
depends O +
on O +
lymphocyte O -
- O -
endothelial O +
cell O +
cross O -
- O -
talk O -
. O +

In O +
vivo O +
IL-12-dependent O +
tumor O +
inhibition O +
rests O +
on O +
the O +
ability O +
of O +
IL-12 O +
to O +
activate O +
a O +
CD8-mediated O +
cytotoxicity O -
, O +
inhibit O +
angiogenesis O -
, O +
and O +
cause O +
vascular O +
injury O -
. O +

Although O +
in O +
vivo O +
studies O +
have O +
shown O +
that O +
such O +
inhibition O +
stems O +
from O +
complex O +
interactions O +
of O +
immune O +
cells O +
and O +
the O +
production O +
of O +
IFN O -
- O -
gamma O +
and O +
other O +
downstream O +
angiostatic O +
chemokines O -
, O +
the O +
mechanisms O +
involved O +
are O +
still O +
poorly O +
defined O -
. O +

Here O +
we O +
show O +
that O +
IL-12 O +
activates O +
an O +
anti O -
- O -
angiogenic O +
program O +
in O +
Con B-Chemical +
A I-Chemical -
- O -
activated O +
mouse O +
spleen O +
cells O +
( O -
activated O +
spc O -
) O +
or O +
human O +
PBMC O +
( O -
activated O +
PBMC O -
) O -
. O +

The O +
soluble O +
factors O +
they O +
release O +
in O +
its O +
presence O +
arrest O +
the O +
cycle O +
of O +
endothelial O +
cells O +
( O -
EC O -
) O -
, O +
inhibit O +
in O +
vitro O +
angiogenesis O -
, O +
negatively O +
modulate O +
the O +
production O +
of O +
matrix O +
metalloproteinase-9 O -
, O +
and O +
the O +
ability O +
of O +
EC O +
to O +
adhere O +
to O +
vitronectin O +
and O +
up O -
- O -
regulate O +
ICAM-1 O +
and O +
VCAM-1 O +
expression O -
. O +

These O +
effects O +
do O +
not O +
require O +
direct O +
cell O -
- O -
cell O +
contact O -
, O +
yet O +
result O +
from O +
continuous O +
interaction O +
between O +
activated O +
lymphoid O +
cells O +
and O +
EC O -
. O +

We O +
used O +
neutralizing O +
Abs O +
to O +
show O +
that O +
the O +
IFN O -
- O -
inducible O +
protein-10 O +
and O +
monokine O -
- O -
induced O +
by O +
IFN O -
- O -
gamma O +
chemokines O +
are O +
pivotal O +
in O +
inducing O +
these O +
effects O -
. O +

Experiments O +
with O +
nu O -
/ O -
nu O +
mice O -
, O +
nonobese O +
diabetic O -
- O -
SCID O +
mice O -
, O +
or O +
activated O +
spc O +
enriched O +
in O +
specific O +
cell O +
subpopulations O +
demonstrated O +
that O +
CD4 O -
( O -
+ O -
) O -
, O +
CD8 O -
( O -
+ O -
) O -
, O +
and O +
NK O +
cells O +
are O +
all O +
needed O +
to O +
mediate O +
the O +
full O +
anti O -
- O -
angiogenetic O +
effect O +
of O +
IL-12 O -
. O +

[ O -
Study O +
of O +
fungus B-Chemical +
polysaccharides I-Chemical +
compounds I-Chemical +
( O -
FPC B-Chemical -
) O +
in O +
inducing O +
the O +
apoptosis O +
of O +
liver O +
cancer O +
cell O +
Bel-7402 O -
] O -
. O +

To O +
observe O +
the O +
influence O +
of O +
fungus B-Chemical +
polysaccharides I-Chemical +
compounds I-Chemical +
( O -
FPC B-Chemical -
) O +
in O +
inducing O +
human O +
liver O +
cancer O +
cell O +
Bel-7402 O +
apoptosis O +
in O +
cell O +
cultivating O +
in O +
vitro O -
, O +
the O +
authors O +
analyzed O +
tumor O +
inhibitive O +
gene O +
P53 O +
expression O +
in O +
Bel-7402 O +
apoptosis O +
by O +
applying O +
double O +
immuno O -
- O -
marker O -
. O +

The O +
result O +
showed O +
that O +
the O +
multilevel O +
of O +
FPC B-Chemical +
could O +
all O +
apparently O +
induce O +
Bel-7402 O +
apoptosis O -
. O +

With O +
the O +
enhancement O +
of O +
FPC B-Chemical +
concentration O -
, O +
the O +
authors O +
observed O +
chromatin O +
condensation O +
in O +
some O +
phases O +
companying O +
with O +
the O +
characteristic O +
apoptosis O -
. O +

In O +
the O +
meantime O -
, O +
it O +
could O +
also O +
greatly O +
reduce O +
the O +
G1 O +
and O +
S O -
, O +
with O +
obviously O +
dose O -
- O -
response O +
relationship O -
. O +

The O +
percentage O +
of O +
cell O +
apoptosis O +
increased O +
with O +
the O +
enhancing O +
of O +
concentration O -
. O +

In O +
the O +
high O -
- O -
level O +
group O +
the O +
authors O +
found O +
typical O +
DNA O +
ladder O +
eletrophoresis O +
stripe O -
. O +

The O +
result O +
showed O +
that O +
the O +
mechanism O +
of O +
the O +
FPC B-Chemical +
antineoplastic O +
effect O +
had O +
an O +
intimate O +
relation O +
with O +
its O +
induction O +
to O +
apoptosis O +
and O +
that O +
the O +
result O +
of O +
FPC B-Chemical +
inducing O +
tumor O +
cell O +
apoptosis O +
had O +
the O +
character O +
of O +
P53 O +
independence O -
. O +

Vascular O +
endothelial O +
growth O +
factor O -
- O -
B O +
and O +
vascular O +
endothelial O +
growth O +
factor O -
- O -
C O +
expression O +
in O +
renal O +
cell O +
carcinomas O -
: O +
regulation O +
by O +
the O +
von O +
Hippel O -
- O -
Lindau O +
gene O +
and O +
hypoxia O -
. O +

Angiogenesis O +
is O +
essential O +
for O +
tumor O +
growth O +
and O +
metastasis O -
. O +

It O +
is O +
regulated O +
by O +
numerous O +
angiogenic O +
factors O -
, O +
one O +
of O +
the O +
most O +
important O +
being O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
. O +

Recently O +
VEGF O -
- O -
B O +
and O +
VEGF O -
- O -
C O -
, O +
two O +
new O +
VEGF O +
family O +
members O -
, O +
have O +
been O +
identified O +
that O +
bind O +
to O +
the O +
tyrosine O +
kinase O +
receptors O +
flt-1 O +
( O -
VEGFR1 O -
) O -
, O +
KDR O +
( O -
VEGFR2 O -
) O -
, O +
and O +
flt-4 O +
( O -
VEGFR3 O -
) O -
. O +

Although O +
the O +
importance O +
of O +
VEGF O -
- O -
A O +
has O +
been O +
shown O +
in O +
renal O +
carcinomas O -
, O +
the O +
contribution O +
of O +
these O +
new O +
ligands O +
in O +
kidney O +
tumors O +
is O +
not O +
clear O -
. O +

We O +
have O -
, O +
therefore O -
, O +
measured O +
the O +
mRNA O +
level O +
of O +
VEGF O -
- O -
B O +
and O +
VEGF O -
- O -
C O +
together O +
with O +
their O +
receptors O +
by O +
RNase O +
protection O +
assay O +
( O -
RPA O -
) O +
in O +
26 O +
normal O +
kidney O +
samples O +
and O +
45 O +
renal O +
cell O +
cancers O -
. O +

We O +
observed O +
a O +
significant O +
up O -
- O -
regulation O +
of O +
VEGF O -
- O -
B O +
( O -
P O +
= O +
0.002 O -
) O +
but O +
not O +
VEGF O -
- O -
C O +
( O -
P O +
= O +
0.3 O -
) O +
in O +
neoplastic O +
kidney O +
compared O +
with O +
normal O +
tissues O -
. O +

In O +
addition O -
, O +
although O +
VEGF O +
receptors O +
were O +
higher O +
in O +
tumors O +
than O +
normal O +
kidney O -
, O +
there O +
was O +
a O +
significant O +
up O -
- O -
regulation O +
of O +
only O +
flt-1 O +
( O -
P O +
= O +
0.003 O -
) O +
but O +
not O +
KDR O +
( O -
P O +
= O +
0.12 O -
) O +
or O +
flt-4 O +
( O -
P O +
= O +
0.09 O -
) O -
. O +

There O +
was O +
also O +
a O +
significant O +
correlation O +
between O +
VEGF O -
- O -
C O +
and O +
both O +
of O +
its O +
receptors O +
flt-4 O +
( O -
P O +
= O +
0.006 O -
) O +
and O +
KDR O +
( O -
P O +
= O +
0.03 O -
) O +
but O +
no O +
association O +
between O +
VEGF O -
- O -
B O +
and O +
its O +
receptor O +
flt-1 O +
( O -
P O +
= O +
0.23 O -
) O -
. O +

A O +
significant O +
increase O +
was O +
observed O +
in O +
flt-1 O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
, O +
KDR O +
( O -
P O +
= O +
0.02 O -
) O -
, O +
and O +
flt-4 O +
( O -
P O +
= O +
0.01 O -
) O +
but O +
not O +
VEGF O -
- O -
B O +
( O -
P O +
= O +
0.82 O -
) O +
or O +
VEGF O -
- O -
C O +
( O -
P O +
= O +
0.52 O -
) O +
expression O +
in O +
clear O +
cell O +
compared O +
with O +
chromophil O +
( O -
papillary O -
) O +
carcinomas O -
. O +

No O +
significant O +
association O +
was O +
demonstrated O +
between O +
VEGF O -
- O -
B O -
, O +
VEGF O -
- O -
C O -
, O +
flt-1 O -
, O +
KDR O -
, O +
and O +
flt-4 O +
with O +
patient O +
sex O -
, O +
patient O +
age O -
, O +
or O +
tumor O +
size O +
( O -
P O +
greater O +
than O +
0.05 O -
) O -
. O +

The O +
effect O +
of O +
von O +
Hippel O -
- O -
Lindau O +
( O -
VHL O -
) O +
gene O +
and O +
hypoxia O +
on O +
VEGF O -
- O -
B O +
and O +
VEGF O -
- O -
C O +
expression O +
in O +
the O +
renal O +
carcinoma O +
cell O +
line O +
786 O -
- O -
0 O +
transfected O +
with O +
wild O -
- O -
type O +
and O +
mutant O +
VHL O +
was O +
determined O +
by O +
growing O +
cells O +
under O +
21 O -
% O +
O2- O +
and O +
0.1 O -
% O +
O2 O -
. O +

In O +
wild O -
- O -
type O +
VHL O +
cells O -
, O +
whereas O +
VEGF O -
- O -
A O +
was O +
significantly O +
up O -
- O -
regulated O +
under O +
hypoxic O +
compared O +
with O +
normoxic O +
conditions O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
, O +
expression O +
of O +
VEGF O -
- O -
C O +
was O +
reduced O +
( O -
P O +
less O +
than O +
0.002 O -
) O -
. O +

Nevertheless O -
, O +
the O +
repression O +
of O +
VEGF O -
- O -
C O +
was O +
lost O +
in O +
mutant O +
VHL O +
cell O +
lines O +
under O +
hypoxia O -
. O +

In O +
contrast O +
VEGF O -
- O -
B O +
was O +
not O +
regulated O +
by O +
VHL O +
despite O +
clear O +
up O -
- O -
regulation O +
in O +
vivo O -
. O +

These O +
findings O +
strongly O +
support O +
an O +
enhanced O +
role O +
for O +
this O +
pathway O +
in O +
clear O +
cell O +
carcinomas O +
by O +
regulating O +
angiogenesis O +
and/or O +
lymphangiogenesis O -
. O +

The O +
study O +
shows O +
that O +
clear O +
cell O +
tumors O +
are O +
able O +
to O +
up O -
- O -
regulate O +
angiogenic O +
growth O +
factor O +
receptors O +
more O +
efficiently O +
than O +
chromophil O +
( O -
papillary O -
) O -
, O +
that O +
clear O +
cell O +
tumors O +
can O +
use O +
pathways O +
independent O +
of O +
VHL O +
to O +
regulate O +
angiogenesis O -
, O +
and O +
that O +
this O +
combined O +
regulation O +
may O +
account O +
for O +
their O +
more O +
aggressive O +
phenotype O -
, O +
which O +
suggests O +
that O +
targeting O +
VEGFR1 O +
( O -
flt O -
- O -
l O -
) O +
may O +
be O +
particularly O +
effective O +
in O +
these O +
tumor O +
types O -
. O +

Effects O +
of O +
morphological O +
patterning O +
on O +
endothelial O +
cell O +
migration O -
. O +

The O +
migration O +
of O +
vascular O +
endothelial O +
cells O +
( O -
ECs O -
) O +
plays O +
an O +
important O +
role O +
in O +
vascular O +
remodeling O -
. O +

Here O +
we O +
studied O +
the O +
effects O +
of O +
cell O +
morphology O +
on O +
the O +
migration O +
of O +
bovine O +
aortic O +
ECs O +
by O +
culturing O +
cells O +
on O +
micropatterned O +
strips O +
of O +
collagen O +
matrix O +
( O -
60- O -
, O +
30- O -
, O +
and O +
15-microm O +
wide O -
) O -
. O +

The O +
spreading O +
areas O +
of O +
the O +
cells O +
on O +
15- O +
and O +
30-microm O +
wide O +
strips O +
were O +
30 O -
% O +
lower O +
than O +
those O +
on O +
60-microm O +
wide O +
strips O +
and O +
unpatterned O +
collagen O -
. O +

The O +
cells O +
on O +
15-microm O +
wide O +
strips O +
completely O +
aligned O +
in O +
the O +
direction O +
of O +
the O +
strip O -
, O +
and O +
had O +
significantly O +
lower O +
shape O +
index O +
than O +
those O +
in O +
all O +
other O +
groups O -
. O +

On O +
strips O +
of O +
all O +
widths O -
, O +
ECs O +
tended O +
to O +
migrate O +
in O +
the O +
direction O +
of O +
strips O -
. O +

ECs O +
on O +
15-microm O +
wide O +
strips O +
had O +
highest O +
speed O -
, O +
particularly O +
in O +
the O +
direction O +
of O +
the O +
strip O -
. O +

Vinculin O +
staining O +
showed O +
that O +
the O +
leading O +
edge O +
of O +
ECs O +
on O +
15-microm O +
wide O +
strips O +
had O +
focal O +
adhesions O +
that O +
were O +
oriented O +
with O +
their O +
lamellipodial O +
protrusion O +
and O +
the O +
direction O +
of O +
cell O +
migration O -
; O +
this O +
arrangement O +
of O +
the O +
focal O +
adhesions O +
may O +
promote O +
EC O +
migration O -
. O +

The O +
present O +
study O +
provides O +
direct O +
evidence O +
on O +
the O +
role O +
of O +
cell O +
morphology O +
in O +
EC O +
migration O -
, O +
and O +
will O +
help O +
us O +
to O +
understand O +
the O +
mechanisms O +
of O +
EC O +
migration O +
during O +
angiogenesis O +
and O +
wound O +
healing O -
. O +

Thrombospondin-2 O +
plays O +
a O +
protective O +
role O +
in O +
multistep O +
carcinogenesis O -
: O +
a O +
novel O +
host O +
anti O -
- O -
tumor O +
defense O +
mechanism O -
. O +

The O +
angiogenic O +
switch O +
during O +
tumorigenesis O +
is O +
thought O +
to O +
be O +
induced O +
by O +
a O +
change O +
in O +
the O +
balance O +
of O +
pro- O +
angiogenic O +
and O +
anti O -
- O -
angiogenic O +
factors O -
. O +

To O +
elucidate O +
the O +
biological O +
role O +
of O +
the O +
endogenous O +
angiogenesis O +
inhibitor O +
thrombospondin-2 O +
( O -
TSP-2 O -
) O +
during O +
multistep O +
carcinogenesis O -
, O +
we O +
subjected O +
TSP-2-deficient O +
and O +
wild O -
- O -
type O +
mice O +
to O +
a O +
chemical O +
skin O +
carcinogenesis O +
regimen O -
. O +

Surprisingly O -
, O +
TSP-2 O +
expression O +
was O +
strongly O +
upregulated O +
in O +
the O +
mesenchymal O +
stroma O +
of O +
wild O -
- O -
type O +
mice O +
throughout O +
the O +
consecutive O +
stages O +
of O +
tumorigenesis O +
whereas O +
the O +
angiogenesis O +
factor O -
, O +
vascular O +
endothelial O +
growth O +
factor O -
, O +
was O +
induced O +
predominantly O +
in O +
tumor O +
cells O -
. O +

TSP-2 O +
deficiency O +
dramatically O +
enhanced O +
susceptibility O +
to O +
skin O +
carcinogenesis O +
and O +
resulted O +
in O +
accelerated O +
and O +
increased O +
tumor O +
formation O -
. O +

The O +
angiogenic O +
switch O +
occurred O +
in O +
early O +
stages O +
of O +
pre O -
- O -
malignant O +
tumor O +
formation O -
, O +
and O +
tumor O +
angiogenesis O +
was O +
significantly O +
enhanced O +
in O +
TSP-2-deficient O +
mice O -
. O +

While O +
TSP-2 O +
deficiency O +
did O +
not O +
affect O +
tumor O +
differentiation O +
or O +
proliferation O -
, O +
tumor O +
cell O +
apoptosis O +
was O +
significantly O +
reduced O -
. O +

These O +
results O +
reveal O +
upregulation O +
of O +
an O +
endogenous O +
angiogenesis O +
inhibitor O +
during O +
multi O +
step O +
tumorigenesis O +
and O +
identify O +
enhanced O +
stromal O +
TSP-2 O +
expression O +
as O +
a O +
novel O +
host O +
anti O -
- O -
tumor O +
defense O +
mechanism O -
. O +

Relationship O +
of O +
p53 O +
and O +
Helicobacter O +
pylori O +
to O +
clinicopathological O +
features O +
of O +
human O +
remnant O +
stomach O +
cancer O +
after O +
gastric O +
surgery O +
for O +
primary O +
gastric O +
cancer O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
biological O +
features O +
of O +
gastric O +
cancer O +
of O +
the O +
remnant O +
stomach O +
( O -
RSC O -
) O -
. O +

Twenty O -
- O -
one O +
patients O +
underwent O +
resection O +
of O +
the O +
remnant O +
stomach O +
for O +
RSC O +
and O +
were O +
divided O +
into O +
two O +
groups O -
: O +
the O +
RSCB O +
group O +
consisted O +
of O +
11 O +
patients O +
who O +
underwent O +
distal O +
gastrectomy O +
for O +
benign O +
disease O +
and O +
the O +
RSCM O +
group O +
consisted O +
of O +
10 O +
patients O +
who O +
underwent O +
gastrectomy O +
for O +
primary O +
gastric O +
cancer O -
. O +

The O +
interval O +
between O +
primary O +
surgery O +
and O +
the O +
appearance O +
of O +
gastric O +
cancer O +
in O +
the O +
remnant O +
stomach O +
was O +
significantly O +
shorter O +
in O +
the O +
RSCM O +
group O +
than O +
in O +
the O +
RSCB O +
group O -
. O +

Invasion O +
of O +
adjacent O +
organs O +
was O +
more O +
frequent O +
in O +
the O +
RSCM O +
group O +
than O +
in O +
the O +
RSCB O +
group O +
and O +
the O +
Ki-67 O +
labeling O +
index O +
of O +
the O +
tumors O +
was O +
significantly O +
higher O +
in O +
the O +
former O +
group O -
. O +

Furthermore O -
, O +
p53 O +
overexpression O +
by O +
tumors O +
was O +
almost O +
twice O +
as O +
common O +
in O +
the O +
RSCM O +
group O +
as O +
in O +
the O +
RSCB O +
group O -
. O +

Although O +
there O +
was O +
no O +
significant O +
difference O +
of O +
the O +
H. O +
pylori O +
positivity O +
between O +
the O +
two O +
groups O -
, O +
the O +
rate O +
for O +
both O +
groups O +
was O +
higher O +
than O +
reported O +
in O +
previous O +
studies O -
. O +

Mutation O +
of O +
p53 O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
high O +
proliferative O +
activity O +
of O +
tumors O +
in O +
the O +
RSCM O +
group O +
and O +
H. O +
pylori O +
infection O +
may O +
be O +
closely O +
related O +
to O +
carcinogenesis O +
in O +
patients O +
with O +
RSC O -
. O +

Coexpression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
p53 O +
protein O +
in O +
squamous O +
cell O +
carcinoma O +
of O +
the O +
esophagus O -
. O +

OBJECTIVE O -
: O +
p53 O +
plays O +
a O +
role O +
in O +
tumor O +
angiogenesis O -
, O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
plays O +
a O +
key O +
role O +
in O +
tumor O +
angiogenesis O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
clarify O +
how O +
expression O +
of O +
p53 O +
protein O +
participates O +
in O +
angiogenesis O -
, O +
and O +
whether O +
the O +
coexpression O +
of O +
VEGF O +
and O +
p53 O +
protein O +
has O +
a O +
significance O +
for O +
angiogenesis O +
and O +
the O +
clinicopathological O +
features O +
in O +
esophageal O +
squamous O +
cell O +
carcinoma O +
( O -
SCC O -
) O -
. O +

METHODS O -
: O +
Tissues O +
samples O +
were O +
taken O +
from O +
60 O +
patients O +
with O +
esophageal O +
SCC O +
after O +
surgery O -
. O +

The O +
expression O +
of O +
VEGF O +
and O +
p53 O +
protein O +
in O +
these O +
SCC O +
was O +
examined O +
immunohistochemically O -
. O +

Microvessel O +
density O +
( O -
MVD O -
) O +
was O +
determined O +
by O +
counting O +
microvessels O +
in O +
tumor O +
sections O +
stained O +
for O +
Factor O +
VIII O -
- O -
related O +
antigen O -
. O +

Ki-67 O +
labeling O +
index O +
( O -
LI O -
) O +
was O +
calculated O -
, O +
based O +
on O +
Ki-67 O +
antigen O +
immunostaining O -
, O +
as O +
a O +
proliferative O +
marker O -
. O +

Apoptotic O +
index O +
( O -
AI O -
) O +
was O +
calculated O -
, O +
based O +
on O +
the O +
terminal O +
deoxynucleotidyl O +
transferase O -
- O -
mediated O +
deoxyuridine B-Chemical +
triphosphate I-Chemical +
biotin I-Chemical +
nick O +
end O +
labeling O -
, O +
to O +
evaluate O +
apoptosis O -
. O +

RESULTS O -
: O +
VEGF O +
expression O +
was O +
observed O +
in O +
58.3 O -
% O -
, O +
and O +
p53 O +
protein O +
expression O +
was O +
observed O +
in O +
61.7 O -
% O +
of O +
the O +
60 O +
patients O -
. O +

VEGF O +
and O +
p53 O +
protein O +
were O +
significantly O +
coexpressed O +
in O +
26 O +
( O -
43.4 O -
% O -
) O -
. O +

Histological O +
venous O +
invasion O +
( O -
p O +
less O +
than O +
0.01 O -
) O +
and O +
distant O +
metastasis O +
( O -
p O +
less O +
than O +
0.05 O -
) O +
were O +
significantly O +
correlated O +
with O +
p53 O +
protein O +
expression O -
. O +

The O +
two O +
parameters O +
were O +
more O +
frequently O +
observed O +
in O +
the O +
SCC O +
with O +
VEGF O -
/ O -
p53 O +
coexpression O +
than O +
in O +
those O +
without O +
the O +
coexpression O -
. O +

The O +
MVD O +
and O +
Ki-67 O +
LI O +
were O +
significantly O +
higher O +
( O -
p O +
less O +
than O +
0.01 O +
and O +
p O +
less O +
than O +
0.001 O -
) O -
, O +
and O +
the O +
AI O +
was O +
significantly O +
lower O +
( O -
p O +
less O +
than O +
0.001 O -
) O +
in O +
the O +
SCC O +
with O +
p53 O +
protein O +
expression O +
than O +
in O +
the O +
SCC O +
without O +
it O -
. O +

The O +
MVD O +
and O +
Ki-67 O +
LI O +
were O +
higher O -
, O +
and O +
the O +
AI O +
was O +
lower O +
in O +
the O +
SCC O +
with O +
VEGF O -
/ O -
p53 O +
coexpression O +
than O +
in O +
those O +
without O +
the O +
coexpression O -
. O +

The O +
5-yr O +
survival O +
rate O +
in O +
patients O +
with O +
the O +
coexpression O +
was O +
poorer O +
than O +
in O +
the O +
other O +
patients O -
. O +

CONCLUSION O -
: O +
These O +
results O +
suggest O +
that O +
mutant O +
p53 O +
expression O +
is O +
associated O +
with O +
angiogenesis O +
and O +
distant O +
metastasis O +
in O +
esophageal O +
SCC O -
, O +
and O +
that O +
the O +
coexpression O +
of O +
p53 O +
and O +
VEGF O +
may O +
play O +
an O +
important O +
role O +
in O +
angiogenesis O -
, O +
and O +
have O +
important O +
clinical O +
significance O -
. O +

Current O +
prospects O +
for O +
controlling O +
cancer O +
growth O +
with O +
non O -
- O -
cytotoxic O +
agents O -
-- O -
nutrients O -
, O +
phytochemicals O -
, O +
herbal O +
extracts O -
, O +
and O +
available O +
drugs O -
. O +

In O +
animal O +
or O +
cell O +
culture O +
studies O -
, O +
the O +
growth O +
and O +
spread O +
of O +
cancer O +
can O +
be O +
slowed O +
by O +
many O +
nutrients O -
, O +
food O +
factors O -
, O +
herbal O +
extracts O -
, O +
and O +
well O -
- O -
tolerated O -
, O +
available O +
drugs O +
that O +
are O +
still O +
rarely O +
used O +
in O +
the O +
clinical O +
management O +
of O +
cancer O -
, O +
in O +
part O +
because O +
they O +
seem O +
unlikely O +
to O +
constitute O +
definitive O +
therapies O +
in O +
themselves O -
. O +

However O -
, O +
it O +
is O +
reasonable O +
to O +
expect O +
that O +
mechanistically O +
complementary O +
combinations O +
of O +
these O +
measures O +
could O +
have O +
a O +
worthwhile O +
impact O +
on O +
survival O +
times O +
and O -
, O +
when O +
used O +
as O +
adjuvants O -
, O +
could O +
improve O +
the O +
cure O +
rates O +
achievable O +
with O +
standard O +
therapies O -
. O +

The O +
therapeutic O +
options O +
available O +
in O +
this O +
regard O +
include O +
measures O +
that O -
: O +
down O -
- O -
regulate O +
serum O +
free O +
IGF O -
- O -
I O -
; O +
suppress O +
the O +
synthesis O +
of O +
mevalonic B-Chemical +
acid I-Chemical +
and/or O +
certain O +
derivatives O +
thereof O -
; O +
modulate O +
arachidonate B-Chemical +
metabolism O +
by O +
inhibiting O +
5-lipoxygenase O -
, O +
12-lipoxygenase O -
, O +
or O +
COX-2 O -
; O +
antagonize O +
the O +
activation O +
of O +
AP-1 O +
transcription O +
factors O -
; O +
promote O +
the O +
activation O +
of O +
PPAR O -
- O -
gamma O +
transcription O +
factors O -
; O +
and O +
that O +
suppress O +
angiogenesis O +
by O +
additional O +
mechanisms O -
. O +

Many O +
of O +
these O +
measures O +
appear O +
suitable O +
for O +
use O +
in O +
cancer O +
prevention O -
. O +

Glucose B-Chemical +
catabolism O +
in O +
cancer O +
cells O -
: O +
identification O +
and O +
characterization O +
of O +
a O +
marked O +
activation O +
response O +
of O +
the O +
type O +
II O +
hexokinase O +
gene O +
to O +
hypoxic O +
conditions O -
. O +

One O +
of O +
the O +
most O +
common O +
signatures O +
of O +
highly O +
malignant O +
tumors O +
is O +
their O +
capacity O +
to O +
metabolize O +
more O +
glucose B-Chemical +
to O +
lactic B-Chemical +
acid I-Chemical +
than O +
their O +
tissues O +
of O +
origin O -
. O +

Hepatomas O +
exhibiting O +
this O +
phenotype O +
are O +
dependent O +
on O +
the O +
high O +
expression O +
of O +
type O +
II O +
hexokinase O -
, O +
which O +
supplies O +
such O +
tumors O +
with O +
abundant O +
amounts O +
of O +
glucose B-Chemical +
6-phosphate I-Chemical -
, O +
a O +
significant O +
carbon B-Chemical +
and O +
energy O +
source O +
especially O +
under O +
hypoxic O +
conditions O -
. O +

Here O +
we O +
report O +
that O +
the O +
distal O +
region O +
of O +
the O +
hepatoma O +
type O +
II O +
hexokinase O +
promoter O +
displays O +
consensus O +
motifs O +
for O +
hypoxia O -
- O -
inducible O +
factor O +
( O -
HIF-1 O -
) O +
that O +
overlap O +
E O -
- O -
box O +
sequences O +
known O +
to O +
be O +
related O +
in O +
other O +
gene O +
promoters O +
to O +
glucose B-Chemical +
response O -
. O +

Moreover O -
, O +
we O +
show O +
that O +
subjecting O +
transfected O +
hepatoma O +
cells O +
to O +
hypoxic O +
conditions O +
activates O +
the O +
type O +
II O +
hexokinase O +
promoter O +
almost O +
3-fold O -
, O +
a O +
value O +
that O +
approaches O +
7-fold O +
in O +
the O +
presence O +
of O +
glucose B-Chemical -
. O +

Consistent O +
with O +
these O +
findings O +
is O +
the O +
induction O +
under O +
hypoxic O +
conditions O +
of O +
the O +
HIF-1 O +
protein O -
. O +

Reporter O +
gene O +
analyses O +
with O +
a O +
series O +
of O +
nested O +
deletion O +
mutants O +
of O +
the O +
hepatoma O +
type O +
II O +
hexokinase O +
promoter O +
show O +
that O +
a O +
significant O +
fraction O +
of O +
the O +
total O +
activation O +
observed O +
under O +
hypoxic O +
conditions O +
localizes O +
to O +
the O +
distal O +
region O +
where O +
the O +
overlapping O +
HIF-1 O -
/ O -
E O -
- O -
box O +
sequences O +
are O +
located O -
. O +

Finally O -
, O +
DNase O +
I O +
footprint O +
analysis O +
with O +
a O +
segment O +
of O +
the O +
promoter O +
containing O +
these O +
elements O +
reveals O +
the O +
binding O +
of O +
several O +
nuclear O +
proteins O -
. O +

In O +
summary O -
, O +
these O +
novel O +
studies O +
identify O +
and O +
characterize O +
a O +
marked O +
glucose B-Chemical -
- O -
modulated O +
activation O +
response O +
of O +
the O +
type O +
II O +
hexokinase O +
gene O +
to O +
hypoxic O +
conditions O +
within O +
highly O +
glycolytic O +
hepatoma O +
cells O -
, O +
a O +
property O +
that O +
may O +
help O +
assure O +
that O +
such O +
cells O +
exhibit O +
a O +
growth O +
and O +
survival O +
advantage O +
over O +
their O +
parental O +
cells O +
of O +
origin O -
. O +

Neoplastic O +
transformation O +
and O +
tumorigenesis O +
associated O +
with O +
overexpression O +
of O +
phospholipase O +
D O +
isozymes O +
in O +
cultured O +
murine O +
fibroblasts O -
. O +

Phospholipase O +
D O +
( O -
PLD O -
) O +
has O +
been O +
suggested O +
to O +
play O +
an O +
important O +
role O +
in O +
a O +
variety O +
of O +
cellular O +
functions O -
. O +

PLD O +
activity O +
has O +
been O +
shown O +
to O +
be O +
significantly O +
elevated O +
in O +
many O +
tumours O +
and O +
transformed O +
cells O -
, O +
suggesting O +
the O +
possibility O +
that O +
PLD O +
might O +
be O +
involved O +
in O +
tumorigenesis O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
established O +
stable O +
cell O +
lines O +
overexpressing O +
PLD1 O +
and O +
PLD2 O +
from O +
fibroblast O +
cells O -
. O +

These O +
cells O -
, O +
but O +
not O +
control O +
cells O -
, O +
showed O +
altered O +
growth O +
properties O +
and O +
anchorage O -
- O -
independent O +
growth O +
in O +
soft O +
agar O -
. O +

Both O +
PLD1 O +
and O +
PLD2 O +
also O +
induced O +
an O +
up O -
- O -
regulation O +
of O +
the O +
activity O +
of O +
matrix O +
metalloprotease-9 O +
as O +
detected O +
by O +
zymograms O -
. O +

Furthermore O -
, O +
both O +
PLD1 O +
and O +
PLD2 O +
transformants O -
, O +
but O +
not O +
vector O -
- O -
transfectants O -
, O +
induced O +
undifferentiated O +
sarcoma O +
when O +
transplanted O +
into O +
nude O +
mice O -
. O +

Both O +
PLD1- O +
and O +
PLD2-mediated O +
cell O +
cycle O +
distributions O +
in O +
stable O +
cell O +
lines O +
revealed O +
an O +
increased O +
fraction O +
of O +
cells O +
in O +
the O +
S O +
phase O +
compared O +
with O +
control O +
cells O -
. O +

Interestingly O -
, O +
the O +
level O +
of O +
cyclin O +
D3 O +
protein O -
, O +
known O +
as O +
an O +
activator O +
of O +
G O -
( O -
1 O -
) O +
to O +
S O +
phase O +
transition O +
in O +
the O +
cell O +
cycle O -
, O +
was O +
aberrantly O +
high O +
in O +
cells O +
overexpressing O +
PLD1 O +
and O +
PLD2 O +
compared O +
with O +
control O +
cells O -
. O +

These O +
results O +
suggest O +
that O +
overexpression O +
of O +
PLD O +
isozymes O +
may O +
play O +
an O +
important O +
role O +
in O +
neoplastic O +
transformation O -
. O +

Antibodies O +
to O +
PAI-1 O +
alter O +
the O +
invasive O +
and O +
migratory O +
properties O +
of O +
human O +
tumour O +
cells O +
in O +
vitro O -
. O +

Recent O +
reports O +
suggest O +
that O +
elevated O +
levels O +
of O +
plasminogen O +
activator O +
inhibitor-1 O +
( O -
PAI-1 O -
) O +
may O +
contribute O +
to O +
tumour O +
progression O -
. O +

The O +
studies O +
reported O +
here O +
were O +
designed O +
to O +
help O +
elucidate O +
PAI-1 O -
's O +
contribution O +
to O +
the O +
invasive O +
and O +
migratory O +
phenotype O -
. O +

Antibodies O +
to O +
PA-1 O +
dose O -
- O -
dependently O -
, O +
and O +
significantly O -
, O +
inhibited O +
the O +
invasive O +
and O +
migratory O +
potential O +
of O +
human O +
HT1080 O +
fibrosarcoma O +
cells O -
, O +
as O +
did O +
an O +
antibody O +
to O +
uPA O +
and O +
the O +
plasmin O +
inhibitor O +
aprotinin O -
. O +

Invasion O +
of O +
the O +
human O +
melanoma O +
cell O +
line O -
, O +
BLM O -
, O +
was O +
also O +
attenuated O +
by O +
the O +
anti O -
- O -
PAI-1 O +
monoclonal O +
antibody O +
MAI-12 O -
. O +

The O +
non O -
- O -
invasive O +
human O +
melanoma O +
cell O +
line O -
, O +
IF6 O -
, O +
which O +
does O +
not O +
express O +
uPA O -
, O +
provided O +
further O +
confirmation O +
of O +
PAI-1 O +
and O +
uPA O -
's O +
role O +
as O -
, O +
upon O +
transfection O +
with O +
uPA O -
, O +
this O +
cell O +
line O +
attained O +
an O +
invasive O +
phenotype O -
, O +
which O +
was O +
again O +
attenuated O +
by O +
MAI-12 O -
. O +

Although O +
antibodies O +
to O +
PAI-1 O +
did O +
not O +
affect O +
the O +
adhesion O +
of O +
HT1080 O +
cells O +
to O +
vitronectin O -
, O +
the O +
antibody O +
to O +
uPA O +
reduced O +
their O +
attachment O -
. O +

Addition O +
of O +
exogenous O +
PAI-1 O -
, O +
however O -
, O +
prevented O +
HT1080 O +
cell O +
adhesion O +
( O -
IC50 O +
180 O +
nM O -
) O +
and O +
promoted O +
cell O +
detachment O +
from O +
vitronectin O -
. O +

Furthermore O +
melanoma O +
cells O +
transfected O +
with O +
a O +
uPA O +
variant O -
, O +
which O +
had O +
an O +
impaired O +
interaction O +
with O +
PAI-1 O -
, O +
were O +
not O +
invasive O +
and O +
had O +
impaired O +
binding O +
to O +
vitronectin O -
. O +

These O +
data O +
highlight O +
the O +
importance O +
of O +
a O +
balanced O +
proteolysis O +
and O +
suggest O +
an O +
additional O +
role O +
for O +
PAI-1 O +
distinct O +
from O +
its O +
role O +
in O +
proteolysis O -
. O +

These O +
data O +
also O +
suggest O +
that O +
uPA O +
and O +
PAI-1 O +
may O +
co O -
- O -
operate O +
in O +
the O +
migratory O +
process O +
by O +
respectively O +
facilitating O +
the O +
attachment O +
to O -
, O +
and O +
subsequent O +
detachment O +
from O -
, O +
vitronectin O +
in O +
the O +
extracellular O +
matrix O -
. O +

These O +
results O +
support O +
the O +
clinical O +
findings O +
and O +
indicate O +
that O +
modulation O +
of O +
PAI-1 O +
activity O +
may O +
be O +
of O +
therapeutic O +
benefit O +
for O +
the O +
treatment O +
of O +
cancer O -
. O +

Troponin O +
I O +
inhibits O +
capillary O +
endothelial O +
cell O +
proliferation O +
by O +
interaction O +
with O +
the O +
cell O -
's O +
bFGF O +
receptor O -
. O +

Troponin O +
I O +
( O -
TnI O -
) O +
is O +
a O +
novel O +
cartilage O -
- O -
derived O +
angiogenesis O +
inhibitor O -
, O +
first O +
demonstrated O +
by O +
Moses O +
et O +
al. O +
( O -
1999 O -
, O +
Proc O -
. O +

Natl O -
. O +

Acad O -
. O +

Sci O -
. O +

USA O +
2645 O -
- O -
2650 O -
) O +
to O +
inhibit O +
endothelial O +
cell O +
proliferation O +
and O +
angiogenesis O -
, O +
both O +
in O +
vivo O +
and O +
in O +
vitro O -
, O +
and O +
to O +
inhibit O +
metastasis O +
of O +
a O +
wide O +
variety O +
of O +
tumors O +
in O +
vivo O -
. O +

Despite O +
convincing O +
evidence O +
of O +
its O +
efficacy O -
, O +
little O +
is O +
known O +
about O +
the O +
mechanism O +
of O +
action O +
of O +
TnI O +
as O +
an O +
anti O -
- O -
proliferative O +
and O +
anti O -
- O -
angiogenic O +
agent O -
. O +

In O +
the O +
current O +
article O +
we O +
demonstrate O +
that O +
TnI O +
inhibits O +
both O +
bFGF O -
- O -
stimulated O +
and O +
basal O +
levels O +
of O +
endothelial O +
cell O +
proliferation O -
, O +
and O +
we O +
hypothesize O +
that O +
this O +
inhibition O +
is O +
occurring O -
, O +
at O +
least O +
in O +
part O -
, O +
via O +
an O +
interaction O +
of O +
TnI O +
with O +
the O +
cell O -
- O -
surface O +
bFGF O +
receptor O +
on O +
capillary O +
endothelial O +
cells O -
. O +

We O +
further O +
support O +
this O +
hypothesis O +
by O +
providing O +
the O +
first O +
evidence O +
that O +
TnI O +
can O +
act O +
on O +
nonendothelial O +
as O +
well O +
as O +
endothelial O +
cells O +
and O +
by O +
demonstrating O +
that O +
this O +
inhibitory O +
action O +
is O +
specific O +
for O +
the O +
bFGF O +
receptor O +
on O +
the O +
target O +
cells O -
. O +

Preliminary O +
data O +
suggest O +
that O +
TnI O +
may O +
be O +
competing O +
with O +
bFGF O +
for O +
interaction O +
with O +
the O +
bFGF O +
receptor O +
on O +
responsive O +
cells O -
. O +

RhoA O +
activation O +
promotes O +
transformation O +
and O +
loss O +
of O +
thyroid O +
cell O +
differentiation O +
interfering O +
with O +
thyroid O +
transcription O +
factor-1 O +
activity O -
. O +

Highly O +
specialized O +
cells O -
, O +
the O +
thyrocytes O -
, O +
express O +
a O +
thyroid O -
- O -
specific O +
set O +
of O +
genes O +
for O +
thyroglobulin O +
( O -
Tg O -
) O -
, O +
thyroperoxidase O -
, O +
and O +
the O +
transcription O +
factors O +
TTF-1 O -
, O +
TTF-2 O -
, O +
and O +
Pax-8 O -
. O +

The O +
implication O +
of O +
the O +
small O +
GTPase O +
RhoA O +
in O +
TSH O -
- O -
mediated O +
proliferation O +
of O +
FRTL-5 O +
rat O +
thyroid O +
cells O +
has O +
been O +
previously O +
demonstrated O -
. O +

To O +
further O +
analyze O +
RhoA O +
function O +
in O +
thyroid O +
cell O +
proliferation O +
and O +
differentiation O +
patterns O -
, O +
we O +
combined O +
transient O +
and O +
stable O +
transfection O +
assays O +
to O +
express O +
different O +
mutant O +
RhoA O +
forms O +
in O +
FRTL-5 O +
cells O -
. O +

Constitutively O +
active O +
RhoA O +
( O -
FRTL-5-RhoA O +
QL O +
cells O -
) O +
exhibited O +
a O +
fibroblast O -
- O -
like O +
phenotype O +
with O +
organized O +
actin O +
fibers O -
, O +
whereas O +
cells O +
expressing O +
the O +
RhoA O +
negative O +
dominant O +
phenotype O +
( O -
FRTL-5-RhoA O +
N19 O +
cells O -
) O +
present O +
a O +
rounded O +
morphology O +
and O +
lose O +
normal O +
cytoskeletal O +
architecture O -
. O +

In O +
addition O -
, O +
expression O +
of O +
the O +
constitutively O +
active O +
form O +
of O +
RhoA O +
results O +
in O +
TSH O -
- O -
independent O +
proliferation O +
and O +
anchorage O -
- O -
independent O +
growth O +
and O +
induces O +
tumors O +
when O +
inoculated O +
in O +
nude O +
mice O -
. O +

Interestingly O -
, O +
FRTL-5-RhoA O +
QL O +
cells O +
express O +
less O +
Tg O +
and O +
TTF-1 O +
than O +
wild O -
- O -
type O +
FRTL-5 O +
( O -
FRTL-5- O +
vector O -
) O +
or O +
FRTL-5-RhoA O +
N19 O -
, O +
suggesting O +
a O +
loss O +
at O +
the O +
differentiation O +
stage O -
. O +

This O +
effect O +
is O +
mediated O -
, O +
at O +
least O +
in O +
part O -
, O +
by O +
a O +
decrease O +
in O +
TTF-1 O +
activity O -
, O +
since O +
transient O +
or O +
stable O +
expression O +
of O +
RhoA O +
QL O +
results O +
in O +
a O +
reduction O +
in O +
the O +
activity O +
of O +
the O +
wild O -
- O -
type O +
Tg O +
promoter O +
as O +
well O +
as O +
an O +
artificial O +
promoter O +
the O +
activation O +
of O +
which O +
depends O +
exclusively O +
on O +
TTF-1 O -
. O +

The O +
similarity O +
between O +
RhoA O +
effects O +
and O +
thyroid O +
transformation O +
by O +
Ras O +
suggests O +
that O +
RhoA O +
may O +
act O +
as O +
a O +
downstream O +
effector O +
of O +
Ras O -
; O +
in O +
fact O -
, O +
the O +
dominant O +
negative O +
RhoA O +
N19 O +
abolished O +
the O +
down- O +
regulatory O +
effect O +
of O +
Ras O +
V12 O +
over O +
the O +
Tg O +
promoter O -
. O +

Taken O +
together O -
, O +
these O +
results O +
show O +
for O +
the O +
first O +
time O +
that O +
active O +
RhoA O +
is O +
able O +
to O +
transform O +
FRTL-5 O +
cells O +
and O +
that O +
this O +
effect O +
is O +
coupled O +
to O +
a O +
loss O +
of O +
thyroid O +
differentiation O +
due O +
to O +
impaired O +
TTF-1 O +
activity O -
. O +

Modulation O +
of O +
angiogenesis O +
and O +
progelatinase O +
a O +
by O +
thrombin O +
receptor O +
mimetics O +
and O +
antagonists O -
. O +

The O +
angiogenic O +
action O +
of O +
thrombin O +
has O +
been O +
shown O +
to O +
be O +
mediated O +
by O +
activation O +
of O +
the O +
thrombin O +
receptor O -
. O +

In O +
this O +
report O +
we O +
studied O +
the O +
effects O +
of O +
SFLLR O -
, O +
an O +
agonist O +
of O +
the O +
activated O +
thrombin O +
receptor O +
and O +
thrombin O +
receptor O +
peptide O +
and O +
non O +
peptide O +
antagonists O +
on O +
angiogenesis O +
in O +
the O +
chick O +
chorioallantoic O +
membrane O +
( O -
CAM O -
) O +
system O -
. O +

As O +
antagonists O +
were O +
used O +
the O +
tripeptide O +
FPR O +
and O +
non O -
- O -
peptide O +
1,4-disubstituted B-Chemical +
piperazine I-Chemical +
derivatives I-Chemical -
. O +

The O +
pentapeptide O +
SFLLR O -
, O +
like O +
thrombin O -
, O +
caused O +
a O +
marked O +
stimulation O +
of O +
angiogenesis O +
in O +
the O +
CAM O -
. O +

FPR O +
and O +
the O +
piperazine B-Chemical +
derivatives I-Chemical +
caused O +
suppression O +
of O +
angiogenesis O +
and O +
in O +
combination O +
with O +
thrombin O +
antagonized O +
its O +
angiogenic O +
effect O -
. O +

Thrombin O +
and O +
SFLLR O +
activated O +
progelatinase O +
A O +
( O -
MMP-2 O -
) O +
in O +
the O +
culture O +
medium O +
of O +
human O +
umbilical O +
cord O +
endothelial O +
cells O +
( O -
HUVECs O -
) O -
. O +

MMP-2 O +
is O +
involved O +
in O +
the O +
early O +
steps O +
of O +
angiogenesis O +
leading O +
to O +
local O +
dissolution O +
of O +
basement O +
membrane O +
collagen O +
and O +
migration O +
of O +
the O +
activated O +
endothelial O +
cells O -
. O +

FPR O +
and O +
the O +
piperazine B-Chemical +
derivatives I-Chemical +
inhibited O +
the O +
activation O +
of O +
this O +
enzyme O -
. O +

They O +
also O +
antagonised O +
the O +
effects O +
of O +
both O +
thrombin O +
and O +
SFLLR O +
on O +
MMP-2 O +
activation O -
. O +

These O +
results O +
suggest O +
that O +
non O -
- O -
thrombogenic O +
agonists O +
or O +
antagonists O +
of O +
the O +
activated O +
thrombin O +
receptor O +
can O +
be O +
used O +
as O +
modulators O +
of O +
angiogenesis O -
. O +

Inhibition O +
of O +
PDGF O -
- O -
stimulated O +
and O +
matrix O -
- O -
mediated O +
proliferation O +
of O +
human O +
vascular O +
smooth O +
muscle O +
cells O +
by O +
SPARC O +
is O +
independent O +
of O +
changes O +
in O +
cell O +
shape O +
or O +
cyclin B-Chemical -
- I-Chemical -
dependent I-Chemical +
kinase I-Chemical +
inhibitors I-Chemical -
. O +

Interactions O +
among O +
growth O +
factors O -
, O +
cells O -
, O +
and O +
extracellular O +
matrix O +
regulate O +
proliferation O +
during O +
normal O +
development O +
and O +
in O +
pathologies O +
such O +
as O +
atherosclerosis O -
. O +

SPARC O +
( O -
secreted O +
protein O -
, O +
acidic O -
, O +
and O +
rich O +
in O +
cysteine O -
) O +
is O +
a O +
matrix O -
- O -
associated O +
glycoprotein O +
that O +
modulates O +
the O +
adhesion O +
and O +
proliferation O +
of O +
vascular O +
cells O -
. O +

In O +
this O +
study O -
, O +
we O +
demonstrate O +
that O +
SPARC O +
inhibits O +
human O +
arterial O +
smooth O +
muscle O +
cell O +
proliferation O +
stimulated O +
by O +
platelet O -
- O -
derived O +
growth O +
factor O +
or O +
by O +
adhesion O +
to O +
monomeric O +
type O +
I O +
collagen O -
. O +

Binding O +
studies O +
with O +
SPARC O +
and O +
SPARC O +
peptides O +
indicate O +
specific O +
and O +
saturable O +
interaction O +
with O +
smooth O +
muscle O +
cells O +
that O +
involves O +
the O +
C O -
- O -
terminal O +
Ca2 O -
+ O -
-binding O +
region O +
of O +
the O +
protein O -
. O +

We O +
also O +
report O +
that O +
SPARC O +
arrests O +
monomeric O +
collagen O -
- O -
supported O +
smooth O +
muscle O +
cell O +
proliferation O +
in O +
the O +
late O +
G1-phase O +
of O +
the O +
cell O +
cycle O +
in O +
the O +
absence O +
of O +
an O +
effect O +
on O +
cell O +
shape O +
or O +
on O +
levels O +
of O +
cyclin B-Chemical -
- I-Chemical -
dependent I-Chemical +
kinase I-Chemical +
inhibitors I-Chemical -
. O +

Cyclin O -
- O -
dependent O +
kinase-2 O +
activity O -
, O +
p107 O +
and O +
cyclin O +
A O +
levels O -
, O +
and O +
retinoblastoma O +
protein O +
phosphorylation O +
are O +
markedly O +
reduced O +
in O +
response O +
to O +
the O +
addition O +
of O +
exogenous O +
SPARC O +
and/or O +
peptides O +
derived O +
from O +
specific O +
domains O +
of O +
SPARC O -
. O +

Thus O -
, O +
SPARC O -
, O +
previously O +
characterized O +
as O +
an O +
inhibitor O +
of O +
platelet O -
- O -
derived O +
growth O +
factor O +
binding O +
to O +
its O +
receptor O -
, O +
also O +
antagonizes O +
smooth O +
muscle O +
cell O +
proliferation O +
mediated O +
by O +
monomeric O +
collagen O +
at O +
the O +
level O +
of O +
cyclin O -
- O -
dependent O +
kinase-2 O +
activity O -
. O +

Prognostic O +
significance O +
of O +
heat O +
shock O +
protein O +
27 O +
( O -
HSP27 O -
) O +
in O +
patients O +
with O +
oral O +
squamous O +
cell O +
carcinoma O -
. O +

Heat O +
shock O +
proteins O +
( O -
HSPs O -
) O +
have O +
been O +
defined O +
as O +
proteins O +
induced O +
by O +
heat O +
shock O +
and O +
other O +
environmental O +
and O +
pathophysiologic O +
stress O -
. O +

Heat O +
shock O +
protein O +
27 O +
( O -
HSP27 O -
) O +
is O +
one O +
of O +
the O +
small O +
heat O +
shock O +
proteins O -
. O +

HSP27 O +
is O +
implicated O +
in O +
protein O -
- O -
protein O +
interactions O +
such O +
as O +
folding O -
, O +
translocation O -
, O +
and O +
prevention O +
of O +
inappropriate O +
protein O +
aggregation O -
. O +

Many O +
of O +
their O +
functions O +
suggest O +
that O +
they O +
play O +
important O +
roles O +
in O +
cancers O -
. O +

Archival O +
tissues O +
from O +
40 O +
patients O +
with O +
oral O +
squamous O +
cell O +
carcinoma O +
who O +
received O +
primary O +
surgical O +
resection O +
were O +
examined O +
for O +
HSP27 O +
by O +
immunohistochemistry O +
and O +
correlated O +
with O +
clinical O +
stage O -
, O +
lymph O +
node O +
metastasis O -
, O +
histological O +
grade O +
and O +
survival O +
period O -
. O +

HSP27 O +
expression O +
was O +
positive O +
staining O +
( O -
+ O -
) O +
in O +
20 O +
( O -
50 O -
% O -
) O -
, O +
weak O +
or O +
negative O +
staining O +
( O -
- O -
) O +
in O +
20 O +
( O -
50 O -
% O -
) O +
of O +
total O +
40 O +
cases O -
. O +

There O +
was O +
no O +
correlation O +
between O +
HSP27 O +
expression O +
and O +
clinical O +
stage O -
, O +
lymph O +
node O +
metastasis O +
and O +
histological O +
grade O -
. O +

However O -
, O +
when O +
compared O +
with O +
clinicopathological O +
features O -
, O +
the O +
expression O +
of O +
HSP27 O +
correlated O +
inversely O +
with O +
survival O +
period O -
. O +

This O +
study O +
suggests O +
that O +
the O +
expression O +
of O +
HSP27 O +
is O +
frequently O +
promoted O +
in O +
patients O +
with O +
oral O +
squamous O +
cell O +
carcinoma O +
and O +
should O +
be O +
considered O +
an O +
independent O +
prognostic O +
factor O +
of O +
oral O +
squamous O +
cell O +
carcinoma O +
patients O -
. O +

Abnormal O +
expression O +
of O +
E O -
- O -
cadherin O +
and O +
beta O -
- O -
catenin O +
may O +
be O +
a O +
molecular O +
marker O +
of O +
submucosal O +
invasion O +
and O +
lymph O +
node O +
metastasis O +
in O +
early O +
gastric O +
cancer O -
. O +

BACKGROUND O -
: O +
Impaired O +
expression O +
of O +
E O -
- O -
cadherin O +
and O +
alpha- O +
and O +
beta O -
- O -
catenin O +
is O +
frequently O +
observed O +
in O +
several O +
human O +
cancers O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
examine O +
immunohistochemical O +
expression O +
of O +
these O +
adhesion O +
molecules O -
, O +
focusing O +
on O +
early O +
gastric O +
carcinomas O -
, O +
and O +
to O +
investigate O +
differences O +
between O +
differentiated O +
and O +
undifferentiated O +
gastric O +
cancer O +
at O +
the O +
early O +
phase O +
of O +
carcinogenesis O -
. O +

METHODS O -
: O +
Immunohistochemical O +
staining O +
of O +
E O -
- O -
cadherin O +
and O +
alpha- O +
and O +
beta O -
- O -
catenin O +
was O +
performed O +
using O +
specimens O +
from O +
143 O +
patients O +
with O +
early O +
gastric O +
cancer O -
. O +

RESULTS O -
: O +
Abnormal O +
E O -
- O -
cadherin O +
and O +
beta O -
- O -
catenin O +
staining O +
correlated O +
with O +
depth O +
of O +
tumour O +
invasion O +
in O +
differentiated O -
- O -
type O +
tumours O -
. O +

In O +
contrast O -
, O +
abnormal O +
staining O +
was O +
frequently O +
found O +
even O +
in O +
intramucosal O +
carcinoma O +
of O +
undifferentiated O -
- O -
type O +
tumours O -
, O +
suggesting O +
an O +
apparent O +
difference O +
in O +
the O +
onset O +
of O +
E O -
- O -
cadherin O -
- O -
catenin O +
complex O +
abnormality O +
between O +
the O +
two O +
cancer O +
types O -
. O +

Absent O +
staining O +
of O +
beta O -
- O -
catenin O +
was O +
associated O +
with O +
lymph O +
node O +
metastasis O -
. O +

Multivariate O +
analysis O +
revealed O +
abnormal O +
E O -
- O -
cadherin O +
expression O +
as O +
an O +
independent O +
factor O +
that O +
correlated O +
with O +
submucosal O +
invasion O +
in O +
early O +
gastric O +
cancer O -
. O +

CONCLUSION O -
: O +
Abnormal O +
E O -
- O -
cadherin O +
expression O +
is O +
a O +
possible O +
marker O +
of O +
submucosal O +
invasion O +
in O +
differentiated O -
- O -
type O +
early O +
gastric O +
cancer O +
and O +
absent O +
beta O -
- O -
catenin O +
staining O +
could O +
be O +
used O +
as O +
a O +
predictor O +
of O +
lymph O +
node O +
metastasis O +
in O +
both O +
types O -
. O +

Membrane O -
- O -
anchored O +
Cbl O +
suppresses O +
Hck O +
protein O -
- O -
tyrosine O +
kinase O +
mediated O +
cellular O +
transformation O -
. O +

The O +
mammalian O +
proto O -
- O -
oncogene O +
Cbl O +
and O +
its O +
cellular O +
homologues O +
in O +
Caenorhabditis O +
elegans O +
( O -
Sli-1 O -
) O +
and O +
Drosophila O +
( O -
D O -
- O -
Cbl O -
) O +
are O +
negative O +
regulators O +
of O +
some O +
growth O +
factor O +
receptor O +
signaling O +
pathways O -
. O +

Herein O +
we O +
show O +
that O +
Cbl O +
can O +
negatively O +
regulate O +
another O +
signaling O +
molecule O -
, O +
namely O +
theSrc O -
- O -
family O +
kinase O +
Hck O +
by O +
targeting O +
it O +
for O +
degradation O -
. O +

Hck O -
- O -
mediated O +
cellular O +
transformation O +
of O +
murine O +
fibroblasts O +
is O +
reverted O +
by O +
ectopic O +
expression O +
of O +
a O +
membrane O -
- O -
anchored O +
allele O +
of O +
Cbl O +
as O +
assessed O +
by O +
the O +
cellular O +
morphology O -
, O +
suppression O +
of O +
anchorage O +
independent O +
growth O -
, O +
and O +
an O +
overall O +
reduction O +
in O +
the O +
total O +
tyrosine O +
phosphorylation O +
levels O +
within O +
the O +
cells O -
. O +

The O +
expression O +
of O +
Cbl O +
at O +
the O +
plasma O +
membrane O +
targets O +
both O +
Hck O +
and O +
itself O +
for O +
ubiquitination O +
and O +
degradation O -
, O +
requiring O +
an O +
intact O +
RING O +
finger O -
. O +

Pharmacological O +
inhibition O +
of O +
the O +
proteasome O +
prevents O +
the O +
degradation O +
of O +
Hck O +
correlating O +
with O +
an O +
increase O +
in O +
the O +
phosphotyrosine O +
levels O +
within O +
the O +
cells O -
. O +

Activated O +
Hck O +
and O +
membrane O -
- O -
anchored O +
Cbl O +
are O +
present O +
in O +
similar O +
subcellular O +
localizations O +
and O +
co O -
- O -
immunoprecipitate O -
, O +
suggesting O +
that O +
their O +
interaction O +
is O +
required O +
for O +
subsequent O +
ubiquitination O +
and O +
degradation O -
. O +

Interestingly O -
, O +
both O +
constitutively O +
active O +
and O +
kinase O -
- O -
inactive O +
Hck O +
interact O +
with O +
and O +
are O +
targeted O +
for O +
degradation O +
by O +
Cbl O -
. O +

This O +
work O +
illustrates O +
alternate O +
means O +
to O +
regulate O +
Src O -
- O -
family O +
kinases O -
, O +
and O +
suggests O +
that O +
Cbl O +
may O +
be O +
able O +
to O +
suppress O +
many O +
signaling O +
pathways O +
that O +
are O +
activated O +
in O +
various O +
proliferative O +
syndromes O +
including O +
cancer O -
. O +

Upregulation O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
receptors O +
is O +
associated O +
with O +
advanced O +
neuroblastoma O -
. O +

BACKGROUND O -
: O +
Angiogenesis O +
is O +
essential O +
for O +
tumor O +
growth O +
and O +
relies O +
on O +
the O +
production O +
of O +
angiogenic O +
factors O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
is O +
a O +
major O +
regulator O +
of O +
angiogenesis O +
that O +
binds O +
to O +
tyrosine O +
kinase O +
receptors O +
Flt-1 O +
and O +
KDR O -
. O +

The O +
interaction O +
of O +
VEGF O +
and O +
its O +
receptors O +
at O +
gene O +
and O +
protein O +
levels O +
in O +
neuroblastoma O +
remains O +
widely O +
unknown O -
. O +

METHODS O -
: O +
Tumor O +
biopsy O +
specimens O +
and O +
serum O +
were O +
obtained O +
from O +
37 O +
neuroblastoma O +
patients O -
; O +
adrenal O +
biopsy O +
sections O +
and O +
sera O +
of O +
7 O +
normal O +
children O +
served O +
as O +
controls O -
. O +

Biopsy O +
specimens O +
were O +
examined O +
by O +
real O -
- O -
time O +
reverse O +
transcription O +
polymerase O +
chain O +
reaction O +
( O -
RT O -
- O -
PCR O -
) O +
and O +
Western O +
blotting O -
; O +
serum O +
was O +
analyzed O +
by O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O +
( O -
ELISA O -
) O -
. O +

VEGF O -
- O -
A O -
( O -
165 O -
) O -
, O +
B O -
, O +
C O -
, O +
Flt-1 O -
, O +
and O +
KDR O +
were O +
analyzed O -
. O +

RESULTS O -
: O +
VEGF O +
isoforms O +
and O +
its O +
receptors O -
' O +
mRNA O +
were O +
expressed O +
in O +
neuroblastoma O +
and O +
control O +
tissues O -
. O +

Whereas O +
the O +
ligands O +
were O +
increased O +
in O +
stages O +
III O +
and O +
IV O -
, O +
the O +
receptors O +
were O +
upregulated O +
in O +
stage O +
III O +
only O -
. O +

At O +
protein O +
level O -
, O +
VEGF O -
- O -
B O +
and O +
C O -
, O +
Flt-1 O -
, O +
and O +
KDR O +
were O +
not O +
detectable O +
in O +
tissue O +
lysates O -
, O +
whereas O +
VEGF O -
- O -
A O +
was O +
increased O +
in O +
stages O +
III O +
and O +
IV O -
. O +

Serum O +
VEGF O +
protein O +
levels O +
were O +
upregulated O +
in O +
stage O +
III O -
. O +

CONCLUSIONS O -
: O +
VEGF O -
- O -
A O -
( O -
165 O -
) O +
is O +
one O +
of O +
the O +
major O +
angiogenesis O +
regulators O +
among O +
the O +
ligands O -
' O +
family O +
of O +
VEGF O -
, O +
whereas O +
its O +
receptors O +
KDR O -
, O +
and O +
most O +
probably O +
Flt-1 O -
, O +
may O +
contribute O +
to O +
a O +
poor O +
prognosis O +
( O -
angiogenic O -
) O +
phenotype O -
, O +
as O +
indicated O +
by O +
their O +
upregulated O +
MRNA O +
levels O +
in O +
stage O +
III O +
neuroblastoma O -
. O +

VEGF O -
- O -
A O -
( O -
165 O -
) O +
mainly O +
contributes O +
to O +
increased O +
serum O +
VEGF O +
levels O +
and O +
may O +
serve O +
as O +
a O +
diagnostic O +
tool O +
in O +
advanced O -
- O -
stage O +
neuroblastoma O -
. O +

Hypoxia O -
- O -
inducible O +
factor O +
1 O +
activation O +
by O +
aerobic O +
glycolysis O +
implicates O +
the O +
Warburg O +
effect O +
in O +
carcinogenesis O -
. O +

Cancer O +
cells O +
display O +
high O +
rates O +
of O +
aerobic O +
glycolysis O -
, O +
a O +
phenomenon O +
known O +
historically O +
as O +
the O +
Warburg O +
effect O -
. O +

Lactate B-Chemical +
and O +
pyruvate B-Chemical -
, O +
the O +
end O +
products O +
of O +
glycolysis O -
, O +
are O +
highly O +
produced O +
by O +
cancer O +
cells O +
even O +
in O +
the O +
presence O +
of O +
oxygen B-Chemical -
. O +

Hypoxia O -
- O -
induced O +
gene O +
expression O +
in O +
cancer O +
cells O +
has O +
been O +
linked O +
to O +
malignant O +
transformation O -
. O +

Here O +
we O +
provide O +
evidence O +
that O +
lactate B-Chemical +
and O +
pyruvate B-Chemical +
regulate O +
hypoxia O -
- O -
inducible O +
gene O +
expression O +
independently O +
of O +
hypoxia O +
by O +
stimulating O +
the O +
accumulation O +
of O +
hypoxia O -
- O -
inducible O +
Factor O +
1alpha O +
( O -
HIF-1alpha O -
) O -
. O +

In O +
human O +
gliomas O +
and O +
other O +
cancer O +
cell O +
lines O -
, O +
the O +
accumulation O +
of O +
HIF-1alpha O +
protein O +
under O +
aerobic O +
conditions O +
requires O +
the O +
metabolism O +
of O +
glucose B-Chemical +
to O +
pyruvate B-Chemical +
that O +
prevents O +
the O +
aerobic O +
degradation O +
of O +
HIF-1alpha O +
protein O -
, O +
activates O +
HIF-1 O +
DNA O +
binding O +
activity O -
, O +
and O +
enhances O +
the O +
expression O +
of O +
several O +
HIF-1-activated O +
genes O +
including O +
erythropoietin O -
, O +
vascular O +
endothelial O +
growth O +
factor O -
, O +
glucose O +
transporter O +
3 O -
, O +
and O +
aldolase O +
A. O +
Our O +
findings O +
support O +
a O +
novel O +
role O +
for O +
pyruvate B-Chemical +
in O +
metabolic O +
signaling O +
and O +
suggest O +
a O +
mechanism O +
by O +
which O +
high O +
rates O +
of O +
aerobic O +
glycolysis O +
can O +
promote O +
the O +
malignant O +
transformation O +
and O +
survival O +
of O +
cancer O +
cells O -
. O +

Risk O +
of O +
myelodysplastic O +
syndrome O +
and O +
acute O +
myeloid O +
leukemia O +
in O +
congenital O +
neutropenias O -
. O +

Granulocyte O +
colony O -
- O -
stimulating O +
factor O +
( O -
G O -
- O -
CSF O -
) O +
has O +
had O +
a O +
major O +
impact O +
on O +
the O +
management O +
of O +
" O -
severe O +
chronic O +
neutropenia O -
" O +
( O -
SCN O -
) O -
, O +
a O +
collective O +
term O +
referring O +
to O +
congenital O -
, O +
idiopathic O -
, O +
or O +
cyclic O +
neutropenia O -
. O +

Almost O +
all O +
patients O +
respond O +
to O +
G O -
- O -
CSF O +
with O +
increased O +
neutrophils O -
, O +
reduced O +
infections O -
, O +
and O +
improved O +
survival O -
. O +

Some O +
responders O +
with O +
congenital O +
neutropenia O +
and O +
Shwachman O -
- O -
Diamond O +
syndrome O +
( O -
SDS O -
) O +
have O +
developed O +
myelodysplastic O +
syndrome O +
and O +
acute O +
myeloid O +
leukemia O +
( O -
MDS O -
/ O -
AML O -
) O -
, O +
which O +
raises O +
the O +
question O +
of O +
the O +
role O +
of O +
G O -
- O -
CSF O +
in O +
pathogenesis O -
. O +

The O +
issue O +
is O +
complicated O +
because O +
both O +
disorders O +
have O +
a O +
propensity O +
for O +
MDS O +
or O +
AML O +
as O +
part O +
of O +
their O +
natural O +
history O -
. O +

To O +
address O +
this O -
, O +
the O +
Severe O +
Chronic O +
Neutropenia O +
International O +
Registry O +
( O -
SCNIR O -
) O +
used O +
its O +
large O +
database O +
of O +
chronic O +
neutropenia O +
patients O +
treated O +
with O +
G O -
- O -
CSF O +
to O +
determine O +
the O +
incidence O +
of O +
malignant O +
myeloid O +
transformation O +
in O +
the O +
two O +
disorders O -
, O +
and O +
its O +
relationship O +
to O +
treatment O +
and O +
to O +
other O +
patient O +
characteristics O -
. O +

No O +
statistically O +
significant O +
relationships O +
were O +
found O +
between O +
age O +
at O +
onset O +
of O +
MDS O +
or O +
AML O +
and O +
patient O +
gender O -
, O +
G O -
- O -
CSF O +
dose O -
, O +
or O +
duration O +
of O +
G O -
- O -
CSF O +
therapy O -
. O +

What O +
was O +
observed O -
, O +
however O -
, O +
was O +
the O +
multistep O +
acquisition O +
of O +
aberrant O +
cellular O +
genetic O +
changes O +
in O +
marrow O +
cells O +
from O +
patients O +
who O +
transformed O -
, O +
including O +
activating O +
ras O +
oncogene O +
mutations O -
, O +
clonal O +
cytogenetic O +
abnormalities O -
, O +
and O +
G O -
- O -
CSF O +
receptor O +
mutations O -
. O +

In O +
murine O +
models O -
, O +
the O +
latter O +
produces O +
a O +
hyperproliferative O +
response O +
to O +
G O -
- O -
CSF O -
, O +
confers O +
resistance O +
to O +
apoptosis O -
, O +
and O +
enhances O +
cell O +
survival O -
. O +

Since O +
congenital O +
neutropenia O +
and O +
SDS O +
are O +
inherited O +
forms O +
of O +
bone O +
marrow O +
failure O -
, O +
G O -
- O -
CSF O +
may O +
accelerate O +
the O +
propensity O +
for O +
MDS O -
/ O -
AML O +
in O +
the O +
genetically O +
altered O +
stem O +
and O +
progenitor O +
cells O -
, O +
especially O +
in O +
those O +
with O +
G O -
- O -
CSF O +
receptor O +
and O +
ras O +
mutations O +
( O -
82 O -
% O +
and O +
50 O -
% O +
of O +
patients O +
who O +
transform O -
, O +
respectively O -
) O -
. O +

Alternatively O -
, O +
and O +
equally O +
plausible O -
, O +
G O -
- O -
CSF O +
may O +
simply O +
be O +
an O +
" O -
innocent O +
bystander O -
" O +
that O +
corrects O +
neutropenia O -
, O +
prolongs O +
patient O +
survival O -
, O +
and O +
allows O +
time O +
for O +
the O +
malignant O +
predisposition O +
to O +
declare O +
itself O -
. O +

In O +
patients O +
who O +
transform O +
to O +
overt O +
MDS O +
or O +
AML O -
, O +
hematopoietic O +
stem O +
cell O +
transplantation O +
is O +
the O +
only O +
chance O +
for O +
cure O -
. O +

In O +
those O +
with O +
" O -
soft O -
" O +
signs O +
of O +
MDS O -
, O +
such O +
as O +
an O +
isolated O +
clonal O +
cytogenetic O +
change O +
but O +
without O +
other O +
evidence O +
of O +
MDS O -
, O +
or O +
with O +
an O +
isolated O +
G O -
- O -
CSF O +
receptor O +
mutation O -
, O +
there O +
is O +
room O +
for O +
conservative O +
management O -
. O +

One O +
option O +
is O +
to O +
reduce O +
the O +
G O -
- O -
CSF O +
dosage O +
as O +
much O +
as O +
possible O -
, O +
and O +
observe O +
the O +
tempo O +
of O +
progression O -
, O +
if O +
any O -
, O +
to O +
more O +
overt O +
signs O +
of O +
malignancy O -
. O +

Hypoxic O +
induction O +
of O +
HIF-1alpha O +
and O +
VEGF O +
expression O +
in O +
head O +
and O +
neck O +
squamous O +
cell O +
carcinoma O +
lines O +
is O +
mediated O +
by O +
stress O +
activated O +
protein O +
kinases O -
. O +

Solid O +
tumors O +
must O +
establish O +
a O +
blood O +
supply O +
in O +
order O +
to O +
proliferate O +
and O +
grow O -
. O +

Cancer O +
cells O +
secrete O +
soluble O +
factors O +
which O +
can O +
induce O +
proliferation O +
and O +
migration O +
of O +
capillary O +
endothelial O +
cells O -
. O +

Among O +
the O +
most O +
potent O +
of O +
the O +
angiogenic O +
factors O +
is O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
. O +

Increased O +
VEGF O +
expression O +
by O +
malignant O +
tumors O +
has O +
been O +
associated O +
with O +
high O +
vascularity O -
, O +
increased O +
cancer O +
cell O +
growth O -
, O +
and O +
lymph O +
node O +
metastasis O -
. O +

Reduced O +
oxygen B-Chemical +
tension O +
has O +
been O +
shown O +
to O +
increase O +
VEGF O +
production O +
by O +
induction O +
of O +
the O +
transcription O +
factor O +
hypoxia O +
inducible O +
factor O +
1 O +
alpha O +
( O -
HIF-1alpha O -
) O -
. O +

The O +
mechanisms O +
by O +
which O +
hypoxic O +
tumor O +
environments O +
induce O +
HIF-1alpha O +
and O +
VEGF O +
expression O +
are O +
largely O +
unknown O -
. O +

Jun O +
N O +
terminal O +
kinase O +
( O -
JNK1 O -
) O +
and O +
p38 O +
kinase O +
are O +
activated O +
by O +
a O +
variety O +
of O +
stress O +
stimuli O -
. O +

To O +
determine O +
if O +
hypoxic O +
activation O +
of O +
these O +
stress O +
activated O +
protein O +
kinases O +
regulated O +
HIF-1alpha O +
and O +
VEGF O +
expression O -
, O +
we O +
assayed O +
JNK1 O +
and O +
p38 O +
activity O +
in O +
squamous O +
cell O +
carcinoma O +
( O -
SCC O -
) O +
lines O +
grown O +
under O +
normoxic O +
or O +
hypoxic O +
conditions O -
. O +

Hypoxia O +
rapidly O +
induced O +
both O +
JNK1 O +
and O +
p38 O +
activity O +
in O +
these O +
cells O -
. O +

This O +
activation O +
correlated O +
with O +
induction O +
of O +
HIF-1alpha O +
expression O +
and O +
DNA O +
binding O +
activity O +
which O +
was O +
blocked O +
by O +
the O +
p38 O +
inhibitor O +
SB203580 B-Chemical -
. O +

Hypoxia O +
also O +
increased O +
VEGF O +
production O +
by O +
SCC O +
lines O -
, O +
which O +
was O +
inhibited O +
by O +
treatment O +
with O +
SB203580 B-Chemical -
. O +

Overexpression O +
of O +
JNK1 O +
or O +
p38 O +
was O +
sufficient O +
to O +
induce O +
HIF-1alpha O +
and O +
VEGF O +
expression O -
. O +

These O +
results O +
indicate O +
that O +
induction O +
of O +
SAPKs O +
by O +
hypoxia O +
regulates O +
HIF-1alpha O +
and O +
VEGF O +
expression O +
in O +
head O +
and O +
neck O +
carcinoma O +
cell O +
lines O -
. O +

[ O -
Radiologic O -
- O -
pathologic O +
correlations O +
in O +
breast O +
diseases O -
] O +
The O +
objective O +
of O +
this O +
article O +
is O +
to O +
explain O +
radiologic O +
patterns O +
of O +
benign O +
and O +
malignant O +
breast O +
lesions O +
( O -
masses O -
, O +
microcalcifications O -
) O +
based O +
on O +
histological O +
correlations O -
. O +

The O +
stromal O +
fibrous O +
reaction O +
associated O +
to O +
infiltrating O +
carcinomas O +
is O +
responsible O +
of O +
focal O +
increased O +
density O -
, O +
and O +
architectural O +
distorsion O -
, O +
ultrasound O +
acoustic O +
shadowing O -
; O +
abnormal O +
neoangiogenesis O +
can O +
be O +
detected O +
by O +
Doppler O -
, O +
CT O +
or O +
MR O +
imaging O -
. O +

Invasive O +
carcinomas O +
without O +
spiculated O +
margins O +
are O +
poorly O +
differentiated O +
tumors O -
. O +

Mammographic O +
patterns O +
of O +
microcalcifications O +
depend O +
on O +
their O +
physiopathological O +
process O +
( O -
necrosis O -
, O +
secretion O -
) O -
, O +
and O +
the O +
shape O +
of O +
clusters O +
( O -
round O -
, O +
triangular O -
) O +
typifies O +
their O +
anatomical O +
site O +
of O +
origin O +
( O -
lobular O -
, O +
ductal O -
) O -
. O +

Less O +
frequent O +
lesions O +
( O -
invasive O +
lobular O -
, O +
mucinous O -
, O +
and O +
medullary O +
carcinomas O -
, O +
radial O +
scar O -
) O +
will O +
be O +
also O +
explained O +
based O +
on O +
radiopathological O +
correlations O -
. O +

Knowledge O +
of O +
radiopathological O +
correlations O +
in O +
breast O +
diseases O +
helps O +
the O +
radiologists O +
to O +
analyze O +
and O +
characterize O +
breast O +
lesions O -
. O +

Multiple O +
stages O +
of O +
malignant O +
transformation O +
of O +
human O +
endothelial O +
cells O +
modelled O +
by O +
co O -
- O -
expression O +
of O +
telomerase O +
reverse O +
transcriptase O -
, O +
SV40 O +
T O +
antigen O +
and O +
oncogenic O +
N O -
- O -
ras O -
. O +

We O +
have O +
modelled O +
multiple O +
stages O +
of O +
malignant O +
transformation O +
of O +
human O +
endothelial O +
cells O +
( O -
ECs O -
) O +
by O +
overexpressing O +
the O +
catalytic O +
subunit O +
of O +
human O +
telomerase O +
( O -
hTERT O -
) O -
, O +
together O +
with O +
SV40 O +
T O +
antigen O +
( O -
SV40 O -
T O -
) O +
and O +
oncogenic O +
N O -
- O -
ras O -
. O +

Transfection O +
with O +
hTERT O +
alone O -
, O +
led O +
to O +
the O +
immortalization O +
of O +
two O +
out O +
of O +
three O +
cultures O +
of O +
bone O +
marrow O -
- O -
derived O +
ECs O +
( O -
BMECs O -
) O -
. O +

One O +
hTERT O +
transduced O +
BMEC O +
culture O +
underwent O +
a O +
long O +
proliferative O +
lag O +
before O +
resuming O +
proliferation O -
. O +

BMECs O +
transfected O +
with O +
hTERT O +
alone O +
were O +
functionally O +
and O +
phenotypically O +
normal O -
. O +

BMECs O +
transfected O +
with O +
SV40 O -
T O +
( O -
BMSVTs O -
) O +
had O +
an O +
extended O +
lifespan O -
, O +
but O +
eventually O +
succumbed O +
to O +
crisis O -
. O +

BMSVTs O +
exhibited O +
a O +
partially O +
transformed O +
phenotype O -
, O +
demonstrating O +
growth O +
factor O +
independence O -
, O +
altered O +
antigen O +
expression O +
and O +
forming O +
tiny O -
, O +
infrequent O +
colonies O +
in O +
vitro O -
. O +

Transduction O +
of O +
BMSVTs O +
with O +
hTERT O +
resulted O +
in O +
immortalization O +
of O +
4 O +
out O +
of O +
4 O +
cultures O -
. O +

BMSVTs O +
immortalized O +
with O +
hTERT O +
formed O +
large O +
colonies O +
in O +
vitro O +
and O +
small O +
transient O +
tumours O +
in O +
vivo O -
. O +

BMECs O +
co O -
- O -
expressing O +
SV40 O -
T O -
, O +
hTERT O +
and O +
N O -
- O -
ras O +
exhibited O +
an O +
overtly O +
transformed O +
phenotype O -
; O +
forming O +
very O +
large O +
colonies O +
with O +
an O +
altered O +
morphology O +
and O +
generating O +
rapidly O +
growing O +
tumours O +
in O +
vivo O -
. O +

These O +
investigations O +
demonstrate O +
transformation O +
of O +
human O +
ECs O +
to O +
an O +
overtly O +
malignant O +
phenotype O -
. O +

This O +
model O +
will O +
be O +
useful O +
for O +
understanding O +
mechanisms O +
underlying O +
vascular O +
and O +
angiogenic O +
neoplasias O -
, O +
as O +
well O +
as O +
for O +
testing O +
drugs O +
designed O +
to O +
curtail O +
aberrant O +
EC O +
growth O -
. O +

Systemic O +
regulation O +
of O +
distraction O +
osteogenesis O -
: O +
a O +
cascade O +
of O +
biochemical O +
factors O -
. O +

This O +
study O +
investigates O +
the O +
systemic O +
biochemical O +
regulation O +
of O +
fracture O +
healing O +
in O +
distraction O +
osteogenesis O +
compared O +
with O +
rigid O +
osteotomy O +
in O +
a O +
prospective O +
in O +
vivo O +
study O +
in O +
humans O -
. O +

To O +
further O +
clarify O +
the O +
influence O +
of O +
mechanical O +
strain O +
on O +
the O +
regulation O +
of O +
bone O +
formation O -
, O +
bone O +
growth O +
factors O +
( O -
insulin O -
- O -
like O +
growth O +
factor O +
[ O -
IGF O -
] O +
I O -
, O +
IGF O +
binding O +
protein O +
[ O -
IGFBP O -
] O +
3 O -
, O +
transforming O +
growth O +
factor O +
[ O -
TGF O -
] O +
beta1 O -
, O +
and O +
basic O +
FGF O +
[ O -
bFGF O -
] O -
) O -
, O +
bone O +
matrix O +
degrading O +
enzymes O +
( O -
matrix O -
- O -
metalloproteinases O +
[ O -
MMPs O -
] O +
1 O -
, O +
2 O -
, O +
and O +
3 O -
) O -
, O +
human O +
growth O +
hormone O +
( O -
hGH O -
) O -
, O +
and O +
bone O +
formation O +
markers O +
( O -
ALP O -
, O +
bone O -
- O -
specific O +
ALP O +
[ O -
BAP O -
] O -
, O +
and O +
osteocalcin O +
[ O -
OC O -
] O -
) O +
have O +
been O +
analyzed O +
in O +
serum O +
samples O +
from O +
10 O +
patients O +
in O +
each O +
group O +
pre- O +
and O +
postoperatively O -
. O +

In O +
the O +
distraction O +
group O -
, O +
a O +
significant O +
postoperative O +
increase O +
in O +
MMP-1 O -
, O +
bFGF O -
, O +
ALP O -
, O +
and O +
BAP O +
could O +
be O +
observed O +
during O +
the O +
lengthening O +
and O +
the O +
consolidation O +
period O +
when O +
compared O +
with O +
the O +
baseline O +
levels O -
. O +

Osteotomy O +
fracture O +
healing O +
without O +
the O +
traction O +
stimulus O +
failed O +
to O +
induce O +
a O +
corresponding O +
increase O +
in O +
these O +
factors O -
. O +

In O +
addition O -
, O +
comparison O +
of O +
both O +
groups O +
revealed O +
a O +
significantly O +
higher O +
increase O +
in O +
TGF O -
- O -
beta1 O -
, O +
IGF O -
- O -
I O -
, O +
IGFBP-3 O -
, O +
and O +
hGH O +
in O +
the O +
lengthening O +
group O +
during O +
the O +
distraction O +
period O -
, O +
indicating O +
key O +
regulatory O +
functions O +
in O +
mechanotransduction O -
. O +

The O +
time O +
courses O +
of O +
changes O +
in O +
MMP-1 O -
, O +
bone O +
growth O +
factors O +
( O -
TGF O -
- O -
beta1 O +
and O +
bFGF O -
) O -
, O +
and O +
hGH O -
, O +
respectively O -
, O +
correlated O +
significantly O +
during O +
the O +
lengthening O +
phase O -
, O +
indicating O +
common O +
regulatory O +
pathways O +
for O +
these O +
factors O +
in O +
distraction O +
osteogenesis O -
. O +

Significant O +
correlation O +
between O +
the O +
osteoblastic O +
marker O +
BAP O -
, O +
TGF O -
- O -
beta1 O -
, O +
and O +
bFGF O +
suggests O +
strain O -
- O -
activated O +
osteoblastic O +
cells O +
as O +
a O +
major O +
source O +
of O +
systemically O +
increased O +
bone O +
growth O +
factors O +
during O +
callus O +
distraction O -
. O +

The O +
systemic O +
increase O +
in O +
bFGF O +
and O +
MMP-1 O +
might O +
reflect O +
an O +
increased O +
local O +
stimulation O +
of O +
angiogenesis O +
during O +
distraction O +
osteogenesis O -
. O +

Human O +
papillomavirus O +
oncoprotein O +
E6 O +
inactivates O +
the O +
transcriptional O +
coactivator O +
human O +
ADA3 O -
. O +

High O -
- O -
risk O +
human O +
papillomaviruses O +
( O -
HPVs O -
) O +
are O +
associated O +
with O +
carcinomas O +
of O +
the O +
cervix O +
and O +
other O +
genital O +
tumors O -
. O +

The O +
HPV O +
oncoprotein O +
E6 O +
is O +
essential O +
for O +
oncogenic O +
transformation O -
. O +

We O +
identify O +
here O +
hADA3 O -
, O +
human O +
homologue O +
of O +
the O +
yeast O +
transcriptional O +
coactivator O +
yADA3 O -
, O +
as O +
a O +
novel O +
E6-interacting O +
protein O +
and O +
a O +
target O +
of O +
E6-induced O +
degradation O -
. O +

hADA3 O +
binds O +
selectively O +
to O +
the O +
high O -
- O -
risk O +
HPV O +
E6 O +
proteins O +
and O +
only O +
to O +
immortalization O -
- O -
competent O +
E6 O +
mutants O -
. O +

hADA3 O +
functions O +
as O +
a O +
coactivator O +
for O +
p53-mediated O +
transactivation O +
by O +
stabilizing O +
p53 O +
protein O -
. O +

Notably O -
, O +
three O +
immortalizing O +
E6 O +
mutants O +
that O +
do O +
not O +
induce O +
direct O +
p53 O +
degradation O +
but O +
do O +
interact O +
with O +
hADA3 O +
induced O +
the O +
abrogation O +
of O +
p53-mediated O +
transactivation O +
and O +
G O -
( O -
1 O -
) O +
cell O +
cycle O +
arrest O +
after O +
DNA O +
damage O -
, O +
comparable O +
to O +
wild O -
- O -
type O +
E6 O -
. O +

These O +
findings O +
reveal O +
a O +
novel O +
strategy O +
of O +
HPV O +
E6-induced O +
loss O +
of O +
p53 O +
function O +
that O +
is O +
independent O +
of O +
direct O +
p53 O +
degradation O -
. O +

Given O +
the O +
likely O +
role O +
of O +
the O +
evolutionarily O +
conserved O +
hADA3 O +
in O +
multiple O +
coactivator O +
complexes O -
, O +
inactivation O +
of O +
its O +
function O +
may O +
allow O +
E6 O +
to O +
perturb O +
numerous O +
cellular O +
pathways O +
during O +
HPV O +
oncogenesis O -
. O +

Immunohistochemical O +
staining O +
for O +
thyroid O +
transcription O +
factor-1 O -
: O +
a O +
helpful O +
aid O +
in O +
discerning O +
primary O +
site O +
of O +
tumor O +
origin O +
in O +
patients O +
with O +
brain O +
metastases O -
. O +

Metastatic O +
carcinoma O +
of O +
unknown O +
primary O +
origin O +
is O +
a O +
perplexing O +
but O +
common O +
problem O -
, O +
accounting O +
for O +
up O +
to O +
10 O -
% O +
to O +
15 O -
% O +
of O +
all O +
solid O +
tumors O +
at O +
presentation O -
. O +

Many O +
of O +
these O +
metastases O +
presumably O +
arise O +
from O +
primary O +
lung O +
carcinomas O -
, O +
but O +
the O +
morphologic O +
features O +
and O +
immunohistochemical O +
profile O +
of O +
lung O +
cancer O +
is O +
often O +
too O +
nonspecific O +
to O +
permit O +
unequivocal O +
confirmation O -
. O +

Thyroid O +
transcription O +
factor-1 O +
( O -
TTF-1 O -
) O +
is O +
expressed O +
in O +
lung O +
adenocarcinomas O +
and O +
thyroid O +
carcinomas O +
but O +
not O +
in O +
adenocarcinomas O +
arising O +
from O +
other O +
sites O -
. O +

For O +
patients O +
with O +
adenocarcinomas O +
in O +
the O +
lung O -
, O +
TTF-1 O +
staining O +
is O +
now O +
routinely O +
used O +
to O +
distinguish O +
a O +
primary O +
lung O +
cancer O +
from O +
a O +
lung O +
metastasis O -
. O +

Along O +
these O +
same O +
lines O -
, O +
TTF-1 O +
staining O +
might O +
prove O +
useful O +
in O +
localizing O +
the O +
tumor O +
origin O +
of O +
adenocarcinomas O +
encountered O +
outside O +
of O +
the O +
lung O -
. O +

The O +
archival O +
surgical O +
pathology O +
files O +
of O +
The O +
Johns O +
Hopkins O +
Hospital O +
were O +
searched O +
for O +
cases O +
of O +
brain O +
metastases O +
biopsied O +
between O +
1990 O +
and O +
2000 O -
. O +

Tissue O +
blocks O +
were O +
obtained O +
and O +
immunoperoxidase O +
staining O +
was O +
performed O +
using O +
the O +
TTF-1 O +
antibody O -
. O +

The O +
medical O +
records O +
were O +
reviewed O +
independent O +
of O +
the O +
staining O +
results O +
to O +
determine O +
site O +
of O +
tumor O +
origin O -
. O +

Seventy O -
- O -
five O +
patients O +
underwent O +
biopsies O +
of O +
carcinomas O +
metastatic O +
to O +
the O +
brain O -
. O +

At O +
the O +
time O +
of O +
brain O +
biopsy O -
, O +
the O +
primary O +
site O +
of O +
tumor O +
origin O +
was O +
known O +
in O +
45 O +
cases O +
and O +
unknown O +
in O +
30 O +
cases O -
. O +

Ultimately O -
, O +
the O +
primary O +
site O +
was O +
established O +
on O +
clinical O +
and O +
radiographic O +
grounds O +
in O +
71 O +
cases O +
( O -
95 O -
% O -
) O -
. O +

These O +
included O +
40 O +
( O -
56 O -
% O -
) O +
metastases O +
from O +
a O +
primary O +
lung O +
carcinoma O +
and O +
31 O +
( O -
44 O -
% O -
) O +
metastases O +
from O +
some O +
nonpulmonary O +
carcinoma O -
. O +

TTF-1 O +
staining O +
was O +
present O +
in O +
31 O +
of O +
the O +
40 O +
( O -
78 O -
% O -
) O +
metastatic O +
lung O +
carcinomas O -
, O +
but O +
in O +
only O +
1 O +
of O +
the O +
31 O +
( O -
3 O -
% O -
) O +
metastatic O +
nonpulmonary O +
carcinomas O +
( O -
a O +
small O -
- O -
cell O +
carcinoma O +
of O +
the O +
sinonasal O +
tract O -
) O -
. O +

When O +
the O +
metastatic O +
lung O +
carcinomas O +
were O +
subtyped O -
, O +
TTF-1 O +
staining O +
was O +
noted O +
in O +
11 O +
of O +
11 O +
( O -
100 O -
% O -
) O +
adenocarcinomas O -
, O +
in O +
6 O +
of O +
7 O +
( O -
86 O -
% O -
) O +
small O -
- O -
cell O +
carcinomas O -
, O +
in O +
15 O +
of O +
19 O +
( O -
79 O -
% O -
) O +
large O -
- O -
cell O +
carcinomas O -
, O +
and O +
in O +
none O +
of O +
3 O +
( O -
0 O -
% O -
) O +
squamous O +
cell O +
carcinomas O -
. O +

TTF-1 O +
staining O +
is O +
very O +
reliable O +
in O +
discerning O +
whether O +
a O +
brain O +
metastasis O +
has O +
arisen O +
from O +
a O +
pulmonary O +
or O +
nonpulmonary O +
site O -
, O +
particularly O +
when O +
dealing O +
with O +
adenocarcinomas O +
and O +
large O -
- O -
cell O +
carcinomas O -
. O +

TTF-1 O +
immunohistochemistry O +
could O +
focus O +
the O +
search O +
for O +
the O +
primary O +
tumor O +
for O +
patients O +
presenting O +
with O +
brain O +
metastasis O +
as O +
the O +
initial O +
manifestation O -
. O +

Molecular O +
characterization O +
of O +
angiogenic O +
properties O +
of O +
human O +
oral O +
squamous O +
cell O +
carcinoma O +
cells O -
. O +

Little O +
is O +
known O +
about O +
the O +
specificity O +
of O +
angiogenic O +
properties O +
of O +
oral O +
cancer O +
cells O +
and O +
the O +
possible O +
mechanisms O -
. O +

Stimulatory O +
effects O +
on O +
proliferation O +
and O +
migration O +
of O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O -
HUVEC O -
) O +
characterized O +
the O +
angiogenic O +
properties O +
of O +
oral O +
cancer O +
cells O +
but O +
not O +
normal O +
oral O +
keratinocytes O +
( O -
NOK O -
) O -
. O +

ELISA O +
found O +
the O +
presence O +
of O +
vascular O +
endothelial O +
growth O +
factors O +
( O -
VEGF O -
) O +
both O +
in O +
the O +
tested O +
oral O +
cancer O +
cells O +
and O +
NOK O -
. O +

Attenuation O +
of O +
the O +
proangiogenic O +
effects O +
by O +
neutralizing O +
VEGF O +
antibodies O +
suggests O +
VEGF O +
play O +
a O +
key O +
role O +
in O +
the O +
acquisition O +
of O +
the O +
angiogenic O +
phenotype O +
in O +
oral O +
cancer O +
cells O -
. O +

Western O +
blotting O +
of O +
p53 O +
and O +
murine O +
double O +
mutant O +
2 O +
( O -
Mdm2 O -
) O +
together O +
with O +
p53 O +
DNA O +
sequencing O +
analysis O +
indicate O +
that O +
p53 O +
function O +
loss O +
by O +
mutation O +
or O +
overexpression O +
of O +
Mdm2 O +
occurred O +
in O +
all O +
tested O +
oral O +
cancer O +
cells O +
regardless O +
of O +
their O +
etiology O -
. O +

In O +
summary O -
, O +
the O +
angiogenic O +
property O +
of O +
oral O +
cancer O +
cells O +
is O +
mediated O +
by O +
many O +
factors O +
in O +
addition O +
to O +
VEGF O +
and O +
the O +
functional O +
status O +
of O +
p53 O -
. O +

Antiangiogenic O +
and O +
antitumor O +
effects O +
of O +
a O +
protein O +
kinase O +
Cbeta O +
inhibitor O +
in O +
human O +
breast O +
cancer O +
and O +
ovarian O +
cancer O +
xenografts O -
. O +

In O +
cell O +
culture O -
, O +
the O +
compound O +
317615 B-Chemical +
2HCl I-Chemical -
, O +
a O +
potent O +
inhibitor O +
of O +
VEGF O -
- O -
stimulated O +
HUVEC O +
proliferation O -
, O +
was O +
not O +
very O +
effective O +
against O +
MX-1 O +
breast O +
cancer O +
cells O +
( O -
IC50= O +
8.1 O +
microM O -
) O +
or O +
SKOV-3 O +
ovarian O +
carcinoma O +
cells O +
( O -
IC50 O +
= O +
9.5 O +
microM O -
) O -
. O +

Exposure O +
to O +
combinations O +
of O +
paclitaxel B-Chemical +
or O +
carboplatin B-Chemical +
and O +
317615 B-Chemical +
x I-Chemical +
2HCl I-Chemical +
with O +
MX-1 O +
cells O +
in O +
culture O +
resulted O +
in O +
cell O +
survival O +
that O +
reflected O +
primarily O +
additivity O +
of O +
the O +
two O +
agents O -
. O +

Exposure O +
of O +
SKOV-3 O +
cells O +
to O +
paclitaxel B-Chemical +
or O +
carboplatin B-Chemical +
along O +
with O +
317615 B-Chemical +
2HCl I-Chemical +
resulted O +
in O +
cell O +
survivals O +
that O +
reflected O +
additivity O +
of O +
317615 B-Chemical +
x I-Chemical +
2HCl I-Chemical +
with O +
paclitaxel B-Chemical +
and O +
greater O -
- O -
than O -
- O -
additive O +
cytotoxicity O +
with O +
carboplatin B-Chemical -
. O +

Administration O +
of O +
317615 B-Chemical +
x I-Chemical +
2HCI I-Chemical +
orally O +
twice O +
daily O +
to O +
nude O +
mice O +
bearing O +
subcutaneous O +
MX-1 O +
tumors O +
or O +
SKOV-3 O +
tumors O +
resulted O +
in O +
a O +
decreased O +
number O +
of O +
intratumoral O +
vessels O +
as O +
determined O +
by O +
CD31 O +
and O +
CD105 O +
staining O +
with O +
decreases O +
of O +
35 O -
% O +
and O +
43 O -
% O +
in O +
MX-1 O +
tumors O +
and O +
60 O -
% O +
and O +
75 O -
% O +
in O +
SKOV-3 O +
tumors O -
, O +
respectively O -
. O +

317615 B-Chemical +
x I-Chemical +
2HCl I-Chemical +
was O +
an O +
active O +
antitumor O +
agent O +
against O +
the O +
MX-1 O +
xenograft O +
and O +
increased O +
the O +
tumor O +
growth O +
delay O +
produced O +
by O +
paclitaxel B-Chemical +
by O +
1.7-fold O +
and O +
the O +
tumor O +
growth O +
delay O +
produced O +
by O +
carboplatin B-Chemical +
by O +
3.8-fold O -
. O +

Administration O +
of O +
317615 B-Chemical +
x I-Chemical +
2HCl I-Chemical +
also O +
increased O +
the O +
tumor O +
growth O +
delay O +
produced O +
by O +
fractionated O +
radiation O +
therapy O +
in O +
the O +
MX-1 O +
tumor O -
. O +

Treatment O +
with O +
317615 B-Chemical +
x I-Chemical +
2HCl I-Chemical +
alone O +
increased O +
the O +
lifespan O +
of O +
animals O +
bearing O +
intraperitoneal O +
SKOV-3 O +
xenografts O +
by O +
1.9 O +
fold O +
compared O +
with O +
untreated O +
control O +
animals O -
. O +

The O +
combination O +
of O +
paclitaxel B-Chemical +
and O +
317615 B-Chemical +
x I-Chemical +
2HCl I-Chemical +
resulted O +
in O +
100 O -
% O +
120-day O +
survival O +
of O +
SKOV-3 O +
bearing O +
animals O -
. O +

Administration O +
of O +
317615 B-Chemical +
x I-Chemical +
2HCl I-Chemical +
along O +
with O +
carboplatin B-Chemical +
to O +
animals O +
bearing O +
the O +
SKOV-3 O +
tumor O +
produced O +
a O +
1.8-fold O +
increase O +
in O +
lifespan O +
compared O +
with O +
carboplatin B-Chemical +
alone O -
. O +

317615 B-Chemical +
x I-Chemical +
2HCl I-Chemical +
is O +
a O +
promising O +
new O +
antiangiogenic O +
agent O +
that O +
is O +
in O +
early O +
phase O +
clinical O +
testing O -
. O +

Expression O +
of O +
CD154 O +
on O +
renal O +
cell O +
carcinomas O +
and O +
effect O +
on O +
cell O +
proliferation O -
, O +
motility O +
and O +
platelet B-Chemical -
- I-Chemical -
activating I-Chemical +
factor I-Chemical +
synthesis O -
. O +

CD40 O +
activation O +
by O +
CD154 O +
may O +
trigger O +
diverse O +
cellular O +
responses O -
, O +
ranging O +
from O +
proliferation O +
and O +
differentiation O +
to O +
growth O +
suppression O +
and O +
cell O +
death O -
, O +
in O +
normal O +
and O +
malignant O +
cells O -
. O +

However O -
, O +
the O +
pathophysiologic O +
role O +
of O +
CD154 O +
expressed O +
by O +
tumor O +
cells O +
remains O +
unclear O -
. O +

We O +
have O +
investigated O +
the O +
expression O +
of O +
the O +
CD40-CD154 O +
system O +
in O +
24 O +
primary O +
cultures O +
derived O +
from O +
renal O +
cell O +
carcinomas O -
, O +
its O +
correlation O +
with O +
tumor O +
stage O +
and O +
its O +
potential O +
functional O +
significance O -
. O +

We O +
found O +
coexpression O +
of O +
CD40 O +
and O +
CD154 O +
in O +
most O +
of O +
the O +
renal O +
carcinoma O +
cell O +
lines O -
. O +

CD154 O -
, O +
but O +
not O +
CD40 O +
expression O -
, O +
significantly O +
correlated O +
with O +
tumor O +
stage O -
. O +

Moreover O -
, O +
renal O +
carcinoma O +
cell O +
lines O +
also O +
released O +
the O +
soluble O +
form O +
of O +
CD154 O +
into O +
the O +
supernatant O -
. O +

CD40 O +
engagement O +
by O +
CD154 O +
did O +
not O +
affect O +
apoptosis O +
or O +
survival O -
. O +

On O +
the O +
contrary O -
, O +
CD154 O +
stimulated O +
cell O +
proliferation O -
, O +
motility O +
and O +
production O +
of O +
PAF B-Chemical -
, O +
a O +
phospholipid O +
mediator O +
of O +
inflammation O +
with O +
angiogenic O +
properties O -
. O +

Furthermore O -
, O +
the O +
renal O +
carcinoma O +
cell O +
lines O +
expressed O +
PAF O -
- O -
R. O +
Blockade O +
of O +
PAF O -
- O -
R O +
by O +
WEB-2170 B-Chemical -
, O +
a O +
PAF O -
- O -
R O +
antagonist O -
, O +
abolished O +
the O +
CD154-dependent O +
motility O -
, O +
indicating O +
a O +
role O +
for O +
PAF B-Chemical +
synthesized O +
after O +
CD154 O +
stimulation O +
in O +
renal O +
carcinoma O +
cell O +
motility O -
. O +

In O +
conclusion O -
, O +
this O +
study O +
identifies O +
new O +
functional O +
properties O +
for O +
CD154 O -
, O +
which O +
are O +
potentially O +
relevant O +
for O +
the O +
growth O +
and O +
dissemination O +
of O +
renal O +
carcinoma O +
cells O -
. O +

Fas O -
- O -
Fas O +
ligand O +
signaling O +
pathway O +
mediates O +
an O +
interleukin-12-induced O +
rejection O +
of O +
a O +
murine O +
prostate O +
tumor O +
system O -
. O +

BACKGROUND O -
: O +
Recent O +
data O +
suggest O +
that O +
anti O -
- O -
tumor O +
activities O +
of O +
interleukin-12 O +
( O -
IL-12 O -
) O +
involve O +
the O +
induction O +
of O +
apoptosis O -
. O +

Fas O +
( O -
APO-1 O -
/ O -
CD95 O -
) O +
is O +
a O +
type O +
I O +
membrane O +
protein O +
that O +
is O +
capable O +
of O +
initiating O +
an O +
apoptosis O +
signaling O +
pathway O +
when O +
bound O +
to O +
its O +
ligand O +
( O -
FasL O -
) O -
. O +

We O +
undertook O +
this O +
study O +
to O +
test O +
the O +
hypothesis O +
that O +
Fas O -
- O -
FasL O -
- O -
mediated O +
apoptosis O +
plays O +
a O +
role O +
in O +
IL-12-induced O +
tumor O +
regression O -
. O +

METHODS O -
: O +
An O +
mIL-12 O +
expression O +
vector O +
driven O +
by O +
cytomegalovirus O +
promoter O +
was O +
used O +
to O +
express O +
murine O +
IL-12 O +
cDNA O +
in O +
the O +
RM-9 O +
murine O +
prostate O +
carcinoma O +
cell O +
line O -
. O +

Control O +
RM-9 O +
cells O +
and O +
RM-9 O +
cells O +
stably O +
transfected O +
with O +
IL-12 O +
gene O +
( O -
RM-9-IL12 O -
) O +
were O +
inoculated O +
subcutaneously O +
in O +
4- O +
to O +
6-week O -
- O -
old O +
male O +
C57BL O -
/ O -
J6 O +
mice O -
. O +

Tumor O +
size O +
was O +
measured O +
every O +
3 O +
days O -
. O +

Western O +
blot O +
and O +
immunohistochemical O +
assays O +
were O +
used O +
to O +
evaluate O +
Fas O +
and O +
FasL O +
protein O +
expression O -
. O +

In O +
situ O +
fluorescent O +
end O +
labeling O +
was O +
used O +
to O +
label O +
apoptotic O +
cells O -
. O +

RESULTS O -
: O +
IL-12-expressing O +
RM-9 O +
prostate O +
carcinoma O +
cells O +
transplanted O +
into O +
C57BL O -
/ O -
J6 O +
mice O +
grew O +
more O +
slowly O +
than O +
control O +
RM-9 O +
cells O +
and O +
vector O +
control O +
RM-9-Luc O +
cells O -
. O +

The O +
average O +
survival O +
time O +
of O +
the O +
RM-9-IL12 O +
mice O +
was O +
longer O +
than O +
53 O +
days O -
, O +
whereas O +
the O +
mean O +
survival O +
for O +
mice O +
transplanted O +
with O +
control O +
RM-9 O +
cells O +
was O +
only O +
16 O +
days O -
. O +

Apoptotic O +
cells O +
were O +
more O +
numerous O +
in O +
RM-9-IL12 O +
tumors O -
: O +
10.3 O -
% O +
vs. O +
1.5 O -
% O +
in O +
control O +
( O -
P O +
= O +
0.001 O -
) O -
. O +

Fas O +
and O +
FasL O +
proteins O +
were O +
increased O +
approximately O +
twofold O +
in O +
the O +
RM-9-IL12 O +
tumors O +
compared O +
with O +
the O +
RM-9 O +
control O +
tumors O +
as O +
determined O +
by O +
Western O +
blot O +
and O +
immunohistochemical O +
analyses O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

CONCLUSION O -
: O +
The O +
Fas O -
- O -
FasL O -
- O -
mediated O +
apoptosis O +
pathway O +
may O +
contribute O +
to O +
the O +
IL-12-induced O +
rejection O +
of O +
prostate O +
carcinoma O -
. O +

DNA O +
damage O +
induces O +
a O +
novel O +
p53-survivin O +
signaling O +
pathway O +
regulating O +
cell O +
cycle O +
and O +
apoptosis O +
in O +
acute O +
lymphoblastic O +
leukemia O +
cells O -
. O +

Survivin O +
is O +
a O +
novel O +
member O +
of O +
the O +
inhibitor O +
of O +
apoptosis O +
protein O +
( O -
IAP O -
) O +
family O -
. O +

Here O +
we O +
report O +
that O +
the O +
chemotherapeutic O +
drug O +
doxorubicin B-Chemical -
, O +
a O +
DNA O -
- O -
damaging O +
agent O -
, O +
activates O +
a O +
p53-survivin O +
signaling O +
pathway O +
inducing O +
cell O +
cycle O +
arrest O +
and O +
apoptosis O +
in O +
childhood O +
acute O +
lymphoblastic O +
leukemia O +
( O -
ALL O -
) O -
. O +

Treatment O +
of O +
wild O -
- O -
type O +
( O -
wt O -
) O +
p53 O +
ALL O +
cells O +
( O -
EU-3 O +
cell O +
line O -
) O +
with O +
doxorubicin B-Chemical +
caused O +
accumulation O +
of O +
p53 O -
, O +
resulting O +
in O +
dramatic O +
down O -
- O -
regulation O +
of O +
survivin O -
, O +
depletion O +
of O +
cells O +
in O +
G O -
( O -
2 O -
) O -
/ O -
M O -
, O +
and O +
apoptosis O +
( O -
increased O +
sub O -
- O -
G O -
( O -
1 O -
) O +
compartment O -
) O -
. O +

In O +
contrast O -
, O +
doxorubicin B-Chemical +
treatment O +
of O +
mutant O +
( O -
mut O -
) O +
p53 O +
cells O +
( O -
EU-6 O -
/ O -
ALL O +
line O -
) O +
up O -
- O -
regulated O +
survivin O +
and O +
induced O +
G O -
( O -
2 O -
) O -
/ O -
M O +
arrest O +
without O +
inducing O +
apoptosis O -
. O +

However O -
, O +
treating O +
EU-6 O +
with O +
anti O -
- O -
survivin O +
antisense O +
resensitized O +
these O +
cells O +
to O +
doxorubicin B-Chemical -
, O +
resulting O +
in O +
apoptosis O -
. O +

With O +
a O +
p53-null O +
cell O +
line O +
( O -
EU-4 O -
) O -
, O +
although O +
doxorubicin B-Chemical +
treatment O +
arrested O +
cells O +
in O +
G O -
( O -
2 O -
) O -
/ O -
M O -
, O +
survivin O +
expression O +
was O +
unchanged O -
, O +
and O +
cells O +
underwent O +
only O +
limited O +
apoptosis O -
. O +

However O -
, O +
re O -
- O -
expression O +
of O +
wt O -
- O -
p53 O +
in O +
EU-4 O +
cells O +
could O +
restore O +
the O +
doxorubicin B-Chemical -
- O -
p53-survivin O +
pathway O -
, O +
resulting O +
in O +
significantly O +
decreased O +
survivin O +
expression O +
and O +
increased O +
apoptosis O +
in O +
these O +
cells O +
after O +
doxorubicin B-Chemical +
treatment O -
. O +

Following O +
cotransfection O +
of O +
p53-null O +
EU-4 O +
cells O +
with O +
survivin O +
promoter O -
- O -
luciferase O +
constructs O +
and O +
either O +
wt O -
- O -
p53 O +
or O +
different O +
mut O -
- O -
p53 O +
expression O +
vectors O -
, O +
wt O -
- O -
p53 O +
inhibited O +
survivin O +
promoter O +
activity O -
; O +
p53-mediated O +
inhibition O +
could O +
be O +
abrogated O +
by O +
overexpression O +
of O +
murine O +
double O +
minute2 O +
( O -
MDM2 O -
) O +
protein O -
. O +

Together O -
, O +
these O +
studies O +
define O +
a O +
novel O +
p53-survivin O +
signaling O +
pathway O +
activated O +
by O +
DNA O +
damage O +
that O +
results O +
in O +
down O -
- O -
regulation O +
of O +
survivin O -
, O +
cell O +
cycle O +
arrest O -
, O +
and O +
apoptosis O -
. O +

Furthermore O -
, O +
our O +
data O +
indicate O +
that O +
loss O +
of O +
wt O -
- O -
p53 O +
function O +
in O +
tumor O +
cells O +
may O +
contribute O +
to O +
up O -
- O -
regulation O +
of O +
survivin O +
and O +
resistance O +
to O +
DNA O -
- O -
damaging O +
agents O -
. O +

Brn-3a O -
, O +
a O +
neuronal O +
transcription O +
factor O +
of O +
the O +
POU O +
gene O +
family O -
: O +
indications O +
for O +
its O +
involvement O +
in O +
cancer O +
and O +
angiogenesis O -
. O +

Brn-3a O -
, O +
a O +
member O +
of O +
the O +
POU O +
gene O +
family O +
( O -
so O -
- O -
called O +
because O +
of O +
the O +
similarity O +
with O +
the O +
group O +
of O +
transcription O +
factors O +
Pit O -
, O +
Oct O -
, O +
and O +
Unc O -
) O -
, O +
was O +
found O +
in O +
neuronal O +
cells O +
engaged O +
in O +
the O +
transcription O +
activity O +
of O +
the O +
p1 O +
and O +
p2 O +
promoters O +
of O +
the O +
most O +
powerful O +
antiapoptotic O +
gene O -
, O +
namely O -
, O +
Bcl-2 O -
. O +

The O +
alternative O +
splicing O +
of O +
Brn-3a O +
mRNA O +
produces O +
two O +
molecular O +
forms O -
: O +
a O +
longer O -
, O +
Bcl-2 O +
transactivating O +
form O -
, O +
and O +
a O +
shorter O +
inactive O +
form O -
, O +
lacking O +
84 O +
AA O +
in O +
the O +
aminoterminus O -
. O +

In O +
neuronal O +
cells O -
, O +
following O +
Brn-3a O +
gene O +
transfection O +
and O +
superexpression O -
, O +
an O +
increase O +
of O +
30 O +
fold O +
of O +
the O +
Bcl-2 O +
protein O +
occurs O -
, O +
leading O +
to O +
apoptosis O +
protection O -
. O +

However O -
, O +
recent O +
works O +
demonstrate O +
that O +
Brn-3a O +
expression O +
is O +
not O +
restricted O +
to O +
neuronal O +
cells O -
, O +
as O +
its O +
activity O +
was O +
detected O +
also O +
in O +
cancer O +
cells O +
of O +
non O -
- O -
neuronal O +
nature O -
. O +

Looking O +
for O +
mechanisms O +
linking O +
Brn-3a O +
to O +
carcinogenesis O -
, O +
we O +
discuss O +
the O +
role O +
of O +
this O +
transcription O +
factor O +
in O +
influencing O +
Bcl-2 O -
/ O -
p53 O +
antagonism O +
and O +
Bcl-2 O -
/ O -
VEGF O +
induction O +
of O +
tumor O +
angiogenesis O -
, O +
concluding O +
this O +
review O +
with O +
a O +
proposal O +
for O +
the O +
oncogenic O +
nature O +
of O +
Brn-3a O -
. O +

Roles O +
of O +
cell O +
adhesion O +
molecules O +
in O +
tumor O +
angiogenesis O +
induced O +
by O +
cotransplantation O +
of O +
cancer O +
and O +
endothelial O +
cells O +
to O +
nude O +
rats O -
. O +

Roles O +
of O +
cell O +
adhesion O +
molecules O +
mediating O +
the O +
interaction O +
of O +
cancer O +
and O +
endothelial O +
cells O +
in O +
tumor O +
angiogenesis O +
were O +
investigated O +
using O +
new O +
in O +
vitro O +
and O +
in O +
vivo O +
model O +
systems O +
with O +
a O +
cultured O +
murine O +
endothelial O +
cell O +
line O +
( O -
F-2 O -
) O +
and O +
human O +
cultured O +
epidermoid O +
cancer O +
cells O +
( O -
A431 O -
) O -
. O +

The O +
A431 O +
cells O +
exhibited O +
typical O +
in O +
vitro O +
cell O +
adhesion O +
to O +
the O +
endothelial O +
F-2 O +
cells O -
. O +

The O +
initial O +
step O +
of O +
adhesion O +
was O +
mediated O +
by O +
sialyl B-Chemical +
Lewis I-Chemical -
( I-Chemical -
x I-Chemical -
) I-Chemical +
( O -
Le B-Chemical -
( I-Chemical -
x I-Chemical -
) I-Chemical -
) O +
and O +
sialyl B-Chemical +
Le I-Chemical -
( I-Chemical -
a I-Chemical -
) I-Chemical -
, O +
the O +
carbohydrate O +
determinants O +
expressed O +
on O +
the O +
cancer O +
cells O -
, O +
and O +
E O -
- O -
selectin O +
expressed O +
constitutively O +
on O +
F-2 O +
cells O -
. O +

Prolonged O +
culture O +
led O +
to O +
the O +
implantation O +
of O +
cancer O +
cells O +
into O +
the O +
monolayer O +
of O +
the O +
F-2 O +
cells O -
, O +
which O +
was O +
mediated O +
mainly O +
by O +
alpha O -
( O -
3 O -
) O -
beta O -
( O -
1 O -
) O -
-integrin O -
. O +

F-2 O +
cells O +
cultured O +
on O +
Matrigel O +
showed O +
evident O +
tube O +
formation O -
, O +
and O +
coculture O +
of O +
F-2 O +
cells O +
with O +
A431 O +
cells O +
led O +
to O +
the O +
formation O +
of O +
A431 O +
cell O +
nests O +
constantly O +
surrounded O +
by O +
tube O -
- O -
like O +
networks O +
consisting O +
of O +
F-2 O +
cells O -
. O +

This O +
in O +
vitro O +
morphogenesis O +
was O +
inhibited O +
by O +
the O +
addition O +
of O +
anti O -
- O -
sialyl B-Chemical +
Le I-Chemical -
( I-Chemical -
x I-Chemical -
) I-Chemical -
/ O -
Le B-Chemical -
( I-Chemical -
a I-Chemical -
) I-Chemical +
or O +
anti O -
- O -
beta O -
( O -
1 O -
) O -
-integrin O +
antibodies O -
, O +
which O +
led O +
to O +
the O +
formation O +
of O +
cancer O +
cell O +
aggregates O +
that O +
were O +
independent O +
from O +
the O +
F-2 O +
cell O +
networks O -
. O +

This O +
in O +
vitro O +
morphological O +
appearance O +
was O +
exactly O +
reproduced O +
in O +
the O +
in O +
vivo O +
tumors O -
, O +
which O +
were O +
formed O +
when O +
the O +
mixture O +
of O +
A431 O +
and O +
F-2 O +
cells O +
at O +
the O +
ratio O +
of O +
10:1 O +
were O +
cotransplanted O +
s.c O -
. O +

into O +
the O +
back O +
of O +
nude O +
rats O -
. O +

The O +
tumors O +
of O +
A431 O +
supplemented O +
with O +
F-2 O +
cells O +
were O +
profoundly O +
vascularized O +
throughout O +
by O +
the O +
tubular O +
structures O +
formed O +
by O +
F-2 O +
cells O -
, O +
the O +
lumen O +
of O +
which O +
contained O +
the O +
host O +
rat O +
blood O +
cells O -
. O +

The O +
tumor O +
mass O +
thus O +
formed O +
was O +
an O +
average O +
5.8-fold O +
as O +
large O +
as O +
control O +
A431 O +
tumors O +
that O +
were O +
grown O +
without O +
F-2 O +
cells O -
. O +

The O +
co O -
- O -
injection O +
of O +
anti O -
- O -
Le B-Chemical -
( I-Chemical -
x I-Chemical -
) I-Chemical -
/ O -
Le B-Chemical -
( I-Chemical -
a I-Chemical -
) I-Chemical +
or O +
anti O -
- O -
beta O -
( O -
1 O -
) O -
-integrin O +
antibodies O +
produced O +
a O +
marked O +
reduction O +
in O +
the O +
size O +
of O +
A431 O +
tumors O -
, O +
which O +
were O +
not O +
vascularized O +
and O +
accompanied O +
an O +
independent O +
tiny O +
remnant O +
clump O +
of O +
F-2 O +
cells O -
. O +

The O +
size O +
of O +
these O +
A431 O +
tumors O +
did O +
not O +
differ O +
significantly O +
from O +
those O +
of O +
control O +
A431 O +
tumors O +
raised O +
without O +
F-2 O +
cells O -
. O +

These O +
results O +
indicate O +
that O +
the O +
interaction O +
of O +
tumor O +
cells O +
and O +
endothelial O +
cells O +
in O +
orderly O +
tumor O +
angiomorphogenesis O +
is O +
highly O +
dependent O +
on O +
the O +
action O +
of O +
cell O +
adhesion O +
molecules O +
mediating O +
the O +
adhesion O +
of O +
cancer O +
cells O +
to O +
endothelial O +
cells O -
, O +
inhibition O +
of O +
which O +
remarkably O +
retards O +
tumor O +
growth O +
and O +
angiogenesis O -
. O +

Identification O +
of O +
Dss1 O +
as O +
a O +
12-O B-Chemical -
- I-Chemical -
tetradecanoylphorbol-13-acetate I-Chemical -
- O -
responsive O +
gene O +
expressed O +
in O +
keratinocyte O +
progenitor O +
cells O -
, O +
with O +
possible O +
involvement O +
in O +
early O +
skin O +
tumorigenesis O -
. O +

This O +
study O +
identifies O +
genes O +
expressed O +
early O +
in O +
12-O B-Chemical -
- I-Chemical -
tetradecanoylphorbol-13-acetate I-Chemical +
( O -
TPA B-Chemical -
) O -
-induced O +
skin O +
carcinogenesis O +
in O +
genetically O +
initiated O +
Tg O -
. O +

AC O +
v O -
- O -
Ha O -
- O -
ras O +
transgenic O +
mice O -
. O +

Keratinocyte O +
progenitor O +
cells O +
from O +
TPA B-Chemical -
- O -
treated O +
Tg O -
. O +

AC O +
mice O +
were O +
isolated O +
with O +
fluorescence O -
- O -
activated O +
cell O +
sorting O +
and O +
expression O +
was O +
analyzed O +
using O +
cDNA O +
microarray O +
technology O -
. O +

Eleven O +
genes O +
were O +
identified O +
whose O +
expression O +
changed O +
significantly O +
in O +
response O +
to O +
carcinogen O +
treatment O -
. O +

Deleted O +
in O +
split O +
hand O -
/ O -
split O +
foot O +
1 O +
( O -
Dss1 O -
) O +
is O +
a O +
gene O +
associated O +
with O +
a O +
heterogeneous O +
limb O +
developmental O +
disorder O +
called O +
split O +
hand O -
/ O -
split O +
foot O +
malformation O -
. O +

cDNA O +
microarray O +
expression O +
analysis O +
showed O +
that O +
the O +
mouse O +
homologue O +
of O +
Dss1 O +
is O +
induced O +
by O +
TPA B-Chemical -
. O +

Dss1 O +
overexpression O +
was O +
detected O +
by O +
Northern O +
blot O +
analysis O +
in O +
early O +
TPA B-Chemical -
- O -
treated O +
hyperplastic O +
skins O +
and O +
in O +
JB6 O +
Cl O +
41 O -
- O -
5a O +
epidermal O +
cells O -
. O +

Interestingly O -
, O +
Dss1 O +
expression O +
was O +
also O +
shown O +
to O +
be O +
elevated O +
in O +
skin O +
papillomas O +
relative O +
to O +
normal O +
skins O -
, O +
and O +
further O +
increased O +
in O +
squamous O +
cell O +
malignancies O -
. O +

Functional O +
studies O +
by O +
ectopically O +
constitutive O +
expression O +
of O +
Dss1 O +
in O +
JB6 O +
Cl O +
41 O -
- O -
5a O +
preneoplastic O +
cells O +
strongly O +
increased O +
focus O +
formation O +
and O +
proliferation O +
of O +
these O +
cells O +
and O +
enhanced O +
efficiency O +
of O +
neoplastic O +
transformation O +
of O +
the O +
cells O +
in O +
soft O +
agar O -
. O +

These O +
results O +
strongly O +
suggest O +
that O +
Dss1 O +
is O +
a O +
TPA B-Chemical -
- O -
inducible O +
gene O +
that O +
may O +
play O +
an O +
important O +
role O +
in O +
the O +
early O +
stages O +
of O +
skin O +
carcinogenesis O -
. O +

Topoisomerase O +
I O +
protein O +
expression O +
in O +
primary O +
colorectal O +
cancer O +
and O +
lymph O +
node O +
metastases O -
. O +

Topoisomerase O +
I O +
( O -
topo O +
I O -
) O +
is O +
an O +
important O +
target O +
for O +
the O +
treatment O +
of O +
malignant O +
disease O -
, O +
especially O +
colorectal O +
cancer O -
. O +

Because O +
there O +
is O +
little O +
information O +
on O +
the O +
expression O +
of O +
topo O +
I O +
in O +
colorectal O +
tumors O -
, O +
this O +
study O +
evaluated O +
and O +
characterized O +
topo O +
I O +
protein O +
expression O +
in O +
primary O +
colorectal O +
cancer O +
and O +
lymph O +
node O +
metastases O +
and O +
studied O +
the O +
association O +
between O +
topo O +
I O +
protein O +
expression O +
and O +
clinicopathologic O +
data O -
, O +
p53 O +
status O -
, O +
and O +
proliferating O +
cell O +
nuclear O +
antigen O +
( O -
PCNA O -
) O +
status O -
. O +

Immunohistochemistry O +
assay O +
was O +
performed O +
for O +
topo O +
I O +
protein O +
expression O +
in O +
249 O +
primary O +
human O +
colorectal O +
cancer O +
and O +
42 O +
paired O +
lymph O +
node O +
metastasis O +
samples O -
. O +

Topo O +
I O +
expression O +
was O +
described O +
as O +
the O +
percentage O +
of O +
cells O +
staining O +
positive O +
for O +
topo O +
I O -
, O +
along O +
with O +
the O +
intensity O +
and O +
localization O +
of O +
the O +
staining O -
. O +

Clinicopathologic O +
data O +
( O -
sex O -
, O +
age O -
, O +
Dukes O -
' O +
stage O -
, O +
differentiation O +
grade O -
, O +
survival O +
status O -
) O -
, O +
p53 O +
status O -
, O +
and O +
PCNA O +
status O +
were O +
statistically O +
analyzed O +
for O +
association O +
with O +
topo O +
I O +
protein O +
expression O -
. O +

Topo O +
I O +
expression O +
in O +
paired O +
primary O +
lymph O +
node O +
metastases O +
were O +
studied O +
for O +
concordance O -
. O +

Topo O +
I O +
protein O +
expression O +
was O +
detected O +
in O +
127 O +
( O -
51 O -
% O -
) O +
samples O -
, O +
including O +
24.4 O -
% O +
with O +
> O -
50 O -
% O +
positive O +
tumor O +
cells O -
. O +

The O +
majority O +
had O +
nuclear O +
( O -
70.1 O -
% O -
) O +
or O +
nuclear O +
and O +
cytoplasmic O +
staining O +
( O -
17.3 O -
% O -
) O -
. O +

A O +
higher O +
percentage O +
of O +
cells O +
expressing O +
topo O +
I O +
in O +
primary O +
colorectal O +
cancer O +
was O +
significantly O +
associated O +
with O +
advanced O +
age O +
( O -
P O +
= O -
.040 O -
) O -
. O +

Patients O +
with O +
rectal O +
cancer O +
had O +
greater O +
topo O +
I O +
expression O +
than O +
those O +
with O +
colon O +
tumors O +
( O -
P O +
= O -
.029 O -
) O -
. O +

No O +
significant O +
correlation O +
was O +
found O +
between O +
topo O +
I O +
protein O +
expression O +
and O +
sex O -
, O +
Dukes O -
' O +
stage O -
, O +
differentiation O +
grade O -
, O +
survival O +
status O -
, O +
p53 O +
status O -
, O +
and O +
PCNA O +
status O -
. O +

Concordance O +
in O +
topo O +
I O +
staining O +
between O +
primary O +
and O +
lymph O +
node O +
metastases O +
was O +
observed O +
in O +
33 O +
of O +
42 O +
cases O +
( O -
P O +
= O -
.029 O -
) O -
. O +

This O +
suggests O +
that O +
the O +
activity O +
of O +
topo O +
I O +
inhibitors O +
will O +
not O +
differ O +
across O +
various O +
tumor O +
stages O -
, O +
pathology O -
, O +
and O +
patient O +
gender O -
. O +

p53 O +
and O +
PCNA O +
status O +
do O +
not O +
appear O +
to O +
influence O +
topo O +
I O +
expression O -
, O +
and O +
topo O +
I O +
has O +
no O +
apparent O +
association O +
with O +
the O +
acquisition O +
of O +
a O +
metastatic O +
phenotype O -
. O +

Topo O +
I O +
expression O +
now O +
needs O +
to O +
be O +
evaluated O +
in O +
patients O +
undergoing O +
topo O +
I O -
- O -
inhibitor O +
therapy O -
, O +
to O +
better O +
define O +
the O +
role O +
of O +
this O +
protein O +
as O +
a O +
predictive O +
marker O -
. O +

Regulation O +
of O +
transforming O +
growth O +
factor O -
- O -
beta O +
signaling O +
and O +
vascular O +
diseases O -
. O +

PURPOSE O -
: O +
Members O +
of O +
the O +
transforming O +
growth O +
factor O +
( O -
TGF O -
) O -
-beta O +
superfamily O +
play O +
critical O +
roles O +
in O +
regulation O +
of O +
various O +
cellular O +
functions O -
. O +

Dysregulation O +
of O +
the O +
signaling O +
mechanisms O +
of O +
the O +
TGF O -
- O -
beta O +
superfamily O +
proteins O +
is O +
associated O +
with O +
clinical O +
diseases O +
such O +
as O +
cancer O -
, O +
fibrotic O +
diseases O -
, O +
and O +
vascular O +
disorders O -
. O +

Therefore O -
, O +
understanding O +
these O +
signaling O +
mechanisms O +
may O +
provide O +
us O +
with O +
novel O +
ways O +
to O +
develop O +
strategies O +
for O +
treating O +
clinical O +
diseases O +
induced O +
by O +
these O +
cytokines O -
. O +

METHODS O -
: O +
This O +
review O +
discusses O +
our O +
current O +
understanding O +
of O +
the O +
mechanisms O +
of O +
TGF O -
- O -
beta O +
signaling O -
, O +
focusing O +
on O +
the O +
roles O +
of O +
TGF O -
- O -
beta O +
in O +
regulation O +
of O +
vascular O +
wall O +
cells O +
and O +
on O +
the O +
regulation O +
of O +
TGF O -
- O -
beta O +
superfamily O +
signals O +
by O +
inhibitory O +
Smads O -
. O +

[ O -
Expression O +
and O +
mutation O +
of O +
c O -
- O -
kit O +
gene O +
in O +
gastrointestinal O +
stromal O +
tumor O -
] O -
. O +

OBJECTIVE O -
: O +
To O +
investigate O +
the O +
effect O +
of O +
the O +
expression O +
and O +
mutation O +
of O +
c O -
- O -
kit O +
gene O +
and O +
its O +
relationship O +
with O +
clinical O +
pathology O +
and O +
prognosis O +
of O +
gastrointestinal O +
stromal O +
tumor O +
( O -
GIST O -
) O -
. O +

METHODS O -
: O +
Immunohistochemical O +
and O +
PCR O -
- O -
SSCP O +
techniques O +
were O +
used O +
to O +
detect O +
c O -
- O -
kit O +
protein O +
expression O +
and O +
c O -
- O -
kit O +
gene O +
exon O +
11 O +
mutation O +
in O +
82 O +
patients O +
with O +
GIST O -
. O +

RESULTS O -
: O +
The O +
positive O +
c O -
- O -
kit O +
protein O +
expression O +
and O +
c O -
- O -
kit O +
gene O +
mutation O +
rates O +
were O +
97.6 O -
% O +
( O -
80 O -
/ O -
82 O -
) O +
and O +
41.5 O -
% O +
( O -
34 O -
/ O -
82 O -
) O -
. O +

Correlating O +
the O +
results O +
of O +
these O +
two O +
methods O +
and O +
clinicopathological O +
factors O -
, O +
the O +
c O -
- O -
kit O +
expression O +
and O +
c O -
- O -
kit O +
gene O +
mutation O +
rates O +
were O +
95.0 O -
% O +
( O -
19 O -
/ O -
20 O -
) O +
and O +
0 O +
in O +
benign O +
GIST O -
, O +
and O +
were O +
98.4 O -
% O +
( O -
61 O -
/ O -
62 O -
) O -
, O +
54.8 O -
% O +
( O -
34 O -
/ O -
62 O -
) O +
in O +
malignant O +
GIST O -
. O +

Mutation O +
positive O +
GIST O +
showed O +
higher O +
frequency O +
of O +
adjacent O +
tissue O +
invasion O -
, O +
metastasis O +
and O +
recurrence O +
as O +
compared O +
with O +
mutation O +
negative O +
ones O -
. O +

CONCLUSION O -
: O +
c O -
- O -
kit O +
protein O +
is O +
an O +
important O +
diagnostic O +
marker O +
of O +
gastrointestinal O +
stromal O +
tumor O -
. O +

c O -
- O -
kit O +
gene O +
mutation O +
may O +
play O +
a O +
significant O +
role O +
in O +
the O +
pathogenesis O +
of O +
GIST O +
and O +
also O +
may O +
be O +
a O +
prognostic O +
marker O -
. O +

Enhanced O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
by O +
periodontal O +
pathogens O +
in O +
gingival O +
fibroblasts O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
has O +
recently O +
attracted O +
attention O +
as O +
a O +
potent O +
inducer O +
of O +
vascular O +
permeability O +
and O +
angiogenesis O -
. O +

Aberrant O +
angiogenesis O +
is O +
often O +
associated O +
with O +
lesion O +
formation O +
in O +
chronic O +
periodontitis O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
properties O +
of O +
VEGF O +
expression O +
in O +
human O +
gingival O +
fibroblasts O +
( O -
HGF O -
) O +
culture O -
. O +

HGF O +
were O +
stimulated O +
with O +
lipopolysaccharide B-Chemical +
( O -
LPS B-Chemical -
) O -
, O +
vesicle O +
( O -
Ve O -
) O +
and O +
outer O +
membrane O +
protein O +
( O -
OMP O -
) O +
from O +
Actinobacillus O +
actinomycetemcomitans O +
and O +
Porphyromonas O +
gingivalis O -
. O +

HGF O +
constitutively O +
produced O +
VEGF O +
and O +
levels O +
were O +
significantly O +
enhanced O +
( O -
P O +
less O +
than O +
0.01 O -
) O +
by O +
stimulation O +
with O +
Ve O +
and O +
OMP O +
from O +
A. O +
actinomycetemcomitans O +
and O +
P. O +
gingivalis O +
at O +
concentrations O +
of O +
10 O +
microg O -
/ O -
ml O +
or O +
higher O -
. O +

On O +
the O +
other O +
hand O -
, O +
VEGF O +
levels O +
were O +
not O +
increased O +
by O +
LPS B-Chemical +
stimulation O -
. O +

VEGF O +
mRNA O +
expression O +
was O +
also O +
observed O +
in O +
Ve- O +
and O +
OMP O -
- O -
stimulated O +
HGF O -
. O +

A O +
vascular O +
permeability O +
enhancement O +
( O -
VPE O -
) O +
assay O +
was O +
performed O +
using O +
guinea O +
pigs O +
to O +
ascertain O +
whether O +
supernatant O +
from O +
cultures O +
of O +
Ve- O +
and O +
OMP O -
- O -
stimulated O +
HGF O +
enhance O +
vascular O +
permeability O +
in O +
vivo O -
. O +

Supernatant O +
from O +
cultures O +
of O +
Ve- O +
and O +
OMP O -
- O -
stimulated O +
HGF O +
strongly O +
induced O +
VPE O -
. O +

This O +
was O +
markedly O +
suppressed O +
upon O +
simultaneous O +
injection O +
of O +
anti O -
- O -
VEGF O +
polyclonal O +
antibodies O +
with O +
the O +
supernatant O -
. O +

Heating O +
and O +
protease O +
treatment O +
of O +
the O +
stimulants O +
reduced O +
the O +
VEGF O +
enhancing O +
levels O +
in O +
Ve O +
and O +
OMP O +
in O +
vitro O -
. O +

These O +
results O +
suggest O +
that O +
Ve O +
and O +
OMP O +
may O +
be O +
crucial O +
heat O -
- O -
labile O +
and O +
protease O -
- O -
sensitive O +
components O +
of O +
periodontal O +
pathogens O +
that O +
enhance O +
VEGF O +
expression O -
. O +

In O +
addition O -
, O +
VEGF O +
might O +
be O +
associated O +
with O +
the O +
etiology O +
of O +
periodontitis O +
in O +
its O +
early O +
stages O +
according O +
to O +
neovascularization O +
stimulated O +
by O +
periodontal O +
pathogens O +
causing O +
swelling O +
and O +
edema O -
. O +

Postoperative O +
progression O +
of O +
pulmonary O +
metastasis O +
in O +
osteosarcoma O -
. O +

Early O +
relapse O +
with O +
distant O +
metastasis O +
often O +
is O +
observed O +
in O +
patients O +
with O +
cancer O +
after O +
resection O +
of O +
the O +
primary O +
tumor O -
. O +

It O +
is O +
considered O +
that O +
resection O +
of O +
the O +
primary O +
tumor O +
induces O +
activation O +
of O +
systemic O +
angiogenesis O +
and O +
enhances O +
progression O +
of O +
remote O +
metastasis O -
. O +

The O +
authors O +
show O +
that O +
resection O +
of O +
the O +
primary O +
osteosarcoma O +
tumor O +
enhances O +
progression O +
of O +
pulmonary O +
metastasis O +
in O +
animal O +
osteosarcoma O +
models O -
. O +

Matrigel O +
plug O +
neovascularization O +
assay O +
revealed O +
that O +
systemic O +
angiogenic O +
activity O +
was O +
elevated O +
after O +
primary O +
tumor O +
removal O +
( O -
tumor O +
intact O +
group O -
, O +
1.61 O +
+ O -
/- O +

0.21 O +
g O -
/ O -
dL O -
; O +
tumor O +
removed O +
group O -
, O +
4.92 O +
+ O -
/- O +

0.35 O +
g O -
/ O -
dL O -
) O -
. O +

In O +
addition O -
, O +
serum O +
concentration O +
of O +
the O +
angiogenesis O +
inhibitor O -
, O +
endostatin O -
, O +
decreased O +
significantly O +
after O +
primary O +
tumor O +
removal O -
. O +

Treatment O +
with O +
the O +
antiangiogenic O +
reagent O +
TNP-470 B-Chemical +
suppressed O +
postoperative O +
progression O +
of O +
pulmonary O +
metastasis O -
. O +

These O +
results O +
indicate O +
the O +
possibility O +
that O +
activation O +
of O +
angiogenic O +
activity O +
after O +
resection O +
of O +
osteosarcoma O +
tumors O +
enhances O +
progression O +
of O +
pulmonary O +
metastasis O -
. O +

The O +
current O +
data O +
also O +
suggest O +
that O +
administration O +
of O +
antiangiogenic O +
reagents O +
can O +
prevent O +
progression O +
of O +
pulmonary O +
metastasis O +
in O +
osteosarcoma O +
postoperatively O -
. O +

Arteriogenesis O -
: O +
the O +
development O +
and O +
growth O +
of O +
collateral O +
arteries O -
. O +

In O +
patients O +
with O +
atherosclerotic O +
vascular O +
diseases O -
, O +
collateral O +
vessels O +
bypassing O +
major O +
arterial O +
obstructions O +
have O +
frequently O +
been O +
observed O -
. O +

This O +
may O +
explain O +
why O +
some O +
patients O +
remain O +
without O +
symptoms O +
or O +
signs O +
of O +
ischemia O -
. O +

The O +
term O +
" O -
arteriogenesis O -
" O +
was O +
introduced O +
to O +
differentiate O +
the O +
formation O +
of O +
collateral O +
arteries O +
from O +
angiogenesis O -
, O +
which O +
mainly O +
occurs O +
in O +
the O +
ischemic O -
, O +
collateral O +
flow O -
- O -
dependent O +
tissue O -
. O +

Many O +
observations O +
in O +
various O +
animal O +
models O +
and O +
humans O +
support O +
that O +
the O +
remodeling O +
of O +
preexisting O +
collateral O +
vessels O +
is O +
the O +
mechanism O +
of O +
collateral O +
artery O +
formation O -
. O +

This O +
remodeling O +
process O +
seems O +
to O +
be O +
mainly O +
flow O -
- O -
mediated O -
. O +

It O +
involves O +
endothelial O +
cell O +
activation O -
, O +
basal O +
membrane O +
degradation O -
, O +
leukocyte O +
invasion O -
, O +
proliferation O +
of O +
vascular O +
cells O -
, O +
neointima O +
formation O +
( O -
in O +
most O +
species O +
studied O -
) O -
, O +
and O +
changes O +
of O +
the O +
extracellular O +
matrix O -
. O +

The O +
contribution O +
of O +
ischemia O +
to O +
arteriogenesis O +
is O +
still O +
unclear O -
, O +
but O +
arteriogenesis O +
clearly O +
can O +
occur O +
in O +
the O +
absence O +
of O +
any O +
significant O +
ischemia O -
. O +

It O +
is O +
questionable O -
, O +
whether O +
collateral O +
arteries O +
also O +
form O +
de O +
novo O +
in O +
ischemic O +
vascular O +
diseases O -
. O +

A O +
better O +
understanding O +
of O +
the O +
mechanisms O +
of O +
arteriogenesis O +
will O +
be O +
important O +
for O +
the O +
design O +
of O +
more O +
effective O +
strategies O +
for O +
the O +
treatment O +
of O +
patients O +
with O +
ischemic O +
vascular O +
diseases O -
. O +

Possible O +
role O +
of O +
cyclooxygenase O +
II O +
in O +
the O +
acquisition O +
of O +
ovarian O +
luteal O +
function O +
in O +
rodents O -
. O +

The O +
development O +
of O +
the O +
corpus O +
luteum O +
( O -
CL O -
) O -
, O +
which O +
involves O +
angiogenesis O -
, O +
is O +
essential O +
for O +
the O +
establishment O +
of O +
early O +
pregnancy O -
. O +

We O +
investigated O +
the O +
roles O +
of O +
the O +
prostaglandin B-Chemical +
synthases O +
cyclooxygenase O +
( O -
COX O -
) O +
I O +
and O +
COX O -
- O -
II O +
in O +
angiogenesis O +
and O +
progesterone B-Chemical +
production O +
in O +
the O +
newly O +
formed O +
CL O -
, O +
using O +
inhibitors O +
of O +
the O +
COX O +
enzymes O +
and O +
the O +
gonadotropin O -
- O -
induced O +
pseudopregnant O +
rat O +
as O +
a O +
model O -
. O +

Injection O +
of O +
indomethacin B-Chemical -
, O +
a O +
nonselective O +
COX O +
inhibitor O -
, O +
on O +
the O +
day O +
of O +
ovulation O +
and O +
the O +
following O +
day O +
decreased O +
serum O +
levels O +
of O +
progesterone B-Chemical -
, O +
as O +
did O +
injection O +
of O +
the O +
selective O +
COX O -
- O -
II O +
inhibitor O +
NS-398 B-Chemical -
. O +

In O +
contrast O -
, O +
a O +
selective O +
COX O -
- O -
I O +
inhibitor O -
, O +
SC-560 B-Chemical -
, O +
had O +
no O +
effect O +
on O +
serum O +
progesterone B-Chemical +
concentrations O -
. O +

None O +
of O +
the O +
inhibitors O +
had O +
any O +
effect O +
on O +
the O +
weight O +
of O +
the O +
superovulated O +
ovaries O +
or O +
on O +
the O +
synthesis O +
of O +
progesterone B-Chemical +
by O +
cultured O +
luteal O +
cells O -
. O +

To O +
determine O +
whether O +
changes O +
in O +
angiogenesis O +
are O +
responsible O +
for O +
the O +
decrease O +
in O +
progesterone B-Chemical +
synthesis O -
, O +
we O +
measured O +
hemoglobin O +
and O +
CD34 O +
levels O +
in O +
luteinized O +
ovaries O +
following O +
injection O +
of O +
COX O +
inhibitors O +
and O +
measured O +
the O +
relative O +
frequency O +
of O +
cells O +
positive O +
for O +
platelet O -
- O -
endothelial O +
cell O +
adhesion O +
molecule O +
as O +
a O +
specific O +
marker O +
for O +
endothelial O +
cells O -
. O +

All O +
of O +
these O +
parameters O +
were O +
reduced O +
by O +
the O +
COX O -
- O -
II O +
inhibitors O -
, O +
suggesting O +
that O +
changes O +
in O +
the O +
vasculature O +
are O +
responsible O +
for O +
the O +
decrease O +
in O +
serum O +
progesterone B-Chemical -
. O +

Histological O +
examination O +
of O +
ovarian O +
corrosion O +
casts O +
indicated O +
that O +
NS-398 B-Chemical +
inhibited O +
the O +
establishment O +
of O +
luteal O +
capillary O +
vessels O +
following O +
the O +
injection O +
of O +
hCG O -
. O +

The O +
results O +
are O +
consistent O +
with O +
the O +
hypothesis O +
that O +
the O +
activity O +
of O +
COX O -
- O -
II O +
is O +
associated O +
with O +
the O +
formation O +
of O +
functional O +
CL O +
via O +
its O +
stimulation O +
of O +
angiogenesis O -
. O +

Antiapoptotic O +
effect O +
of O +
coagulation O +
factor O +
VIIa O -
. O +

Binding O +
of O +
factor O +
VIIa O +
( O -
FVIIa O -
) O +
to O +
its O +
cellular O +
receptor O +
tissue O +
factor O +
( O -
TF O -
) O +
was O +
previously O +
shown O +
to O +
induce O +
various O +
intracellular O +
signaling O +
events O -
, O +
which O +
were O +
thought O +
to O +
be O +
responsible O +
for O +
TF O -
- O -
mediated O +
biologic O +
effects O -
, O +
including O +
angiogenesis O -
, O +
tumor O +
metastasis O -
, O +
and O +
restenosis O -
. O +

To O +
understand O +
the O +
mechanisms O +
behind O +
these O +
processes O -
, O +
we O +
have O +
examined O +
the O +
effect O +
of O +
FVIIa O +
on O +
apoptosis O -
. O +

Serum O +
deprivation O -
- O -
induced O +
apoptosis O +
of O +
BHK O -
( O -
+TF O -
) O +
cells O +
was O +
characterized O +
by O +
apoptotic O +
blebs O -
, O +
nuclei O +
with O +
chromatin O -
- O -
condensed O +
bodies O -
, O +
DNA O +
degradation O -
, O +
and O +
activation O +
of O +
caspase O +
3 O -
. O +

FVIIa O +
markedly O +
decreased O +
the O +
number O +
of O +
cells O +
with O +
apoptotic O +
morphology O +
and O +
prevented O +
the O +
DNA O +
degradation O +
as O +
measured O +
by O +
means O +
of O +
TdT O -
- O -
mediated O +
dUTP B-Chemical +
nick O +
end O +
labeling O +
( O -
TUNEL O -
) O -
. O +

The O +
antiapoptotic O +
effect O +
of O +
FVIIa O +
was O +
confirmed O +
by O +
the O +
observation O +
that O +
FVIIa O +
attenuated O +
caspase O +
3 O +
activation O -
. O +

FVIIa O -
- O -
induced O +
antiapoptotic O +
effect O +
was O +
dependent O +
on O +
its O +
proteolytic O +
activity O +
and O +
TF O +
but O +
independent O +
of O +
factor O +
Xa O +
and O +
thrombin O -
. O +

FVIIa O -
- O -
induced O +
cell O +
survival O +
correlated O +
with O +
the O +
activation O +
of O +
Akt O +
and O +
was O +
inhibited O +
markedly O +
by O +
the O +
specific O +
PI3-kinase O +
inhibitor O -
, O +
LY294002 B-Chemical -
. O +

Blocking O +
the O +
activation O +
of O +
p44 O -
/ O -
42 O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
by O +
the O +
specific O +
mitogen O -
- O -
induced O +
extracellular O +
kinase O +
( O -
MEK O -
) O +
inhibitor O -
, O +
U0126 B-Chemical -
, O +
impaired O +
modestly O +
the O +
ability O +
of O +
FVIIa O +
to O +
promote O +
cell O +
survival O -
. O +

In O +
conclusion O -
, O +
FVIIa O +
binding O +
to O +
TF O +
provided O +
protection O +
against O +
apoptosis O +
induced O +
by O +
growth O +
factor O +
deprivation O -
, O +
primarily O +
through O +
activation O +
of O +
PI3-kinase O -
/ O -
Akt O +
pathway O -
, O +
and O +
to O +
a O +
lesser O +
extent O -
, O +
p44 O -
/ O -
42 O +
MAPK O +
pathway O -
. O +

Solid O +
tumor O +
therapy O -
: O +
manipulation O +
of O +
the O +
vasculature O +
with O +
TNF O -
. O +

Drug O +
delivery O +
to O +
solid O +
tumors O +
is O +
one O +
of O +
the O +
most O +
challenging O +
aspects O +
in O +
cancer O +
therapy O -
. O +

Whereas O +
agents O +
seem O +
promising O +
in O +
the O +
test O +
tube O -
, O +
clinical O +
trials O +
often O +
fail O +
due O +
to O +
unfavorable O +
pharmacokinetics O -
, O +
poor O +
delivery O -
, O +
low O +
local O +
concentrations O -
, O +
and O +
limited O +
accumulation O +
in O +
the O +
target O +
cell O -
. O +

A O +
major O +
step O +
forwards O +
in O +
the O +
treatment O +
of O +
solid O +
tumors O +
is O +
the O +
recognition O +
of O +
the O +
tumor O -
- O -
associated O +
vasculature O +
as O +
an O +
important O +
target O +
for O +
therapy O -
. O +

Inhibition O +
of O +
tumor O +
vascular O +
development O +
has O +
a O +
direct O +
effect O +
on O +
the O +
growth O +
and O +
progression O +
of O +
the O +
tumor O -
. O +

Destruction O +
of O +
an O +
existing O +
vasculature O +
also O +
directly O +
inflicts O +
serious O +
damage O +
to O +
the O +
tumor O +
cell O -
. O +

Moreover O -
, O +
the O +
tumor O +
vascular O +
bed O +
can O +
be O +
manipulated O +
facilitating O +
enhanced O +
permissiveness O +
of O +
the O +
tumor O +
for O +
administered O +
chemotherapeutics O -
. O +

In O +
this O +
review O -
, O +
we O +
focus O +
on O +
the O +
use O +
of O +
tumor O +
necrosis O +
factor O +
alpha O +
( O -
TNF O -
) O +
in O +
local O +
and O +
systemic O +
therapy O +
in O +
conjunction O +
with O +
chemotherapy O -
. O +

In O +
these O +
settings O +
TNF O +
demonstrates O +
potent O +
and O +
selective O +
activity O +
on O +
the O +
tumor O +
vascular O +
bed O -
, O +
which O +
strongly O +
improves O +
tumor O +
response O -
. O +

Truncated O +
galectin-3 O +
inhibits O +
tumor O +
growth O +
and O +
metastasis O +
in O +
orthotopic O +
nude O +
mouse O +
model O +
of O +
human O +
breast O +
cancer O -
. O +

PURPOSE O -
: O +
The O +
goal O +
of O +
this O +
research O +
was O +
to O +
evaluate O +
a O +
potential O +
therapeutic O +
agent O +
for O +
breast O +
cancer O +
based O +
on O +
galectin-3 O +
that O +
has O +
been O +
implicated O +
in O +
tumorigenicity O +
and O +
metastasis O +
of O +
breast O +
cancer O -
. O +

The O +
hypothesis O +
was O +
that O +
therapy O +
with O +
NH O -
( O -
2 O -
) O -
-terminally O +
truncated O +
form O +
of O +
galectin-3 O +
( O -
galectin-3C O -
) O +
will O +
be O +
efficacious O +
for O +
reduction O +
in O +
tumor O +
growth O +
and O +
for O +
inhibition O +
of O +
metastases O -
. O +

EXPERIMENTAL O +
DESIGN O -
: O +
Recombinant O +
human O +
galectin-3 O +
was O +
produced O +
in O +
Escherichia O +
coli O +
from O +
which O +
galectin-3C O +
was O +
derived O +
by O +
collagenase O +
enzyme O +
digestion O -
. O +

Toxicity O -
, O +
pharmacokinetic O -
, O +
and O +
organ O +
biodistribution O +
studies O +
were O +
performed O +
in O +
nude O +
mice O -
. O +

For O +
efficacy O +
studies O -
, O +
nude O +
mice O +
bearing O +
orthotopically O +
implanted O +
tumors O +
derived O +
from O +
breast O +
cancer O +
cell O +
line O +
MDA O -
- O -
MB-435 O +
were O +
treated O +
with O +
galectin-3C O +
or O +
a O +
vehicle O +
control O +
i.m O -
. O +

twice O +
daily O +
for O +
90 O +
days O -
. O +

RESULTS O -
: O +
The O +
maximum O +
tolerated O +
dose O +
of O +
galectin-3C O +
in O +
nude O +
mice O +
was O +
determined O +
to O +
be O +
> O -
125 O +
mg O -
/ O -
kg O +
without O +
overt O +
adverse O +
effects O -
. O +

The O +
elimination O +
half O -
- O -
life O +
when O +
administered O +
i.m O -
. O +
was O +
found O +
to O +
be O +
3.0 O +
h O +
in O +
the O +
serum O +
and O +
4.3 O +
h O +
in O +
the O +
cellular O +
fraction O +
of O +
the O +
blood O -
. O +

Organ O +
biodistribution O +
studies O +
revealed O +
that O +
galectin-3C O +
localized O +
in O +
the O +
liver O -
, O +
kidneys O -
, O +
and O +
spleen O +
but O +
not O +
in O +
the O +
heart O +
or O +
lungs O -
. O +

We O +
found O +
that O +
the O +
mean O +
tumor O +
volumes O +
and O +
weights O +
were O +
statistically O +
significantly O +
less O +
in O +
mice O +
treated O +
with O +
galectin-3C O +
compared O +
with O +
control O +
mice O -
, O +
and O +
that O +
fewer O +
numbers O +
of O +
mice O +
exhibited O +
lymph O +
node O +
metastases O +
in O +
the O +
treated O +
group O +
compared O +
with O +
the O +
control O +
group O -
. O +

CONCLUSIONS O -
: O +
Galectin-3C O +
is O +
not O +
overtly O +
toxic O -
, O +
and O +
is O +
efficacious O +
in O +
reducing O +
metastases O +
and O +
tumor O +
volumes O +
and O +
weights O +
in O +
primary O +
tumors O +
in O +
an O +
orthotopic O +
nude O +
mouse O +
model O +
of O +
human O +
breast O +
cancer O -
. O +

Comparison O +
of O +
tissue O +
integration O +
between O +
polyester B-Chemical +
and O +
polypropylene B-Chemical +
prostheses O +
in O +
the O +
preperitoneal O +
space O -
. O +

Tissue O +
integration O +
and O +
implant O +
characteristics O +
of O +
various O +
biomaterials O +
commonly O +
used O +
for O +
inguinal O +
hernia O +
repair O +
have O +
not O +
been O +
studied O +
extensively O -
. O +

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
compare O +
behavior O +
and O +
tissue O +
response O +
between O +
two O +
new O +
polyester B-Chemical +
prostheses O +
and O +
a O +
commonly O +
used O +
polypropylene B-Chemical +
( O -
PP B-Chemical -
) O +
mesh O -
. O +

The O +
polyester B-Chemical +
prostheses O +
utilized O +
were O +
polyester B-Chemical +
flat O +
( O -
PF O -
) O +
and O +
polyester B-Chemical +
soft O +
three O -
- O -
dimensional O +
( O -
PS O -
) O -
; O +
the O +
PP O +
mesh O +
utilized O +
was O +
Marlex O -
. O +

Eight O +
randomly O +
assigned O +
4 O +
x O +
4-cm2 O +
pieces O +
of O +
two O +
different O +
meshes O +
were O +
fixed O +
in O +
the O +
preperitoneal O +
space O +
with O +
a O +
centrally O +
placed O +
single O +
suture O -
. O +

Gross O +
evaluation O +
included O +
shrinkage O +
and O +
stiffness O -
. O +

Histological O +
evaluation O +
included O +
amount O +
of O +
fibrous O +
and O +
fat O +
encapsulation O -
, O +
connective O +
tissue O -
, O +
foreign O -
- O -
body O +
reaction O -
, O +
neovascularization O -
, O +
hemorrhage O -
, O +
necrosis O -
, O +
and O +
exudate O -
. O +

Evaluations O +
were O +
graded O +
on O +
a O +
zero O +
to O +
four O +
scale O -
. O +

The O +
area O +
and O +
the O +
area O +
ratio O +
were O +
measured O +
using O +
a O +
calibrated O +
micrometer O -
. O +

PP B-Chemical +
mesh O +
resulted O +
in O +
more O +
fibrous O +
encapsulation O +
and O +
stiffness O +
than O +
PF O +
and O +
PS O +
prostheses O -
. O +

PP B-Chemical +
also O +
resulted O +
in O +
less O +
connective O +
tissue O +
formation O +
and O +
foreign O -
- O -
body O +
reaction O +
than O +
PF O +
and O +
PS O +
prostheses O -
. O +

There O +
was O +
no O +
difference O +
in O +
fat O +
encapsulation O -
, O +
necrosis O -
, O +
hemorrhage O -
, O +
or O +
exudate O +
between O +
prostheses O -
. O +

Both O +
polyester B-Chemical +
prostheses O +
( O -
PF O +
and O +
PS O -
) O +
have O +
better O +
tissue O +
integration O +
than O +
the O +
PP B-Chemical +
mesh O -
, O +
as O +
evidenced O +
by O +
the O +
higher O +
amount O +
of O +
connective O +
tissue O +
and O +
lower O +
extent O +
of O +
fibrous O +
encapsulation O -
. O +

Therapeutic O +
targeting O +
of O +
the O +
survivin O +
pathway O +
in O +
cancer O -
: O +
initiation O +
of O +
mitochondrial O +
apoptosis O +
and O +
suppression O +
of O +
tumor O -
- O -
associated O +
angiogenesis O -
. O +

PURPOSE O -
: O +
Molecular O +
antagonists O +
of O +
the O +
inhibitor O +
of O +
apoptosis O +
protein O +
survivin O +
have O +
shown O +
promise O +
as O +
novel O +
anticancer O +
strategies O +
for O +
triggering O +
tumor O +
cell O +
apoptosis O -
, O +
dysregulating O +
mitotic O +
progression O -
, O +
and O +
inhibiting O +
tumor O +
growth O +
in O +
preclinical O +
models O -
. O +

However O -
, O +
how O +
survivin O +
couples O +
to O +
the O +
cell O +
death O +
machinery O +
has O +
remained O +
elusive O -
, O +
and O +
the O +
relevant O +
cellular O +
targets O +
of O +
survivin O +
antagonists O +
have O +
not O +
been O +
completely O +
elucidated O -
. O +

Experimental O +
Design O -
: O +
Human O +
umbilical O +
vein O +
and O +
dermal O +
microvascular O +
endothelial O +
cells O +
were O +
infected O +
with O +
replication O -
- O -
deficient O +
adenoviruses O +
encoding O +
survivin O +
( O -
pAd O -
- O -
Survivin O -
) O -
, O +
green O +
fluorescent O +
protein O +
( O -
pAd O -
- O -
GFP O -
) O -
, O +
or O +
a O +
phosphorylation O -
- O -
defective O +
survivin O +
Thr O -
( O -
34 O -
) O -
-->Ala O +
( O -
pAd O -
- O -
T34A O -
) O +
dominant O +
negative O +
mutant O -
. O +

The O +
effect O +
of O +
wild O -
- O -
type O +
or O +
mutant O +
survivin O +
was O +
investigated O +
on O +
capillary O +
network O +
stability O -
, O +
endothelial O +
cell O +
viability O -
, O +
and O +
caspase O +
activation O +
in O +
vitro O +
and O +
on O +
kinetics O +
of O +
tumor O +
growth O +
and O +
development O +
of O +
angiogenesis O +
in O +
a O +
breast O +
cancer O +
xenograft O +
model O +
in O +
vivo O -
. O +

The O +
cell O +
death O +
pathway O +
initiated O +
by O +
survivin O +
targeting O +
was O +
mapped O +
with O +
respect O +
to O +
cytochrome O +
c O +
release O -
, O +
changes O +
in O +
mitochondrial O +
transmembrane O +
potential O -
, O +
and O +
apoptosome O +
requirements O +
using O +
mouse O +
embryonic O +
fibroblasts O +
deficient O +
in O +
Apaf-1 O +
or O +
caspase-9 O -
. O +

RESULTS O -
: O +
Adenoviral O +
transduction O +
of O +
endothelial O +
cells O +
with O +
pAd O -
- O -
Survivin O +
inhibited O +
growth O +
factor O +
deprivation- O +
or O +
ceramide B-Chemical -
- O -
induced O +
apoptosis O -
, O +
reduced O +
caspase-3 O +
and O +
-7 O +
generation O -
, O +
and O +
stabilized O +
three O -
- O -
dimensional O +
capillary O +
networks O +
in O +
vitro O -
. O +

Conversely O -
, O +
expression O +
of O +
pAd O -
- O -
T34A O +
caused O +
apoptosis O +
in O +
umbilical O +
vein O +
and O +
dermal O +
microvascular O +
endothelial O +
cells O +
and O +
resulted O +
in O +
caspase-3 O +
activity O -
. O +

Cell O +
death O +
induced O +
by O +
survivin O +
targeting O +
exhibited O +
the O +
hallmarks O +
of O +
mitochondrial O -
- O -
dependent O +
apoptosis O +
with O +
release O +
of O +
cytochrome O +
c O +
and O +
loss O +
of O +
mitochondrial O +
transmembrane O +
potential O +
and O +
was O +
suppressed O +
in O +
Apaf-1 O +
or O +
caspase-9 O +
knockout O +
mouse O +
embryonic O +
fibroblasts O -
. O +

When O +
injected O +
in O +
human O +
breast O +
cancer O +
xenografts O -
, O +
pAd O -
- O -
T34A O +
inhibited O +
growth O +
of O +
established O +
tumors O +
and O +
triggered O +
tumor O +
cell O +
apoptosis O +
in O +
vivo O -
. O +

This O +
was O +
associated O +
with O +
a O +
approximately O +
60 O -
% O +
reduction O +
in O +
tumor O -
- O -
derived O +
blood O +
vessels O +
by O +
quantitative O +
morphometry O +
of O +
CD31-stained O +
tumor O +
areas O -
, O +
and O +
appearance O +
of O +
endothelial O +
cell O +
apoptosis O +
by O +
internucleosomal O +
DNA O +
fragmentation O +
in O +
vivo O -
. O +

CONCLUSIONS O -
: O +
Survivin O +
functions O +
as O +
a O +
novel O +
upstream O +
regulator O +
of O +
mitochondrial O -
- O -
dependent O +
apoptosis O -
, O +
and O +
molecular O +
targeting O +
of O +
this O +
pathway O +
results O +
in O +
anticancer O +
activity O +
via O +
a O +
dual O +
mechanism O +
of O +
induction O +
of O +
tumor O +
cell O +
apoptosis O +
and O +
suppression O +
of O +
angiogenesis O -
. O +

Integration O +
of O +
interferon O -
- O -
alpha O -
/ O -
beta O +
signalling O +
to O +
p53 O +
responses O +
in O +
tumour O +
suppression O +
and O +
antiviral O +
defence O -
. O +

Swift O +
elimination O +
of O +
undesirable O +
cells O +
is O +
an O +
important O +
feature O +
in O +
tumour O +
suppression O +
and O +
immunity O -
. O +

The O +
tumour O +
suppressor O +
p53 O +
and O +
interferon O -
- O -
alpha O +
and O +
-beta O +
( O -
IFN O -
- O -
alpha O -
/ O -
beta O -
) O +
are O +
essential O +
for O +
the O +
induction O +
of O +
apoptosis O +
in O +
cancerous O +
cells O +
and O +
in O +
antiviral O +
immune O +
responses O -
, O +
respectively O -
, O +
but O +
little O +
is O +
known O +
about O +
their O +
interrelationship O -
. O +

Here O +
we O +
show O +
that O +
transcription O +
of O +
the O +
p53 O +
gene O +
is O +
induced O +
by O +
IFN O -
- O -
alpha O -
/ O -
beta O -
, O +
accompanied O +
by O +
an O +
increase O +
in O +
p53 O +
protein O +
level O -
. O +

IFN O -
- O -
alpha O -
/ O -
beta O +
signalling O +
itself O +
does O +
not O +
activate O +
p53 O -
; O +
rather O -
, O +
it O +
contributes O +
to O +
boosting O +
p53 O +
responses O +
to O +
stress O +
signals O -
. O +

We O +
show O +
examples O +
in O +
which O +
p53 O +
gene O +
induction O +
by O +
IFN O -
- O -
alpha O -
/ O -
beta O +
contributes O +
to O +
tumour O +
suppression O -
. O +

Furthermore O -
, O +
we O +
show O +
that O +
p53 O +
is O +
activated O +
in O +
virally O +
infected O +
cells O +
to O +
evoke O +
an O +
apoptotic O +
response O +
and O +
that O +
p53 O +
is O +
critical O +
for O +
antiviral O +
defence O +
of O +
the O +
host O -
. O +

Our O +
study O +
reveals O +
a O +
hitherto O +
unrecognized O +
link O +
between O +
p53 O +
and O +
IFN O -
- O -
alpha O -
/ O -
beta O +
in O +
tumour O +
suppression O +
and O +
antiviral O +
immunity O -
, O +
which O +
may O +
have O +
therapeutic O +
implications O -
. O +

Proliferative O +
diabetic O +
retinopathy O +
is O +
associated O +
with O +
a O +
low O +
level O +
of O +
the O +
natural O +
ocular O +
anti O -
- O -
angiogenic O +
agent O +
pigment O +
epithelium O -
- O -
derived O +
factor O +
( O -
PEDF O -
) O +
in O +
aqueous O +
humor O -
. O +

a O +
pilot O +
study O -
. O +

Retinopathy O +
is O +
the O +
most O +
common O +
microvascular O +
diabetes O +
complication O +
and O +
represents O +
a O +
major O +
threat O +
to O +
the O +
eyesight O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
address O +
the O +
role O +
of O +
pro- O +
and O +
anti O -
- O -
angiogenic O +
molecules O +
in O +
diabetic O +
retinopathy O +
in O +
the O +
aqueous O +
humor O +
of O +
the O +
eye O -
. O +

Aqueous O +
humor O +
was O +
collected O +
at O +
cataract O +
surgery O +
from O +
19 O +
diabetic O +
patients O +
and O +
from O +
13 O +
age- O +
and O +
sex O -
- O -
matched O +
normoglycemic O +
controls O -
. O +

Levels O +
of O +
pro O -
- O -
angiogenic O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
and O +
angiogenic O +
inhibitor O +
pigment O +
epithelium O -
- O -
derived O +
factor O +
( O -
PEDF O -
) O +
were O +
determined O -
. O +

Angiogenic O +
activity O +
of O +
the O +
aqueous O +
humor O +
was O +
quantified O +
by O +
measuring O +
its O +
effect O +
on O +
the O +
migration O +
of O +
capillary O +
endothelial O +
cells O -
. O +

In O +
the O +
aqueous O +
fluid O -
, O +
VEGF O +
levels O +
were O +
increased O +
in O +
diabetics O +
( O -
mean O +
values O -
: O +
501 O +
vs. O +
367 O +
pg O -
/ O -
ml O -
; O +
p O +
= O +
0.05 O -
) O -
, O +
compared O +
to O +
controls O -
. O +

PEDF O +
was O +
found O +
to O +
be O +
decreased O +
in O +
diabetics O +
( O -
mean O +
values O -
: O +
2080 O +
vs. O +
5780 O +
ng O -
/ O -
ml O -
; O +
p O +
= O +
0.04 O -
) O +
compared O +
to O +
controls O -
. O +

In O +
seven O +
diabetic O +
patients O +
with O +
proliferative O +
retinopathy O -
, O +
the O +
most O +
profound O +
finding O +
was O +
a O +
significant O +
decrease O +
of O +
the O +
PEDF O +
level O +
( O -
mean O +
value O -
: O +
237 O +
ng O -
/ O -
ml O -
) O -
, O +
whereas O +
VEGF O +
levels O +
were O +
comparable O +
to O +
diabetic O +
patients O +
without O +
proliferation O +
( O -
mean O +
value O -
: O +
3153 O -
; O +
p O +
= O +
0.003 O -
) O -
. O +

Angiogenic O +
activity O +
in O +
samples O +
of O +
patients O +
from O +
the O +
control O +
group O +
was O +
generally O +
inhibitory O +
due O +
to O +
PEDF O -
, O +
and O +
inhibition O +
was O +
blocked O +
by O +
neutralizing O +
antibodies O +
to O +
PEDF O -
. O +

Likewise O -
, O +
in O +
diabetics O +
without O +
proliferation O -
, O +
angiogenic O +
activity O +
was O +
also O +
blocked O +
by O +
antibodies O +
to O +
PEDF O -
. O +

We O +
will O +
demonstrate O +
here O +
that O +
the O +
level O +
of O +
the O +
natural O +
ocular O +
anti O -
- O -
angiogenic O +
agent O +
PEDF O +
is O +
inversely O +
associated O +
with O +
proliferative O +
retinopathy O -
. O +

PEDF O +
is O +
an O +
important O +
negative O +
regulator O +
of O +
angiogenic O +
activity O +
of O +
aqueous O +
humor O -
. O +

Our O +
data O +
may O +
have O +
implications O +
for O +
the O +
development O +
of O +
novel O +
regimens O +
for O +
diabetic O +
retinopathy O -
. O +

T140 B-Chemical +
analogs I-Chemical +
as O +
CXCR4 O +
antagonists O +
identified O +
as O +
anti O -
- O -
metastatic O +
agents O +
in O +
the O +
treatment O +
of O +
breast O +
cancer O -
. O +

A O +
chemokine O +
receptor O -
, O +
CXCR4 O -
, O +
and O +
its O +
endogenous O +
ligand O -
, O +
stromal O +
cell O -
- O -
derived O +
factor-1 O +
( O -
SDF-1 O -
) O -
, O +
have O +
been O +
recognized O +
to O +
be O +
involved O +
in O +
the O +
metastasis O +
of O +
several O +
types O +
of O +
cancers O -
. O +

T140 B-Chemical +
analogs I-Chemical +
are O +
peptidic O +
CXCR4 O +
antagonists O +
composed O +
of O +
14 O +
amino O +
acid O +
residues O +
that O +
were O +
previously O +
developed O +
as O +
anti O -
- O -
HIV O +
agents O +
having O +
inhibitory O +
activity O +
against O +
HIV O -
- O -
entry O +
through O +
its O +
co O -
- O -
receptor O -
, O +
CXCR4 O -
. O +

Herein O -
, O +
we O +
report O +
that O +
these O +
compounds O +
effectively O +
inhibited O +
SDF-1-induced O +
migration O +
of O +
human O +
breast O +
cancer O +
cells O +
( O -
MDA O -
- O -
MB-231 O -
) O -
, O +
human O +
leukemia O +
T O +
cells O +
( O -
Sup O -
- O -
T1 O -
) O +
and O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
at O +
concentrations O +
of O +
10 O -
- O -
100 O +
nM O +
in O +
vitro O -
. O +

Furthermore O -
, O +
slow O +
release O +
administration O +
by O +
subcutaneous O +
injection O +
using O +
an O +
Alzet O +
osmotic O +
pump O +
of O +
a O +
potent O +
and O +
bio O -
- O -
stable O +
T140 B-Chemical +
analog I-Chemical -
, O +
4F B-Chemical -
- I-Chemical -
benzoyl I-Chemical -
- I-Chemical -
TN14003 I-Chemical -
, O +
gave O +
a O +
partial O -
, O +
but O +
statistically O +
significant O +
( O -
P< O -
/ O -
=0.05 O +
( O -
t O -
- O -
test O -
) O -
) O +
reduction O +
in O +
pulmonary O +
metastasis O +
of O +
MDA O -
- O -
MB-231 O +
in O +
SCID O +
mice O -
, O +
even O +
though O +
no O +
attempt O +
was O +
made O +
to O +
inhibit O +
other O +
important O +
targets O +
such O +
as O +
CCR7 O -
. O +

These O +
results O +
suggest O +
that O +
T140 B-Chemical +
analogs I-Chemical +
have O +
potential O +
use O +
for O +
cancer O +
therapy O -
, O +
and O +
that O +
small O +
molecular O +
CXCR4 O +
antagonists O +
could O +
potentially O +
replace O +
neutralizing O +
antibodies O +
as O +
anti O -
- O -
metastatic O +
agents O +
for O +
breast O +
cancer O -
. O +

CCL16 O +
activates O +
an O +
angiogenic O +
program O +
in O +
vascular O +
endothelial O +
cells O -
. O +

Besides O +
regulating O +
leukocyte O +
trafficking O +
in O +
normal O +
and O +
injured O +
tissues O -
, O +
several O +
chemokines O +
may O +
positively O +
or O +
negatively O +
regulate O +
angiogenesis O -
. O +

Here O +
we O +
report O +
that O +
CCL16 O +
activates O +
an O +
angiogenic O +
program O +
in O +
vascular O +
endothelial O +
cells O +
by O +
activating O +
CCR1 O -
. O +

CCL16 O +
induces O +
dose O -
- O -
dependent O +
random O +
and O +
directional O +
migration O +
of O +
endothelial O +
cells O +
isolated O +
from O +
large O +
vessels O +
and O +
liver O +
capillaries O +
without O +
inducing O +
their O +
proliferation O -
. O +

It O +
also O +
promotes O +
endothelial O +
differentiation O +
into O +
capillary O -
- O -
like O +
structures O +
in O +
an O +
in O +
vitro O +
assay O +
and O +
is O +
angiogenic O +
in O +
the O +
chick O +
chorionallantoic O +
membrane O -
. O +

These O +
angiogenic O +
activities O +
are O +
neutralized O +
by O +
a O +
specific O +
antibody O +
against O +
CCL16 O -
. O +

The O +
direct O +
angiogenic O +
activity O +
of O +
CCL16 O +
is O +
further O +
amplified O +
by O +
its O +
ability O +
to O +
prime O +
endothelium O +
to O +
a O +
mitogen O +
signal O +
induced O +
by O +
vascular O +
endothelial O +
growth O +
factor O +
A O +
and O +
to O +
raise O +
their O +
basal O +
production O +
of O +
CXCL8 O +
and O +
CCL2 O -
, O +
2 O +
other O +
angiogenic O +
chemokines O -
. O +

BX471 B-Chemical +
( O -
R B-Chemical -
- I-Chemical -
N- I-Chemical -
[ I-Chemical -
5-chloro-2- I-Chemical -
[ I-Chemical -
2- I-Chemical -
[ I-Chemical -
4 I-Chemical -
( I-Chemical -
4-fluorophenyl I-Chemical -
) I-Chemical +
methyl I-Chemical -
] I-Chemical -
-2-methyl-1-piperazinyl I-Chemical -
] I-Chemical -
-2-oxoethoxy I-Chemical -
] I-Chemical -
phenyl I-Chemical -
] I-Chemical +
urea I-Chemical +
hydrochloric I-Chemical +
acid I-Chemical +
salt I-Chemical -
) O -
, O +
a O +
CCR1 O +
antagonist O -
, O +
inhibits O +
angiogenic O +
properties O +
of O +
CCL16 O -
, O +
whereas O +
blocking O +
of O +
CCR8 O +
or O +
desensitizing O +
CCR2 O -
, O +
which O +
are O +
both O +
well O +
known O +
receptors O +
for O +
CCL16 O -
, O +
did O +
not O +
abolish O +
endothelial O +
activation O -
. O +

CCL16 O +
may O +
be O +
specifically O +
cross O -
- O -
linked O +
to O +
CCR1 O +
expressed O +
on O +
endothelial O +
cells O -
. O +

The O +
largely O +
restricted O +
CCL16 O +
expression O +
in O +
the O +
liver O +
suggests O +
that O +
this O +
chemokine O +
may O +
play O +
a O +
role O +
in O +
hepatic O +
vascular O +
formation O +
during O +
development O +
and O +
in O +
angiogenesis O +
associated O +
to O +
hepatic O +
diseases O -
. O +

Simvastatin B-Chemical +
induces O +
apoptosis O +
of O +
B O -
- O -
CLL O +
cells O +
by O +
activation O +
of O +
mitochondrial O +
caspase O +
9 O -
. O +

BACKGROUND O +
AND O +
OBJECTIVES O -
: O +
Chronic O +
lymphocytic O +
leukemia O +
( O -
CLL O -
) O +
is O +
the O +
most O +
common O +
leukemia O +
in O +
the O +
western O +
world O -
. O +

Despite O +
several O +
advances O +
in O +
therapeutic O +
options O -
, O +
the O +
disease O +
remains O +
incurable O -
. O +

Recently O -
, O +
it O +
was O +
repeatedly O +
demonstrated O +
that O +
statins B-Chemical -
, O +
competitive O +
inhibitors O +
of O +
3-hydroxy-3-methyl O +
glutaryl O +
coenzyme O +
A O +
( O -
HMG O -
- O -
CoA O -
) O +
reductase O -
, O +
have O +
antineoplastic O +
effects O -
. O +

Therefore O +
we O +
aimed O +
to O +
study O +
the O +
effects O +
of O +
simvastatin B-Chemical +
( O -
Sim B-Chemical -
) O +
on O +
malignant O +
B O +
cells O +
derived O +
from O +
patients O +
with O +
CLL O +
and O +
mechanisms O +
of O +
action O +
of O +
the O +
drug O -
. O +

METHODS O +
AND O +
RESULTS O -
: O +
Purified O +
B O -
- O -
CLL O +
cells O +
from O +
15 O +
patients O +
were O +
cultured O +
either O +
alone O +
or O +
with O +
Sim B-Chemical +
at O +
concentrations O +
of O +
10 O -
, O +
50 O -
, O +
and O +
100 O +
microM. O +
Viability O -
, O +
measured O +
by O +
the O +
activity O +
of O +
mitochondrial O +
dehydrogenases O -
, O +
was O +
reduced O +
significantly O +
in O +
the O +
cells O +
treated O +
with O +
Sim B-Chemical +
at O +
50 O +
and O +
100 O +
microM O +
for O +
24 O +
hours O +
( O -
p<0.005 O -
) O -
. O +

The O +
level O +
of O +
apoptosis O -
, O +
as O +
measured O +
by O +
annexin O +
binding O +
to O +
exposed O +
phosphatidylserine O +
moieties O -
, O +
increased O +
significantly O +
in O +
the O +
treated O +
cells O +
at O +
concentrations O +
higher O +
than O +
50 O +
microM O +
for O +
24 O +
hours O +
( O -
p<0.003 O -
) O -
. O +

The O +
level O +
of O +
necrosis O -
, O +
as O +
measured O +
by O +
propidium B-Chemical +
iodide I-Chemical +
internalization O -
, O +
increased O +
significantly O +
after O +
24 O +
hours O +
exposure O +
to O +
Sim B-Chemical +
at O +
50 O +
microM O +
( O -
p<0.01 O -
) O -
. O +

The O +
apoptotic O +
cascade O +
was O +
studied O +
by O +
immunoblot O +
analysis O +
of O +
caspases O +
following O +
Sim B-Chemical +
treatment O -
. O +

These O +
showed O +
cleavage O +
of O +
caspases O +
9 O -
, O +
8 O -
, O +
and O +
3 O -
. O +

Addition O +
of O +
the O +
caspase O +
inhibitor O +
Z-VAD.fmk B-Chemical +
inhibited O +
caspase O +
8 O +
and O +
3 O +
significantly O +
but O +
did O +
not O +
affect O +
caspase O +
9 O -
. O +

CONCLUSION O -
: O +
Exposure O +
of O +
clonal O +
B O +
lymphocytes O +
from O +
patients O +
with O +
CLL O +
to O +
simvastatin B-Chemical +
decreases O +
viability O +
significantly O +
by O +
the O +
induction O +
of O +
apoptosis O -
. O +

The O +
apoptosis O +
induced O +
by O +
Sim B-Chemical +
is O +
probably O +
initiated O +
by O +
the O +
mitochondrial O +
caspase O +
9 O -
, O +
which O +
indirectly O +
leads O +
to O +
activation O +
of O +
caspase O +
3 O +
and O +
8 O -
. O +

Autocrine O +
angiotensin O +
system O +
regulation O +
of O +
bovine O +
aortic O +
endothelial O +
cell O +
migration O +
and O +
plasminogen O +
activator O +
involves O +
modulation O +
of O +
proto O -
- O -
oncogene O +
pp60c O -
- O -
src O +
expression O -
. O +

Rapid O +
endothelial O +
cell O +
migration O +
and O +
inhibition O +
of O +
thrombosis O +
are O +
critical O +
for O +
the O +
resolution O +
of O +
denudation O +
injuries O +
to O +
the O +
vessel O +
wall O -
. O +

Inhibition O +
of O +
the O +
endothelial O +
cell O +
autocrine O +
angiotensin O +
system O -
, O +
with O +
either O +
the O +
angiotensin O -
- O -
converting O +
enzyme O +
inhibitor O +
lisinopril B-Chemical +
or O +
the O +
angiotensin O +
II O +
receptor O +
antagonist O +
sar1 O -
, O +
ile8-angiotensin B-Chemical +
II I-Chemical -
, I-Chemical +
leads O +
to O +
increased O +
endothelial O +
cell O +
migration O +
and O +
urokinase O -
- O -
like O +
plasminogen O +
activator O +
( O -
u O -
- O -
PA O -
) O +
activity O +
( O -
Bell O -
, O +
L. O -
, O +
and O +
J. O +
A. O +
Madri O -
. O +
1990 O -
. O +

Am O -
. O +

J. O +
Pathol O -
. O +

137:7 O -
- O -
12 O -
) O -
. O +

Inhibition O +
of O +
the O +
autocrine O +
angiotensin O +
system O +
with O +
the O +
converting O -
- O -
enzyme O +
inhibitor O +
or O +
the O +
receptor O +
antagonist O +
also O +
leads O +
to O +
increased O +
expression O +
of O +
the O +
proto O -
- O -
oncogene O +
c O -
- O -
src O -
: O +
pp60c O -
- O -
src O +
mRNA O +
increased O +
7 O -
- O -
11-fold O -
, O +
c O -
- O -
src O +
protein O +
3-fold O -
, O +
and O +
c O -
- O -
src O +
kinase O +
activity O +
2 O -
- O -
3-fold O -
. O +

Endothelial O +
cell O +
expression O +
of O +
c O -
- O -
src O +
was O +
constitutively O +
elevated O +
after O +
stable O +
infection O +
with O +
a O +
retroviral O +
vector O +
containing O +
the O +
c O -
- O -
src O +
coding O +
sequence O -
. O +

Constitutively O +
increased O +
c O -
- O -
src O +
kinase O +
activity O +
reconstituted O +
the O +
increases O +
in O +
migration O +
and O +
u O -
- O -
PA O +
observed O +
with O +
angiotensin O +
system O +
interruption O -
. O +

Antisera O +
to O +
bovine O +
u O -
- O -
PA O +
blocked O +
the O +
increase O +
in O +
migration O +
associated O +
with O +
increased O +
c O -
- O -
src O +
expression O -
. O +

These O +
data O +
suggest O +
that O +
increases O +
in O +
endothelial O +
cell O +
migration O +
and O +
plasminogen O +
activator O +
after O +
angiotensin O +
system O +
inhibition O +
are O +
at O +
least O +
partially O +
pp60c O -
- O -
src O +
mediated O -
. O +

Elevated O +
c O -
- O -
src O +
expression O +
with O +
angiotensin O +
system O +
inhibition O +
may O +
act O +
to O +
enhance O +
intimal O +
wound O +
closure O +
and O +
to O +
reduce O +
luminal O +
thrombogenicity O +
in O +
vivo O -
. O +

Interleukin-1 O +
receptor O +
antagonist O +
inhibits O +
ischaemic O +
and O +
excitotoxic O +
neuronal O +
damage O +
in O +
the O +
rat O -
. O +

Interleukin-1 O +
( O -
IL-1 O -
) O +
synthesis O +
in O +
the O +
brain O +
is O +
stimulated O +
by O +
mechanical O +
injury O +
and O +
IL-1 O +
mimics O +
some O +
effects O +
of O +
injury O -
, O +
such O +
as O +
gliosis O +
and O +
neovascularization O -
. O +

We O +
report O +
that O +
neuronal O +
death O +
resulting O +
from O +
focal O +
cerebral O +
ischaemia O +
( O -
middle O +
cerebral O +
artery O +
occlusion O -
, O +
24 O +
h O -
) O +
is O +
significantly O +
inhibited O +
( O -
by O +
50 O -
% O -
) O +
in O +
rats O +
injected O +
with O +
a O +
recombinant O +
IL-1 O +
receptor O +
antagonist O +
( O -
IL-1ra O -
, O +
10 O +
micrograms O -
, O +
icv O +
30 O +
min O +
before O +
and O +
10 O +
min O +
after O +
ischaemia O -
) O -
. O +

Excitotoxic O +
damage O +
due O +
to O +
striatal O +
infusion O +
of O +
an O +
NMDA B-Chemical -
- O -
receptor O +
agonist O +
( O -
cis-2,4-methanoglutamate B-Chemical -
) O +
was O +
also O +
markedly O +
inhibited O +
( O -
71 O -
% O -
) O +
by O +
injection O +
of O +
the O +
IL-1ra O -
. O +

These O +
data O +
indicate O +
that O +
endogenous O +
IL-1 O +
is O +
a O +
mediator O +
of O +
ischaemic O +
and O +
excitotoxic O +
brain O +
damage O -
, O +
and O +
that O +
inhibitors O +
of O +
IL-1 O +
action O +
may O +
be O +
of O +
therapeutic O +
value O +
in O +
the O +
treatment O +
of O +
acute O +
or O +
chronic O +
neuronal O +
death O -
. O +

Cell O +
type O -
- O -
specific O +
regulation O +
of O +
angiogenic O +
growth O +
factor O +
gene O +
expression O +
and O +
induction O +
of O +
angiogenesis O +
in O +
nonischemic O +
tissue O +
by O +
a O +
constitutively O +
active O +
form O +
of O +
hypoxia O -
- O -
inducible O +
factor O +
1 O -
. O +

Understanding O +
molecular O +
mechanisms O +
regulating O +
angiogenesis O +
may O +
lead O +
to O +
novel O +
therapies O +
for O +
ischemic O +
disorders O -
. O +

Hypoxia O -
- O -
inducible O +
factor O +
1 O +
( O -
HIF-1 O -
) O +
activates O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
gene O +
expression O +
in O +
hypoxic O -
/ O -
ischemic O +
tissue O -
. O +

In O +
this O +
study O +
we O +
demonstrate O +
that O +
exposure O +
of O +
primary O +
cultures O +
of O +
cardiac O +
and O +
vascular O +
cells O +
to O +
hypoxia O +
or O +
AdCA5 O -
, O +
an O +
adenovirus O +
encoding O +
a O +
constitutively O +
active O +
form O +
of O +
HIF-1alpha O -
, O +
modulates O +
the O +
expression O +
of O +
genes O +
encoding O +
the O +
angiogenic O +
factors O +
angiopoietin-1 O +
( O -
ANGPT1 O -
) O -
, O +
ANGPT2 O -
, O +
placental O +
growth O +
factor O -
, O +
and O +
platelet O -
- O -
derived O +
growth O +
factor O -
- O -
B. O +
Loss O -
- O -
of O -
- O -
function O +
effects O +
were O +
also O +
observed O +
in O +
HIF-1alpha O -
- O -
null O +
embryonic O +
stem O +
cells O -
. O +

Depending O +
on O +
the O +
cell O +
type O -
, O +
expression O +
of O +
ANGPT1 O +
and O +
ANGPT2 O +
was O +
either O +
activated O +
or O +
repressed O +
in O +
response O +
to O +
hypoxia O +
or O +
AdCA5 O -
. O +

In O +
all O +
cases O -
, O +
there O +
was O +
complete O +
concordance O +
between O +
the O +
effects O +
of O +
hypoxia O +
and O +
AdCA5 O -
. O +

Injection O +
of O +
AdCA5 O +
into O +
mouse O +
eyes O +
induced O +
neovascularization O +
in O +
multiple O +
capillary O +
beds O -
, O +
including O +
those O +
not O +
responsive O +
to O +
VEGF O +
alone O -
. O +

Analysis O +
of O +
gene O +
expression O +
revealed O +
increased O +
expression O +
of O +
ANGPT1 O -
, O +
ANGPT2 O -
, O +
platelet O -
- O -
derived O +
growth O +
factor O -
- O -
B O -
, O +
placental O +
growth O +
factor O -
, O +
and O +
VEGF O +
mRNA O +
in O +
AdCA5-injected O +
eyes O -
. O +

These O +
results O +
indicate O +
that O +
HIF-1 O +
functions O +
as O +
a O +
master O +
regulator O +
of O +
angiogenesis O +
by O +
controlling O +
the O +
expression O +
of O +
multiple O +
angiogenic O +
growth O +
factors O +
and O +
that O +
adenovirus O -
- O -
mediated O +
expression O +
of O +
a O +
constitutively O +
active O +
form O +
of O +
HIF-1alpha O +
is O +
sufficient O +
to O +
induce O +
angiogenesis O +
in O +
nonischemic O +
tissue O +
of O +
an O +
adult O +
animal O -
. O +

Differential O +
regulation O +
of O +
in O +
vivo O +
angiogenesis O +
by O +
angiotensin O +
II O +
receptors O -
. O +

Angiotensin O +
II O +
( O -
ANG O +
II O -
) O -
, O +
a O +
key O +
regulator O +
of O +
blood O +
pressure O +
and O +
body O +
fluid O +
homeostasis O -
, O +
exerts O +
mitogenic O +
effects O +
on O +
endothelial O +
cells O -
. O +

We O +
therefore O +
hypothesized O +
that O +
ANG O +
II O +
could O +
be O +
a O +
mediator O +
between O +
homeostatic O +
changes O +
within O +
the O +
vascular O +
perfusion O +
bed O +
and O +
growth O +
factor O -
- O -
driven O +
angiogenesis O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
applied O +
the O +
alginate B-Chemical +
implant O +
angiogenesis O +
model O +
in O +
mice O +
with O +
normal O +
ANG O +
II O +
levels O -
, O +
elevated O +
ANG O +
II O +
levels O +
by O +
transgenic O +
overexpression O +
of O +
angiotensinogen O +
( O -
AOGEN O -
) O -
, O +
or O +
in O +
AT2 O +
receptor O -
- O -
deficient O +
mice O -
. O +

We O +
demonstrate O +
that O +
a O +
decrease O +
in O +
the O +
amount O +
of O +
circulating O +
ANG O +
II O +
by O +
the O +
angiotensin O -
- O -
converting O +
enzyme O +
( O -
ACE O -
) O +
inhibitor O +
enalapril B-Chemical +
or O +
the O +
AT1 O +
receptor O +
antagonist O +
losartan B-Chemical +
induced O +
a O +
stimulation O +
of O +
in O +
vivo O +
angiogenesis O +
implying O +
an O +
inhibitory O +
function O +
of O +
ANG O +
II O +
through O +
the O +
AT1 O +
receptor O -
. O +

However O -
, O +
the O +
strong O +
increase O +
of O +
angiogenesis O +
in O +
AOGEN O -
- O -
transgenic O +
mice O +
compared O +
with O +
mice O +
with O +
normal O +
ANG O +
II O +
levels O +
suggests O +
additional O +
stimulatory O +
activity O -
. O +

We O +
showed O +
that O +
the O +
ANG O +
II O -
- O -
induced O +
stimulation O +
of O +
angiogenesis O +
is O +
linked O +
to O +
the O +
AT2 O +
receptor O +
as O +
an O +
impaired O +
induction O +
of O +
angiogenesis O +
was O +
obtained O +
in O +
AT2 O +
receptor O +
knockout O +
mice O -
. O +

These O +
findings O +
provide O +
the O +
first O +
evidence O +
that O +
the O +
AT2 O +
receptor O +
mediates O +
a O +
stimulation O +
of O +
in O +
vivo O +
angiogenesis O +
and O +
indicate O +
that O +
ANG O +
II O +
is O +
a O +
humoral O +
regulator O +
of O +
peripheral O +
angiogenesis O +
involving O +
two O +
receptor O +
subtypes O +
with O +
opposing O +
actions O -
. O +

Expression O -
, O +
regulation O -
, O +
and O +
function O +
of O +
IGF-1 O -
, O +
IGF-1R O -
, O +
and O +
IGF-1 O +
binding O +
proteins O +
in O +
blood O +
vessels O -
. O +

The O +
vascular O +
insulin O -
- O -
like O +
growth O +
factor O +
( O -
IGF O -
) O -
-1 O +
system O +
includes O +
the O +
IGFs O -
, O +
the O +
IGF-1 O +
receptor O +
( O -
IGF-1R O -
) O -
, O +
and O +
multiple O +
binding O +
proteins O -
. O +

This O +
growth O +
factor O +
system O +
exerts O +
multiple O +
physiologic O +
effects O +
on O +
the O +
vasculature O +
through O +
both O +
endocrine O +
and O +
autocrine O -
/ O -
paracrine O +
mechanisms O -
. O +

The O +
effects O +
of O +
IGF-1 O +
are O +
mediated O +
principally O +
through O +
the O +
IGF-1R O +
but O +
are O +
modulated O +
by O +
complex O +
interactions O +
with O +
multiple O +
IGF O +
binding O +
proteins O +
that O +
themselves O +
are O +
regulated O +
by O +
phosphorylation O -
, O +
proteolysis O -
, O +
polymerization O -
, O +
and O +
cell O +
or O +
matrix O +
association O -
. O +

During O +
the O +
last O +
decade O -
, O +
a O +
significant O +
body O +
of O +
evidence O +
has O +
accumulated O -
, O +
indicating O +
that O +
expression O +
of O +
the O +
components O +
of O +
the O +
IGF O +
system O +
are O +
regulated O +
by O +
multiple O +
factors O -
, O +
including O +
growth O +
factors O -
, O +
cytokines O -
, O +
lipoproteins O -
, O +
reactive B-Chemical +
oxygen I-Chemical +
species I-Chemical -
, O +
and O +
hemodynamic O +
forces O -
. O +

In O +
addition O -
, O +
cross O -
- O -
talk O +
between O +
the O +
IGF O +
system O +
and O +
other O +
growth O +
factors O +
and O +
integrin O +
receptors O +
has O +
been O +
demonstrated O -
. O +

There O +
is O +
accumulating O +
evidence O +
of O +
a O +
role O +
for O +
IGF-1 O +
in O +
multiple O +
vascular O +
pathologies O -
, O +
including O +
atherosclerosis O -
, O +
hypertension O -
, O +
restenosis O -
, O +
angiogenesis O -
, O +
and O +
diabetic O +
vascular O +
disease O -
. O +

This O +
review O +
will O +
discuss O +
the O +
regulation O +
of O +
expression O +
of O +
IGF-1 O -
, O +
IGF-1R O -
, O +
and O +
IGF O +
binding O +
proteins O +
in O +
the O +
vasculature O +
and O +
summarize O +
evidence O +
implicating O +
involvement O +
of O +
this O +
system O +
in O +
vascular O +
diseases O -
. O +

Microvascular O +
density O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
immunoreactivity O +
as O +
predictors O +
of O +
regional O +
lymph O +
node O +
metastasis O +
from O +
betel O -
- O -
associated O +
oral O +
squamous O +
cell O +
carcinoma O -
. O +

PURPOSE O -
: O +
Neovascularization O +
has O +
profound O +
effects O +
on O +
tumor O +
growth O +
and O +
metastasis O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
is O +
a O +
mitogen O +
that O +
acts O +
exclusively O +
on O +
endothelial O +
cells O -
. O +

The O +
roles O +
of O +
miscrovascularity O +
density O +
( O -
MVD O -
) O +
and O +
VEGF O +
expression O +
in O +
the O +
progression O +
of O +
oral O +
squamous O +
cell O +
carcinoma O +
( O -
OSCC O -
) O +
have O +
been O +
controversial O -
. O +

The O +
purpose O +
of O +
the O +
present O +
study O +
was O +
to O +
measure O +
the O +
MVD O +
and O +
VEGF O +
expression O +
in O +
a O +
cohort O +
of O +
patients O +
with O +
betel O -
- O -
associated O +
OSCC O +
and O +
to O +
evaluate O +
for O +
possible O +
clinicopathologic O +
correlations O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
The O +
paraffin O +
sections O +
from O +
49 O +
subjects O +
with O +
OSCC O +
were O +
subjected O +
to O +
immunohistochemical O +
studies O +
to O +
measure O +
the O +
highest O +
MVD O +
( O -
h O -
- O -
MVD O -
) O +
and O +
cytoplasmic O +
immunoreactivity O +
of O +
VEGF O -
. O +

The O +
findings O +
in O +
the O +
tissue O +
samples O +
were O +
analyzed O +
with O +
regard O +
to O +
the O +
patients O -
' O +
risk O +
factors O +
and O +
clinical O +
course O -
. O +

RESULTS O -
: O +
The O +
OSCC O +
samples O +
had O +
an O +
average O +
h O -
- O -
MVD O +
score O +
of O +
27.7 O -
/ O -
mm O -
( O -
2 O -
) O -
. O +

VEGF O +
immunoreactivity O +
was O +
positive O +
in O +
75.5 O -
% O +
of O +
samples O -
. O +

Both O +
h O -
- O -
MVD O +
and O +
VEGF O +
immunoreactivity O +
were O +
statistically O +
associated O +
with O +
lymph O +
node O +
metastasis O +
( O -
P O +
= O -
.012 O +
and.037 O -
, O +
respectively O -
) O -
. O +

A O +
marginally O +
significant O +
association O +
was O +
also O +
noted O +
between O +
the O +
h O -
- O -
MVD O +
and O +
patient O +
survival O +
( O -
P O +
= O -
.056 O -
) O -
. O +

The O +
age O +
and O +
oral O +
habits O +
of O +
patients O -
, O +
as O +
well O +
as O +
the O +
tumor O +
site O +
and O +
size O -
, O +
did O +
not O +
appear O +
to O +
be O +
correlated O +
with O +
h O -
- O -
MVD O +
or O +
VEGF O +
immunoreactivity O -
. O +

CONCLUSION O -
: O +
The O +
data O +
suggest O +
that O +
both O +
h O -
- O -
MVD O +
and O +
VEGF O +
immunoreactivity O +
may O +
be O +
useful O +
predictors O +
for O +
the O +
progression O +
of O +
a O +
subset O +
of O +
OSCC O +
associated O +
mostly O +
with O +
betel O +
use O -
. O +

Antiangiogenesis O +
therapy O +
might O +
have O +
a O +
role O +
in O +
reducing O +
regional O +
metastasis O -
. O +

Insulin O -
- O -
like O +
growth O +
factor O +
1 O +
receptor O +
enhances O +
invasion O +
and O +
induces O +
resistance O +
to O +
apoptosis O +
of O +
colon O +
cancer O +
cells O +
through O +
the O +
Akt O -
/ O -
Bcl O -
- O -
x O -
( O -
L O -
) O +
pathway O -
. O +

Colon O +
cancer O +
overexpresses O +
insulin O -
- O -
like O +
growth O +
factor O +
1 O +
( O -
IGF1 O -
) O +
and O +
insulin O -
- O -
like O +
growth O +
factor O +
1 O +
receptor O +
( O -
IGF1-R O -
) O -
, O +
as O +
compared O +
with O +
normal O +
or O +
adenomatous O +
mucosa O -
, O +
and O +
it O +
has O +
been O +
postulated O +
that O +
colorectal O +
cancer O +
cells O +
depend O +
on O +
the O +
IGF1 O -
/ O -
IGF1-R O +
pathway O +
for O +
their O +
growth O +
and O +
progression O -
. O +

In O +
this O +
study O -
, O +
using O +
the O +
human O +
colon O +
cancer O +
cell O +
line O +
HCT116 O -
, O +
we O +
find O +
that O +
established O +
HCT116 O -
/ O -
IGF1-R O +
transfectants O +
exhibit O +
a O +
more O +
aggressive O +
transformed O +
phenotype O +
than O +
the O +
parental O +
cell O +
line O -
, O +
as O +
demonstrated O +
by O +
their O +
higher O +
proliferation O +
rate O +
in O +
response O +
to O +
IGF1 O -
, O +
higher O +
degree O +
of O +
anchorage O -
- O -
independent O +
growth O -
, O +
resistance O +
to O +
serum O +
deprivation O -
- O -
induced O +
apoptosis O -
, O +
and O +
higher O +
migratory O +
capability O +
in O +
a O +
monolayer O +
" O -
wounding O +
assay O -
. O -
" O +

When O +
injected O +
into O +
nude O +
mice O -
, O +
HCT116 O -
/ O -
IGF1-R O +
transfectants O +
were O +
highly O +
invasive O +
and O +
produced O +
distant O +
metastases O -
, O +
whereas O +
the O +
parental O +
cell O +
did O +
not O -
. O +

Moreover O -
, O +
the O +
overexpression O +
of O +
IGF1-R O +
in O +
these O +
cells O +
was O +
associated O +
with O +
IGF1-R O -
- O -
induced O +
activation O +
of O +
Akt O +
and O +
up O -
- O -
regulation O +
of O +
the O +
antiapoptotic O +
protein O +
Bcl O -
- O -
x O -
( O -
L O -
) O -
. O +

We O +
also O +
show O +
that O +
Akt O +
pathway O +
mediates O +
IGF1-R O -
- O -
induced O +
Bcl O -
- O -
x O -
( O -
L O -
) O +
expression O +
at O +
transcriptional O +
level O -
. O +

Our O +
data O +
demonstrate O -
, O +
for O +
the O +
first O +
time O -
, O +
that O +
IGF1-R O -
/ O -
Akt O -
/ O -
Bcl O -
- O -
x O -
( O -
L O -
) O +
pathway O +
may O +
contribute O +
to O +
a O +
more O +
aggressive O +
malignant O +
phenotype O -
, O +
in O +
a O +
subset O +
of O +
colorectal O +
cancers O -
. O +

Promotion O +
of O +
tumorigenesis O +
by O +
heterozygous O +
disruption O +
of O +
the O +
beclin O +
1 O +
autophagy O +
gene O -
. O +

Malignant O +
cells O +
often O +
display O +
defects O +
in O +
autophagy O -
, O +
an O +
evolutionarily O +
conserved O +
pathway O +
for O +
degrading O +
long O -
- O -
lived O +
proteins O +
and O +
cytoplasmic O +
organelles O -
. O +

However O -
, O +
as O +
yet O -
, O +
there O +
is O +
no O +
genetic O +
evidence O +
for O +
a O +
role O +
of O +
autophagy O +
genes O +
in O +
tumor O +
suppression O -
. O +

The O +
beclin O +
1 O +
autophagy O +
gene O +
is O +
monoallelically O +
deleted O +
in O +
40 O -
- O -
75 O -
% O +
of O +
cases O +
of O +
human O +
sporadic O +
breast O -
, O +
ovarian O -
, O +
and O +
prostate O +
cancer O -
. O +

Therefore O -
, O +
we O +
used O +
a O +
targeted O +
mutant O +
mouse O +
model O +
to O +
test O +
the O +
hypothesis O +
that O +
monoallelic O +
deletion O +
of O +
beclin O +
1 O +
promotes O +
tumorigenesis O -
. O +

Here O +
we O +
show O +
that O +
heterozygous O +
disruption O +
of O +
beclin O +
1 O +
increases O +
the O +
frequency O +
of O +
spontaneous O +
malignancies O +
and O +
accelerates O +
the O +
development O +
of O +
hepatitis O +
B O +
virus O -
- O -
induced O +
premalignant O +
lesions O -
. O +

Molecular O +
analyses O +
of O +
tumors O +
in O +
beclin O +
1 O +
heterozygous O +
mice O +
show O +
that O +
the O +
remaining O +
wild O -
- O -
type O +
allele O +
is O +
neither O +
mutated O +
nor O +
silenced O -
. O +

Furthermore O -
, O +
beclin O +
1 O +
heterozygous O +
disruption O +
results O +
in O +
increased O +
cellular O +
proliferation O +
and O +
reduced O +
autophagy O +
in O +
vivo O -
. O +

These O +
findings O +
demonstrate O +
that O +
beclin O +
1 O +
is O +
a O +
haplo O -
- O -
insufficient O +
tumor O -
- O -
suppressor O +
gene O +
and O +
provide O +
genetic O +
evidence O +
that O +
autophagy O +
is O +
a O +
novel O +
mechanism O +
of O +
cell O -
- O -
growth O +
control O +
and O +
tumor O +
suppression O -
. O +

Thus O -
, O +
mutation O +
of O +
beclin O +
1 O +
or O +
other O +
autophagy O +
genes O +
may O +
contribute O +
to O +
the O +
pathogenesis O +
of O +
human O +
cancers O -
. O +

Effect O +
of O +
antitumor O +
agents O +
on O +
cytotoxicity O +
induction O +
by O +
sodium B-Chemical +
fluoride I-Chemical -
. O +

We O +
have O +
recently O +
found O +
that O +
sodium B-Chemical +
fluoride I-Chemical +
( O -
NaF B-Chemical -
) O +
induced O +
apoptotic O +
cell O +
death O +
in O +
tumor O +
cell O +
lines O -
. O +

We O +
investigated O +
here O +
whether O +
6 O +
popular O +
antitumor O +
compounds O +
modify O +
the O +
cytotoxic O +
activity O +
of O +
NaF B-Chemical +
against O +
human O +
squamous O +
cell O +
carcinoma O +
( O -
HSC-2 O -
) O +
and O +
human O +
promyelocytic O +
leukemia O +
( O -
HL-60 O -
) O +
cell O +
lines O -
. O +

Cytotoxic O +
concentrations O +
of O +
cisplatin B-Chemical -
, O +
etoposide B-Chemical -
, O +
doxorubicin B-Chemical +
or O +
peplomycin B-Chemical +
( O -
tentatively O +
termed O +
as O +
Group O +
I O +
compounds O -
) O -
, O +
but O +
not O +
methotrexate B-Chemical +
and O +
5-FU B-Chemical +
( O -
tentatively O +
termed O +
as O +
Group O +
II O +
compounds O -
) O -
, O +
enhanced O +
the O +
cytotoxic O +
activity O +
of O +
NaF. B-Chemical +
NaF B-Chemical +
and O +
Group O +
I O +
compounds O +
induced O +
internucleosomal O +
DNA O +
fragmentation O +
in O +
HL-60 O +
cells O -
, O +
whereas O +
Group O +
II O +
compounds O +
were O +
inactive O +
even O +
in O +
the O +
presence O +
of O +
NaF. B-Chemical +
Most O +
Group O +
I O +
compounds O +
except O +
doxorubicin B-Chemical +
( O -
which O +
induced O +
DNA O +
fragmentation O +
less O +
effectively O +
than O +
others O -
) O +
activated O +
caspase O +
3 O +
more O +
efficiently O +
than O +
Group O +
II O +
compounds O -
. O +

Caspase O +
8 O +
( O -
involved O +
in O +
non O -
- O -
mitochondrial O +
extrinsic O +
pathway O -
) O +
and O +
caspase O +
9 O +
( O -
involved O +
in O +
mitochondrial O +
intrinsic O +
pathway O -
) O +
were O +
also O +
activated O -
, O +
but O +
to O +
a O +
much O +
lesser O +
extent O -
. O +

NaF B-Chemical +
reduced O +
the O +
glucose B-Chemical +
consumption O +
at O +
early O +
stage O -
, O +
possibly O +
by O +
inhibition O +
of O +
glycolysis O -
, O +
whereas O +
cisplatin B-Chemical +
and O +
etoposide B-Chemical +
reduced O +
the O +
glucose B-Chemical +
consumption O +
at O +
later O +
stage O -
, O +
suggesting O +
that O +
early O +
decline O +
of O +
glucose B-Chemical +
consumption O +
is O +
rather O +
specific O +
to O +
NaF. B-Chemical +

Angiopoietin O -
/ O -
tie-2 O +
as O +
mediators O +
of O +
angiogenesis O -
: O +
a O +
role O +
in O +
congestive O +
heart O +
failure O -
? O +

Angiogenic O +
factors O -
, O +
in O +
particular O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
and O +
the O +
angiopoietins O -
, O +
Ang-1 O +
and O +
-2 O -
, O +
have O +
recently O +
generated O +
significant O +
interest O -
, O +
especially O +
in O +
oncology O -
. O +

The O +
process O +
of O +
angiogenesis O +
is O +
also O +
thought O +
to O +
occur O +
in O +
response O +
to O +
ischaemic O +
conditions O -
, O +
which O +
lie O +
at O +
the O +
core O +
of O +
cardiovascular O +
disease O +
states O +
such O +
as O +
coronary O +
artery O +
disease O +
and O +
congestive O +
heart O +
failure O -
. O +

However O -
, O +
current O +
data O +
do O +
not O +
conclusively O +
show O +
evidence O +
of O +
angiogenesis O +
per O +
se O +
in O +
these O +
conditions O -
, O +
despite O +
( O -
for O +
example O -
) O +
the O +
presence O +
of O +
high O +
levels O +
of O +
VEGF O +
and O +
Ang-2 O -
. O +

High O +
levels O +
of O +
these O +
angiogenic O +
factors O +
in O +
heart O +
disease O +
also O +
have O +
not O +
translated O +
into O +
clinically O +
significant O +
new O +
vessel O +
formation O -
, O +
as O +
in O +
accelerated O +
cancer O +
growth O +
or O +
proliferative O +
retinopathy O -
. O +

Indeed O -
, O +
we O +
would O +
hypothesize O +
that O +
these O +
angiogenic O +
markers O -
-- O -
especially O +
the O +
angiopoietins O -
-- O -
do O +
not O +
necessarily O +
translate O +
into O +
new O +
vessel O +
formation O +
in O +
congestive O +
heart O +
failure O +
( O -
CHF O -
) O -
, O +
but O +
may O +
well O +
reflect O +
disturbances O +
of O +
endothelial O +
integrity O +
in O +
CHF O -
. O +

Morphogenesis O +
of O +
embryonic O +
CNS O +
vessels O -
. O +

This O +
chapter O +
focuses O +
on O +
the O +
morphology O +
of O +
blood O +
vessel O +
formation O +
in O +
and O +
around O +
the O +
early O +
central O +
nervous O +
system O +
( O -
CNS O -
, O +
i.e. O -
, O +
brain O +
and O +
spinal O +
cord O -
) O +
of O +
avian O +
embryos O -
. O +

We O +
discuss O +
cell O +
lineages O -
, O +
proliferation O +
and O +
interactions O +
of O +
endothelial O +
cells O -
, O +
pericytes O +
and O +
smooth O +
muscle O +
cells O -
, O +
and O +
macrophages O -
. O +

Due O +
to O +
space O +
limitations O -
, O +
we O +
can O +
not O +
review O +
the O +
molecular O +
control O +
of O +
CNS O +
angiogenesis O -
, O +
but O +
refer O +
the O +
reader O +
to O +
other O +
chapters O +
in O +
this O +
book O +
and O +
to O +
recent O +
publications O +
on O +
the O +
assembly O +
of O +
the O +
vasculature O +
( O -
1,2 O -
) O -
. O +

The O +
candidate O +
tumour O +
suppressor O +
protein O +
ING4 O +
regulates O +
brain O +
tumour O +
growth O +
and O +
angiogenesis O -
. O +

Gliomas O +
are O +
the O +
most O +
common O +
primary O +
tumours O +
of O +
the O +
central O +
nervous O +
system O -
, O +
with O +
nearly O +
15,000 O +
diagnosed O +
annually O +
in O +
the O +
United O +
States O +
and O +
a O +
lethality O +
approaching O +
80 O -
% O +
within O +
the O +
first O +
year O +
of O +
glioblastoma O +
diagnosis O -
. O +

The O +
marked O +
induction O +
of O +
angiogenesis O +
in O +
glioblastomas O +
suggests O +
that O +
it O +
is O +
a O +
necessary O +
part O +
of O +
malignant O +
progression O -
; O +
however O -
, O +
the O +
precise O +
molecular O +
mechanisms O +
underlying O +
the O +
regulation O +
of O +
brain O +
tumour O +
growth O +
and O +
angiogenesis O +
remain O +
unresolved O -
. O +

Here O +
we O +
report O +
that O +
a O +
candidate O +
tumour O +
suppressor O +
gene O -
, O +
ING4 O -
, O +
is O +
involved O +
in O +
regulating O +
brain O +
tumour O +
growth O +
and O +
angiogenesis O -
. O +

Expression O +
of O +
ING4 O +
is O +
significantly O +
reduced O +
in O +
gliomas O +
as O +
compared O +
with O +
normal O +
human O +
brain O +
tissue O -
, O +
and O +
the O +
extent O +
of O +
reduction O +
correlates O +
with O +
the O +
progression O +
from O +
lower O +
to O +
higher O +
grades O +
of O +
tumours O -
. O +

In O +
mice O -
, O +
xenografts O +
of O +
human O +
glioblastoma O +
U87MG O -
, O +
which O +
has O +
decreased O +
expression O +
of O +
ING4 O -
, O +
grow O +
significantly O +
faster O +
and O +
have O +
higher O +
vascular O +
volume O +
fractions O +
than O +
control O +
tumours O -
. O +

We O +
show O +
that O +
ING4 O +
physically O +
interacts O +
with O +
p65 O +
( O -
RelA O -
) O +
subunit O +
of O +
nuclear O +
factor O +
NF O -
- O -
kappaB O -
, O +
and O +
that O +
ING4 O +
regulates O +
brain O +
tumour O +
angiogenesis O +
through O +
transcriptional O +
repression O +
of O +
NF O -
- O -
kappaB O -
- O -
responsive O +
genes O -
. O +

These O +
results O +
indicate O +
that O +
ING4 O +
has O +
an O +
important O +
role O +
in O +
brain O +
tumour O +
pathogenesis O -
. O +

Role O +
of O +
thrombin O +
in O +
angiogenesis O +
and O +
tumor O +
progression O -
. O +

Clinical O -
, O +
laboratory O -
, O +
histopathological O -
, O +
and O +
pharmacological O +
evidence O +
support O +
the O +
notion O +
that O +
the O +
coagulation O +
system O -
, O +
which O +
is O +
activated O +
in O +
most O +
cancer O +
patients O -
, O +
plays O +
an O +
important O +
role O +
in O +
tumor O +
biology O -
. O +

Our O +
laboratory O +
has O +
provided O +
evidence O +
that O +
thrombin O +
activates O +
angiogenesis O -
, O +
a O +
process O +
which O +
is O +
essential O +
in O +
tumor O +
growth O +
and O +
metastasis O -
. O +

This O +
event O +
is O +
independent O +
of O +
fibrin O +
formation O -
. O +

At O +
the O +
cellular O +
level O +
many O +
actions O +
of O +
thrombin O +
can O +
contribute O +
to O +
activation O +
of O +
angiogenesis O -
: O +
( O -
1 O -
) O -
. O +

Thrombin O +
decreases O +
the O +
ability O +
of O +
endothelial O +
cells O +
to O +
attach O +
to O +
basement O +
membrane O +
proteins O -
. O +

( O -
2 O -
) O -
. O +

Thrombin O +
greatly O +
potentiates O +
vascular O +
endothelial O +
growth O +
factor- O +
( O -
VEGF- O -
) O +
induced O +
endothelial O +
cell O +
proliferation O -
. O +

This O +
potentiation O +
is O +
accompanied O +
by O +
up O -
- O -
regulation O +
of O +
the O +
expression O +
of O +
VEGF O +
receptors O +
( O -
kinase O +
insert O +
domain O -
- O -
containing O +
receptor O +
[ O -
KDR O -
] O +
and O +
fms O -
- O -
like O +
tyrosine O +
kinase O +
[ O -
Flt-1 O -
] O -
) O -
. O +

( O -
3 O -
) O -
. O +

Thrombin O +
increases O +
the O +
mRNA O +
and O +
protein O +
levels O +
of O +
alpha O +
( O -
v O -
) O -
beta O +
( O -
3 O -
) O +
integrin O +
and O +
serves O +
as O +
a O +
ligand O +
to O +
this O +
receptor O -
. O +

Furthermore O -
, O +
thrombin O +
increases O +
the O +
secretion O +
of O +
VEGF O +
and O +
enhances O +
the O +
expression O +
and O +
protein O +
synthesis O +
of O +
matrix O +
metalloprotease-9 O +
and O +
alpha O +
( O -
v O -
) O -
beta O +
( O -
3 O -
) O +
integrin O +
in O +
human O +
prostate O +
cancer O +
PC-3 O +
cells O -
. O +

These O +
results O +
could O +
explain O +
the O +
angiogenic O +
and O +
tumor O -
- O -
promoting O +
effect O +
of O +
thrombin O +
and O +
provide O +
the O +
basis O +
for O +
development O +
of O +
thrombin O +
receptor O +
mimetics O +
or O +
antagonists O +
for O +
therapeutic O +
application O -
. O +

Dynein O +
light O +
chain O +
1 O -
, O +
a O +
p21-activated O +
kinase O +
1-interacting O +
substrate O -
, O +
promotes O +
cancerous O +
phenotypes O -
. O +

We O +
identified O +
dynein O +
light O +
chain O +
1 O +
( O -
DLC1 O -
) O +
as O +
a O +
physiologic O +
substrate O +
of O +
p21-activated O +
kinase O +
1 O +
( O -
Pak1 O -
) O -
. O +

Pak1-DLC1 O +
interaction O +
plays O +
an O +
essential O +
role O +
in O +
cell O +
survival O -
, O +
which O +
depends O +
on O +
Pak1 O -
's O +
phosphorylation O +
of O +
DLC1 O +
on O +
Ser88 O -
. O +

Pak1 O +
associates O +
with O +
the O +
complex O +
of O +
DLC1 O +
and O +
BimL O -
, O +
a O +
proapoptotic O +
BH3-only O +
protein O -
, O +
and O +
phosphorylates O +
both O +
proteins O -
. O +

Phosphorylation O +
of O +
BimL O +
by O +
Pak1 O +
prevents O +
it O +
from O +
interacting O +
with O +
and O +
inactivation O +
of O +
Bcl-2 O -
, O +
an O +
antiapoptotic O +
protein O -
. O +

Overexpression O +
of O +
DLC1 O +
but O +
not O +
DLC1-Ser88Ala O +
mutant O +
promotes O +
cancerous O +
properties O +
of O +
breast O +
cancer O +
cells O -
. O +

DLC1 O +
protein O +
level O +
is O +
elevated O +
in O +
more O +
than O +
90 O -
% O +
of O +
human O +
breast O +
tumors O -
. O +

The O +
regulation O +
of O +
cell O +
survival O +
functions O +
by O +
Pak1-DLC1 O +
interaction O +
represents O +
a O +
novel O +
mechanism O +
by O +
which O +
a O +
signaling O +
kinase O +
might O +
regulate O +
the O +
cancerous O +
phenotypes O -
. O +

Hypothesis O -
: O +
Induced O +
angiogenesis O +
after O +
surgery O +
in O +
premenopausal O +
node O -
- O -
positive O +
breast O +
cancer O +
patients O +
is O +
a O +
major O +
underlying O +
reason O +
why O +
adjuvant O +
chemotherapy O +
works O +
particularly O +
well O +
for O +
those O +
patients O -
. O +

BACKGROUND O -
: O +
We O +
suggest O +
that O +
surgical O +
extirpation O +
of O +
primary O +
breast O +
cancer O +
among O +
other O +
effects O +
accelerates O +
relapse O +
for O +
some O +
premenopausal O +
node O -
- O -
positive O +
patients O -
. O +

These O +
accelerated O +
relapses O +
occur O +
within O +
10 O +
months O +
of O +
surgery O +
for O +
untreated O +
patients O -
. O +

The O +
mechanism O +
proposed O +
is O +
a O +
stimulation O +
of O +
angiogenesis O +
for O +
distant O +
dormant O +
micrometastases O -
. O +

This O +
has O +
been O +
suggested O +
as O +
one O +
of O +
the O +
mechanisms O +
to O +
explain O +
the O +
mammography O +
paradox O +
for O +
women O +
aged O +
40 O -
- O -
49 O +
years O -
. O +

We O +
could O +
imagine O +
that O +
it O +
also O +
plays O +
a O +
role O +
in O +
adjuvant O +
chemotherapy O +
effectiveness O +
since O -
, O +
perhaps O +
not O +
coincidentally O -
, O +
this O +
is O +
most O +
beneficial O +
for O +
premenopausal O +
node O -
- O -
positive O +
patients O -
. O +

HYPOTHESIS O -
: O +
We O +
speculate O +
that O +
there O +
is O +
a O +
burst O +
of O +
angiogenesis O +
of O +
distant O +
dormant O +
micrometastases O +
after O +
surgery O +
in O +
approximately O +
20 O -
% O +
of O +
premenopausal O +
node O -
- O -
positive O +
patients O -
. O +

We O +
also O +
speculate O +
that O +
this O +
synchronizes O +
them O +
into O +
a O +
temporal O +
highly O +
chemosensitive O +
state O +
and O +
is O +
the O +
underlying O +
reason O +
why O +
adjuvant O +
chemotherapy O +
works O +
particularly O +
well O +
for O +
that O +
patient O +
category O -
. O +

Furthermore O -
, O +
this O +
may O +
explain O +
why O +
cancer O +
in O +
younger O +
patients O +
is O +
more O +
often O +
' O -
aggressive O -
' O -
. O +

TESTING O +
THE O +
HYPOTHESIS O -
: O +
Stimulation O +
of O +
dormant O +
micrometastases O +
by O +
primary O +
tumor O +
removal O +
is O +
known O +
to O +
occur O +
in O +
animal O +
models O -
. O +

However O -
, O +
we O +
need O +
to O +
determine O +
whether O +
it O +
happens O +
in O +
breast O +
cancer O -
. O +

Transient O +
circulating O +
levels O +
of O +
angioactive O +
molecules O +
and O +
serial O +
high O -
- O -
resolution O +
imaging O +
studies O +
of O +
focal O +
angiogenesis O +
might O +
help O -
. O +

IMPLICATIONS O -
: O +
Short O -
- O -
course O +
cytotoxic O +
chemotherapy O +
after O +
surgery O +
has O +
probably O +
reached O +
its O +
zenith O -
, O +
and O +
other O +
strategies O -
, O +
perhaps O +
antiangiogenic O +
methods O -
, O +
are O +
needed O +
to O +
successfully O +
treat O +
more O +
patients O -
. O +

In O +
addition O -
, O +
the O +
hypothesis O +
predicts O +
that O +
early O +
detection O -
, O +
which O +
is O +
designed O +
to O +
find O +
more O +
patients O +
without O +
involved O +
lymph O +
nodes O -
, O +
may O +
not O +
be O +
a O +
synergistic O +
strategy O +
with O +
adjuvant O +
chemotherapy O -
, O +
which O +
works O +
best O +
with O +
positive O +
lymph O +
node O +
patients O -
. O +

Targeting O +
wide O -
- O -
range O +
oncogenic O +
transformation O +
via O +
PU24FCl B-Chemical -
, O +
a O +
specific O +
inhibitor O +
of O +
tumor O +
Hsp90 O -
. O +

Agents O +
that O +
inhibit O +
Hsp90 O +
function O +
hold O +
significant O +
promise O +
in O +
cancer O +
therapy O -
. O +

Here O +
we O +
present O +
PU24FCl B-Chemical -
, O +
a O +
representative O +
of O +
the O +
first O +
class O +
of O +
designed O +
Hsp90 O +
inhibitors O -
. O +

By O +
specifically O +
and O +
potently O +
inhibiting O +
tumor O +
Hsp90 O -
, O +
PU24FCl B-Chemical +
exhibits O +
wide O -
- O -
ranging O +
anti O -
- O -
cancer O +
activities O +
that O +
occur O +
at O +
similar O +
doses O +
in O +
all O +
tested O +
tumor O +
types O -
. O +

Normal O +
cells O +
are O +
10- O +
to O +
50-fold O +
more O +
resistant O +
to O +
these O +
effects O -
. O +

Its O +
Hsp90 O +
inhibition O +
results O +
in O +
multiple O +
anti O -
- O -
tumor O -
- O -
specific O +
effects O -
, O +
such O +
as O +
degradation O +
of O +
Hsp90-client O +
proteins O +
involved O +
in O +
cell O +
growth O -
, O +
survival O -
, O +
and O +
specific O +
transformation O -
, O +
inhibition O +
of O +
cancer O +
cell O +
growth O -
, O +
delay O +
of O +
cell O +
cycle O +
progression O -
, O +
induction O +
of O +
morphological O +
and O +
functional O +
changes O -
, O +
and O +
apoptosis O -
. O +

In O +
concordance O +
with O +
its O +
higher O +
affinity O +
for O +
tumor O +
Hsp90 O -
, O +
in O +
vivo O +
PU24FCl B-Chemical +
accumulates O +
in O +
tumors O +
while O +
being O +
rapidly O +
cleared O +
from O +
normal O +
tissue O -
. O +

Concentrations O +
achieved O +
in O +
vivo O +
in O +
tumors O +
lead O +
to O +
single O -
- O -
agent O +
anti O -
- O -
tumor O +
activity O +
at O +
non O -
- O -
toxic O +
doses O -
. O +

Matrix O +
metalloproteinase O +
activity O +
and O +
immunohistochemical O +
profile O +
of O +
matrix O +
metalloproteinase-2 O +
and O +
-9 O +
and O +
tissue O +
inhibitor O +
of O +
metalloproteinase-1 O +
during O +
human O +
dermal O +
wound O +
healing O -
. O +

Proteolytic O +
activity O +
is O +
required O +
for O +
the O +
turnover O +
of O +
the O +
extracellular O +
matrix O +
during O +
wound O +
healing O -
. O +

Matrix O +
metalloproteinases O +
can O +
collectively O +
cleave O +
all O +
components O +
of O +
the O +
extracellular O +
matrix O -
, O +
with O +
the O +
endogenous O +
tissue O +
inhibitor O +
of O +
metalloproteinase-1 O +
regulating O +
their O +
activity O -
. O +

Breast O +
tissue O +
taken O +
at O +
varying O +
postoperative O +
times O +
( O -
n= O +
92 O -
) O +
or O +
during O +
surgery O +
( O -
controls O -
, O +
n= O +
17 O -
) O -
, O +
was O +
used O +
to O +
investigate O +
the O +
temporal O +
and O +
spatial O +
activity O +
of O +
matrix O +
metalloproteinase-2 O +
and O +
-9 O +
and O +
tissue O +
inhibitor O +
of O +
metalloproteinase-1 O +
during O +
human O +
wound O +
healing O -
. O +

Matrix O +
metalloproteinase O +
activity O -
, O +
determined O +
using O +
a O +
quenched O +
fluorescence O +
substrate O +
assay O -
, O +
increased O +
during O +
early O +
healing O +
( O -
3 O -
- O -
8 O +
weeks O -
) O +
compared O +
to O +
controls O -
, O +
and O +
then O +
decreased O +
between O +
24 O +
and O +
36 O +
weeks O +
after O +
surgery O +
( O -
p O +
less O +
than O +
0.05 O +
until O +
24 O +
weeks O -
, O +
Mann O -
- O -
Whitney O +
U O -
- O -
test O -
) O -
. O +

Immunohistochemistry O +
scores O +
for O +
matrix O +
metalloproteinase-9 O +
expression O +
were O +
significantly O +
elevated O +
compared O +
to O +
controls O +
in O +
scar O +
endothelial O +
cells O +
and O +
fibroblasts O +
from O +
2 O +
until O +
12 O +
and O +
20 O +
weeks O -
, O +
respectively O -
. O +

Matrix O +
metalloproteinase-2 O +
staining O +
was O +
observed O +
exclusively O +
in O +
fibroblasts O -
, O +
reaching O +
maximum O +
levels O +
8 O -
- O -
12 O +
weeks O +
after O +
surgery O -
, O +
decreasing O +
by O +
1.5 O +
years O +
but O +
remaining O +
significantly O +
increased O -
. O +

Tissue O +
inhibitor O +
of O +
metalloproteinase-1 O +
staining O +
was O +
relatively O +
sparse O +
but O +
was O +
significantly O +
increased O +
until O +
8 O +
weeks O +
after O +
surgery O -
. O +

These O +
results O +
show O +
that O +
matrix O +
metalloproteinases O +
are O +
present O +
at O +
elevated O +
levels O +
during O +
early O +
wound O +
healing O -
, O +
when O +
angiogenesis O +
occurs O -
, O +
and O +
suggest O +
that O +
matrix O +
metalloproteinase-9 O +
may O +
play O +
a O +
significant O +
role O -
. O +

The O +
later O +
expression O +
of O +
matrix O +
metalloproteinase-2 O +
and O +
-9 O +
in O +
fibroblasts O +
suggests O +
a O +
role O +
in O +
extracellular O +
matrix O +
remodeling O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
in O +
seizures O -
: O +
a O +
double O -
- O -
edged O +
sword O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
is O +
a O +
vascular O +
growth O +
factor O +
which O +
induces O +
angiogenesis O +
( O -
the O +
development O +
of O +
new O +
blood O +
vessels O -
) O -
, O +
vascular O +
permeability O -
, O +
and O +
inflammation O -
. O +

In O +
brain O -
, O +
receptors O +
for O +
VEGF O +
have O +
been O +
localized O +
to O +
vascular O +
endothelium O -
, O +
neurons O -
, O +
and O +
glia O -
. O +

VEGF O +
is O +
upregulated O +
after O +
hypoxic O +
injury O +
to O +
the O +
brain O -
, O +
which O +
can O +
occur O +
during O +
cerebral O +
ischemia O +
or O +
high O -
- O -
altitude O +
edema O -
, O +
and O +
has O +
been O +
implicated O +
in O +
the O +
blood O -
- O -
brain O +
barrier O +
breakdown O +
associated O +
with O +
these O +
conditions O -
. O +

Given O +
its O +
recently O -
- O -
described O +
role O +
as O +
an O +
inflammatory O +
mediator O -
, O +
VEGF O +
could O +
also O +
contribute O +
to O +
the O +
inflammatory O +
responses O +
observed O +
in O +
cerebral O +
ischemia O -
. O +

After O +
seizures O -
, O +
blood O -
- O -
brain O +
barrier O +
breakdown O +
and O +
inflammation O +
is O +
also O +
observed O +
in O +
brain O -
, O +
albeit O +
on O +
a O +
lower O +
scale O +
than O +
that O +
observed O +
after O +
stroke O -
. O +

Recent O +
evidence O +
has O +
suggested O +
a O +
role O +
for O +
inflammation O +
in O +
seizure O +
disorders O -
. O +

We O +
have O +
described O +
striking O +
increases O +
in O +
VEGF O +
protein O +
in O +
both O +
neurons O +
and O +
glia O +
after O +
pilocarpine B-Chemical -
- O -
induced O +
status O +
epilepticus O +
in O +
the O +
brain O -
. O +

Increases O +
in O +
VEGF O +
could O +
contribute O +
to O +
the O +
blood O -
- O -
brain O +
barrier O +
breakdown O +
and O +
inflammation O +
observed O +
after O +
seizures O -
. O +

However O -
, O +
VEGF O +
has O +
also O +
been O +
shown O +
to O +
be O +
neuroprotective O +
across O +
several O +
experimental O +
paradigms O -
, O +
and O +
hence O +
could O +
potentially O +
protect O +
vulnerable O +
cells O +
from O +
damage O +
associated O +
with O +
seizures O -
. O +

Therefore O -
, O +
the O +
role O +
of O +
VEGF O +
after O +
seizures O +
could O +
be O +
either O +
protective O +
or O +
destructive O -
. O +

Although O +
only O +
further O +
research O +
will O +
determine O +
the O +
exact O +
nature O +
of O +
VEGF O -
's O +
role O +
after O +
seizures O -
, O +
preliminary O +
data O +
indicate O +
that O +
VEGF O +
plays O +
a O +
protective O +
role O +
after O +
seizures O -
. O +

Clinical O +
implication O +
of O +
expression O +
of O +
cyclooxygenase-2 O +
and O +
peroxisome O +
proliferator O +
activated O -
- O -
receptor O +
gamma O +
in O +
epithelial O +
ovarian O +
tumours O -
. O +

Expression O +
of O +
cyclooxygenase O +
( O -
COX O -
) O -
-2 O +
plays O +
a O +
key O +
role O +
in O +
tumorigenesis O +
and O +
development O +
and O +
peroxisome O +
proliferator O -
- O -
activated O +
receptor O +
gamma O +
( O -
PPARgamma O -
) O +
has O +
been O +
implicated O +
in O +
the O +
control O +
of O +
COX-2 O +
expression O +
in O +
some O +
tissues O -
. O +

The O +
aim O +
of O +
this O +
study O +
is O +
to O +
investigate O +
( O -
1 O -
) O +
whether O +
expression O +
of O +
COX-2 O +
and O +
PPARgamma O +
is O +
associated O +
with O +
ovarian O +
carcinogenesis O +
and O +
progression O +
of O +
ovarian O +
tumours O +
and O +
( O -
2 O -
) O +
whether O +
COX-2 O +
expression O +
is O +
controlled O +
through O +
ligand O -
- O -
mediated O +
activation O +
of O +
PPARgamma O +
in O +
ovarian O +
carcinoma O +
cells O -
. O +

For O +
this O +
purpose O -
, O +
the O +
presence O +
of O +
COX-2 O +
and O +
PPARgamma O +
was O +
immunohistochemically O +
examined O +
in O +
71 O +
epithelial O +
ovarian O +
carcinomas O -
, O +
18 O +
borderline O +
tumours O +
and O +
23 O +
benign O +
tumours O +
and O +
the O +
levels O +
of O +
COX-2 O +
and O +
PPARgamma O +
proteins O +
were O +
determined O +
by O +
enzyme O +
immunoassay O +
in O +
four O +
benign O +
tumours O -
, O +
three O +
borderline O +
tumours O +
and O +
12 O +
carcinomas O -
. O +

The O +
frequency O +
of O +
COX-2 O +
and O +
PPARgamma O +
detection O +
was O +
significantly O +
increased O +
and O +
decreased O +
as O +
lesions O +
progressed O +
to O +
carcinoma O -
, O +
respectively O -
. O +

The O +
COX-2 O +
protein O +
was O +
not O +
detected O +
in O +
the O +
three O +
borderline O +
tumours O -
, O +
whereas O +
PPARgamma O +
protein O +
was O +
detected O +
in O +
all O +
of O +
them O -
. O +

COX-2 O +
protein O +
was O +
detected O +
in O +
eight O +
of O +
the O +
12 O +
carcinomas O -
, O +
whereas O +
PPARgamma O +
protein O +
was O +
detected O +
in O +
only O +
two O +
cases O -
. O +

In O +
addition O -
, O +
PPARgamma O +
protein O +
was O +
not O +
detected O +
in O +
all O +
of O +
the O +
eight O +
carcinomas O +
in O +
which O +
COX-2 O +
protein O +
was O +
detected O -
, O +
suggesting O +
that O +
expression O +
of O +
PPARgamma O +
and O +
COX-2 O +
was O +
in O +
a O +
reciprocal O +
relationship O -
. O +

Furthermore O -
, O +
in O +
cultured O +
ovarian O +
carcinoma O +
cells O -
, O +
Western O +
blot O +
revealed O +
that O +
PPARgamma O +
and O +
COX-2 O +
expression O +
was O +
regulated O +
conversely O +
as O +
a O +
result O +
of O +
stimulation O +
by O +
15-deoxy B-Chemical -
- I-Chemical -
Delta I-Chemical -
( I-Chemical -
12 I-Chemical -
, I-Chemical +
14 I-Chemical -
) I-Chemical +
PGJ I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
( O -
15-PGJ B-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical -
) O -
, O +
a O +
PPARgamma O +
activator O -
. O +

In O +
addition O -
, O +
15d B-Chemical -
- I-Chemical -
PGJ I-Chemical -
( I-Chemical -
2 I-Chemical -
) I-Chemical +
suppressed O +
tumour O +
necrosis O +
factor O -
- O -
alpha O -
- O -
induced O -
- O -
COX-2 O +
expression O -
, O +
confirming O +
the O +
reciprocal O +
correlation O +
between O +
COX-2 O +
and O +
PPARgamma O -
. O +

From O +
these O +
results O -
, O +
it O +
was O +
suggested O +
that O +
PPARgamma O +
activation O +
might O +
suppress O +
COX-2 O +
expression O +
via O +
the O +
nuclear O +
factor O -
- O -
kappaB O +
pathway O +
in O +
the O +
ovarian O +
carcinoma O +
cells O +
and O +
that O +
low O +
expression O +
of O +
PPARgamma O +
and O +
high O +
expression O +
of O +
COX-2 O +
might O +
be O +
involved O +
in O +
carcinogenesis O +
and O +
progression O +
of O +
ovarian O +
tumours O -
. O +

Retrospective O +
case O +
series O +
of O +
juxtafoveal O +
choroidal O +
neovascularization O +
treated O +
with O +
photodynamic O +
therapy O +
with O +
verteporfin B-Chemical -
. O +

PURPOSE O -
: O +
To O +
describe O +
visual O +
acuity O +
and O +
angiographic O +
outcomes O +
of O +
juxtafoveal O +
choroidal O +
neovascularization O +
( O -
CNV O -
) O +
treated O +
with O +
photodynamic O +
therapy O +
and O +
verteporfin B-Chemical +
( O -
PDT O -
) O -
. O +

METHODS O -
: O +
Four O +
hundred O +
eighty O -
- O -
four O +
consecutive O +
eyes O +
of O +
446 O +
patients O +
treated O +
with O +
PDT O +
from O +
January O +
1 O -
, O +
2001 O -
, O +
to O +
June O +
30 O -
, O +
2002 O -
, O +
were O +
identified O +
from O +
billing O +
records O -
. O +

Fluorescein B-Chemical +
angiograms O +
were O +
reviewed O +
retrospectively O +
to O +
identify O +
juxtafoveal O +
CNV O -
. O +

Eligible O +
patients O +
had O +
CNV O +
in O +
which O +
the O +
central O +
boundary O +
of O +
the O +
lesion O +
was O +
between O +
1 O +
and O +
199 O +
microm O +
from O +
the O +
geometric O +
center O +
of O +
the O +
foveal O +
avascular O +
zone O +
( O -
FAZ O -
) O -
. O +

Patient O +
charts O +
were O +
reviewed O +
for O +
visual O +
acuity O +
of O +
the O +
treated O +
eye O +
before O +
PDT O +
and O +
at O +
6- O +
and O +
12-month O +
follow O -
- O -
up O +
examinations O -
. O +

Presence O +
of O +
subfoveal O +
CNV O +
at O +
6 O +
and O +
12 O +
months O +
of O +
follow O -
- O -
up O +
was O +
determined O +
by O +
review O +
of O +
fluorescein B-Chemical +
angiograms O -
. O +

A O +
lesion O +
was O +
considered O +
subfoveal O +
if O +
it O +
extended O +
underneath O +
the O +
geometric O +
center O +
of O +
the O +
FAZ O -
. O +

RESULTS O -
: O +
Twenty O -
- O -
one O +
eyes O +
had O +
juxtafoveal O +
CNV O -
. O +

Median O +
change O +
in O +
visual O +
acuity O +
both O +
6 O +
and O +
12 O +
months O +
after O +
the O +
initial O +
PDT O +
was O +
0 O +
lines O +
( O -
n O +
= O +
18 O +
at O +
6 O +
months O -
, O +
range O +
-14 O +
to O +
+ O +
8 O +
lines O -
; O +
n O +
= O +
17 O +
at O +
12 O +
months O -
, O +
range O +
-18 O +
to O +
+ O +
7 O +
lines O -
) O -
. O +

Eleven O +
lesions O +
progressed O +
to O +
a O +
subfoveal O +
location O +
by O +
12 O +
months O -
. O +

Visual O +
acuity O +
in O +
eyes O +
with O +
progressive O +
lesions O +
decreased O +
a O +
median O +
of O +
4 O +
lines O +
of O +
vision O -
. O +

CONCLUSIONS O -
: O +
Despite O +
a O +
small O +
sample O +
size O +
and O +
limited O +
length O +
of O +
follow O -
- O -
up O -
, O +
this O +
study O +
shows O +
that O +
visual O +
acuity O +
on O +
average O +
can O +
remain O +
stable O +
for O +
at O +
least O +
12 O +
months O +
after O +
PDT O +
of O +
juxtafoveal O +
lesions O -
. O +

Growth O +
through O +
the O +
foveal O +
center O +
still O +
can O +
occur O -
, O +
however O -
, O +
and O +
this O +
can O +
be O +
associated O +
with O +
substantial O +
visual O +
loss O -
. O +

Convergence O +
of O +
p53 O +
and O +
TGF O -
- O -
beta O +
signaling O +
networks O -
. O +

p53 O +
is O +
a O +
protein O +
with O +
many O +
talents O -
. O +

One O +
of O +
the O +
most O +
fundamental O +
is O +
the O +
ability O +
to O +
act O +
as O +
essential O +
growth O +
checkpoint O +
that O +
protects O +
cells O +
against O +
cellular O +
transformation O -
. O +

p53 O +
does O +
so O +
through O +
the O +
induction O +
of O +
genes O +
leading O +
to O +
growth O +
arrest O +
or O +
apoptosis O -
. O +

Most O +
of O +
the O +
studies O +
focusing O +
on O +
the O +
mechanisms O +
of O +
p53 O +
activity O +
have O +
been O +
performed O +
in O +
cultured O +
cells O +
upon O +
treatment O +
with O +
well O -
- O -
established O +
p53-activating O +
inputs O -
, O +
such O +
as O +
high O +
doses O +
of O +
radiations O -
, O +
DNA O -
- O -
damaging O +
drugs O +
and O +
activated O +
oncogenes O -
. O +

However O -
, O +
how O +
the O +
tumor O +
suppressive O +
functions O +
of O +
p53 O +
become O +
concerted O +
with O +
the O +
extracellular O +
cues O +
arriving O +
at O +
the O +
cell O +
surface O +
during O +
tissue O +
homeostasis O -
, O +
remains O +
largely O +
unknown O -
. O +

Intriguingly O -
, O +
two O +
recent O +
papers O +
have O +
shed O +
new O +
light O +
into O +
this O +
unexplored O +
field O -
, O +
indicating O +
that O +
p53 O +
plays O +
a O +
key O +
role O +
in O +
TGF O -
- O -
beta O -
- O -
induced O +
growth O +
arrest O +
and O -
, O +
unexpectedly O -
, O +
in O +
the O +
developmental O +
effects O +
of O +
TGF O -
- O -
beta O +
in O +
early O +
embryos O -
. O +

Here O +
we O +
review O +
and O +
comment O +
on O +
these O +
findings O +
and O +
on O +
their O +
implications O +
for O +
cancer O +
biology O -
. O +

Enhanced O +
IGF-1 O +
expression O +
improves O +
smooth O +
muscle O +
cell O +
engraftment O +
after O +
cell O +
transplantation O -
. O +

The O +
functional O +
benefit O +
of O +
cell O +
transplantation O +
after O +
a O +
myocardial O +
infarction O +
is O +
diminished O +
by O +
early O +
cell O +
losses O -
. O +

IGF-1 O +
enhances O +
cell O +
proliferation O +
and O +
survival O -
. O +

We O +
hypothesized O +
that O +
IGF-1-transfected O +
smooth O +
muscle O +
cells O +
( O -
SMCs O -
) O +
would O +
enhance O +
cell O +
survival O +
and O +
improve O +
engraftment O +
after O +
cell O +
transplantation O -
. O +

The O +
IGF-1 O +
gene O +
was O +
transfected O +
into O +
male O +
SMCs O +
and O +
compared O +
with O +
SMCs O +
transfected O +
with O +
a O +
plasmid O +
vector O +
( O -
vector O +
control O -
) O +
and O +
nontransfected O +
SMCs O +
( O -
cell O +
control O -
) O -
. O +

IGF-1 O +
mRNA O +
( O -
n=10 O -
/ O -
group O -
) O +
and O +
protein O +
levels O +
( O -
n=6 O -
/ O -
group O -
) O +
were O +
higher O +
( O -
P O +
less O +
than O +
0.05 O +
for O +
all O +
groups O -
) O +
at O +
3 O -
, O +
7 O -
, O +
and O +
14 O +
days O +
compared O +
with O +
controls O -
. O +

VEGF O +
was O +
also O +
increased O +
in O +
parallel O +
to O +
enhanced O +
IGF-1 O +
expression O -
. O +

IGF-1-transfected O +
cells O +
demonstrated O +
greater O +
cell O +
proliferation O -
, O +
stimulated O +
angiogenesis O -
, O +
and O +
decreased O +
caspase-3 O +
activity O +
after O +
simulated O +
ischemia O +
and O +
reperfusion O +
( O -
P O +
less O +
than O +
0.05 O +
for O +
all O +
groups O +
compared O +
with O +
vector O +
or O +
cell O +
controls O -
) O -
. O +

A O +
uniform O +
left O +
ventricular O +
injury O +
was O +
produced O +
in O +
female O +
rats O +
using O +
a O +
cryoprobe O -
. O +

Three O +
weeks O +
later O -
, O +
2 O +
x O +
10 O -
( O -
6 O -
) O +
cells O +
from O +
three O +
groups O +
were O +
implanted O +
into O +
the O +
scar O -
. O +

One O +
week O +
later O -
, O +
IGF-1-transfected O +
SMCs O +
had O +
increased O +
myocardial O +
IGF-1 O +
and O +
VEGF O +
levels O -
, O +
increased O +
Bcl2 O +
expression O -
, O +
limited O +
cell O +
apoptosis O -
, O +
and O +
enhanced O +
vessel O +
formation O +
in O +
the O +
myocardial O +
scar O +
compared O +
with O +
the O +
two O +
control O +
groups O +
( O -
P O +
less O +
than O +
0.05 O +
for O +
all O +
groups O -
) O -
. O +

The O +
proportion O +
of O +
SMCs O +
surviving O +
in O +
the O +
implanted O +
region O +
was O +
greater O +
( O -
P O +
less O +
than O +
0.05 O -
) O +
in O +
the O +
IGF-1-transfected O +
group O +
than O +
in O +
the O +
vector O +
or O +
cell O +
controls O -
. O +

Gene O +
enhancement O +
with O +
IGF-1 O +
improved O +
donor O +
cell O +
proliferation O -
, O +
survival O -
, O +
and O +
engraftment O +
after O +
cell O +
transplantation O -
, O +
perhaps O +
mediated O +
by O +
enhanced O +
angiogenesis O +
and O +
reduced O +
apoptosis O -
. O +

[ O -
Altered O +
expression O +
of O +
PTEN O +
gene O +
and O +
LOH O +
of O +
its O +
epigenetic O +
microsatellite O +
in O +
gastric O +
carcinoma O -
] O -
. O +

OBJECTIVE O -
: O +
To O +
investigate O +
the O +
expression O +
of O +
PTEN O +
and O +
loss O +
of O +
heterozygosity O +
( O -
LOH O -
) O +
of O +
its O +
epigenetic O +
microsatellite O +
in O +
gastric O +
carcinoma O +
and O +
explore O +
their O +
roles O +
in O +
progression O +
of O +
gastric O +
carcinoma O -
. O +

METHODS O -
: O +
LOH O +
of O +
epigenetic O +
microsatellites O +
of O +
PTEN O +
( O -
D10S541 O -
, O +
D10S583 O +
and O +
D10S1687 O -
) O +
in O +
advanced O +
gastric O +
cancer O +
was O +
detected O +
by O +
PCR O -
- O -
SSCP O -
. O +

Expression O +
of O +
PTEN O +
mRNA O +
and O +
protein O +
in O +
normal O +
gastric O +
mucosa O +
and O +
gastric O +
cancer O +
was O +
evaluated O +
by O +
RT O -
- O -
PCR O +
and O +
SABC O +
immunohistochemistry O -
, O +
respectively O -
. O +

The O +
relationship O +
between O +
expression O +
of O +
PTEN O +
mRNA O +
and O +
protein O +
and O +
lymph O +
node O +
metastasis O +
or O +
LOH O +
of O +
microsatellites O +
was O +
discussed O -
. O +

RESULTS O -
: O +
LOH O +
of O +
D10S541 O -
, O +
D10S583 O +
and O +
D10S1687 O +
was O +
found O +
in O +
37.5 O -
% O +
( O -
21 O -
/ O -
56 O -
) O +
of O +
advanced O +
gastric O +
cancers O -
. O +

The O +
positive O +
rates O +
of O +
PTEN O +
mRNA O +
expression O +
were O +
80.4 O -
% O +
( O -
45 O -
/ O -
56 O -
) O -
, O +
45.5 O -
% O +
( O -
5 O -
/ O -
11 O -
) O +
and O +
32.1 O -
% O +
( O -
18 O -
/ O -
56 O -
) O +
in O +
normal O +
mucosa O -
, O +
early O +
and O +
advanced O +
gastric O +
carcinomas O -
, O +
respectively O -
, O +
while O +
78.6 O -
% O +
( O -
44 O -
/ O -
56 O -
) O -
, O +
44.5 O -
% O +
( O -
5 O -
/ O -
11 O -
) O +
and O +
28.6 O -
% O +
( O -
16 O -
/ O -
56 O -
) O +
at O +
the O +
protein O +
level O -
. O +

PTEN O +
mRNA O +
and O +
protein O +
were O +
less O +
frequently O +
expressed O +
in O +
early O +
and O +
advanced O +
gastric O +
carcinomas O +
than O +
that O +
in O +
normal O +
gastric O +
mucosa O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

There O +
was O +
positive O +
correlation O +
between O +
PTEN O +
mRNA O +
expression O +
and O +
LOH O +
of O +
microsatellites O +
in O +
advanced O +
gastric O +
carcinomas O -
. O +

PTEN O +
protein O +
expression O +
paralleled O +
with O +
its O +
mRNA O +
expression O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

The O +
expression O +
of O +
PTEN O +
mRNA O +
and O +
protein O +
was O +
negatively O +
correlated O +
with O +
lymph O +
node O +
metastasis O +
of O +
advanced O +
gastric O +
carcinomas O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

CONCLUSION O -
: O +
Down O -
- O -
regulated O +
expression O +
of O +
PTEN O +
gene O +
is O +
found O +
in O +
different O +
stages O +
of O +
gastric O +
carcinoma O -
, O +
and O +
is O +
closely O +
correlated O +
with O +
LOH O +
of O +
its O +
epigenetic O +
microsatellites O -
, O +
which O +
probably O +
is O +
its O +
underlying O +
molecular O +
mechanisms O -
. O +

It O +
suggests O +
that O +
altered O +
PTEN O +
gene O +
contributes O +
to O +
tumorigenesis O +
and O +
progression O +
of O +
gastric O +
carcinomas O -
. O +

Role O +
of O +
osteopontin O +
in O +
adhesion O -
, O +
migration O -
, O +
cell O +
survival O +
and O +
bone O +
remodeling O -
. O +

Osteopontin O +
( O -
OPN O -
) O +
is O +
a O +
secreted O +
adhesive O +
glycophosphoprotein O +
expressed O +
by O +
several O +
cell O +
types O -
. O +

It O +
is O +
normally O +
produced O +
in O +
bone O -
, O +
teeth O -
, O +
kidney O +
and O +
epithelial O +
lining O +
tissues O +
and O +
is O +
found O +
in O +
plasma O +
and O +
breast O +
milk O -
. O +

It O +
is O +
involved O +
in O +
a O +
number O +
of O +
physiologic O +
and O +
pathologic O +
events O +
including O +
angiogenesis O -
, O +
apoptosis O -
, O +
inflammation O -
, O +
wound O +
healing O +
and O +
tumor O +
metastasis O -
. O +

In O +
this O +
review O +
focus O +
will O +
be O +
on O +
OPN O +
in O +
bone O +
and O +
its O +
role O +
in O +
adhesion O -
, O +
migration O +
and O +
cell O +
survival O -
. O +

These O +
aspects O +
of O +
OPN O +
biology O +
are O +
important O +
in O +
tumorigenesis O -
. O +

Granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
and O +
interleukin-3 O +
enhance O +
the O +
incorporation O +
of O +
cytosine B-Chemical +
arabinoside I-Chemical +
into O +
the O +
DNA O +
of O +
leukemic O +
blasts O +
and O +
the O +
cytotoxic O +
effect O +
on O +
clonogenic O +
cells O +
from O +
patients O +
with O +
acute O +
myeloid O +
leukemia O -
. O +

In O +
the O +
present O +
study O +
the O +
effects O +
of O +
the O +
48-hour O +
administration O +
of O +
granulocyte O -
- O -
macrophage O +
colony O -
- O -
stimulating O +
factor O +
( O -
GM O -
- O -
CSF O -
) O +
( O -
100 O +
U O -
/ O -
mL O -
) O +
or O +
interleukin-3 O +
( O -
IL-3 O -
) O +
( O -
100 O +
U O -
/ O -
mL O -
) O +
on O +
the O +
proliferative O +
activity O +
of O +
leukemic O +
cells O +
and O +
on O +
the O +
intracellular O +
metabolism O +
and O +
cytotoxic O +
efficacy O +
of O +
a O +
subsequent O +
12-hour O +
application O +
of O +
cytosine B-Chemical +
arabinoside I-Chemical +
( O -
ara B-Chemical -
- I-Chemical -
C I-Chemical -
) O +
at O +
doses O +
of O +
0.1 O -
, O +
1.0 O -
, O +
10.0 O -
, O +
and O +
100.0 O +
mumol O -
/ O -
L O +
were O +
evaluated O +
on O +
bone O +
marrow O +
cells O +
from O +
17 O +
patients O +
with O +
acute O +
myeloid O +
leukemia O -
. O +

After O +
GM O -
- O -
CSF O +
or O +
IL-3 O -
, O +
a O +
1.2- O +
to O +
2.4-fold O +
increase O +
in O +
S O -
- O -
phase O +
cells O +
was O +
observed O +
in O +
nine O +
of O +
14 O +
GM O -
- O -
CSF O +
and O +
seven O +
of O +
11 O +
IL-3 O +
cases O -
. O +

3H B-Chemical -
- I-Chemical -
Cytosine I-Chemical +
arabinoside I-Chemical +
incorporation O +
into O +
the O +
DNA O +
was O +
enhanced O +
1.33- O +
to O +
18.3-fold O +
over O +
respective O +
controls O +
in O +
14 O +
of O +
17 O +
patients O -
. O +

While O +
in O +
control O +
specimens O +
are O +
ara B-Chemical -
- I-Chemical -
C I-Chemical +
dose O -
- O -
dependent O +
increase O +
in O +
3H B-Chemical -
- I-Chemical -
ara I-Chemical -
- I-Chemical -
C I-Chemical +
uptake O +
was O +
accompanied O +
by O +
a O +
corresponding O +
rise O +
in O +
intracellular O +
ara B-Chemical -
- I-Chemical -
C-5 I-Chemical -
' I-Chemical +
triphosphate I-Chemical +
( O -
ara B-Chemical -
- I-Chemical -
CTP I-Chemical -
) O +
levels O -
, O +
ara B-Chemical -
- I-Chemical -
CTP I-Chemical +
concentrations O +
were O +
not O +
increased O +
after O +
GM O -
- O -
CSF O +
or O +
IL-3 O +
exposure O -
, O +
resulting O +
in O +
a O +
higher O +
ara B-Chemical -
- I-Chemical -
C I-Chemical +
to O +
ara B-Chemical -
- I-Chemical -
CTP I-Chemical +
ratio O +
over O +
controls O -
. O +

This O +
finding O +
may O +
be O +
explained O +
by O +
a O +
stimulatory O +
effect O +
of O +
GM O -
- O -
CSF O +
and O +
IL-3 O +
on O +
ara B-Chemical -
- I-Chemical -
C I-Chemical +
phosphorylating O +
enzymes O +
and O +
a O +
more O +
rapid O +
incorporation O +
of O +
ara B-Chemical -
- I-Chemical -
CTP I-Chemical +
into O +
the O +
DNA O +
of O +
leukemic O +
blasts O -
. O +

These O +
effects O +
translated O +
into O +
a O +
2.2- O +
to O +
229.0-fold O +
increase O +
in O +
the O +
cytotoxic O +
activity O +
of O +
ara B-Chemical -
- I-Chemical -
C I-Chemical +
against O +
clonogenic O +
leukemic O +
cells O +
after O +
GM O -
- O -
CSF O +
or O +
IL-3 O +
pretreatment O -
. O +

Hence O -
, O +
GM O -
- O -
CSF O +
and O +
IL-3 O +
enhance O +
the O +
intracellular O +
metabolism O +
of O +
ara B-Chemical -
- I-Chemical -
C I-Chemical +
and O +
its O +
incorporation O +
into O +
the O +
DNA O +
of O +
leukemic O +
cells O +
leading O +
to O +
a O +
higher O +
antileukemic O +
activity O +
of O +
ara B-Chemical -
- I-Chemical -
C I-Chemical +
on O +
clonogenic O +
leukemic O +
cells O +
( O -
CFU O -
- O -
L O -
) O -
. O +

Oxidation O +
in O +
rheumatoid O +
arthritis O -
. O +

Oxygen B-Chemical +
metabolism O +
has O +
an O +
important O +
role O +
in O +
the O +
pathogenesis O +
of O +
rheumatoid O +
arthritis O -
. O +

Reactive B-Chemical +
oxygen I-Chemical +
species I-Chemical +
( O -
ROS B-Chemical -
) O +
produced O +
in O +
the O +
course O +
of O +
cellular O +
oxidative O +
phosphorylation O -
, O +
and O +
by O +
activated O +
phagocytic O +
cells O +
during O +
oxidative O +
bursts O -
, O +
exceed O +
the O +
physiological O +
buffering O +
capacity O +
and O +
result O +
in O +
oxidative O +
stress O -
. O +

The O +
excessive O +
production O +
of O +
ROS B-Chemical +
can O +
damage O +
protein O -
, O +
lipids B-Chemical -
, O +
nucleic B-Chemical +
acids I-Chemical -
, O +
and O +
matrix O +
components O -
. O +

They O +
also O +
serve O +
as O +
important O +
intracellular O +
signaling O +
molecules O +
that O +
amplify O +
the O +
synovial O +
inflammatory O -
- O -
proliferative O +
response O -
. O +

Repetitive O +
cycles O +
of O +
hypoxia O +
and O +
reoxygenation O +
associated O +
with O +
changes O +
in O +
synovial O +
perfusion O +
are O +
postulated O +
to O +
activate O +
hypoxia O -
- O -
inducible O +
factor-1alpha O +
and O +
nuclear O +
factor O -
- O -
kappaB O -
, O +
two O +
key O +
transcription O +
factors O +
that O +
are O +
regulated O +
by O +
changes O +
in O +
cellular O +
oxygenation O +
and O +
cytokine O +
stimulation O -
, O +
and O +
that O +
in O +
turn O +
orchestrate O +
the O +
expression O +
of O +
a O +
spectrum O +
of O +
genes O +
critical O +
to O +
the O +
persistence O +
of O +
synovitis O -
. O +

An O +
understanding O +
of O +
the O +
complex O +
interactions O +
involved O +
in O +
these O +
pathways O +
might O +
allow O +
the O +
development O +
of O +
novel O +
therapeutic O +
strategies O +
for O +
rheumatoid O +
arthritis O -
. O +

Silencing O +
of O +
monocarboxylate O +
transporters O +
via O +
small O +
interfering O +
ribonucleic O +
acid O +
inhibits O +
glycolysis O +
and O +
induces O +
cell O +
death O +
in O +
malignant O +
glioma O -
: O +
an O +
in O +
vitro O +
study O -
. O +

OBJECTIVE O -
: O +
Dependence O +
on O +
glycolysis O +
is O +
a O +
hallmark O +
of O +
malignant O +
tumors O -
. O +

As O +
a O +
consequence O -
, O +
these O +
tumors O +
generate O +
more O +
lactate B-Chemical -
, O +
which O +
is O +
effluxed O +
from O +
cells O +
by O +
monocarboxylate O +
transporters O +
( O -
MCTs O -
) O -
. O +

We O +
hypothesized O +
that O +
1 O -
) O +
MCT O +
expression O +
in O +
malignant O +
tumors O +
may O +
differ O +
from O +
normal O +
tissue O +
in O +
quantity O -
, O +
isoform O -
, O +
or O +
both O -
; O +
and O +
2 O -
) O +
silencing O +
MCT O +
expression O +
would O +
induce O +
intracellular O +
acidification O -
, O +
resulting O +
in O +
decreased O +
proliferation O +
and/or O +
increased O +
cell O +
death O -
. O +

METHODS O -
: O +
We O +
quantified O +
expression O +
of O +
MCT O +
isoforms O +
in O +
human O +
glioblastoma O +
multiforme O +
and O +
glioma O -
- O -
derived O +
cells O +
lines O +
by O +
Western O +
blot O +
analysis O -
. O +

MCTs O +
that O +
were O +
abundant O +
or O +
specific O +
to O +
glioma O +
then O +
were O +
targeted O +
in O +
the O +
model O +
U-87 O +
MG O +
glioma O +
cell O +
line O +
via O +
small O +
interfering O +
ribonucleic O +
acid O -
- O -
mediated O +
gene O +
silencing O +
and O +
tested O +
for O +
inhibition O +
of O +
lactate B-Chemical +
efflux O -
, O +
intracellular O +
pH O +
changes O -
, O +
reduced O +
proliferation O -
, O +
and/or O +
induction O +
of O +
cell O +
death O -
. O +

RESULTS O -
: O +
MCT O +
1 O +
and O +
2 O +
were O +
the O +
primary O +
isoforms O +
expressed O +
in O +
human O +
glioblastoma O +
multiforme O +
and O +
glioma O -
- O -
derived O +
cell O +
lines O -
. O +

In O +
contrast O -
, O +
MCT O +
3 O +
was O +
the O +
predominantly O +
expressed O +
isoform O +
in O +
normal O +
brain O -
. O +

Small O +
interfering O +
ribonucleic O +
acid O +
specific O +
for O +
MCT O +
1 O +
and O +
2 O +
reduced O +
expression O +
of O +
these O +
isoforms O +
in O +
U-87 O +
MG O +
cells O +
to O +
barely O +
detectable O +
levels O +
and O +
reduced O +
lactate B-Chemical +
efflux O +
by O +
30 O -
% O +
individually O +
and O +
85 O -
% O +
in O +
combination O -
, O +
with O +
a O +
concomitant O +
decrease O +
of O +
intracellular O +
pH O +
by O +
0.6 O +
units O +
( O -
a O +
fourfold O +
increase O +
in O +
intracellular O +
H O -
( O -
+ O -
) O -
) O -
. O +

Prolonged O +
silencing O +
of O +
both O +
MCTs O +
reduced O +
viability O +
by O +
75 O -
% O +
individually O +
and O +
92 O -
% O +
in O +
combination O -
, O +
as O +
measured O +
by O +
both O +
phenotypic O +
and O +
flow O +
cytometric O +
analyses O -
. O +

CONCLUSION O -
: O +
MCT O +
targeting O +
significantly O +
reduced O +
the O +
viability O +
of O +
U-87 O +
MG O +
cells O +
mediated O +
by O +
both O +
apoptosis O +
and O +
necrosis O -
. O +

This O +
indicates O +
that O +
the O +
strategy O +
may O +
be O +
a O +
useful O +
therapeutic O +
avenue O +
for O +
treatment O +
of O +
patients O +
with O +
malignant O +
glioma O -
. O +

Glucocorticoid O +
receptor O -
- O -
induced O +
MAPK O +
phosphatase-1 O +
( O -
MPK-1 O -
) O +
expression O +
inhibits O +
paclitaxel B-Chemical -
- O -
associated O +
MAPK O +
activation O +
and O +
contributes O +
to O +
breast O +
cancer O +
cell O +
survival O -
. O +

Glucocorticoid O +
receptor O +
( O -
GR O -
) O +
activation O +
has O +
recently O +
been O +
shown O +
to O +
inhibit O +
apoptosis O +
in O +
breast O +
epithelial O +
cells O -
. O +

We O +
have O +
previously O +
described O +
a O +
group O +
of O +
genes O +
that O +
is O +
rapidly O +
up O -
- O -
regulated O +
in O +
these O +
cells O +
following O +
dexamethasone B-Chemical +
( O -
Dex B-Chemical -
) O +
treatment O -
. O +

In O +
an O +
effort O +
to O +
dissect O +
the O +
mechanisms O +
of O +
GR O -
- O -
mediated O +
breast O +
epithelial O +
cell O +
survival O -
, O +
we O +
now O +
examine O +
the O +
molecular O +
events O +
downstream O +
of O +
GR O +
activation O -
. O +

Here O +
we O +
show O +
that O +
GR O +
activation O +
leads O +
to O +
both O +
the O +
rapid O +
induction O +
of O +
MAPK O +
phosphatase-1 O +
( O -
MKP-1 O -
) O +
mRNA O +
and O +
its O +
sustained O +
expression O -
. O +

Induction O +
of O +
the O +
MKP-1 O +
protein O +
in O +
the O +
MCF10A O -
- O -
Myc O +
and O +
MDA O -
- O -
MB-231 O +
breast O +
epithelial O +
cell O +
lines O +
was O +
also O +
seen O -
. O +

Paclitaxel B-Chemical +
treatment O +
resulted O +
in O +
MAPK O +
activation O +
and O +
apoptosis O +
of O +
MDA O -
- O -
MB-231 O +
breast O +
cancer O +
cells O -
, O +
and O +
both O +
processes O +
were O +
inhibited O +
by O +
Dex B-Chemical +
pretreatment O -
. O +

Furthermore O -
, O +
induction O +
of O +
MKP-1 O +
correlated O +
with O +
the O +
inhibition O +
of O +
extracellular O +
signal O -
- O -
regulated O +
kinase O +
( O -
ERK1 O -
/ O -
2 O -
) O +
and O +
c O -
- O -
Jun O +
N O -
- O -
terminal O +
kinase O +
( O -
JNK O -
) O +
activity O -
, O +
whereas O +
p38 O +
activity O +
was O +
minimally O +
affected O -
. O +

Blocking O +
Dex B-Chemical -
- O -
induced O +
MKP-1 O +
induction O +
using O +
small O +
interfering O +
RNA O +
increased O +
ERK1 O -
/ O -
2 O +
and O +
JNK O +
phosphorylation O +
and O +
decreased O +
cell O +
survival O -
. O +

ERK1 O -
/ O -
2 O +
and O +
JNK O +
inactivation O +
was O +
associated O +
with O +
Ets O -
- O -
like O +
transcription O +
factor-1 O +
( O -
ELK-1 O -
) O +
dephosphorylation O -
. O +

To O +
explore O +
the O +
gene O +
expression O +
changes O +
that O +
occur O +
downstream O +
of O +
ELK-1 O +
dephosphorylation O -
, O +
we O +
used O +
a O +
combination O +
of O +
temporal O +
gene O +
expression O +
data O +
and O +
promoter O +
element O +
analyses O -
. O +

This O +
approach O +
revealed O +
a O +
previously O +
unrecognized O +
transcriptional O +
target O +
of O +
ELK-1 O -
, O +
the O +
human O +
tissue O +
plasminogen O +
activator O +
( O -
tPA O -
) O -
. O +

We O +
verified O +
the O +
predicted O +
ELK-1 O -
- O -
- O -
> O +
tPA O +
transcriptional O +
regulatory O +
relationship O +
using O +
a O +
luciferase O +
reporter O +
assay O -
. O +

We O +
conclude O +
that O +
GR O -
- O -
mediated O +
MAPK O +
inactivation O +
contributes O +
to O +
cell O +
survival O +
and O +
that O +
the O +
potential O +
transcriptional O +
targets O +
of O +
this O +
inhibition O +
can O +
be O +
identified O +
from O +
large O +
scale O +
gene O +
array O +
analysis O -
. O +

Proteome O +
analysis O +
of O +
NIH3T3 O +
cells O +
transformed O +
by O +
activated O +
Galpha12 O -
: O +
regulation O +
of O +
leukemia O -
- O -
associated O +
protein O +
SET O -
. O +

Galpha O -
( O -
12 O -
) O -
, O +
the O +
alpha O -
- O -
subunit O +
of O +
the O +
G12 O +
family O +
of O +
heterotrimeric O +
G O +
proteins O +
is O +
involved O +
in O +
the O +
regulation O +
of O +
cell O +
proliferation O +
and O +
neoplastic O +
transformation O -
. O +

GTPase O -
- O -
deficient O -
, O +
constitutively O +
activated O +
mutant O +
of O +
Galpha O -
( O -
12 O -
) O +
( O -
Galpha O -
( O -
12 O -
) O -
Q229L O +
or O +
Galpha O -
( O -
12 O -
) O -
QL O -
) O +
has O +
been O +
previously O +
shown O +
to O +
induce O +
oncogenic O +
transformation O +
of O +
NIH3T3 O +
cells O +
promoting O +
serum- O +
and O +
anchorage O -
- O -
independent O +
growth O -
. O +

Reduced O +
growth O -
- O -
factor O +
dependent O -
, O +
autonomous O +
cell O +
growth O +
forms O +
a O +
critical O +
defining O +
point O +
at O +
which O +
a O +
normal O +
cell O +
turns O +
into O +
an O +
oncogenic O +
one O -
. O +

To O +
identify O +
the O +
underlying O +
mechanism O +
involved O +
in O +
such O +
growth O -
- O -
factor O -
/ O -
serum O +
independent O +
growth O +
of O +
Galpha O -
( O -
12 O -
) O -
QL O -
- O -
transformed O +
NIH3T3 O -
, O +
we O +
carried O +
out O +
a O +
two O -
- O -
dimensional O +
differential O +
proteome O +
analysis O +
of O +
Galpha O -
( O -
12 O -
) O -
QL O -
- O -
transformed O +
NIH3T3 O +
cells O +
and O +
cells O +
expressing O +
vector O +
control O -
. O +

This O +
analysis O +
revealed O +
a O +
total O +
of O +
22 O +
protein O -
- O -
spots O +
whose O +
expression O +
was O +
altered O +
by O +
more O +
than O +
3-folds O -
. O +

Two O +
of O +
these O +
spots O +
were O +
identified O +
by O +
MALDI O -
- O -
MS O +
analysis O +
as O +
proliferating O +
cell O +
nuclear O +
antigen O +
( O -
PCNA O -
) O +
and O +
myeloid O -
- O -
leukemia O -
- O -
associated O +
SET O +
protein O -
. O +

The O +
increased O +
expressions O +
of O +
these O +
proteins O +
in O +
Galpha O -
( O -
12 O -
) O -
QL O +
cells O +
were O +
validated O +
by O +
immunoblot O +
analysis O -
. O +

Furthermore O -
, O +
transient O +
transfection O +
studies O +
with O +
NIH3T3 O +
cells O +
indicated O +
that O +
the O +
expression O +
of O +
activated O +
Galpha O -
( O -
12 O -
) O +
readily O +
increased O +
the O +
expression O +
of O +
SET O +
protein O +
by O +
24 O +
h. O +
As O +
SET O +
has O +
been O +
previously O +
reported O +
to O +
be O +
an O +
inhibitor O +
of O +
phosphatase O +
PP2A O -
, O +
the O +
nuclear O +
phosphatase O +
activity O +
was O +
monitored O +
in O +
cells O +
expressing O +
activated O +
Galpha O -
( O -
12 O -
) O -
. O +

Our O +
results O +
indicate O +
that O +
the O +
nuclear O +
phosphatase O +
activity O +
is O +
inhibited O +
by O +
greater O +
than O +
50 O -
% O +
in O +
Galpha O -
( O -
12 O -
) O -
QL O +
cells O +
compared O +
to O +
vector O +
control O +
cells O -
. O +

Thus O -
, O +
our O +
results O +
from O +
differential O +
proteome O +
analysis O +
presented O +
here O +
report O +
for O +
the O +
first O +
time O +
a O +
role O +
for O +
SET O +
in O +
Galpha O -
( O -
12 O -
) O -
-mediated O +
signaling O +
pathways O +
and O +
a O +
role O +
for O +
Galpha O -
( O -
12 O -
) O +
in O +
the O +
regulation O +
of O +
the O +
leukemia O -
- O -
associated O +
SET O -
- O -
protein O +
expression O -
. O +

Expression O +
and O +
purification O +
of O +
the O +
catalytic O +
domain O +
of O +
human O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
2 O +
for O +
inhibitor O +
screening O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
, O +
an O +
endothelial O +
cell O -
- O -
specific O +
mitogen O -
, O +
can O +
act O +
in O +
tumor O -
- O -
induced O +
angiogenesis O +
by O +
binding O +
to O +
specific O +
receptors O +
on O +
the O +
surface O +
of O +
endothelial O +
cells O -
. O +

One O +
such O +
receptor O -
, O +
VEGFR-2 O -
/ O -
KDR O -
, O +
plays O +
a O +
key O +
role O +
in O +
VEGF O -
- O -
induced O +
angiogenesis O -
. O +

Here O -
, O +
we O +
expressed O +
the O +
catalytic O +
domain O +
of O +
VEGFR-2 O +
as O +
a O +
soluble O +
active O +
kinase O +
using O +
Bac O -
- O -
to O -
- O -
Bac O +
expression O +
system O -
, O +
and O +
investigated O +
correlations O +
between O +
VEGFR-2 O +
activity O +
and O +
enzyme O +
concentration O -
, O +
ATP B-Chemical +
concentration O -
, O +
substrate O +
concentration O +
and O +
divalent O +
cation O +
type O -
. O +

We O +
used O +
these O +
data O +
to O +
establish O +
a O +
convenient O -
, O +
effective O +
and O +
non O -
- O -
radioactive O +
ELISA O +
screening O +
technique O +
for O +
the O +
identification O +
and O +
evaluation O +
of O +
potential O +
inhibitors O +
for O +
VEGFR-2 O +
kinase O -
. O +

We O +
screened O +
200 O +
RTK O +
target O -
- O -
based O +
compounds O +
and O +
identified O +
one O +
( O -
TKI-31 B-Chemical -
) O +
that O +
potently O +
inhibited O +
VEGFR-2 O +
kinase O +
activity O +
( O -
IC50=0.596 O +
microM O -
) O -
. O +

Treatment O +
of O +
NIH3T3 O -
/ O -
KDR O +
cells O +
with O +
TKI-31 B-Chemical +
blocked O +
VEGF O -
- O -
induced O +
phosphorylation O +
of O +
KDR O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

Moreover O -
, O +
TKI-31 B-Chemical +
dose O -
- O -
dependently O +
suppressed O +
HUVEC O +
tube O +
formation O -
. O +

Thus O -
, O +
we O +
herein O +
report O +
a O +
novel O -
, O +
efficient O +
method O +
for O +
identifying O +
VEGFR-2 O +
kinase O +
inhibitors O +
and O +
introduce O +
one O -
, O +
TKI-31 B-Chemical -
, O +
that O +
may O +
prove O +
to O +
be O +
a O +
useful O +
new O +
angiogenesis O +
inhibitor O -
. O +

An O +
evaluation O +
of O +
low B-Chemical +
molecular I-Chemical +
weight I-Chemical +
heparin I-Chemical +
and O +
hyperbaric B-Chemical +
oxygen I-Chemical +
treatment O +
in O +
the O +
prevention O +
of O +
intra O -
- O -
abdominal O +
adhesions O +
and O +
wound O +
healing O -
. O +

BACKGROUND O -
: O +
Abdominal O +
surgery O +
can O +
lead O +
to O +
intra O -
- O -
abdominal O +
adhesions O +
with O +
significant O +
morbidity O +
and O +
mortality O -
. O +

To O +
prevent O +
adhesions O -
, O +
an O +
experimental O +
study O +
was O +
planned O +
to O +
designate O +
the O +
effects O +
of O +
low B-Chemical +
molecular I-Chemical +
weight I-Chemical +
( I-Chemical -
LMW I-Chemical -
) I-Chemical +
heparins I-Chemical +
and O +
hyperbaric B-Chemical +
oxygen I-Chemical +
( O -
HBO B-Chemical -
) O +
therapy O +
both O +
on O +
the O +
formation O +
of O +
adhesions O +
and O +
wound O +
healing O -
. O +

METHODS O -
: O +
Thirty O -
- O -
eight O +
Wistar O +
albino O +
rats O +
underwent O +
laparotomy O +
to O +
cause O +
intra O -
- O -
abdominal O +
adhesions O +
by O +
mechanical O +
abrasion O +
of O +
the O +
cecum O +
and O +
ethanol B-Chemical +
application O -
. O +

The O +
rats O +
were O +
divided O +
into O +
4 O +
groups O -
. O +

In O +
the O +
control O +
group O +
( O -
group O +
1 O -
) O +
no O +
further O +
management O +
was O +
undertaken O -
. O +

Group O +
2 O +
was O +
treated O +
by O +
Enoxaparine B-Chemical +
Na I-Chemical -
, O +
group O +
3 O +
received O +
HBO B-Chemical +
therapy O -
, O +
and O +
group O +
4 O +
was O +
given O +
both O +
enoxaparine B-Chemical +
Na I-Chemical +
and O +
HBO B-Chemical +
treatment O -
. O +

RESULTS O -
: O +
There O +
was O +
a O +
statistically O +
significant O +
difference O +
between O +
the O +
control O +
and O +
enoxaparine B-Chemical +
Na I-Chemical +
groups O +
regarding O +
adhesions O -
. O +

Statistically O +
significant O +
differences O +
were O +
observed O +
between O +
groups O +
1 O +
and O +
4 O +
and O +
between O +
groups O +
1 O +
and O +
3 O +
regarding O +
the O +
hydroxyproline O +
content O +
of O +
the O +
abdominal O +
wounds O -
. O +

In O +
the O +
pathologic O +
analysis O +
of O +
the O +
abdominal O +
wounds O -
, O +
there O +
was O +
no O +
statistically O +
significant O +
difference O +
between O +
any O +
of O +
the O +
groups O -
, O +
including O +
the O +
control O +
group O -
, O +
regarding O +
inflammation O -
. O +

Statistically O +
significant O +
differences O +
were O +
observed O +
regarding O +
angiogenesis O +
between O +
the O +
control O +
group O +
and O +
groups O +
3 O +
and O +
4 O -
. O +

There O +
was O +
also O +
a O +
statistically O +
significant O +
difference O +
regarding O +
fibrosis O +
between O +
groups O +
1 O +
and O +
4 O -
. O +

CONCLUSIONS O -
: O +

Enoxaparine B-Chemical +
Na I-Chemical +
decreased O +
intra O -
- O -
abdominal O +
adhesions O -
, O +
and O +
HBO B-Chemical +
therapy O +
had O +
no O +
beneficial O +
effect O +
on O +
adhesions O -
. O +

Enoxaparine B-Chemical +
Na I-Chemical +
had O +
no O +
harmful O +
effects O +
on O +
wound O +
healing O -
, O +
and O +
HBO B-Chemical +
therapy O +
increased O +
the O +
process O +
of O +
wound O +
healing O -
. O +

Investigating O +
the O +
causes O +
of O +
low O +
birth O +
weight O +
in O +
contrasting O +
ovine O +
paradigms O -
. O +

Intrauterine O +
growth O +
restriction O +
( O -
IUGR O -
) O +
still O +
accounts O +
for O +
a O +
large O +
incidence O +
of O +
infant O +
mortality O +
and O +
morbidity O +
worldwide O -
. O +

Many O +
of O +
the O +
circulatory O +
and O +
transport O +
properties O +
of O +
the O +
sheep O +
placenta O +
are O +
similar O +
to O +
those O +
of O +
the O +
human O +
placenta O +
and O +
as O +
such O -
, O +
the O +
pregnant O +
sheep O +
offers O +
an O +
excellent O +
model O +
in O +
which O +
to O +
study O +
the O +
development O +
of O +
IUGR O -
. O +

Two O +
natural O +
models O +
of O +
ovine O +
IUGR O +
are O +
those O +
of O +
hyperthermic O +
exposure O +
during O +
pregnancy O -
, O +
and O +
adolescent O +
overfeeding O -
, O +
also O +
during O +
pregnancy O -
. O +

Both O +
models O +
yield O +
significantly O +
reduced O +
placental O +
weights O +
and O +
an O +
asymmetrically O +
growth O -
- O -
restricted O +
fetus O -
, O +
and O +
display O +
altered O +
maternal O +
hormone O +
concentrations O -
, O +
indicative O +
of O +
an O +
impaired O +
trophoblast O +
capacity O -
. O +

Additionally O -
, O +
impaired O +
placental O +
angiogenesis O +
and O +
uteroplacental O +
blood O +
flow O +
appears O +
to O +
be O +
an O +
early O +
defect O +
in O +
both O +
the O +
hyperthermic O +
and O +
adolescent O +
paradigms O -
. O +

The O +
effects O +
of O +
these O +
alterations O +
in O +
placental O +
functional O +
development O +
appear O +
to O +
be O +
irreversible O -
. O +

IUGR O +
fetuses O +
are O +
both O +
hypoxic O +
and O +
hypoglycaemic O -
, O +
and O +
have O +
reduced O +
insulin O +
and O +
insulin O -
- O -
like O +
growth O +
factor-1 O +
( O -
IGF-1 O -
) O -
, O +
and O +
elevated O +
concentrations O +
of O +
lactate B-Chemical -
. O +

However O -
, O +
fetal O +
utilization O +
of O +
oxygen B-Chemical +
and O +
glucose B-Chemical -
, O +
on O +
a O +
weight O +
basis O -
, O +
remain O +
constant O +
compared O +
with O +
control O +
pregnancies O -
. O +

Maintained O +
utilization O +
of O +
these O +
substrates O -
, O +
in O +
a O +
substrate O -
- O -
deficient O +
environment O -
, O +
suggests O +
increased O +
sensitivities O +
to O +
metabolic O +
signals O -
, O +
which O +
may O +
play O +
a O +
role O +
in O +
the O +
development O +
of O +
metabolic O +
diseases O +
in O +
later O +
adult O +
life O -
. O +

Hereditary O +
paraganglioma O -
/ O -
pheochromocytoma O +
and O +
inherited O +
succinate O +
dehydrogenase O +
deficiency O -
. O +

Mitochondrial O +
complex O +
II O -
, O +
or O +
succinate O +
dehydrogenase O -
, O +
is O +
a O +
key O +
enzymatic O +
complex O +
involved O +
in O +
both O +
the O +
tricarboxylic B-Chemical +
acid I-Chemical +
( O -
TCA B-Chemical -
) O +
cycle O +
and O +
oxidative O +
phosphorylation O +
as O +
part O +
of O +
the O +
mitochondrial O +
respiratory O +
chain O -
. O +

Germline O +
succinate O +
dehydrogenase O +
subunit O +
A O +
( O -
SDHA O -
) O +
mutations O +
have O +
been O +
reported O +
in O +
a O +
few O +
patients O +
with O +
a O +
classical O +
mitochondrial O +
neurodegenerative O +
disease O -
. O +

Mutations O +
in O +
the O +
genes O +
encoding O +
the O +
three O +
other O +
succinate O +
dehydrogenase O +
subunits O +
( O -
SDHB O -
, O +
SDHC O +
and O +
SDHD O -
) O +
have O +
been O +
identified O +
in O +
patients O +
affected O +
by O +
familial O +
or O +
' O -
apparently O +
sporadic O -
' O +
paraganglioma O +
and/or O +
pheochromocytoma O -
, O +
an O +
autosomal O +
inherited O +
cancer O -
- O -
susceptibility O +
syndrome O -
. O +

These O +
discoveries O +
have O +
dramatically O +
changed O +
the O +
work O -
- O -
up O +
and O +
genetic O +
counseling O +
of O +
patients O +
and O +
families O +
with O +
paragangliomas O +
and/or O +
pheochromocytomas O -
. O +

The O +
subsequent O +
identification O +
of O +
germline O +
mutations O +
in O +
the O +
gene O +
encoding O +
fumarase O -
-- O -
another O +
TCA B-Chemical +
cycle O +
enzyme O -
-- O -
in O +
a O +
new O +
hereditary O +
form O +
of O +
susceptibility O +
to O +
renal O -
, O +
uterine O +
and O +
cutaneous O +
tumors O +
has O +
highlighted O +
the O +
potential O +
role O +
of O +
the O +
TCA B-Chemical +
cycle O +
and O -
, O +
more O +
generally O -
, O +
of O +
the O +
mitochondria O +
in O +
cancer O -
. O +

p53 O +
mutation O +
heterogeneity O +
in O +
cancer O -
. O +

The O +
p53 O +
gene O +
is O +
inactivated O +
in O +
about O +
50 O -
% O +
of O +
human O +
cancers O +
and O +
the O +
p53 O +
protein O +
is O +
an O +
essential O +
component O +
of O +
the O +
cell O +
response O +
induced O +
by O +
genotoxic O +
stresses O +
such O +
as O +
those O +
generated O +
by O +
radiotherapy O +
or O +
chemotherapy O -
. O +

It O +
is O +
therefore O +
highly O +
likely O +
that O +
these O +
alterations O +
are O +
an O +
important O +
component O +
in O +
tumor O +
resistance O +
to O +
therapy O -
. O +

The O +
particular O +
characteristics O +
of O +
these O +
alterations O -
, O +
80 O -
% O +
of O +
which O +
are O +
missense O +
mutations O +
leading O +
to O +
functionally O +
heterogeneous O +
proteins O -
, O +
make O +
p53 O +
a O +
unique O +
gene O +
in O +
the O +
class O +
of O +
tumor O +
suppressor O +
genes O -
. O +

A O +
considerable O +
number O +
of O +
mutant O +
p53 O +
proteins O +
probably O +
have O +
an O +
oncogenic O +
activity O +
per O +
se O +
and O +
therefore O +
actively O +
participate O +
in O +
cell O +
transformation O -
. O +

The O +
fact O +
that O +
the O +
apoptotic O +
and O +
antiproliferative O +
functions O +
of O +
p53 O +
can O +
be O +
dissociated O +
in O +
certain O +
mutants O +
also O +
suggests O +
another O +
level O +
of O +
complexity O +
in O +
the O +
relationships O +
between O +
p53 O +
inactivation O +
and O +
neoplasia O -
. O +

Rofecoxib B-Chemical +
as O +
adjunctive O +
therapy O +
for O +
haemophilic O +
arthropathy O -
. O +

Joint O +
haemorrhage O +
and O +
subsequent O +
haemophilic O +
arthropathy O +
are O +
significant O +
complications O +
in O +
haemophilia O -
. O +

The O +
pathophysiology O +
involves O +
inflammation O +
and O +
angiogenesis O -
. O +

Cyclooxygenase-2 O +
( O -
COX-2 O -
) O +
inhibitors O +
are O +
anti O -
- O -
inflammatory O +
agents O -
, O +
which O +
have O +
potent O +
anti O -
- O -
inflammatory O -
, O +
anti O -
- O -
angiogenic O +
and O +
analgesic O +
properties O +
yet O +
do O +
not O +
affect O +
platelet O +
function O +
in O +
the O +
manner O +
of O +
traditional O +
non B-Chemical -
- I-Chemical -
steroidal I-Chemical +
anti I-Chemical -
- I-Chemical -
inflammatory I-Chemical +
drugs I-Chemical -
. O +

These O +
properties O +
make O +
such O +
agents O +
potentially O +
useful O +
as O +
adjunctive O +
therapy O +
in O +
haemophilia O -
. O +

There O +
is O +
only O +
one O +
prior O +
report O +
describing O +
rofecoxib B-Chemical +
treatment O +
in O +
a O +
single O +
haemophilia O +
patient O -
. O +

Our O +
objectives O +
were O +
to O +
determine O +
the O +
safety O +
and O +
efficacy O +
of O +
rofecoxib B-Chemical +
in O +
treating O +
acute O +
haemarthrosis O -
, O +
chronic O +
synovitis O -
, O +
target O +
joints O +
and O +
pain O -
. O +

We O +
conducted O +
a O +
retrospective O +
medical O +
record O +
review O +
of O +
patients O +
treated O +
with O +
rofecoxib B-Chemical +
for O +
acute O +
haemarthrosis O -
, O +
chronic O +
synovitis O -
, O +
target O +
joint O +
or O +
pain O -
. O +

The O +
safety O +
and O +
efficacy O +
of O +
rofecoxib B-Chemical +
treatment O +
were O +
determined O +
based O +
on O +
subjective O +
patient O +
reports O +
and O +
physical O +
examinations O +
during O +
follow O -
- O -
up O +
clinic O +
visits O -
. O +

A O +
total O +
of O +
28 O +
patients O +
between O +
3 O +
and O +
37 O +
years O +
of O +
age O +
were O +
treated O +
for O +
a O +
total O +
of O +
42 O +
courses O +
of O +
rofecoxib B-Chemical +
treatment O -
. O +

All O +
courses O +
were O +
evaluated O +
for O +
safety O +
and O +
31 O +
for O +
efficacy O -
. O +

Rofecoxib B-Chemical +
was O +
used O +
for O +
eight O +
acute O +
haemarthrosis O -
, O +
four O +
target O +
joints O -
, O +
seven O +
cases O +
of O +
synovitis O +
and O +
12 O +
episodes O +
of O +
pain O -
. O +

Efficacy O +
was O +
demonstrated O +
particularly O +
for O +
chronic O +
synovitis O +
and O +
pain O +
and O +
no O +
serious O +
adverse O +
events O +
occurred O -
. O +

This O +
is O +
the O +
largest O +
study O +
to O +
date O +
evaluating O +
COX-2 O +
inhibitors O +
as O +
adjunctive O +
therapy O +
in O +
haemophilia O +
and O +
suggests O +
that O +
these O +
agents O +
may O +
be O +
an O +
important O +
adjunctive O +
therapy O +
in O +
the O +
management O +
of O +
haemophilia O -
. O +

Randomized O -
, O +
open O +
label O -
, O +
prospective O +
study O +
on O +
the O +
effect O +
of O +
zoledronic B-Chemical +
acid I-Chemical +
on O +
the O +
prevention O +
of O +
bone O +
metastases O +
in O +
patients O +
with O +
recurrent O +
solid O +
tumors O +
that O +
did O +
not O +
present O +
with O +
bone O +
metastases O +
at O +
baseline O -
. O +

OBJECTIVES O -
: O +
Bisphosphonates B-Chemical +
have O +
been O +
used O +
successfully O +
in O +
the O +
treatment O +
of O +
hypercalcemia O +
and O +
to O +
reduce O +
skeletal O -
- O -
related O +
complications O +
of O +
bone O +
metastases O -
. O +

Recent O +
in O +
vitro O +
and O +
in O +
vivo O +
evidence O +
suggest O +
that O +
they O +
may O +
also O +
have O +
direct O +
antitumor O +
effects O +
via O +
induction O +
of O +
apoptosis O -
, O +
inhibition O +
of O +
the O +
invasive O +
potential O +
of O +
tumor O +
cell O +
lines O +
in O +
vitro O -
, O +
inhibition O +
of O +
angiogenesis O -
, O +
and O +
reduction O +
in O +
tumor O +
growth O +
indirectly O +
via O +
effects O +
on O +
accessory O +
cells O -
. O +

This O +
is O +
a O +
randomized O -
, O +
open O +
label O -
, O +
prospective O +
study O +
that O +
examined O +
the O +
effect O +
of O +
preventive O +
zoledronic B-Chemical +
acid I-Chemical +
treatment O +
on O +
the O +
development O +
of O +
bone O +
metastases O +
in O +
patients O +
with O +
recurrent O +
solid O +
tumors O -
, O +
without O +
bone O +
metastases O +
at O +
the O +
time O +
of O +
randomization O -
. O +

METHODS O -
: O +
Forty O +
patients O +
with O +
recurrent O +
or O +
metastatic O +
advanced O +
cancer O -
, O +
without O +
bone O +
metastases O -
, O +
were O +
randomized O +
into O +
the O +
trial O +
to O +
either O +
receive O +
zoledronic B-Chemical +
acid I-Chemical +
or O +
no O +
treatment O -
. O +

Patients O +
were O +
followed O +
up O +
until O +
bone O +
metastases O +
were O +
established O -
. O +

RESULTS O -
: O +
The O +
percentage O +
of O +
patients O +
being O +
bone O +
metastases O +
free O +
at O +
12 O +
mo O +
was O +
60 O -
% O +
in O +
the O +
zoledronic B-Chemical +
acid I-Chemical +
and O +
10 O -
% O +
in O +
the O +
control O +
group O +
( O -
p O +
less O +
than O +
0.0005 O -
) O -
, O +
while O +
the O +
percentages O +
at O +
18 O +
mo O +
were O +
20 O -
% O +
and O +
5 O -
% O +
respectively O +
( O -
p=0.0002 O -
) O -
. O +

CONCLUSIONS O -
: O +
The O +
results O +
have O +
shown O +
that O +
bisphosphonates B-Chemical +
as O +
adjuvant O +
treatment O +
might O +
be O +
useful O +
for O +
the O +
prevention O +
of O +
bone O +
metastases O -
; O +
however O -
, O +
there O +
is O +
need O +
for O +
blinded O +
randomized O +
data O +
before O +
such O +
an O +
approach O +
would O +
be O +
confirmed O -
. O +

In O +
the O +
meantime O +
preventive O +
use O +
of O +
bisphosphonates B-Chemical +
in O +
patients O +
without O +
any O +
bone O +
metastases O +
should O +
not O +
be O +
used O +
outside O +
the O +
scope O +
of O +
a O +
clinical O +
trial O -
. O +

Thalidomide B-Chemical +
and O +
angiostatin O +
inhibit O +
tumor O +
growth O +
in O +
a O +
murine O +
xenograft O +
model O +
of O +
human O +
cervical O +
cancer O -
. O +

OBJECTIVE O -
: O +
To O +
determine O +
the O +
impact O +
of O +
thalidomide B-Chemical +
and O +
angiostatin O +
on O +
tumor O +
growth O -
, O +
angiogenesis O -
, O +
and O +
apoptosis O +
in O +
a O +
xenograft O +
model O +
of O +
cervical O +
cancer O -
. O +

METHODS O -
: O +
Human O +
umbilical O +
endothelial O +
cells O +
were O +
treated O +
with O +
angiostatin O +
or O +
thalidomide B-Chemical +
and O +
bFGF O -
- O -
induced O +
proliferation O +
was O +
assessed O +
with O +
the O +
MTT O +
assay O -
. O +

Human O +
cervical O +
cancer O +
cells O +
( O -
CaSki O +
and O +
SiHa O -
) O +
were O +
injected O +
into O +
the O +
flanks O +
of O +
nude O +
mice O -
. O +

After O +
tumors O +
developed O -
, O +
mice O +
were O +
treated O +
with O +
angiostatin O +
20 O +
mg O -
/ O -
kg O -
/ O -
day O +
or O +
thalidomide B-Chemical +
200 O +
mg O -
/ O -
kg O -
/ O -
day O +
for O +
30 O +
days O -
. O +

Fractional O +
tumor O +
growth O +
was O +
determined O +
and O +
immunohistochemical O +
analysis O +
of O +
tumors O +
was O +
used O +
to O +
determine O +
degree O +
of O +
angiogenesis O -
. O +

TUNEL O +
assay O +
was O +
used O +
to O +
assess O +
apoptosis O -
. O +

RESULTS O -
: O +
Angiostatin O +
inhibited O +
endothelial O +
cell O +
proliferation O +
by O +
50 O -
- O -
60 O -
% O -
. O +

Thalidomide B-Chemical +
had O +
no O +
direct O +
effect O +
on O +
endothelial O +
cells O -
. O +

Angiostatin O +
and O +
thalidomide B-Chemical +
both O +
inhibited O +
tumor O +
growth O +
by O +
about O +
55 O -
% O -
. O +

We O +
found O +
no O +
additive O +
or O +
synergistic O +
effect O +
when O +
the O +
two O +
agents O +
were O +
combined O -
. O +

Both O +
agents O +
inhibited O +
angiogenesis O +
and O +
induced O +
apoptosis O +
when O +
compared O +
to O +
tumors O +
from O +
control O +
animals O -
. O +

CONCLUSIONS O -
: O +
Angiostatin O +
and O +
thalidomide B-Chemical +
inhibit O +
tumor O +
growth O -
, O +
angiogenesis O -
, O +
and O +
induce O +
apoptosis O +
in O +
this O +
xenograft O +
model O +
of O +
cervical O +
cancer O -
. O +

Minimal O +
contribution O +
of O +
marrow O -
- O -
derived O +
endothelial O +
precursors O +
to O +
tumor O +
vasculature O -
. O +

During O +
embryogenesis O -
, O +
vascular O +
and O +
hemopoietic O +
cells O +
originate O +
from O +
a O +
common O +
precursor O -
, O +
the O +
hemangioblast O -
. O +

Recent O +
evidence O +
suggests O +
the O +
existence O +
of O +
endothelial O +
precursors O +
in O +
adult O +
bone O +
marrow O +
cells O -
, O +
but O +
it O +
is O +
unclear O +
whether O +
those O +
precursors O +
have O +
a O +
role O +
in O +
tumor O +
neovascularization O -
. O +

In O +
this O +
report O -
, O +
we O +
demonstrate O +
that O +
murine O +
bone O +
marrow O +
contains O +
endothelial O +
progenitors O -
, O +
which O +
arise O +
from O +
a O +
cell O +
with O +
self O -
- O -
renewing O +
capacity O -
, O +
and O +
can O +
integrate O +
into O +
tumor O +
microvasculature O -
, O +
albeit O +
at O +
a O +
very O +
low O +
frequency O -
. O +

A O +
transgenic O +
double O -
- O -
reporter O +
strategy O +
allowed O +
us O +
to O +
demonstrate O +
definitively O +
that O +
tumor O +
bone O +
marrow O -
- O -
derived O +
endothelial O +
cells O +
arise O +
by O +
transdifferentiation O +
of O +
marrow O +
progenitors O +
rather O +
than O +
by O +
cell O +
fusion O -
. O +

Single O +
cell O +
transplants O +
showed O +
that O +
a O +
common O +
precursor O +
contributes O +
to O +
both O +
the O +
hemopoietic O +
and O +
endothelial O +
lineages O -
, O +
thus O +
demonstrating O +
the O +
presence O +
of O +
an O +
adult O +
hemangioblast O -
. O +

Furthermore O -
, O +
we O +
demonstrate O +
that O +
increased O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
-A O +
secretion O +
by O +
tumor O +
cells O -
, O +
as O +
well O +
as O +
activation O +
of O +
VEGF O +
receptor-2 O +
in O +
bone O +
marrow O +
cells O +
does O +
not O +
alter O +
the O +
mobilization O +
and O +
incorporation O +
of O +
marrow O -
- O -
derived O +
endothelial O +
progenitors O +
into O +
tumor O +
vasculature O -
. O +

Finally O -
, O +
in O +
human O +
umbilical O +
cord O +
blood O +
cells O -
, O +
we O +
show O +
that O +
endothelial O +
precursors O +
make O +
up O +
only O +
approximately O +
1 O +
in O +
10 O -
( O -
7 O -
) O +
mononuclear O +
cells O +
but O +
are O +
highly O +
enriched O +
in O +
the O +
CD133 O -
+ O +
cell O +
population O -
. O +

By O +
ruling O +
out O +
cell O +
fusion O -
, O +
we O +
clearly O +
demonstrate O +
the O +
existence O +
of O +
an O +
adult O +
hemangioblast O -
, O +
but O +
the O +
differentiation O +
of O +
marrow O +
stem O +
cells O +
toward O +
the O +
endothelial O +
lineage O +
is O +
an O +
extremely O +
rare O +
event O -
. O +

Furthermore O -
, O +
we O +
show O +
that O +
VEGF O -
- O -
A O +
stimulation O +
of O +
hemopoietic O +
cells O +
does O +
not O +
significantly O +
alter O +
this O +
process O -
. O +

The O +
merits O +
of O +
vascular O +
targeting O +
for O +
gynecologic O +
malignancies O -
. O +

Neovascularization O +
is O +
an O +
early O +
and O +
critical O +
step O +
in O +
tumor O +
development O +
and O +
progression O -
. O +

Tumor O +
vessels O +
are O +
distinct O +
from O +
their O +
normal O +
counterparts O +
morphologically O +
as O +
well O +
as O +
at O +
a O +
molecular O +
level O -
. O +

Recent O +
studies O +
on O +
factors O +
involved O +
in O +
tumor O +
vascular O +
development O +
have O +
identified O +
new O +
therapeutic O +
targets O +
for O +
inhibiting O +
tumor O +
neovascularization O +
and O +
thus O +
tumor O +
progression O -
. O +

However O -
, O +
the O +
process O +
of O +
tumor O +
blood O +
vessel O +
formation O +
is O +
complex O -
, O +
and O +
each O +
tumor O +
exhibits O +
unique O +
features O +
in O +
its O +
vasculature O -
. O +

An O +
understanding O +
of O +
the O +
relative O +
contribution O +
of O +
various O +
pathways O +
in O +
the O +
development O +
of O +
tumor O +
vasculature O +
is O +
critical O +
for O +
developing O +
effective O +
and O +
selective O +
therapeutic O +
approaches O -
. O +

Several O +
such O +
agents O +
are O +
currently O +
in O +
clinical O +
trials O -
, O +
and O +
many O +
others O +
are O +
under O +
development O -
. O +

In O +
this O +
review O -
, O +
the O +
mechanisms O +
and O +
factors O +
involved O +
in O +
tumor O +
blood O +
vessel O +
formation O +
are O +
discussed O -
. O +

In O +
addition O -
, O +
selected O +
novel O +
classes O +
of O +
antivascular O +
therapies O -
, O +
including O +
those O +
targeting O +
tumor O +
endothelial O +
cells O +
and O +
other O +
components O +
of O +
the O +
tumor O +
vasculature O -
, O +
are O +
summarized O -
. O +

Domain O +
5 O +
of O +
cleaved O +
high O +
molecular O +
weight O +
kininogen O +
inhibits O +
endothelial O +
cell O +
migration O +
through O +
Akt O -
. O +

Domain O +
5 O +
( O -
D5 O -
) O +
of O +
cleaved O +
high O +
molecular O +
weight O +
kininogen O +
( O -
HKa O -
) O +
inhibits O +
angiogenesis O +
in O +
vivo O +
and O +
endothelial O +
cell O +
migration O +
in O +
vitro O -
, O +
but O +
the O +
cell O +
signaling O +
pathways O +
involved O +
in O +
HKa O +
and O +
D5 O +
inhibition O +
of O +
endothelial O +
cell O +
migration O +
are O +
incompletely O +
delineated O -
. O +

This O +
study O +
examines O +
the O +
mechanism O +
of O +
HKa O +
and O +
D5 O +
inhibition O +
of O +
two O +
potent O +
stimulators O +
of O +
endothelial O +
cell O +
migration O -
, O +
sphingosine O +
1-phosphate O +
( O -
S1P O -
) O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
, O +
that O +
act O +
through O +
the O +
P13-kinase O -
- O -
Akt O +
signaling O +
pathway O -
. O +

HKa O +
and O +
D5 O +
inhibit O +
bovine O +
pulmonary O +
artery O +
endothelial O +
cell O +
( O -
BPAE O -
) O +
or O +
human O +
umbilical O +
vein O +
endothelial O +
cell O +
chemotaxis O +
in O +
the O +
modified O -
- O -
Boyden O +
chamber O +
in O +
response O +
toVEGF O +
or O +
S1P O -
. O +

The O +
inhibition O +
of O +
migration O +
by O +
HKa O +
is O +
reversed O +
by O +
antibodies O +
to O +
urokinase O -
- O -
type O +
plasminogen O +
activator O +
receptor O -
. O +

Both O +
HKa O +
and O +
D5 O +
decrease O +
the O +
speed O +
of O +
BPAE O +
cell O +
migration O +
and O +
alter O +
the O +
morphology O +
in O +
live O -
, O +
time O -
- O -
lapse O +
microscopy O +
after O +
stimulation O +
with O +
S1P O +
or O +
VEGF O -
. O +

HKa O +
and O +
D5 O +
reduce O +
the O +
localization O +
of O +
paxillin O +
to O +
the O +
focal O +
adhesions O +
after O +
S1P O +
and O +
VEGF O +
stimulation O -
. O +

To O +
better O +
understand O +
the O +
intracellular O +
signaling O +
pathways O -
, O +
we O +
examined O +
the O +
effect O +
of O +
HKa O +
on O +
the O +
phosphorylation O +
of O +
Akt O +
and O +
its O +
downstream O +
effector O -
, O +
GSK-3alpha O +
HKa O +
and O +
D5 O +
inhibit O +
phosphorylation O +
of O +
Akt O +
and O +
GSK-3alpha O +
after O +
stimulation O +
withVEGF O +
and O +
S1P O -
. O +

Inhibitors O +
of O +
Akt O +
and O +
P13-kinase O -
, O +
the O +
upstream O +
activator O +
of O +
Akt O -
, O +
block O +
endothelial O +
cell O +
migration O +
and O +
disrupt O +
paxillin O +
localization O +
to O +
the O +
focal O +
adhesions O +
after O +
stimulation O +
with O +
VEGF O +
and O +
S1P O -
. O +

Therefore O +
we O +
suggest O +
that O +
HKa O +
through O +
its O +
D5 O +
domain O +
alters O +
P13-kinase O -
- O -
Akt O +
signaling O +
to O +
inhibit O +
endothelial O +
cell O +
migration O +
through O +
alterations O +
in O +
the O +
focal O +
adhesions O -
. O +

Histopathological O +
development O +
of O +
gastric O +
tumors O +
induced O +
by O +
N B-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
N'-nitro I-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
nitrosoguanidine I-Chemical +
in O +
rats O -
. O +

The O +
development O +
of O +
carcinoma O +
was O +
examined O +
in O +
male O +
Wistar O +
rats O +
( O -
n O +
= O +
120 O -
) O +
exposed O +
to O +
N B-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
N'-nitro I-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
nitrosoguanidine I-Chemical +
( O -
MNNG B-Chemical -
) O +
in O +
the O +
drinking O +
water B-Chemical +
( O -
83 O +
micrograms O -
/ O -
ml O -
) O +
for O +
16 O +
weeks O -
. O +

After O +
MNNG B-Chemical +
administration O -
, O +
rats O +
were O +
investigated O +
by O +
endoscopic O +
observation O -
, O +
visualization O +
of O +
microvascular O +
structure O -
, O +
and O +
estimation O +
of O +
lectin O +
binding O +
sites O -
. O +

Changes O +
of O +
bile O +
reflux O +
to O +
the O +
stomach O +
was O +
observed O +
endoscopically O +
at O +
24 O +
weeks O +
as O +
well O +
as O +
the O +
development O +
of O +
gastric O +
mucosal O +
erosions O -
. O +

Protruding O +
and O +
expansive O +
ulcerating O +
carcinomas O +
developed O +
at O +
36 O +
weeks O +
and O +
had O +
a O +
microvascular O +
pattern O +
similar O +
to O +
that O +
of O +
human O +
adenocarcinoma O -
. O +

Estimation O +
of O +
lectin O +
binding O +
site O +
and O +
pattern O +
was O +
useful O +
to O +
evaluate O +
the O +
malignant O +
potential O +
of O +
cell O +
proliferation O -
. O +

We O +
postulate O +
that O +
endoscopic O +
observation O +
is O +
valuable O +
in O +
investigating O +
the O +
development O +
of O +
gastric O +
carcinoma O -
, O +
and O +
microvascular O +
structure O +
and O +
lectin O +
binding O +
pattern O +
may O +
be O +
useful O +
to O +
demonstrate O +
the O +
mechanism O +
of O +
growth O +
of O +
gastric O +
carcinoma O -
. O +

Effect O +
of O +
thalidomide B-Chemical +
affecting O +
VEGF O +
secretion O -
, O +
cell O +
migration O -
, O +
adhesion O +
and O +
capillary O +
tube O +
formation O +
of O +
human O +
endothelial O +
EA.hy O +
926 O +
cells O -
. O +

Angiogenesis O -
, O +
new O +
blood O +
vessel O +
formation O -
, O +
is O +
a O +
multistep O +
process O -
, O +
precisely O +
regulated O +
by O +
pro O -
- O -
angiogenic O +
cytokines O -
, O +
which O +
stimulate O +
endothelial O +
cells O +
to O +
migrate O -
, O +
proliferate O +
and O +
differentiate O +
to O +
form O +
new O +
capillary O +
microvessels O -
. O +

Excessive O +
vascular O +
development O +
and O +
blood O +
vessel O +
remodeling O +
appears O +
in O +
psoriasis O -
, O +
rheumatoid O +
arthritis O -
, O +
diabetic O +
retinopathy O +
and O +
solid O +
tumors O +
formation O -
. O +

Thalidomide B-Chemical +
[ O -
alpha- B-Chemical -
( I-Chemical -
N I-Chemical -
- I-Chemical -
phthalimido I-Chemical -
) I-Chemical -
-glutarimide I-Chemical -
] O +
is O +
known O +
to O +
be O +
a O +
potent O +
inhibitor O +
of O +
angiogenesis O -
, O +
but O +
the O +
mechanism O +
of O +
its O +
inhibitory O +
action O +
remains O +
unclear O -
. O +

The O +
aim O +
of O +
the O +
study O +
was O +
to O +
investigate O +
the O +
potential O +
influence O +
of O +
thalidomide B-Chemical +
on O +
the O +
several O +
steps O +
of O +
angiogenesis O -
, O +
using O +
in O +
vitro O +
models O -
. O +

We O +
have O +
evaluated O +
the O +
effect O +
of O +
thalidomide B-Chemical +
on O +
VEGF O +
secretion O -
, O +
cell O +
migration O -
, O +
adhesion O +
as O +
well O +
as O +
in O +
capillary O +
formation O +
of O +
human O +
endothelial O +
cell O +
line O +
EA.hy O +
926 O -
. O +

Thalidomide B-Chemical +
at O +
the O +
concentrations O +
of O +
0.01 O +
microM O +
and O +
10 O +
microM O +
inhibited O +
VEGF O +
secretion O +
into O +
supernatants O -
, O +
decreased O +
the O +
number O +
of O +
formed O +
capillary O +
tubes O +
and O +
increased O +
cell O +
adhesion O +
to O +
collagen O -
. O +

Administration O +
of O +
thalidomide B-Chemical +
at O +
the O +
concentration O +
of O +
0.01 O +
microM O +
increased O +
cell O +
migration O -
, O +
while O +
at O +
10 O +
microM O -
, O +
it O +
decreased O +
cell O +
migration O -
. O +

Thalidomide B-Chemical +
in O +
concentrations O +
from O +
0.1 O +
microM O +
to O +
10 O +
microM O +
did O +
not O +
change O +
cell O +
proliferation O +
of O +
72-h O +
cell O +
cultures O -
. O +

We O +
conclude O +
that O +
anti O -
- O -
angiogenic O +
action O +
of O +
thalidomide B-Chemical +
is O +
due O +
to O +
direct O +
inhibitory O +
action O +
on O +
VEGF O +
secretion O +
and O +
capillary O +
microvessel O +
formation O +
as O +
well O +
as O +
immunomodulatory O +
influence O +
on O +
EA.hy O +
926 O +
cells O +
migration O +
and O +
adhesion O -
. O +

VEGFR1-positive O +
haematopoietic O +
bone O +
marrow O +
progenitors O +
initiate O +
the O +
pre O -
- O -
metastatic O +
niche O -
. O +

The O +
cellular O +
and O +
molecular O +
mechanisms O +
by O +
which O +
a O +
tumour O +
cell O +
undergoes O +
metastasis O +
to O +
a O +
predetermined O +
location O +
are O +
largely O +
unknown O -
. O +

Here O +
we O +
demonstrate O +
that O +
bone O +
marrow O -
- O -
derived O +
haematopoietic O +
progenitor O +
cells O +
that O +
express O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
1 O +
( O -
VEGFR1 O -
; O +
also O +
known O +
as O +
Flt1 O -
) O +
home O +
to O +
tumour O -
- O -
specific O +
pre O -
- O -
metastatic O +
sites O +
and O +
form O +
cellular O +
clusters O +
before O +
the O +
arrival O +
of O +
tumour O +
cells O -
. O +

Preventing O +
VEGFR1 O +
function O +
using O +
antibodies O +
or O +
by O +
the O +
removal O +
of O +
VEGFR1 O -
( O -
+ O -
) O +
cells O +
from O +
the O +
bone O +
marrow O +
of O +
wild O -
- O -
type O +
mice O +
abrogates O +
the O +
formation O +
of O +
these O +
pre O -
- O -
metastatic O +
clusters O +
and O +
prevents O +
tumour O +
metastasis O -
, O +
whereas O +
reconstitution O +
with O +
selected O +
Id3 O +
( O -
inhibitor O +
of O +
differentiation O +
3 O -
) O -
-competent O +
VEGFR1 O -
+ O +
cells O +
establishes O +
cluster O +
formation O +
and O +
tumour O +
metastasis O +
in O +
Id3 O +
knockout O +
mice O -
. O +

We O +
also O +
show O +
that O +
VEGFR1 O -
+ O +
cells O +
express O +
VLA-4 O +
( O -
also O +
known O +
as O +
integrin O +
alpha4beta1 O -
) O -
, O +
and O +
that O +
tumour O -
- O -
specific O +
growth O +
factors O +
upregulate O +
fibronectin O -
-- O -
a O +
VLA-4 O +
ligand O -
-- O -
in O +
resident O +
fibroblasts O -
, O +
providing O +
a O +
permissive O +
niche O +
for O +
incoming O +
tumour O +
cells O -
. O +

Conditioned O +
media O +
obtained O +
from O +
distinct O +
tumour O +
types O +
with O +
unique O +
patterns O +
of O +
metastatic O +
spread O +
redirected O +
fibronectin O +
expression O +
and O +
cluster O +
formation O -
, O +
thereby O +
transforming O +
the O +
metastatic O +
profile O -
. O +

These O +
findings O +
demonstrate O +
a O +
requirement O +
for O +
VEGFR1 O -
+ O +
haematopoietic O +
progenitors O +
in O +
the O +
regulation O +
of O +
metastasis O -
, O +
and O +
suggest O +
that O +
expression O +
patterns O +
of O +
fibronectin O +
and O +
VEGFR1+VLA-4 O -
+ O +
clusters O +
dictate O +
organ O -
- O -
specific O +
tumour O +
spread O -
. O +

Regulation O +
of O +
skin O +
microvasculature O +
angiogenesis O -
, O +
cell O +
migration O -
, O +
and O +
permeability O +
by O +
a O +
specific O +
inhibitor O +
of O +
PKCalpha O -
. O +

Activation O +
of O +
protein O +
kinase O +
C O +
( O -
PKC O -
) O +
induces O +
phenotypic O +
changes O +
in O +
the O +
morphology O +
of O +
microvascular O +
endothelial O +
cells O +
that O +
affect O +
major O +
functions O +
of O +
the O +
microvasculature O -
. O +

These O +
functions O +
include O +
the O +
first O +
stages O +
of O +
sprouting O +
in O +
angiogenesis O -
, O +
cell O +
migration O +
following O +
wounding O -
, O +
and O +
vascular O +
permeability O -
. O +

The O +
specific O +
isoform O -
( O -
s O -
) O +
of O +
PKC O +
responsible O +
for O +
each O +
of O +
these O +
changes O +
has O +
not O +
been O +
previously O +
identified O -
. O +

In O +
this O +
study O -
, O +
we O +
used O +
two O +
inflammatory O +
agents O -
, O +
IL-1beta O +
and O +
phorbol B-Chemical +
myristic I-Chemical +
acetate I-Chemical -
, O +
to O +
activate O +
PKC O +
isozymes O +
and O +
specific O +
inhibitors O +
of O +
PKCalpha O +
( O -
Go6976 B-Chemical -
) O +
and O +
PKCbeta O +
( O -
hispidin B-Chemical -
) O +
to O +
distinguish O +
how O +
each O +
of O +
these O +
isoform O -
( O -
s O -
) O +
controls O +
angiogenesis O -
, O +
wound O +
healing O -
, O +
and O +
permeability O -
. O +

In O +
all O +
cases O -
, O +
only O +
inhibition O +
of O +
PKCalpha O +
inhibited O +
each O +
of O +
these O +
functions O +
when O +
compared O +
to O +
the O +
inhibition O +
of O +
PKCbeta O -
. O +

Additional O +
analysis O +
of O +
the O +
mechanism O +
of O +
action O +
of O +
Go6976 B-Chemical +
( O -
RT O -
- O -
PCR O -
, O +
Western O +
blots O -
, O +
and O +
immunohistochemistry O -
) O +
of O +
the O +
changes O +
in O +
the O +
phosphorylated O +
and O +
nonphosphorylated O +
forms O +
of O +
PKCalpha O +
in O +
the O +
cell O +
membrane O +
and O +
cytoplasm O +
confirmed O +
the O +
specificity O +
of O +
PKCalpha O +
inhibition O +
by O +
Go6976 B-Chemical -
. O +

These O +
studies O +
therefore O +
indicate O +
a O +
specific O +
and O +
a O +
regulatory O +
role O +
of O +
the O +
PKCalpha O +
isoform O +
in O +
three O +
major O +
endothelial O +
cell O +
functions O +
that O +
are O +
important O +
in O +
the O +
maintenance O +
of O +
microvascular O +
homeostasis O -
. O +

The O +
Kaposi O -
's O +
sarcoma O -
- O -
associated O +
herpesvirus O +
G O +
protein O -
- O -
coupled O +
receptor O +
as O +
a O +
therapeutic O +
target O +
for O +
the O +
treatment O +
of O +
Kaposi O -
's O +
sarcoma O -
. O +

The O +
Kaposi O -
's O +
sarcoma O -
- O -
associated O +
herpesvirus O +
( O -
KSHV O -
) O +
encodes O +
a O +
G O +
protein O -
- O -
coupled O +
receptor O +
( O -
vGPCR O -
) O +
that O +
has O +
been O +
implicated O +
in O +
the O +
initiation O +
of O +
Kaposi O -
's O +
sarcoma O -
, O +
identifying O +
vGPCR O +
as O +
an O +
attractive O +
target O +
for O +
preventing O +
Kaposi O -
's O +
sarcoma O -
. O +

However O -
, O +
as O +
only O +
a O +
fraction O +
of O +
cells O +
in O +
advanced O +
Kaposi O -
's O +
sarcoma O +
lesions O +
express O +
vGPCR O -
, O +
it O +
is O +
unclear O +
whether O +
this O +
unique O +
viral O +
oncogene O +
contributes O +
to O +
Kaposi O -
's O +
sarcoma O +
progression O -
. O +

We O +
therefore O +
set O +
out O +
to O +
determine O +
whether O +
the O +
few O +
cells O +
that O +
express O +
vGPCR O +
in O +
established O +
tumors O +
represent O +
an O +
appropriate O +
therapeutic O +
target O +
for O +
the O +
treatment O +
of O +
patients O +
with O +
preexisting O +
Kaposi O -
's O +
sarcoma O -
. O +

To O +
this O +
end O -
, O +
we O +
generated O +
endothelial O +
cell O +
lines O +
stably O +
expressing O +
vGPCR O +
or O +
key O +
KSHV O +
latently O +
expressed O +
proteins O +
( O -
vCyclin O -
, O +
vFlip O -
, O +
and O +
LANA1 O -
) O -
. O +

The O +
endothelial O +
cell O +
line O +
expressing O +
vGPCR O +
was O +
rendered O +
sensitive O +
to O +
treatment O +
with O +
the O +
nucleoside B-Chemical +
analogue O +
ganciclovir B-Chemical +
by O +
using O +
a O +
bicistronic O +
construct O +
coexpressing O +
the O +
herpes O +
simplex O +
virus O +
1 O +
thymidine O +
kinase O -
. O +

S.c O -
. O +
injection O +
into O +
nude O +
mice O +
with O +
mixed O -
- O -
cell O +
populations O +
formed O +
tumors O +
that O +
approximate O +
the O +
ratio O +
of O +
vGPCR O -
- O -
expressing O +
and O +
KSHV O +
latent O +
gene O -
- O -
expressing O +
cells O -
. O +

These O +
mice O +
were O +
then O +
treated O +
with O +
ganciclovir B-Chemical +
to O +
specifically O +
target O +
only O +
the O +
vGPCR O -
- O -
expressing O +
cells O -
. O +

Surprisingly O -
, O +
despite O +
the O +
expression O +
of O +
KSHV O +
latent O +
genes O +
in O +
the O +
vast O +
majority O +
of O +
tumor O +
cells O -
, O +
specifically O +
targeting O +
only O +
the O +
few O +
vGPCR O -
- O -
expressing O +
cells O +
in O +
established O +
tumors O +
resulted O +
in O +
tumor O +
regression O -
. O +

Moreover O -
, O +
we O +
observed O +
an O +
increase O +
in O +
apoptosis O +
of O +
latent O +
gene O -
- O -
expressing O +
cells O +
after O +
the O +
pharmacologic O +
deletion O +
of O +
the O +
vGPCR O -
- O -
expressing O +
cells O -
. O +

These O +
findings O +
indicate O +
that O +
vGPCR O +
may O +
play O +
a O +
key O +
role O +
in O +
Kaposi O -
's O +
sarcoma O +
progression O +
and O +
provide O +
experimental O +
justification O +
for O +
developing O +
molecular O -
- O -
based O +
therapies O +
specifically O +
targeting O +
vGPCR O +
and O +
its O +
effectors O +
for O +
the O +
treatment O +
of O +
Kaposi O -
's O +
sarcoma O +
patients O -
. O +

Sensitization O +
to O +
gimatecan B-Chemical -
- O -
induced O +
apoptosis O +
by O +
tumor O +
necrosis O +
factor O -
- O -
related O +
apoptosis O +
inducing O +
ligand O +
in O +
prostate O +
carcinoma O +
cells O -
. O +

Since O +
the O +
intrinsic O +
resistance O +
of O +
prostate O +
carcinoma O +
likely O +
reflects O +
a O +
low O +
susceptibility O +
to O +
drug O -
- O -
induced O +
apoptosis O -
, O +
in O +
this O +
study O +
we O +
explored O +
the O +
possibility O +
of O +
sensitizing O +
prostate O +
carcinoma O +
cells O +
to O +
apoptosis O +
by O +
combination O +
of O +
TRAIL O +
with O +
camptothecins B-Chemical -
. O +

Indeed O -
, O +
these O +
agents O +
are O +
known O +
to O +
activate O +
different O +
pathways O +
of O +
apoptosis O -
. O +

Topotecan- B-Chemical +
and O +
gimatecan B-Chemical +
induced O +
moderate O +
up O -
- O -
regulation O +
of O +
TRAIL O -
- O -
R1 O +
and O +
-R2 O +
which O +
resulted O +
in O +
a O +
different O +
cell O +
response O +
to O +
the O +
combination O +
in O +
androgen B-Chemical -
- O -
independent O +
cells O +
( O -
DU-145 O +
and O +
PC-3 O -
) O -
. O +

In O +
DU-145 O +
cells O +
apoptosis O +
was O +
increased O +
by O +
lower O +
TRAIL O +
concentrations O +
and O +
was O +
earlier O +
than O +
in O +
PC-3 O +
cells O -
, O +
as O +
shown O +
using O +
Annexin O +
V O -
- O -
binding O +
assay O -
. O +

The O +
relative O +
resistance O +
of O +
PC-3 O +
cells O +
to O +
drug O -
- O -
induced O +
apoptosis O +
was O +
associated O +
with O +
constitutive O +
Akt O +
activation O -
, O +
higher O +
levels O +
of O +
cFLIP O -
- O -
L O +
and O +
Bcl-2 O -
, O +
and O +
lower O +
levels O +
of O +
Bax O -
. O +

The O +
different O +
expression O -
/ O -
activation O +
of O +
apoptosis O -
- O -
related O +
factors O +
appears O +
to O +
influence O +
the O +
sensitization O +
of O +
prostate O +
carcinoma O +
cells O +
by O +
TRAIL O -
. O +

Potentiation O +
of O +
camptothecin B-Chemical -
- O -
induced O +
apoptosis O +
by O +
TRAIL O +
appears O +
dependent O +
on O +
cooperation O +
between O +
extrinsic O +
and O +
intrinsic O +
pathways O -
, O +
as O +
documented O +
by O +
loss O +
of O +
the O +
sensitization O +
to O +
apoptosis O +
following O +
reduction O +
of O +
caspase O +
8 O +
after O +
small O +
interfering O +
RNA O +
transfection O -
. O +

The O +
efficacy O +
of O +
the O +
approach O +
may O +
be O +
critically O +
dependent O +
on O +
the O +
intrinsic O +
susceptibility O +
to O +
apoptosis O +
of O +
different O +
tumors O -
. O +

These O +
observations O +
support O +
that O +
the O +
activation O +
of O +
multiple O +
signals O +
could O +
enhance O +
apoptotic O +
response O +
and O +
suggest O +
the O +
therapeutic O +
interest O +
of O +
the O +
TRAIL O -
/ O -
camptothecin B-Chemical +
combination O -
. O +

c O -
- O -
Met O +
expression O +
is O +
regulated O +
by O +
Mitf O +
in O +
the O +
melanocyte O +
lineage O -
. O +

Hepatocyte O +
growth O +
factor O +
( O -
HGF O -
) O -
/ O -
c O -
- O -
Met O +
signaling O +
is O +
thought O +
to O +
be O +
a O +
key O +
pathway O +
in O +
both O +
melanocyte O +
development O +
and O +
melanoma O +
metastasis O -
. O +

Here O -
, O +
HGF O +
stimulation O +
of O +
melanocytes O +
was O +
seen O +
to O +
up O -
- O -
regulate O +
c O -
- O -
Met O +
expression O -
. O +

In O +
an O +
effort O +
to O +
decipher O +
the O +
mechanism O +
by O +
which O +
HGF O +
up O -
- O -
regulates O +
its O +
receptor O -
, O +
we O +
found O +
that O +
c O -
- O -
Met O +
is O +
a O +
direct O +
transcriptional O +
target O +
of O +
Mitf O -
. O +

This O +
was O +
confirmed O +
with O +
chromatin O +
immunoprecipitation O +
experiments O +
of O +
the O +
human O +
c O -
- O -
Met O +
promoter O -
, O +
as O +
well O +
as O +
by O +
the O +
ability O +
of O +
adenovirally O +
expressed O +
Mitf O +
to O +
modulate O +
endogenous O +
c O -
- O -
Met O +
protein O +
levels O +
in O +
melanocytes O -
. O +

Disruption O +
of O +
Mitf O +
blocked O +
HGF O -
- O -
dependent O +
increases O +
in O +
endogenous O +
c O -
- O -
Met O +
message O +
and O +
protein O +
levels O -
, O +
indicating O +
that O +
HGF O +
regulates O +
its O +
own O +
receptor O +
levels O +
via O +
Mitf O -
. O +

Finally O -
, O +
dominant O -
- O -
negative O +
inhibition O +
of O +
Mitf O +
resulted O +
in O +
profound O +
resistance O +
of O +
melanocytes O +
and O +
melanoma O +
cells O +
to O +
HGF O -
- O -
dependent O +
matrix O +
invasion O -
, O +
suggesting O +
a O +
physiologic O +
role O +
for O +
this O +
pathway O +
in O +
melanocytic O +
development O +
and O +
melanoma O -
. O +

L B-Chemical -
- I-Chemical -
Carnitine I-Chemical +
ameliorates O +
methotrexate B-Chemical -
- O -
induced O +
oxidative O +
organ O +
injury O +
and O +
inhibits O +
leukocyte O +
death O -
. O +

Methotrexate B-Chemical +
( O -
MTX B-Chemical -
) O -
, O +
a O +
folic B-Chemical +
acid I-Chemical +
antagonist O +
widely O +
used O +
for O +
the O +
treatment O +
of O +
a O +
variety O +
of O +
tumors O +
and O +
inflammatory O +
diseases O -
, O +
affects O +
normal O +
tissues O +
that O +
have O +
a O +
high O +
rate O +
of O +
proliferation O -
, O +
including O +
the O +
hematopoietic O +
cells O +
of O +
the O +
bone O +
marrow O +
and O +
the O +
gastrointestinal O +
mucosal O +
cells O -
. O +

To O +
elucidate O +
the O +
role O +
of O +
free O +
radicals O +
and O +
leukocytes O +
in O +
MTX B-Chemical -
- O -
induced O +
oxidative O +
organ O +
damage O +
and O +
the O +
putative O +
protective O +
effect O +
of O +
L B-Chemical -
- I-Chemical -
carnitine I-Chemical +
( O -
L B-Chemical -
- I-Chemical -
Car I-Chemical -
) O -
, O +
Wistar O +
albino O +
rats O +
were O +
administered O +
a O +
single O +
dose O +
of O +
MTX B-Chemical +
( O -
20 O +
mg O -
/ O -
kg O -
) O +
followed O +
by O +
either O +
saline B-Chemical +
or O +
L B-Chemical -
- I-Chemical -
Car I-Chemical +
( O -
500 O +
mg O -
/ O -
kg O -
) O +
for O +
5 O +
days O -
. O +

After O +
decapitation O +
of O +
the O +
rats O -
, O +
trunk O +
blood O +
was O +
obtained O -
, O +
and O +
the O +
ileum O -
, O +
liver O -
, O +
and O +
kidney O +
were O +
removed O +
for O +
histological O +
examination O +
and O +
for O +
the O +
measurement O +
of O +
malondialdehyde B-Chemical +
( O -
MDA B-Chemical -
) O +
and O +
glutathione B-Chemical +
( O -
GSH B-Chemical -
) O +
levels O -
, O +
myeloperoxidase B-Chemical +
( O -
MPO B-Chemical -
) O +
activity O -
, O +
and O +
collagen O +
content O -
. O +

Our O +
results O +
showed O +
that O +
MTX B-Chemical +
administration O +
increased O +
the O +
MDA B-Chemical +
and O +
MPO B-Chemical +
activities O +
and O +
collagen O +
content O +
and O +
decreased O +
GSH B-Chemical +
levels O +
in O +
all O +
tissues O -
, O +
while O +
these O +
alterations O +
were O +
reversed O +
in O +
L B-Chemical -
- I-Chemical -
Car I-Chemical -
- O -
treated O +
group O -
. O +

The O +
elevated O +
serum O +
TNF O -
- O -
alpha O +
level O +
observed O +
following O +
MTX B-Chemical +
treatment O +
was O +
depressed O +
with O +
L B-Chemical -
- I-Chemical -
Car I-Chemical -
. O +

The O +
oxidative O +
burst O +
of O +
neutrophils O +
stimulated O +
by O +
Annexin O +
V O +
was O +
reduced O +
in O +
the O +
saline B-Chemical -
- O -
treated O +
MTX B-Chemical +
group O -
, O +
while O +
L B-Chemical -
- I-Chemical -
Car I-Chemical +
abolished O +
this O +
inhibition O -
. O +

Similarly O -
, O +
flow O +
cytometric O +
measurements O +
revealed O +
that O +
leukocyte O +
apoptosis O +
was O +
increased O +
in O +
MTX B-Chemical -
- O -
treated O +
animals O -
, O +
while O +
L B-Chemical -
- I-Chemical -
Car I-Chemical +
reversed O +
these O +
effects O -
. O +

Severe O +
degeneration O +
of O +
the O +
intestinal O +
mucosa O -
, O +
liver O +
parenchyma O -
, O +
and O +
glomerular O +
and O +
tubular O +
epithelium O +
observed O +
in O +
the O +
saline B-Chemical -
- O -
treated O +
MTX B-Chemical +
group O +
was O +
improved O +
by O +
L B-Chemical -
- I-Chemical -
Car I-Chemical +
treatment O -
. O +

These O +
results O +
suggest O +
that O +
L B-Chemical -
- I-Chemical -
Car I-Chemical -
, O +
possibly O +
via O +
its O +
free O +
radical O +
scavenging O +
and O +
antioxidant O +
properties O -
, O +
ameliorates O +
MTX B-Chemical -
- O -
induced O +
oxidative O +
organ O +
injury O +
and O +
inhibits O +
leukocyte O +
apoptosis O -
. O +

Thus O -
, O +
supplementation O +
with O +
L B-Chemical -
- I-Chemical -
Carnitine I-Chemical +
as O +
an O +
adjuvant O +
therapy O +
may O +
be O +
promising O +
in O +
alleviating O +
the O +
systemic O +
side O -
- O -
effects O +
of O +
chemotherapeutics O -
. O +

Pericytes O +
limit O +
tumor O +
cell O +
metastasis O -
. O +

Previously O +
we O +
observed O +
that O +
neural O +
cell O +
adhesion O +
molecule O +
( O -
NCAM O -
) O +
deficiency O +
in O +
beta O +
tumor O +
cells O +
facilitates O +
metastasis O +
into O +
distant O +
organs O +
and O +
local O +
lymph O +
nodes O -
. O +

Here O -
, O +
we O +
show O +
that O +
NCAM O -
- O -
deficient O +
beta O +
cell O +
tumors O +
grew O +
leaky O +
blood O +
vessels O +
with O +
perturbed O +
pericyte O -
- O -
endothelial O +
cell O -
- O -
cell O +
interactions O +
and O +
deficient O +
perivascular O +
deposition O +
of O +
ECM O +
components O -
. O +

Conversely O -
, O +
tumor O +
cell O +
expression O +
of O +
NCAM O +
in O +
a O +
fibrosarcoma O +
model O +
( O -
T241 O -
) O +
improved O +
pericyte O +
recruitment O +
and O +
increased O +
perivascular O +
deposition O +
of O +
ECM O +
molecules O -
. O +

Together O -
, O +
these O +
findings O +
suggest O +
that O +
NCAM O +
may O +
limit O +
tumor O +
cell O +
metastasis O +
by O +
stabilizing O +
the O +
microvessel O +
wall O -
. O +

To O +
directly O +
address O +
whether O +
pericyte O +
dysfunction O +
increases O +
the O +
metastatic O +
potential O +
of O +
solid O +
tumors O -
, O +
we O +
studied O +
beta O +
cell O +
tumorigenesis O +
in O +
primary O +
pericyte O -
- O -
deficient O +
Pdgfb O -
( O -
ret O -
/ O -
ret O -
) O +
mice O -
. O +

This O +
resulted O +
in O +
beta O +
tumor O +
cell O +
metastases O +
in O +
distant O +
organs O +
and O +
local O +
lymph O +
nodes O -
, O +
demonstrating O +
a O +
role O +
for O +
pericytes O +
in O +
limiting O +
tumor O +
cell O +
metastasis O -
. O +

These O +
data O +
support O +
a O +
new O +
model O +
for O +
how O +
tumor O +
cells O +
trigger O +
metastasis O +
by O +
perturbing O +
pericyte O -
- O -
endothelial O +
cell O -
- O -
cell O +
interactions O -
. O +

NF O -
- O -
kappaB O +
and O +
IKK O +
as O +
therapeutic O +
targets O +
in O +
cancer O -
. O +

The O +
transcription O +
factor O +
NF O -
- O -
kappaB O +
and O +
associated O +
regulatory O +
factors O +
( O -
including O +
IkappaB O +
kinase O +
subunits O +
and O +
the O +
IkappaB O +
family O +
member O +
Bcl-3 O -
) O +
are O +
strongly O +
implicated O +
in O +
a O +
variety O +
of O +
hematologic O +
and O +
solid O +
tumor O +
malignancies O -
. O +

A O +
role O +
for O +
NF O -
- O -
kappaB O +
in O +
cancer O +
cells O +
appears O +
to O +
involve O +
regulation O +
of O +
cell O +
proliferation O -
, O +
control O +
of O +
apoptosis O -
, O +
promotion O +
of O +
angiogenesis O -
, O +
and O +
stimulation O +
of O +
invasion O -
/ O -
metastasis O -
. O +

Consistent O +
with O +
a O +
role O +
for O +
NF O -
- O -
kappaB O +
in O +
oncogenesis O +
are O +
observations O +
that O +
inhibition O +
of O +
NF O -
- O -
kappaB O +
alone O +
or O +
in O +
combination O +
with O +
cancer O +
therapies O +
leads O +
to O +
tumor O +
cell O +
death O +
or O +
growth O +
inhibition O -
. O +

However O -
, O +
other O +
experimental O +
data O +
indicate O +
that O +
NF O -
- O -
kappaB O +
can O +
play O +
a O +
tumor O +
suppressor O +
role O +
in O +
certain O +
settings O +
and O +
that O +
it O +
can O +
be O +
important O +
in O +
promoting O +
an O +
apoptotic O +
signal O +
downstream O +
of O +
certain O +
cancer O +
therapy O +
regimens O -
. O +

In O +
order O +
to O +
appropriately O +
move O +
NF O -
- O -
kappaB O +
inhibitors O +
in O +
the O +
clinic O -
, O +
thorough O +
approaches O +
must O +
be O +
initiated O +
to O +
determine O +
the O +
molecular O +
mechanisms O +
that O +
dictate O +
the O +
complexity O +
of O +
oncologic O +
and O +
therapeutic O +
outcomes O +
that O +
are O +
controlled O +
by O +
NF O -
- O -
kappaB. O +

Runx2 O +
and O +
MYC O +
collaborate O +
in O +
lymphoma O +
development O +
by O +
suppressing O +
apoptotic O +
and O +
growth O +
arrest O +
pathways O +
in O +
vivo O -
. O +

Members O +
of O +
the O +
Runx O +
and O +
MYC O +
families O +
have O +
been O +
implicated O +
as O +
collaborating O +
oncogenes O -
. O +

The O +
mechanism O +
of O +
this O +
potent O +
collaboration O +
is O +
elucidated O +
in O +
this O +
study O +
of O +
Runx2 O -
/ O -
MYC O +
mice O -
. O +

As O +
shown O +
previously O -
, O +
ectopic O +
expression O +
of O +
Runx2 O +
in O +
the O +
thymus O +
leads O +
to O +
a O +
preneoplastic O +
state O +
defined O +
by O +
an O +
accumulation O +
of O +
cells O +
with O +
an O +
immature O +
phenotype O +
and O +
a O +
low O +
proliferative O +
rate O -
. O +

We O +
now O +
show O +
that O +
c O -
- O -
MYC O +
overexpression O +
is O +
sufficient O +
to O +
rescue O +
proliferation O +
and O +
to O +
release O +
the O +
differentiation O +
block O +
imposed O +
by O +
Runx2 O -
. O +

Analysis O +
of O +
Runx2-expressing O +
lymphomas O +
reveals O +
a O +
consistently O +
low O +
rate O +
of O +
apoptosis O -
, O +
in O +
contrast O +
to O +
lymphomas O +
of O +
MYC O +
mice O +
which O +
are O +
often O +
highly O +
apoptotic O -
. O +

The O +
low O +
apoptosis O +
phenotype O +
is O +
dominant O +
in O +
Runx2 O -
/ O -
MYC O +
tumors O -
, O +
indicating O +
that O +
Runx2 O +
confers O +
a O +
potent O +
survival O +
advantage O +
to O +
MYC O -
- O -
expressing O +
tumor O +
cells O -
. O +

The O +
role O +
of O +
the O +
p53 O +
pathway O +
in O +
Runx2 O -
/ O -
MYC O +
tumors O +
was O +
explored O +
on O +
a O +
p53 O +
heterozygote O +
background O -
. O +

Surprisingly O -
, O +
functional O +
p53 O +
was O +
retained O +
in O +
vivo O -
, O +
even O +
after O +
transplantation O -
, O +
whereas O +
explanted O +
tumor O +
cells O +
displayed O +
rapid O +
allele O +
loss O +
in O +
vitro O -
. O +

Our O +
results O +
show O +
that O +
Runx2 O +
and O +
MYC O +
overcome O +
distinct O +
" O -
fail O -
- O -
safe O -
" O +
responses O +
and O +
that O +
their O +
selection O +
as O +
collaborating O +
genes O +
is O +
due O +
to O +
their O +
ability O +
to O +
neutralize O +
each O +
other O -
's O +
negative O +
growth O +
effect O -
. O +

Furthermore O -
, O +
the O +
Runx2 O -
/ O -
MYC O +
combination O +
overcomes O +
the O +
requirement O +
for O +
genetic O +
inactivation O +
of O +
the O +
p53 O +
pathway O +
in O +
vivo O -
. O +

Circulating O +
endothelial O +
cells O +
in O +
malignant O +
disease O -
. O +

Cancer O +
is O +
a O +
disease O +
largely O +
dependent O +
on O +
neoangiogenesis O -
. O +

Cancer O +
neoangiogenesis O +
is O +
often O +
disordered O +
and O +
abnormal O -
, O +
with O +
evidence O +
of O +
coexisting O +
vascular O +
endothelial O +
dysfunction O -
. O +

A O +
novel O +
method O +
of O +
assessing O +
vascular O +
endothelial O +
function O +
in O +
cancer O +
is O +
via O +
the O +
quantification O +
of O +
circulating O +
endothelial O +
cells O +
( O -
CEC O -
) O -
. O +

Unusual O +
in O +
healthy O +
individuals O -
, O +
their O +
presence O +
in O +
elevated O +
numbers O +
often O +
indicates O +
substantial O +
vascular O +
endothelial O +
perturbation O -
. O +

Another O +
interesting O +
cell O +
type O +
is O +
the O +
endothelial O +
progenitor O +
cell O +
( O -
EPC O -
) O -
, O +
whose O +
numbers O +
increase O +
in O +
the O +
presence O +
of O +
vascular O +
damage O -
. O +

Recent O +
research O +
suggests O +
that O +
EPCs O +
have O +
an O +
important O +
role O +
in O +
tumor O +
vasculogenesis O -
. O +

Another O +
marker O +
being O +
investigated O +
in O +
the O +
context O +
of O +
vascular O +
dysfunction O +
and O +
coagulopathy O +
is O +
the O +
endothelial O +
microparticle O +
( O -
EMP O -
) O -
. O +

Thus O -
, O +
CECs O -
, O +
EPCs O +
and O +
EMPs O +
may O +
represent O +
potentially O +
novel O +
methods O +
for O +
evaluating O +
the O +
vascular O +
status O +
of O +
cancer O +
patients O -
. O +

This O +
review O +
will O +
summarize O +
the O +
current O +
position O +
of O +
CECs O -
, O +
EPCs O +
and O +
EMPs O +
in O +
cell O +
biology O +
terms O -
, O +
with O +
particular O +
emphasis O +
on O +
their O +
relationship O +
to O +
malignant O +
disease O -
. O +

Targeting O +
PIM O +
kinases O +
impairs O +
survival O +
of O +
hematopoietic O +
cells O +
transformed O +
by O +
kinase O +
inhibitor O -
- O -
sensitive O +
and O +
kinase O +
inhibitor O -
- O -
resistant O +
forms O +
of O +
Fms O -
- O -
like O +
tyrosine O +
kinase O +
3 O +
and O +
BCR O -
/ O -
ABL O -
. O +

Previous O +
studies O +
have O +
shown O +
that O +
activation O +
of O +
the O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
5 O +
( O -
STAT5 O -
) O +
plays O +
an O +
essential O +
role O +
in O +
leukemogenesis O +
mediated O +
through O +
constitutive O +
activated O +
protein O +
tyrosine O +
kinases O +
( O -
PTK O -
) O -
. O +

Because O +
PIM-1 O +
is O +
a O +
STAT5 O +
target O +
gene O -
, O +
we O +
analyzed O +
the O +
role O +
of O +
the O +
family O +
of O +
PIM O +
serine O -
/ O -
threonine O +
kinases O +
( O -
PIM-1 O +
to O +
PIM-3 O -
) O +
in O +
PTK O -
- O -
mediated O +
transformation O +
of O +
hematopoietic O +
cells O -
. O +

Ba O -
/ O -
F3 O +
cells O +
transformed O +
to O +
growth O +
factor O +
independence O +
by O +
various O +
oncogenic O +
PTKs O +
( O -
TEL O -
/ O -
JAK2 O -
, O +
TEL O -
/ O -
TRKC O -
, O +
TEL O -
/ O -
ABL O -
, O +
BCR O -
/ O -
ABL O -
, O +
FLT3-ITD O -
, O +
and O +
H4 O -
/ O -
PDGFbetaR O -
) O +
show O +
abundant O +
expression O +
of O +
PIM-1 O +
and O +
PIM-2 O -
. O +

Suppression O +
of O +
PIM-1 O +
activity O +
had O +
a O +
negligible O +
effect O +
on O +
transformation O -
. O +

In O +
contrast O -
, O +
expression O +
of O +
kinase O -
- O -
dead O +
PIM-2 O +
mutant O +
( O -
PIM-2KD O -
) O +
led O +
to O +
a O +
rapid O +
decline O +
of O +
survival O +
in O +
Ba O -
/ O -
F3 O +
cells O +
transformed O +
by O +
FLT3-ITD O +
but O +
not O +
by O +
other O +
oncogenic O +
PTKs O +
tested O -
. O +

Coexpression O +
of O +
PIM-1KD O +
and O +
PIM-2KD O +
abrogated O +
growth O +
factor O -
- O -
independent O +
growth O +
of O +
Ba O -
/ O -
F3 O +
transformed O +
by O +
several O +
PTKs O -
, O +
including O +
BCR O -
/ O -
ABL O -
. O +

Targeted O +
down O -
- O -
regulation O +
of O +
PIM-2 O +
by O +
RNA O +
interference O +
( O -
RNAi O -
) O +
selectively O +
abrogated O +
survival O +
of O +
Ba O -
/ O -
F3 O +
cells O +
transformed O +
by O +
various O +
Fms O -
- O -
like O +
tyrosine O +
kinase O +
3 O +
( O -
FLT3 O -
) O -
-activating O +
mutants O +
[ O -
internal O +
tandem O +
duplication O +
( O -
ITD O -
) O +
and O +
kinase O +
domain O -
] O +
and O +
attenuated O +
growth O +
of O +
human O +
cell O +
lines O +
containing O +
FLT3 O +
mutations O -
. O +

Interestingly O -
, O +
cells O +
transformed O +
by O +
FLT3 O +
and O +
BCR O -
/ O -
ABL O +
mutations O +
that O +
confer O +
resistance O +
to O +
small O -
- O -
molecule O +
tyrosine O +
kinase O +
inhibitors O +
were O +
still O +
sensitive O +
to O +
knockdown O +
of O +
PIM-2 O -
, O +
or O +
PIM-1 O +
and O +
PIM-2 O +
by O +
RNAi O -
. O +

Our O +
observations O +
indicate O +
that O +
combined O +
inactivation O +
of O +
PIM-1 O +
and O +
PIM-2 O +
interferes O +
with O +
oncogenic O +
PTKs O +
and O +
suggest O +
that O +
PIMs O +
are O +
alternative O +
therapeutic O +
targets O +
in O +
PTK O -
- O -
mediated O +
leukemia O -
. O +

Targeting O +
the O +
PIM O +
kinase O +
family O +
could O +
provide O +
a O +
new O +
avenue O +
to O +
overcome O +
resistance O +
against O +
small O -
- O -
molecule O +
tyrosine O +
kinase O +
inhibitors O -
. O +

GDP B-Chemical +
and O +
AGE B-Chemical +
receptors O -
: O +
mechanisms O +
of O +
peritoneal O +
damage O -
. O +

Long O -
- O -
term O +
peritoneal O +
dialysis O +
( O -
PD O -
) O +
is O +
limited O +
by O +
morphological O +
changes O +
of O +
the O +
peritoneal O +
membrane O -
. O +

Structural O +
changes O +
were O +
promoted O +
by O +
toxicity O +
of O +
glucose B-Chemical +
degradation I-Chemical +
products I-Chemical +
( O -
GDPs B-Chemical -
) O +
which O +
are O +
generated O +
during O +
heat O +
sterilization O +
in O +
peritoneal O +
dialysis O +
fluids O +
( O -
PDFs O -
) O -
. O +

Besides O +
their O +
direct O +
toxicity O +
GDPs B-Chemical +
promote O +
formation O +
of O +
advanced B-Chemical +
glycation I-Chemical +
endproducts I-Chemical +
( O -
AGEs B-Chemical -
) O -
. O +

RAGE O +
( O -
receptor O +
for O +
AGE O -
) O +
is O +
the O +
best O +
characterized O +
signal O +
transduction O +
receptor O +
for O +
AGEs B-Chemical +
and O +
is O +
expressed O +
on O +
mesothelial O +
cells O -
. O +

The O +
effects O +
of O +
PDFs O +
with O +
different O +
amounts O +
of O +
GDPs B-Chemical +
were O +
compared O +
on O +
morphological O +
changes O +
in O +
the O +
peritoneal O +
membrane O +
in O +
a O +
RAGE O +
- O -
/ O -
- O +
mouse O +
model O -
. O +

It O +
could O +
be O +
demonstrated O +
that O +
RAGE O +
plays O +
a O +
pivotal O +
role O +
in O +
structural O +
damage O +
( O -
e.g. O +
inflammation O -
, O +
neoangiogenesis O +
and O +
fibrosis O -
) O +
of O +
the O +
peritoneal O +
membrane O -
. O +

Further O +
investigations O +
of O +
this O +
pathway O +
with O +
regard O +
to O +
preventing O +
peritoneal O +
fibrosis O +
should O +
be O +
performed O +
to O +
maintain O +
the O +
integrity O +
of O +
the O +
peritoneal O +
membrane O +
in O +
peritoneal O +
dialysis O +
patients O -
. O +

Hyperfibrinogenemia O +
is O +
associated O +
with O +
lymphatic O +
as O +
well O +
as O +
hematogenous O +
metastasis O +
and O +
worse O +
clinical O +
outcome O +
in O +
T2 O +
gastric O +
cancer O -
. O +

BACKGROUND O -
: O +
Abnormal O +
hemostasis O +
in O +
cancer O +
patients O +
has O +
previously O +
been O +
described O -
, O +
however O +
the O +
correlation O +
between O +
the O +
plasma O +
fibrinogen O +
level O +
and O +
cancer O +
metastasis O +
and O +
prognosis O +
has O +
not O +
been O +
reported O +
in O +
a O +
large O -
- O -
scale O +
clinical O +
study O -
. O +

METHODS O -
: O +
Preoperative O +
plasma O +
fibrinogen O +
levels O +
were O +
retrospectively O +
examined O +
in O +
405 O +
patients O +
who O +
underwent O +
surgery O +
for O +
advanced O +
gastric O +
cancer O -
. O +

The O +
association O +
of O +
fibrinogen O +
levels O +
with O +
clinical O -
/ O -
pathological O +
findings O +
and O +
clinical O +
outcome O +
was O +
evaluated O -
. O +

RESULTS O -
: O +
There O +
was O +
a O +
positive O +
correlation O +
between O +
plasma O +
fibrinogen O +
levels O +
and O +
the O +
depth O +
of O +
invasion O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

Hyperfibrinogenemia O +
( O -
> O -
310 O +
mg O -
/ O -
dl O -
) O +
was O +
independently O +
associated O +
with O +
lymph O +
node O +
( O -
Odds O +
Ratio O -
; O +
2.342 O -
, O +
P O +
= O +
0.0032 O -
) O +
and O +
liver O +
( O -
Odds O +
Ratio O -
; O +
2.933 O -
, O +
P O +
= O +
0.0147 O -
) O +
metastasis O -
, O +
not O +
with O +
peritoneal O +
metastasis O +
in O +
this O +
series O -
. O +

Patients O +
with O +
hyperfibrinogenemia O +
showed O +
worse O +
clinical O +
outcome O +
in O +
T2 O +
gastric O +
cancer O -
, O +
however O -
, O +
there O +
was O +
no O +
correlation O +
of O +
plasma O +
fibrinogen O +
level O +
with O +
prognosis O +
in O +
T3 O -
/ O -
T4 O +
gastric O +
cancer O -
. O +

CONCLUSION O -
: O +
Our O +
results O +
might O +
support O +
the O +
idea O +
that O +
hyperfibrinogenemia O +
can O +
augment O +
lymphatic O +
and O +
hematogeneous O +
metastasis O +
of O +
advanced O +
gastric O +
cancer O -
, O +
which O +
is O +
major O +
determinant O +
of O +
the O +
prognosis O +
in O +
T2 O +
gastric O +
cancer O -
. O +

Therefore O -
, O +
in O +
the O +
situation O +
without O +
peritoneal O +
involvement O -
, O +
hyperfibrinogenemia O +
is O +
a O +
useful O +
biomarker O +
to O +
predict O +
the O +
possible O +
metastasis O +
and O +
worse O +
clinical O +
outcome O +
in O +
T2 O +
gastric O +
cancer O -
. O +

Alteration O +
of O +
homeobox O +
gene O +
expression O +
by O +
N O -
- O -
ras O +
transformation O +
of O +
PA-1 O +
human O +
teratocarcinoma O +
cells O -
. O +

We O +
used O +
a O +
series O +
of O +
cell O +
clones O +
from O +
a O +
human O +
teratocarcinoma O +
cell O +
line O -
, O +
PA-1 O -
, O +
to O +
study O +
the O +
effect O +
of O +
transformation O +
by O +
an O +
activated O +
N O -
- O -
ras O +
oncogene O +
on O +
the O +
expression O +
of O +
genes O +
involved O +
in O +
retinoic B-Chemical +
acid I-Chemical +
( O -
RA B-Chemical -
) O -
-induced O +
differentiation O +
and O +
growth O +
regulation O -
. O +

Recently O -
, O +
it O +
has O +
been O +
shown O +
that O +
expression O +
of O +
human O +
HOX O +
2 O +
genes O +
is O +
sequentially O +
activated O +
by O +
RA B-Chemical +
beginning O +
from O +
Hox O +
2.9 O +
at O +
the O +
3 O -
' O +
end O +
of O +
the O +
HOX O +
2 O +
cluster O +
( O -
A. O +
Simeone O -
, O +
D. O +
Acampora O -
, O +
L. O +
Arcioni O -
, O +
P. O +
W. O +
Andrews O -
, O +
E. O +
Boncinelli O -
, O +
and O +
F. O +
Mavilio O -
, O +
Nature O +
[ O -
London O -
] O +
346:763 O -
- O -
766 O -
, O +
1990 O -
) O -
. O +

We O +
now O +
report O +
that O +
six O +
different O +
genes O +
of O +
the O +
cluster O +
HOX O +
1 O +
are O +
sequentially O +
induced O +
by O +
RA B-Chemical +
in O +
a O +
similar O +
temporal O +
pattern O -
, O +
beginning O +
with O +
genes O +
at O +
the O +
3 O -
' O +
end O +
of O +
the O +
cluster O -
. O +

However O -
, O +
in O +
N O -
- O -
ras O -
- O -
transformed O +
cell O +
clones O -
, O +
RA B-Chemical -
- O -
induced O +
expression O +
of O +
these O +
homeobox O +
genes O +
is O +
delayed O -
. O +

Hox O +
1.4 O +
and O +
Hox O +
1.3 O -
, O +
genes O +
abundantly O +
induced O +
in O +
nontransformed O +
clones O +
after O +
3 O +
days O +
of O +
RA B-Chemical +
treatment O -
, O +
are O +
expressed O +
in O +
N O -
- O -
ras O -
- O -
transformed O +
cells O +
only O +
after O +
10 O +
days O +
of O +
RA B-Chemical +
treatment O -
. O +

At O +
this O +
time O -
, O +
the O +
cells O -
' O +
growth O +
is O +
arrested O +
at O +
very O +
high O +
density O -
, O +
and O +
no O +
differentiated O +
morphologic O +
characteristics O +
are O +
observed O -
. O +

Constitutive O +
expression O +
of O +
a O +
transfected O +
Hox O +
1.4 O +
gene O +
under O +
the O +
control O +
of O +
a O +
simian O +
virus O +
40 O +
promotor O +
leads O +
to O +
differentiated O +
cell O +
morphology O +
similar O +
to O +
that O +
of O +
the O +
RA B-Chemical -
- O -
induced O +
phenotype O +
and O +
restores O +
the O +
growth O -
- O -
inhibitory O +
effects O +
of O +
RA B-Chemical +
in O +
N O -
- O -
ras O -
- O -
transformed O +
cells O -
. O +

These O +
observations O +
provide O +
evidence O +
that O +
enhanced O +
proliferation O +
in O +
N O -
- O -
ras O -
- O -
transformed O +
cells O +
compromises O +
teratocarcinoma O +
cell O +
differentiation O +
by O +
a O +
mechanism O +
that O +
transiently O +
suppresses O +
homeobox O +
gene O +
induction O +
and O +
implies O +
a O +
central O +
role O +
for O +
homeobox O +
genes O +
in O +
RA B-Chemical -
- O -
induced O +
cell O +
differentiation O -
. O +

We O +
conclude O +
that O +
stimulation O +
of O +
a O +
putative O +
growth O +
factor O +
signal O +
pathway O -
, O +
associated O +
with O +
ras O -
- O -
induced O +
proliferation O -
, O +
transiently O +
suppresses O +
the O +
induction O +
of O +
transcription O +
factors O +
functionally O +
involved O +
in O +
cell O +
growth O +
and O +
differentiation O -
. O +

Prostate O -
- O -
specific O +
membrane O +
antigen O +
regulates O +
angiogenesis O +
by O +
modulating O +
integrin O +
signal O +
transduction O -
. O +

The O +
transmembrane O +
peptidase O +
prostate O -
- O -
specific O +
membrane O +
antigen O +
( O -
PSMA O -
) O +
is O +
universally O +
upregulated O +
in O +
the O +
vasculature O +
of O +
solid O +
tumors O -
, O +
but O +
its O +
functional O +
role O +
in O +
tumor O +
angiogenesis O +
has O +
not O +
been O +
investigated O -
. O +

Here O +
we O +
show O +
that O +
angiogenesis O +
is O +
severely O +
impaired O +
in O +
PSMA O -
- O -
null O +
animals O +
and O +
that O +
this O +
angiogenic O +
defect O +
occurs O +
at O +
the O +
level O +
of O +
endothelial O +
cell O +
invasion O +
through O +
the O +
extracellular O +
matrix O +
barrier O -
. O +

Because O +
proteolytic O +
degradation O +
of O +
the O +
extracellular O +
matrix O +
is O +
a O +
critical O +
component O +
of O +
endothelial O +
invasion O +
in O +
angiogenesis O -
, O +
it O +
is O +
logical O +
to O +
assume O +
that O +
PSMA O +
participates O +
in O +
matrix O +
degradation O -
. O +

However O -
, O +
we O +
demonstrate O +
a O +
novel O +
and O +
more O +
complex O +
role O +
for O +
PSMA O +
in O +
angiogenesis O -
, O +
where O +
it O +
is O +
a O +
principal O +
component O +
of O +
a O +
regulatory O +
loop O +
that O +
is O +
tightly O +
modulating O +
laminin O -
- O -
specific O +
integrin O +
signaling O +
and O +
GTPase O -
- O -
dependent O -
, O +
p21-activated O +
kinase O +
1 O +
( O -
PAK-1 O -
) O +
activity O -
. O +

We O +
show O +
that O +
PSMA O +
inhibition O -
, O +
knockdown O -
, O +
or O +
deficiency O +
decreases O +
endothelial O +
cell O +
invasion O +
in O +
vitro O +
via O +
integrin O +
and O +
PAK O -
, O +
thus O +
abrogating O +
angiogenesis O -
. O +

Interestingly O -
, O +
the O +
neutralization O +
of O +
beta O -
( O -
1 O -
) O +
or O +
the O +
inactivation O +
of O +
PAK O +
increases O +
PSMA O +
activity O -
, O +
suggesting O +
that O +
they O +
negatively O +
regulate O +
PSMA O -
. O +

This O +
negative O +
regulation O +
is O +
mediated O +
by O +
the O +
cytoskeleton O +
as O +
the O +
disruption O +
of O +
interactions O +
between O +
the O +
PSMA O +
cytoplasmic O +
tail O +
and O +
the O +
anchor O +
protein O +
filamin O +
A O +
decreases O +
PSMA O +
activity O -
, O +
integrin O +
function O -
, O +
and O +
PAK O +
activation O -
. O +

Finally O -
, O +
the O +
inhibition O +
of O +
PAK O +
activation O +
enhances O +
the O +
PSMA O -
/ O -
filamin O +
A O +
interaction O +
and O -
, O +
thus O -
, O +
boosts O +
PSMA O +
activity O -
. O +

These O +
data O +
imply O +
that O +
PSMA O +
participates O +
in O +
an O +
autoregulatory O +
loop O -
, O +
wherein O +
active O +
PSMA O +
facilitates O +
integrin O +
signaling O +
and O +
PAK O +
activation O -
, O +
leading O +
to O +
both O +
productive O +
invasion O +
and O +
downregulation O +
of O +
integrin O +
beta O -
( O -
1 O -
) O +
signaling O +
via O +
reduced O +
PSMA O +
activity O -
. O +

Therefore O -
, O +
we O +
have O +
identified O +
a O +
novel O +
role O +
for O +
PSMA O +
as O +
a O +
true O +
molecular O +
interface O -
, O +
integrating O +
both O +
extracellular O +
and O +
intracellular O +
signals O +
during O +
angiogenesis O -
. O +

Differential O +
mechanisms O +
of O +
radiosensitization O +
by O +
2-deoxy B-Chemical -
- I-Chemical -
D I-Chemical -
- I-Chemical -
glucose I-Chemical +
in O +
the O +
monolayers O +
and O +
multicellular O +
spheroids O +
of O +
a O +
human O +
glioma O +
cell O +
line O -
. O +

In O +
vitro O +
studies O +
using O +
monolayer O +
cultures O +
of O +
human O +
tumor O +
cell O +
lines O +
have O +
shown O +
that O +
2-DG B-Chemical +
selectively O +
inhibits O +
energy O -
- O -
dependent O +
DNA O +
repair O +
and O +
cellular O +
recovery O +
processes O +
in O +
cancer O +
cells O -
. O +

However O -
, O +
monolayer O +
cultures O +
differ O +
greatly O +
from O +
the O +
complex O +
environmental O +
conditions O +
generated O +
in O +
solid O +
tumors O +
that O +
develop O +
inhomogeneous O +
hypoxic O +
and O +
necrotic O +
regions O -
. O +

In O +
contrast O -
, O +
multicellular O +
spheroids O +
mimic O +
heterogeneous O +
cellular O +
behavior O +
and O +
the O +
consequent O +
functional O +
characteristics O +
of O +
in O +
vivo O +
solid O +
tumors O -
, O +
and O +
serve O +
as O +
important O +
in O +
vitro O +
model O +
to O +
investigate O +
tumor O +
biology O +
and O +
responses O +
to O +
potential O +
therapeutic O +
agents O -
. O +

The O +
present O +
study O +
compares O +
the O +
radiomodification O +
by O +
2-DG B-Chemical +
in O +
monolayer O +
cultures O +
and O +
spheroids O +
of O +
a O +
human O +
glioma O +
cell O +
line O +
( O -
BMG-1 O -
) O +
to O +
gain O +
insight O +
into O +
the O +
effects O +
in O +
solid O +
tumors O -
. O +

In O +
spheroids O -
, O +
the O +
glucose B-Chemical +
consumption O +
( O -
2.1 O +
p O +
mole O -
/ O -
cell O -
/ O -
h O -
) O +
and O +
lactate B-Chemical +
production O +
( O -
3.67 O +
p O +
mole O -
/ O -
cell O -
/ O -
h O -
) O +
was O +
nearly O +
2 O -
- O -
3 O +
fold O +
higher O +
than O +
in O +
monolayer O +
cells O +
( O -
0.83 O +
and O +
1.43 O +
p O +
mole O -
/ O -
cell O -
/ O -
h O +
respectively O -
) O -
. O +

Presence O +
of O +
2-DG B-Chemical +
( O -
5 O +
mM O -
) O +
for O +
2 O -
- O -
4 O +
h O +
inhibited O +
the O +
glucose B-Chemical +
usage O +
and O +
lactate B-Chemical +
production O +
by O +
70 O -
% O +
in O +
spheroids O -
, O +
while O +
a O +
35 O -
% O +
reduction O +
was O +
observed O +
in O +
monolayer O +
cells O -
. O +

Under O +
these O +
conditions O -
, O +
2-DG B-Chemical +
drastically O +
enhanced O +
the O +
radiation O -
- O -
induced O +
cell O +
death O +
of O +
spheroids O +
( O -
by O +
2 O -
- O -
3 O +
folds O -
) O -
; O +
while O +
a O +
40 O -
% O +
increase O +
was O +
observed O +
in O +
monolayer O +
cells O -
. O +

Radiosensitization O +
by O +
2-DG B-Chemical +
in O +
monolayer O +
cells O +
was O +
primarily O +
due O +
to O +
an O +
increase O +
in O +
mitotic O +
death O +
( O -
23 O -
% O -
) O +
linked O +
to O +
cytogenetic O +
damage O +
( O -
micronuclei O -
) O -
, O +
whereas O +
a O +
profound O +
induction O +
of O +
apoptosis O +
( O -
40 O -
% O -
) O +
accounted O +
for O +
the O +
sensitization O +
in O +
spheroids O -
. O +

Although O +
the O +
Bcl-2 O +
and O +
Bax O +
levels O +
were O +
significantly O +
higher O +
in O +
spheroids O -
, O +
Bcl-2 O -
/ O -
Bax O +
ratio O +
was O +
similar O +
in O +
monolayers O +
and O +
spheroids O -
. O +

Comet O +
assay O +
revealed O +
a O +
late O +
onset O +
of O +
DNA O +
breaks O +
in O +
the O +
presence O +
of O +
2- B-Chemical +
DG I-Chemical +
following O +
irradiation O +
only O +
in O +
spheroids O -
, O +
which O +
corroborated O +
well O +
with O +
the O +
late O +
onset O +
of O +
oxidative O +
stress O -
. O +

2-DG B-Chemical +
did O +
not O +
induce O +
a O +
significant O +
cell O +
cycle O +
delay O +
in O +
monolayers O -
, O +
while O +
a O +
transient O +
G O -
( O -
2 O -
) O +
delay O +
was O +
apparent O +
in O +
spheroids O -
. O +

[ O -
Autologous O +
bone O +
marrow O +
stem O +
cell O +
or O +
peripheral O +
blood O +
endothelial O +
progenitor O +
cell O +
therapy O +
in O +
patients O +
with O +
peripheral O +
limb O +
ischaemia O -
] O +
No O +
effective O +
medical O +
therapies O +
have O +
been O +
developed O +
sofar O +
to O +
enhance O +
blood O +
flow O +
in O +
the O +
legs O +
of O +
patients O +
with O +
peripheral O +
arterial O +
disease O +
( O -
PAD O -
) O -
. O +

For O +
patients O +
with O +
limb O +
threatening O +
ischaemia O +
the O +
only O +
option O +
for O +
relief O +
of O +
rest O +
pain O +
or O +
gangraena O +
is O +
amputation O -
. O +

There O +
is O +
evidence O +
in O +
experimental O +
and O +
clinical O +
studies O +
that O +
adult O +
bone O +
marrow O -
- O -
derived O +
stem O +
cells O +
and O +
endothelial O +
progenitor O +
cells O +
participate O +
in O +
the O +
development O +
of O +
new O +
blood O +
vessels O -
, O +
called O +
neoangiogenesis O +
or O +
neovascularization O -
. O +

Clinical O +
results O +
induced O +
by O +
autologous O +
bone O +
marrow O +
stem O +
cells O +
or O +
angiogenic O +
growth O -
/ O -
differentiation O +
factors O +
in O +
end O -
- O -
stage O +
patients O +
with O +
PAD O +
are O +
summarized O -
. O +

Considering O +
the O +
relatively O +
few O +
number O +
of O +
patients O +
treated O +
by O +
angiogenic O +
therapy O -
, O +
the O +
interpretation O +
of O +
clinical O +
results O +
needs O +
cautiousness O -
. O +

Formation O +
of O +
new O +
bone O +
during O +
vertical O +
distraction O +
osteogenesis O +
of O +
the O +
human O +
mandible O +
is O +
related O +
to O +
the O +
presence O +
of O +
blood O +
vessels O -
. O +

We O +
examined O +
the O +
effect O +
of O +
distraction O +
rate O +
on O +
blood O +
vessel O +
growth O +
in O +
intramembraneous O +
ossification O +
after O +
vertical O +
distraction O +
osteogenesis O +
in O +
the O +
human O +
mandible O -
. O +

Six O +
edentulous O +
patients O +
( O -
aged O +
60+ O -
/ O -
-9 O +
years O -
) O +
with O +
a O +
severely O +
atrophic O +
mandible O +
underwent O +
bone O +
augmentation O +
with O +
distraction O +
osteogenesis O -
. O +

Two O +
distraction O +
rates O +
( O -
0.5 O +
and O +
1 O +
mm O -
/ O -
day O -
) O +
were O +
compared O +
and O +
for O +
each O +
group O +
three O +
patients O +
were O +
analyzed O -
. O +

Vascular O +
histomorphometry O +
was O +
carried O +
out O +
in O +
two O +
different O +
areas O +
in O +
the O +
distraction O +
gap O -
: O +
( O -
1 O -
) O +
in O +
the O +
first O +
and O +
( O -
2 O -
) O +
in O +
the O +
second O +
1 O +
mm O +
area O +
from O +
the O +
osteotomy O +
line O -
, O +
representing O +
the O +
oldest O +
and O +
younger O +
new O -
- O -
bone O +
area O -
, O +
respectively O -
. O +

Correlation O +
analysis O +
was O +
performed O +
between O +
blood O +
vessel O +
parameters O +
and O +
the O +
amount O +
of O +
new O +
bone O +
formed O +
during O +
distraction O -
. O +

Histological O +
analysis O +
demonstrated O +
the O +
presence O +
of O +
blood O +
vessels O +
throughout O +
the O +
soft O +
connective O +
tissue O +
in O +
the O +
distraction O +
gap O -
. O +

The O +
volume O +
density O +
of O +
blood O +
vessels O +
between O +
the O +
two O +
investigated O +
areas O +
was O +
significantly O +
lower O +
in O +
the O +
1 O +
mm O -
/ O -
day O +
groups O -
, O +
suggesting O +
a O +
delay O +
in O +
angiogenesis O +
in O +
this O +
group O +
of O +
patients O -
. O +

A O +
positive O +
correlation O +
between O +
blood O +
vessel O +
volume O +
and O +
bone O +
volume O +
density O +
was O +
found O +
in O +
the O +
younger O +
new O -
- O -
bone O +
area O +
but O +
not O +
in O +
the O +
oldest O +
new O -
- O -
bone O +
area O -
. O +

This O +
correlation O +
was O +
due O +
to O +
a O +
higher O +
number O +
of O +
blood O +
vessels O +
rather O +
than O +
to O +
a O +
larger O +
size O +
of O +
the O +
blood O +
vessels O -
. O +

Our O +
data O +
suggest O +
that O +
the O +
lower O +
blood O +
vessel O +
density O +
found O +
in O +
the O +
patients O +
with O +
1 O +
mm O -
/ O -
day O +
distraction O +
rate O +
may O +
be O +
related O +
to O +
disruption O +
of O +
angiogenesis O +
in O +
the O +
soft O +
connective O +
tissue O +
of O +
the O +
gap O +
or O +
to O +
a O +
less O +
optimal O +
mechanical O +
stimulation O +
of O +
cells O +
involved O +
in O +
angiogenesis O -
. O +

This O +
probably O +
results O +
in O +
the O +
slower O +
rate O +
of O +
osteogenesis O +
seen O +
at O +
the O +
1 O +
mm O -
/ O -
day O +
distraction O +
rate O +
compared O +
with O +
the O +
0.5 O +
mm O -
/ O -
day O +
distraction O +
rate O -
. O +

The O +
data O +
support O +
the O +
concept O +
that O +
a O +
positive O +
relationship O +
exists O +
between O +
the O +
density O +
of O +
blood O +
vessels O +
and O +
the O +
formation O +
of O +
bone O -
. O +

For O +
distraction O +
of O +
the O +
human O +
mandible O +
in O +
elderly O +
patients O -
, O +
a O +
distraction O +
rate O +
of O +
0.5 O +
mm O -
/ O -
day O +
seems O +
beneficial O -
. O +

The O +
role O +
of O +
syndecans O +
in O +
disease O +
and O +
wound O +
healing O -
. O +

Syndecans O +
are O +
a O +
family O +
of O +
transmembrane O +
heparan B-Chemical +
sulfate I-Chemical +
proteoglycans O +
widely O +
expressed O +
in O +
both O +
developing O +
and O +
adult O +
tissues O -
. O +

Until O +
recently O -
, O +
their O +
role O +
in O +
pathogenesis O +
was O +
largely O +
unexplored O -
. O +

In O +
this O +
review O -
, O +
we O +
discuss O +
the O +
reported O +
involvement O +
of O +
syndecans O +
in O +
human O +
cancers O -
, O +
infectious O +
diseases O -
, O +
obesity O -
, O +
wound O +
healing O +
and O +
angiogenesis O -
. O +

In O +
some O +
cancers O -
, O +
syndecan O +
expression O +
has O +
been O +
shown O +
to O +
regulate O +
tumor O +
cell O +
function O +
( O -
e.g. O +
proliferation O -
, O +
adhesion O -
, O +
and O +
motility O -
) O +
and O +
serve O +
as O +
a O +
prognostic O +
marker O +
for O +
tumor O +
progression O +
and O +
patient O +
survival O -
. O +

The O +
ectodomains O +
and O +
heparan B-Chemical +
sulfate I-Chemical +
glycosaminoglycan I-Chemical +
chains O +
of O +
syndecans O +
can O +
also O +
act O +
as O +
receptors O -
/ O -
co O -
- O -
receptors O +
for O +
some O +
bacterial O +
and O +
viral O +
pathogens O -
, O +
mediating O +
infection O -
. O +

In O +
addition O -
, O +
syndecans O +
bind O +
to O +
obesity O -
- O -
related O +
factors O +
and O +
regulate O +
their O +
signaling O -
, O +
in O +
turn O +
modulating O +
food O +
consumption O +
and O +
weight O +
balance O -
. O +

In O +
vivo O +
animal O +
models O +
of O +
tissue O +
injury O +
and O +
in O +
vitro O +
data O +
also O +
implicate O +
syndecans O +
in O +
processes O +
necessary O +
for O +
wound O +
healing O -
, O +
including O +
fibroblast O +
and O +
endothelial O +
proliferation O -
, O +
cell O +
motility O -
, O +
angiogenesis O -
, O +
and O +
extracellular O +
matrix O +
organization O -
. O +

These O +
new O +
insights O +
into O +
the O +
involvement O +
of O +
syndecans O +
in O +
disease O +
and O +
tissue O +
repair O +
coupled O +
with O +
the O +
emergence O +
of O +
syndecan O -
- O -
specific O +
molecular O +
tools O +
may O +
lead O +
to O +
novel O +
therapies O +
for O +
a O +
variety O +
of O +
human O +
diseases O -
. O +

High O -
- O -
Dose O +
celecoxib B-Chemical +
and O +
metronomic O +
" O -
low O -
- O -
dose O -
" O +
cyclophosphamide B-Chemical +
is O +
an O +
effective O +
and O +
safe O +
therapy O +
in O +
patients O +
with O +
relapsed O +
and O +
refractory O +
aggressive O +
histology O +
non O -
- O -
Hodgkin O -
's O +
lymphoma O -
. O +

PURPOSE O -
: O +
Angiogenesis O +
is O +
increased O +
in O +
aggressive O +
histology O +
non O -
- O -
Hodgkin O -
's O +
lymphoma O +
and O +
may O +
be O +
a O +
target O +
with O +
selective O +
cyclooxygenase-2 O +
inhibition O +
and O +
metronomic O +
chemotherapy O -
. O +

EXPERIMENTAL O +
DESIGN O -
: O +
We O +
assessed O +
response O -
, O +
toxicity O -
, O +
and O +
biomarkers O +
of O +
angiogenesis O +
to O +
low O -
- O -
dose O +
cyclophosphamide B-Chemical +
( O -
50 O +
mg O +
p.o O -
. O +

o.d O -
. O -
) O +
and O +
high O -
- O -
dose O +
celecoxib B-Chemical +
( O -
400 O +
mg O +
p.o O -
. O +

b.i.d O -
. O -
) O +
in O +
adult O +
patients O +
with O +
relapsed O +
or O +
refractory O +
aggressive O +
non O -
- O -
Hodgkin O -
's O +
lymphoma O +
in O +
a O +
multicenter O +
phase O +
II O +
prospective O +
study O -
. O +

RESULTS O -
: O +
Thirty O -
- O -
two O +
of O +
35 O +
patients O +
( O -
median O +
age O -
, O +
62 O +
years O -
) O +
are O +
evaluable O +
for O +
response O -
. O +

Patients O +
had O +
primarily O +
relapsed O +
diffuse O +
large O +
B O -
- O -
cell O +
lymphoma O +
( O -
63 O -
% O -
) O +
were O +
heavily O +
pretreated O +
( O -
median O +
of O +
three O +
regimens O -
) O +
and O +
high O +
risk O +
( O -
79 O -
% O +
international O +
prognostic O +
index O -
, O +
greater O +
than O +
or=2 O -
) O +
and O +
34 O -
% O +
were O +
relapsed O +
after O +
autologous O +
stem O +
cell O +
transplant O -
. O +

With O +
a O +
median O +
follow O -
- O -
up O +
of O +
8.4 O +
months O -
, O +
the O +
overall O +
best O +
response O +
rate O +
is O +
37 O -
% O +
( O -
2 O +
complete O +
clinical O +
response O -
/ O -
complete O +
clinical O +
response O +
unconfirmed O +
and O +
9 O +
partial O +
response O -
) O -
, O +
with O +
22 O -
% O +
achieving O +
stable O +
disease O -
. O +

Median O +
overall O +
and O +
progression O -
- O -
free O +
survivals O +
are O +
14.4 O +
and O +
4.7 O +
months O -
, O +
respectively O -
. O +

The O +
median O +
response O +
duration O +
was O +
8.2 O +
months O -
. O +

The O +
most O +
common O +
toxicity O +
was O +
skin O +
rash O +
( O -
40 O -
% O -
) O -
; O +
myelosuppression O +
and O +
gastrointestinal O +
side O +
effects O +
were O +
uncommon O -
. O +

Three O +
patients O +
developed O +
deep O +
vein O +
thromboses O +
and O +
two O +
heavily O +
pretreated O +
patients O +
developed O +
treatment O -
- O -
related O +
acute O +
myelogenous O +
leukemia O +
or O +
myelodysplasia O +
after O +
3.7 O +
and O +
12 O +
months O +
of O +
therapy O -
. O +

Circulating O +
endothelial O +
cells O +
and O +
their O +
precursors O +
declined O +
and O +
remained O +
low O +
in O +
responders O -
, O +
whereas O +
plasma O +
vascular O +
endothelial O +
growth O +
factor O +
trended O +
to O +
decline O +
in O +
responding O +
patients O +
but O +
increase O +
in O +
nonresponders O -
. O +

Trough O +
celecoxib B-Chemical +
levels O +
achieved O +
targeted O +
" O -
antiangiogenic O -
" O +
levels O -
. O +

CONCLUSIONS O -
: O +
Low O -
- O -
dose O +
cyclophosphamide B-Chemical +
and O +
high O -
- O -
dose O +
celecoxib B-Chemical +
is O +
well O +
tolerated O +
and O +
active O +
in O +
pretreated O +
aggressive O +
non O -
- O -
Hodgkin O -
's O +
lymphoma O -
. O +

Close O +
surveillance O +
for O +
arterial O +
and O +
venous O +
thrombotic O +
events O +
is O +
recommended O -
. O +

The O +
decline O +
in O +
circulating O +
endothelial O +
cells O +
and O +
their O +
precursors O +
suggests O +
that O +
this O +
combination O +
may O +
be O +
working O +
by O +
inhibiting O +
angiogenesis O +
but O +
should O +
be O +
validated O +
in O +
a O +
larger O +
patient O +
sample O -
. O +

Photodynamic O +
therapy O +
with O +
verteporfin B-Chemical +
for O +
subfoveal O +
choroidal O +
neovascularization O +
secondary O +
to O +
pathologic O +
myopia O -
: O +
long O -
- O -
term O +
study O -
. O +

PURPOSE O -
: O +
To O +
assess O +
the O +
safety O +
and O +
effectiveness O +
of O +
photodynamic O +
therapy O +
( O -
PDT O -
) O +
with O +
verteporfin B-Chemical +
for O +
subfoveal O +
choroidal O +
neovascularization O +
( O -
CNV O -
) O +
secondary O +
to O +
pathologic O +
myopia O +
( O -
PM O -
) O -
. O +

METHODS O -
: O +
Sixty O -
- O -
two O +
patients O +
( O -
62 O +
eyes O -
) O +
with O +
PM O +
underwent O +
PDT O +
according O +
to O +
the O +
guidelines O +
of O +
the O +
Verteporfin B-Chemical +
in O +
Photodynamic O +
Therapy O +
Study O -
. O +

Clinical O +
evaluations O +
performed O +
at O +
all O +
study O +
visits O +
included O +
measurement O +
of O +
best O -
- O -
corrected O +
Snellen O +
visual O +
acuity O -
, O +
slit O -
- O -
lamp O +
biomicroscopy O -
, O +
and O +
fundus O +
fluorescein B-Chemical +
angiography O -
. O +

Patients O +
were O +
followed O +
up O +
at O +
1 O +
month O +
and O +
3 O +
months O +
after O +
treatment O +
and O +
thereafter O +
at O +
3-month O +
intervals O -
. O +

RESULTS O -
: O +
The O +
final O +
visual O +
acuity O +
of O +
the O +
study O +
patients O -
, O +
after O +
a O +
median O +
follow O -
- O -
up O +
of O +
31 O +
months O -
, O +
improved O +
by O +
greater O +
than O +
or=1 O +
Snellen O +
lines O +
in O +
8 O +
patients O +
( O -
13 O -
% O -
) O -
, O +
deteriorated O +
in O +
20 O +
( O -
32 O -
% O -
) O -
, O +
and O +
remained O +
stable O +
in O +
34 O +
( O -
55 O -
% O -
) O -
. O +

The O +
baseline O +
visual O +
acuity O +
was O +
similar O +
in O +
the O +
various O +
study O +
groups O -
. O +

The O +
final O +
mean O +
visual O +
acuity O +
in O +
group O +
A O +
( O -
55 O +
years O +
of O +
age O +
or O +
younger O -
) O +
was O +
20 O -
/ O -
80 O +
and O +
significantly O +
( O -
P=0.006 O -
) O +
better O +
than O +
that O +
( O -
20 O -
/ O -
138 O -
) O +
in O +
group O +
B O +
( O -
older O +
than O +
55 O +
years O +
of O +
age O -
) O -
. O +

The O +
mean O +
final O +
visual O +
acuity O +
in O +
eyes O +
with O +
higher O +
refractive O +
error O +
at O +
baseline O +
( O -
greater O +
than O +
-17 O +
diopters O -
) O +
was O +
significantly O +
better O +
( O -
P=0.014 O -
) O +
than O +
that O +
in O +
eyes O +
with O +
lower O +
refractive O +
error O +
( O -
-6 O +
to O +
-10 O +
diopters O -
) O -
. O +

CNV O +
size O +
did O +
not O +
affect O +
visual O +
outcomes O -
. O +

CONCLUSION O -
: O +
PDT O +
preserves O +
vision O +
in O +
patients O +
with O +
CNV O +
associated O +
with O +
PM O -
. O +

Younger O +
patients O +
and O +
eyes O +
with O +
higher O +
refractive O +
error O +
appear O +
more O +
likely O +
to O +
benefit O +
from O +
PDT O +
with O +
verteporfin B-Chemical -
. O +

Neoplastic O +
transformation O +
of O +
ciliary O +
body O +
epithelium O +
is O +
associated O +
with O +
loss O +
of O +
opticin O +
expression O -
. O +

BACKGROUND O -
: O +
Opticin O +
is O +
a O +
recently O +
discovered O +
glycoprotein O +
present O +
predominantly O +
in O +
the O +
vitreous O +
humour O -
. O +

It O +
is O +
synthesised O +
and O +
secreted O +
by O +
the O +
ciliary O +
body O +
epithelium O +
( O -
CBE O -
) O +
from O +
the O +
initiation O +
of O +
CBE O +
development O +
in O +
the O +
embryo O -
, O +
and O +
production O +
continues O +
throughout O +
life O -
. O +

AIM O -
: O +
To O +
determine O +
whether O +
a O +
variety O +
of O +
ciliary O +
body O +
tumours O +
synthesise O +
opticin O +
to O +
characterise O +
further O +
its O +
role O +
in O +
ciliary O +
body O +
health O +
and O +
disease O -
. O +

METHODS O -
: O +
Immunohistochemistry O +
was O +
used O +
to O +
determine O +
the O +
distribution O +
of O +
opticin O +
in O +
normal O +
human O +
CBE O -
, O +
and O +
in O +
hyperplastic O +
and O +
neoplastic O +
CBE O +
lesions O -
. O +

RESULTS O -
: O +
Opticin O +
was O +
immunolocalised O +
to O +
the O +
basal O +
cell O +
surface O +
and O +
basement O +
membrane O +
material O +
of O +
the O +
non O -
- O -
pigmented O +
CBE O +
in O +
nine O +
donor O +
eyes O +
as O +
well O +
as O +
four O +
hyperplastic O +
lesions O +
of O +
the O +
CBE O +
( O -
Fuchs O -
's O +
adenoma O -
) O -
. O +

By O +
contrast O -
, O +
none O +
of O +
eight O +
neoplastic O +
lesions O +
( O -
two O +
adenoma O +
and O +
six O +
adenocarcinoma O -
) O +
of O +
CBE O +
stained O +
for O +
opticin O -
. O +

CONCLUSION O -
: O +
The O +
present O +
series O +
supports O +
the O +
theory O +
that O +
opticin O +
is O +
produced O +
by O +
the O +
non O -
- O -
pigmented O +
CBE O +
throughout O +
adult O +
life O -
. O +

Loss O +
of O +
opticin O +
expression O +
by O +
this O +
tissue O +
is O +
associated O +
with O +
and O +
could O +
contribute O +
towards O +
neoplastic O +
transformation O -
. O +

Carcinogenesis O +
and O +
transcriptional O +
regulation O +
through O +
Maf O +
recognition O +
elements O -
. O +

Many O +
studies O +
on O +
carcinogenesis O +
carried O +
out O +
early O +
in O +
the O +
last O +
century O +
are O +
united O +
on O +
the O +
consensus O +
that O +
cancer O +
is O +
a O +
genetic O +
disease O -
. O +

Cancer O +
cells O +
typically O +
display O +
gene O +
dysfunction O +
and O +
endogenous O +
or O +
exogenous O +
insults O +
resulting O +
in O +
gene O +
dysfunction O +
are O +
often O +
carcinogenic O -
. O +

Recent O +
advances O +
in O +
stem O +
cell O +
biology O +
added O +
the O +
new O +
concept O +
that O +
cancer O +
originates O +
from O +
a O +
single O +
cancer O -
- O -
initiating O +
cell O -
. O +

To O +
understand O +
the O +
molecular O +
basis O +
of O +
carcinogenesis O +
from O +
the O +
beginning O +
to O +
the O +
full O +
acquirement O +
of O +
malignancy O -
, O +
factors O +
concerned O +
with O +
carcinogenesis O +
were O +
categorized O +
into O +
three O +
groups O -
: O +
those O +
guarding O +
and O +
stabilizing O +
genomes O -
, O +
those O +
regulating O +
cell O +
proliferation O -
, O +
and O +
those O +
conferring O +
resistance O +
to O +
various O +
micro O -
- O -
environmental O +
stresses O -
. O +

One O +
example O +
of O +
particular O +
interest O +
is O +
the O +
Keap1-Nrf2 O +
system O +
since O -
, O +
according O +
to O +
recent O +
studies O -
, O +
it O +
has O +
turned O +
out O +
to O +
be O +
ambivalent O -
. O +

Nrf2 O +
heterodimerizes O +
with O +
small O +
Maf O +
protein O +
to O +
strongly O +
activate O +
transcription O +
through O +
the O +
Maf O +
recognition O +
element O +
( O -
MARE O -
) O +
and O +
Keap1 O +
is O +
an O +
inhibitory O +
regulator O +
of O +
Nrf2 O -
. O +

The O +
genes O +
regulated O +
by O +
Nrf2 O +
are O +
very O +
important O +
for O +
cellular O +
protection O +
of O +
the O +
genome O +
from O +
xenobiotic O +
and O +
oxidative O +
stresses O +
and O -
, O +
consequently O -
, O +
for O +
preventing O +
carcinogenesis O -
. O +

This O +
implies O +
that O +
enhancing O +
Nrf2 O +
activity O +
is O +
a O +
promising O +
method O +
for O +
thwarting O +
cancer O -
. O +

On O +
the O +
contrary O -
, O +
the O +
constitutive O +
activation O +
of O +
Nrf2 O +
due O +
to O +
mutations O +
in O +
the O +
keap1 O +
gene O +
is O +
characteristically O +
observed O +
in O +
lung O +
cancer O +
cells O -
, O +
suggesting O +
that O +
induced O +
expression O +
of O +
Nrf2 O +
target O +
genes O +
favors O +
the O +
prevalence O +
of O +
cancer O +
cells O -
. O +

Lysophosphatidic B-Chemical +
acid I-Chemical +
downregulates O +
tissue O +
inhibitor O +
of O +
metalloproteinases O -
, O +
which O +
are O +
negatively O +
involved O +
in O +
lysophosphatidic B-Chemical +
acid I-Chemical -
- O -
induced O +
cell O +
invasion O -
. O +

Ovarian O +
cancer O +
is O +
a O +
highly O +
metastatic O +
disease O -
. O +

Lysophosphatidic B-Chemical +
acid I-Chemical +
( O -
LPA B-Chemical -
) O +
levels O +
are O +
elevated O +
in O +
ascites O +
from O +
ovarian O +
cancer O +
patients O -
, O +
but O +
its O +
potential O +
role O +
in O +
ovarian O +
cancer O +
metastasis O +
has O +
just O +
begun O +
to O +
be O +
revealed O -
. O +

In O +
this O +
work O -
, O +
we O +
show O +
that O +
LPA B-Chemical +
stimulates O +
invasion O +
of O +
primary O +
ovarian O +
cancer O +
cells O -
, O +
but O +
not O +
ovarian O +
epithelial O +
or O +
borderline O +
ovarian O +
tumor O +
cells O -
, O +
although O +
these O +
benign O +
cells O +
indeed O +
respond O +
to O +
LPA B-Chemical +
in O +
cell O +
migration O -
. O +

We O +
have O +
found O +
that O +
LPA B-Chemical +
downregulates O +
tissue O +
inhibitor O +
of O +
metalloproteinases O +
( O -
TIMPs O -
) O -
. O +

TIMP2 O +
and O +
TIMP3 O +
play O +
functional O +
role O +
in O +
LPA B-Chemical -
- O -
induced O +
invasion O +
as O +
negative O +
regulators O -
. O +

G O -
( O -
i O -
) O +
protein O -
, O +
phosphatidylinositol-3 O +
kinase O +
( O -
PI3 O -
K O -
) O -
, O +
p38 O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O -
, O +
cytosolic O +
phospholipase O +
A O -
( O -
2 O -
) O +
and O +
urokinase O +
type O +
plasminogen O +
activator O +
( O -
uPA O -
) O +
are O +
required O +
for O +
LPA B-Chemical -
- O -
induced O +
cells O +
invasion O -
. O +

TIMP3 O +
may O +
affect O +
two O +
independent O +
downstream O +
targets O -
, O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
and O +
p38 O +
MAPK O -
. O +

In O +
vivo O -
, O +
LPA B-Chemical +
stimulates O +
tumor O +
metastasis O +
in O +
an O +
orthotopic O +
ovarian O +
tumor O +
model O -
, O +
which O +
can O +
be O +
inhibited O +
by O +
a O +
PI3 O -
K O +
inhibitor O -
, O +
LY294002 B-Chemical -
. O +

In O +
summary O -
, O +
LPA B-Chemical +
is O +
likely O +
a O +
key O +
component O +
for O +
promoting O +
ovarian O +
metastasis O +
in O +
vivo O -
. O +

LPA B-Chemical +
downregulates O +
TIMP3 O -
, O +
which O +
may O +
have O +
targets O +
other O +
than O +
metalloproteinases O -
. O +

Our O +
in O +
vivo O +
metastasis O +
mouse O +
model O +
is O +
useful O +
for O +
studying O +
the O +
efficacy O +
of O +
therapeutic O +
regimes O +
of O +
ovarian O +
cancer O -
. O +

Angiotensin O +
II O +
induces O +
soluble O +
fms O -
- O -
Like O +
tyrosine O +
kinase-1 O +
release O +
via O +
calcineurin O +
signaling O +
pathway O +
in O +
pregnancy O -
. O +

Maternal O +
endothelial O +
dysfunction O +
in O +
preeclampsia O +
is O +
associated O +
with O +
increased O +
soluble O +
fms O -
- O -
like O +
tyrosine O +
kinase-1 O +
( O -
sFlt-1 O -
) O -
, O +
a O +
circulating O +
antagonist O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
placental O +
growth O +
factor O -
. O +

Angiotensin O +
II O +
( O -
Ang O +
II O -
) O +
is O +
a O +
potent O +
vasoconstrictor O +
that O +
increases O +
concomitant O +
with O +
sFlt-1 O +
during O +
pregnancy O -
. O +

Therefore O -
, O +
we O +
speculated O +
that O +
Ang O +
II O +
may O +
promote O +
the O +
expression O +
of O +
sFlt-1 O +
in O +
pregnancy O -
. O +

Here O +
we O +
report O +
that O +
infusion O +
of O +
Ang O +
II O +
significantly O +
increases O +
circulating O +
levels O +
of O +
sFlt-1 O +
in O +
pregnant O +
mice O -
, O +
thereby O +
demonstrating O +
that O +
Ang O +
II O +
is O +
a O +
regulator O +
of O +
sFlt-1 O +
secretion O +
in O +
vivo O -
. O +

Furthermore O -
, O +
Ang O +
II O +
stimulated O +
sFlt-1 O +
production O +
in O +
a O +
dose- O +
and O +
time O -
- O -
dependent O +
manner O +
from O +
human O +
villous O +
explants O +
and O +
cultured O +
trophoblasts O +
but O +
not O +
from O +
endothelial O +
cells O -
, O +
suggesting O +
that O +
trophoblasts O +
are O +
the O +
primary O +
source O +
of O +
sFlt-1 O +
during O +
pregnancy O -
. O +

As O +
expected O -
, O +
Ang O +
II O -
- O -
induced O +
sFlt-1 O +
secretion O +
resulted O +
in O +
the O +
inhibition O +
of O +
endothelial O +
cell O +
migration O +
and O +
in O +
vitro O +
tube O +
formation O -
. O +

In O +
vitro O +
and O +
in O +
vivo O +
studies O +
with O +
losartan B-Chemical -
, O +
small O +
interfering O +
RNA O +
specific O +
for O +
calcineurin O +
and O +
FK506 B-Chemical +
demonstrated O +
that O +
Ang O +
II O -
- O -
mediated O +
sFlt-1 O +
release O +
was O +
via O +
Ang O +
II O +
type O +
1 O +
receptor O +
activation O +
and O +
calcineurin O +
signaling O -
, O +
respectively O -
. O +

These O +
findings O +
reveal O +
a O +
previously O +
unrecognized O +
regulatory O +
role O +
for O +
Ang O +
II O +
on O +
sFlt-1 O +
expression O +
in O +
murine O +
and O +
human O +
pregnancy O +
and O +
suggest O +
that O +
elevated O +
sFlt-1 O +
levels O +
in O +
preeclampsia O +
may O +
be O +
caused O +
by O +
a O +
dysregulation O +
of O +
the O +
local O +
renin O -
/ O -
angiotensin O +
system O -
. O +

p21 O +
delays O +
tumor O +
onset O +
by O +
preservation O +
of O +
chromosomal O +
stability O -
. O +

The O +
p53 O +
protein O +
suppresses O +
tumorigenesis O +
by O +
initiating O +
cellular O +
functions O +
such O +
as O +
cell O +
cycle O +
arrest O +
and O +
apoptosis O +
in O +
response O +
to O +
DNA O +
damage O -
. O +

A O +
p53 O +
mutant O -
, O +
p53R172P O -
, O +
which O +
is O +
deficient O +
for O +
apoptosis O +
but O +
retains O +
a O +
partial O +
cell O +
cycle O +
arrest O +
function O -
, O +
delays O +
tumor O +
onset O +
in O +
mice O -
. O +

Remarkably O -
, O +
lymphomas O +
arising O +
in O +
Trp53 O -
( O -
515C O -
/ O -
515C O -
) O +
mice O +
( O -
encoding O +
p53R172P O -
) O +
retain O +
stable O +
genomes O -
. O +

Given O +
the O +
dominant O +
role O +
of O +
p21 O +
in O +
p53 O +
cell O +
cycle O +
control O -
, O +
we O +
crossed O +
Trp53 O -
( O -
515C O -
/ O -
515C O -
) O +
mice O +
onto O +
a O +
p21-null O +
background O +
to O +
determine O +
whether O +
p21 O +
was O +
required O +
for O +
maintaining O +
chromosomal O +
stability O +
and O +
delaying O +
tumor O +
onset O -
. O +

Loss O +
of O +
p21 O +
completely O +
abolished O +
the O +
cell O +
cycle O +
arrest O +
function O +
of O +
p53R172P O +
and O +
accelerated O +
tumor O +
onset O +
in O +
Trp53 O -
( O -
515C O -
/ O -
515C O -
) O +
mice O -
. O +

Cytogenetic O +
examination O +
of O +
Trp53 O -
( O -
515C O -
/ O -
515C O -
) O +
p21 O -
( O -
- O -
/ O -
- O -
) O +
sarcomas O +
and O +
lymphomas O +
revealed O +
aneuploidy O +
and O +
chromosomal O +
aberrations O +
that O +
were O +
absent O +
in O +
Trp53 O -
( O -
515C O -
/ O -
515C O -
) O +
malignancies O -
. O +

Thus O -
, O +
p21 O +
coupled O +
p53-dependent O +
checkpoint O +
control O +
and O +
preservation O +
of O +
chromosomal O +
stability O -
, O +
and O +
cooperated O +
with O +
apoptosis O +
in O +
suppressing O +
tumor O +
onset O +
in O +
mice O -
. O +

Role O +
of O +
the O +
fibrinolytic O +
and O +
matrix O +
metalloproteinase O +
systems O +
in O +
development O +
of O +
adipose O +
tissue O -
. O +

Obesity O +
is O +
a O +
common O +
disorder O +
and O +
related O +
diseases O +
such O +
as O +
diabetes O -
, O +
atherosclerosis O -
, O +
hypertension O -
, O +
cardiovascular O +
disease O +
and O +
cancer O +
are O +
a O +
major O +
cause O +
of O +
mortality O +
and O +
morbidity O +
in O +
Western O -
- O -
type O +
societies O -
. O +

Development O +
of O +
obesity O +
is O +
associated O +
with O +
extensive O +
modifications O +
in O +
adipose O +
tissue O +
involving O +
adipogenesis O -
, O +
angiogenesis O +
and O +
extracellular O +
matrix O +
proteolysis O -
. O +

The O +
fibrinolytic O +
( O -
plasminogen O -
/ O -
plasmin O -
) O +
and O +
matrix O +
metalloproteinase O +
( O -
MMP O -
) O +
systems O +
cooperate O +
in O +
these O +
processes O -
. O +

A O +
nutritionally O +
induced O +
obesity O +
model O +
in O +
transgenic O +
mice O +
has O +
been O +
used O +
extensively O +
to O +
study O +
the O +
role O +
of O +
the O +
fibrinolytic O +
and O +
MMP O +
systems O +
in O +
the O +
development O +
of O +
obesity O -
. O +

These O +
studies O +
support O +
a O +
role O +
of O +
both O +
systems O +
in O +
adipogenesis O +
and O +
obesity O -
; O +
the O +
role O +
of O +
specific O +
members O +
of O +
these O +
families O -
, O +
however O -
, O +
remains O +
to O +
be O +
determined O -
. O +

Extracellular O +
matrix O +
as O +
a O +
bioactive O +
material O +
for O +
soft O +
tissue O +
reconstruction O -
. O +

The O +
extracellular O +
matrix O +
( O -
ECM O -
) O +
directs O +
all O +
phases O +
of O +
healing O +
following O +
trauma O +
or O +
disease O +
and O +
is O +
therefore O +
a O +
natural O +
source O +
of O +
prosthetic O +
mesh O +
material O +
that O +
can O +
be O +
used O +
strategically O +
to O +
induce O +
the O +
repair O +
and O +
restoration O +
of O +
soft O +
tissues O +
following O +
surgery O -
. O +

Biomaterials O +
such O +
as O +
Surgisis O +
( O -
Cook O +
Biotech O +
Incorporated O -
, O +
West O +
Lafayette O -
, O +
IN O -
, O +
USA O -
) O -
, O +
which O +
are O +
derived O +
from O +
natural O +
ECM O -
, O +
provide O +
the O +
extracellular O +
components O +
necessary O +
to O +
direct O +
the O +
healing O +
response O -
, O +
allow O +
for O +
the O +
proliferation O +
of O +
new O -
, O +
healthy O +
tissue O +
and O +
restore O +
tissue O +
integrity O +
to O +
the O +
damaged O +
site O -
. O +

The O +
3-D O +
organization O +
of O +
these O +
extracellular O +
components O +
distinguishes O +
the O +
Surgisis O +
mesh O +
from O +
synthetic O +
materials O +
and O +
is O +
associated O +
with O +
constructive O +
tissue O +
remodelling O +
instead O +
of O +
scar O +
tissue O -
. O +

Common O +
features O +
of O +
this O +
ECM O -
- O -
assisted O +
tissue O +
remodelling O +
include O +
angiogenesis O -
, O +
recruitment O +
of O +
circulating O +
progenitor O +
cells O +
and O +
constructive O +
remodelling O +
of O +
damaged O +
tissue O +
structures O -
. O +

The O +
tissue O +
response O +
to O +
this O +
biologic O +
mesh O +
is O +
discussed O +
in O +
the O +
context O +
of O +
recent O +
reports O +
on O +
clinical O +
hernia O +
repair O -
. O +

Relationship O +
of O +
cellular O +
immunity O -
, O +
cytokines O +
and O +
CRP O +
with O +
clinical O +
course O +
in O +
breast O +
cancer O +
patients O +
with O +
endocrine O -
- O -
dependent O +
distant O +
metastases O +
treated O +
with O +
immunotherapy O -
. O +

We O +
have O +
reported O +
important O +
benefits O +
and O +
survival O +
with O +
an O +
immunotherapy O +
schedule O +
in O +
patients O +
with O +
endocrine O -
- O -
dependent O +
breast O +
cancer O +
and O +
distant O +
metastases O -
. O +

Here O +
clinical O +
outcome O +
is O +
updated O +
and O +
its O +
correlation O +
with O +
new O +
immunological O +
data O +
is O +
shown O -
. O +

In O +
32 O +
evaluated O +
breast O +
cancer O +
patients O +
with O +
endocrine O -
- O -
dependent O +
distant O +
metastases O +
treated O +
with O +
a O +
new O +
immunotherapy O +
schedule O +
( O -
cyclic O +
administration O +
of O +
beta O -
- O -
interferon O +
and O +
interleukin-2 O -
) O -
, O +
cellular O +
immunity O -
, O +
cytokines O +
and O +
CRP O +
were O +
related O +
to O +
the O +
clinical O +
course O -
. O +

Estimated O +
and O +
true O +
5 O -
- O -
10 O +
year O +
overall O +
survival O +
rates O +
from O +
first O +
line O +
antiestrogen O +
and O +
distant O +
metastases O +
were O +
higher O +
than O +
previously O +
reported O +
in O +
a O +
similar O +
population O -
. O +

Interleukin-2 O +
administration O +
was O +
followed O +
by O +
a O +
significant O +
increase O +
in O +
total O +
lymphocytes O -
, O +
CD4 O -
+ O -
, O +
CD8 O -
+ O -
, O +
CD16 O -
+ O -
56 O -
+ O +
( O -
NK O -
) O +
cells O -
, O +
IL-6 O -
, O +
IL-12 O -
, O +
and O +
CRP O +
( O -
from O +
P<0.04 O +
to O +
P<0.000 O -
) O +
but O +
no O +
change O +
in O +
IL-10 O +
and O +
TGFbeta1 O +
during O +
clinical O +
benefit O -
. O +

During O +
progressive O +
disease O +
no O +
change O +
was O +
observed O +
in O +
the O +
former O +
parameters O -
, O +
concomitant O +
with O +
a O +
significant O +
increase O +
in O +
IL-10 O +
( O -
P=0.020 O -
) O +
and O +
a O +
significant O +
decrease O +
in O +
TGFbeta1 O +
( O -
P=0.023 O -
) O -
. O +

These O +
findings O +
confirm O +
that O +
cellular O +
immunity O +
is O +
significantly O +
stimulated O +
by O +
IL-2 O +
only O +
during O +
clinical O +
benefit O -
. O +

Furthermore O -
, O +
these O +
results O +
demonstrate O +
that O +
different O +
changes O +
of O +
proinflammatory O +
cytokines O -
, O +
CRP O +
and O +
inhibiting O +
factors O +
are O +
consistent O +
with O +
associated O +
clinical O +
benefit O +
or O +
with O +
disease O +
progression O -
, O +
respectively O -
. O +

Trib1 O +
and O +
Evi1 O +
cooperate O +
with O +
Hoxa O +
and O +
Meis1 O +
in O +
myeloid O +
leukemogenesis O -
. O +

Cooperative O +
activation O +
of O +
Meis1 O +
and O +
Hoxa9 O +
perturbs O +
myeloid O +
differentiation O +
and O +
eventually O +
leads O +
myeloid O +
progenitors O +
to O +
leukemia O -
, O +
yet O +
it O +
remains O +
to O +
be O +
clarified O +
what O +
kinds O +
of O +
subsequent O +
molecular O +
processes O +
are O +
required O +
for O +
development O +
of O +
overt O +
leukemia O -
. O +

To O +
understand O +
the O +
molecular O +
pathway O +
in O +
Hoxa9 O -
/ O -
Meis1-induced O +
leukemogenesis O -
, O +
retroviral O +
insertional O +
mutagenesis O +
was O +
applied O +
using O +
retrovirus O -
- O -
mediated O +
gene O +
transfer O -
. O +

The O +
mice O +
that O +
received O +
Hoxa9 O -
/ O -
Meis1-transduced O +
bone O +
marrow O +
cells O +
developed O +
acute O +
myeloid O +
leukemia O +
( O -
AML O -
) O -
, O +
and O +
Trib1 O -
, O +
Evi1 O -
, O +
Ahi1 O -
, O +
Raralpha O -
, O +
Pitpnb O -
, O +
and O +
AK039950 O +
were O +
identified O +
as O +
candidate O +
cooperative O +
genes O +
located O +
near O +
common O +
retroviral O +
integration O +
sites O -
. O +

Trib1 O +
and O +
Evi1 O +
were O +
up O -
- O -
regulated O +
due O +
to O +
retroviral O +
insertions O -
, O +
and O +
coexpression O +
of O +
these O +
genes O +
significantly O +
accelerated O +
the O +
onset O +
of O +
Hoxa9 O -
/ O -
Meis1-induced O +
AML O -
, O +
suggesting O +
that O +
Trib1 O +
and O +
Evi1 O +
are O +
the O +
key O +
collaborators O -
. O +

Furthermore O -
, O +
Trib1 O +
by O +
itself O +
is O +
a O +
novel O +
myeloid O +
oncogene O -
, O +
enhancing O +
phosphorylation O +
of O +
ERK O -
, O +
resulting O +
in O +
inhibition O +
of O +
apoptosis O -
. O +

These O +
results O +
demonstrate O +
the O +
importance O +
of O +
specific O +
oncogene O +
interaction O +
in O +
myeloid O +
leukemogenesis O -
. O +

Impaired O +
apoptosis O +
of O +
pulmonary O +
endothelial O +
cells O +
is O +
associated O +
with O +
intimal O +
proliferation O +
and O +
irreversibility O +
of O +
pulmonary O +
hypertension O +
in O +
congenital O +
heart O +
disease O -
. O +

OBJECTIVES O -
: O +
This O +
study O +
sought O +
to O +
assess O +
the O +
cellular O +
and O +
histologic O +
basis O +
of O +
irreversible O +
pulmonary O +
hypertension O +
( O -
PHT O -
) O +
in O +
the O +
clinical O +
setting O +
of O +
congenital O +
heart O +
disease O +
( O -
CHD O -
) O -
. O +

BACKGROUND O -
: O +
Although O +
many O +
children O +
with O +
CHD O +
develop O +
pulmonary O +
vascular O +
disease O -
, O +
it O +
is O +
unclear O +
why O +
this O +
complication O +
is O +
reversible O +
after O +
complete O +
repair O +
in O +
some O +
cases O +
but O +
irreversible O +
in O +
others O -
. O +

Because O +
failure O +
of O +
endothelial O +
cell O +
apoptosis O +
might O +
lead O +
to O +
intimal O +
proliferation O +
and O +
lack O +
of O +
reversibility O +
of O +
PHT O -
, O +
we O +
investigated O +
this O +
and O +
other O +
key O +
markers O +
of O +
vasoactivity O +
and O +
angiogenesis O +
in O +
subjects O +
with O +
PHT O +
and O +
CHD O -
. O +

METHODS O -
: O +
We O +
assessed O +
antiapoptotic O +
and O +
proapoptotic O +
markers O +
in O +
vascular O +
and O +
perivascular O +
cells O +
in O +
lung O +
biopsy O +
samples O +
from O +
18 O +
patients O +
with O +
CHD O -
, O +
7 O +
with O +
reversible O +
and O +
11 O +
with O +
irreversible O +
PHT O -
, O +
and O +
6 O +
control O +
patients O -
. O +

Immunostaining O +
for O +
endothelial O +
nitric O +
oxide O +
synthase O -
, O +
vascular O +
endothelial O +
growth O +
factor O -
, O +
and O +
CD34 O +
( O -
markers O +
of O +
vasoactivity O +
and O +
neoangiogenesis O -
) O +
was O +
also O +
performed O -
. O +

RESULTS O -
: O +
The O +
antiapoptotic O +
protein O +
Bcl-2 O +
was O +
highly O +
expressed O +
by O +
pulmonary O +
endothelial O +
cells O +
in O +
all O +
cases O +
of O +
irreversible O +
PHT O +
but O +
in O +
no O +
cases O +
of O +
reversible O +
PHT O -
, O +
nor O +
in O +
control O +
patients O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
. O +

Intimal O +
proliferation O +
was O +
present O +
in O +
10 O +
of O +
11 O +
irreversible O +
PHT O +
cases O -
, O +
but O +
never O +
observed O +
in O +
reversible O +
PHT O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
. O +

Similarly O -
, O +
perivascular O +
inflammatory O +
T O -
- O -
cells O +
expressed O +
more O +
antiapoptotic O +
proteins O +
in O +
irreversible O +
PHT O +
( O -
p O +
less O +
than O +
0.01 O -
) O -
. O +

Irreversible O +
PHT O +
cases O +
were O +
also O +
more O +
likely O +
to O +
show O +
compensatory O +
upregulation O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
new O +
small O +
vessel O +
formation O +
at O +
the O +
sites O +
of O +
native O +
vessel O +
stenosis O +
or O +
occlusion O +
( O -
p O +
less O +
than O +
0.001 O -
) O -
. O +

CONCLUSIONS O -
: O +
Irreversible O +
PHT O +
is O +
strongly O +
associated O +
with O +
impaired O +
endothelial O +
cell O +
apoptosis O +
and O +
antiapoptotic O +
signaling O +
from O +
perivascular O +
inflammatory O +
cells O -
. O +

These O +
changes O +
are O +
associated O +
with O +
intimal O +
proliferation O +
and O +
vessel O +
narrowing O -
, O +
and O +
thereby O +
may O +
contribute O +
to O +
clinical O +
outcomes O +
associated O +
with O +
pulmonary O +
hypertension O -
. O +

Inhibition O +
of O +
Dll4-mediated O +
signaling O +
induces O +
proliferation O +
of O +
immature O +
vessels O +
and O +
results O +
in O +
poor O +
tissue O +
perfusion O -
. O +

Vascular O +
development O +
is O +
dependent O +
on O +
various O +
growth O +
factors O +
and O +
certain O +
modifiers O +
critical O +
for O +
providing O +
arterial O +
or O +
venous O +
identity O -
, O +
interaction O +
with O +
the O +
surrounding O +
stroma O +
and O +
tissues O -
, O +
hierarchic O +
network O +
formation O -
, O +
and O +
recruitment O +
of O +
pericytes O -
. O +

Notch O +
receptors O +
and O +
ligands O +
( O -
Jagged O +
and O +
Delta O -
- O -
like O -
) O +
play O +
a O +
critical O +
role O +
in O +
this O +
process O +
in O +
addition O +
to O +
VEGF O -
. O +

Dll4 O +
is O +
one O +
of O +
the O +
Notch O +
ligands O +
that O +
regulates O +
arterial O +
specification O +
and O +
maturation O +
events O -
. O +

In O +
the O +
current O +
study O -
, O +
we O +
have O +
shown O +
that O +
loss O +
of O +
function O +
by O +
either O +
targeted O +
allele O +
deletion O +
or O +
use O +
of O +
a O +
soluble O +
form O +
of O +
Dll4 O +
extracellular O +
domain O +
leads O +
to O +
inhibition O +
of O +
Notch O +
signaling O -
, O +
resulting O +
in O +
increased O +
vascular O +
proliferation O +
but O +
defective O +
maturation O -
. O +

Newly O +
forming O +
vessels O +
have O +
thin O +
caliber O -
, O +
a O +
markedly O +
reduced O +
vessel O +
lumen O -
, O +
markedly O +
reduced O +
pericyte O +
recruitment O -
, O +
and O +
deficient O +
vascular O +
perfusion O -
. O +

sDll4 O +
similarly O +
induced O +
defective O +
vascular O +
response O +
in O +
tumor O +
implants O +
leading O +
to O +
reduced O +
tumor O +
growth O -
. O +

Interference O +
with O +
Dll4-Notch O +
signaling O +
may O +
be O +
particularly O +
desirable O +
in O +
tumors O +
that O +
have O +
highly O +
induced O +
Dll4-Notch O +
pathway O -
. O +

SWAP-70 O +
is O +
required O +
for O +
oncogenic O +
transformation O +
by O +
v O -
- O -
Src O +
in O +
mouse O +
embryo O +
fibroblasts O -
. O +

SWAP-70 O +
is O +
a O +
phosphatidylinositol B-Chemical +
trisphosphate I-Chemical +
( O -
PtdIns B-Chemical -
( I-Chemical -
3,4,5 I-Chemical -
) I-Chemical -
P I-Chemical -
( I-Chemical -
3 I-Chemical -
) I-Chemical -
) O +
binding O +
protein O -
, O +
which O +
acts O +
in O +
F O -
- O -
actin O +
rearrangement O -
. O +

The O +
role O +
of O +
SWAP-70 O +
in O +
oncogenic O +
transformation O +
of O +
mouse O +
embryo O +
fibroblasts O +
( O -
MEFs O -
) O +
by O +
v O -
- O -
Src O +
was O +
examined O +
by O +
use O +
of O +
MEFs O +
defective O +
in O +
SWAP-70 O -
. O +

v O -
- O -
Src O +
morphologically O +
transformed O +
MEFs O +
lacking O +
SWAP-70 O -
, O +
but O +
growth O +
of O +
the O +
transformed O +
cells O +
in O +
culture O +
was O +
slower O +
than O +
that O +
of O +
cells O +
supplemented O +
with O +
exogenous O +
SWAP-70 O -
. O +

The O +
v O -
- O -
Src O -
- O -
transformed O +
MEFs O +
deficient O +
in O +
SWAP-70 O +
were O +
unable O +
to O +
grow O +
in O +
soft O +
agar O +
while O +
those O +
expressing O +
SWAP70 O +
readily O +
formed O +
colonies O -
, O +
suggesting O +
that O +
SWAP-70 O +
is O +
required O +
for O +
anchorage O +
independent O +
growth O +
of O +
v O -
- O -
Src O +
transformed O +
MEFs O -
. O +

When O +
transplanted O +
in O +
nude O +
mice O -
, O +
tumors O +
formed O +
by O +
the O +
v O -
- O -
Src O +
transformed O +
SWAP-70 O -
( O -
- O -
/ O -
- O -
) O +
MEFs O +
were O +
smaller O +
than O +
those O +
formed O +
by O +
cells O +
expressing O +
exogenous O +
SWAP-70 O -
. O +

These O +
results O +
suggest O +
that O +
SWAP-70 O +
may O +
be O +
required O +
for O +
oncogenic O +
transformation O +
and O +
contributes O +
to O +
cell O +
growth O +
in O +
MEFs O +
transformed O +
by O +
v O -
- O -
Src O -
. O +

Tsg101 O +
is O +
upregulated O +
in O +
a O +
subset O +
of O +
invasive O +
human O +
breast O +
cancers O +
and O +
its O +
targeted O +
overexpression O +
in O +
transgenic O +
mice O +
reveals O +
weak O +
oncogenic O +
properties O +
for O +
mammary O +
cancer O +
initiation O -
. O +

Previous O +
studies O +
reported O +
that O +
the O +
Tumor O +
Susceptibility O +
Gene O +
101 O +
( O -
TSG101 O -
) O +
is O +
upregulated O +
in O +
selected O +
human O +
malignancies O -
, O +
and O +
the O +
expression O +
of O +
exogenous O +
Tsg101 O +
was O +
suggested O +
to O +
transform O +
immortalized O +
fibroblasts O +
in O +
culture O -
. O +

To O +
date O -
, O +
the O +
potential O +
oncogenic O +
properties O +
of O +
Tsg101 O +
have O +
not O +
been O +
examined O +
in O +
vivo O +
owing O +
to O +
the O +
lack O +
of O +
appropriate O +
model O +
systems O -
. O +

In O +
this O +
study O -
, O +
we O +
show O +
that O +
Tsg101 O +
is O +
highly O +
expressed O +
in O +
a O +
subset O +
of O +
invasive O +
human O +
breast O +
cancers O -
. O +

Based O +
on O +
this O +
observation O -
, O +
we O +
generated O +
the O +
first O +
transgenic O +
mouse O +
model O +
with O +
a O +
targeted O +
overexpression O +
of O +
Tsg101 O +
in O +
the O +
developing O +
mammary O +
gland O +
to O +
test O +
whether O +
exogenous O +
Tsg101 O +
is O +
capable O +
of O +
initiating O +
tumorigenesis O -
. O +

Normal O +
functionality O +
of O +
exogenous O +
Tsg101 O +
was O +
tested O +
by O +
rescuing O +
the O +
survival O +
of O +
Tsg101-deficient O +
mammary O +
epithelial O +
cells O +
in O +
conditional O +
knockout O +
mice O -
. O +

The O +
overexpression O +
of O +
Tsg101 O +
resulted O +
in O +
increased O +
phosphorylation O +
of O +
the O +
epidermal O +
growth O +
factor O +
receptor O +
and O +
downstream O +
activation O +
of O +
MAP O +
kinases O -
. O +

Despite O +
an O +
increase O +
in O +
the O +
activation O +
of O +
these O +
signal O +
transducers O -
, O +
the O +
mammary O +
gland O +
of O +
females O +
expressing O +
exogenous O +
Tsg101 O +
developed O +
normally O +
throughout O +
the O +
reproductive O +
cycle O -
. O +

In O +
aging O +
females O -
, O +
the O +
overexpression O +
of O +
Tsg101 O +
seemed O +
to O +
increase O +
the O +
susceptibility O +
of O +
mammary O +
epithelia O +
toward O +
malignant O +
transformation O -
. O +

However O -
, O +
owing O +
to O +
the O +
long O +
latency O +
of O +
tumor O +
formation O +
and O +
the O +
sporadic O +
occurrence O +
of O +
bona O +
fide O +
mammary O +
cancers O -
, O +
we O +
conclude O +
that O +
the O +
Tsg101 O +
protein O +
has O +
only O +
weak O +
oncogenic O +
properties O -
. O +

Instead O +
of O +
cancer O +
initiation O -
, O +
it O +
is O +
therefore O +
likely O +
that O +
Tsg101 O +
plays O +
a O +
more O +
predominant O +
role O +
in O +
the O +
progression O +
of O +
a O +
subset O +
of O +
spontaneously O +
arising O +
breast O +
cancers O -
. O +

Expression O +
of O +
Bcl O -
- O -
xL O -
, O +
Bax O -
, O +
and O +
p53 O +
in O +
primary O +
tumors O +
and O +
lymph O +
node O +
metastases O +
in O +
oral O +
squamous O +
cell O +
carcinoma O -
. O +

Disturbances O +
in O +
expression O +
of O +
apoptosis O -
- O -
associated O +
proteins O +
take O +
part O +
in O +
the O +
development O +
and O +
progression O +
of O +
many O +
human O +
malignancies O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
the O +
assessment O +
of O +
correlations O +
among O +
proteins O +
involved O +
in O +
apoptosis O -
- O -
Bcl O -
- O -
xL O -
, O +
Bax O -
, O +
and O +
p53-as O +
well O +
as O +
relationships O +
of O +
these O +
proteins O +
with O +
selected O +
clinicopathological O +
features O +
in O +
oral O +
squamous O +
cell O +
carcinoma O -
. O +

Consequently O -
, O +
we O +
examined O +
by O +
immunohistochemistry O -
, O +
using O +
the O +
avidin O -
- O -
biotin B-Chemical -
- O -
peroxidase O +
method O -
, O +
Bcl O -
- O -
xL O -
, O +
Bax O -
, O +
and O +
p53 O +
expression O +
in O +
56 O +
samples O +
of O +
primary O +
oral O +
squamous O +
cell O +
carcinoma O +
and O +
in O +
22 O +
matched O +
pairs O +
of O +
primary O +
and O +
metastatic O +
tumors O -
. O +

The O +
evaluation O +
of O +
immunostaining O +
of O +
Bcl O -
- O -
xL O -
, O +
Bax O -
, O +
and O +
p53 O +
was O +
analyzed O +
in O +
10 O +
different O +
tumor O +
fields O -
, O +
and O +
the O +
mean O +
percentage O +
of O +
tumor O +
cells O +
with O +
positive O +
staining O +
was O +
evaluated O -
. O +

The O +
significance O +
of O +
the O +
associations O +
was O +
determined O +
using O +
Spearman O +
correlation O +
analysis O +
and O +
the O +
chi O -
- O -
square O +
test O -
. O +

We O +
found O +
positive O +
Bcl O -
- O -
xL O -
, O +
Bax O -
, O +
and O +
p53 O +
immunostaining O +
in O +
44.6 O -
% O -
, O +
28.6 O -
% O -
, O +
and O +
58.9 O -
% O +
of O +
the O +
studied O +
primary O +
tumors O +
and O +
in O +
63.6 O -
% O -
, O +
45.5 O -
% O -
, O +
and O +
72.7 O -
% O +
of O +
lymph O +
node O +
metastases O -
, O +
respectively O -
. O +

Analysis O +
of O +
associations O +
among O +
studied O +
proteins O +
revealed O +
positive O +
correlation O +
between O +
Bcl O -
- O -
xL O +
and O +
Bax O +
in O +
primary O +
tumors O +
( O -
P<0.03 O -
, O +
r=0.307 O -
) O -
. O +

Statistically O +
significant O +
relationship O +
between O +
p53 O +
expression O +
in O +
primary O +
oral O +
cancers O +
and O +
its O +
expression O +
in O +
lymph O +
node O +
metastases O +
( O -
P<0.02 O -
) O +
as O +
well O +
as O +
increased O +
expression O +
of O +
Bcl O -
- O -
xL O -
, O +
Bax O -
, O +
and O +
p53 O +
in O +
metastatic O +
sites O +
compared O +
with O +
primary O +
tumors O +
could O +
indicate O +
an O +
association O +
of O +
these O +
proteins O +
with O +
oral O +
cancer O +
progression O +
and O +
development O +
of O +
metastases O -
. O +

Moreover O -
, O +
we O +
suppose O +
that O +
knowledge O +
about O +
heterogeneity O +
between O +
primary O +
and O +
metastatic O +
tumor O +
might O +
help O +
to O +
understand O +
mechanisms O +
of O +
oral O +
cancer O +
progression O -
. O +

Mechanisms O +
for O +
the O +
magnolol B-Chemical -
- O -
induced O +
cell O +
death O +
of O +
CGTH O +
W-2 O +
thyroid O +
carcinoma O +
cells O -
. O +

Magnolol B-Chemical -
, O +
a O +
substance O +
purified O +
from O +
the O +
bark O +
of O +
Magnolia O +
officialis O -
, O +
inhibits O +
cell O +
proliferation O +
and O +
induces O +
apoptosis O +
in O +
a O +
variety O +
of O +
cancer O +
cells O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
study O +
the O +
effects O +
of O +
magnolol B-Chemical +
on O +
CGTH O +
W-2 O +
thyroid O +
carcinoma O +
cells O -
. O +

After O +
24 O +
h O +
treatment O +
with O +
80 O +
microM O +
magnolol B-Chemical +
in O +
serum O -
- O -
containing O +
medium O -
, O +
about O +
50 O -
% O +
of O +
the O +
cells O +
exhibited O +
apoptotic O +
features O +
and O +
20 O -
% O +
necrotic O +
features O -
. O +

Cytochrome O -
- O -
c O +
staining O +
was O +
diffused O +
in O +
the O +
cytoplasm O +
of O +
the O +
apoptotic O +
cells O -
, O +
but O +
restricted O +
to O +
the O +
mitochondria O +
in O +
control O +
cells O -
. O +

Western O +
blot O +
analyses O +
showed O +
an O +
increase O +
in O +
levels O +
of O +
activated O +
caspases O +
( O -
caspase-3 O +
and O +
-7 O -
) O +
and O +
of O +
cleaved O +
poly O +
( O -
ADP O -
- O -
ribose O -
) O +
polymerase O +
( O -
PARP O -
) O +
by O +
magnolol B-Chemical -
. O +

Concomitantly O -
, O +
immunostaining O +
for O +
apoptosis O +
inducing O +
factor O +
( O -
AIF O -
) O +
showed O +
a O +
time O -
- O -
dependent O +
translocation O +
from O +
the O +
mitochondria O +
to O +
the O +
nucleus O -
. O +

Inhibition O +
of O +
either O +
PARP O +
or O +
caspase O +
activity O +
blocked O +
magnolol B-Chemical -
- O -
induced O +
apoptosis O -
, O +
supporting O +
the O +
involvement O +
of O +
the O +
caspases O +
and O +
PARP O -
. O +

In O +
addition O -
, O +
magnolol B-Chemical +
activated O +
phosphatase O +
and O +
tensin O +
homolog O +
deleted O +
on O +
chromosome O +
10 O +
( O -
PTEN O -
) O +
and O +
inactivated O +
Akt O +
by O +
decreasing O +
levels O +
of O +
phosphorylated O +
PTEN O +
and O +
phosphorylated O +
Akt O -
. O +

These O +
data O +
suggest O +
that O +
magnolol B-Chemical +
promoted O +
apoptosis O +
probably O +
by O +
alleviating O +
the O +
inhibitory O +
effect O +
of O +
Akt O +
on O +
caspase O +
9 O -
. O +

Furthermore O -
, O +
inhibition O +
of O +
PARP O +
activity O -
, O +
but O +
not O +
of O +
caspase O +
activity O -
, O +
completely O +
prevented O +
magnolol B-Chemical -
- O -
induced O +
necrosis O -
, O +
suggesting O +
the O +
notion O +
that O +
it O +
might O +
be O +
caused O +
by O +
depletion O +
of O +
intracellular O +
ATP B-Chemical +
levels O +
due O +
to O +
PARP O +
activation O -
. O +

These O +
results O +
show O +
that O +
magnolol B-Chemical +
initiates O +
apoptosis O +
via O +
the O +
cytochrome O -
- O -
c O -
/ O -
caspase O +
3 O -
/ O -
PARP O -
/ O -
AIF O +
and O +
PTEN O -
/ O -
Akt O -
/ O -
caspase O +
9 O -
/ O -
PARP O +
pathways O +
and O +
necrosis O +
via O +
PARP O +
activation O -
. O +

The O +
cancer O +
cell O -
's O +
" O -
power O +
plants O -
" O +
as O +
promising O +
therapeutic O +
targets O -
: O +
an O +
overview O -
. O +

This O +
introductory O +
article O +
to O +
the O +
review O +
series O +
entitled O +
" O -
The O +
Cancer O +
Cell O -
's O +
Power O +
Plants O +
as O +
Promising O +
Therapeutic O +
Targets O -
" O +
is O +
written O +
while O +
more O +
than O +
20 O +
million O +
people O +
suffer O +
from O +
cancer O -
. O +

It O +
summarizes O +
strategies O +
to O +
destroy O +
or O +
prevent O +
cancers O +
by O +
targeting O +
their O +
energy O +
production O +
factories O -
, O +
i.e. O -
, O +
" O -
power O +
plants O -
. O -
" O +

All O +
nucleated O +
animal O -
/ O -
human O +
cells O +
have O +
two O +
types O +
of O +
power O +
plants O -
, O +
i.e. O -
, O +
systems O +
that O +
make O +
the O +
" O -
high O +
energy O -
" O +
compound O +
ATP B-Chemical +
from O +
ADP B-Chemical +
and O +
P B-Chemical -
( I-Chemical +
i I-Chemical +
) I-Chemical -
. O +

One O +
type O +
is O +
" O -
glycolysis O -
, O -
" O +
the O +
other O +
the O +
" O -
mitochondria O -
. O -
" O +

In O +
contrast O +
to O +
most O +
normal O +
cells O +
where O +
the O +
mitochondria O +
are O +
the O +
major O +
ATP B-Chemical +
producers O +
( O -
> O -
90 O -
% O -
) O +
in O +
fueling O +
growth O -
, O +
human O +
cancers O +
detected O +
via O +
Positron O +
Emission O +
Tomography O +
( O -
PET O -
) O +
rely O +
on O +
both O +
types O +
of O +
power O +
plants O -
. O +

In O +
such O +
cancers O -
, O +
glycolysis O +
may O +
contribute O +
nearly O +
half O +
the O +
ATP B-Chemical +
even O +
in O +
the O +
presence O +
of O +
oxygen B-Chemical +
( O -
" O -
Warburg O +
effect O -
" O -
) O -
. O +

Based O +
solely O +
on O +
cell O +
energetics O -
, O +
this O +
presents O +
a O +
challenge O +
to O +
identify O +
curative O +
agents O +
that O +
destroy O +
only O +
cancer O +
cells O +
as O +
they O +
must O +
destroy O +
both O +
of O +
their O +
power O +
plants O +
causing O +
" O -
necrotic O +
cell O +
death O -
" O +
and O +
leave O +
normal O +
cells O +
alone O -
. O +

One O +
such O +
agent O -
, O +
3-bromopyruvate B-Chemical +
( O -
3-BrPA B-Chemical -
) O -
, O +
a O +
lactic B-Chemical +
acid I-Chemical +
analog I-Chemical -
, O +
has O +
been O +
shown O +
to O +
inhibit O +
both O +
glycolytic O +
and O +
mitochondrial O +
ATP B-Chemical +
production O +
in O +
rapidly O +
growing O +
cancers O +
( O -
Ko O +
et O +
al. O -
, O +
Cancer O +
Letts O -
. O -
, O +
173 O -
, O +
83 O -
- O -
91 O -
, O +
2001 O -
) O -
, O +
leave O +
normal O +
cells O +
alone O -
, O +
and O +
eradicate O +
advanced O +
cancers O +
( O -
19 O +
of O +
19 O -
) O +
in O +
a O +
rodent O +
model O +
( O -
Ko O +
et O +
al. O -
, O +
Biochem O -
. O +

Biophys O -
. O +

Res O -
. O +

Commun O -
. O -
, O +
324 O -
, O +
269 O -
- O -
275 O -
, O +
2004 O -
) O -
. O +

A O +
second O +
approach O +
is O +
to O +
induce O +
only O +
cancer O +
cells O +
to O +
undergo O +
" O -
apoptotic O +
cell O +
death O -
. O -
" O +

Here O -
, O +
mitochondria O +
release O +
cell O +
death O +
inducing O +
factors O +
( O -
e.g. O -
, O +
cytochrome O +
c O -
) O -
. O +

In O +
a O +
third O +
approach O -
, O +
cancer O +
cells O +
are O +
induced O +
to O +
die O +
by O +
both O +
apoptotic O +
and O +
necrotic O +
events O -
. O +

In O +
summary O -
, O +
much O +
effort O +
is O +
being O +
focused O +
on O +
identifying O +
agents O +
that O +
induce O +
" O -
necrotic O -
, O -
" O +
" O -
apoptotic O -
" O +
or O +
apoptotic O +
plus O +
necrotic O +
cell O +
death O +
only O +
in O +
cancer O +
cells O -
. O +

Regardless O +
how O +
death O +
is O +
inflicted O -
, O +
every O +
cancer O +
cell O +
must O +
die O -
, O +
be O +
it O +
fast O +
or O +
slow O -
. O +

Pathological O +
animal O +
models O +
in O +
the O +
experimental O +
evaluation O +
of O +
tumour O +
microvasculature O +
with O +
magnetic O +
resonance O +
imaging O -
. O +

PURPOSE O -
: O +
The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
evaluate O +
the O +
applications O +
of O +
magnetic O +
resonance O +
imaging O +
( O -
MRI O -
) O -
, O +
and O +
in O +
particular O -
, O +
dynamic O +
contrast O -
- O -
enhanced O +
MRI O +
( O -
DCE O -
- O -
MRI O -
) O -
, O +
in O +
the O +
assessment O +
of O +
tumour O +
microvasculature O +
by O +
means O +
of O +
animal O +
tumour O +
models O +
evaluated O +
before O +
and O +
after O +
antiangiogenic O +
treatment O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
Forty O -
- O -
two O +
MRI O +
exams O +
were O +
performed O +
with O +
intravascular O +
contrast O +
media O +
in O +
21 O +
rats O -
: O +
tumours O +
were O +
induced O +
by O +
subcutaneous O +
injection O +
of O +
colon O +
carcinoma O +
cells O +
in O +
7 O +
rats O +
and O +
mammary O +
adenocarcinoma O +
cells O +
in O +
14 O +
rats O -
. O +

Perfusion O +
and O +
permeability O +
parameters O +
of O +
the O +
implanted O +
tumours O +
were O +
evaluated O +
by O +
using O +
two O +
contrast O +
media O +
( O -
B22956 B-Chemical -
/ I-Chemical -
1 I-Chemical +
and O +
Gd B-Chemical -
- I-Chemical -
DTPA37-albumin I-Chemical -
) O +
to O +
establish O +
response O +
to O +
treatment O +
with O +
two O +
different O +
antiangiogenic O +
drugs O +
( O -
tamoxifen B-Chemical +
and O +
SU6668 B-Chemical -
) O -
. O +

These O +
parameters O +
were O +
correlated O +
with O +
histology O +
to O +
obtain O +
a O +
radiological O -
- O -
histological O +
map O +
of O +
tumour O +
microvasculature O -
. O +

RESULTS O -
: O +
DCE O -
- O -
MRI O +
revealed O +
greater O +
enhancement O +
in O +
the O +
peripheral O +
area O +
than O +
in O +
the O +
central O +
area O +
in O +
all O +
the O +
examined O +
animal O +
models O -
. O +

In O +
the O +
mammary O +
carcinoma O +
experiment O -
, O +
vascular O +
permeability O +
measured O +
by O +
means O +
of O +
B22956 B-Chemical -
/ I-Chemical -
1 I-Chemical +
in O +
the O +
animals O +
treated O +
with O +
the O +
antiangiogenic O +
drug O +
( O -
0.0043317+ O -
/ O -
-0.0040418 O +
ml O -
/ O -
min O -
( O -
-1 O -
) O -
/ O -
ml O -
( O -
-1 O -
) O -
) O +
was O +
significantly O +
less O +
than O +
in O +
untreated O +
animals O +
( O -
0.0090460+ O -
/ O -
-0.0043680 O +
ml O -
/ O -
min O -
( O -
-1 O -
) O -
/ O -
ml O -
( O -
-1 O -
) O -
) O -
, O +
whereas O +
no O +
significant O +
difference O +
was O +
observed O +
with O +
Gd B-Chemical -
- I-Chemical -
DTPA I-Chemical -
- I-Chemical -
albumin I-Chemical +
( O -
13.14+ O -
/ O -
-13.94 O +
ml O -
/ O -
min O -
( O -
-1 O -
) O -
/ O -
ml O -
( O -
-1 O -
) O +
in O +
treated O +
animals O +
and O +
18.07+ O -
/ O -
-11.92 O +
ml O -
/ O -
min O -
( O -
-1 O -
) O -
/ O -
ml O -
( O -
-1 O -
) O +
in O +
untreated O +
animals O -
) O -
. O +

In O +
the O +
colon O +
carcinoma O +
experiment O -
, O +
mean O +
permeability O +
and O +
perfusion O +
decreased O +
by O +
51 O -
% O +
( O -
from O +
5.2+ O -
/ O -
-1.1 O +
to O +
2.5+ O -
/ O -
-0.8 O +
ml O -
/ O -
100 O +
ml O -
) O +
and O +
59 O -
% O +
( O -
from O +
0.00165+ O -
/ O -
-5.1 O +
to O +
0.0067+ O -
/ O -
-4.8 O +
ml O -
/ O -
min O -
( O -
-1 O -
) O -
/ O -
ml O -
( O -
-1 O -
) O +
of O +
tissue O -
) O -
, O +
respectively O -
, O +
in O +
all O +
animals O +
after O +
antiangiogenic O +
drug O +
administration O -
. O +

CONCLUSIONS O -
: O +
DCE O -
- O -
MRI O +
permits O +
a O +
noninvasive O +
evaluation O +
of O +
tumour O +
microcirculation O +
and O +
in O +
particular O +
of O +
its O +
dynamic O +
characteristics O +
and O +
vascularity O +
before O +
and O +
after O +
antiangiogenic O +
treatment O -
. O +

Angiogenesis O +
in O +
the O +
caprine O +
caruncles O +
in O +
non O -
- O -
pregnant O +
and O +
pregnant O +
normal O +
and O +
swainsonine B-Chemical -
- O -
treated O +
does O -
. O +

Microvascular O +
corrosion O +
casts O +
of O +
caruncles O +
from O +
non O -
- O -
pregnant O +
and O +
pregnant O +
doe O +
goats O +
at O +
4 O -
, O +
7 O -
, O +
10 O -
, O +
13 O -
, O +
16 O -
, O +
and O +
18 O +
weeks O +
were O +
examined O +
with O +
scanning O +
electron O +
microscopy O -
. O +

The O +
internal O +
convex O +
surface O +
of O +
the O +
caruncles O +
of O +
non O -
- O -
pregnant O +
does O +
was O +
covered O +
with O +
capillary O +
meshes O +
of O +
regular O +
diameter O +
and O +
form O -
, O +
without O +
crypts O -
. O +

As O +
pregnancy O +
advanced O +
the O +
complexity O +
of O +
the O +
vasculature O +
increased O -
: O +
at O +
4 O +
weeks O +
the O +
surface O +
showed O +
a O +
pattern O +
of O +
ridges O +
separated O +
by O +
troughs O -
. O +

At O +
later O +
stages O -
, O +
branches O +
of O +
radial O +
arteries O +
penetrated O +
the O +
periphery O +
forming O +
an O +
extensive O +
mesh O +
of O +
capillaries O +
on O +
the O +
concave O +
surface O -
. O +

Capillary O +
diameters O +
increased O +
significantly O +
during O +
pregnancy O -
, O +
especially O +
after O +
4 O +
weeks O -
, O +
when O +
large O +
flattened O +
sinusoids O +
formed O -
. O +

These O +
sinusoids O +
had O +
a O +
great O +
deal O +
of O +
surface O +
area O +
for O +
potential O +
contact O +
with O +
the O +
fetal O +
component O -
. O +

The O +
caprine O +
placenta O +
is O +
usually O +
considered O +
to O +
have O +
increased O +
interhemal O +
distance O +
compared O +
with O +
endotheliochorial O +
and O +
hemochorial O +
types O -
: O +
our O +
results O +
suggest O +
that O +
the O +
very O +
extensive O +
development O +
of O +
sinusoids O +
and O +
crypts O +
may O +
compensate O +
for O +
any O +
negative O +
consequences O +
of O +
the O +
placental O +
architecture O -
. O +

Placental O +
angiogenesis O -
, O +
which O +
is O +
physiologically O +
normal O -
, O +
may O +
serve O +
as O +
a O +
general O +
model O +
of O +
this O +
process O +
in O +
other O +
circumstances O -
, O +
such O +
as O +
tumor O -
. O +

The O +
effect O +
of O +
swainsonine B-Chemical +
( O -
active O +
compound O +
of O +
locoweed O +
and O +
a O +
potential O +
anticancer O +
drug O -
) O +
on O +
vascular O +
development O +
showed O +
no O +
differences O +
in O +
sinusoidal O +
diameters O +
at O +
7 O +
weeks O -
, O +
but O +
a O +
decrease O +
in O +
capillary O +
density O +
was O +
noted O -
. O +

Swainsonine B-Chemical +
caused O +
a O +
great O +
distortion O +
to O +
the O +
vasculature O +
at O +
18 O +
weeks O -
. O +

The O +
effects O +
of O +
this O +
compound O +
on O +
the O +
vascular O +
development O +
lend O +
credibility O +
to O +
its O +
potential O +
as O +
an O +
anticancer O +
agent O -
. O +

High O -
- O -
grade O +
clear O +
cell O +
renal O +
cell O +
carcinoma O +
has O +
a O +
higher O +
angiogenic O +
activity O +
than O +
low O -
- O -
grade O +
renal O +
cell O +
carcinoma O +
based O +
on O +
histomorphological O +
quantification O +
and O +
qRT O -
- O -
PCR O +
mRNA O +
expression O +
profile O -
. O +

Clear O +
cell O +
renal O +
cell O +
carcinoma O +
( O -
CC O -
- O -
RCC O -
) O +
is O +
a O +
highly O +
vascularised O +
tumour O +
and O +
is O +
therefore O +
an O +
attractive O +
disease O +
to O +
study O +
angiogenesis O +
and O +
to O +
test O +
novel O +
angiogenesis O +
inhibitors O +
in O +
early O +
clinical O +
development O -
. O +

Endothelial O +
cell O +
proliferation O +
plays O +
a O +
pivotal O +
role O +
in O +
the O +
process O +
of O +
angiogenesis O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
compare O +
angiogenesis O +
parameters O +
in O +
low O +
nuclear O +
grade O +
( O -
n=87 O -
) O +
vs O +
high O +
nuclear O +
grade O +
CC O -
- O -
RCC O +
( O -
n=63 O -
) O -
. O +

A O +
panel O +
of O +
antibodies O +
was O +
used O +
for O +
immunohistochemistry O -
: O +
CD34 O -
/ O -
Ki-67 O -
, O +
carbonic O +
anhydrase O +
IX O -
, O +
hypoxia O -
- O -
inducible O +
factor-1alpha O +
( O -
HIF-1alpha O -
) O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
. O +

Vessel O +
density O +
( O -
MVD O +
- O +
microvessel O +
density O -
) O -
, O +
endothelial O +
cell O +
proliferation O +
fraction O +
( O -
ECP% O -
) O +
and O +
tumour O +
cell O +
proliferation O +
fraction O +
( O -
TCP% O -
) O +
were O +
assessed O -
. O +

mRNA O +
expression O +
levels O +
of O +
angiogenesis O +
stimulators O +
and O +
inhibitors O +
were O +
determined O +
by O +
quantitative O +
RT O -
- O -
PCR O -
. O +

High O -
- O -
grade O +
CC O -
- O -
RCC O +
showed O +
a O +
higher O +
ECP% O +
( O -
P=0.049 O -
) O -
, O +
a O +
higher O +
TCP% O +
( O -
P=0.009 O -
) O -
, O +
a O +
higher O +
VEGF O +
protein O +
expression O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
, O +
a O +
lower O +
MVD O +
( O -
P O +
less O +
than O +
0.001 O -
) O +
and O +
a O +
lower O +
HIF-1alpha O +
protein O +
expression O +
( O -
P=0.002 O -
) O +
than O +
low O -
- O -
grade O +
CC O -
- O -
RCC O -
. O +

Growth O +
factor O +
mRNA O +
expression O +
analyses O +
revealed O +
a O +
higher O +
expression O +
of O +
angiopoietin O +
2 O +
in O +
low O -
- O -
grade O +
CC O -
- O -
RCC O -
. O +

Microvessel O +
density O +
and O +
ECP% O +
were O +
inversely O +
correlated O +
( O -
Rho=-0.26 O -
, O +
P=0.001 O -
) O -
. O +

Because O +
of O +
the O +
imperfect O +
association O +
of O +
nuclear O +
grade O +
and O +
ECP% O +
or O +
MVD O -
, O +
CC O -
- O -
RCC O +
was O +
also O +
grouped O +
based O +
on O +
low O -
/ O -
high O +
MVD O +
and O +
ECP% O -
. O +

This O +
analysis O +
revealed O +
a O +
higher O +
expression O +
of O +
vessel O +
maturation O +
and O +
stabilisation O +
factors O +
( O -
placental O +
growth O +
factor O -
, O +
PDGFB1 O -
, O +
angiopoietin O +
1 O -
) O +
in O +
CC O -
- O -
RCC O +
with O +
high O +
MVD O -
, O +
a O +
group O +
of O +
CC O -
- O -
RCC O +
highly O +
enriched O +
in O +
low O +
nuclear O +
grade O +
CC O -
- O -
RCC O -
, O +
with O +
low O +
ECP% O -
. O +

Our O +
results O +
suggest O +
heterogeneity O +
in O +
angiogenic O +
activity O +
and O +
vessel O +
maturation O +
of O +
CC O -
- O -
RCC O -
, O +
to O +
a O +
large O +
extent O +
linked O +
to O +
nuclear O +
grade O -
, O +
and O -
, O +
with O +
probable O +
therapeutic O +
implications O -
. O +

Deletion O +
of O +
Tip30 O +
leads O +
to O +
rapid O +
immortalization O +
of O +
murine O +
mammary O +
epithelial O +
cells O +
and O +
ductal O +
hyperplasia O +
in O +
the O +
mammary O +
gland O -
. O +

Transformation O +
of O +
mammary O +
epithelial O +
cells O +
( O -
MECs O -
) O +
from O +
the O +
normal O +
to O +
the O +
neoplastic O +
stage O +
requires O +
the O +
dysregulation O +
of O +
tumor O +
suppressor O +
genes O +
and O +
proto O -
- O -
oncogenes O -
. O +

Tip30 O +
is O +
a O +
tumor O +
suppressor O +
that O +
can O +
inhibit O +
estrogen O +
receptor O -
- O -
mediated O +
transcription O +
in O +
MECs O -
, O +
but O +
its O +
role O +
in O +
MEC O +
proliferation O +
remains O +
unknown O -
. O +

Here O -
, O +
we O +
show O +
that O +
deleting O +
the O +
Tip30 O +
gene O +
leads O +
to O +
ductal O +
hyperplasia O +
in O +
mouse O +
mammary O +
glands O +
early O +
in O +
life O +
and O +
extensive O +
mammary O +
hyperplasia O +
with O +
age O -
. O +

Tip30 O -
( O -
- O -
/ O -
- O -
) O +
mammary O +
glands O +
transplanted O +
into O +
wild O -
- O -
type O +
mammary O +
fat O +
pads O +
also O +
display O +
mammary O +
trees O +
with O +
extensive O +
ductal O +
hyperplasia O -
. O +

Strikingly O -
, O +
Tip30 O +
deletion O +
promotes O +
proliferation O +
of O +
primary O +
MECs O +
and O +
results O +
in O +
rapid O +
immortalization O +
of O +
MECs O +
in O +
vitro O +
relative O +
to O +
wild O -
- O -
type O +
cells O -
. O +

Gene O +
array O +
analysis O +
identified O +
significant O +
increases O +
in O +
the O +
expression O +
of O +
mammary O +
epithelial O +
growth O +
factors O +
Wisp2 O +
and O +
Igf-1 O +
in O +
Tip30 O -
( O -
- O -
/ O -
- O -
) O +
cells O -
. O +

Knockdown O +
of O +
either O +
Wisp2 O +
or O +
Igf-1 O +
using O +
short O +
interfering O +
RNA O +
dramatically O +
inhibited O +
proliferation O +
of O +
Tip30 O -
( O -
- O -
/ O -
- O -
) O +
cells O -
. O +

Together O -
, O +
these O +
results O +
suggest O +
that O +
Tip30 O +
is O +
an O +
intrinsic O +
and O +
negative O +
regulator O +
of O +
MEC O +
proliferation O +
partly O +
through O +
the O +
inhibition O +
of O +
Wisp2 O +
and O +
Igf-1 O +
expression O -
, O +
and O +
its O +
absence O +
in O +
the O +
mammary O +
gland O +
may O +
predispose O +
MECs O +
to O +
neoplastic O +
transformation O -
. O +

The O +
contribution O +
of O +
Harold O +
F. O +
Dvorak O +
to O +
the O +
study O +
of O +
tumor O +
angiogenesis O +
and O +
stroma O +
generation O +
mechanisms O -
. O +

In O +
1983 O -
, O +
Harold O +
Dvorak O +
and O +
his O +
colleagues O +
were O +
the O +
first O +
to O +
show O +
that O +
tumor O +
cells O +
secreted O +
vascular O +
permeability O +
factor O +
( O -
VPF O -
) O +
and O +
that O +
a O +
blocking O +
antibody O +
to O +
VPF O +
could O +
prevent O +
the O +
edema O +
and O +
fluid O +
accumulation O +
that O +
is O +
characteristic O +
of O +
human O +
cancers O -
. O +

In O +
1986 O -
, O +
Dvorak O +
went O +
on O +
to O +
demonstrate O +
that O +
VPF O +
was O +
secreted O +
by O +
a O +
variety O +
of O +
human O +
tumor O +
cell O +
lines O +
and O +
proposed O +
that O +
VPF O +
was O +
in O +
part O +
responsible O +
for O +
the O +
abnormal O +
vasculature O +
seen O +
in O +
human O +
tumors O -
. O +

As O +
a O +
result O -
, O +
he O +
and O +
other O +
investigators O +
demonstrated O +
that O +
VPF O +
was O +
capable O +
of O +
stimulating O +
endothelial O +
cell O +
growth O +
and O +
angiogenesis O -
. O +

These O +
fundamental O +
discoveries O +
led O +
to O +
additional O +
research O +
conducted O +
by O +
Napoleone O +
Ferrara O +
and O +
his O +
laboratory O -
, O +
confirming O +
the O +
cloning O +
of O +
VPF O +
and O +
renaming O +
the O +
protein O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
. O +

In O +
1986 O -
, O +
Dvorak O +
proposed O +
that O +
by O +
secreting O +
VPF O -
, O +
tumors O +
induce O +
angiogenesis O +
by O +
turning O +
on O +
the O +
wound O +
healing O +
response O -
. O +

He O +
noted O +
that O +
wounds O -
, O +
like O +
tumors O -
, O +
secrete O +
VPF O -
, O +
causing O +
blood O +
vessels O +
to O +
leak O +
plasma O +
fibrinogen O -
, O +
which O +
stimulates O +
blood O +
vessel O +
growth O +
and O +
provides O +
a O +
matrix O +
on O +
which O +
they O +
can O +
spread O -
. O +

Unlike O +
wounds O -
, O +
however O -
, O +
that O +
turn O +
off O +
VPF O +
production O +
after O +
healing O -
, O +
tumors O +
did O +
not O +
turn O +
off O +
their O +
VPF O +
production O +
and O +
instead O +
continued O +
to O +
make O +
large O +
amounts O +
of O +
VPF O -
, O +
allowing O +
malignant O +
cells O +
to O +
continue O +
to O +
induce O +
new O +
blood O +
vessels O +
and O +
so O +
to O +
grow O +
and O +
spread O -
. O +

Thus O -
, O +
tumors O +
behave O +
like O +
wounds O +
that O +
fail O +
to O +
heal O -
. O +

This O +
work O +
is O +
again O +
extremely O +
significant O +
for O +
patients O +
worldwide O -
, O +
as O +
Dvorak O -
's O +
scientific O +
research O +
is O +
leading O +
his O +
colleagues O +
all O +
over O +
the O +
world O +
to O +
examine O +
how O +
to O +
treat O +
a O +
tumor O +
through O +
its O +
blood O +
supply O -
. O +

Modulating O +
metastasis O +
by O +
a O +
lymphangiogenic O +
switch O +
in O +
prostate O +
cancer O -
. O +

Prostate O +
cancer O +
dissemination O +
is O +
difficult O +
to O +
detect O +
in O +
the O +
clinic O -
, O +
and O +
few O +
treatment O +
options O +
exist O +
for O +
patients O +
with O +
advanced O -
- O -
stage O +
disease O -
. O +

Our O +
aim O +
was O +
to O +
investigate O +
the O +
role O +
of O +
tumor O +
lymphangiogenesis O +
during O +
metastasis O -
. O +

Further O -
, O +
we O +
implemented O +
a O +
noninvasive O +
molecular O +
imaging O +
technique O +
to O +
facilitate O +
the O +
assessment O +
of O +
the O +
metastatic O +
process O -
. O +

The O +
metastatic O +
potentials O +
of O +
several O +
human O +
prostate O +
cancer O +
xenograft O +
models O -
, O +
LAPC-4 O -
, O +
LAPC-9 O -
, O +
PC3 O +
and O +
CWR22Rv-1 O +
were O +
compared O -
. O +

The O +
cells O +
were O +
labeled O +
with O +
luciferase O -
, O +
a O +
bioluminescence O +
imaging O +
reporter O +
gene O -
, O +
to O +
enable O +
optical O +
imaging O -
. O +

After O +
tumor O +
implantation O +
the O +
animals O +
were O +
examined O +
weekly O +
during O +
several O +
months O +
for O +
the O +
appearance O +
of O +
metastases O -
. O +

Metastatic O +
lesions O +
were O +
confirmed O +
by O +
immunohistochemistry O -
. O +

Additionally O -
, O +
the O +
angiogenic O +
and O +
lymphangiogenic O +
profiles O +
of O +
the O +
tumors O +
were O +
characterized O -
. O +

To O +
confirm O +
the O +
role O +
of O +
lymphangiogenesis O +
in O +
mediating O +
metastasis O -
, O +
the O +
low O -
- O -
metastatic O +
LAPC-9 O +
tumor O +
cells O +
were O +
engineered O +
to O +
overexpress O +
VEGF O -
- O -
C O -
, O +
and O +
the O +
development O +
of O +
metastases O +
was O +
evaluated O -
. O +

Our O +
results O +
show O +
CWR22Rv-1 O +
and O +
PC3 O +
tumor O +
cell O +
lines O +
to O +
be O +
more O +
metastatic O +
than O +
LAPC-4 O -
, O +
which O +
in O +
turn O +
disseminates O +
more O +
readily O +
than O +
LAPC-9 O -
. O +

The O +
difference O +
in O +
metastatic O +
potential O +
correlated O +
with O +
the O +
endogenous O +
production O +
levels O +
of O +
lymphangiogenic O +
growth O +
factor O +
VEGF O -
- O -
C O +
and O +
the O +
presence O +
of O +
tumor O +
lymphatics O -
. O +

In O +
agreement O -
, O +
induced O +
overexpression O +
of O +
VEGF O -
- O -
C O +
in O +
LAPC-9 O +
enhanced O +
tumor O +
lymphangiogenesis O +
leading O +
to O +
the O +
development O +
of O +
metastatic O +
lesions O -
. O +

Taken O +
together O -
, O +
our O +
studies O -
, O +
based O +
on O +
a O +
molecular O +
imaging O +
approach O +
for O +
semiquantitative O +
detection O +
of O +
micrometastases O -
, O +
point O +
to O +
an O +
important O +
role O +
of O +
tumor O +
lymphatics O +
in O +
the O +
metastatic O +
process O +
of O +
human O +
prostate O +
cancer O -
. O +

In O +
particular O -
, O +
VEGF O -
- O -
C O +
seems O +
to O +
play O +
a O +
key O +
role O +
in O +
prostate O +
cancer O +
metastasis O -
. O +

An O +
assay O +
to O +
measure O +
angiogenesis O +
in O +
human O +
fat O +
tissue O -
. O +

BACKGROUND O -
: O +
Inhibition O +
of O +
angiogenesis O +
reverses O +
rodent O +
obesity O -
. O +

A O +
validated O +
assay O +
in O +
human O +
fat O +
tissue O +
is O +
needed O +
to O +
study O +
the O +
role O +
of O +
angiogenesis O +
in O +
human O +
obesity O -
. O +

METHODS O -
: O +
Human O +
fat O +
tissue O +
fragments O +
from O +
surgery O +
were O +
placed O +
in O +
96-well O +
plates O -
, O +
embedded O +
in O +
fibrin O +
thrombin O +
clot O +
and O +
overlaid O +
with O +
cell O +
culture O +
media O +
containing O +
20 O -
% O +
fetal O +
bovine O +
serum O -
. O +

After O +
15 O +
days O -
, O +
the O +
clots O +
were O +
examined O +
by O +
histology O +
and O +
electron O +
microscopy O -
. O +

The O +
effect O +
of O +
taxol B-Chemical -
, O +
cobalt B-Chemical +
chloride I-Chemical +
and O +
a O +
heparin B-Chemical -
- I-Chemical -
steroid I-Chemical +
combination O +
was O +
tested O +
in O +
the O +
fat O +
tissue O +
assay O +
and O +
compared O +
to O +
the O +
validated O +
human O +
placental O +
vein O +
angiogenesis O +
model O +
( O -
HPVAM O -
) O -
. O +

RESULTS O -
: O +
Blood O +
vessels O +
initiated O +
growth O +
and O +
elongated O +
from O +
the O +
fat O +
tissue O +
fragments O +
over O +
15 O +
days O -
. O +

Presence O +
of O +
blood O +
vessels O +
was O +
confirmed O +
with O +
histology O +
and O +
electron O +
microscopy O -
. O +

Taxol B-Chemical +
at O +
10 O -
( O -
-6 O -
) O +
and O +
10 O -
( O -
-7 O -
) O +
M O +
completely O +
inhibited O +
angiogenesis O -
, O +
while O +
Taxol B-Chemical +
10 O -
( O -
-8 O -
) O +
and O +
10 O -
( O -
-9 O -
) O +
M O +
and O +
the O +
heparin B-Chemical -
- I-Chemical -
steroid I-Chemical +
partially O +
inhibited O +
angiogenesis O -
. O +

The O +
response O +
to O +
taxol B-Chemical +
and O +
heparin B-Chemical -
- I-Chemical -
steroid I-Chemical +
was O +
similar O +
to O +
that O +
of O +
the O +
HPVAM O -
, O +
a O +
validated O +
angiogenesis O +
assay O -
. O +

Cobalt B-Chemical +
chloride I-Chemical -
, O +
a O +
stimulator O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
stimulated O +
angiogenesis O +
initiation O +
at O +
10 O -
( O -
-9 O -
) O +
M O +
in O +
fat O +
tissue O +
and O +
the O +
HPVAM O -
, O +
but O +
at O +
10 O -
( O -
-10 O -
) O +
M O +
blood O +
vessel O +
growth O +
was O +
stimulated O +
only O +
in O +
the O +
fat O +
assay O -
. O +

CONCLUSION O -
: O +
This O +
angiogenesis O +
assay O +
based O +
on O +
human O +
fat O +
tissue O +
uses O +
three O -
- O -
dimensionally O +
intact O +
human O +
tissue O -
. O +

The O +
vessels O +
are O +
derived O +
from O +
quiescient O +
vessels O +
within O +
the O +
fat O -
. O +

These O +
properties O +
allow O +
the O +
angiogenic O +
switch O +
to O +
be O +
evaluated O +
in O +
an O +
in O +
vitro O +
setting O -
. O +

The O +
angiogenic O +
response O +
of O +
fat O +
tissue O +
is O +
not O +
identical O +
to O +
placental O +
tissue O -
. O +

This O +
assay O +
allows O +
exploration O +
of O +
angiogenesis O +
in O +
fat O +
tissue O -
. O +

Adaptive O +
landscapes O +
and O +
emergent O +
phenotypes O -
: O +
why O +
do O +
cancers O +
have O +
high O +
glycolysis O -
? O +

Investigating O +
the O +
causes O +
of O +
increased O +
aerobic O +
glycolysis O +
in O +
tumors O +
( O -
Warburg O +
Effect O -
) O +
has O +
gone O +
in O +
and O +
out O +
of O +
fashion O +
many O +
times O +
since O +
it O +
was O +
first O +
described O +
almost O +
a O +
century O +
ago O -
. O +

The O +
field O +
is O +
currently O +
in O +
ascendance O +
due O +
to O +
two O +
factors O -
. O +

Over O +
a O +
million O +
FDG O -
- O -
PET O +
studies O +
have O +
unequivocally O +
identified O +
increased O +
glucose B-Chemical +
uptake O +
as O +
a O +
hallmark O +
of O +
metastatic O +
cancer O +
in O +
humans O -
. O +

These O +
observations O -
, O +
combined O +
with O +
new O +
molecular O +
insights O +
with O +
HIF-1alpha O +
and O +
c O -
- O -
myc O -
, O +
have O +
rekindled O +
an O +
interest O +
in O +
this O +
important O +
phenotype O -
. O +

A O +
preponderance O +
of O +
work O +
has O +
been O +
focused O +
on O +
the O +
molecular O +
mechanisms O +
underlying O +
this O +
effect O -
, O +
with O +
the O +
expectation O +
that O +
a O +
mechanistic O +
understanding O +
may O +
lead O +
to O +
novel O +
therapeutic O +
approaches O -
. O +

There O +
is O +
also O +
an O +
implicit O +
assumption O +
that O +
a O +
mechanistic O +
understanding O -
, O +
although O +
fundamentally O +
reductionist O -
, O +
will O +
nonetheless O +
lead O +
to O +
a O +
more O +
profound O +
teleological O +
understanding O +
of O +
the O +
need O +
for O +
altered O +
metabolism O +
in O +
invasive O +
cancers O -
. O +

In O +
this O +
communication O -
, O +
we O +
describe O +
an O +
alternative O +
approach O +
that O +
begins O +
with O +
teleology O -
; O +
i.e. O +
adaptive O +
landscapes O +
and O +
selection O +
pressures O +
that O +
promote O +
emergence O +
of O +
aerobic O +
glycolysis O +
during O +
the O +
somatic O +
evolution O +
of O +
invasive O +
cancer O -
. O +

Mathematical O +
models O +
and O +
empirical O +
observations O +
are O +
used O +
to O +
define O +
the O +
adaptive O +
advantage O +
of O +
aerobic O +
glycolysis O +
that O +
would O +
explain O +
its O +
remarkable O +
prevalence O +
in O +
human O +
cancers O -
. O +

These O +
studies O +
have O +
led O +
to O +
the O +
hypothesis O +
that O +
increased O +
consumption O +
of O +
glucose B-Chemical +
in O +
metastatic O +
lesions O +
is O +
not O +
used O +
for O +
substantial O +
energy O +
production O +
via O +
Embden O -
- O -
Meyerhoff O +
glycolysis O -
, O +
but O +
rather O +
for O +
production O +
of O +
acid B-Chemical -
, O +
which O +
gives O +
the O +
cancer O +
cells O +
a O +
competitive O +
advantage O +
for O +
invasion O -
. O +

Alternative O +
hypotheses O -
, O +
wherein O +
the O +
glucose B-Chemical +
is O +
used O +
for O +
generation O +
of O +
reducing O +
equivalents O +
( O -
NADPH B-Chemical -
) O +
or O +
anabolic O +
precursors O +
( O -
ribose B-Chemical -
) O +
are O +
also O +
discussed O -
. O +

Subcellular O +
localisation O +
of O +
BAG-1 O +
and O +
its O +
regulation O +
of O +
vitamin O +
D O +
receptor O -
- O -
mediated O +
transactivation O +
and O +
involucrin O +
expression O +
in O +
oral O +
keratinocytes O -
: O +
implications O +
for O +
oral O +
carcinogenesis O -
. O +

In O +
oral O +
cancers O -
, O +
cytoplasmic O +
BAG-1 O +
overexpression O +
is O +
a O +
marker O +
of O +
poor O +
prognosis O -
. O +

BAG-1 O +
regulates O +
cellular O +
growth O -
, O +
differentiation O +
and O +
survival O +
through O +
interactions O +
with O +
diverse O +
proteins O -
, O +
including O +
the O +
vitamin O +
D O +
receptor O +
( O -
VDR O -
) O -
, O +
a O +
key O +
regulator O +
of O +
keratinocyte O +
growth O +
and O +
differentiation O -
. O +

BAG-1 O +
is O +
expressed O +
ubiquitously O +
in O +
human O +
cells O +
as O +
three O +
major O +
isoforms O +
of O +
50 O +
kDa O +
( O -
BAG-1L O -
) O -
, O +
46 O +
kDa O +
( O -
BAG-1 O -
M O -
) O +
and O +
36 O +
kDa O +
( O -
BAG-1S O -
) O +
from O +
a O +
single O +
mRNA O -
. O +

In O +
oral O +
keratinocytes O +
BAG-1L O -
, O +
but O +
not O +
BAG-1 O -
M O +
and O +
BAG-1S O -
, O +
enhanced O +
VDR O +
transactivation O +
in O +
response O +
to O +
1alpha,25-dihydroxyvitamin B-Chemical +
D3 I-Chemical -
. O +

BAG-1L O +
was O +
nucleoplasmic O +
and O +
nucleolar O -
, O +
whereas O +
BAG-1S O +
and O +
BAG-1 O -
M O +
were O +
cytoplasmic O +
and O +
nucleoplasmic O +
in O +
localisation O -
. O +

Having O +
identified O +
the O +
nucleolar O +
localisation O +
sequence O +
in O +
BAG-1L O -
, O +
we O +
showed O +
that O +
mutation O +
of O +
this O +
sequence O +
did O +
not O +
prevent O +
BAG-1L O +
from O +
potentiating O +
VDR O +
activity O -
. O +

BAG-1L O +
also O +
potentiated O +
transactivation O +
of O +
known O +
vitamin B-Chemical -
- I-Chemical -
D I-Chemical -
- O -
responsive O +
gene O +
promoters O -
, O +
osteocalcin O +
and O +
24-hydroxylase O -
, O +
and O +
enhanced O +
VDR O -
- O -
dependent O +
transcription O +
and O +
protein O +
expression O +
of O +
the O +
keratinocyte O +
differentiation O +
marker O -
, O +
involucrin O -
. O +

These O +
results O +
demonstrate O +
endogenous O +
gene O +
regulation O +
by O +
BAG-1L O +
by O +
potentiating O +
nuclear O +
hormone O +
receptor O +
function O +
and O +
suggest O +
a O +
role O +
for O +
BAG-1L O +
in O +
24-hydroxylase O +
regulation O +
of O +
vitamin B-Chemical +
D I-Chemical +
metabolism O +
and O +
the O +
cellular O +
response O +
of O +
oral O +
keratinocytes O +
to O +
1alpha,25-dihydroxyvitamin B-Chemical +
D3 I-Chemical -
. O +

By O +
contrast O +
to O +
the O +
cytoplasmic O +
BAG-1 O +
isoforms O -
, O +
BAG-1L O +
may O +
act O +
to O +
suppress O +
tumorigenesis O -
. O +

Hedgehog O +
signaling O +
in O +
the O +
murine O +
melanoma O +
microenvironment O -
. O +

The O +
Hedgehog O +
intercellular O +
signaling O +
pathway O +
regulates O +
cell O +
proliferation O +
and O +
differentiation O -
. O +

This O +
pathway O +
has O +
been O +
implicated O +
to O +
play O +
a O +
role O +
in O +
the O +
pathogenesis O +
of O +
cancer O +
and O +
in O +
embryonic O +
blood O +
vessel O +
development O -
. O +

In O +
the O +
current O +
study O -
, O +
Hedgehog O +
signaling O +
in O +
tumor O +
related O +
vasculature O +
and O +
microenvironment O +
was O +
examined O +
using O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
and O +
B16F0 O +
( O -
murine O +
melanoma O -
) O +
tumors O +
models O -
. O +

Use O +
of O +
exogenous O +
Sonic O +
hedgehog O +
( O -
Shh O -
) O +
peptide O +
significantly O +
increased O +
BrdU B-Chemical +
incorporation O +
in O +
endothelial O +
cells O +
in O +
vitro O +
by O +
a O +
factor O +
of O +
2 O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
. O +

The O +
Hedgehog O +
pathway O +
antagonist O +
cyclopamine B-Chemical +
effectively O +
reduced O +
Shh O -
- O -
induced O +
proliferation O +
to O +
control O +
levels O -
. O +

To O +
study O +
Hedgehog O +
signaling O +
in O +
vivo O +
a O +
hind O +
limb O +
tumor O +
model O +
with O +
the O +
B16F0 O +
cell O +
line O +
was O +
used O -
. O +

Treatment O +
with O +
25 O +
mg O -
/ O -
kg O +
cyclopamine B-Chemical +
significantly O +
attenuated O +
BrdU B-Chemical +
incorporation O +
in O +
tumor O +
cells O +
threefold O +
( O -
P O +
less O +
than O +
0.001 O -
) O -
, O +
in O +
tumor O +
related O +
endothelial O +
cells O +
threefold O +
( O -
P O +
= O +
0.004 O -
) O -
, O +
and O +
delayed O +
tumor O +
growth O +
by O +
4 O +
days O -
. O +

Immunohistochemistry O +
revealed O +
that O +
the O +
Hedgehog O +
receptor O +
Patched O +
was O +
localized O +
to O +
the O +
tumor O +
stroma O +
and O +
that O +
B16F0 O +
cells O +
expressed O +
Shh O +
peptide O -
. O +

Furthermore O -
, O +
mouse O +
embryonic O +
fibroblasts O +
required O +
the O +
presence O +
of O +
B16F0 O +
cells O +
to O +
express O +
Patched O +
in O +
a O +
co O -
- O -
culture O +
assay O +
system O -
. O +

These O +
studies O +
indicate O +
that O +
Shh O +
peptide O +
produced O +
by O +
melanoma O +
cells O +
induces O +
Patched O +
expression O +
in O +
fibroblasts O -
. O +

To O +
study O +
tumor O +
related O +
angiogenesis O +
a O +
vascular O +
window O +
model O +
was O +
used O +
to O +
monitor O +
tumor O +
vascularity O -
. O +

Treatment O +
with O +
cyclopamine B-Chemical +
significantly O +
attenuated O +
vascular O +
formation O +
by O +
a O +
factor O +
of O +
2.5 O +
( O -
P O +
less O +
than O +
0.001 O -
) O +
and O +
altered O +
vascular O +
morphology O -
. O +

Furthermore O -
, O +
cyclopamine B-Chemical +
reduced O +
tumor O +
blood O +
vessel O +
permeability O +
to O +
FITC B-Chemical +
labeled O +
dextran B-Chemical +
while O +
having O +
no O +
effect O +
on O +
normal O +
blood O +
vessels O -
. O +

These O +
studies O +
suggest O +
that O +
Hedgehog O +
signaling O +
regulates O +
melanoma O +
related O +
vascular O +
formation O +
and O +
function O -
. O +

Transporters O -
, O +
enzymes O -
, O +
and O +
enalapril B-Chemical +
removal O +
in O +
a O +
rat O +
( O -
CC531-induced O -
) O +
liver O +
metastatic O +
model O -
. O +

Temporal O +
changes O +
in O +
physiological O +
spaces O -
, O +
protein O +
expression O +
of O +
transporters O +
and O +
enzymes O -
, O +
and O +
enalapril B-Chemical +
removal O +
were O +
appraised O +
in O +
the O +
metastatic O +
liver O +
tumor O +
model O +
developed O +
from O +
male O +
Wag O -
/ O -
Rij O +
rats O +
after O +
the O +
intraportal O +
injection O +
of O +
CC531 O +
colon O +
adenocarcinoma O +
cells O -
; O +
sham O -
- O -
operated O +
preparations O +
received O +
PBS O -
. O +

Liver O +
tissue O +
spaces O -
, O +
investigated O +
with O +
multiple O +
indicator O +
dilution O +
technique O +
in O +
liver O +
perfusion O +
studies O -
, O +
were O +
unchanged O +
at O +
week O +
3 O +
after O +
tumor O +
induction O -
. O +

At O +
week O +
4 O -
, O +
however O -
, O +
the O +
sinusoidal O +
blood O +
volume O +
and O +
albumin O +
Disse O +
space O +
in O +
tumor O -
- O -
bearing O +
livers O +
were O +
slightly O +
lower O +
compared O +
with O +
those O +
of O +
shams O -
. O +

Increased O +
levels O +
of O +
the O +
canalicular O +
ATP B-Chemical +
transporters O -
, O +
P O -
- O -
glycoprotein O -
, O +
multidrug O +
resistance O -
- O -
associated O +
protein O +
2 O +
( O -
Mrp2 O -
) O -
, O +
and O +
bile B-Chemical +
salt I-Chemical +
export O +
pump O +
( O -
Bsep O -
) O +
at O +
week O +
2 O +
( O -
P O +
< O +
0.05 O -
) O -
, O +
unchanged O +
levels O +
of O +
Ntcp O -
, O +
Oatp1a1 O -
, O +
Oatp1a4 O -
, O +
and O +
Mct2 O -
, O +
but O +
decreased O +
levels O +
of O +
cytochrome O +
P450 O +
3a2 O +
( O -
Cyp3a2 O -
) O +
and O +
glutathione O +
S O -
- O -
transferase O +
( O -
Gst4 O -
- O -
4 O -
) O +
at O +
week O +
4 O +
( O -
P O +
< O +
0.05 O -
) O +
were O +
observed O +
in O +
peritumor O +
vs. O +
sham O -
- O -
operated O +
liver O +
tissues O +
with O +
Western O +
blotting O -
. O +

The O +
steady O -
- O -
state O +
extraction O +
ratio O +
of O +
enalapril B-Chemical -
, O +
a O +
substrate O +
that O +
enters O +
the O +
liver O +
rapidly O +
via O +
Oatp1a1 O +
and O +
primarily O +
undergoes O +
metabolism O +
by O +
the O +
carboxylesterases O -
, O +
was O +
unaffected O +
by O +
liver O +
metastasis O +
at O +
week O +
4 O +
regardless O +
of O +
its O +
delivery O +
via O +
the O +
portal O +
vein O +
or O +
hepatic O +
artery O +
into O +
the O +
perfused O +
liver O +
preparations O -
. O +

Wnt O +
signaling O -
, O +
stem O +
cells O -
, O +
and O +
the O +
cellular O +
origin O +
of O +
breast O +
cancer O -
. O +

The O +
breast O +
epithelium O +
comprises O +
cells O +
at O +
different O +
stages O +
of O +
differentiation O -
, O +
including O +
stem O +
cells O -
, O +
progenitor O +
cells O -
, O +
and O +
more O +
differentiated O +
epithelial O +
and O +
myoepithelial O +
cells O -
. O +

Wnt O +
signaling O +
plays O +
a O +
critical O +
role O +
in O +
regulating O +
stem O -
/ O -
progenitor O +
cells O +
in O +
the O +
mammary O +
gland O +
as O +
well O +
as O +
other O +
tissue O +
compartments O -
. O +

Furthermore O -
, O +
there O +
is O +
strong O +
evidence O +
suggesting O +
that O +
aberrant O +
activation O +
of O +
Wnt O +
signaling O +
induces O +
mammary O +
tumors O +
from O +
stem O -
/ O -
progenitor O +
cells O -
, O +
and O +
that O +
Wnt O +
exerts O +
its O +
oncogenic O +
effects O +
through O +
LRP5 O -
/ O -
6-mediated O +
activation O +
of O +
beta O -
- O -
catenin O +
and O +
mTOR O +
pathways O -
. O +

Recent O +
studies O +
using O +
avian O +
retrovirus O -
- O -
mediated O +
introduction O +
of O +
oncogenes O +
into O +
a O +
small O +
subset O +
of O +
somatic O +
mammary O +
cells O +
suggest O +
that O +
polyoma O +
middle O +
T O +
antigen O +
( O -
PyMT O -
) O +
may O +
also O +
preferentially O +
transform O +
stem O -
/ O -
progenitor O +
cells O -
. O +

These O +
observations O +
suggest O +
that O +
stem O -
/ O -
progenitor O +
cells O +
in O +
the O +
mammary O +
gland O +
may O +
be O +
especially O +
susceptible O +
to O +
oncogenic O +
transformation O -
. O +

Whether O +
more O +
differentiated O +
cells O +
may O +
also O +
be O +
transformed O +
by O +
particular O +
oncogenes O +
is O +
actively O +
debated O -
; O +
it O +
is O +
presently O +
unclear O +
whether O +
stem O +
cells O +
or O +
differentiated O +
mammary O +
cells O +
are O +
more O +
susceptible O +
to O +
transformation O +
by O +
individual O +
oncogenes O -
. O +

Better O +
stem O +
cell O +
and O +
progenitor O +
cell O +
markers O +
as O +
well O +
as O +
the O +
ability O +
to O +
specifically O +
target O +
oncogenes O +
into O +
different O +
mammary O +
cell O +
types O +
will O +
be O +
needed O +
to O +
determine O +
the O +
spectrum O +
of O +
oncogene O +
transformation O +
for O +
stem O +
cells O +
versus O +
more O +
differentiated O +
cells O -
. O +

CX3CR1-dependent O +
subretinal O +
microglia O +
cell O +
accumulation O +
is O +
associated O +
with O +
cardinal O +
features O +
of O +
age O -
- O -
related O +
macular O +
degeneration O -
. O +

The O +
role O +
of O +
retinal O +
microglial O +
cells O +
( O -
MCs O -
) O +
in O +
age O -
- O -
related O +
macular O +
degeneration O +
( O -
AMD O -
) O +
is O +
unclear O -
. O +

Here O +
we O +
demonstrated O +
that O +
all O +
retinal O +
MCs O +
express O +
CX3C O +
chemokine O +
receptor O +
1 O +
( O -
CX3CR1 O -
) O +
and O +
that O +
homozygosity O +
for O +
the O +
CX3CR1 O +
M280 O +
allele O -
, O +
which O +
is O +
associated O +
with O +
impaired O +
cell O +
migration O -
, O +
increases O +
the O +
risk O +
of O +
AMD O -
. O +

In O +
humans O +
with O +
AMD O -
, O +
MCs O +
accumulated O +
in O +
the O +
subretinal O +
space O +
at O +
sites O +
of O +
retinal O +
degeneration O +
and O +
choroidal O +
neovascularization O +
( O -
CNV O -
) O -
. O +

In O +
CX3CR1-deficient O +
mice O -
, O +
MCs O +
accumulated O +
subretinally O +
with O +
age O +
and O +
albino O +
background O +
and O +
after O +
laser O +
impact O +
preceding O +
retinal O +
degeneration O -
. O +

Raising O +
the O +
albino O +
mice O +
in O +
the O +
dark O +
prevented O +
both O +
events O -
. O +

The O +
appearance O +
of O +
lipid B-Chemical -
- O -
bloated O +
subretinal O +
MCs O +
was O +
drusen O -
- O -
like O +
on O +
funduscopy O +
of O +
senescent O +
mice O -
, O +
and O +
CX3CR1-dependent O +
MC O +
accumulation O +
was O +
associated O +
with O +
an O +
exacerbation O +
of O +
experimental O +
CNV O -
. O +

These O +
results O +
show O +
that O +
CX3CR1-dependent O +
accumulation O +
of O +
subretinal O +
MCs O +
evokes O +
cardinal O +
features O +
of O +
AMD O -
. O +

These O +
findings O +
reveal O +
what O +
we O +
believe O +
to O +
be O +
a O +
novel O +
pathogenic O +
process O +
with O +
important O +
implications O +
for O +
the O +
development O +
of O +
new O +
therapies O +
for O +
AMD O -
. O +

Conditional O +
deletion O +
of O +
Smad1 O +
and O +
Smad5 O +
in O +
somatic O +
cells O +
of O +
male O +
and O +
female O +
gonads O +
leads O +
to O +
metastatic O +
tumor O +
development O +
in O +
mice O -
. O +

The O +
transforming O +
growth O +
factor O +
beta O +
( O -
TGFbeta O -
) O +
family O +
has O +
critical O +
roles O +
in O +
the O +
regulation O +
of O +
fertility O -
. O +

In O +
addition O -
, O +
the O +
pathogenesis O +
of O +
some O +
human O +
cancers O +
is O +
attributed O +
to O +
misregulation O +
of O +
TGFbeta O +
function O +
and O +
SMAD2 O +
or O +
SMAD4 O +
mutations O -
. O +

There O +
are O +
limited O +
mouse O +
models O +
for O +
the O +
BMP O +
signaling O +
SMADs O +
( O -
BR O -
- O -
SMADs O -
) O +
1 O -
, O +
5 O -
, O +
and O +
8 O +
because O +
of O +
embryonic O +
lethality O +
and O +
suspected O +
genetic O +
redundancy O -
. O +

Using O +
tissue O -
- O -
specific O +
ablation O +
in O +
mice O -
, O +
we O +
deleted O +
the O +
BR O -
- O -
SMADs O +
from O +
somatic O +
cells O +
of O +
ovaries O +
and O +
testes O -
. O +

Single O +
conditional O +
knockouts O +
for O +
Smad1 O +
or O +
Smad5 O +
or O +
mice O +
homozygous O +
null O +
for O +
Smad8 O +
are O +
viable O +
and O +
fertile O -
. O +

Female O +
double O +
Smad1 O +
Smad5 O +
and O +
triple O +
Smad1 O +
Smad5 O +
Smad8 O +
conditional O +
knockout O +
mice O +
become O +
infertile O +
and O +
develop O +
metastatic O +
granulosa O +
cell O +
tumors O -
. O +

Male O +
double O +
Smad1 O +
Smad5 O +
conditional O +
knockout O +
mice O +
are O +
fertile O +
but O +
demonstrate O +
metastatic O +
testicular O +
tumor O +
development O -
. O +

Microarray O +
analysis O +
indicated O +
significant O +
alterations O +
in O +
expression O +
of O +
genes O +
related O +
to O +
the O +
TGFbeta O +
pathway O -
, O +
as O +
well O +
as O +
genes O +
involved O +
in O +
infertility O +
and O +
extracellular O +
matrix O +
production O -
. O +

These O +
data O +
strongly O +
implicate O +
the O +
BR O -
- O -
SMADs O +
as O +
part O +
of O +
a O +
critical O +
developmental O +
pathway O +
in O +
ovaries O +
and O +
testis O +
that O -
, O +
when O +
disrupted O -
, O +
leads O +
to O +
malignant O +
transformation O -
. O +

Tumor O +
microenvironment O -
, O +
a O +
dangerous O +
society O +
leading O +
to O +
cancer O +
metastasis O -
. O +

From O +
mechanisms O +
to O +
therapy O +
and O +
prevention O -
. O +

Cancer O +
is O +
no O +
longer O +
considered O +
by O +
scientists O +
just O +
a O +
jumble O +
of O +
mutated O +
cells O -
. O +

To O +
grow O -
, O +
invade O +
and O +
metastasize O -
, O +
a O +
treacherous O +
society O +
between O +
cancer O +
and O +
host O +
cells O +
must O +
be O +
formed O -
, O +
and O +
this O +
association O +
provides O +
novel O +
and O +
effective O +
clinical O +
targets O +
for O +
cancer O +
control O +
and O +
prevention O -
. O +

This O +
collection O +
of O +
reviews O +
at O +
the O +
front O -
- O -
edge O +
of O +
scientific O +
knowledge O +
focuses O +
on O +
host O -
- O -
tumor O +
cell O +
interactions O -
, O +
the O +
disastrous O +
consequences O +
they O +
can O +
produce O +
and O +
approaches O +
the O +
ways O +
to O +
break O +
up O +
these O +
cellular O +
conspiracies O -
, O +
to O +
leave O +
the O +
tumor O +
cells O +
unattended O +
and O +
vulnerable O -
. O +

Effects O +
of O +
spironolactone B-Chemical +
on O +
corneal O +
allograft O +
survival O +
in O +
the O +
rat O -
. O +

PURPOSE O -
: O +
Spironolactone B-Chemical +
has O +
recently O +
been O +
shown O +
to O +
have O +
suppressive O +
effects O +
on O +
several O +
immunoactive O +
and O +
proinflammatory O +
cytokines O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
effects O +
of O +
spironolactone B-Chemical +
on O +
the O +
prevention O +
of O +
corneal O +
allograft O +
rejection O +
in O +
a O +
MHC O +
class O +
I O -
/ O -
II O +
mismatch O +
rat O +
corneal O +
transplant O +
model O -
. O +

METHODS O -
: O +
Grafted O +
animals O +
for O +
corneal O +
survival O +
analysis O +
were O +
assigned O +
to O +
receive O +
either O +
spironolactone B-Chemical +
suspension O +
( O -
orally O -
, O +
100 O +
mg O -
/ O -
kg O -
/ O -
day O -
, O +
n O +
= O +
7 O -
) O -
, O +
phosphate B-Chemical -
- I-Chemical -
buffered I-Chemical +
saline I-Chemical +
( O -
PBS B-Chemical -
, O +
orally O -
, O +
same O +
volume O +
as O +
spironolactone B-Chemical -
, O +
n O +
= O +
9 O -
) O +
or O +
remained O +
untreated O +
( O -
n O +
= O +
16 O -
) O -
. O +

Additional O +
grafted O +
rats O +
treated O +
with O +
spironolactone B-Chemical +
( O -
n O +
= O +
6 O -
) O +
or O +
PBS B-Chemical +
( O -
n O +
= O +
8) O +
were O +
sacrificed O +
on O +
day O +
12 O +
for O +
quantitative O +
RT O -
- O -
PCR O +
analysis O +
for O +
mechanistic O +
studies O -
. O +

RESULTS O -
: O +
Mean O +
( O -
+ O -
/-SEM O -
) O +
graft O +
survival O +
was O +
significantly O +
prolonged O +
in O +
animals O +
receiving O +
spironolactone B-Chemical +
( O -
14.9 O +
+ O -
/- O +

2.0 O +
days O -
) O +
compared O +
with O +
both O +
PBS B-Chemical -
- O -
treated O +
( O -
12.3 O +
+ O -
/- O +

1.2 O +
days O -
, O +
p O +
= O +
0.007 O -
) O +
and O +
untreated O +
controls O +
( O -
13.0 O +
+ O -
/- O +

1.0 O +
days O -
, O +
p O +
= O +
0.01 O -
) O -
. O +

We O +
found O +
a O +
decrease O +
in O +
corneal O +
neovascularization O +
in O +
spironolactone B-Chemical -
- O -
treated O +
rats O +
compared O +
with O +
the O +
PBS B-Chemical -
- O -
treated O +
group O -
, O +
although O +
the O +
difference O +
was O +
not O +
statistically O +
significant O -
. O +

Spironolactone B-Chemical +
affected O +
both O +
systemic O +
( O -
down O -
- O -
regulation O +
of O +
CD25 O -
+ O +
cells O +
in O +
spleen O -
) O +
and O +
local O +
immune O +
response O +
( O -
up O -
- O -
regulation O +
of O +
IL-10 O +
in O +
cornea O -
) O -
. O +

CONCLUSION O -
: O +
We O +
present O +
initial O +
results O +
demonstrating O +
anti O -
- O -
inflammatory O +
effects O +
of O +
spironolactone B-Chemical -
. O +

FAS O +
-1377 O +
G O -
/ O -
A O +
polymorphism O +
and O +
the O +
risk O +
of O +
lymph O +
node O +
metastasis O +
in O +
cervical O +
cancer O -
. O +

Single O -
- O -
nucleotide O +
polymorphisms O +
of O +
the O +
FAS O +
-1377G O -
/ O -
A O -
, O +
FAS O +
-670A O -
/ O -
G O -
, O +
and O +
FASL O +
-844T O -
/ O -
C O +
genes O +
may O +
alter O +
transcriptional O +
activity O +
of O +
these O +
genes O -
. O +

Recent O +
evidence O +
suggests O +
an O +
association O +
of O +
these O +
polymorphisms O +
with O +
an O +
increased O +
risk O +
of O +
cervical O +
cancer O -
, O +
so O +
we O +
explored O +
this O +
relationship O -
. O +

Genotypes O +
of O +
155 O +
patients O +
with O +
cervical O +
cancer O +
and O +
160 O +
healthy O +
control O +
subjects O +
were O +
determined O +
using O +
polymerase O +
chain O +
reaction O -
- O -
based O +
restriction O +
fragment O +
length O +
polymorphism O +
( O -
PCR O -
- O -
RFLP O -
) O -
. O +

Associations O +
with O +
cancer O +
risk O +
were O +
estimated O +
using O +
two O -
- O -
sided O +
logistic O +
regression O -
. O +

We O +
observed O +
a O +
significantly O +
increased O +
risk O +
of O +
lymph O +
node O +
metastasis O +
associated O +
with O +
the O +
FAS O +
-1377 O +
GA O +
or O +
AA O +
polymorphism O +
[ O -
odds O +
ratio O +
( O -
OR O -
) O +
= O +
4.16 O -
, O +
95 O -
% O +
confidence O +
interval O +
( O -
CI O -
) O +
= O +
1.10 O +
to O +
15.74 O -
; O +
P O +
= O +
0.036 O -
] O -
. O +

In O +
addition O -
, O +
the O +
FAS O +
-670AG O +
or O +
GG O +
genotype O +
showed O +
an O +
increased O +
incidence O +
of O +
node O +
metastasis O -
, O +
but O +
these O +
findings O +
were O +
not O +
statistically O +
significant O +
( O -
OR O +
= O +
3.67 O -
, O +
95 O -
% O +
CI O +
= O +
0.96 O -
- O -
14.00 O -
, O +
P O +
= O +
0.059 O -
) O -
. O +

There O +
was O +
no O +
significant O +
association O +
between O +
an O +
increased O +
risk O +
of O +
cervical O +
cancer O +
and O +
polymorphisms O +
of O +
the O +
death O +
pathway O +
genes O +
FAS O +
and O +
FASL O -
. O +

None O +
of O +
the O +
polymorphisms O +
were O +
associated O +
with O +
risk O +
of O +
advanced O +
stage O +
or O +
histologic O +
subtype O +
of O +
cervical O +
cancer O -
. O +

In O +
conclusion O -
, O +
FAS O +
-1377 O +
G-->A O +
polymorphism O +
may O +
be O +
associated O +
with O +
an O +
increased O +
risk O +
of O +
lymph O +
node O +
metastasis O +
in O +
Korean O +
cervical O +
cancer O +
patients O -
. O +

N O -
- O -
myc O +
augments O +
death O +
and O +
attenuates O +
protective O +
effects O +
of O +
Bcl-2 O +
in O +
trophically O +
stressed O +
neuroblastoma O +
cells O -
. O +

N O -
- O -
myc O +
has O +
proapoptotic O +
functions O -
, O +
yet O +
it O +
acts O +
as O +
an O +
oncogene O +
in O +
neuroblastoma O -
. O +

Thus O -
, O +
antiapoptotic O +
mechanisms O +
have O +
to O +
be O +
operative O +
in O +
neuroblastoma O +
cells O +
that O +
antagonize O +
the O +
proapoptotic O +
effects O +
of O +
N O -
- O -
myc O -
. O +

We O +
conditionally O +
activated O +
N O -
- O -
myc O +
in O +
SH O -
- O -
EP O +
neuroblastoma O +
cells O +
subjected O +
to O +
the O +
trophic O +
stress O +
of O +
serum O +
or O +
nutrient O +
deprivation O +
while O +
changing O +
the O +
expression O +
of O +
Bcl-2 O -
, O +
survivin O +
and O +
FLIP O -
( O -
L O -
) O -
, O +
antiapoptotic O +
molecules O +
often O +
overexpressed O +
in O +
poor O +
prognosis O +
neuroblastomas O -
. O +

Bcl-2 O +
protected O +
SH O -
- O -
EP O +
cells O +
from O +
death O +
during O +
nutritional O +
deprivation O +
by O +
activating O +
energetically O +
advantageous O +
oxidative O +
phosphorylation O -
. O +

N O -
- O -
myc O +
overrode O +
the O +
metabolic O +
protection O +
provided O +
by O +
Bcl-2-induced O +
oxidative O +
phosphorylation O +
by O +
reestablishing O +
the O +
glycolytic O +
phenotype O +
and O +
attenuated O +
the O +
antiapoptotic O +
effect O +
of O +
Bcl-2 O +
during O +
metabolic O +
stress O -
. O +

Survivin O +
partially O +
antagonized O +
the O +
growth O +
suppressive O +
function O +
of O +
N O -
- O -
myc O +
in O +
SH O -
- O -
EP O +
neuroblastoma O +
cells O +
during O +
serum O +
deprivation O +
whereas O +
FLIP O -
( O -
L O -
) O +
did O +
not O -
. O +

These O +
findings O +
advance O +
our O +
understanding O +
of O +
the O +
functions O +
of O +
N O -
- O -
myc O +
in O +
neuroblastoma O +
cells O -
. O +

Angiopoietin-1 O +
prevents O +
VEGF O -
- O -
induced O +
endothelial O +
permeability O +
by O +
sequestering O +
Src O +
through O +
mDia O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
and O +
Angiopoietin O +
1 O +
( O -
Ang1 O -
) O +
are O +
both O +
potent O +
proangiogenic O +
factors O -
, O +
but O -
, O +
whereas O +
VEGF O +
causes O +
vascular O +
permeability O -
, O +
Ang1 O +
stabilizes O +
blood O +
vessels O +
and O +
protects O +
them O +
from O +
VEGF O -
- O -
induced O +
plasma O +
leakage O -
. O +

The O +
antivascular O +
permeability O +
mechanisms O +
deployed O +
by O +
Ang1 O +
are O +
still O +
undefined O -
. O +

Here O -
, O +
we O +
demonstrate O +
that O +
Ang1 O +
halts O +
the O +
ability O +
of O +
VEGF O +
to O +
induce O +
the O +
phosphorylation O -
- O -
dependent O +
redistribution O +
of O +
the O +
adhesion O +
molecule O +
VE O -
- O -
cadherin O -
, O +
thereby O +
rescuing O +
the O +
endothelial O +
barrier O +
function O -
. O +

Ang1 O +
inhibits O +
the O +
activation O +
of O +
Src O +
by O +
VEGF O -
, O +
the O +
most O +
upstream O +
component O +
of O +
the O +
pathway O +
linking O +
VEGF O +
receptors O +
to O +
VE O -
- O -
cadherin O +
internalization O -
. O +

Indeed O -
, O +
Ang1 O +
promotes O +
the O +
activation O +
of O +
mDia O +
through O +
RhoA O -
, O +
resulting O +
in O +
the O +
association O +
of O +
mDia O +
with O +
Src O -
. O +

This O +
ultimately O +
deprives O +
VEGF O +
receptors O +
of O +
an O +
essential O +
molecule O +
required O +
for O +
promoting O +
the O +
disruption O +
of O +
endothelial O +
cell O -
- O -
cell O +
contacts O +
and O +
paracellular O +
permeability O -
. O +

A O +
novel O +
putative O +
tyrosine O +
kinase O +
receptor O +
with O +
oncogenic O +
potential O -
. O +

We O +
have O +
detected O +
transforming O +
activity O +
by O +
a O +
tumorigenicity O +
assay O +
using O +
NIH3T3 O +
cells O +
transfected O +
with O +
DNA O +
from O +
a O +
chronic O +
myeloproliferative O +
disorder O +
patient O -
. O +

Here O -
, O +
we O +
report O +
the O +
cDNA O +
cloning O +
of O +
the O +
corresponding O +
oncogene O -
, O +
designated O +
UFO O -
, O +
in O +
allusion O +
to O +
the O +
as O +
yet O +
unidentified O +
function O +
of O +
its O +
protein O -
. O +

Nucleotide O +
sequence O +
analysis O +
of O +
a O +
3116bp O +
cDNA O +
clone O +
revealed O +
a O +
2682-bp O -
- O -
long O +
open O +
reading O +
frame O +
capable O +
of O +
directing O +
the O +
synthesis O +
of O +
a O +
894 O +
amino O +
acid O +
polypeptide O -
. O +

The O +
predicted O +
UFO O +
protein O +
exhibits O +
characteristic O +
features O +
of O +
a O +
transmembrane O +
receptor O +
with O +
associated O +
tyrosine O +
kinase O +
activity O -
. O +

The O +
UFO O +
proto O -
- O -
oncogene O +
maps O +
to O +
human O +
chromosome O +
19q13.1 O +
and O +
is O +
transcribed O +
into O +
two O +
5.0 O +
kb O +
and O +
3.2 O +
kb O +
mRNAs O +
in O +
human O +
bone O +
marrow O +
and O +
human O +
tumor O +
cell O +
lines O -
. O +

The O +
UFO O +
locus O +
is O +
evolutionarily O +
conserved O +
between O +
vertebrate O +
species O -
. O +

A O +
4.0 O +
kb O +
mRNA O +
of O +
the O +
murine O +
UFO O +
homolog O +
is O +
expressed O +
in O +
a O +
variety O +
of O +
different O +
mouse O +
tissues O -
. O +

We O +
thus O +
have O +
identified O +
a O +
novel O +
element O +
of O +
the O +
complex O +
signaling O +
network O +
involved O +
in O +
the O +
control O +
of O +
cell O +
proliferation O +
and O +
differentiation O -
. O +

Functional O +
significance O +
of O +
VEGF O -
- O -
a O +
in O +
human O +
ovarian O +
carcinoma O -
: O +
role O +
in O +
vasculogenic O +
mimicry O -
. O +

Ovarian O +
cancer O +
is O +
a O +
silent O +
killer O -
, O +
and O +
shows O +
early O +
extensive O +
tumor O +
invasion O +
and O +
peritoneal O +
metastasis O -
. O +

The O +
microcirculation O +
of O +
most O +
tumors O +
includes O +
cooperation O +
of O +
pre O -
- O -
existing O +
vessels O -
, O +
intussusceptive O +
microvascular O +
growth O -
, O +
postnatal O +
vasculogenesis O -
, O +
glomeruloid O +
angiogenesis O +
and O +
vasculogenic O +
mimicry O +
( O -
VM O -
) O -
. O +

VM O +
is O +
critical O +
for O +
a O +
tumor O +
blood O +
supply O +
and O +
is O +
asscociated O +
with O +
aggressive O +
features O +
and O +
metastasis O -
. O +

Our O +
studies O +
highlight O +
the O +
plasticity O +
of O +
aggressive O +
human O +
ovarian O +
carcinoma O +
cells O +
and O +
call O +
into O +
question O +
the O +
underlying O +
significance O +
of O +
their O +
ability O +
to O +
form O +
VM O +
in O +
vitro O +
induced O +
by O +
VEGF O -
- O -
a O -
. O +

These O +
studies O +
also O +
show O +
their O +
clinicalpathological O +
features O +
of O +
the O +
cancers O +
with O +
human O +
Paraffin B-Chemical -
- O -
embedded O +
tumor O +
tissue O +
samples O -
. O +

Results O +
show O +
that O +
the O +
process O -
: O +
VEGF O -
- O -
a-- O +
greater O +
than O +
EphA2 O -
- O -
- O +
greater O +
than O +
MMPs-- O +
greater O +
than O +
VM O +
is O +
the O +
main O +
pathway O +
for O +
VM O +
formation O +
and O +
VEGF O -
- O -
a O +
appears O +
to O +
play O +
an O +
important O +
role O +
in O +
the O +
formation O +
of O +
VM O +
based O +
on O +
our O +
in O +
vitro O +
assays O +
and O +
clinical O +
immunohistochemical O +
analyses O -
. O +

VM O -
- O -
targeting O +
strategies O +
for O +
ovarian O +
cancer O +
include O +
anti O -
- O -
VEGF O -
- O -
a O +
treatment O -
, O +
knocking O +
down O +
the O +
EphA2 O +
gene O +
and O +
using O +
antibodies O +
against O +
human O +
MMPs O +
if O +
the O +
tumor O +
is O +
VM O +
positive O -
. O +

This O +
strategy O +
may O +
be O +
of O +
significant O +
value O +
in O +
laying O +
the O +
foundation O +
for O +
a O +
more O +
explicit O +
anti O -
- O -
tumor O +
angiogenesis O +
therapy O -
. O +

Proteomic O +
comparison O +
of O +
nasopharyngeal O +
cancer O +
cell O +
lines O +
C666 O -
- O -
1 O +
and O +
NP69 O +
identifies O +
down O -
- O -
regulation O +
of O +
annexin O +
II O +
and O +
beta2-tubulin O +
for O +
nasopharyngeal O +
carcinoma O -
. O +

CONTEXT O -
: O +
Nasopharyngeal O +
carcinoma O +
( O -
NPC O -
) O -
, O +
common O +
in O +
southern O +
China O +
and O +
North O +
Africa O -
, O +
has O +
a O +
complex O +
etiology O +
involving O +
interplay O +
between O +
viral O -
, O +
environmental O -
, O +
and O +
hereditary O +
factors O +
and O +
is O +
almost O +
constantly O +
associated O +
with O +
the O +
Epstein O -
- O -
Barr O +
virus O -
. O +

Since O +
the O +
prognosis O +
of O +
locally O +
advanced O +
and O +
metastatic O +
diseases O +
is O +
poor O -
, O +
increased O +
understanding O +
of O +
the O +
pathogenesis O +
of O +
NPC O +
would O +
be O +
important O +
for O +
discovering O +
novel O +
markers O +
for O +
patients O -
' O +
management O -
. O +

OBJECTIVES O -
: O +
To O +
compare O +
the O +
proteomic O +
expression O +
profile O +
between O +
an O +
Epstein O -
- O -
Barr O +
virus O -
- O -
associated O +
NPC O +
cell O +
line O +
( O -
C666 O -
- O -
1 O -
) O +
and O +
a O +
normal O +
NP O +
cell O +
line O +
( O -
NP69 O -
) O -
. O +

The O +
proteins O +
with O +
differential O +
expression O +
were O +
analyzed O +
in O +
40 O +
undifferentiated O +
NPC O +
paraffin O -
- O -
embedded O +
specimens O -
. O +

DESIGN O -
: O +
Differentially O +
expressed O +
proteins O +
discovered O +
between O +
the O +
two O +
cell O +
lines O +
were O +
identified O +
by O +
mass O +
spectrometry O -
. O +

After O +
confirmation O +
by O +
immunocytochemical O +
staining O -
, O +
their O +
expression O +
in O +
patient O +
samples O +
was O +
measured O +
using O +
40 O +
pairs O +
of O +
undifferentiated O +
NPCs O +
together O +
with O +
their O +
adjacent O +
normal O +
epithelia O -
. O +

RESULTS O -
: O +
Proteomic O +
findings O +
indicated O +
that O +
adenosine O +
triphosphate O +
synthase O +
alpha O +
chain O +
was O +
up O -
- O -
regulated O -
, O +
whereas O +
annexin O +
II O -
, O +
annexin O +
V O -
, O +
beta O -
( O -
2 O -
) O -
-tubulin O -
, O +
and O +
profilin O +
1 O +
were O +
down O -
- O -
regulated O -
. O +

After O +
confirming O +
the O +
results O +
in O +
agar O -
- O -
processed O +
cell O +
lines O -
, O +
annexin O +
II O +
and O +
beta O -
( O -
2 O -
) O -
-tubulin O +
expression O +
were O +
found O +
to O +
be O +
lower O +
in O +
tumor O +
cells O +
than O +
in O +
adjacent O +
normal O +
epithelial O +
cells O +
in O +
100 O -
% O +
and O +
90 O -
% O +
of O +
the O +
patients O -
' O +
specimens O -
, O +
respectively O -
. O +

Finally O -
, O +
annexin O +
II O +
down O -
- O -
regulation O +
was O +
positively O +
associated O +
with O +
lymph O +
node O +
metastasis O -
, O +
suggesting O +
that O +
it O +
may O +
be O +
a O +
prognostic O +
factor O +
in O +
NPC O -
. O +

CONCLUSIONS O -
: O +
The O +
results O +
suggest O +
that O +
annexin O +
II O +
and O +
beta O -
( O -
2 O -
) O -
-tubulin O +
down O -
- O -
regulation O +
is O +
important O +
in O +
NPC O +
formation O +
and O +
may O +
represent O +
potential O +
targets O +
for O +
further O +
investigations O -
. O +

MMTV O -
- O -
cre O -
- O -
mediated O +
fur O +
inactivation O +
concomitant O +
with O +
PLAG1 O +
proto O -
- O -
oncogene O +
activation O +
delays O +
salivary O +
gland O +
tumorigenesis O +
in O +
mice O -
. O +

Proprotein O +
convertases O +
are O +
serine O +
endoproteases O +
implicated O +
in O +
the O +
proteolytic O +
processing O +
of O +
a O +
large O +
variety O +
of O +
regulatory O +
proteins O -
. O +

An O +
important O +
role O +
of O +
proprotein O +
convertases O +
in O +
tumorigenic O +
processes O +
has O +
been O +
suggested O +
by O +
various O +
studies O -
. O +

In O +
this O +
study O -
, O +
the O +
role O +
of O +
the O +
proprotein O +
convertase O +
furin O +
in O +
PLAG1 O +
proto O -
- O -
oncogene O -
- O -
induced O +
salivary O +
gland O +
tumorigenesis O +
was O +
investigated O -
. O +

PLAG1 O +
overexpression O +
in O +
salivary O +
glands O +
has O +
previously O +
been O +
shown O +
to O +
result O +
in O +
salivary O +
gland O +
tumors O +
in O +
100 O -
% O +
of O +
mice O +
within O +
5 O +
weeks O +
after O +
birth O -
. O +

MMTV O -
- O -
cre O -
- O -
mediated O +
inactivation O +
of O +
fur O +
without O +
over O -
- O -
expression O +
of O +
PLAG1 O +
caused O +
smaller O +
but O +
histologically O +
normal O +
salivary O +
glands O -
. O +

Moreover O -
, O +
the O +
lymph O +
nodes O +
close O +
to O +
the O +
salivary O +
glands O +
were O +
enlarged O -
, O +
and O +
histology O +
showed O +
that O +
they O +
had O +
activated O +
follicles O -
. O +

When O +
genetic O +
ablation O +
of O +
1 O +
or O +
2 O +
alleles O +
of O +
fur O +
and O +
overexpression O +
of O +
the O +
PLAG1 O +
transgene O +
were O +
simultaneously O +
achieved O -
, O +
a O +
significant O +
delay O +
in O +
tumorigenesis O +
was O +
observed O -
. O +

Collectively O -
, O +
these O +
results O +
suggest O +
an O +
important O +
role O +
for O +
furin O +
in O +
PLAG1-induced O +
salivary O +
gland O +
tumorigenesis O +
in O +
mice O -
. O +

Isotype O -
- O -
specific O +
inhibitors O +
of O +
the O +
glycolytic O +
key O +
regulator O +
pyruvate O +
kinase O +
subtype O +
M2 O +
moderately O +
decelerate O +
tumor O +
cell O +
proliferation O -
. O +

Tumor O +
cells O +
express O +
the O +
glycolytic O +
regulator O +
pyruvate O +
kinase O +
subtype O +
M2 O +
( O -
M2-PK O -
) O -
, O +
which O +
can O +
occur O +
in O +
a O +
tetrameric O +
form O +
with O +
high O +
affinity O +
to O +
its O +
substrate O +
phosphoenolpyruvate B-Chemical +
( O -
PEP B-Chemical -
) O +
and O +
a O +
dimeric O +
form O +
with O +
a O +
low O +
PEP B-Chemical +
affinity O -
. O +

The O +
transition O +
between O +
both O +
conformations O +
contributes O +
to O +
the O +
control O +
of O +
glycolysis O +
and O +
is O +
important O +
for O +
tumor O +
cell O +
proliferation O +
and O +
survival O -
. O +

Here O +
we O +
targeted O +
M2-PK O +
by O +
synthetic O +
peptide O +
aptamers O -
, O +
which O +
specifically O +
bind O +
to O +
M2-PK O +
and O +
shift O +
the O +
isoenzyme O +
into O +
its O +
low O +
affinity O +
dimeric O +
conformation O -
. O +

The O +
aptamer O -
- O -
induced O +
dimerization O +
and O +
inactivation O +
of O +
M2-PK O +
led O +
to O +
a O +
significant O +
decrease O +
in O +
the O +
PK O +
mass O -
- O -
action O +
ratio O +
as O +
well O +
as O +
ATP B-Chemical -
: O -
ADP B-Chemical +
ratio O +
in O +
the O +
target O +
cells O -
. O +

Furthermore O -
, O +
the O +
expression O +
of O +
M2-PK O -
- O -
binding O +
peptide O +
aptamers O +
moderately O +
reduced O +
the O +
growth O +
of O +
immortalized O +
NIH3T3 O +
cell O +
populations O +
by O +
decelerating O +
cell O +
proliferation O -
, O +
but O +
without O +
affecting O +
apoptotic O +
cell O +
death O -
. O +

Moreover O -
, O +
the O +
M2-PK O -
- O -
binding O +
peptide O +
aptamers O +
also O +
reduced O +
the O +
proliferation O +
rate O +
of O +
human O +
U-2 O +
OS O +
osteosarcoma O +
cells O -
. O +

In O +
the O +
present O +
study O -
, O +
we O +
developed O +
the O +
first O +
specific O +
inhibitors O +
of O +
the O +
pyruvate O +
kinase O +
isoenzyme O +
type O +
M2 O +
and O +
present O +
evidence O +
that O +
these O +
inhibitors O +
moderately O +
decelerate O +
tumor O +
cell O +
proliferation O -
. O +

Acute O +
ethanol B-Chemical +
exposure O +
disrupts O +
VEGF O +
receptor O +
cell O +
signaling O +
in O +
endothelial O +
cells O -
. O +

Physiological O +
angiogenesis O +
is O +
regulated O +
by O +
various O +
factors O -
, O +
including O +
signaling O +
through O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
receptors O -
. O +

We O +
previously O +
reported O +
that O +
a O +
single O +
dose O +
of O +
ethanol B-Chemical +
( O -
1.4 O +
g O -
/ O -
kg O -
) O -
, O +
yielding O +
a O +
blood O +
alcohol B-Chemical +
concentration O +
of O +
100 O +
mg O -
/ O -
dl O -
, O +
significantly O +
impairs O +
angiogenesis O +
in O +
murine O +
wounds O -
, O +
despite O +
adequate O +
levels O +
of O +
VEGF O -
, O +
suggesting O +
direct O +
effects O +
of O +
ethanol B-Chemical +
on O +
endothelial O +
cell O +
signaling O +
( O -
40 O -
) O -
. O +

To O +
examine O +
the O +
mechanism O +
by O +
which O +
ethanol B-Chemical +
influences O +
angiogenesis O +
in O +
wounds O -
, O +
we O +
employed O +
two O +
different O +
in O +
vitro O +
angiogenesis O +
assays O +
to O +
determine O +
whether O +
acute O +
ethanol B-Chemical +
exposure O +
( O -
100 O +
mg O -
/ O -
dl O -
) O +
would O +
have O +
long O -
- O -
lasting O +
effects O +
on O +
VEGF O -
- O -
induced O +
capillary O +
network O +
formation O -
. O +

Ethanol B-Chemical +
exposure O +
resulted O +
in O +
reduced O +
VEGF O -
- O -
induced O +
cord O +
formation O +
on O +
collagen O +
and O +
reduced O +
capillary O +
network O +
structure O +
on O +
Matrigel O +
in O +
vitro O -
. O +

In O +
addition O -
, O +
ethanol B-Chemical +
exposure O +
decreased O +
expression O +
of O +
endothelial O +
VEGF O +
receptor-2 O -
, O +
as O +
well O +
as O +
VEGF O +
receptor-2 O +
phosphorylation O +
in O +
vitro O -
. O +

Inhibition O +
of O +
ethanol B-Chemical +
metabolism O +
by O +
4-methylpyrazole B-Chemical +
partially O +
abrogated O +
the O +
effect O +
of O +
ethanol B-Chemical +
on O +
endothelial O +
cell O +
cord O +
formation O -
. O +

However O -
, O +
mice O +
treated O +
with O +
t B-Chemical -
- I-Chemical -
butanol I-Chemical -
, O +
an O +
alcohol B-Chemical +
not O +
metabolized O +
by O +
alcohol O +
dehydrogenase O -
, O +
exhibited O +
no O +
change O +
in O +
wound O +
vascularity O -
. O +

These O +
results O +
suggest O +
that O +
products O +
of O +
ethanol B-Chemical +
metabolism O +
are O +
important O +
factors O +
in O +
the O +
development O +
of O +
ethanol B-Chemical -
- O -
induced O +
changes O +
in O +
endothelial O +
cell O +
responsiveness O +
to O +
VEGF O -
. O +

In O +
vivo O -
, O +
ethanol B-Chemical +
exposure O +
caused O +
both O +
decreased O +
angiogenesis O +
and O +
increased O +
hypoxia O +
in O +
wounds O -
. O +

Moreover O -
, O +
in O +
vitro O +
experiments O +
demonstrated O +
a O +
direct O +
effect O +
of O +
ethanol B-Chemical +
on O +
the O +
response O +
to O +
hypoxia O +
in O +
endothelial O +
cells O -
, O +
as O +
ethanol B-Chemical +
diminished O +
nuclear O +
hypoxia O -
- O -
inducible O +
factor-1alpha O +
protein O +
levels O -
. O +

Together O -
, O +
the O +
data O +
establish O +
that O +
acute O +
ethanol B-Chemical +
exposure O +
significantly O +
impairs O +
angiogenesis O +
and O +
suggest O +
that O +
this O +
effect O +
is O +
mediated O +
by O +
changes O +
in O +
endothelial O +
cell O +
responsiveness O +
to O +
both O +
VEGF O +
and O +
hypoxia O -
. O +

Microscopic O +
technique O +
for O +
the O +
detection O +
of O +
nitric B-Chemical +
oxide I-Chemical -
- O -
dependent O +
angiogenesis O +
in O +
an O +
animal O +
model O -
. O +

Nitric B-Chemical +
oxide I-Chemical +
( O -
NO B-Chemical -
) O +
plays O +
an O +
important O +
role O +
in O +
maintaining O +
vascular O +
homeostasis O -
. O +

The O +
importance O +
of O +
NO B-Chemical +
in O +
the O +
vasculature O +
is O +
demonstrated O +
by O +
several O +
experimental O +
conditions O -
, O +
such O +
as O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
-induced O +
angiogenesis O -
. O +

Thus O -
, O +
the O +
NO B-Chemical +
metabolic O +
pathway O +
in O +
endothelial O +
cells O +
could O +
be O +
one O +
of O +
the O +
main O +
contributing O +
factors O +
for O +
angiogenesis O -
. O +

Although O +
several O +
methods O +
have O +
been O +
used O +
for O +
measuring O +
in O +
vitro O +
angiogenesis O -
, O +
a O +
proper O +
technique O +
has O +
not O +
been O +
developed O +
for O +
identifying O +
in O +
vivo O +
NO B-Chemical -
- O -
dependent O +
angiogenesis O -
. O +

This O +
chapter O +
provides O +
a O +
new O +
intravital O +
microscopic O +
method O +
for O +
detecting O +
and O +
measuring O +
NO B-Chemical -
- O -
dependent O +
angiogenesis O +
in O +
a O +
mouse O +
model O -
. O +

This O +
technique O +
showed O +
strong O +
abdominal O +
neovascularization O +
in O +
wild O -
- O -
type O +
mice O -
, O +
but O +
not O +
eNOS O +
knockout O +
mice O -
, O +
locally O +
injected O +
with O +
VEGF O -
, O +
as O +
well O +
as O +
stimulation O +
of O +
angiogenesis O +
in O +
NO B-Chemical +
donor O -
- O -
injected O +
mice O -
. O +

This O +
technique O +
also O +
revealed O +
the O +
inhibitory O +
effect O +
of O +
the O +
NOS O +
inhibitor O +
N B-Chemical -
( I-Chemical -
G I-Chemical -
) I-Chemical -
-iminoethyl I-Chemical -
- I-Chemical -
L I-Chemical -
- I-Chemical -
ornithine I-Chemical +
in O +
VEGF O -
- O -
mediated O +
in O +
vivo O +
angiogenesis O -
. O +

This O +
chapter O +
describes O +
intravital O +
microscopy O +
as O +
a O +
new O +
imaging O +
technique O +
for O +
detecting O +
NO B-Chemical -
- O -
dependent O +
angiogenesis O +
in O +
an O +
animal O +
model O -
. O +

Effects O +
of O +
cyclooxygenase-2 O +
non O -
- O -
selective O +
and O +
selective O +
inhibitors O +
on O +
proliferation O +
inhibition O +
and O +
apoptosis O +
induction O +
of O +
esophageal O +
squamous O +
carcinoma O +
cells O -
. O +

The O +
objective O +
of O +
this O +
study O +
is O +
to O +
investigate O +
the O +
effects O +
of O +
aspirin B-Chemical +
and O +
nimesulide B-Chemical +
on O +
cell O +
proliferation O -
, O +
apoptosis O +
and O +
its O +
potential O +
mechanisms O +
in O +
EC9706 O +
and O +
EC109 O +
esophageal O +
squamous O +
carcinoma O +
cells O -
. O +

EC9706 O +
and O +
EC109 O +
cells O +
were O +
incubated O +
with O +
varying O +
concentrations O +
of O +
aspirin B-Chemical +
and O +
nimesulide B-Chemical -
, O +
and O +
the O +
effects O +
on O +
cell O +
proliferation O +
and O +
apoptosis O +
were O +
monitored O +
by O +
3- B-Chemical -
( I-Chemical -
4,5-dimethyl I-Chemical -
- I-Chemical -
thiazol-2yl I-Chemical -
) I-Chemical -
-2,5-diphenyltetrazolium I-Chemical +
bromide I-Chemical +
and O +
flow O +
cytometry O -
. O +

Reverse O +
transcription O -
- O -
polymerase O +
chain O +
reaction O +
and O +
Western O +
blot O +
assays O +
were O +
used O +
to O +
investigate O +
expression O +
of O +
Bcl-2 O +
and O +
Bax O -
. O +

Prostaglandin O +
E2 O +
production O +
was O +
measured O +
by O +
enzyme O +
linked O +
immunosorbent O +
assay O -
. O +

Pretreatment O +
with O +
aspirin B-Chemical +
and O +
nimesulide B-Chemical +
inhibited O +
EC9706 O +
and O +
EC109 O +
cell O +
growth O +
in O +
a O +
time O +
and O +
dose O -
- O -
dependent O +
manner O -
, O +
accompanied O +
with O +
a O +
decrease O +
of O +
prostaglandin O +
E2 O +
production O -
. O +

In O +
EC9706 O +
cells O -
, O +
the O +
mechanism O +
of O +
aspirin B-Chemical +
and O +
nimesulide B-Chemical +
induced O +
growth O +
inhibition O +
was O +
a O +
consequence O +
of O +
cell O +
cycle O +
arrest O +
at O +
the O +
G O -
( O -
0 O -
) O -
/ O -
G O -
( O -
1 O -
) O +
check O +
point O -
. O +

In O +
EC109 O +
cells O -
, O +
growth O +
arrest O +
was O +
by O +
induction O +
of O +
apoptosis O -
, O +
associated O +
with O +
downregulation O +
of O +
Bcl-2 O -
, O +
but O +
not O +
Bax O -
. O +

In O +
conclusion O -
, O +
aspirin B-Chemical +
and O +
nimesulide B-Chemical +
could O +
inhibit O +
cell O +
proliferation O +
and O +
induce O +
apoptosis O +
in O +
esophageal O +
squamous O +
carcinoma O +
cells O -
. O +

Cyclooxygenase-2 O +
inhibitor O +
may O +
be O +
a O +
promising O +
therapeutic O +
agent O +
for O +
human O +
esophageal O +
squamous O +
cell O +
carcinoma O -
. O +

Neurotrophin O +
p75 O +
receptor O +
( O -
p75NTR O -
) O +
promotes O +
endothelial O +
cell O +
apoptosis O +
and O +
inhibits O +
angiogenesis O -
: O +
implications O +
for O +
diabetes O -
- O -
induced O +
impaired O +
neovascularization O +
in O +
ischemic O +
limb O +
muscles O -
. O +

Diabetes O +
impairs O +
endothelial O +
function O +
and O +
reparative O +
neovascularization O -
. O +

The O +
p75 O +
receptor O +
of O +
neurotrophins O +
( O -
p75 O -
( O -
NTR O -
) O -
) O -
, O +
which O +
is O +
scarcely O +
present O +
in O +
healthy O +
endothelial O +
cells O +
( O -
ECs O -
) O -
, O +
becomes O +
strongly O +
expressed O +
by O +
capillary O +
ECs O +
after O +
induction O +
of O +
peripheral O +
ischemia O +
in O +
type-1 O +
diabetic O +
mice O -
. O +

Here O -
, O +
we O +
show O +
that O +
gene O +
transfer O -
- O -
induced O +
p75 O -
( O -
NTR O -
) O +
expression O +
impairs O +
the O +
survival O -
, O +
proliferation O -
, O +
migration O -
, O +
and O +
adhesion O +
capacities O +
of O +
cultured O +
ECs O +
and O +
endothelial O +
progenitor O +
cells O +
( O -
EPCs O -
) O +
and O +
inhibits O +
angiogenesis O +
in O +
vitro O -
. O +

Moreover O -
, O +
intramuscular O +
p75 O -
( O -
NTR O -
) O +
gene O +
delivery O +
impairs O +
neovascularization O +
and O +
blood O +
flow O +
recovery O +
in O +
a O +
mouse O +
model O +
of O +
limb O +
ischemia O -
. O +

These O +
disturbed O +
functions O +
are O +
associated O +
with O +
suppression O +
of O +
signaling O +
mechanisms O +
implicated O +
in O +
EC O +
survival O +
and O +
angiogenesis O -
. O +

In O +
fact O -
, O +
p75 O -
( O -
NTR O -
) O +
depresses O +
the O +
VEGF O -
- O -
A O -
/ O -
Akt O -
/ O -
eNOS O -
/ O -
NO B-Chemical +
pathway O +
and O +
additionally O +
reduces O +
the O +
mRNA O +
levels O +
of O +
ITGB1 O +
[ O -
beta O +
( O -
1 O -
) O +
integrin O -
] O -
, O +
BIRC5 O +
( O -
survivin O -
) O -
, O +
PTTG1 O +
( O -
securin O -
) O +
and O +
VEZF1 O -
. O +

Diabetic O +
mice O -
, O +
which O +
typically O +
show O +
impaired O +
postischemic O +
muscular O +
neovascularization O +
and O +
blood O +
perfusion O +
recovery O -
, O +
have O +
these O +
defects O +
corrected O +
by O +
intramuscular O +
gene O +
transfer O +
of O +
a O +
dominant O +
negative O +
mutant O +
form O +
of O +
p75 O -
( O -
NTR O -
) O -
. O +

Collectively O -
, O +
our O +
data O +
newly O +
demonstrate O +
the O +
antiangiogenic O +
action O +
of O +
p75 O -
( O -
NTR O -
) O +
and O +
open O +
new O +
avenues O +
for O +
the O +
therapeutic O +
use O +
of O +
p75 O -
( O -
NTR O -
) O +
inhibition O +
to O +
combat O +
diabetes O -
- O -
induced O +
microvascular O +
liabilities O -
. O +

Tumor O +
endothelial O +
cell O +
targeted O +
cyclic B-Chemical +
RGD I-Chemical -
- I-Chemical -
modified I-Chemical +
heparin I-Chemical +
derivative I-Chemical -
: O +
inhibition O +
of O +
angiogenesis O +
and O +
tumor O +
growth O -
. O +

PURPOSE O +

: O +
We O +
prepared O +
tumor O +
endothelium O +
targeted O +
cRGD B-Chemical -
- I-Chemical -
modified I-Chemical +
heparin I-Chemical +
derivative I-Chemical +
( O -
cRGD B-Chemical -
- I-Chemical -
HL I-Chemical -
) O +
by O +
coupling O +
heparin B-Chemical -
- I-Chemical -
lithocholic I-Chemical +
acid I-Chemical +
( O -
HL B-Chemical -
) O +
with O +
cRGDyK B-Chemical -
, O +
and O +
evaluated O +
inhibition O +
effects O +
of O +
cRGD B-Chemical -
- I-Chemical -
HL I-Chemical +
on O +
angiogenesis O +
and O +
tumor O +
growth O -
. O +

METHODS O -
: O +
To O +
evaluate O +
antiangiogenic O +
activity O +
of O +
cRGD B-Chemical -
- I-Chemical -
HL I-Chemical -
, O +
we O +
performed O +
tests O +
on O +
endothelial O +
cell O +
adhesion O +
and O +
migration O +
to O +
vitronectin O -
, O +
tube O +
formation O -
, O +
binding O +
affinity O +
to O +
purified O +
alpha O -
( O -
v O -
) O -
beta O -
( O -
3 O -
) O +
integrin O -
, O +
and O +
in O +
vivo O +
Matrigel O +
plug O +
assay O -
. O +

The O +
antitumor O +
activity O +
of O +
cRGD B-Chemical -
- I-Chemical -
HL I-Chemical +
was O +
also O +
evaluated O +
by O +
monitoring O +
tumor O +
growth O +
and O +
microvessel O +
formation O +
in O +
squamous O +
cell O +
carcinoma O +
( O -
SCC7 O -
) O +
tumor O -
. O +

RESULTS O -
: O +
The O +
cRGD B-Chemical -
- I-Chemical -
HL I-Chemical +
significantly O +
inhibited O +
adhesion O +
and O +
migration O +
of O +
endothelial O +
cells O +
to O +
vitronectin O -
, O +
and O +
tubular O +
structures O +
of O +
endothelial O +
cells O -
. O +

Compared O +
to O +
cRGDyK B-Chemical +
and O +
HL B-Chemical -
, O +
cRGD B-Chemical -
- I-Chemical -
HL I-Chemical +
has O +
high O +
binding O +
affinity O +
to O +
purified O +
alpha O -
( O -
v O -
) O -
beta O -
( O -
3 O -
) O +
integrin O -
. O +

The O +
enhanced O +
antiangiogenic O +
effect O +
of O +
cRGD B-Chemical -
- I-Chemical -
HL I-Chemical +
was O +
confirmed O +
in O +
Matrigel O +
assay O +
by O +
showing O +
the O +
significant O +
inhibition O +
of O +
bFGF O -
- O -
driven O +
angiogenesis O +
and O +
blood O +
vessel O +
formation O -
. O +

It O +
was O +
thought O +
that O +
potent O +
antiangiogenic O +
effect O +
of O +
cRGD B-Chemical -
- I-Chemical -
HL I-Chemical +
was O +
probably O +
due O +
to O +
the O +
interference O +
of O +
alpha O -
( O -
v O -
) O -
beta O -
( O -
3 O -
) O -
-mediated O +
interaction O -
, O +
resulting O +
in O +
the O +
enhanced O +
antitumoral O +
activity O +
against O +
SCC7 O +
tumor O -
. O +

CONCLUSION O -
: O +
These O +
results O +
demonstrated O +
that O +
cRGD B-Chemical -
- I-Chemical -
modified I-Chemical +
heparin I-Chemical +
derivative I-Chemical +
enhanced O +
anti O -
- O -
angiotherapeutic O +
effects O +
against O +
solid O +
tumor O -
, O +
and O +
therefore O -
, O +
it O +
could O +
be O +
applied O +
to O +
treat O +
various O +
cancers O +
and O +
angiogenic O +
diseases O +
as O +
a O +
potent O +
angiogenesis O +
inhibitor O -
. O +

The O +
role O +
of O +
platelet O -
- O -
derived O +
endothelial O +
cell O +
growth O +
factor O -
/ O -
thymidine O +
phosphorylase O +
in O +
tumor O +
behavior O -
. O +

Platelet O -
- O -
derived O +
endothelial O +
cell O +
growth O -
- O -
factor O +
( O -
PD O -
- O -
ECGF O -
) O +
is O +
similar O +
to O +
the O +
pyrimidine O +
enzyme O +
thymidine O +
phosphorylase O +
( O -
TP O -
) O -
. O +

A O +
high O +
TP O +
expression O +
at O +
tumor O +
sites O +
is O +
correlated O +
with O +
tumor O +
growth O -
, O +
induction O +
of O +
angiogenesis O -
, O +
and O +
metastasis O -
. O +

Therefore O -
, O +
high O +
TP O +
is O +
most O +
likely O +
associated O +
with O +
a O +
poor O +
prognosis O -
. O +

TP O +
is O +
not O +
only O +
expressed O +
in O +
tumor O +
cells O +
but O +
also O +
in O +
tumor O +
surrounding O +
tissues O -
, O +
such O +
as O +
tumor O +
infiltrating O +
macrophages O -
. O +

TP O +
catalyzes O +
the O +
conversion O +
of O +
thymidine B-Chemical +
to O +
thymine B-Chemical +
and O +
doxyribose-1-phosphate B-Chemical +
( O -
dR-1-P B-Chemical -
) O -
. O +

The O +
latter O +
in O +
its O +
parent O +
form O +
or O +
in O +
its O +
sugar B-Chemical +
form O -
, O +
deoxyribose B-Chemical +
( O -
dR B-Chemical -
) O +
may O +
play O +
a O +
role O +
in O +
the O +
induction O +
of O +
angiogenesis O -
. O +

It O +
may O +
modulate O +
cellular O +
energy O +
metabolism O +
or O +
be O +
a O +
substrate O +
in O +
a O +
chemical O +
reaction O +
generating O +
reactive B-Chemical +
oxygen I-Chemical +
species I-Chemical -
. O +

L B-Chemical -
- I-Chemical -
deoxyribose I-Chemical +
( O -
L B-Chemical -
- I-Chemical -
dR I-Chemical -
) O +
and O +
thymidine B-Chemical +
phosphorylase I-Chemical +
inhibitor I-Chemical +
( O -
TPI B-Chemical -
) O +
can O +
reverse O +
these O +
effects O -
. O +

The O +
mechanism O +
of O +
TP O +
induction O +
is O +
not O +
yet O +
completely O +
clear O -
, O +
but O +
TNF O -
, O +
IL10 O +
and O +
other O +
cytokines O +
have O +
been O +
clearly O +
shown O +
to O +
induce O +
its O +
expression O -
. O +

The O +
various O +
complex O +
interactions O +
of O +
TP O +
give O +
it O +
an O +
essential O +
role O +
in O +
cellular O +
functioning O +
and O -
, O +
hence O -
, O +
it O +
is O +
an O +
ideal O +
target O +
in O +
cancer O +
therapy O -
. O +

[ O -
Inhibitory O +
effect O +
of O +
adenovirus O -
- O -
mediated O +
endostatin O +
gene O +
transfer O +
on O +
transplanted O +
lung O +
carcinoma O +
in O +
mice O -
] O +
OBJECTIVE O -
: O +
To O +
investigate O +
the O +
effect O +
of O +
adenovirus O -
- O -
mediated O +
endostatin O +
gene O +
transfer O +
on O +
transplanted O +
lung O +
cancer O +
in O +
mice O +
and O +
its O +
mechanism O +
of O +
action O -
. O +

METHODS O -
: O +
Transplant O +
tumor O +
model O +
was O +
induced O +
by O +
subcutaneous O +
inoculation O +
of O +
2 O +
x O +
10 O -
( O -
6 O -
) O +

Lewis O +
lung O +
cancer O +
( O -
LLC O -
) O +
cells O +
into O +
the O +
back O +
of O +
C57BL O -
/ O -
6 O +
mice O -
. O +

The O +
mice O +
were O +
treated O +
by O +
intratumoral O +
injection O +
of O +
2 O +
x O +
10 O -
( O -
9 O -
) O +
pfu O +
Ad O -
- O -
mEndostatin O -
. O +

The O +
expression O +
of O +
endostatin O +
in O +
situ O +
and O +
its O +
maintaining O +
time O +
were O +
detected O +
by O +
immunohistochemistry O +
and O +
Western O +
Blot O -
, O +
respectively O -
. O +

The O +
endostatin O +
level O +
in O +
serum O +
was O +
determined O +
by O +
ELISA O +
. O +

The O +
inhibition O +
of O +
tumor O +
growth O +
and O +
changes O +
of O +
survival O +
were O +
recorded O +
and O +
the O +
microvessel O +
density O +
( O -
MVD O -
) O +
was O +
determined O +
by O +
histochemical O +
stainingwith O +
CD31 O +
and O +
CD105 O +
antibodies O -
. O +

The O +
tumor O +
apoptosis O +
was O +
observed O +
by O +
electron O +
microscopy O -
. O +

RESULTS O -
: O +
In O +
comparison O +
with O +
controls O -
, O +
intratumoral O +
injection O +
of O +
Ad O -
- O -
mEndostatin O +
significantly O +
inhibited O +
the O +
tumor O +
growth O +
and O +
metastasis O -
, O +
and O +
prolonged O +
the O +
survival O +
rate O +
of O +
mice O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O +

Strong O +
positive O +
expression O +
of O +
mEndostatin O +
was O +
seen O +
in O +
the O +
tumor O +
tissue O +
after O +
injection O +
of O +
Ad O -
- O -
mEndostatin O -
, O +
immunhistochemically O +
ostained O +
by O +
mouse O +
endostatin O +
monoclonal O +
antibody O -
, O +
while O +
the O +
control O +
groups O +
showed O +
only O +
very O +
low O +
expression O +
or O +
absence O -
. O +

Serum O +
endostatin O +
concentration O +
was O +
1540 O +
+ O -
/- O +

560 O +
ng O -
/ O -
ml O +
at O +
the O +
second O +
week O +
of O +
administration O -
, O +
the O +
expression O +
of O +
endostatin O +
diminished O +
a O +
month O +
later O -
. O +

The O +
microvessel O +
density O +
( O -
MVD O -
) O -
) O +
decreased O +
from O +
42.4 O +
+ O -
/- O +

4.8 O +
to O +
10.5 O +
+ O -
/- O +

3.2 O +
per O +
x O +
200 O +
magnificetion O +
microscopic O +
field O +
by O +
CD10 O +
staining O +
and O +
from O +
68.5 O +
+ O -
/- O +

4.5 O +
to O +
37.5 O +
+ O -
/- O +

4.6 O +
by O +
CD31 O +
staining O -
, O +
respectively O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O +

More O +
apoptotic O +
tumor O +
cells O +
were O +
seen O +
under O +
the O +
transmission O +
electron O +
microscope O -
. O +

CONCLUSION O -
: O +
Endostatin O +
gene O +
therapy O +
mediated O +
by O +
adenoviral O +
vector O +
efficiently O +
induces O +
expression O +
of O +
endostatin O +
in O +
vivo O -
, O +
and O +
inhibits O +
the O +
growth O +
and O +
metastasis O +
of O +
tumor O -
. O +

It O +
is O +
concluded O +
that O +
its O +
action O +
is O +
targeted O +
to O +
tumor O +
neovasculature O +
and O +
the O +
mechanism O +
is O +
inhibition O +
of O +
tumor O +
angiogenesis O -
. O +

Reversal O +
of O +
the O +
malignant O +
phenotype O +
of O +
ovarian O +
cancer O +
A2780 O +
cells O +
through O +
transfection O +
with O +
wild O -
- O -
type O +
PTEN O +
gene O -
. O +

OBJECTIVE O -
: O +
PTEN O +
( O -
phosphatase O +
and O +
tensin O +
homologue O +
deleted O +
on O +
chromosome O +
10 O -
) O +
is O +
a O +
tumor O +
suppressor O +
gene O +
identified O +
on O +
human O +
chromosome O +
10q23 O -
. O +

Substantial O +
studies O +
have O +
demonstrated O +
that O +
PTEN O +
can O +
inhibit O +
cell O +
proliferation O -
, O +
migration O +
and O +
invasion O +
of O +
many O +
cancer O +
cells O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
determine O +
whether O +
upregulation O +
of O +
PTEN O +
gene O +
by O +
transfection O +
wild O -
- O -
type O +
PTEN O +
gene O +
to O +
ovarian O +
cancer O +
cells O +
can O +
inhibit O +
growth O +
and O +
migration O +
and O +
to O +
explore O +
the O +
potential O +
for O +
PTEN O +
gene O +
therapy O +
of O +
ovarian O +
cancers O -
. O +

METHOD O -
: O +
Wild O -
- O -
type O +
and O +
phosphatase O -
- O -
inactive O +
( O -
C124A O -
) O +
PTEN O +
plasmids O +
were O +
transfected O +
into O +
ovarian O +
epithelial O +
cancer O +
A2780 O +
cells O -
, O +
and O +
their O +
effects O +
on O +
cell O +
apoptosis O -
, O +
cell O +
proliferation O -
, O +
cell O +
migration O +
and O +
cell O +
invasion O +
were O +
analyzed O +
by O +
flow O +
cytometry O +
analysis O -
, O +
TUNEL O +
assay O -
, O +
MTT O +
assay O -
, O +
wound O -
- O -
healing O +
assay O +
and O +
transwell O +
assay O -
. O +

RESULTS O -
: O +
Both O +
wild O -
- O -
type O +
and O +
mutant O +
PTEN O +
can O +
upregulate O +
the O +
expression O +
of O +
PTEN O +
gene O +
dramatically O -
; O +
however O -
, O +
it O +
is O +
wild O -
- O -
type O +
PTEN O +
not O +
phosphatase B-Chemical -
- O -
inactive O +
PTEN O +
that O +
can O +
induce O +
apoptosis O +
and O +
decrease O +
cell O +
migration O -
, O +
invasion O +
and O +
proliferation O +
in O +
ovarian O +
cancer O +
cells O -
. O +

CONCLUSION O -
: O +
These O +
results O +
demonstrated O +
that O +
PTEN O +
had O +
played O +
an O +
important O +
role O +
in O +
the O +
cell O +
proliferation O -
, O +
cell O +
migration O +
and O +
invasion O +
dependent O +
on O +
its O +
phosphatase O +
activity O -
. O +

Enhanced O +
expression O +
of O +
PTEN O +
by O +
gene O +
transfer O +
is O +
sufficient O +
to O +
reverse O +
the O +
malignant O +
phenotype O +
of O +
ovarian O +
cancer O +
cells O +
and O +
transfection O +
of O +
ovarian O +
cancer O +
cells O +
with O +
wild O -
- O -
type O +
PTEN O +
gene O +
might O +
be O +
another O +
novel O +
approach O +
for O +
therapeutic O +
intervention O +
in O +
ovarian O +
cancer O -
. O +

Regulation O +
of O +
the O +
Warburg O +
effect O +
in O +
early O -
- O -
passage O +
breast O +
cancer O +
cells O -
. O +

Malignancy O +
in O +
cancer O +
is O +
associated O +
with O +
aerobic O +
glycolysis O +
( O -
Warburg O +
effect O -
) O +
evidenced O +
by O +
increased O +
trapping O +
of O +
[ B-Chemical -
( I-Chemical -
18 I-Chemical -
) I-Chemical -
F I-Chemical -
] I-Chemical -
deoxyglucose I-Chemical +
( O -
FdG B-Chemical -
) O +
in O +
patients O +
imaged O +
by O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O -
. O +

[ B-Chemical -
( I-Chemical -
18 I-Chemical -
) I-Chemical -
F I-Chemical -
] I-Chemical -
deoxyglucose I-Chemical +
uptake O +
correlates O +
with O +
glucose O +
transporter O +
( O -
GLUT-1 O -
) O +
expression O -
, O +
which O +
can O +
be O +
regulated O +
by O +
hypoxia O -
- O -
inducible O +
factor O +
1 O +
alpha O +
( O -
HIF-1alpha O -
) O -
. O +

We O +
have O +
previously O +
reported O +
in O +
established O +
breast O +
lines O +
that O +
HIF-1alpha O +
levels O +
in O +
the O +
presence O +
of O +
oxygen B-Chemical +
leads O +
to O +
the O +
Warburg O +
effect O -
. O +

However O -
, O +
glycolysis O +
and O +
GLUT-1 O +
can O +
also O +
be O +
induced O +
independent O +
of O +
HIF-1alpha O +
by O +
other O +
factors O -
, O +
such O +
as O +
c O -
- O -
Myc O +
and O +
phosphorylated O +
Akt O +
( O -
pAkt O -
) O -
. O +

This O +
study O +
investigates O +
HIF-1alpha O -
, O +
c O -
- O -
Myc O -
, O +
pAkt O -
, O +
and O +
aerobic O +
glycolysis O +
in O +
low O -
- O -
passage O +
breast O +
cancer O +
cells O +
under O +
the O +
assumption O +
that O +
these O +
represent O +
the O +
in O +
vivo O +
condition O +
better O +
than O +
established O +
lines O -
. O +

Similar O +
to O +
in O +
vivo O +
FdG B-Chemical -
- O -
PET O +
or O +
primary O +
breast O +
cancers O -
, O +
rates O +
of O +
glycolysis O +
were O +
diverse O -
, O +
being O +
higher O +
in O +
cells O +
expressing O +
both O +
c O -
- O -
Myc O +
and O +
HIF-1alpha O +
and O +
lower O +
in O +
cell O +
lines O +
low O +
or O +
negative O +
in O +
both O +
transcription O +
factors O -
. O +

No O +
correlations O +
were O +
observed O +
between O +
glycolytic O +
rates O +
and O +
pAkt O +
levels O -
. O +

Two O +
of O +
12 O +
cell O +
lines O +
formed O +
xenografts O +
in O +
mice O -
. O +

Both O +
were O +
positive O +
for O +
HIF-1alpha O +
and O +
phosphorylated O +
c O -
- O -
Myc O -
, O +
and O +
only O +
one O +
was O +
positive O +
for O +
pAkt O -
. O +

Glycolysis O +
was O +
affected O +
by O +
pharmacological O +
regulation O +
of O +
c O -
- O -
Myc O +
and O +
HIF-1alpha O -
. O +

These O +
findings O +
suggest O +
that O +
c O -
- O -
Myc O +
and/or O +
HIF-1alpha O +
activities O +
are O +
both O +
involved O +
in O +
the O +
regulation O +
of O +
glycolysis O +
in O +
breast O +
cancers O -
. O +

Intracerebral O +
grafting O +
of O +
cultured O +
autologous O +
skin O +
fibroblasts O +
into O +
the O +
rat O +
striatum O -
: O +
an O +
assessment O +
of O +
graft O +
size O +
and O +
ultrastructure O -
. O +

To O +
identify O +
a O +
suitable O +
donor O +
cell O +
population O +
for O +
gene O +
therapy O +
applications O +
to O +
the O +
central O +
nervous O +
system O -
, O +
primary O +
fibroblasts O +
isolated O +
from O +
skin O +
biopsies O +
and O +
maintained O +
in O +
culture O +
are O +
employed O +
as O +
autologous O +
cells O +
for O +
intracerebral O +
grafting O +
within O +
the O +
adult O +
rat O +
striatum O -
. O +

Results O +
from O +
the O +
present O +
investigation O +
reveal O +
that O +
cultured O +
primary O +
skin O +
fibroblasts O +
cease O +
to O +
proliferate O +
once O +
they O +
reach O +
confluence O -
; O +
these O +
cells O +
are O +
thus O +
contact O +
inhibited O +
in O +
vitro O -
. O +

Following O +
implantation O +
within O +
the O +
striatum O -
, O +
the O +
volume O +
of O +
the O +
primary O +
fibroblast O +
grafts O -
, O +
stained O +
immunohistochemically O +
for O +
fibronectin O -
, O +
does O +
not O +
differ O +
significantly O +
at O +
3 O +
and O +
8 O +
weeks O -
. O +

The O +
graft O +
size O +
is O +
dependent O +
on O +
the O +
density O +
of O +
the O +
cell O +
suspension O -
, O +
but O +
not O +
dependent O +
on O +
either O +
the O +
number O +
of O +
passages O +
the O +
cells O +
are O +
taken O +
through O +
in O +
culture O +
prior O +
to O +
grafting O +
or O +
on O +
the O +
postoperative O +
survival O +
period O -
. O +

Ultrastructural O +
evidence O +
reveals O +
that O +
at O +
8 O +
weeks O +
the O +
grafts O +
are O +
composed O +
primarily O +
of O +
collagen O +
and O +
fibroblasts O +
with O +
rough O +
endoplasmic O +
reticulum O +
and O +
vesicles O -
. O +

Reactive O +
astrocytic O +
processes O +
and O +
phagocytic O +
cells O +
are O +
also O +
present O +
in O +
the O +
grafts O -
. O +

The O +
grafts O +
are O +
extensively O +
vascularized O +
with O +
capillaries O +
composed O +
of O +
nonfenestrated O +
endothelium O -
; O +
intercellular O +
junctions O +
are O +
evident O +
at O +
sites O +
of O +
apposition O +
between O +
endothelial O +
cells O -
. O +

It O +
is O +
concluded O +
that O +
primary O +
skin O +
fibroblasts O +
are O +
able O +
to O +
survive O +
for O +
at O +
least O +
8 O +
weeks O +
following O +
intracerebral O +
implantation O +
and O +
continue O +
to O +
synthesize O +
collagen O +
and O +
fibronectin O +
in O +
vivo O -
. O +

Also O -
, O +
the O +
grafts O +
maintain O +
a O +
constant O +
volume O +
between O +
3 O +
and O +
8 O +
weeks O -
, O +
thereby O +
indicating O +
that O +
primary O +
skin O +
fibroblasts O +
do O +
not O +
produce O +
tumors O -
. O +

Finally O -
, O +
dynamic O +
host O -
- O -
to O -
- O -
graft O +
interactions O -
-- O -
including O +
phagocytic O +
migration O -
, O +
astrocytic O +
hypertrophy O +
and O +
infiltration O +
within O +
the O +
grafts O -
, O +
and O +
angiogenesis O -
-- O -
are O +
features O +
that O +
constitute O +
the O +
structural O +
integration O +
of O +
primary O +
skin O +
fibroblasts O +
grafted O +
within O +
the O +
adult O +
rat O +
central O +
nervous O +
system O -
. O +

Enhancement O +
of O +
docetaxel B-Chemical -
- O -
induced O +
cytotoxicity O +
and O +
apoptosis O +
by O +
all B-Chemical -
- I-Chemical -
trans I-Chemical +
retinoic I-Chemical +
acid I-Chemical +
( O -
ATRA B-Chemical -
) O +
through O +
downregulation O +
of O +
survivin O +
( O -
BIRC5 O -
) O -
, O +
MCL-1 O +
and O +
LTbeta O -
- O -
R O +
in O +
hormone- O +
and O +
drug O +
resistant O +
prostate O +
cancer O +
cell O +
line O -
, O +
DU-145 O -
. O +

BACKGROUND O -
: O +
The O +
management O +
of O +
hormone O -
- O -
refractory O +
prostate O +
cancer O +
( O -
HRPC O -
) O +
still O +
remains O +
as O +
an O +
important O +
challenge O +
of O +
daily O +
oncology O +
practice O -
. O +

Docetaxel B-Chemical +
has O +
proved O +
to O +
be O +
a O +
first O +
line O +
treatment O +
choice O -
. O +

All B-Chemical -
- I-Chemical -
trans I-Chemical +
retinoic I-Chemical +
acid I-Chemical +
( O -
ATRA B-Chemical -
) O +
could O +
potently O +
inhibit O +
the O +
growth O +
of O +
prostate O +
cancer O +
cells O +
in O +
vitro O +
and O +
its O +
combination O +
with O +
various O +
anticancer O +
agents O +
results O +
in O +
increased O +
cytotoxicity O -
. O +

Based O +
on O +
these O +
data O -
, O +
our O +
aim O +
was O +
to O +
examine O +
the O +
synergistic O -
/ O -
additive O +
cytotoxic O +
and O +
apoptotic O +
effects O +
of O +
combination O +
of O +
docetaxel B-Chemical +
and O +
ATRA B-Chemical -
, O +
in O +
hormone- O +
and O +
drug O +
refractory O +
human O +
DU-145 O +
prostate O +
cancer O +
cells O -
. O +

Furthermore O -
, O +
we O +
have O +
searched O +
for O +
the O +
underlying O +
mechanisms O +
of O +
apoptosis O +
by O +
demonstrating O +
apoptosis O -
- O -
related O +
genes O -
. O +

METHODS O -
: O +
XTT O +
cell O +
proliferation O +
assay O +
was O +
used O +
for O +
showing O +
cytotoxicity O -
. O +

For O +
verifying O +
apoptosis O -
, O +
both O +
DNA O +
Fragmentation O +
by O +
ELISA O +
assay O +
and O +
caspase O +
3 O -
/ O -
7 O +
activity O +
measurement O +
were O +
used O -
. O +

For O +
detecting O +
the O +
mechanism O +
of O +
apoptosis O +
induced O +
by O +
docetaxel B-Chemical -
- O -
ATRA B-Chemical +
combination O -
, O +
OligoGeArray O +
which O +
consists O +
of O +
112 O +
apoptosis O +
related O +
genes O +
was O +
used O -
. O +

RESULTS O -
: O +
Our O +
results O +
revealed O +
that O +
docetaxel B-Chemical +
and O +
ATRA B-Chemical +
were O +
synergistically O +
cytotoxic O +
and O +
apoptotic O +
in O +
DU-145 O +
cells O -
, O +
in O +
a O +
dose- O +
and O +
time O +
dependent O +
manner O -
. O +

It O +
was O +
also O +
shown O +
by O +
our O +
studies O +
that O +
apoptosis O +
was O +
induced O +
in O +
DU-145 O +
prostate O +
carcinoma O +
cells O +
with O +
significant O +
cytotoxicity O -
, O +
no O +
matter O +
which O +
agent O +
applied O +
first O -
. O +

We O +
have O +
found O +
out O +
that O +
docetaxel B-Chemical -
- O -
ATRA B-Chemical +
combination O +
significantly O +
downregulates O +
survivin O +
( O -
BIRC5 O -
) O -
, O +
myeloid O +
cell O +
leukemia-1 O +
( O -
MCL-1 O -
) O +
and O +
lymphotoxin O +
beta O -
- O -
receptor O +
( O -
LTbetaR O -
) O +
genes O -
, O +
which O +
all O +
three O +
have O +
pivotal O +
roles O +
in O +
regulation O +
of O +
apoptosis O +
and O +
cell O +
cycle O +
progression O -
. O +

CONCLUSION O -
: O +
In O +
conclusion O -
, O +
we O +
strongly O +
suggest O +
that O +
docetaxel B-Chemical +
and O +
ATRA B-Chemical +
combination O +
is O +
a O +
good O +
candidate O +
for O +
this O +
challenging O +
era O +
of O +
daily O +
oncologic O +
practice O -
. O +

Also O -
, O +
the O +
combination O +
of O +
docetaxel B-Chemical +
and O +
ATRA B-Chemical +
might O +
allow O +
a O +
reduction O +
in O +
docetaxel B-Chemical +
doses O +
and O +
by O +
this O +
way O +
may O +
diminish O +
docetaxel B-Chemical +
adverse O +
effects O +
while O +
maintaining O +
the O +
therapeutic O +
effect O +
in O +
patients O +
with O +
HRPC O -
. O +

Efficient O +
inhibition O +
of O +
ovarian O +
cancer O +
growth O +
and O +
prolonged O +
survival O +
by O +
transfection O +
with O +
a O +
novel O +
pro O -
- O -
apoptotic O +
gene O -
, O +
hPNAS-4 O -
, O +
in O +
a O +
mouse O +
model O -
. O +

In O +
vivo O +
and O +
in O +
vitro O +
results O -
. O +

OBJECTIVE O -
: O +
We O +
transfected O +
ovarian O +
cancer O +
cells O +
and O +
administered O +
recombinant O +
plasmid O +
encoding O +
hPNAS-4 O +
to O +
nude O +
mice O +
bearing O +
ovarian O +
cancer O -
, O +
aiming O +
to O +
evaluate O +
the O +
effect O +
of O +
hPNAS-4 O +
against O +
ovarian O +
cancer O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

METHODS O -
: O +
Ovarian O +
cancer O +
SKOV3 O +
cells O +
were O +
transfected O +
with O +
hPNAS-4-plasmid O -
, O +
and O +
cell O +
proliferation O +
was O +
evaluated O +
by O +
MTT O +
assay O -
; O +
apoptosis O +
was O +
examined O +
by O +
DNA O +
ladder O -
, O +
Hoechst33258 O +
staining O +
and O +
flow O -
- O -
cytometric O +
assays O -
. O +

Nude O +
mice O +
bearing O +
ovarian O +
cancers O +
were O +
treated O +
with O +
hPNAS-4-p O -
/ O -
liposome B-Chemical -
. O +

Tumor O +
growth O +
was O +
determined O +
and O +
survival O +
was O +
recorded O -
. O +

TUNEL O +
assay O +
and O +
microvessel O +
density O +
was O +
assessed O +
to O +
evaluate O +
apoptosis O +
and O +
angiogenesis O -
. O +

RESULTS O -
: O +
Both O +
inhibition O +
of O +
proliferation O +
( O -
p O +
< O +
0.05 O -
) O +
and O +
induction O +
of O +
apoptosis O +
( O -
p O +
< O +
0.05 O -
) O +
were O +
observed O +
in O +
SKOV3 O +
cells O +
transfected O +
with O +
hPNAS-4-p O +
in O +
vitro O -
. O +

In O +
hPNAS-4-p O -
- O -
treated O +
tumor O +
cells O +
in O +
vivo O -
, O +
tumor O +
growth O +
significantly O +
decreased O -
, O +
while O +
the O +
survival O +
time O +
of O +
tumor O -
- O -
bearing O +
mice O +
was O +
prolonged O +
compared O +
with O +
control O +
groups O +
( O -
p O +
< O +
0.05 O -
) O -
. O +

Increased O +
apoptosis O +
of O +
tumor O +
cells O +
and O +
decreased O +
angiogenesis O +
in O +
tumor O +
tissue O +
were O +
also O +
observed O -
. O +

CONCLUSIONS O -
: O +
Our O +
promising O +
results O +
on O +
the O +
potential O +
antitumor O +
effects O +
of O +
hPNAS-4 O +
on O +
ovarian O +
cancer O +
in O +
vitro O +
and O +
in O +
vivo O +
may O +
be O +
explained O -
, O +
in O +
part O -
, O +
by O +
the O +
induction O +
of O +
apoptosis O +
and O +
inhibition O +
of O +
angiogenesis O -
. O +

Consequently O -
, O +
hPNAS-4 O +
has O +
potential O +
as O +
a O +
new O +
gene O +
therapy O +
for O +
human O +
ovarian O +
cancer O -
. O +

Diverse O +
cell O +
signaling O +
events O +
modulated O +
by O +
perlecan O -
. O +

Perlecan O +
is O +
a O +
ubiquitous O +
pericellular O +
proteoglycan O +
ideally O +
placed O +
to O +
mediate O +
cell O +
signaling O +
events O +
controlling O +
migration O -
, O +
proliferation O -
, O +
and O +
differentiation O -
. O +

Its O +
control O +
of O +
growth O +
factor O +
signaling O +
usually O +
involves O +
interactions O +
with O +
the O +
heparan O +
sulfate O +
chains O +
covalently O +
coupled O +
to O +
the O +
protein O +
core O -
's O +
N O -
- O -
terminus O -
. O +

However O -
, O +
this O +
modular O +
protein O +
core O +
also O +
binds O +
with O +
relatively O +
high O +
affinity O +
to O +
a O +
number O +
of O +
growth O +
factors O +
and O +
surface O +
receptors O -
, O +
thereby O +
stabilizing O +
cell O -
- O -
matrix O +
links O -
. O +

This O +
review O +
will O +
focus O +
on O +
perlecan O -
- O -
growth O +
factor O +
interactions O +
and O +
describe O +
recent O +
advances O +
in O +
our O +
understanding O +
of O +
this O +
highly O +
conserved O +
proteoglycan O +
during O +
development O -
, O +
cancer O +
growth O -
, O +
and O +
angiogenesis O -
. O +

The O +
pro O -
- O -
angiogenic O +
capacities O +
of O +
perlecan O +
that O +
involve O +
proliferative O +
and O +
migratory O +
signals O +
in O +
response O +
to O +
bound O +
growth O +
factors O +
will O +
be O +
explored O -
, O +
as O +
well O +
as O +
the O +
anti O -
- O -
angiogenic O +
signals O +
resulting O +
from O +
interactions O +
between O +
the O +
C O -
- O -
terminal O +
domain O +
known O +
as O +
endorepellin O +
and O +
integrins O +
that O +
control O +
adhesion O +
of O +
cells O +
to O +
the O +
extracellular O +
matrix O -
. O +

These O +
two O +
somewhat O +
diametrically O +
opposed O +
roles O +
will O +
be O +
discussed O +
in O +
light O +
of O +
new O +
data O +
emerging O +
from O +
various O +
fields O +
which O +
converge O +
on O +
perlecan O +
as O +
a O +
key O +
regulator O +
of O +
cell O +
growth O +
and O +
angiogenesis O -
. O +

Activation O +
of O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
3 O +
through O +
a O +
phosphomimetic O +
serine O +
727 O +
promotes O +
prostate O +
tumorigenesis O +
independent O +
of O +
tyrosine O +
705 O +
phosphorylation O -
. O +

Aberrantly O +
activated O +
signal O +
transducer O +
and O +
activator O +
of O +
transcription O +
3 O +
( O -
Stat3 O -
) O +
is O +
implicated O +
in O +
the O +
development O +
of O +
various O +
human O +
cancers O -
. O +

Y705 O +
phosphorylation O +
is O +
conventionally O +
thought O +
to O +
be O +
required O +
for O +
Stat3 O +
signal O -
- O -
dependent O +
activation O +
and O +
seems O +
to O +
play O +
an O +
essential O +
role O +
in O +
some O +
malignancies O -
. O +

Recently O -
, O +
it O +
was O +
shown O +
that O +
Stat3 O +
is O +
activated O +
through O +
novel O +
and O +
noncanonical O +
mechanisms O -
, O +
including O +
phosphorylation O +
at O +
S727 O -
. O +

Here O -
, O +
we O +
investigate O +
S727 O +
phosphorylation O +
of O +
Stat3 O +
and O +
its O +
subsequent O +
effects O +
in O +
prostate O +
cancer O +
development O -
, O +
independent O +
of O +
Y705 O +
phosphorylation O -
, O +
using O +
mutated O +
Stat3 O +
in O +
the O +
human O +
prostate O +
cancer O +
cell O +
line O +
LNCaP. O +
We O +
show O +
mutation O +
of O +
S727 O +
to O +
the O +
phosphomimetic O +
residue O +
Glu O -
, O +
and O +
inactivation O +
of O +
Y705 O +
( O -
Y705F O -
/ O -
S727E O -
) O +
resulted O +
in O +
a O +
remarkable O +
growth O +
advantage O +
in O +
low O -
- O -
serum O -
, O +
enhanced O +
anchorage O -
- O -
independent O +
growth O +
in O +
soft O +
agar O -
, O +
and O +
increased O +
tumorigenicity O +
in O +
nonobese O +
diabetic O -
/ O -
severe O +
combined O +
immunodeficient O +
( O -
NOD O -
/ O -
SCID O -
) O +
mice O -
, O +
possibly O +
by O +
direct O +
activation O +
of O +
downstream O +
proto O -
- O -
oncogenes O +
c O -
- O -
myc O -
, O +
mcl-1 O -
, O +
and O +
survivin O -
. O +

Y705F O -
/ O -
S727E O +
mutant O +
cells O +
were O +
more O +
invasive O +
than O +
Y705F O -
/ O -
S727A O +
( O -
inactivation O +
of O +
Y705 O +
and O +
S727 O -
) O +
mutant O +
cells O -
, O +
and O +
more O +
Y705F O -
/ O -
S727E O +
mutant O +
Stat3 O +
was O +
localized O +
in O +
the O +
nuclei O +
relative O +
to O +
Y705F O -
/ O -
S727A O +
mutant O +
Stat3 O +
at O +
the O +
steady O +
state O -
. O +

Furthermore O -
, O +
the O +
Y705F O -
/ O -
S727E O +
but O +
not O +
the O +
Y705F O -
/ O -
S727A O +
mutant O +
induced O +
anchorage O -
- O -
independent O +
growth O +
of O +
noncancerous O +
prostate O +
epithelial O +
cells O +
( O -
RWPE-1 O -
) O -
. O +

We O +
further O +
show O +
that O +
Stat3 O +
is O +
phosphorylated O +
at O +
S727 O +
in O +
65 O -
% O +
of O +
malignant O +
prostate O +
tissues O +
( O -
n O +
= O +
20 O -
) O +
relative O +
to O +
25 O -
% O +
of O +
normal O +
prostate O +
tissues O +
( O -
n O +
= O +
4 O -
) O -
. O +

Moreover O -
, O +
there O +
is O +
a O +
positive O +
correlation O +
between O +
phosphoS727-Stat3 O +
expression O +
and O +
Gleason O +
score O +
in O +
these O +
prostate O +
cancer O +
tissues O +
( O -
P O +
= O +
0.05 O -
) O -
. O +

Our O +
data O +
suggest O +
for O +
the O +
first O +
time O +
that O +
S727 O +
phosphorylation O +
is O +
sufficient O +
to O +
activate O +
Stat3 O -
, O +
thereby O +
driving O +
prostate O +
tumorigenesis O +
independent O +
of O +
Y705 O +
phosphorylation O -
. O +

Angiogenesis O +
associated O +
with O +
visceral O +
and O +
subcutaneous O +
adipose O +
tissue O +
in O +
severe O +
human O +
obesity O -
. O +

OBJECTIVE O -
: O +
The O +
expansion O +
of O +
adipose O +
tissue O +
is O +
linked O +
to O +
the O +
development O +
of O +
its O +
vasculature O -
. O +

However O -
, O +
the O +
regulation O +
of O +
adipose O +
tissue O +
angiogenesis O +
in O +
humans O +
has O +
not O +
been O +
extensively O +
studied O -
. O +

Our O +
aim O +
was O +
to O +
compare O +
the O +
angiogenesis O +
associated O +
with O +
subcutaneous O +
adipose O +
tissue O +
( O -
SAT O -
) O +
and O +
visceral O +
adipose O +
tissue O +
( O -
VAT O -
) O +
from O +
the O +
same O +
obese O +
patients O +
in O +
an O +
in O +
vivo O +
model O -
. O +

RESEARCH O +
DESIGN O +
AND O +
METHODS O -
: O +
Adipose O +
tissue O +
samples O +
from O +
visceral O +
( O -
VAT O -
) O +
and O +
subcutaneous O +
( O -
SAT O -
) O +
sites O -
, O +
obtained O +
from O +
36 O +
obese O +
patients O +
( O -
mean O +
BMI O +
46.5 O +
kg O -
/ O -
m O -
( O -
2 O -
) O -
) O +
during O +
bariatric O +
surgery O -
, O +
were O +
layered O +
on O +
chick O +
chorioallantoic O +
membrane O +
( O -
CAM O -
) O -
. O +

RESULTS O -
: O +
Both O +
SAT O +
and O +
VAT O +
expressed O +
angiogenic O +
factors O +
without O +
significant O +
difference O +
for O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
expression O -
. O +

Adipose O +
tissue O +
layered O +
on O +
CAM O +
stimulated O +
angiogenesis O -
. O +

Angiogenic O +
stimulation O +
was O +
macroscopically O +
detectable O -
, O +
with O +
engulfment O +
of O +
the O +
samples O -
, O +
in O +
39 O -
% O +
and O +
was O +
evidenced O +
by O +
angiography O +
in O +
59 O -
% O +
of O +
the O +
samples O -
. O +

A O +
connection O +
between O +
CAM O +
and O +
adipose O +
tissue O +
vessels O +
was O +
evidenced O +
by O +
immunohistochemistry O -
, O +
with O +
recruitment O +
of O +
both O +
avian O +
and O +
human O +
endothelial O +
cells O -
. O +

The O +
angiogenic O +
potency O +
of O +
adipose O +
tissue O +
was O +
not O +
related O +
to O +
its O +
localization O +
( O -
with O +
an O +
angiogenic O +
stimulation O +
in O +
60 O -
% O +
of O +
SAT O +
samples O +
and O +
61 O -
% O +
of O +
VAT O +
samples O -
) O +
or O +
to O +
adipocyte O +
size O +
or O +
inflammatory O +
infiltrate O +
assessed O +
in O +
adipose O +
samples O +
before O +
the O +
graft O +
on O +
CAM O -
. O +

Stimulation O +
of O +
angiogenesis O +
by O +
adipose O +
tissue O +
was O +
nearly O +
abolished O +
by O +
bevacizumab B-Chemical -
, O +
which O +
specifically O +
targets O +
human O +
VEGF O -
. O +

CONCLUSIONS O -
: O +
We O +
have O +
established O +
a O +
model O +
to O +
study O +
the O +
regulation O +
of O +
angiogenesis O +
by O +
human O +
adipose O +
tissue O -
. O +

This O +
model O +
highlighted O +
the O +
role O +
of O +
VEGF O +
in O +
angiogenesis O +
in O +
both O +
SAT O +
and O +
VAT O -
. O +

The O +
in O +
vivo O +
properties O +
of O +
STX243 B-Chemical -
: O +
a O +
potent O +
angiogenesis O +
inhibitor O +
in O +
breast O +
cancer O -
. O +

The O +
steroidal O -
- O -
based O +
drug O +
2-ethyloestradiol-3,17-O B-Chemical -
, I-Chemical -
O I-Chemical -
- I-Chemical -
bis I-Chemical -
- I-Chemical -
sulphamate I-Chemical +
( O -
STX243 B-Chemical -
) O +
has O +
been O +
developed O +
as O +
a O +
potent O +
antiangiogenic O +
and O +
antitumour O +
compound O -
. O +

The O +
objective O +
of O +
this O +
study O +
was O +
to O +
ascertain O +
whether O +
STX243 B-Chemical +
is O +
more O +
active O +
in O +
vivo O +
than O +
the O +
clinically O +
relevant O +
drug O +
2-methoxyoestradiol B-Chemical +
( O -
2-MeOE2 B-Chemical -
) O +
and O +
the O +
structurally O +
similar O +
compound O +
2-MeOE2 B-Chemical -
- I-Chemical -
3,17-O I-Chemical -
, I-Chemical -
O I-Chemical -
- I-Chemical -
bis I-Chemical -
- I-Chemical -
sulphamate I-Chemical +
( O -
STX140 B-Chemical -
) O -
. O +

The O +
tumour O +
growth O +
inhibition O +
efficacy O -
, O +
antiangiogenic O +
potential O +
and O +
pharmacokinetics O +
of O +
STX243 B-Chemical +
were O +
examined O +
using O +
four O +
in O +
vivo O +
models O -
. O +

Both O +
STX243 B-Chemical +
and O +
STX140 B-Chemical +
were O +
capable O +
of O +
retarding O +
the O +
growth O +
of O +
MDA O -
- O -
MB-231 O +
xenograft O +
tumours O +
( O -
72 O +
and O +
63 O -
% O -
, O +
respectively O -
) O -
, O +
whereas O +
no O +
inhibition O +
was O +
observed O +
for O +
animals O +
treated O +
with O +
2-MeOE2 B-Chemical -
. O +

Further O +
tumour O +
inhibition O +
studies O +
showed O +
that O +
STX243 B-Chemical +
was O +
also O +
active O +
against O +
MCF-7 O +
paclitaxel B-Chemical -
- O -
resistant O +
tumours O -
. O +

Using O +
a O +
Matrigel O +
plug O -
- O -
based O +
model O -
, O +
in O +
vivo O +
angiogenesis O +
was O +
restricted O +
with O +
STX243 B-Chemical +
and O +
STX140 B-Chemical +
( O -
50 O +
and O +
72 O -
% O -
, O +
respectively O -
, O +
using O +
a O +
10 O +
mg O +
kg O -
( O -
-1 O -
) O +
oral O +
dose O -
) O -
, O +
thereby O +
showing O +
the O +
antiangiogenic O +
activity O +
of O +
both O +
compounds O -
. O +

The O +
pharmacokinetics O +
of O +
STX243 B-Chemical +
were O +
examined O +
at O +
two O +
different O +
doses O +
using O +
adult O +
female O +
rats O -
. O +

The O +
compound O +
was O +
orally O +
bioavailable O +
( O -
31 O -
% O +
after O +
a O +
single O +
10 O +
mg O +
kg O -
( O -
-1 O -
) O +
dose O -
) O +
and O +
resistant O +
to O +
metabolism O -
. O +

These O +
results O +
show O +
that O +
STX243 B-Chemical +
is O +
a O +
potent O +
in O +
vivo O +
drug O +
and O +
could O +
be O +
clinically O +
effective O +
at O +
treating O +
a O +
number O +
of O +
oncological O +
conditions O -
. O +

M O -
- O -
CSF O +
signals O +
through O +
the O +
MAPK O -
/ O -
ERK O +
pathway O +
via O +
Sp1 O +
to O +
induce O +
VEGF O +
production O +
and O +
induces O +
angiogenesis O +
in O +
vivo O -
. O +

BACKGROUND O -
: O +
M O -
- O -
CSF O +
recruits O +
mononuclear O +
phagocytes O +
which O +
regulate O +
processes O +
such O +
as O +
angiogenesis O +
and O +
metastases O +
in O +
tumors O -
. O +

VEGF O +
is O +
a O +
potent O +
activator O +
of O +
angiogenesis O +
as O +
it O +
promotes O +
endothelial O +
cell O +
proliferation O +
and O +
new O +
blood O +
vessel O +
formation O -
. O +

Previously O -
, O +
we O +
reported O +
that O +
in O +
vitro O +
M O -
- O -
CSF O +
induces O +
the O +
expression O +
of O +
biologically O -
- O -
active O +
VEGF O +
from O +
human O +
monocytes O -
. O +

METHODOLOGY O +
AND O +
RESULTS O -
: O +
In O +
this O +
study O -
, O +
we O +
demonstrate O +
the O +
molecular O +
mechanism O +
of O +
M O -
- O -
CSF O -
- O -
induced O +
VEGF O +
production O -
. O +

Using O +
a O +
construct O +
containing O +
the O +
VEGF O +
promoter O +
linked O +
to O +
a O +
luciferase O +
reporter O -
, O +
we O +
found O +
that O +
a O +
mutation O +
reducing O +
HIF O +
binding O +
to O +
the O +
VEGF O +
promoter O +
had O +
no O +
significant O +
effect O +
on O +
luciferase O +
production O +
induced O +
by O +
M O -
- O -
CSF O +
stimulation O -
. O +

Further O +
analysis O +
revealed O +
that O +
M O -
- O -
CSF O +
induced O +
VEGF O +
through O +
the O +
MAPK O -
/ O -
ERK O +
signaling O +
pathway O +
via O +
the O +
transcription O +
factor O -
, O +
Sp1 O -
. O +

Thus O -
, O +
inhibition O +
of O +
either O +
ERK O +
or O +
Sp1 O +
suppressed O +
M O -
- O -
CSF O -
- O -
induced O +
VEGF O +
at O +
the O +
mRNA O +
and O +
protein O +
level O -
. O +

M O -
- O -
CSF O +
also O +
induced O +
the O +
nuclear O +
localization O +
of O +
Sp1 O -
, O +
which O +
was O +
blocked O +
by O +
ERK O +
inhibition O -
. O +

Finally O -
, O +
mutating O +
the O +
Sp1 O +
binding O +
sites O +
within O +
the O +
VEGF O +
promoter O +
or O +
inhibiting O +
ERK O +
decreased O +
VEGF O +
promoter O +
activity O +
in O +
M O -
- O -
CSF O -
- O -
treated O +
human O +
monocytes O -
. O +

To O +
evaluate O +
the O +
biological O +
significance O +
of O +
M O -
- O -
CSF O +
induced O +
VEGF O +
production O -
, O +
we O +
used O +
an O +
in O +
vivo O +
angiogenesis O +
model O +
to O +
illustrate O +
the O +
ability O +
of O +
M O -
- O -
CSF O +
to O +
recruit O +
mononuclear O +
phagocytes O -
, O +
increase O +
VEGF O +
levels O -
, O +
and O +
enhance O +
angiogenesis O -
. O +

Importantly O -
, O +
the O +
addition O +
of O +
a O +
neutralizing O +
VEGF O +
antibody O +
abolished O +
M O -
- O -
CSF O -
- O -
induced O +
blood O +
vessel O +
formation O -
. O +

CONCLUSION O -
: O +
These O +
data O +
delineate O +
an O +
ERK- O +
and O +
Sp1-dependent O +
mechanism O +
of O +
M O -
- O -
CSF O +
induced O +
VEGF O +
production O +
and O +
demonstrate O +
for O +
the O +
first O +
time O +
the O +
ability O +
of O +
M O -
- O -
CSF O +
to O +
induce O +
angiogenesis O +
via O +
VEGF O +
in O +
vivo O -
. O +

[ O -
Retinochoroidopathy O +
after O +
intravitreal O +
anti O -
- O -
VEGF O +
treatment O -
] O +
A O +
74-year O -
- O -
old O +
man O +
presented O +
with O +
persistent O +
metamorphopsias O +
of O +
the O +
right O +
eye O +
2 O +
weeks O +
after O +
intravitreal O +
injection O +
of O +
bevacizumab B-Chemical +
to O +
treat O +
choroidal O +
neovascularization O +
due O +
to O +
exudative O +
age O -
- O -
related O +
macular O +
degeneration O -
. O +

The O +
diagnosis O +
reached O +
was O +
retinochoroiditis O +
as O +
an O +
occult O +
manifestation O +
of O +
sarcoidosis O -
, O +
possibly O +
resulting O +
from O +
an O +
intravitreal O +
injection O +
of O +
bevacizumab B-Chemical -
. O +

The O +
patient O +
received O +
a O +
prescription O +
for O +
100 O +
mg O +
Ultralan B-Chemical +
to O +
be O +
taken O +
daily O +
for O +
3 O +
days O +
and O +
then O +
tapered O +
in O +
3 O +
day O +
steps O -
. O +

During O +
the O +
further O +
course O +
no O +
deterioration O +
of O +
the O +
condition O +
was O +
observed O -
. O +

Silencing O +
of O +
directional O +
migration O +
in O +
roundabout4 O +
knockdown O +
endothelial O +
cells O -
. O +

BACKGROUND O -
: O +
Roundabouts O +
are O +
axon O +
guidance O +
molecules O +
that O +
have O +
recently O +
been O +
identified O +
to O +
play O +
a O +
role O +
in O +
vascular O +
guidance O +
as O +
well O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
investigated O +
gene O +
knockdown O +
analysis O +
of O +
endothelial O +
Robos O -
, O +
in O +
particular O +
roundabout O +
4 O +
( O -
robo4 O -
) O -
, O +
the O +
predominant O +
Robo O +
in O +
endothelial O +
cells O +
using O +
small O +
interfering O +
RNA O +
technology O +
in O +
vitro O -
. O +

RESULTS O -
: O +
Robo1 O +
and O +
Robo4 O +
knockdown O +
cells O +
display O +
distinct O +
activity O +
in O +
endothelial O +
cell O +
migration O +
assay O -
. O +

The O +
knockdown O +
of O +
robo4 O +
abrogated O +
the O +
chemotactic O +
response O +
of O +
endothelial O +
cells O +
to O +
serum O +
but O +
enhanced O +
a O +
chemokinetic O +
response O +
to O +
Slit2 O -
, O +
while O +
robo1 O +
knockdown O +
cells O +
do O +
not O +
display O +
chemotactic O +
response O +
to O +
serum O +
or O +
VEGF O -
. O +

Robo4 O +
knockdown O +
endothelial O +
cells O +
unexpectedly O +
show O +
up O +
regulation O +
of O +
Rho O +
GTPases O -
. O +

Zebrafish O +
Robo4 O +
rescues O +
both O +
Rho O +
GTPase O +
homeostasis O +
and O +
serum O +
reduced O +
chemotaxis O +
in O +
robo4 O +
knockdown O +
cells O -
. O +

Robo1 O +
and O +
Robo4 O +
interact O +
and O +
share O +
molecules O +
such O +
as O +
Slit2 O -
, O +
Mena O +
and O +
Vilse O -
, O +
a O +
Cdc42-GAP O -
. O +

In O +
addition O -
, O +
this O +
study O +
mechanistically O +
implicates O +
IRSp53 O +
in O +
the O +
signaling O +
nexus O +
between O +
activated O +
Cdc42 O +
and O +
Mena O -
, O +
both O +
of O +
which O +
have O +
previously O +
been O +
shown O +
to O +
be O +
involved O +
with O +
Robo4 O +
signaling O +
in O +
endothelial O +
cells O -
. O +

CONCLUSION O -
: O +
This O +
study O +
identifies O +
specific O +
components O +
of O +
the O +
Robo O +
signaling O +
apparatus O +
that O +
work O +
together O +
to O +
guide O +
directional O +
migration O +
of O +
endothelial O +
cells O -
. O +

Effect O +
of O +
transplanted O +
mesenchymal O +
stem O +
cells O +
from O +
rats O +
of O +
different O +
ages O +
on O +
the O +
improvement O +
of O +
heart O +
function O +
after O +
acute O +
myocardial O +
infarction O -
. O +

BACKGROUND O -
: O +
Mesenchymal O +
stem O +
cells O +
( O -
MSCs O -
) O +
transplantation O +
is O +
of O +
therapeutic O +
potential O +
after O +
ischemic O +
injury O +
in O +
both O +
experimental O +
and O +
clinical O +
studies O -
. O +

Clinically O -
, O +
elderly O +
patients O +
are O +
more O +
vulnerable O +
to O +
acute O +
myocardial O +
infarction O +
( O -
AMI O -
) O -
. O +

But O +
little O +
is O +
known O +
about O +
the O +
characteristics O +
of O +
young O +
donor O -
- O -
derived O +
MSCs O +
transplanted O +
to O +
old O +
patients O +
with O +
AMI O -
. O +

The O +
present O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
effect O +
of O +
transplanted O +
MSCs O +
from O +
rats O +
of O +
different O +
ages O +
on O +
the O +
improvement O +
of O +
heart O +
function O +
after O +
AMI O -
. O +

METHODS O -
: O +
MSCs O +
from O +
Sprague O -
- O -
Dawley O +
( O -
SD O -
) O +
rats O +
were O +
isolated O +
and O +
cultured O +
in O +
vitro O -
. O +

The O +
apoptosis O +
characteristics O +
of O +
MSCs O +
were O +
observed O +
under O +
conditions O +
of O +
ischemia O +
and O +
anoxia O -
. O +

SD O +
rats O +
underwent O +
MI O +
received O +
intramyocardial O +
injection O +
of O +
MSCs O +
from O +
young O +
donor O +
rats O +
( O -
n O +
= O +
8) O -
, O +
old O +
donor O +
rats O +
( O -
n O +
= O +
8) O -
, O +
respectively O -
. O +

AMI O +
control O +
group O +
received O +
equal O +
volume O +
physiological O +
saline O -
. O +

Immunofluorescence O +
was O +
used O +
to O +
observe O +
the O +
differentiation O +
of O +
the O +
grafted O +
cells O +
into O +
cardiomyocytes O -
. O +

Four O +
weeks O +
after O +
cell O +
transplantation O -
, O +
reverse O +
transcriptase O -
- O -
polymerase O +
chain O +
reaction O +
( O -
RT O -
- O -
PCR O -
) O +
and O +
immunohistochemistry O +
for O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
, O +
VIII O -
- O -
factor O +
immunohistochemistry O +
for O +
vessel O +
density O -
, O +
TUNEL O -
, O +
caspase-3 O +
for O +
cardiomyocyte O +
apoptosis O -
, O +
echocardiography O +
and O +
hemodynamic O +
detection O +
for O +
heart O +
function O +
were O +
performed O -
. O +

RESULTS O -
: O +
The O +
apoptosis O +
rate O +
of O +
the O +
old O +
donor O -
- O -
derived O +
MSCs O +
group O +
was O +
significantly O +
higher O +
than O +
that O +
of O +
the O +
young O +
donor O -
- O -
derived O +
MSCs O +
group O +
under O +
conditions O +
of O +
ischemia O +
and O +
anoxia O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O +

Engrafted O +
MSCs O +
survived O -
, O +
proliferated O +
and O +
differentiated O +
into O +
myocardium O -
- O -
like O +
cells O -
. O +

VEGF O +
gene O +
expression O +
and O +
capillary O +
density O +
in O +
the O +
old O +
donor O -
- O -
derived O +
group O +
were O +
lower O +
than O +
those O +
in O +
the O +
young O +
donor O -
- O -
derived O +
group O +
but O +
higher O +
than O +
those O +
in O +
the O +
control O +
group O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O +

The O +
transplantation O +
of O +
old O +
donor O -
- O -
derived O +
MSCs O +
attenuated O +
apoptosis O +
of O +
cardiomyocytes O +
in O +
the O +
peri O -
- O -
infarct O +
region O +
compared O +
with O +
the O +
control O +
group O +
and O +
the O +
effect O +
was O +
elevated O +
in O +
young O +
donor O -
- O -
derived O +
MSCs O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O +

The O +
heart O +
functions O +
( O -
left O +
ventricle O +
ejection O +
fraction O +
( O -
LVEF O -
) O -
, O +
left O +
ventricle O +
fractional O +
shortening O +
( O -
LVFS O -
) O -
) O +
were O +
improved O +
more O +
significantly O +
in O +
the O +
old O +
donor O -
- O -
derived O +
MSCs O +
group O +
than O +
in O +
the O +
control O +
group O +
and O +
the O +
heart O +
function O +
in O +
the O +
young O +
donor O -
- O -
derived O +
MSCs O +
group O +
further O +
improved O +
( O -
P O +
less O +
than O +
0.05 O -
) O -
. O +

CONCLUSIONS O -
: O +
Young O +
donor O -
- O -
derived O +
MSCs O +
can O +
improve O +
heart O +
function O +
significantly O +
through O +
angiogenesis O +
and O +
decreasing O +
cardiomyocyte O +
apoptosis O +
when O +
transplanted O +
to O +
the O +
infarcted O +
area O -
. O +

Homeostatic O +
functions O +
of O +
the O +
p53 O +
tumor O +
suppressor O -
: O +
regulation O +
of O +
energy O +
metabolism O +
and O +
antioxidant O +
defense O -
. O +

The O +
p53 O +
tumor O +
suppressor O +
plays O +
pivotal O +
role O +
in O +
the O +
organism O +
by O +
supervising O +
strict O +
compliance O +
of O +
individual O +
cells O +
to O +
needs O +
of O +
the O +
whole O +
organisms O -
. O +

It O +
has O +
been O +
widely O +
accepted O +
that O +
p53 O +
acts O +
in O +
response O +
to O +
stresses O +
and O +
abnormalities O +
in O +
cell O +
physiology O +
by O +
mobilizing O +
the O +
repair O +
processes O +
or O +
by O +
removing O +
the O +
diseased O +
cells O +
through O +
initiating O +
the O +
cell O +
death O +
programs O -
. O +

Recent O +
studies O -
, O +
however O -
, O +
indicate O +
that O +
even O +
under O +
normal O +
physiological O +
conditions O +
certain O +
activities O +
of O +
p53 O +
participate O +
in O +
homeostatic O +
regulation O +
of O +
metabolic O +
processes O +
and O +
that O +
these O +
activities O +
are O +
important O +
for O +
prevention O +
of O +
cancer O -
. O +

These O +
novel O +
functions O +
of O +
p53 O +
help O +
to O +
align O +
metabolic O +
processes O +
with O +
the O +
proliferation O +
and O +
energy O +
status O -
, O +
to O +
maintain O +
optimal O +
mode O +
of O +
glucose B-Chemical +
metabolism O +
and O +
to O +
boost O +
the O +
energy O +
efficient O +
mitochondrial O +
respiration O +
in O +
response O +
to O +
ATP B-Chemical +
deficiency O -
. O +

Additional O +
activities O +
of O +
p53 O +
in O +
non O -
- O -
stressed O +
cells O +
tune O +
up O +
the O +
antioxidant O +
defense O +
mechanisms O +
reducing O +
the O +
probability O +
of O +
mutations O +
caused O +
by O +
DNA O +
oxidation O +
under O +
conditions O +
of O +
daily O +
stresses O -
. O +

The O +
deficiency O +
in O +
the O +
p53-mediated O +
regulation O +
of O +
glycolysis O +
and O +
mitochondrial O +
respiration O +
greatly O +
accounts O +
for O +
the O +
deficient O +
respiration O +
of O +
the O +
predominance O +
of O +
aerobic O +
glycolysis O +
in O +
cancer O +
cells O +
( O -
the O +
Warburg O +
effect O -
) O -
, O +
while O +
the O +
deficiency O +
in O +
the O +
p53-modulated O +
antioxidant O +
defense O +
mechanisms O +
contributes O +
to O +
mutagenesis O +
and O +
additionally O +
boosts O +
the O +
carcinogenesis O +
process O -
. O +

Estradiol B-Chemical +
increases O +
IL-8 O +
secretion O +
of O +
normal O +
human O +
breast O +
tissue O +
and O +
breast O +
cancer O +
in O +
vivo O -
. O +

IL-8 O +
or O +
CXCL8 O +
has O +
been O +
associated O +
with O +
tumor O +
angiogenesis O -
, O +
metastasis O -
, O +
and O +
poor O +
prognosis O +
in O +
breast O +
cancer O -
. O +

Estrogen B-Chemical +
is O +
crucial O +
in O +
breast O +
carcinogenesis O +
and O +
tumor O +
progression O -
. O +

Whether O +
sex O +
steroids O +
affect O +
IL-8 O +
secretion O +
of O +
normal O +
breast O +
tissue O +
or O +
breast O +
cancer O +
is O +
not O +
known O -
. O +

Several O +
cell O +
types O +
in O +
a O +
tissue O +
secrete O +
IL-8 O -
. O +

Hence O -
, O +
regulatory O +
mechanisms O +
of O +
IL-8 O +
need O +
to O +
be O +
investigated O +
in O +
whole O +
tissue O -
. O +

We O +
used O +
microdialysis O +
to O +
sample O +
IL-8 O +
in O +
normal O +
human O +
breast O +
tissue O +
in O +
situ O +
in O +
pre- O +
and O +
postmenopausal O +
women O -
, O +
preoperatively O +
in O +
breast O +
cancers O +
of O +
women O -
, O +
and O +
in O +
experimental O +
breast O +
cancer O +
in O +
mice O -
. O +

We O +
found O +
a O +
significant O +
positive O +
correlation O +
between O +
IL-8 O +
and O +
estradiol B-Chemical +
in O +
normal O +
breast O +
tissue O +
and O +
hormone O -
- O -
dependent O +
breast O +
cancer O +
in O +
vivo O -
. O +

Ex O +
vivo O -
, O +
estradiol B-Chemical +
exposure O +
increased O +
the O +
IL-8 O +
secretion O +
of O +
normal O +
whole O +
breast O +
tissue O +
in O +
culture O -
. O +

In O +
experimental O +
breast O +
cancer O -
, O +
estradiol B-Chemical +
increased O +
IL-8 O +
whereas O +
the O +
anti O -
- O -
estrogen B-Chemical +
tamoxifen B-Chemical +
inhibited O +
the O +
secretion O +
of O +
IL-8 O +
both O +
in O +
vitro O +
and O +
extracellularly O +
in O +
vivo O +
in O +
tumors O +
of O +
nude O +
mice O -
. O +

An O +
anti B-Chemical -
- I-Chemical -
IL-8 I-Chemical +
Ab I-Chemical +
inhibited O +
endothelial O +
cell O +
proliferation O +
induced O +
by O +
cancer O +
cell O +
produced O +
IL-8 O +
and O +
tumors O +
with O +
low O +
IL-8 O +
levels O +
exhibited O +
decreased O +
angiogenesis O -
. O +

Our O +
results O +
strongly O +
suggest O +
that O +
estradiol B-Chemical +
has O +
a O +
critical O +
role O +
in O +
the O +
regulation O +
of O +
IL-8 O +
in O +
normal O +
human O +
breast O +
tissue O +
and O +
human O +
breast O +
cancer O -
. O +

IL-8 O +
may O +
present O +
a O +
novel O +
therapeutic O +
target O +
for O +
estrogen B-Chemical +
driven O +
breast O +
carcinogenesis O +
and O +
tumor O +
progression O -
. O +

Grape O +
seed O +
extract O +
inhibits O +
angiogenesis O +
via O +
suppression O +
of O +
the O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
signaling O +
pathway O -
. O +

Blockade O +
of O +
angiogenesis O +
is O +
an O +
important O +
approach O +
for O +
cancer O +
treatment O +
and O +
prevention O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
is O +
one O +
of O +
the O +
most O +
critical O +
factors O +
that O +
induce O +
angiogenesis O +
and O +
has O +
thus O +
become O +
an O +
attractive O +
target O +
for O +
antiangiogenesis O +
treatment O -
. O +

However O -
, O +
most O +
current O +
anti O -
- O -
VEGF O +
agents O +
often O +
cause O +
some O +
side O +
effects O +
when O +
given O +
chronically O -
. O +

Identification O +
of O +
naturally O +
occurring O +
VEGF O +
inhibitors O +
derived O +
from O +
diet O +
would O +
be O +
one O +
alternative O +
approach O +
with O +
an O +
advantage O +
of O +
known O +
safety O -
. O +

Grape O +
seed O +
extract O +
( O -
GSE O -
) O -
, O +
a O +
widely O +
used O +
dietary O +
supplement O -
, O +
is O +
known O +
to O +
have O +
antitumor O +
activity O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
explored O +
the O +
activity O +
of O +
GSE O +
on O +
VEGF O +
receptor O +
and O +
angiogenesis O -
. O +

We O +
found O +
that O +
GSE O +
could O +
directly O +
inhibit O +
the O +
kinase O +
activity O +
of O +
purified O +
VEGF O +
receptor O +
2 O -
, O +
a O +
novel O +
activity O +
of O +
GSE O +
that O +
has O +
not O +
been O +
characterized O -
. O +

GSE O +
could O +
also O +
inhibit O +
the O +
VEGF O +
receptor O -
/ O -
mitogen O -
- O -
activated O +
protein O +
kinase O -
- O -
mediated O +
signaling O +
pathway O +
in O +
endothelial O +
cells O -
. O +

As O +
a O +
result O -
, O +
GSE O +
could O +
inhibit O +
VEGF O -
- O -
induced O +
endothelial O +
cell O +
proliferation O +
and O +
migration O +
as O +
well O +
as O +
sprout O +
formation O +
from O +
aorta O +
ring O -
. O +

In O +
vivo O +
assay O +
further O +
showed O +
that O +
GSE O +
could O +
inhibit O +
tumor O +
growth O +
and O +
tumor O +
angiogenesis O +
of O +
MDA O -
- O -
MB-231 O +
breast O +
cancer O +
cells O +
in O +
mice O -
. O +

Consistent O +
with O +
the O +
in O +
vitro O +
data O -
, O +
GSE O +
treatment O +
of O +
tumor O -
- O -
bearing O +
mice O +
led O +
to O +
concomitant O +
reduction O +
of O +
blood O +
vessel O +
density O +
and O +
phosphorylation O +
of O +
mitogen O -
- O -
activated O +
protein O +
kinase O -
. O +

Depletion O +
of O +
polyphenol B-Chemical +
with O +
polyvinylpyrrolidone B-Chemical +
abolished O +
the O +
antiangiogenic O +
activity O +
of O +
GSE O -
, O +
suggesting O +
a O +
water O -
- O -
soluble O +
fraction O +
of O +
polyphenol B-Chemical +
in O +
GSE O +
is O +
responsible O +
for O +
the O +
antiangiogenic O +
activity O -
. O +

Taken O +
together O -
, O +
this O +
study O +
indicates O +
that O +
GSE O +
is O +
a O +
well O -
- O -
tolerated O +
and O +
inexpensive O +
natural O +
VEGF O +
inhibitor O +
and O +
could O +
potentially O +
be O +
useful O +
in O +
cancer O +
prevention O +
or O +
treatment O -
. O +

Chemokine O +
receptor O +
CXCR4 O +
expression O -
, O +
function O -
, O +
and O +
clinical O +
implications O +
in O +
gastric O +
cancer O -
. O +

The O +
chemokine O +
receptor O +
CXCR4 O +
is O +
associated O +
with O +
the O +
biological O +
behavior O +
of O +
cancer O -
, O +
but O +
few O +
studies O +
have O +
addressed O +
the O +
expression O +
and O +
function O +
of O +
CXCR4 O +
in O +
human O +
gastric O +
cancer O +
and O +
its O +
impact O +
on O +
disease O +
prognosis O -
. O +

We O +
studied O +
the O +
expression O +
of O +
CXCR4 O +
using O +
RT O -
- O -
PCR O -
, O +
Western O +
blotting O -
, O +
flow O +
cytometry O -
, O +
and O +
confocal O +
microscopy O +
in O +
five O +
gastric O +
cancer O +
cell O +
lines O -
. O +

We O +
also O +
examined O +
cell O +
proliferation O -
, O +
migration O -
, O +
and O +
anti O -
- O -
apoptotic O +
activity O +
in O +
response O +
to O +
stromal O +
cell O -
- O -
derived O +
factor O +
( O -
SDF O -
) O -
-1alpha O +
and O +
evaluated O +
SDF-1alpha O -
/ O -
CXCR4 O +
signaling O +
pathways O -
. O +

Furthermore O -
, O +
we O +
investigated O +
the O +
correlation O +
between O +
CXCR4 O +
expression O +
and O +
the O +
clinical O +
features O +
of O +
221 O +
gastric O +
cancer O +
tissue O +
samples O -
. O +

CXCR4 O +
transcripts O +
and O +
proteins O +
were O +
detectable O +
in O +
all O +
five O +
gastric O +
cancer O +
cell O +
lines O -
. O +

However O -
, O +
MKN-28 O -
, O +
MKN-45 O -
, O +
MKN-74 O -
, O +
and O +
SNU16 O +
cells O +
did O +
not O +
express O +
membrane O +
CXCR4 O -
. O +

In O +
contrast O -
, O +
KATO O +
III O +
cells O +
expressed O +
membrane O +
CXCR4 O -
. O +

In O +
these O +
cells O -
, O +
SDF-1alpha O -
- O -
induced O +
migration O +
was O +
observed O +
and O +
was O +
blocked O +
by O +
AMD3100 B-Chemical -
, O +
a O +
specific O +
inhibitor O +
of O +
CXCR4 O -
. O +

SDF-1alpha O +
induced O +
rapid O +
phosphorylation O +
of O +
Erk1 O -
/ O -
2 O +
MAPK O +
but O +
did O +
not O +
promote O +
phosphorylation O +
of O +
Stat3 O +
or O +
Akt O -
. O +

Gastric O +
cancer O +
tissue O +
samples O +
expressed O +
CXCR4 O +
with O +
variable O +
intensities O -
. O +

Strong O +
CXCR4 O +
expression O +
was O +
significantly O +
associated O +
with O +
lymph O +
node O +
metastases O +
( O -
P=0.028 O -
) O +
and O +
higher O +
stages O +
III O -
/ O -
IV O +
( O -
P=0.047 O -
) O -
, O +
and O +
further O +
tended O +
to O +
be O +
correlated O +
with O +
a O +
reduced O +
5-year O +
survival O +
rate O +
( O -
42.6 O -
% O +
vs. O +
53.9 O -
% O -
; O +
P=0.1 O -
) O -
. O +

In O +
conclusion O -
, O +
CXCR4 O +
expression O +
is O +
associated O +
with O +
gastric O +
cancer O +
cell O +
migration O +
in O +
vitro O -
, O +
and O +
strong O +
expression O +
of O +
CXCR4 O +
by O +
gastric O +
cancer O +
cells O +
is O +
significantly O +
associated O +
with O +
lymphatic O +
metastasis O +
in O +
patients O +
with O +
gastric O +
cancer O -
, O +
suggesting O +
that O +
CXCR4 O +
plays O +
an O +
important O +
role O +
during O +
gastric O +
cancer O +
progression O -
. O +

Effect O +
of O +
estrogen B-Chemical +
and O +
progesterone B-Chemical +
on O +
macrophage O +
activation O +
during O +
wound O +
healing O -
. O +

Age O -
- O -
related O +
impaired O +
wound O +
healing O +
leads O +
to O +
substantial O +
morbidity O +
and O +
mortality O +
along O +
with O +
a O +
large O +
financial O +
burden O +
to O +
health O +
services O -
. O +

There O +
is O +
accumulating O +
evidence O +
that O +
the O +
tissue O +
damage O +
associated O +
with O +
chronic O +
wounds O +
is O +
initiated O +
and O +
propagated O +
by O +
an O +
inappropriately O +
excessive O +
inflammatory O +
response O -
. O +

Research O +
on O +
age O -
- O -
related O +
impaired O +
wound O +
healing O +
suggests O +
that O +
the O +
decline O +
in O +
sex B-Chemical +
steroid I-Chemical +
hormones I-Chemical +
with O +
age O +
may O +
have O +
a O +
substantial O +
influence O +
on O +
the O +
inflammatory O +
response O +
in O +
vivo O -
. O +

Topical O +
and O +
systemic O +
estrogen B-Chemical +
treatments O +
have O +
shown O +
an O +
increased O +
rate O +
of O +
healing O +
by O +
reducing O +
inflammation O -
, O +
however O +
the O +
underlying O +
mechanisms O +
are O +
little O +
understood O -
. O +

In O +
vitro O +
studies O +
also O +
suggest O +
progesterone B-Chemical +
may O +
play O +
a O +
role O +
in O +
modulating O +
inflammation O -
. O +

Macrophages O +
are O +
essential O +
mediators O +
of O +
inflammation O +
and O +
wound O +
healing O -
. O +

Macrophages O +
can O +
be O +
activated O +
in O +
a O +
classical O +
or O +
alternative O +
manner O +
in O +
parallel O +
with O +
the O +
T O -
( O -
H O -
) O -
1 O -
/ O -
T O -
( O -
H O -
) O -
2 O +
dichotomy O -
, O +
respectively O -
. O +

Using O +
a O +
murine O +
incisional O +
wound O +
healing O +
model O +
this O +
study O +
was O +
carried O +
out O +
to O +
investigate O +
the O +
roles O +
of O +
estrogen B-Chemical +
and O +
progesterone B-Chemical +
on O +
macrophage O +
activation O +
during O +
the O +
wound O +
healing O +
response O -
. O +

Our O +
findings O +
suggest O +
with O +
a O +
reduction O +
of O +
steroid B-Chemical +
hormones I-Chemical +
following O +
ovariectomy O -
, O +
alternatively O +
activated O +
macrophage O +
markers O +
( O -
Fizz1 O +
and O +
Ym1 O -
) O +
were O +
reduced O -
, O +
with O +
this O +
effect O +
being O +
reversed O +
with O +
the O +
administration O +
of O +
estrogen B-Chemical +
or O +
progesterone B-Chemical -
; O +
suggesting O +
that O +
with O +
the O +
reduction O +
of O +
steroid B-Chemical +
hormones I-Chemical +
macrophages O +
are O +
activated O +
in O +
a O +
classical O +
manner O -
, O +
promoting O +
inflammation O -
, O +
whereas O +
estrogen B-Chemical +
or O +
progesterone B-Chemical +
are O +
contributing O +
toward O +
macrophage O +
activation O +
in O +
an O +
alternative O +
manner O -
, O +
driving O +
wound O +
repair O -
, O +
angiogenesis O -
, O +
and O +
remodeling O -
. O +

Liposomal O +
honokiol B-Chemical +
inhibits O +
VEGF O -
- O -
D O -
- O -
induced O +
lymphangiogenesis O +
and O +
metastasis O +
in O +
xenograft O +
tumor O +
model O -
. O +

Lymph O +
nodes O +
metastasis O +
of O +
tumor O +
could O +
be O +
a O +
crucial O +
early O +
step O +
in O +
the O +
metastatic O +
process O -
. O +

Induction O +
of O +
tumor O +
lymphangiogenesis O +
by O +
vascular O +
endothelial O +
growth O +
factor O -
- O -
D O +
may O +
play O +
an O +
important O +
role O +
in O +
promoting O +
tumor O +
metastasis O +
to O +
regional O +
lymph O +
nodes O +
and O +
these O +
processes O +
can O +
be O +
inhibited O +
by O +
inactivation O +
of O +
the O +
VEGFR-3 O +
signaling O +
pathway O -
. O +

Honokiol B-Chemical +
has O +
been O +
reported O +
to O +
possess O +
potent O +
antiangiogenesis O +
and O +
antitumor O +
properties O +
in O +
several O +
cell O +
lines O +
and O +
xenograft O +
tumor O +
models O -
. O +

However O -
, O +
its O +
role O +
in O +
tumor O -
- O -
associated O +
lymphangiogenesis O +
and O +
lymphatic O +
metastasis O +
remains O +
unclear O -
. O +

Here O -
, O +
we O +
established O +
lymph O +
node O +
metastasis O +
models O +
by O +
injecting O +
overexpressing O +
VEGF O -
- O -
D O +
Lewis O +
lung O +
carcinoma O +
cells O +
into O +
C57BL O -
/ O -
6 O +
mice O +
to O +
explore O +
the O +
effect O +
of O +
honokiol B-Chemical +
on O +
tumor O -
- O -
associated O +
lymphangiogenesis O +
and O +
related O +
lymph O +
node O +
metastasis O -
. O +

The O +
underlying O +
mechanisms O +
were O +
systematically O +
investigated O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

In O +
in O +
vivo O +
study O -
, O +
liposomal O +
honokiol B-Chemical +
significantly O +
inhibited O +
the O +
tumor O -
- O -
associated O +
lymphangiogenesis O +
and O +
metastasis O +
in O +
Lewis O +
lung O +
carcinoma O +
model O -
. O +

A O +
remarkable O +
delay O +
of O +
tumor O +
growth O +
and O +
prolonged O +
life O +
span O +
were O +
also O +
observed O -
. O +

In O +
in O +
vitro O +
study O -
, O +
honokiol B-Chemical +
inhibited O +
VEGF O -
- O -
D O -
- O -
induced O +
survival O -
, O +
proliferation O +
and O +
tube O -
- O -
formation O +
of O +
both O +
human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O -
HUVECs O -
) O +
and O +
lymphatic O +
vascular O +
endothelial O +
cells O +
( O -
HLECs O -
) O -
. O +

Western O +
blotting O +
analysis O +
showed O +
that O +
liposomal O +
honokiol B-Chemical -
- O -
inhibited O +
Akt O +
and O +
MAPK O +
phosphorylation O +
in O +
2 O +
endothelial O +
cells O -
, O +
and O +
downregulated O +
expressions O +
of O +
VEGFR-2 O +
of O +
human O +
vascular O +
endothelial O +
cells O +
and O +
VEGFR-3 O +
of O +
lymphatic O +
endothelial O +
cells O -
. O +

Thus O -
, O +
we O +
identified O +
for O +
the O +
first O +
time O +
that O +
honokiol B-Chemical +
provided O +
therapeutic O +
benefit O +
not O +
only O +
by O +
direct O +
effects O +
on O +
tumor O +
cells O +
and O +
antiangiogenesis O +
but O +
also O +
by O +
inhibiting O +
lymphangiogenesis O +
and O +
metastasis O +
via O +
the O +
VEGFR-3 O +
pathway O -
. O +

The O +
present O +
findings O +
may O +
be O +
of O +
importance O +
to O +
investigate O +
the O +
molecular O +
mechanisms O +
underlying O +
the O +
spread O +
of O +
cancer O +
via O +
the O +
lymphatics O +
and O +
explore O +
the O +
therapeutical O +
strategy O +
of O +
honokiol B-Chemical +
on O +
antilymphangiogenesis O +
and O +
antimetastasis O -
. O +

Short O +
pigment O +
epithelial O -
- O -
derived O +
factor O -
- O -
derived O +
peptide O +
inhibits O +
angiogenesis O +
and O +
tumor O +
growth O -
. O +

PURPOSE O -
: O +
Pigment O +
epithelial O -
- O -
derived O +
factor O +
( O -
PEDF O -
) O +
is O +
a O +
potent O +
angiogenesis O +
inhibitor O +
with O +
multiple O +
other O +
functions O -
, O +
some O +
of O +
which O +
enhance O +
tumor O +
growth O -
. O +

Our O +
previous O +
studies O +
mapped O +
PEDF O +
antiangiogenic O +
and O +
prosurvival O +
activities O +
to O +
distinct O +
epitopes O -
. O +

This O +
study O +
was O +
aimed O +
to O +
determine O +
the O +
minimal O +
fragment O +
of O +
PEDF O -
, O +
which O +
maintains O +
antiangiogenic O +
and O +
antitumor O +
efficacy O -
. O +

EXPERIMENTAL O +
DESIGN O -
: O +
We O +
analyzed O +
antigenicity O -
, O +
hydrophilicity O -
, O +
and O +
charge O +
distribution O +
of O +
the O +
angioinhibitory O +
epitope O +
( O -
the O +
34-mer O -
) O +
and O +
designed O +
three O +
peptides O +
covering O +
its O +
COOH O +
terminus O -
, O +
P14 O -
, O +
P18 O -
, O +
and O +
P23 O -
. O +

We O +
analyzed O +
their O +
ability O +
to O +
block O +
endothelial O +
cell O +
chemotaxis O +
and O +
induce O +
apoptosis O +
in O +
vitro O +
and O +
their O +
antiangiogenic O +
activity O +
in O +
vivo O -
. O +

The O +
selected O +
peptide O +
was O +
tested O +
for O +
the O +
antitumor O +
activity O +
against O +
mildly O +
aggressive O +
xenografted O +
prostate O +
carcinoma O +
and O +
highly O +
aggressive O +
renal O +
cell O +
carcinoma O -
. O +

To O +
verify O +
that O +
P18 O +
acts O +
in O +
the O +
same O +
manner O +
as O +
PEDF O -
, O +
we O +
used O +
immunohistochemistry O +
to O +
measure O +
PEDF O +
targets O -
, O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
2 O -
, O +
and O +
CD95 O +
ligand O +
expression O +
in O +
P18-treated O +
vasculature O -
. O +

RESULTS O -
: O +
P14 O +
and O +
P18 O +
blocked O +
endothelial O +
cell O +
chemotaxis O -
; O +
P18 O +
and O +
P23 O +
induced O +
apoptosis O -
. O +

P18 O +
showed O +
the O +
highest O +
IC50 O +
and O +
blocked O +
angiogenesis O +
in O +
vivo O -
: O +
P23 O +
was O +
inactive O +
and O +
P14 O +
was O +
proangiogenic O -
. O +

P18 O +
increased O +
the O +
production O +
of O +
CD95 O +
ligand O +
and O +
reduced O +
the O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
2 O +
by O +
the O +
endothelial O +
cells O +
in O +
vivo O -
. O +

In O +
tumor O +
studies O -
, O +
P18 O +
was O +
more O +
effective O +
in O +
blocking O +
the O +
angiogenesis O +
and O +
growth O +
of O +
the O +
prostate O +
cancer O +
than O +
parental O +
34-mer O -
; O +
in O +
the O +
renal O +
cell O +
carcinoma O -
, O +
P18 O +
strongly O +
decreased O +
angiogenesis O +
and O +
halted O +
the O +
progression O +
of O +
established O +
tumors O -
. O +

CONCLUSIONS O -
: O +
P18 O +
is O +
a O +
novel O +
and O +
potent O +
antiangiogenic O +
biotherapeutic O +
agent O +
that O +
has O +
potential O +
to O +
be O +
developed O +
for O +
the O +
treatment O +
of O +
prostate O +
and O +
renal O +
cancer O -
. O +

Aflibercept B-Chemical +
( O -
AVE0005 B-Chemical -
) O -
: O +
an O +
alternative O +
strategy O +
for O +
inhibiting O +
tumour O +
angiogenesis O +
by O +
vascular O +
endothelial O +
growth O +
factors O -
. O +

BACKGROUND O -
: O +
Aberrant O +
angiogenesis O +
is O +
a O +
landmark O +
feature O +
in O +
cancer O -
, O +
which O +
is O +
important O +
for O +
proliferation O -
, O +
growth O +
and O +
metastasis O -
, O +
and O +
is O +
mediated O +
by O +
various O +
pro O -
- O -
angiogenic O +
factors O -
. O +

The O +
VEGF O +
pathway O +
is O +
one O +
of O +
the O +
most O +
important O +
and O +
best O -
- O -
studied O +
angiogenic O +
pathways O -
. O +

Inhibition O +
of O +
this O +
pathway O +
may O +
provide O +
clinical O +
benefits O +
to O +
cancer O +
patients O -
. O +

OBJECTIVES O -
: O +
Strategies O +
to O +
inhibit O +
the O +
VEGF O +
pathway O -
, O +
including O +
antibodies O +
to O +
VEGF O -
, O +
antibodies O +
to O +
the O +
extracellular O +
domain O +
of O +
VEGFR-1 O +
or O +
VEGFR-2 O -
, O +
decoy O +
receptors O +
for O +
VEGF O +
and O +
tyrosine B-Chemical +
kinase I-Chemical +
inhibitors I-Chemical +
of O +
VEGFRs O -
, O +
are O +
summarized O -
. O +

METHODS O -
: O +
This O +
review O +
outlines O +
and O +
compares O +
the O +
latest O +
development O +
of O +
these O +
strategies O -
, O +
with O +
emphasis O +
on O +
aflibercept B-Chemical -
, O +
a O +
novel O +
decoy O +
fusion O +
protein O +
of O +
domain O +
2 O +
of O +
VEGFR-1 O +
and O +
domain O +
3 O +
of O +
VEGFR-2 O +
with O +
the O +
Fc O +
fragment O +
of O +
IgG1 O -
. O +

RESULTS O -
: O +
Aflibercept B-Chemical +
was O +
shown O +
to O +
have O +
early O +
clinical O +
activity O -
. O +

Multiple O +
studies O +
are O +
ongoing O +
to O +
determine O +
the O +
clinical O +
benefits O +
of O +
aflibercept B-Chemical +
in O +
cancer O +
patients O -
. O +

The O +
effect O +
of O +
perfluorocarbon B-Chemical -
- O -
based O +
artificial O +
oxygen B-Chemical +
carriers O +
on O +
tissue O -
- O -
engineered O +
trachea O -
. O +

The O +
biological O +
effect O +
of O +
the O +
perfluorocarbon B-Chemical -
- O -
based O +
artificial O +
oxygen B-Chemical +
carrier O +
( O -
Oxygent B-Chemical -
) O +
was O +
investigated O +
in O +
tissue O -
- O -
engineered O +
trachea O +
( O -
TET O -
) O +
construction O -
. O +

Media O +
supplemented O +
with O +
and O +
without O +
10 O -
% O +
Oxygent B-Chemical +
were O +
compared O +
in O +
all O +
assessments O -
. O +

Partial O +
tissue O +
oxygen B-Chemical +
tension O +
( O -
PtO O -
( O -
2 O -
) O -
) O +
was O +
measured O +
with O +
polarographic O +
microprobes O -
; O +
epithelial O +
metabolism O +
was O +
monitored O +
by O +
microdialysis O +
inside O +
the O +
TET O +
epithelium O +
perfused O +
with O +
the O +
medium O +
underneath O -
. O +

Chondrocyte O -
- O -
DegraPol O +
constructs O +
were O +
cultured O +
for O +
1 O +
month O +
with O +
the O +
medium O +
before O +
glycosaminoglycan B-Chemical +
assessment O +
and O +
histology O -
. O +

Tissue O +
reaction O +
of O +
TET O +
epithelial O +
scaffolds O +
immersed O +
with O +
the O +
medium O +
was O +
evaluated O +
on O +
the O +
chick O +
embryo O +
chorioallantoic O +
membrane O -
. O +

Oxygent B-Chemical +
perfusion O +
medium O +
increased O +
the O +
TET O +
epithelial O +
PtO O -
( O -
2 O -
) O +
( O -
51.2 O +
+ O -
/- O +

0.3 O +
mm O +
Hg O +
vs. O +
33.4 O +
+ O -
/- O +

0.3 O +
mm O +
Hg O +
at O +
200 O +
microm O +
thickness O -
; O +
12.5 O +
+ O -
/- O +

0.1 O +
mm O +
Hg O +
vs. O +
3.1 O +
+ O -
/- O +

0.1 O +
mm O +
Hg O +
at O +
400 O +
microm O +
thickness O -
, O +
p O +
less O +
than O +
0.01 O -
) O +
and O +
decreased O +
the O +
lactate B-Chemical +
concentration O +
( O -
0.63 O +
+ O -
/- O +
0.08 O +
vs. O +
0.80 O +
+ O -
/- O +

0.06 O +
mmol O -
/ O -
L O -
, O +
p O +
less O +
than O +
0.05 O -
) O -
, O +
lactate B-Chemical -
/ O -
pyruvate B-Chemical +
( O -
1.87 O +
+ O -
/- O +
0.26 O +
vs. O +
3.36 O +
+ O -
/- O +

10.13 O -
, O +
p O +
less O +
than O +
0.05 O -
) O -
, O +
and O +
lactate B-Chemical -
/ O -
glucose B-Chemical +
ratios O +
( O -
0.10 O +
+ O -
/- O +

0.00 O +
vs. O +
0.29 O +
+ O -
/- O +

0.14 O -
, O +
p O +
less O +
than O +
0.05 O -
) O -
. O +

Chondrocyte O -
- O -
DegraPol O +
in O +
Oxygent B-Chemical +
group O +
presented O +
lower O +
glycosaminoglycan B-Chemical +
value O +
( O -
0.03 O +
+ O -
/- O +

0.00 O +
vs. O +
0.13 O +
+ O -
/- O +

0.00 O -
, O +
p O +
less O +
than O +
0.05 O -
) O -
; O +
histology O +
slides O +
showed O +
poor O +
acid O +
mucopolysaccharides B-Chemical +
formation O -
. O +

Orthogonal O +
polarization O +
spectral O +
imaging O +
showed O +
no O +
difference O +
in O +
functional O +
capillary O +
density O +
between O +
the O +
scaffolds O +
cultured O +
on O +
chorioallantoic O +
membranes O -
. O +

The O +
foreign O +
body O +
reaction O +
was O +
similar O +
in O +
both O +
groups O -
. O +

We O +
conclude O +
that O +
Oxygent B-Chemical +
increases O +
TET O +
epithelial O +
PtO O -
( O -
2 O -
) O -
, O +
improves O +
epithelial O +
metabolism O -
, O +
does O +
not O +
impair O +
angiogenesis O -
, O +
and O +
tends O +
to O +
slow O +
cartilage O +
tissue O +
formation O -
. O +

Distinct O +
role O +
of O +
PLCbeta3 O +
in O +
VEGF O -
- O -
mediated O +
directional O +
migration O +
and O +
vascular O +
sprouting O -
. O +

Endothelial O +
cell O +
proliferation O +
and O +
migration O +
is O +
essential O +
to O +
angiogenesis O -
. O +

Typically O -
, O +
proliferation O +
and O +
chemotaxis O +
of O +
endothelial O +
cells O +
is O +
driven O +
by O +
growth O +
factors O +
such O +
as O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
and O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
) O -
. O +

VEGF O +
activates O +
phospholipases O +
( O -
PLCs O -
) O +
- O +
specifically O +
PLCgamma1 O +
- O +
that O +
are O +
important O +
for O +
tubulogenesis O -
, O +
differentiation O +
and O +
DNA O +
synthesis O -
. O +

However O -
, O +
we O +
show O +
here O +
that O +
VEGF O -
, O +
specifically O +
through O +
VEGFR2 O -
, O +
induces O +
phosphorylation O +
of O +
two O +
serine O +
residues O +
on O +
PLCbeta3 O -
, O +
and O +
this O +
was O +
confirmed O +
in O +
an O +
ex O +
vivo O +
embryoid O +
body O +
model O -
. O +

Knockdown O +
of O +
PLCbeta3 O +
in O +
HUVEC O +
cells O +
affects O +
IP3 O +
production O -
, O +
actin O +
reorganization O -
, O +
migration O +
and O +
proliferation O -
; O +
whereas O +
migration O +
is O +
inhibited O -
, O +
proliferation O +
is O +
enhanced O -
. O +

Our O +
data O +
suggest O +
that O +
enhanced O +
proliferation O +
is O +
precipitated O +
by O +
an O +
accelerated O +
cell O +
cycle O -
, O +
and O +
decreased O +
migration O +
by O +
an O +
inability O +
to O +
activate O +
CDC42 O -
. O +

Given O +
that O +
PLCbeta3 O +
is O +
typically O +
known O +
as O +
an O +
effector O +
of O +
heterotrimeric O +
G O -
- O -
proteins O -
, O +
our O +
data O +
demonstrate O +
a O +
unique O +
crosstalk O +
between O +
the O +
G O -
- O -
protein O +
and O +
receptor O +
tyrosine O +
kinase O +
( O -
RTK O -
) O +
axes O +
and O +
reveal O +
a O +
novel O +
molecular O +
mechanism O +
of O +
VEGF O +
signaling O +
and O -
, O +
thus O -
, O +
angiogenesis O -
. O +

The O +
semaphorin O +
7A O +
receptor O +
Plexin O +
C1 O +
is O +
lost O +
during O +
melanoma O +
metastasis O -
. O +

The O +
transformation O +
of O +
normal O +
melanocytes O -
, O +
or O +
melanocyte O +
stem O +
cells O -
, O +
to O +
melanoma O -
, O +
is O +
a O +
complex O +
process O +
involving O +
multiple O +
mechanisms O -
. O +

Loss O +
of O +
tumor O +
suppressor O +
proteins O -
, O +
which O +
function O +
as O +
brakes O +
on O +
cell O +
growth O -
, O +
migration O -
, O +
or O +
cell O +
survival O -
, O +
was O +
recognized O +
early O +
on O +
as O +
an O +
important O +
mechanism O +
for O +
initiation O +
and O +
progression O +
of O +
melanoma O -
. O +

Semaphorins O +
and O +
their O +
cognate O +
receptors O -
, O +
Plexins O +
and O +
neuropilins O -
, O +
are O +
involved O +
in O +
neuronal O +
pathfinding O -
, O +
immune O +
function O -
, O +
and O +
tumor O +
progression O +
through O +
effects O +
on O +
blood O +
vessel O +
growth O +
and O +
cell O +
migration O -
. O +

Semaphorin O +
7A O +
( O -
Sema7A O -
) O +
is O +
a O +
membrane O -
- O -
linked O +
semaphorin O +
that O +
is O +
expressed O +
by O +
human O +
keratinocytes O -
, O +
and O +
we O +
have O +
shown O +
that O +
Sema7A O +
binds O +
to O +
human O +
melanocytes O +
through O +
beta1-integrins O +
and O +
the O +
Plexin O +
C1 O +
receptor O -
. O +

Functional O +
studies O +
showed O +
that O +
Sema7A O +
stimulates O +
cytoskeletal O +
reorganization O +
in O +
human O +
melanocytes O -
, O +
resulting O +
in O +
adhesion O +
and O +
dendrite O +
formation O -
. O +

Downstream O +
targets O +
of O +
Plexin O +
C1 O +
signaling O +
in O +
human O +
melanocytes O +
include O +
cofilin O +
and O +
LIM O +
kinase O +
II O -
, O +
both O +
of O +
which O +
are O +
critical O +
mediators O +
of O +
cell O +
adhesion O +
and O +
migration O -
. O +

In O +
this O +
report O -
, O +
we O +
analyzed O +
the O +
expression O +
of O +
Plexin O +
C1 O +
using O +
immunohistochemistry O +
on O +
sections O +
of O +
primary O +
and O +
matched O +
metastatic O +
lesions O +
from O +
19 O +
subjects O +
and O +
in O +
a O +
large O +
melanoma O +
tumor O +
microarray O -
. O +

Our O +
data O +
show O +
a O +
significant O +
loss O +
of O +
Plexin O +
C1 O +
in O +
metastatic O +
melanoma O +
compared O +
with O +
primary O +
melanoma O -
, O +
suggesting O +
the O +
possibility O +
that O +
the O +
Plexin O +
C1 O +
receptor O +
is O +
a O +
tumor O +
suppressor O +
protein O +
for O +
melanoma O -
. O +

Coagulation O +
function O +
in O +
patients O +
with O +
pancreatic O +
carcinoma O -
. O +

BACKGROUND O -
: O +
The O +
coagulation O +
function O +
in O +
patients O +
with O +
pancreatic O +
carcinoma O +
is O +
abnormal O +
and O +
the O +
reason O +
is O +
not O +
very O +
clear O -
. O +

In O +
this O +
study O -
, O +
we O +
retrospectively O +
analyzed O +
the O +
coagulation O +
function O +
in O +
patients O +
with O +
pancreatic O +
carcinoma O -
. O +

METHODS O -
: O +
From O +
June O +
2004 O +
to O +
December O +
2007 O -
, O +
132 O +
patients O +
received O +
diagnosis O +
and O +
treatment O +
in O +
our O +
hospital O -
. O +

The O +
coagulative O +
parameters O +
including O +
the O +
prothrombin O +
time O -
, O +
activated O +
partial O +
thromboplastin O +
time O -
, O +
and O +
fibrinogen O +
levels O +
were O +
collected O +
and O +
studied O +
retrospectively O -
. O +

RESULTS O -
: O +
The O +
average O +
fibrinogen O +
levels O +
in O +
patients O +
with O +
pancreatic O +
carcinoma O -
, O +
( O -
476.21 O +
+ O -
/- O +

142.05 O -
) O +
mg O -
/ O -
dl O -
, O +
were O +
significantly O +
higher O +
than O +
in O +
patients O +
with O +
cholangiolithiasis O -
, O +
( O -
403.28 O +
+ O -
/- O +

126.41 O -
) O +
mg O -
/ O -
dl O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

In O +
patients O +
with O +
pancreatic O +
carcinoma O -
, O +
the O +
levels O +
of O +
fibrinogen O +
in O +
the O +
group O +
with O +
jaundice O +
were O +
significantly O +
higher O +
than O +
in O +
patients O +
without O +
jaundice O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

In O +
patients O +
who O +
received O +
Pancreaticoduodenectomy O -
, O +
Whipple O -
's O +
operation O -
, O +
the O +
level O +
of O +
fibrinogen O +
in O +
the O +
group O +
with O +
local O +
invasiveness O +
was O +
significantly O +
higher O +
than O +
in O +
the O +
group O +
without O +
invasiveness O -
. O +

The O +
group O +
with O +
lymphatic O +
metastasis O +
had O +
higher O +
levels O +
than O +
the O +
group O +
without O +
lymphatic O +
metastasis O +
( O -
P O +
< O +
0.05 O -
) O -
. O +

There O +
was O +
no O +
significant O +
difference O +
of O +
intraoperative O +
blood O +
loss O +
between O +
patients O +
with O +
vitamin B-Chemical +
K I-Chemical -
, O +
( O -
748.27 O +
+ O -
/- O +

448.51 O -
) O +
ml O -
, O +
and O +
those O +
without O +
vitamin B-Chemical +
K I-Chemical -
, O +
( O -
767.31 O +
+ O -
/- O +

547.89 O -
) O +
ml O +
( O -
P O +
> O +
0.05 O -
) O -
. O +

CONCLUSIONS O -
: O +
The O +
level O +
of O +
fibrinogen O +
in O +
patients O +
with O +
pancreatic O +
carcinoma O +
was O +
elevated O -
. O +

The O +
elevated O +
fibrinogen O +
level O +
may O +
be O +
associated O +
with O +
invasiveness O +
and O +
lymphatic O +
metastasis O -
. O +

Using O +
vitamin B-Chemical +
K I-Chemical +
in O +
perioperation O +
management O +
did O +
not O +
reduce O +
intraoperative O +
blood O +
loss O -
. O +

Role O +
of O +
the O +
interferon O -
- O -
inducible O +
IFI16 O +
gene O +
in O +
the O +
induction O +
of O +
ICAM-1 O +
by O +
TNF O -
- O -
alpha O -
. O +

The O +
Interferon O -
- O -
inducible O +
gene O +
IFI16 O -
, O +
a O +
member O +
of O +
the O +
HIN200 O +
family O -
, O +
is O +
activated O +
by O +
oxidative O +
stress O +
and O +
cell O +
density O -
, O +
in O +
addition O +
to O +
Interferons O -
, O +
and O +
it O +
is O +
implicated O +
in O +
the O +
regulation O +
of O +
endothelial O +
cell O +
proliferation O +
and O +
vessel O +
formation O +
in O +
vitro O -
. O +

We O +
have O +
previously O +
shown O +
that O +
IFI16 O +
is O +
required O +
for O +
proinflammatory O +
gene O +
stimulation O +
by O +
IFN O -
- O -
gamma O +
through O +
the O +
NF O -
- O -
kappaB O +
complex O -
. O +

To O +
examine O +
whether O +
IFI16 O +
induction O +
might O +
be O +
extended O +
to O +
other O +
proinflammatory O +
cytokines O +
such O +
as O +
tumor O +
necrosis O +
factor O +
( O -
TNF O -
) O -
-alpha O -
, O +
we O +
used O +
the O +
strategy O +
of O +
the O +
RNA O +
interference O +
to O +
knock O +
down O +
IFI16 O +
expression O -
, O +
and O +
analyze O +
the O +
capability O +
of O +
TNF O -
- O -
alpha O +
to O +
stimulate O +
intercellular O +
adhesion O +
molecule-1 O +
( O -
ICAM-1 O +
or O +
CD54 O -
) O +
expression O +
in O +
the O +
absence O +
of O +
functional O +
IFI16 O -
. O +

Our O +
studies O +
demonstrate O +
that O +
IFI16 O +
mediates O +
ICAM-1 O +
stimulation O +
by O +
TNF O -
- O -
alpha O +
through O +
the O +
NF O -
- O -
kappaB O +
pathway O -
, O +
thus O +
reinforcing O +
the O +
role O +
of O +
the O +
IFI16 O +
molecule O +
in O +
the O +
inflammation O +
process O -
. O +

Molecular O +
analysis O +
of O +
genetic O +
instability O +
caused O +
by O +
chronic O +
inflammation O -
. O +

Genetic O +
instability O +
is O +
a O +
hallmark O +
of O +
human O +
cancers O -
. O +

It O +
is O +
the O +
driving O +
force O +
for O +
tumor O +
development O +
as O +
it O +
facilitates O +
the O +
accumulation O +
of O +
mutations O +
in O +
genes O +
that O +
regulate O +
cell O +
death O +
and O +
proliferation O +
and O +
therefore O +
promotes O +
malignant O +
transformation O -
. O +

Chronic O +
inflammation O +
is O +
a O +
common O +
underlying O +
condition O +
for O +
human O +
tumor O +
development O -
, O +
accounting O +
for O +
approximately O +
20 O -
% O +
of O +
human O +
cancers O -
. O +

TNFalpha O +
is O +
an O +
important O +
inflammation O +
cytokine O +
and O +
is O +
crucial O +
to O +
the O +
development O +
of O +
inflammation O -
- O -
associated O +
cancers O -
. O +

We O +
have O +
shown O +
that O +
TNFalpha O +
can O +
cause O +
DNA O +
damages O +
through O +
reactive B-Chemical +
oxygen I-Chemical +
species I-Chemical +
( O -
ROS B-Chemical -
) O -
. O +

TNFalpha O +
treatment O +
in O +
cultured O +
cells O +
resulted O +
in O +
increased O +
gene O +
mutations O -
, O +
gene O +
amplification O -
, O +
micronuclei O +
formation O +
and O +
chromosomal O +
instability O -
. O +

Antioxidants O +
significantly O +
reduced O +
TNFalpha O -
- O -
induced O +
genetic O +
damage O -
. O +

In O +
addition O -
, O +
TNFalpha O +
treatment O +
alone O +
led O +
to O +
increased O +
malignant O +
transformation O +
of O +
mouse O +
embryo O +
fibroblasts O -
, O +
which O +
could O +
be O +
partially O +
suppressed O +
by O +
antioxidants O -
. O +

Therefore O -
, O +
genetic O +
instability O +
plays O +
an O +
important O +
role O +
in O +
inflammation O -
- O -
associated O +
cancers O -
. O +

Antivascular O +
actions O +
of O +
microtubule B-Chemical -
- I-Chemical -
binding I-Chemical +
drugs I-Chemical -
. O +

Microtubule B-Chemical -
- I-Chemical -
binding I-Chemical +
drugs I-Chemical +
( O -
MBD B-Chemical -
) O +
are O +
widely O +
used O +
in O +
cancer O +
chemotherapy O +
and O +
also O +
have O +
clinically O +
relevant O +
antiangiogenic O +
and O +
vascular O -
- O -
disrupting O +
properties O -
. O +

These O +
antivascular O +
actions O +
are O +
due O +
in O +
part O +
to O +
direct O +
effects O +
on O +
endothelial O +
cells O -
, O +
and O +
all O +
MBDs B-Chemical +
( O -
both O +
microtubule O -
- O -
stabilizing O +
and O +
microtubule O -
- O -
destabilizing O -
) O +
inhibit O +
endothelial O +
cell O +
proliferation O -
, O +
migration O -
, O +
and O +
tube O +
formation O +
in O +
vitro O -
, O +
actions O +
that O +
are O +
thought O +
to O +
correspond O +
to O +
therapeutic O +
antiangiogenic O +
actions O -
. O +

In O +
addition O -
, O +
the O +
microtubule B-Chemical -
- I-Chemical -
destabilizing I-Chemical +
agents I-Chemical +
cause O +
prominent O +
changes O +
in O +
endothelial O +
cell O +
morphology O -
, O +
an O +
action O +
associated O +
with O +
rapid O +
vascular O +
collapse O +
in O +
vivo O -
. O +

The O +
effects O +
on O +
endothelial O +
cells O +
occur O +
in O +
vitro O +
at O +
low O +
drug O +
concentrations O -
, O +
which O +
do O +
not O +
affect O +
microtubule O +
gross O +
morphology O -
, O +
do O +
not O +
cause O +
microtubule O +
bundling O +
or O +
microtubule O +
loss O +
and O +
do O +
not O +
induce O +
cell O +
cycle O +
arrest O -
, O +
apoptosis O -
, O +
or O +
cell O +
death O -
. O +

Rather O -
, O +
it O +
has O +
been O +
hypothesized O +
that O -
, O +
at O +
low O +
concentrations O -
, O +
MBDs B-Chemical +
produce O +
more O +
subtle O +
effects O +
on O +
microtubule O +
dynamics O -
, O +
block O +
critical O +
cell O +
signaling O +
pathways O -
, O +
and O +
prevent O +
the O +
microtubules O +
from O +
properly O +
interacting O +
with O +
transient O +
subcellular O +
assemblies O +
( O -
focal O +
adhesions O +
and O +
adherens O +
junctions O -
) O +
whose O +
subsequent O +
stabilization O +
and/or O +
maturation O +
are O +
required O +
for O +
cell O +
motility O +
and O +
cell O -
- O -
cell O +
interactions O -
. O +

This O +
review O +
will O +
focus O +
on O +
recent O +
studies O +
to O +
define O +
the O +
molecular O +
mechanisms O +
for O +
the O +
antivascular O +
actions O +
of O +
the O +
MBDs B-Chemical -
, O +
information O +
that O +
could O +
be O +
useful O +
in O +
the O +
identification O +
or O +
design O +
of O +
agents O +
whose O +
actions O +
more O +
selectively O +
target O +
the O +
tumor O +
vasculature O -
. O +

Neurovascular O +
effects O +
of O +
CD47 O +
signaling O -
: O +
promotion O +
of O +
cell O +
death O -
, O +
inflammation O -
, O +
and O +
suppression O +
of O +
angiogenesis O +
in O +
brain O +
endothelial O +
cells O +
in O +
vitro O -
. O +

The O +
concept O +
of O +
the O +
neurovascular O +
unit O +
emphasizes O +
that O +
common O +
signals O +
and O +
substrates O +
underlie O +
the O +
physiology O +
and O +
pathophysiology O +
of O +
neuronal O +
and O +
endothelial O +
compartments O +
in O +
brain O -
. O +

Recent O +
data O +
suggest O +
that O +
activation O +
of O +
the O +
integrin O -
- O -
associated O +
protein O +
CD47 O +
promotes O +
neuronal O +
cell O +
death O -
. O +

Is O +
it O +
possible O +
that O +
CD47 O +
may O +
also O +
negatively O +
affect O +
cerebral O +
endothelial O +
cells O -
? O +

Exposure O +
of O +
wild O -
- O -
type O +
primary O +
mouse O +
cerebral O +
endothelial O +
cells O +
to O +
the O +
CD47 O +
ligand O +
thrombospondin O +
1 O +
( O -
TSP-1 O -
) O +
induced O +
an O +
increasing O +
amount O +
of O +
cell O +
death O -
, O +
whereas O +
cytotoxicity O +
was O +
significantly O +
decreased O +
in O +
cerebral O +
endothelial O +
cells O +
derived O +
from O +
CD47 O +
knockout O +
mice O -
. O +

The O +
specific O +
CD47-activating O +
peptide O -
, O +
4N1 O -
K O -
, O +
similarly O +
induced O +
cell O +
death O +
in O +
human O +
brain O +
microvascular O +
endothelial O +
cells O -
. O +

Promotion O +
of O +
inflammation O +
was O +
also O +
involved O +
because O +
lower O +
TSP-1 O +
was O +
able O +
to O +
up O -
- O -
regulate O +
the O +
adhesion O +
molecules O +
intercellular O +
adhesion O +
molecule-1 O +
and O +
vascular O +
cell O +
adhesion O +
molecule-1 O -
. O +

Finally O -
, O +
CD47 O +
signaling O +
may O +
suppress O +
angiogenesis O +
because O +
4N1 O -
K O +
significantly O +
inhibited O +
endothelial O +
cell O +
migration O +
and O +
tube O +
formation O +
in O +
vitro O -
. O +

We O +
conclude O +
that O +
CD47 O +
signaling O +
can O +
negatively O +
affect O +
the O +
viability O +
and O +
function O +
of O +
cerebral O +
endothelial O +
cells O -
, O +
further O +
supporting O +
the O +
notion O +
that O +
CD47 O +
may O +
be O +
a O +
potential O +
neurovascular O +
target O +
for O +
stroke O +
and O +
brain O +
injury O -
. O +

Erbb2 O +
suppresses O +
DNA O +
damage O -
- O -
induced O +
checkpoint O +
activation O +
and O +
UV O -
- O -
induced O +
mouse O +
skin O +
tumorigenesis O -
. O +

The O +
Erbb2 O +
receptor O +
is O +
activated O +
by O +
UV O +
irradiation O -
, O +
the O +
primary O +
cause O +
of O +
non O -
- O -
melanoma O +
skin O +
cancer O -
. O +

We O +
hypothesized O +
that O +
Erbb2 O +
activation O +
contributes O +
to O +
UV O -
- O -
induced O +
skin O +
tumorigenesis O +
by O +
suppressing O +
cell O +
cycle O +
arrest O -
. O +

Consistent O +
with O +
this O +
hypothesis O -
, O +
inhibition O +
of O +
Erbb2 O +
in O +
v O -
- O -
ras O -
( O -
Ha O -
) O +
transgenic O +
mice O +
before O +
UV O +
exposure O +
resulted O +
in O +
both O +
56 O -
% O +
fewer O +
skin O +
tumors O +
and O +
tumors O +
that O +
were O +
70 O -
% O +
smaller O -
. O +

Inhibition O +
of O +
the O +
UV O -
- O -
induced O +
activation O +
of O +
Erbb2 O +
also O +
resulted O +
in O +
milder O +
epidermal O +
hyperplasia O -
, O +
S O -
- O -
phase O +
accumulation O -
, O +
and O +
decreased O +
levels O +
of O +
the O +
cell O +
cycle O +
regulator O +
Cdc25a O -
, O +
suggesting O +
altered O +
cell O +
cycle O +
regulation O +
on O +
inhibition O +
of O +
Erbb2 O -
. O +

Further O +
investigation O +
using O +
inhibition O +
or O +
genetic O +
deletion O +
of O +
Erbb2 O +
in O +
vitro O +
revealed O +
reduced O +
Cdc25a O +
levels O +
and O +
increased O +
S O -
- O -
phase O +
arrest O +
in O +
UV O -
- O -
irradiated O +
cells O +
lacking O +
Erbb2 O +
activity O -
. O +

Ectopic O +
expression O +
of O +
Cdc25a O +
prevented O +
UV O -
- O -
induced O +
S O -
- O -
phase O +
arrest O +
in O +
keratinocytes O +
lacking O +
Erbb2 O +
activity O -
, O +
demonstrating O +
that O +
maintenance O +
of O +
Cdc25a O +
by O +
Erbb2 O +
suppresses O +
cell O +
cycle O +
arrest O -
. O +

Examination O +
of O +
checkpoint O +
pathway O +
activation O +
upstream O +
of O +
Cdc25a O +
revealed O +
Erbb2 O +
activation O +
did O +
not O +
alter O +
Ataxia O +
Telangiectasia O +
and O +
Rad3-related O -
/ O -
Ataxia O +
Telangiectasia O +
Mutated O +
activity O +
but O +
increased O +
inhibitory O +
phosphorylation O +
of O +
Chk1-Ser O -
( O -
280 O -
) O -
. O +

Since O +
Akt O +
phosphorylates O +
Chk1-Ser O -
( O -
280 O -
) O -
, O +
the O +
effect O +
of O +
Erbb2 O +
on O +
phosphatidyl O +
inositol-3-kinase O +
( O -
PI3K O -
) O -
/ O -
Akt O +
signaling O +
during O +
UV O -
- O -
induced O +
cell O +
cycle O +
arrest O +
was O +
determined O -
. O +

Erbb2 O +
ablation O +
reduced O +
the O +
UV O -
- O -
induced O +
activation O +
of O +
PI3 O -
K O +
while O +
inhibition O +
of O +
PI3K O -
/ O -
Akt O +
increased O +
UV O -
- O -
induced O +
S O -
- O -
phase O +
arrest O -
. O +

Thus O -
, O +
UV O -
- O -
induced O +
Erbb2 O +
activation O +
increases O +
skin O +
tumorigenesis O +
through O +
inhibitory O +
phosphorylation O +
of O +
Chk1 O -
, O +
Cdc25a O +
maintenance O -
, O +
and O +
suppression O +
of O +
S O -
- O -
phase O +
arrest O +
via O +
a O +
PI3K O -
/ O -
Akt O -
- O -
dependent O +
mechanism O -
. O +

Met O +
amplification O +
and O +
tumor O +
progression O +
in O +
Cdkn2a O -
- O -
deficient O +
melanocytes O -
. O +

While O +
many O +
genetic O +
alterations O +
have O +
been O +
identified O +
in O +
melanoma O -
, O +
the O +
relevant O +
molecular O +
events O +
that O +
contribute O +
to O +
disease O +
progression O +
are O +
poorly O +
understood O -
. O +

Most O +
primary O +
human O +
melanomas O +
exhibit O +
loss O +
of O +
expression O +
of O +
the O +
CDKN2A O +
locus O +
in O +
addition O +
to O +
activation O +
of O +
the O +
canonical O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
signaling O +
pathway O -
. O +

In O +
this O +
study O -
, O +
we O +
used O +
a O +
Cdkn2a O -
- O -
deficient O +
mouse O +
melanocyte O +
cell O +
line O +
to O +
screen O +
for O +
secondary O +
genetic O +
events O +
in O +
melanoma O +
tumor O +
progression O -
. O +

Upon O +
investigation O -
, O +
intrachromosomal O +
gene O +
amplification O +
of O +
Met O -
, O +
a O +
receptor O +
tyrosine O +
kinase O +
implicated O +
in O +
melanoma O +
progression O -
, O +
was O +
identified O +
in O +
Cdkn2a O -
- O -
deficient O +
tumors O -
. O +

RNA O +
interference O +
targeting O +
Met O +
in O +
these O +
tumor O +
cells O +
resulted O +
in O +
a O +
significant O +
delay O +
in O +
tumor O +
growth O +
in O +
vivo O +
compared O +
with O +
the O +
control O +
cells O -
. O +

MET O +
expression O +
is O +
rarely O +
detected O +
in O +
primary O +
human O +
melanoma O +
but O +
is O +
frequently O +
observed O +
in O +
metastatic O +
disease O -
. O +

This O +
study O +
validates O +
a O +
role O +
for O +
Met O +
activation O +
in O +
melanoma O +
tumor O +
progression O +
in O +
the O +
context O +
of O +
Cdkn2a O +
deficiency O -
. O +

Activated O +
platelets O +
enhance O +
ovarian O +
cancer O +
cell O +
invasion O +
in O +
a O +
cellular O +
model O +
of O +
metastasis O -
. O +

Increased O +
platelet O +
counts O +
and O +
systemic O +
coagulation O +
activation O +
are O +
associated O +
with O +
ovarian O +
cancer O +
progression O -
. O +

Platelet O +
activation O +
occurs O +
in O +
the O +
tumor O +
microenvironment O +
and O +
may O +
influence O +
local O +
invasion O +
and O +
metastasis O -
. O +

We O +
used O +
a O +
cellular O +
model O +
of O +
tumor O +
invasion O +
to O +
investigate O +
the O +
effect O +
of O +
activated O +
platelets O +
on O +
the O +
human O +
ovarian O +
cancer O +
cell O +
line O -
, O +
SKOV3 O -
. O +

SKOV3 O +
cells O +
were O +
exposed O +
to O +
washed O -
, O +
thrombin O +
receptor O +
activating O +
peptide O +
( O -
TRAP O -
) O -
-activated O +
or O +
TRAP O -
- O -
naive O +
platelets O +
under O +
various O +
experimental O +
conditions O -
, O +
and O +
tumor O +
cell O +
invasion O +
was O +
assayed O +
in O +
Matrigel O +
chambers O -
. O +

The O +
effect O +
of O +
platelets O +
on O +
the O +
content O +
of O +
urokinase O +
plasminogen O +
activator O +
( O -
uPA O -
) O +
and O +
VEGF O +
in O +
SKOV3 O +
cell O +
conditioned O +
medium O +
was O +
measured O +
using O +
an O +
ELISA O +
assay O -
. O +

TRAP O -
- O -
activated O +
platelets O +
stimulated O +
a O +
dose O -
- O -
dependent O +
increase O +
in O +
SKOV3 O +
cell O +
invasion O -
. O +

Exposure O +
to O +
activated O +
platelet O +
membranes O +
and O +
to O +
soluble O +
proteins O +
contained O +
in O +
activated O +
platelet O +
releasate O +
both O +
contributed O +
to O +
the O +
observed O +
increase O +
in O +
invasion O -
. O +

The O +
inhibition O +
of O +
platelet O +
activation O +
with O +
prostaglandin B-Chemical +
E1 I-Chemical +
( O -
PGE B-Chemical -
( I-Chemical -
1 I-Chemical -
) I-Chemical -
) O +
attenuated O +
the O +
invasive O +
capacity O +
of O +
SKOV3 O +
cells O -
. O +

Exposure O +
to O +
platelets O +
resulted O +
in O +
significantly O +
increased O +
uPA O +
and O +
VEGF O +
content O +
of O +
SKOV3 O +
cell O +
conditioned O +
medium O -
. O +

Activated O +
platelets O +
enhance O +
SKOV3 O +
human O +
ovarian O +
cancer O +
cell O +
invasion O +
through O +
Matrigel O +
and O +
increase O +
the O +
amount O +
of O +
uPA O +
and O +
VEGF O +
secreted O +
into O +
SKOV3 O +
cell O +
conditioned O +
medium O -
. O +

If O +
generalizable O +
to O +
additional O +
cell O +
lines O +
and O +
human O +
disease O -
, O +
this O +
observation O +
may O +
partially O +
explain O +
the O +
adverse O +
prognosis O +
associated O +
with O +
thrombocytosis O +
in O +
ovarian O +
cancer O -
. O +

Platelets O -
, O +
therefore O -
, O +
may O +
represent O +
a O +
potential O +
target O +
for O +
therapeutic O +
intervention O +
in O +
human O +
ovarian O +
cancer O -
. O +

Cisplatin B-Chemical +
reduces O +
endothelial O +
cell O +
migration O +
via O +
regulation O +
of O +
type O +
2-matrix O +
metalloproteinase O +
activity O -
. O +

AIMS O -
: O +
In O +
this O +
study O +
we O +
investigated O +
the O +
effect O +
of O +
cisplatin B-Chemical +
on O +
endothelial O +
cell O +
migration O -
, O +
an O +
essential O +
process O +
for O +
vascular O +
remodeling O +
and O +
regeneration O +
in O +
several O +
physiological O +
and O +
pathological O +
situations O -
. O +

MATERIAL O +
AND O +
METHODS O -
: O +
Human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O -
HUVEC O -
) O +
were O +
treated O +
with O +
cisplatin B-Chemical +
and O +
endothelial O +
cell O +
migration O +
analyzed O +
by O +
fluorescence O +
and O +
scratch O -
- O -
wound O +
migration O +
assay O -
. O +

MMP2 O +
and O +
MMP9 O +
activity O +
were O +
determined O +
by O +
zymographic O +
assay O -
, O +
and O +
MAPK O +
activation O +
by O +
Western O +
blotting O +
analysis O -
. O +

RESULTS O -
: O +
We O +
demonstrated O +
that O +
cisplatin B-Chemical +
provoked O +
a O +
time- O +
and O +
dose O -
- O -
dependent O +
decrease O +
of O +
HUVEC O +
migration O -
; O +
this O +
effect O +
was O +
clearly O +
independent O +
from O +
its O +
well O +
known O +
cytotoxic O +
activity O -
. O +

In O +
addition O -
, O +
cisplatin B-Chemical +
markedly O +
reduced O +
MMP2 O +
activity O +
in O +
both O +
conditioned O +
media O +
and O +
cell O +
lysates O -
, O +
increased O +
p38 O +
MAPK O +
and O +
JNK O +
phosphorylation O -
, O +
but O +
did O +
not O +
affect O +
ERK O +
phosphorylation O -
. O +

Endothelial O +
cell O +
migration O +
was O +
attenuated O +
by O +
treatment O +
of O +
cells O +
with O +
GM6001 B-Chemical -
, O +
a O +
non O -
- O -
specific O +
inhibitor O +
of O +
MMPs O -
, O +
or O +
by O +
a O +
selective O +
anti O -
- O -
MMP2 O +
antibody O -
. O +

However O -
, O +
treatment O +
of O +
cells O +
with O +
SB202190 B-Chemical +
or O +
SP600125 B-Chemical -
, O +
inhibitors O +
of O +
p38 O +
MAPK O +
and O +
JNK O +
respectively O -
, O +
did O +
not O +
affect O +
HUVEC O +
migration O -
. O +

CONCLUSION O -
: O +
These O +
results O +
suggested O +
that O +
cisplatin B-Chemical +
induced O +
a O +
reduction O +
of O +
endothelial O +
cell O +
migration O +
through O +
an O +
inhibition O +
of O +
MMP2 O +
activity O +
by O +
downstream O +
signal O +
transduction O +
pathways O +
independent O +
of O +
JNK O +
and O +
p38 O +
MAPK O +
activation O -
. O +

Promoting O +
angiogenesis O +
via O +
manipulation O +
of O +
VEGF O +
responsiveness O +
with O +
notch O +
signaling O -
. O +

Promoting O +
angiogenesis O +
via O +
delivery O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
and O +
other O +
angiogenic O +
factors O +
is O +
both O +
a O +
potential O +
therapy O +
for O +
cardiovascular O +
diseases O +
and O +
a O +
critical O +
aspect O +
for O +
tissue O +
regeneration O -
. O +

The O +
recent O +
demonstration O +
that O +
VEGF O +
signaling O +
is O +
modulated O +
by O +
the O +
Notch O +
signaling O +
pathway O -
, O +
however O -
, O +
suggests O +
that O +
inhibiting O +
Notch O +
signaling O +
may O +
enhance O +
regional O +
neovascularization O -
, O +
by O +
altering O +
the O +
responsiveness O +
of O +
local O +
endothelial O +
cells O +
to O +
angiogenic O +
stimuli O -
. O +

We O +
tested O +
this O +
possibility O +
with O +
in O +
vitro O +
assays O +
using O +
human O +
endothelial O +
cells O -
, O +
as O +
well O +
as O +
in O +
a O +
rodent O +
hindlimb O +
ischemia O +
model O -
. O +

Treatment O +
of O +
cultured O +
human O +
endothelial O +
cells O +
with O +
DAPT B-Chemical -
, O +
a O +
gamma O +
secretase O +
inhibitor O -
, O +
increased O +
cell O +
migration O +
and O +
sprout O +
formation O +
in O +
response O +
to O +
VEGF O +
stimulation O +
with O +
a O +
biphasic O +
dependence O +
on O +
DAPT B-Chemical +
concentration O -
. O +

Further O -
, O +
delivery O +
of O +
an O +
appropriate O +
combination O +
of O +
DAPT B-Chemical +
and O +
VEGF O +
from O +
an O +
injectable O +
alginate O +
hydrogel O +
system O +
into O +
ischemic O +
hindlimbs O +
led O +
to O +
a O +
faster O +
recovery O +
of O +
blood O +
flow O +
than O +
VEGF O +
or O +
DAPT B-Chemical +
alone O -
; O +
perfusion O +
levels O +
reached O +
80 O -
% O +
of O +
the O +
normal O +
level O +
by O +
week O +
4 O +
with O +
combined O +
DAPT B-Chemical +
and O +
VEGF O +
delivery O -
. O +

Direct O +
intramuscular O +
or O +
intraperitoneal O +
injection O +
of O +
DAPT B-Chemical +
did O +
not O +
result O +
in O +
the O +
same O +
level O +
of O +
improvement O -
, O +
suggesting O +
that O +
appropriate O +
presentation O +
of O +
DAPT B-Chemical +
( O -
gel O +
delivery O -
) O +
is O +
important O +
for O +
its O +
activity O -
. O +

DAPT B-Chemical +
delivery O +
from O +
the O +
hydrogels O +
also O +
did O +
not O +
lead O +
to O +
any O +
adverse O +
side O +
effects O -
, O +
in O +
contrast O +
to O +
systemic O +
introduction O +
of O +
DAPT B-Chemical -
. O +

Altogether O -
, O +
these O +
results O +
suggest O +
a O +
new O +
approach O +
to O +
promote O +
angiogenesis O +
by O +
controlling O +
Notch O +
signaling O -
, O +
and O +
may O +
provide O +
new O +
options O +
to O +
treat O +
patients O +
with O +
diseases O +
that O +
diminish O +
angiogenic O +
responsiveness O -
. O +

[ O -
Activation O +
of O +
sterol O +
regulatory O +
element O +
binding O +
protein O +
and O +
its O +
involvement O +
in O +
endothelial O +
cell O +
migration O -
] O +
OBJECTIVE O -
: O +
To O +
study O +
the O +
activation O +
of O +
sterol O +
regulatory O +
element O +
binding O +
protein O +
( O -
SREBP O -
) O +
and O +
its O +
critical O +
role O +
in O +
endothelial O +
cell O +
migration O -
. O +

METHODS O -
: O +
Bovine O +
aortic O +
endothelial O +
cells O +
( O -
ECs O -
) O +
were O +
cultured O -
. O +

The O +
expression O +
of O +
SREBP O +
and O +
Cdc42 O +
were O +
determined O +
by O +
Western O +
blot O +
and O +
quantitative O +
real O -
- O -
time O +
PCR O -
. O +

Moreover O -
, O +
outward O +
growth O +
migration O +
model O +
and O +
transwell O +
chamber O +
assay O +
were O +
used O +
to O +
detect O +
ECs O +
migration O -
. O +

RESULTS O -
: O +
( O -
1 O -
) O +
SREBP O +
was O +
activated O +
during O +
ECs O +
migration O -
. O +

Western O +
blot O +
analysis O +
demonstrated O +
increased O +
active O +
form O +
SREBP O +
in O +
migrating O +
as O +
compared O +
to O +
non O -
- O -
migrating O +
ECs O +
population O -
. O +

SREBP O +
activation O +
decreased O +
as O +
ECs O +
migration O +
slowed; O -
( O -
2 O -
) O +

Coincidental O +
with O +
SREBP O +
activation O -
, O +
mRNA O +
expression O +
of O +
its O +
target O +
genes O +
such O +
as O +
low O +
density O +
lipoprotein O +
receptor O -
, O +
HMG O -
- O -
CoA O +
reductase O -
, O +
and O +
fatty O +
acid O +
synthase O +
also O +
increased O +
in O +
migrating O +
ECs O +
population O +
as O +
detected O +
by O +
real O -
- O -
time O +
PCR O -
; O +
( O -
3 O -
) O +
Migration O +
induced O +
SREBP O +
activation O +
in O +
ECs O +
was O +
inhibited O +
by O +
SREBP O -
- O -
acting O +
protein O +
RNAi O +
and O +
pharmacologically O +
by O +
25-hydroxycholesterol B-Chemical -
; O +
( O -
4 O -
) O +
Inhibition O +
of O +
SREBP O +
led O +
to O +
decreased O +
ECs O +
migration O +
in O +
various O +
models O -
; O +
( O -
5 O -
) O +
Cells O +
genetically O +
deficient O +
in O +
SREBP O -
- O -
acting O +
protein O -
, O +
S1P O -
, O +
or O +
S2P O -
, O +
phenotypically O +
exhibited O +
impaired O +
migration O -
; O +
( O -
6 O -
) O +
SREBP O +
inhibition O +
in O +
ECs O +
suppressed O +
the O +
activity O +
of O +
small O +
GTPase O +
Cdc42 O -
, O +
a O +
key O +
molecule O +
for O +
ECs O +
motility O -
. O +

CONCLUSIONS O -
: O +
SREBP O +
is O +
activated O +
during O +
and O +
plays O +
a O +
critical O +
role O +
in O +
ECs O +
migration O -
. O +

Targeting O +
SREBP O +
could O +
become O +
a O +
novel O +
approach O +
in O +
fighting O +
diseases O +
involving O +
abnormal O +
ECs O +
migration O -
. O +

Fibroblast O +
growth O +
factor O +
receptor O +
2-positive O +
fibroblasts O +
provide O +
a O +
suitable O +
microenvironment O +
for O +
tumor O +
development O +
and O +
progression O +
in O +
esophageal O +
carcinoma O -
. O +

PURPOSE O -
: O +
Tumor O +
fibroblasts O +
( O -
TF O -
) O +
have O +
been O +
suggested O +
to O +
play O +
an O +
essential O +
role O +
in O +
the O +
complex O +
process O +
of O +
tumor O -
- O -
stroma O +
interactions O +
and O +
tumorigenesis O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
specific O +
role O +
of O +
TF O +
in O +
the O +
esophageal O +
cancer O +
microenvironment O -
. O +

EXPERIMENTAL O +
DESIGN O -
: O +
An O +
Affymetrix O +
expression O +
microarray O +
was O +
used O +
to O +
compare O +
gene O +
expression O +
profiles O +
between O +
six O +
pairs O +
of O +
TFs O +
and O +
normal O +
fibroblasts O +
from O +
esophageal O +
squamous O +
cell O +
carcinoma O +
( O -
ESCC O -
) O -
. O +

Differentially O +
expressed O +
genes O +
were O +
identified O -
, O +
and O +
a O +
subset O +
was O +
evaluated O +
by O +
quantitative O +
real O -
- O -
time O +
PCR O +
and O +
immunohistochemistry O -
. O +

RESULTS O -
: O +
About O +
43 O -
% O +
( O -
126 O +
of O +
292 O -
) O +
of O +
known O +
deregulated O +
genes O +
in O +
TFs O +
were O +
associated O +
with O +
cell O +
proliferation O -
, O +
extracellular O +
matrix O +
remodeling O -
, O +
and O +
immune O +
response O -
. O +

Up O -
- O -
regulation O +
of O +
fibroblast O +
growth O +
factor O +
receptor O +
2 O +
( O -
FGFR2 O -
) O -
, O +
which O +
showed O +
the O +
most O +
significant O +
change O -
, O +
was O +
detected O +
in O +
all O +
six O +
tested O +
TFs O +
compared O +
with O +
their O +
paired O +
normal O +
fibroblasts O -
. O +

A O +
further O +
study O +
found O +
that O +
FGFR2-positive O +
fibroblasts O +
were O +
only O +
observed O +
inside O +
the O +
tumor O +
tissues O +
and O +
not O +
in O +
tumor O -
- O -
surrounding O +
stromal O +
tissues O -
, O +
suggesting O +
that O +
FGFR2 O +
could O +
be O +
used O +
as O +
a O +
TF O -
- O -
specific O +
marker O +
in O +
ESCC O -
. O +

Moreover O -
, O +
the O +
conditioned O +
medium O +
from O +
TFs O +
was O +
found O +
to O +
be O +
able O +
to O +
promote O +
ESCC O +
tumor O +
cell O +
growth O -
, O +
migration O -
, O +
and O +
invasion O +
in O +
vitro O -
. O +

CONCLUSIONS O -
: O +
Our O +
study O +
provides O +
new O +
candidate O +
genes O +
for O +
the O +
esophageal O +
cancer O +
microenvironment O -
. O +

Based O +
on O +
our O +
results O -
, O +
we O +
hypothesize O +
that O +
FGFR2 O -
( O -
+ O -
) O -
-TFs O +
might O +
provide O +
cancer O +
cells O +
with O +
a O +
suitable O +
microenvironment O +
via O +
secretion O +
of O +
proteins O +
that O +
could O +
promote O +
cancer O +
development O +
and O +
progression O +
through O +
stimulation O +
of O +
cancer O +
cell O +
proliferation O -
, O +
induction O +
of O +
angiogenesis O -
, O +
inhibition O +
of O +
cell O +
adhesion O -
, O +
enhancement O +
of O +
cell O +
mobility O -
, O +
and O +
promotion O +
of O +
the O +
epithelial O -
- O -
mesenchymal O +
transition O -
. O +

[ O -
Role O +
of O +
the O +
tumor O +
suppressor O +
ARF O +
in O +
oncogenesis O -
] O +
The O +
paper O +
reviews O +
the O +
data O +
available O +
in O +
the O +
literature O +
on O +
a O +
role O +
of O +
the O +
tumor O +
suppressor O +
ARF O +
in O +
oncogenesis O +
and O +
considers O +
the O +
structure O +
of O +
a O +
gene O +
encoding O +
ARF O +
protein O -
. O +

The O +
p53-dependent O +
and O +
p-53-independent O +
functions O +
of O +
this O +
protein O +
are O +
under O +
many O +
studies O -
. O +

There O +
is O +
evidence O +
for O +
the O +
implication O +
of O +
ARF O +
in O +
angiogenesis O -
. O +

There O +
is O +
more O +
and O +
more O +
information O +
on O +
the O +
role O +
of O +
ARF O +
in O +
the O +
regulation O +
of O +
a O +
cell O +
cycle O -
, O +
apoptosis O -
, O +
and O +
autophagy O -
. O +

The O +
importance O +
of O +
this O +
tumor O +
suppressor O +
in O +
the O +
mechanisms O +
of O +
carcinogenesis O +
is O +
beyond O +
question O +
as O +
the O +
inactivation O +
of O +
ARF O +
suppressor O +
activity O +
leads O +
to O +
the O +
rapid O +
growth O +
of O +
neoplasia O -
. O +

However O -
, O +
the O +
exact O +
mechanisms O +
of O +
ARF O +
action O +
yet O +
remain O +
unclear O +
and O +
require O +
further O +
studies O +
by O +
different O +
specialists O +
at O +
both O +
the O +
molecular O +
genetic O +
and O +
other O +
levels O +
of O +
investigation O -
. O +

Impact O +
of O +
tumor O +
cell O +
VEGF O +
expression O +
on O +
the O +
in O +
vivo O +
efficacy O +
of O +
vandetanib B-Chemical +
( O -
ZACTIMA B-Chemical -
; O +
ZD6474 B-Chemical -
) O -
. O +

VEGF O +
is O +
the O +
key O +
player O +
in O +
tumor O +
angiogenesis O -
. O +

In O +
the O +
current O +
study O -
, O +
the O +
impact O +
of O +
VEGF O +
expression O +
on O +
the O +
response O +
of O +
tumors O +
to O +
the O +
VEGFR2 O +
associated O +
tyrosine O +
kinase O +
inhibitor O +
vandetanib B-Chemical +
was O +
evaluated O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
Human O +
colon O +
carcinoma O +
( O -
HT29 O -
) O +
and O +
murine O +
squamous O +
carcinoma O +
( O -
SCCVII O -
) O +
clonal O +
cell O +
lines O +
expressing O +
varying O +
levels O +
of O +
VEGF O +
were O +
established O +
and O +
their O +
response O +
to O +
vandetanib B-Chemical +
was O +
assessed O +
in O +
tissue O +
culture O +
and O +
as O +
solid O +
tumors O -
. O +

RESULTS O -
: O +
Vandetanib B-Chemical +
treatment O +
had O +
no O +
effect O +
on O +
tumor O +
cell O +
clonogenic O +
cell O +
survival O +
in O +
vitro O +
but O +
doses O +
> O -
or=10 O +
nM O +
significantly O +
reduced O +
endothelial O +
cell O +
migration O -
. O +

In O +
vivo O -
, O +
tumors O +
derived O +
from O +
cell O +
clones O +
expressing O +
high O +
levels O +
of O +
VEGF O +
displayed O +
significantly O +
enhanced O +
angiogenesis O +
and O +
more O +
aggressive O +
growth O -
. O +

An O +
intradermal O +
angiogenesis O +
assay O +
was O +
used O +
to O +
demonstrate O +
that O +
a O +
4-day O +
treatment O +
with O +
vandetanib B-Chemical +
( O -
50 O +
mg O -
/ O -
kg O -
/ O -
day O -
) O +
was O +
able O +
to O +
significantly O +
inhibit O +
blood O +
vessel O +
growth O +
induced O +
by O +
both O +
parental O +
and O +
high O +
VEGF O -
- O -
expressing O +
tumor O +
cell O +
clones O -
. O +

In O +
the O +
HT29 O +
tumor O +
model O -
, O +
treatment O +
response O +
to O +
vandetanib B-Chemical +
( O -
50 O +
mg O -
/ O -
kg O -
/ O -
day O -
, O +
Monday O -
- O -
Friday O +
for O +
2 O +
weeks O -
) O +
was O +
greatest O +
in O +
xenografts O +
derived O +
from O +
the O +
highest O +
VEGF O -
- O -
expressing O +
cell O +
clones O -
. O +

A O +
similar O +
trend O +
was O +
noted O +
in O +
the O +
SCCVII O +
tumor O +
model O -
. O +

The O +
present O +
findings O +
indicate O +
that O +
vandetanib B-Chemical +
therapy O +
effectively O +
counteracted O +
the O +
aggressive O +
feature O +
of O +
tumor O +
growth O +
resulting O +
from O +
VEGF O +
over O -
- O -
expressing O +
tumor O +
cells O +
and O +
suggest O +
that O +
such O +
tumors O +
may O +
be O +
particularly O +
well O +
suited O +
for O +
anti O -
- O -
VEGF O +
interventions O -
. O +

Mechanical O +
regulation O +
of O +
the O +
proangiogenic O +
factor O +
CCN1 O -
/ O -
CYR61 O +
gene O +
requires O +
the O +
combined O +
activities O +
of O +
MRTF O -
- O -
A O +
and O +
CREB O -
- O -
binding O +
protein O +
histone O +
acetyltransferase O -
. O +

Smooth O +
muscle O -
- O -
rich O +
tissues O +
respond O +
to O +
mechanical O +
overload O +
by O +
an O +
adaptive O +
hypertrophic O +
growth O +
combined O +
with O +
activation O +
of O +
angiogenesis O -
, O +
which O +
potentiates O +
their O +
mechanical O +
overload O -
- O -
bearing O +
capabilities O -
. O +

Neovascularization O +
is O +
associated O +
with O +
mechanical O +
strain O -
- O -
dependent O +
induction O +
of O +
angiogenic O +
factors O +
such O +
as O +
CCN1 O -
, O +
an O +
immediate O -
- O -
early O +
gene O -
- O -
encoded O +
matricellular O +
molecule O +
critical O +
for O +
vascular O +
development O +
and O +
repair O -
. O +

Here O +
we O +
have O +
demonstrated O +
that O +
mechanical O +
strain O -
- O -
dependent O +
induction O +
of O +
the O +
CCN1 O +
gene O +
involves O +
signaling O +
cascades O +
through O +
RhoA O -
- O -
mediated O +
actin O +
remodeling O +
and O +
the O +
p38 O +
stress O -
- O -
activated O +
protein O +
kinase O +
( O -
SAPK O -
) O -
. O +

Actin O +
signaling O +
controls O +
serum O +
response O +
factor O +
( O -
SRF O -
) O +
activity O +
via O +
SRF O +
interaction O +
with O +
the O +
myocardin O -
- O -
related O +
transcriptional O +
activator O +
( O -
MRTF O -
) O -
-A O +
and O +
tethering O +
to O +
a O +
single O +
CArG O +
box O +
sequence O +
within O +
the O +
CCN1 O +
promoter O -
. O +

Such O +
activity O +
was O +
abolished O +
in O +
mechanically O +
stimulated O +
mouse O +
MRTF O -
- O -
A O -
( O -
- O -
/ O -
- O -
) O +
cells O +
or O +
upon O +
inhibition O +
of O +
CREB O -
- O -
binding O +
protein O +
( O -
CBP O -
) O +
histone O +
acetyltransferase O +
( O -
HAT O -
) O +
either O +
pharmacologically O +
or O +
by O +
siRNAs O -
. O +

Mechanical O +
strain O +
induced O +
CBP O -
- O -
mediated O +
acetylation O +
of O +
histones O +
3 O +
and O +
4 O +
at O +
the O +
SRF O -
- O -
binding O +
site O +
and O +
within O +
the O +
CCN1 O +
gene O +
coding O +
region O -
. O +

Inhibition O +
of O +
p38 O +
SAPK O +
reduced O +
CBP O +
HAT O +
activity O +
and O +
its O +
recruitment O +
to O +
the O +
SRF.MRTF O -
- O -
A O +
complex O -
, O +
whereas O +
enforced O +
induction O +
of O +
p38 O +
by O +
upstream O +
activators O +
( O -
e.g. O +
MKK3 O +
and O +
MKK6 O -
) O +
enhanced O +
both O +
CBP O +
HAT O +
and O +
CCN1 O +
promoter O +
activities O -
. O +

Similarly O -
, O +
mechanical O +
overload O -
- O -
induced O +
CCN1 O +
gene O +
expression O +
in O +
vivo O +
was O +
associated O +
with O +
nuclear O +
localization O +
of O +
MRTF O -
- O -
A O +
and O +
enrichment O +
of O +
the O +
CCN1 O +
promoter O +
with O +
both O +
MRTF O -
- O -
A O +
and O +
acetylated O +
histone O +
H3 O -
. O +

Taken O +
together O -
, O +
these O +
data O +
suggest O +
that O +
signal O -
- O -
controlled O +
activation O +
of O +
SRF O -
, O +
MRTF O -
- O -
A O -
, O +
and O +
CBP O +
provides O +
a O +
novel O +
connection O +
between O +
mechanical O +
stimuli O +
and O +
angiogenic O +
gene O +
expression O -
. O +

Tumour O +
angiogenesis O -
: O +
its O +
mechanism O +
and O +
therapeutic O +
implications O +
in O +
malignant O +
gliomas O -
. O +

Angiogenesis O +
is O +
a O +
key O +
event O +
in O +
the O +
progression O +
of O +
malignant O +
gliomas O -
. O +

The O +
presence O +
of O +
microvascular O +
proliferation O +
leads O +
to O +
the O +
histological O +
diagnosis O +
of O +
glioblastoma O +
multiforme O -
. O +

Tumour O +
angiogenesis O +
involves O +
multiple O +
cellular O +
processes O +
including O +
endothelial O +
cell O +
proliferation O -
, O +
migration O -
, O +
reorganisation O +
of O +
extracellular O +
matrix O +
and O +
tube O +
formation O -
. O +

These O +
processes O +
are O +
regulated O +
by O +
numerous O +
pro O -
- O -
angiogenic O +
and O +
anti O -
- O -
angiogenic O +
growth O +
factors O -
. O +

Angiogenesis O +
inhibitors O +
have O +
been O +
developed O +
to O +
interrupt O +
the O +
angiogenic O +
process O +
at O +
the O +
growth O +
factor O -
, O +
receptor O +
tyrosine O +
kinase O +
and O +
intracellular O +
kinase O +
levels O -
. O +

Other O +
anti O -
- O -
angiogenic O +
therapies O +
alter O +
the O +
immune O +
response O +
and O +
endogeneous O +
angiogenesis O +
inhibitor O +
levels O -
. O +

Most O +
anti O -
- O -
angiogenic O +
therapies O +
for O +
malignant O +
gliomas O +
are O +
in O +
Phase O +
I O -
/ O -
II O +
trials O +
and O +
only O +
modest O +
efficacies O +
are O +
reported O +
for O +
monotherapies O -
. O +

The O +
greatest O +
potential O +
for O +
angiogenesis O +
inhibitors O +
may O +
lie O +
in O +
their O +
ability O +
to O +
combine O +
safely O +
with O +
chemotherapy O +
and O +
radiotherapy O -
. O +

Regulation O +
of O +
thrombospondin-1 O +
by O +
natural O +
and O +
synthetic O +
progestins B-Chemical +
in O +
human O +
breast O +
cancer O +
cells O -
. O +

Our O +
recent O +
studies O +
show O +
that O +
progestins B-Chemical +
induce O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
in O +
breast O +
cancer O +
cells O +
that O +
express O +
mutant O +
p53 O +
protein O -
. O +

Here O -
, O +
we O +
show O +
that O +
natural O +
and O +
synthetic O +
progestins B-Chemical +
also O +
induce O +
thrombospondin-1 O +
( O -
TSP-1 O -
) O +
mRNA O +
and O +
protein O +
in O +
T47-D O +
and O +
BT-474 O +
breast O +
cancer O +
cells O -
. O +

Antiprogestin B-Chemical +
RU-486 I-Chemical +
inhibits O +
the O +
induction O +
of O +
VEGF O +
and O +
TSP-1 O +
by O +
progestins B-Chemical -
, O +
suggesting O +
that O +
this O +
effect O +
of O +
progestin B-Chemical +
is O +
mediated O +
by O +
the O +
progesterone O +
receptor O +
( O -
PR O -
) O -
. O +

Actinomycin B-Chemical -
- I-Chemical -
D I-Chemical -
, O +
but O +
not O +
puromycin B-Chemical -
, O +
also O +
blocks O +
progestin B-Chemical -
- O -
dependent O +
induction O +
of O +
TSP-1 O -
. O +

A O +
putative O +
progestin B-Chemical -
- O -
response O +
element O +
was O +
identified O +
in O +
the O +
human O +
TSP-1 O +
promoter O -
, O +
which O +
is O +
consistent O +
with O +
the O +
hypothesis O +
that O +
a O +
progestin B-Chemical -
- O -
PR O +
complex O +
might O +
directly O +
regulate O +
transcription O +
of O +
the O +
TSP-1 O +
gene O +
in O +
human O +
cells O -
. O +

Conditioned O +
medium O +
from O +
progestin B-Chemical -
- O -
treated O +
breast O +
cancer O +
cells O +
stimulates O +
endothelial O +
cell O +
proliferation O +
in O +
the O +
absence O +
though O +
not O +
in O +
the O +
presence O +
of O +
antibody O +
to O +
TSP-1 O -
, O +
indicating O +
that O +
TSP-1 O +
secreted O +
by O +
breast O +
cancer O +
cells O +
could O +
be O +
pro O -
- O -
angiogenic O -
. O +

Since O +
tumor O +
cell O -
- O -
derived O +
TSP-1 O +
has O +
the O +
potential O +
to O +
promote O +
angiogenesis O +
in O +
the O +
tumor O +
microenvironment O -
, O +
it O +
could O +
be O +
a O +
potential O +
target O +
for O +
breast O +
cancer O +
therapy O -
. O +

WNT O -
/ O -
TCF O +
signaling O +
through O +
LEF1 O +
and O +
HOXB9 O +
mediates O +
lung O +
adenocarcinoma O +
metastasis O -
. O +

Metastasis O +
from O +
lung O +
adenocarcinoma O +
can O +
occur O +
swiftly O +
to O +
multiple O +
organs O +
within O +
months O +
of O +
diagnosis O -
. O +

The O +
mechanisms O +
that O +
confer O +
this O +
rapid O +
metastatic O +
capacity O +
to O +
lung O +
tumors O +
are O +
unknown O -
. O +

Activation O +
of O +
the O +
canonical O +
WNT O -
/ O -
TCF O +
pathway O +
is O +
identified O +
here O +
as O +
a O +
determinant O +
of O +
metastasis O +
to O +
brain O +
and O +
bone O +
during O +
lung O +
adenocarcinoma O +
progression O -
. O +

Gene O +
expression O +
signatures O +
denoting O +
WNT O -
/ O -
TCF O +
activation O +
are O +
associated O +
with O +
relapse O +
to O +
multiple O +
organs O +
in O +
primary O +
lung O +
adenocarcinoma O -
. O +

Metastatic O +
subpopulations O +
isolated O +
from O +
independent O +
lymph O +
node O -
- O -
derived O +
lung O +
adenocarcinoma O +
cell O +
lines O +
harbor O +
a O +
hyperactive O +
WNT O -
/ O -
TCF O +
pathway O -
. O +

Reduction O +
of O +
TCF O +
activity O +
in O +
these O +
cells O +
attenuates O +
their O +
ability O +
to O +
form O +
brain O +
and O +
bone O +
metastases O +
in O +
mice O -
, O +
independently O +
of O +
effects O +
on O +
tumor O +
growth O +
in O +
the O +
lungs O -
. O +

The O +
WNT O -
/ O -
TCF O +
target O +
genes O +
HOXB9 O +
and O +
LEF1 O +
are O +
identified O +
as O +
mediators O +
of O +
chemotactic O +
invasion O +
and O +
colony O +
outgrowth O -
. O +

Thus O -
, O +
a O +
distinct O +
WNT O -
/ O -
TCF O +
signaling O +
program O +
through O +
LEF1 O +
and O +
HOXB9 O +
enhances O +
the O +
competence O +
of O +
lung O +
adenocarcinoma O +
cells O +
to O +
colonize O +
the O +
bones O +
and O +
the O +
brain O -
. O +

For O +
a O +
video O +
summary O +
of O +
this O +
article O -
, O +
see O +
the O +
PaperFlick O +
file O +
available O +
with O +
the O +
online O +
Supplemental O +
Data O -
. O +

MEK5 O -
/ O -
ERK5 O +
signaling O +
modulates O +
endothelial O +
cell O +
migration O +
and O +
focal O +
contact O +
turnover O -
. O +

The O +
formation O +
of O +
new O +
blood O +
vessels O +
from O +
pre O -
- O -
existing O +
ones O +
requires O +
highly O +
coordinated O +
restructuring O +
of O +
endothelial O +
cells O +
( O -
EC O -
) O +
and O +
the O +
surrounding O +
extracellular O +
matrix O -
. O +

Directed O +
EC O +
migration O +
is O +
a O +
central O +
step O +
in O +
this O +
process O +
and O +
depends O +
on O +
cellular O +
signaling O +
cascades O +
that O +
initiate O +
and O +
control O +
the O +
structural O +
rearrangements O -
. O +

On O +
the O +
basis O +
of O +
earlier O +
findings O +
that O +
ERK5 O +
deficiency O +
in O +
mouse O +
EC O +
results O +
in O +
massive O +
defects O +
in O +
vessel O +
architecture O -
, O +
we O +
focused O +
on O +
the O +
impact O +
of O +
the O +
MEK5 O -
/ O -
ERK5 O +
signaling O +
pathway O +
on O +
EC O +
migration O -
. O +

Using O +
a O +
retroviral O +
gene O +
transfer O +
approach O -
, O +
we O +
found O +
that O +
constitutive O +
activation O +
of O +
MEK5 O -
/ O -
ERK5 O +
signaling O +
strongly O +
inhibits O +
EC O +
migration O +
and O +
results O +
in O +
massive O +
morphological O +
changes O -
. O +

The O +
area O +
covered O +
by O +
spread O +
EC O +
was O +
dramatically O +
enlarged O -
, O +
accompanied O +
by O +
an O +
increase O +
in O +
focal O +
contacts O +
and O +
altered O +
organization O +
of O +
actin O +
filaments O -
. O +

Consequently O -
, O +
cells O +
were O +
more O +
rigid O +
and O +
show O +
reduced O +
motility O -
. O +

This O +
phenotype O +
was O +
most O +
likely O +
based O +
on O +
decreased O +
focal O +
contact O +
turnover O +
caused O +
by O +
reduced O +
expression O +
of O +
p130Cas O -
, O +
a O +
key O +
player O +
in O +
directed O +
cell O +
migration O -
. O +

We O +
demonstrate O +
for O +
the O +
first O +
time O +
that O +
ERK5 O +
signaling O +
not O +
only O +
is O +
involved O +
in O +
EC O +
survival O +
and O +
stress O +
response O +
but O +
also O +
controls O +
migration O +
and O +
morphology O +
of O +
EC O -
. O +

The O +
Down O +
syndrome O +
critical O +
region O +
gene O +
1 O +
short O +
variant O +
promoters O +
direct O +
vascular O +
bed O -
- O -
specific O +
gene O +
expression O +
during O +
inflammation O +
in O +
mice O -
. O +

Down O +
syndrome O +
critical O +
region O +
gene O +
1 O +
( O -
DSCR-1 O -
) O +
short O +
variant O +
( O -
DSCR-1s O -
) O +
is O +
an O +
inhibitor O +
of O +
calcineurin O -
/ O -
NFAT O +
signaling O +
encoded O +
by O +
exons O +
4 O -
- O -
7 O +
of O +
DSCR1 O -
. O +

We O +
previously O +
reported O +
that O +
VEGF O +
induces O +
DSCR-1s O +
expression O +
in O +
endothelial O +
cells O -
, O +
which O +
in O +
turn O +
negatively O +
feeds O +
back O +
to O +
attenuate O +
endothelial O +
cell O +
activation O -
. O +

Here O -
, O +
in O +
order O +
to O +
characterize O +
the O +
role O +
of O +
the O +
promoter O +
that O +
drives O +
DSCR-1s O +
expression O +
in O +
mediating O +
inducible O +
expression O +
in O +
vivo O +
and O +
to O +
determine O +
the O +
functional O +
relevance O +
of O +
DSCR-1s O +
in O +
inflammation O -
, O +
we O +
targeted O +
a O +
DNA O +
construct O +
containing O +
1.7 O +
kb O +
of O +
the O +
human O +
DSCR1s O +
promoter O +
coupled O +
to O +
the O +
lacZ O +
reporter O +
to O +
the O +
hypoxanthine O +
guanine O +
phosphoribosyl O +
transferase O +
( O -
Hprt O -
) O +
locus O +
of O +
mice O -
. O +

We O +
determined O +
that O +
lacZ O +
was O +
uniformly O +
expressed O +
in O +
the O +
endothelium O +
of O +
transgenic O +
embryos O +
but O +
was O +
markedly O +
downregulated O +
postnatally O -
. O +

Systemic O +
administration O +
of O +
VEGF O +
or O +
LPS B-Chemical +
in O +
adult O +
mice O +
resulted O +
in O +
cyclosporine B-Chemical +
A I-Chemical -
- O -
sensitive O +
reactivation O +
of O +
the O +
DSCR1s O +
promoter O +
and O +
endogenous O +
gene O +
expression O +
in O +
a O +
subset O +
of O +
organs O -
, O +
including O +
the O +
heart O +
and O +
brain O -
. O +

The O +
DSCR1s O +
promoter O +
was O +
similarly O +
induced O +
in O +
the O +
endothelium O +
of O +
tumor O +
xenografts O -
. O +

In O +
a O +
mouse O +
model O +
of O +
endotoxemia O -
, O +
DSCR-1s O -
- O -
deficient O +
mice O +
demonstrated O +
increased O +
sepsis O +
mortality O -
, O +
whereas O +
adenovirus O -
- O -
mediated O +
DSCR-1s O +
overexpression O +
protected O +
against O +
LPS B-Chemical -
- O -
induced O +
lethality O -
. O +

Collectively O -
, O +
these O +
data O +
suggest O +
that O +
the O +
DSCR1s O +
promoter O +
directs O +
vascular O +
bed O -
- O -
specific O +
expression O +
in O +
activated O +
endothelium O +
and O +
that O +
DSCR-1s O +
serves O +
to O +
dampen O +
the O +
host O +
response O +
to O +
infection O -
. O +

Angiogenesis O -
- O -
a O +
novel O +
therapeutic O +
approach O +
for O +
ischemic O +
heart O +
disease O -
. O +

Angiogenesis O +
is O +
the O +
biologic O +
process O +
of O +
forming O +
new O +
blood O +
vessels O -
. O +

Undoubtedly O -
, O +
blood O +
vessels O +
growth O +
regulation O +
is O +
a O +
vital O +
aspect O +
in O +
health O +
and O +
disease O -
. O +

Under O +
physiological O +
conditions O -
, O +
angiogenesis O +
is O +
regulated O +
by O +
local O +
balance O +
between O +
endogenous O +
stimulators O +
and O +
inhibitors O +
of O +
this O +
process O -
. O +

In O +
many O +
diseases O +
state O +
body O +
loses O +
control O +
over O +
angiogenesis O -
. O +

Angiogenesis O -
- O -
dependent O +
diseases O +
result O +
when O +
new O +
blood O +
vessels O +
either O +
grow O +
excessively O +
or O +
insufficiently O -
. O +

Insufficient O +
angiogenesis O +
occurs O +
in O +
diseases O +
such O +
as O +
coronary O +
artery O +
disease O -
, O +
stroke O +
and O +
chronic O +
wounds O -
. O +

Myocardial O +
ischemia O +
both O +
acute O +
and O +
chronic O +
has O +
been O +
clearly O +
shown O +
to O +
stimulate O +
angiogenesis O +
in O +
many O +
experimental O +
models O -
. O +

Therapeutic O +
angiogenesis O +
is O +
the O +
biological O +
agents O +
or O +
bioactive O +
material O +
to O +
stimulate O +
the O +
growth O +
of O +
new O +
blood O +
vessels O -
. O +

Traditional O +
coronary O +
revascularization O +
therapies O +
such O +
as O +
coronary O +
angioplasty O +
or O +
bypass O +
graft O +
surgery O -
, O +
act O +
by O +
restoring O +
blood O +
flow O +
through O +
the O +
preexisting O +
coronary O +
vessels O -
. O +

One O +
limitation O +
of O +
these O +
approaches O -
, O +
however O -
, O +
may O +
be O +
the O +
failure O +
to O +
normalize O +
myocardial O +
perfusion O -
, O +
due O +
to O +
the O +
concomitant O +
presence O +
or O +
small O +
of O +
resistance O +
vessel O +
disease O -
. O +

In O +
contrast O -
, O +
therapeutic O +
angiogenesis O +
is O +
based O +
on O +
the O +
concept O +
that O +
coronary O +
collateral O +
development O +
may O +
be O +
stimulated O +
by O +
pharmacological O +
or O +
molecular O +
means O +
and O +
can O +
limit O +
myocardial O +
ischemia O -
. O +

Studies O -
, O +
both O +
in O +
human O +
and O +
animal O +
models O +
support O +
the O +
notion O +
that O -
, O +
various O +
angiogenic O +
growth O +
factors O +
and O +
progenitor O +
cells O +
can O +
enhance O +
new O +
blood O +
vessels O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
, O +
fibroblast O +
growth O +
factor O +
( O -
FGF O -
) O -
, O +
recombinant O +
proteins O +
and O +
bone O +
marrow O +
stem O +
cells O +
are O +
currently O +
used O +
therapeutic O +
stimulators O +
for O +
angiogenesis O -
. O +

As O +
coronary O +
artery O +
disease O +
is O +
the O +
major O +
cause O +
of O +
death O +
in O +
the O +
developed O +
societies O +
and O +
also O +
an O +
emerging O +
health O +
problem O +
in O +
developing O +
countries O +
like O +
Bangladesh O +
therapeutic O +
angiogenesis O +
may O +
provide O +
hope O +
as O +
a O +
new O +
treatment O +
modality O +
for O +
ischemic O +
heart O +
disease O +
with O +
or O +
in O +
place O +
of O +
current O +
therapies O -
. O +

Metronomic O +
5-fluorouracil B-Chemical -
, O +
oxaliplatin B-Chemical +
and O +
irinotecan B-Chemical +
in O +
colorectal O +
cancer O -
. O +

Metronomic O +
chemotherapy O +
( O -
the O +
frequent O -
, O +
long O +
term O -
, O +
low O +
dose O +
administration O +
of O +
chemotherapeutic O +
drugs O -
) O +
is O +
a O +
promising O +
therapy O +
because O +
it O +
enhances O +
the O +
anti O -
- O -
endothelial O +
activity O +
of O +
conventional O +
chemotherapeutics O -
, O +
but O +
with O +
lower O +
or O +
no O +
toxic O +
effects O +
compared O +
to O +
maximum O +
tolerated O +
dose O +
administration O -
. O +

The O +
aims O +
of O +
the O +
present O +
study O +
were O +
to O +
compare O -
, O +
in O +
vitro O +
and O +
in O +
vivo O -
, O +
the O +
antiangiogenic O +
and O +
antitumor O +
activities O +
of O +
metronomic O +
irinotecan B-Chemical +
( O -
CPT-11 B-Chemical -
) O -
, O +
oxaliplatin B-Chemical +
( O -
L B-Chemical -
- I-Chemical -
OHP I-Chemical -
) O +
and O +
5-fluorouracil B-Chemical +
( O -
5-FU B-Chemical -
) O +
in O +
colorectal O +
cancer O +
and O +
to O +
investigate O +
the O +
metronomic O +
combination O +
of O +
these O +
drugs O -
. O +

In O +
vitro O +
cell O +
proliferation O -
, O +
combination O +
studies O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
secretion O +
analyses O +
were O +
performed O +
on O +
endothelial O +
( O -
HMVEC O -
- O -
d O -
) O +
and O +
colorectal O +
cancer O +
( O -
HT-29 O -
) O +
cells O +
exposed O +
for O +
144 O +
h O +
to O +
metronomic O +
concentrations O +
of O +
SN-38 B-Chemical -
, O +
the O +
active O +
metabolite O +
of O +
CPT-11 B-Chemical -
, O +
L B-Chemical -
- I-Chemical -
OHP I-Chemical +
and O +
5-FU B-Chemical -
. O +

HT-29 O +
human O +
colorectal O +
cancer O +
xenograft O +
model O +
was O +
used O +
and O +
tumour O +
growth O -
, O +
microvessel O +
density O +
and O +
VEGF O +
quantification O +
were O +
performed O +
in O +
tumours O +
after O +
the O +
administration O +
of O +
metronomic O +
CPT-11 B-Chemical -
, O +
L B-Chemical -
- I-Chemical -
OHP I-Chemical -
, O +
5-FU B-Chemical +
and O +
their O +
simultaneous O +
combination O -
. O +

Low O +
concentrations O +
of O +
SN-38 B-Chemical -
, O +
but O +
not O +
5-FU B-Chemical +
and O +
L B-Chemical -
- I-Chemical -
OHP I-Chemical -
, O +
preferentially O +
inhibited O +
endothelial O +
cell O +
proliferation O -
. O +

Simultaneous O +
and O +
continuous O +
exposure O +
of O +
HT-29 O +
and O +
HMVEC O -
- O -
d O +
cells O +
to O +
low O +
concentrations O +
SN-38+L B-Chemical -
- B-Chemical -
OHP+5-FU I-Chemical +
for O +
144 O +
h O +
showed O +
a O +
strong O +
antagonism O +
and O +
an O +
unfavorable O +
dose O -
- O -
reduction O +
index O -
. O +

Moreover O -
, O +
the O +
ternary O +
combination O +
resulted O +
in O +
a O +
significant O +
increase O +
of O +
VEGF O +
secretion O +
in O +
HT-29 O +
cancer O +
cells O -
. O +

In O +
a O +
xenograft O +
model O +
metronomic O +
CPT-11 B-Chemical -
, O +
but O +
not O +
5-FU B-Chemical +
and O +
L B-Chemical -
- I-Chemical -
OHP I-Chemical -
, O +
significantly O +
inhibits O +
HT-29 O +
tumor O +
growth O +
and O +
microvessel O +
density O +
in O +
the O +
absence O +
of O +
toxicity O -
. O +

On O +
the O +
contrary O -
, O +
metronomic O +
5-FU+L B-Chemical -
- B-Chemical -
OHP+CPT-11 I-Chemical +
therapy O +
did O +
not O +
affect O +
the O +
microvascular O +
count O -
. O +

The O +
metronomic O +
concept O +
might O +
not O +
universally O +
apply O +
to O +
every O +
cytotoxic O +
drug O +
in O +
colorectal O +
cancer O +
and O +
metronomic O +
combination O +
regimens O +
should O +
be O +
used O +
with O +
caution O -
. O +

A O +
key O +
role O +
for O +
the O +
integrin O +
alpha2beta1 O +
in O +
experimental O +
and O +
developmental O +
angiogenesis O -
. O +

The O +
alpha2beta1 O +
integrin O +
receptor O +
plays O +
a O +
key O +
role O +
in O +
angiogenesis O -
. O +

Here O +
we O +
investigated O +
the O +
effects O +
of O +
small O +
molecule O +
inhibitors O +
( O -
SMIs O -
) O +
designed O +
to O +
disrupt O +
integrin O +
alpha2 O +
I O +
or O +
beta1 O +
I O -
- O -
like O +
domain O +
function O +
on O +
angiogenesis O -
. O +

In O +
unchallenged O +
endothelial O +
cells O -
, O +
fibrillar O +
collagen O +
induced O +
robust O +
capillary O +
morphogenesis O -
. O +

In O +
contrast O -
, O +
tube O +
formation O +
was O +
significantly O +
reduced O +
by O +
SMI496 B-Chemical -
, O +
a O +
beta1 O +
I O -
- O -
like O +
domain O +
inhibitor O +
and O +
by O +
function O -
- O -
blocking O +
anti B-Chemical -
- I-Chemical -
alpha2beta1 I-Chemical +
but O +
not O +
-alpha1beta1 B-Chemical +
antibodies I-Chemical -
. O +

Endothelial O +
cells O +
bound O +
fluorescein B-Chemical -
- O -
labeled O +
collagen O +
I O +
fibrils O -
, O +
an O +
interaction O +
specifically O +
inhibited O +
by O +
SMI496 B-Chemical -
. O +

Moreover O -
, O +
SMI496 B-Chemical +
caused O +
cell O +
retraction O +
and O +
cytoskeletal O +
collapse O +
of O +
endothelial O +
cells O +
as O +
well O +
as O +
delayed O +
endothelial O +
cell O +
wound O +
healing O -
. O +

SMI O +
activities O +
were O +
examined O +
in O +
vivo O +
by O +
supplementing O +
the O +
growth O +
medium O +
of O +
zebrafish O +
embryos O +
expressing O +
green O +
fluorescent O +
protein O +
under O +
the O +
control O +
of O +
the O +
vascular O +
endothelial O +
growth O +
factor O +
receptor-2 O +
promoter O -
. O +

SMI496 B-Chemical -
, O +
but O +
not O +
a O +
control O +
compound O -
, O +
interfered O +
with O +
angiogenesis O +
in O +
vivo O +
by O +
reversibly O +
inhibiting O +
sprouting O +
from O +
the O +
axial O +
vessels O -
. O +

We O +
further O +
characterized O +
zebrafish O +
alpha2 O +
integrin O +
and O +
discovered O +
that O +
this O +
integrin O +
is O +
highly O +
conserved O -
, O +
especially O +
the O +
I O +
domain O -
. O +

Notably O -
, O +
a O +
similar O +
vascular O +
phenotype O +
was O +
induced O +
by O +
morpholino O -
- O -
mediated O +
knockdown O +
of O +
the O +
integrin O +
alpha2 O +
subunit O -
. O +

By O +
live O +
videomicroscopy O -
, O +
we O +
confirmed O +
that O +
the O +
vessels O +
were O +
largely O +
nonfunctional O +
in O +
the O +
absence O +
of O +
alpha2beta1 O +
integrin O -
. O +

Collectively O -
, O +
our O +
results O +
provide O +
strong O +
biochemical O +
and O +
genetic O +
evidence O +
of O +
a O +
central O +
role O +
for O +
alpha2beta1 O +
integrin O +
in O +
experimental O +
and O +
developmental O +
angiogenesis O -
. O +

Dopamine B-Chemical +
regulates O +
phosphorylation O +
of O +
VEGF O +
receptor O +
2 O +
by O +
engaging O +
Src O -
- O -
homology-2-domain O -
- O -
containing O +
protein O +
tyrosine O +
phosphatase O +
2 O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
-induced O +
receptor O +
phosphorylation O +
is O +
the O +
crucial O +
step O +
for O +
initiating O +
downstream O +
signaling O +
pathways O +
that O +
lead O +
to O +
angiogenesis O +
or O +
related O +
pathophysiological O +
outcomes O -
. O +

Our O +
previous O +
studies O +
have O +
shown O +
that O +
the O +
neurotransmitter O +
dopamine B-Chemical +
could O +
inhibit O +
VEGF O -
- O -
induced O +
phosphorylation O +
of O +
VEGF O +
receptor O +
2 O +
( O -
VEGFR-2 O -
) O -
, O +
endothelial O +
cell O +
proliferation O -
, O +
migration O -
, O +
microvascular O +
permeability O -
, O +
and O +
thus O -
, O +
angiogenesis O -
. O +

In O +
this O +
study O -
, O +
we O +
address O +
the O +
mechanism O +
by O +
which O +
VEGFR-2 O +
phosphorylation O +
is O +
regulated O +
by O +
dopamine B-Chemical -
. O +

Here O -
, O +
we O +
demonstrate O +
that O +
D2 O +
dopamine O +
receptor O +
( O -
D2DR O -
) O +
colocalizes O +
with O +
VEGFR-2 O +
at O +
the O +
cell O +
surface O -
. O +

Dopamine B-Chemical +
pretreatment O +
increases O +
the O +
translocation O +
and O +
colocalization O +
of O +
Src O -
- O -
homology-2-domain O -
- O -
containing O +
protein O +
tyrosine O +
phosphatase O +
( O -
SHP-2 O -
) O +
with O +
D2DR O +
at O +
the O +
cell O +
surface O -
. O +

Dopamine B-Chemical +
administration O +
leads O +
to O +
increased O +
VEGF O -
- O -
induced O +
phosphorylation O +
of O +
SHP-2 O +
and O +
this O +
increased O +
phosphorylation O +
parallels O +
the O +
increased O +
phosphatase O +
activity O +
of O +
SHP-2 O -
. O +

Active O +
SHP-2 O +
then O +
dephosphorylates O +
VEGFR-2 O +
at O +
Y951 O -
, O +
Y996 O +
and O +
Y1059 O -
, O +
but O +
not O +
Y1175 O -
. O +

We O +
also O +
observe O +
that O +
SHP-2 O +
knockdown O +
impairs O +
the O +
dopamine B-Chemical -
- O -
regulated O +
inhibition O +
of O +
VEGF O -
- O -
induced O +
phosphorylation O +
of O +
VEGFR-2 O +
and O -
, O +
subsequently O -
, O +
Src O +
phosphorylation O +
and O +
migration O -
. O +

Our O +
data O +
establish O +
a O +
novel O +
role O +
for O +
SHP-2 O +
phosphatase O +
in O +
the O +
dopamine B-Chemical -
- O -
mediated O +
regulation O +
of O +
VEGFR-2 O +
phosphorylation O -
. O +

Netrin-1 O +
up O -
- O -
regulation O +
in O +
inflammatory O +
bowel O +
diseases O +
is O +
required O +
for O +
colorectal O +
cancer O +
progression O -
. O +

Chronic O +
inflammation O +
and O +
cancer O +
are O +
intimately O +
associated O -
. O +

This O +
is O +
particularly O +
true O +
for O +
inflammatory O +
bowel O +
diseases O +
( O -
IBD O -
) O -
, O +
such O +
as O +
ulcerative O +
colitis O +
and O +
Crohn O -
's O +
disease O -
, O +
which O +
show O +
a O +
major O +
increased O +
risk O +
for O +
colorectal O +
cancer O -
. O +

While O +
the O +
understanding O +
of O +
the O +
molecular O +
pathogenesis O +
of O +
IBD O +
has O +
recently O +
improved O -
, O +
the O +
mechanisms O +
that O +
link O +
these O +
chronic O +
inflammatory O +
states O +
to O +
colorectal O +
cancer O +
development O +
are O +
in O +
large O +
part O +
unknown O -
. O +

One O +
of O +
these O +
mechanisms O +
is O +
NF O -
- O -
kappaB O +
pathway O +
activation O +
which O +
in O +
turn O +
may O +
contribute O +
to O +
tumor O +
formation O +
by O +
providing O +
anti O -
- O -
apoptotic O +
survival O +
signals O +
to O +
the O +
epithelial O +
cells O -
. O +

Based O +
on O +
the O +
observation O +
that O +
netrin-1 O -
, O +
the O +
anti O -
- O -
apoptotic O +
ligand O +
for O +
the O +
dependence O +
receptors O +
DCC O +
and O +
UNC5H O +
is O +
up O -
- O -
regulated O +
in O +
colonic O +
crypts O +
in O +
response O +
to O +
NF O -
- O -
kappaB O -
, O +
we O +
show O +
here O +
that O +
colorectal O +
cancers O +
from O +
inflammatory O +
bowel O +
diseases O +
patients O +
have O +
selected O +
up O -
- O -
regulation O +
of O +
netrin-1 O -
. O +

Moreover O -
, O +
we O +
demonstrate O +
that O +
this O +
inflammation O -
- O -
driven O +
netrin-1 O +
up O -
- O -
regulation O +
is O +
causal O +
for O +
colorectal O +
cancer O +
development O +
as O +
interference O +
with O +
netrin-1 O +
autocrine O +
loop O +
in O +
a O +
mouse O +
model O +
for O +
ulcerative O +
colitis O -
- O -
associated O +
colorectal O +
cancer O -
, O +
while O +
showing O +
no O +
effect O +
on O +
inflammation O -
, O +
inhibits O +
colorectal O +
cancer O +
progression O -
. O +

Glioma O +
tumor O +
stem O -
- O -
like O +
cells O +
promote O +
tumor O +
angiogenesis O +
and O +
vasculogenesis O +
via O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
stromal O -
- O -
derived O +
factor O +
1 O -
. O +

Cancer O +
stem O +
cells O +
( O -
CSC O -
) O +
are O +
predicted O +
to O +
be O +
critical O +
drivers O +
of O +
tumor O +
progression O +
due O +
to O +
their O +
self O -
- O -
renewal O +
capacity O +
and O +
limitless O +
proliferative O +
potential O -
. O +

An O +
emerging O +
area O +
of O +
research O +
suggests O +
that O +
CSC O +
may O +
also O +
support O +
tumor O +
progression O +
by O +
promoting O +
tumor O +
angiogenesis O -
. O +

To O +
investigate O +
how O +
CSC O +
contribute O +
to O +
tumor O +
vascular O +
development O -
, O +
we O +
used O +
an O +
approach O +
comparing O +
tumor O +
xenografts O +
of O +
the O +
C6 O +
glioma O +
cell O +
line O +
containing O +
either O +
a O +
low O +
or O +
a O +
high O +
fraction O +
of O +
CSC O -
. O +

Compared O +
with O +
CSC O -
- O -
low O +
tumors O -
, O +
CSC O -
- O -
high O +
tumors O +
exhibited O +
increased O +
microvessel O +
density O +
and O +
blood O +
perfusion O +
and O +
induced O +
increased O +
mobilization O +
and O +
tumor O +
recruitment O +
of O +
bone O +
marrow O -
- O -
derived O +
endothelial O +
progenitor O +
cells O +
( O -
EPC O -
) O -
. O +

CSC O -
- O -
high O +
C6 O +
cell O +
cultures O +
also O +
induced O +
higher O +
levels O +
of O +
endothelial O +
cell O +
proliferation O +
and O +
tubule O +
organization O +
in O +
vitro O +
compared O +
with O +
CSC O -
- O -
low O +
cultures O -
. O +

CSC O -
- O -
high O +
cultures O +
and O +
tumors O +
expressed O +
increased O +
levels O +
of O +
the O +
proangiogenic O +
factors O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
stromal O -
- O -
derived O +
factor O +
1 O -
, O +
and O +
when O +
signaling O +
by O +
either O +
factor O +
was O +
blocked O -
, O +
all O +
aspects O +
of O +
angiogenesis O +
observed O +
in O +
CSC O -
- O -
high O +
cultures O +
and O +
tumors O -
, O +
including O +
microvessel O +
density O -
, O +
perfusion O -
, O +
EPC O +
mobilization O -
/ O -
recruitment O -
, O +
and O +
stimulation O +
of O +
endothelial O +
cell O +
activity O -
, O +
were O +
reduced O +
to O +
levels O +
comparable O +
with O +
those O +
observed O +
in O +
CSC O -
- O -
low O +
cultures O -
/ O -
tumors O -
. O +

These O +
results O +
suggest O +
that O +
CSC O +
contribute O +
to O +
tumor O +
angiogenesis O +
by O +
promoting O +
both O +
local O +
endothelial O +
cell O +
activity O +
and O +
systemic O +
angiogenic O +
processes O +
involving O +
bone O +
marrow O -
- O -
derived O +
EPC O +
in O +
a O +
vascular O +
endothelial O +
growth O +
factor O -
- O -
dependent O +
and O +
stromal O -
- O -
derived O +
factor O +
1-dependent O +
manner O -
. O +

AVE8062 B-Chemical -
: O +
a O +
new O +
combretastatin B-Chemical +
derivative O +
vascular O +
disrupting O +
agent O -
. O +

Angiogenesis O +
has O +
an O +
essential O +
role O +
in O +
promoting O +
and O +
supporting O +
tumor O +
growth O +
and O +
it O +
is O +
an O +
important O +
therapeutic O +
target O -
. O +

The O +
tumor O +
vascular O +
network O +
is O +
the O +
result O +
of O +
pro O -
- O -
angiogenic O +
and O +
inhibitory O +
factors O +
as O +
well O +
as O +
of O +
the O +
interaction O +
between O +
endothelial O +
cells O +
and O +
extracellular O +
matrix O -
. O +

Different O +
antiangiogenic O +
therapeutics O +
have O +
been O +
developed O +
to O +
improve O +
tumor O +
control O +
through O +
vascular B-Chemical -
- I-Chemical -
targeting I-Chemical +
agents I-Chemical +
( O -
VTA B-Chemical -
) O -
. O +

VTAs B-Chemical +
can O +
be O +
divided O +
into O +
two O +
groups O -
: O +
antiangiogenic B-Chemical +
agents I-Chemical +
and O +
vascular B-Chemical -
- I-Chemical -
disrupting I-Chemical +
agents I-Chemical +
( O -
VDAs B-Chemical -
) O -
. O +

VTAs B-Chemical +
inhibit O +
specific O +
factors O +
required O +
to O +
induce O +
and O +
direct O +
the O +
angiogenic O +
process O -
, O +
with O +
major O +
activity O +
against O +
small O +
tumor O +
masses O +
and O +
at O +
the O +
tumor O +
periphery O -
, O +
encompassing O +
monoclonal O +
antibodies O +
and O +
small O +
molecules O +
inhibitors O +
of O +
the O +
tyrosine O +
kinase O +
domain O +
of O +
the O +
VEGF O +
receptor O -
. O +

VDAs B-Chemical +
specifically O +
target O +
and O +
destroy O +
well O -
- O -
established O +
tumor O +
vessels O +
with O +
ischemia O +
and O +
destruction O +
of O +
large O +
masses O +
with O +
central O +
hemorrhagic O +
necrosis O +
and O +
survival O +
of O +
a O +
thin O +
peripheral O +
tumor O +
layer O -
. O +

VDAs B-Chemical +
can O +
be O +
divided O +
into O +
biologics O -
, O +
such O +
as O +
ligand O -
- O -
based O -
, O +
and O +
small O -
- O -
molecule O +
agents O -
; O +
this O +
second O +
group O +
includes O +
small B-Chemical -
- I-Chemical -
molecule I-Chemical +
VDAs I-Chemical +
like O +
flavonoids B-Chemical -
, O +
such O +
as O +
5,6-dimethylxanthenone-4-acetic B-Chemical +
acid I-Chemical +
( O -
DMXAA B-Chemical -
) O -
, O +
and O +
microtubule B-Chemical -
- I-Chemical -
destabilizing I-Chemical +
agents I-Chemical -
. O +

In O +
this O +
review O +
we O +
will O +
discuss O +
the O +
mechanism O +
of O +
action O -
, O +
as O +
well O +
as O +
the O +
preclinical O +
and O +
clinical O +
results O -
, O +
of O +
one O +
of O +
the O +
most O +
promising O +
antitubulin B-Chemical +
agents I-Chemical -
: O +
the O +
combretastatin B-Chemical +
A4-phosphate I-Chemical +
derivative I-Chemical -
, O +
AVE8062A B-Chemical -
. O +

Targeting O +
TNF O +
for O +
Treatment O +
of O +
Cancer O +
and O +
Autoimmunity O -
. O +

Tumor O +
necrosis O +
factor O -
- O -
alpha O +
( O -
TNF O -
- O -
alpha O -
) O +
was O +
first O +
isolated O +
two O +
decades O +
ago O +
as O +
a O +
macrophageproduced O +
protein O +
that O +
can O +
effectively O +
kill O +
tumor O +
cells O -
. O +

TNF O -
- O -
alpha O +
is O +
also O +
an O +
essential O +
component O +
of O +
the O +
immune O +
system O +
and O +
is O +
required O +
for O +
hematopoiesis O -
, O +
for O +
protection O +
from O +
bacterial O +
infection O +
and O +
for O +
immune O +
cell O -
- O -
mediated O +
cytotoxicity O -
. O +

Extensive O +
research O -
, O +
however O -
, O +
has O +
revealed O +
that O +
TNF O -
- O -
alpha O +
is O +
one O +
of O +
the O +
major O +
players O +
in O +
tumor O +
initiation O -
, O +
proliferation O -
, O +
invasion O -
, O +
angiogenesis O +
and O +
metastasis O -
. O +

The O +
proinflammatory O +
activities O +
link O +
TNF O -
- O -
alpha O +
with O +
a O +
wide O +
variety O +
of O +
autoimmune O +
diseases O -
, O +
including O +
psoriasis O -
, O +
inflammatory O +
bowel O +
disease O -
, O +
rheumatoid O +
arthritis O -
, O +
systemic O +
sclerosis O -
, O +
systemic O +
lupus O +
erythematosus O -
, O +
multiple O +
sclerosis O -
, O +
diabetes O +
and O +
ankylosing O +
spondylitis O -
. O +

Systemic O +
inhibitors O +
of O +
TNF O +
such O +
as O +
etanercept B-Chemical +
( O -
Enbrel B-Chemical -
) O +
( O -
a O +
soluble O +
TNF O +
receptor O -
) O +
and O +
infliximab B-Chemical +
( O -
Remicade B-Chemical -
) O +
and O +
adalimumab B-Chemical +
( O -
Humira B-Chemical -
) O +
( O -
anti O -
- O -
TNF O +
antibodies O -
) O +
have O +
been O +
approved O +
for O +
the O +
treatment O +
inflammatory O +
bowel O +
disease O -
, O +
psoriasis O +
and O +
rheumatoid O +
arthritis O -
. O +

These O +
drugs O -
, O +
however O -
, O +
exhibit O +
severe O +
side O +
effects O +
and O +
are O +
expensive O -
. O +

Hence O +
orally O +
active O +
blockers O +
of O +
TNF O -
- O -
alpha O +
that O +
are O +
safe O -
, O +
efficacious O +
and O +
inexpensive O +
are O +
urgently O +
needed O -
. O +

Numerous O +
products O +
from O +
fruits O -
, O +
vegetable O +
and O +
traditional O +
medicinal O +
plants O +
have O +
been O +
described O +
which O +
can O +
suppress O +
TNF O +
expression O +
and O +
TNF O +
signaling O +
but O +
their O +
clinical O +
potential O +
is O +
yet O +
uncertain O -
. O +

Pbx1 O +
is O +
a O +
downstream O +
target O +
of O +
Evi-1 O +
in O +
hematopoietic O +
stem O -
/ O -
progenitors O +
and O +
leukemic O +
cells O -
. O +

Ecotropic O +
viral O +
integration O +
site-1 O +
( O -
Evi-1 O -
) O +
is O +
a O +
nuclear O +
transcription O +
factor O -
, O +
which O +
is O +
essential O +
for O +
the O +
proliferation O -
/ O -
maintenance O +
of O +
hematopoietic O +
stem O +
cells O +
( O -
HSCs O -
) O -
. O +

Aberrant O +
expression O +
of O +
Evi-1 O +
has O +
been O +
frequently O +
found O +
in O +
myeloid O +
leukemia O -
, O +
and O +
is O +
associated O +
with O +
a O +
poor O +
patient O +
survival O -
. O +

Recently O -
, O +
we O +
reported O +
candidate O +
target O +
genes O +
of O +
Evi-1 O +
shared O +
in O +
HSCs O +
and O +
leukemic O +
cells O +
using O +
gene O +
expression O +
profiling O +
analysis O -
. O +

In O +
this O +
study O -
, O +
we O +
identified O +
Pbx1 O -
, O +
a O +
proto O -
- O -
oncogene O +
in O +
hematopoietic O +
malignancy O -
, O +
as O +
a O +
target O +
gene O +
of O +
Evi-1 O -
. O +

Overexpression O +
of O +
Evi-1 O +
increased O +
Pbx1 O +
expression O +
in O +
hematopoietic O +
stem O -
/ O -
progenitor O +
cells O -
. O +

An O +
analysis O +
of O +
the O +
Pbx1 O +
promoter O +
region O +
revealed O +
that O +
Evi-1 O +
upregulates O +
Pbx1 O +
transcription O -
. O +

Furthermore O -
, O +
reduction O +
of O +
Pbx1 O +
levels O +
through O +
RNAi O -
- O -
mediated O +
knockdown O +
significantly O +
inhibited O +
Evi-1-induced O +
transformation O -
. O +

In O +
contrast O -
, O +
knockdown O +
of O +
Pbx1 O +
did O +
not O +
impair O +
bone O +
marrow O +
transformation O +
by O +
E2A O -
/ O -
HLF O +
or O +
AML1 O -
/ O -
ETO O -
, O +
suggesting O +
that O +
Pbx1 O +
is O +
specifically O +
required O +
for O +
the O +
maintenance O +
of O +
bone O +
marrow O +
transformation O +
mediated O +
by O +
Evi-1 O -
. O +

These O +
results O +
indicate O +
that O +
Pbx1 O +
is O +
a O +
target O +
gene O +
of O +
Evi-1 O +
involved O +
in O +
Evi-1-mediated O +
leukemogenesis O -
. O +

The O +
role O +
of O +
hypoxia O +
in O +
2-butoxyethanol B-Chemical -
- O -
induced O +
hemangiosarcoma O -
. O +

To O +
understand O +
the O +
molecular O +
mechanisms O +
underlying O +
compound O -
- O -
induced O +
hemangiosarcomas O +
in O +
mice O -
, O +
and O +
therefore O -
, O +
their O +
human O +
relevance O -
, O +
a O +
systems O +
biology O +
approach O +
was O +
undertaken O +
using O +
transcriptomics O +
and O +
Causal O +
Network O +
Modeling O +
from O +
mice O +
treated O +
with O +
2-butoxyethanol B-Chemical +
( O -
2-BE B-Chemical -
) O -
. O +

2-BE B-Chemical +
is O +
a O +
hemolytic O +
agent O +
that O +
induces O +
hemangiosarcomas O +
in O +
mice O -
. O +

We O +
hypothesized O +
that O +
the O +
hemolysis O +
induced O +
by O +
2-BE B-Chemical +
would O +
result O +
in O +
local O +
tissue O +
hypoxia O -
, O +
a O +
well O -
- O -
documented O +
trigger O +
for O +
endothelial O +
cell O +
proliferation O +
leading O +
to O +
hemangiosarcoma O -
. O +

Gene O +
expression O +
data O +
from O +
bone O +
marrow O +
( O -
BM O -
) O -
, O +
liver O -
, O +
and O +
spleen O +
of O +
mice O +
exposed O +
to O +
a O +
single O +
dose O +
( O -
4 O +
h O -
) O +
or O +
seven O +
daily O +
doses O +
of O +
2-BE B-Chemical +
were O +
used O +
to O +
develop O +
a O +
mechanistic O +
model O +
of O +
hemangiosarcoma O -
. O +

The O +
resulting O +
mechanistic O +
model O +
confirms O +
previous O +
work O +
proposing O +
that O +
2-BE B-Chemical +
induces O +
macrophage O +
activation O +
and O +
inflammation O +
in O +
the O +
liver O -
. O +

In O +
addition O -
, O +
the O +
model O +
supports O +
local O +
tissue O +
hypoxia O +
in O +
the O +
liver O +
and O +
spleen O -
, O +
coupled O +
with O +
increased O +
erythropoeitin O +
signaling O +
and O +
erythropoiesis O +
in O +
the O +
spleen O +
and O +
BM O -
, O +
and O +
suppression O +
of O +
mechanisms O +
that O +
contribute O +
to O +
genomic O +
stability O -
, O +
events O +
that O +
could O +
be O +
contributing O +
factors O +
to O +
hemangiosarcoma O +
formation O -
. O +

Finally O -
, O +
an O +
immunohistochemistry O +
method O +
( O -
Hypoxyprobe O -
) O +
demonstrated O +
that O +
tissue O +
hypoxia O +
was O +
present O +
in O +
the O +
spleen O +
and O +
BM O -
. O +

Together O -
, O +
the O +
results O +
of O +
this O +
study O +
identify O +
molecular O +
mechanisms O +
that O +
initiate O +
hemangiosarcoma O -
, O +
a O +
key O +
step O +
in O +
understanding O +
safety O +
concerns O +
that O +
can O +
impact O +
drug O +
decision O +
processes O -
, O +
and O +
identified O +
hypoxia O +
as O +
a O +
possible O +
contributing O +
factor O +
for O +
2-BE B-Chemical -
- O -
induced O +
hemangiosarcoma O +
in O +
mice O -
. O +

Magnitude O +
of O +
malate B-Chemical -
- I-Chemical -
aspartate I-Chemical +
reduced I-Chemical +
nicotinamide I-Chemical +
adenine I-Chemical +
dinucleotide I-Chemical +
shuttle O +
activity O +
in O +
intact O +
respiring O +
tumor O +
cells O -
. O +

Measurements O +
of O +
respiration O -
, O +
CO2 B-Chemical +
and O +
lactate B-Chemical +
production O -
, O +
and O +
changes O +
in O +
the O +
levels O +
of O +
various O +
key O +
metabolites O +
of O +
the O +
glycolytic O +
sequence O +
and O +
tricarboxylic B-Chemical +
acid I-Chemical +
cycle O +
were O +
made O +
on O +
five O +
lines O +
of O +
rodent O +
ascites O +
tumor O +
cells O +
( O -
two O +
strains O +
of O +
Ehrlich O +
ascites O +
tumor O +
cells O -
, O +
Krebs O +
II O +
carcinoma O -
, O +
AS-30D O +
carcinoma O -
, O +
and O +
L1210 O +
cells O -
) O +
incubated O +
aerobically O +
in O +
the O +
presence O +
of O +
uniformly O +
labeled O +
D- B-Chemical -
[ I-Chemical -
14C I-Chemical -
] I-Chemical -
glucose I-Chemical -
. O +

From O +
these O +
data O -
, O +
as O +
well O +
as O +
earlier O +
evidence O +
demonstrating O +
that O +
the O +
reduced O +
nicotinamide B-Chemical +
adenine I-Chemical +
dinucleotide I-Chemical +
( O -
NADH B-Chemical -
) O +
shuttle O +
in O +
these O +
cells O +
requires O +
a O +
transaminase O +
step O +
and O +
is O +
thus O +
identified O +
as O +
the O +
malate B-Chemical -
- O -
aspartate B-Chemical +
shuttle O +
( O -
W.V.V. O +
Greenhouse O +
and O +
A.L. O +
Lehninger O -
, O +
Cancer O +
Res O -
. O -
, O +
36 O -
: O +
1392 O -
- O -
1396 O -
, O +
1976 O -
) O -
, O +
metabolic O +
flux O +
diagrams O +
were O +
constructed O +
for O +
the O +
five O +
cell O +
lines O -
. O +

These O +
diagrams O +
show O +
the O +
relative O +
rates O +
of O +
glycolysis O -
, O +
the O +
tricarboxylic B-Chemical +
acid I-Chemical +
cycle O -
, O +
electron B-Chemical +
transport O -
, O +
and O +
the O +
malate B-Chemical -
- O -
aspartate B-Chemical +
shuttle O +
in O +
these O +
tumors O -
. O +

Large O +
amounts O +
of O +
cytosolic O +
NADH B-Chemical +
were O +
oxidized O +
by O +
the O +
mitochondrial O +
respiratory O +
chain O +
via O +
the O +
NADH B-Chemical +
shuttle O -
, O +
comprising O +
anywhere O +
from O +
about O +
20 O +
to O +
80 O -
% O +
of O +
the O +
total O +
flow O +
of O +
reducing O +
equivalents O +
to O +
oxygen B-Chemical +
in O +
these O +
tumors O -
. O +

Calculations O +
of O +
the O +
sources O +
of O +
energy O +
for O +
adenosine B-Chemical +
triphosphate I-Chemical +
synthesis O +
indicated O +
that O +
on O +
the O +
average O +
about O +
one O -
- O -
third O +
of O +
the O +
respiratory O +
adenosine B-Chemical +
triphosphate I-Chemical +
is O +
generated O +
by O +
electron B-Chemical +
flow O +
originating O +
from O +
cytosolic O +
NADH B-Chemical +
via O +
the O +
malate B-Chemical -
- O -
aspartate B-Chemical +
shuttle O -
. O +

AKT2 O +
is O +
a O +
downstream O +
target O +
of O +
metabotropic O +
glutamate O +
receptor O +
1 O +
( O -
Grm1 O -
) O -
. O +

We O +
reported O +
earlier O +
on O +
the O +
oncogenic O +
properties O +
of O +
Grm1 O +
by O +
demonstrating O +
that O +
stable O +
Grm1-mouse O -
- O -
melanocytic O +
clones O +
proliferate O +
in O +
the O +
absence O +
of O +
growth O +
supplement O +
and O +
anchorage O +
in O +
vitro O -
. O +

In O +
addition O -
, O +
these O +
clones O +
also O +
exhibit O +
aggressive O +
tumorigenic O +
phenotypes O +
in O +
vivo O +
with O +
short O +
latency O +
in O +
tumor O +
formation O +
in O +
both O +
immunodeficient O +
and O +
syngeneic O +
mice O -
. O +

We O +
also O +
detected O +
strong O +
activation O +
of O +
AKT O +
in O +
allograft O +
tumors O +
specifically O +
AKT2 O +
as O +
the O +
predominant O +
isoform O +
involved O -
. O +

In O +
parallel O -
, O +
we O +
assessed O +
several O +
human O +
melanoma O +
biopsy O +
samples O +
and O +
found O +
again O +
that O +
AKT2 O +
was O +
the O +
predominantly O +
activated O +
AKT O +
in O +
these O +
human O +
melanoma O +
biopsies O -
. O +

In O +
cultured O +
stable O +
Grm1-mouse O -
- O -
melanocytic O +
clones O -
, O +
as O +
well O +
as O +
an O +
metabotropic O +
glutamate O +
receptor O +
1 O +
( O -
Grm1 O -
) O +
expressing O +
human O +
melanoma O +
cell O +
line O -
, O +
C8161 O -
, O +
stimulation O +
of O +
Grm1 O +
by O +
its O +
agonist O +
led O +
to O +
the O +
activation O +
of O +
AKT O -
, O +
while O +
preincubation O +
with O +
Grm1-antagonist O +
abolished O +
Grm1-agonist O -
- O -
induced O +
AKT O +
activation O -
. O +

In O +
addition O -
, O +
a O +
reduction O +
in O +
tumor O +
volume O +
of O +
Grm1-mouse O -
- O -
melanocytic O -
- O -
allografts O +
was O +
detected O +
in O +
the O +
presence O +
of O +
small O +
interfering O +
AKT2 O +
RNA O +
( O -
siAKT2 O -
) O -
. O +

Taken O +
together O -
, O +
these O +
results O +
showed O +
that O -
, O +
in O +
addition O +
to O +
the O +
MAPK O +
pathway O +
previously O +
reported O +
being O +
a O +
downstream O +
target O +
of O +
stimulated O +
Grm1 O -
, O +
AKT2 O +
is O +
another O +
downstream O +
target O +
in O +
Grm1 O +
mediated O +
melanocyte O +
transformation O -
. O +

ICAM-3 O +
enhances O +
the O +
migratory O +
and O +
invasive O +
potential O +
of O +
human O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
cells O +
by O +
inducing O +
MMP-2 O +
and O +
MMP-9 O +
via O +
Akt O +
and O +
CREB O -
. O +

We O +
have O +
previously O +
reported O +
that O +
intercellular O +
adhesion O +
molecule-3 O +
( O -
ICAM-3 O -
) O +
is O +
associated O +
with O +
an O +
increase O +
of O +
cellular O +
radio O -
- O -
resistance O +
and O +
cancer O +
cell O +
proliferation O -
. O +

In O +
this O +
study O -
, O +
we O +
hypothesized O +
that O +
ICAM-3 O +
has O +
an O +
additional O +
effect O +
on O +
cancer O +
cell O +
migration O +
and O +
invasion O +
because O +
molecules O +
induced O +
by O +
ICAM-3 O +
are O +
known O +
as O +
regulators O +
of O +
cell O +
migration O +
and O +
invasion O -
. O +

To O +
examine O +
this O +
hypothesis O -
, O +
we O +
used O +
NCI O -
- O -
H1299 O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
( O -
NSCLC O -
) O +
cell O +
line O +
( O -
p53 O +
and O +
PTEN O +
null O +
cell O -
) O +
and O +
constructed O +
an O +
ICAM-3-over O -
- O -
expressing O +
stable O +
transfectant O -
, O +
which O +
exhibited O +
increased O +
cell O +
migration O +
and O +
invasion O -
. O +

The O +
increased O +
migration O +
and O +
invasion O +
resulted O +
from O +
up O -
- O -
regulation O +
of O +
expression O +
and O +
activities O +
of O +
MMP-2 O +
and O +
MMP-9 O -
. O +

ICAM-3 O +
also O +
increased O +
Akt O +
phosphorylation O -
, O +
which O +
caused O +
an O +
increase O +
in O +
cellular O +
migration O -
/ O -
invasion O +
and O +
MMP O +
activities O -
. O +

Activity O +
of O +
several O +
transcriptional O +
factors O +
located O +
downstream O +
in O +
the O +
Akt O +
pathway O +
was O +
also O +
tested O -
, O +
and O +
constitutive O +
activation O +
of O +
adenosine O +
3 O -
' O -
, O +
5'-monophosphate O +
response O +
element O -
- O -
binding O +
protein O +
( O -
CREB O -
) O +
by O +
ICAM-3 O +
was O +
detected O -
. O +

Blockage O +
of O +
the O +
Akt O +
pathway O +
attenuated O +
CREB O +
activation O -
, O +
and O +
a O +
decrease O +
in O +
CREB O +
expression O +
reduced O +
cellular O +
migration O -
/ O -
invasion O +
and O +
activity O +
of O +
MMPs O -
. O +

This O +
result O +
indicates O +
that O +
CREB O +
functions O +
in O +
the O +
signaling O +
pathway O +
between O +
Akt O +
and O +
MMP O -
. O +

We O +
also O +
showed O +
ICAM-3-induced O +
cell O +
migration O +
and O +
invasion O +
in O +
NCI O -
- O -
H460 O +
NSCLC O +
cells O +
( O -
wild O -
- O -
type O +
p53 O +
and O +
PTEN O +
cell O -
) O +
through O +
the O +
same O +
signaling O +
pathway O -
. O +

Taken O +
together O -
, O +
our O +
findings O +
suggest O +
that O +
ICAM-3 O +
stimulates O +
cancer O +
cell O +
migration O -
/ O -
invasion O +
via O +
ICAM-3 O -
/ O -
Akt O -
/ O -
CREB O -
/ O -
MMP O +
pathway O +
regardless O +
of O +
p53 O +
and O +
PTEN O +
status O -
, O +
and O +
this O +
reflects O +
the O +
possibility O +
that O +
ICAM-3 O +
could O +
be O +
considered O +
as O +
a O +
candidate O +
for O +
anti O -
- O -
cancer O +
drug O +
development O +
and O +
as O +
a O +
cancer O +
diagnostic O +
marker O -
. O +

Phenolic O +
fraction O +
of O +
tobacco B-Chemical +
smoke I-Chemical +
condensate I-Chemical +
potentiates O +
benzo B-Chemical -
[ I-Chemical -
a I-Chemical -
] I-Chemical -
pyerene I-Chemical +
diol I-Chemical +
epoxide I-Chemical -
- O -
induced O +
cell O +
transformation O -
: O +
role O +
of O +
protein O +
kinase O +
C. O +
In O +
this O +
study O +
we O +
separated O +
weakly O +
acidic O +
phenolic O +
components O +
from O +
other O +
neutral O -
, O +
acidic O +
and O +
basic O +
components O +
of O +
tobacco B-Chemical +
smoke I-Chemical +
condensate I-Chemical +
( O -
TSC B-Chemical -
) O +
and O +
observed O +
that O +
phenolic B-Chemical +
fraction I-Chemical +
of O +
TSC B-Chemical +
significantly O +
increased O +
the O +
number O +
of O +
colonies O +
of O +
promotion O -
- O -
sensitive O +
JB6 O +
Cl41 O +
cells O +
that O +
showed O +
anchorage O -
- O -
independent O +
growth O +
on O +
soft O +
agar O +
in O +
response O +
to O +
BPDE B-Chemical +
( O -
an O +
ultimate O +
carcinogen O +
produced O +
by O +
metabolic O +
activation O +
of O +
the O +
PAH B-Chemical +
benzo I-Chemical -
[ I-Chemical -
a I-Chemical -
] I-Chemical -
pyrene I-Chemical -
) O -
. O +

Anchorage O -
- O -
independent O +
cell O +
growth O +
is O +
indicative O +
of O +
cell O +
transformation O +
resulting O +
in O +
acquisition O +
of O +
tumorigenic O +
potential O -
. O +

In O +
order O +
to O +
understand O +
the O +
underlying O +
mechanism O +
by O +
which O +
TSC B-Chemical +
phenolic I-Chemical +
fraction I-Chemical +
potentiates O +
BPDE B-Chemical -
- O -
induced O +
tumorigenicity O -
, O +
we O +
examined O +
its O +
effect O +
on O +
the O +
activation O +
of O +
two O +
transcription O +
factors O +
AP-1 O +
and O +
NF O -
- O -
kappaB O +
which O +
are O +
known O +
to O +
be O +
influenced O +
by O +
established O +
tumor O +
promoter O +
TPA B-Chemical -
. O +

BPDE B-Chemical +
treatment O +
caused O +
induction O +
of O +
both O +
AP-1 O +
and O +
NF O -
- O -
kappaB O +
activity O +
as O +
determined O +
by O +
luciferase O +
reporter O +
assay O +
and O +
only O +
NF O -
- O -
kappaB O +
induction O +
in O +
response O +
to O +
BPDE B-Chemical +
was O +
significantly O +
attenuated O +
by O +
TSC B-Chemical +
phenolic I-Chemical +
fraction I-Chemical +
whereas O +
AP-1 O +
induction O +
remains O +
unaltered O -
. O +

Attenuation O +
of O +
NF O -
- O -
kappaB O +
activation O +
by O +
TSC B-Chemical +
phenolic I-Chemical +
fraction I-Chemical +
was O +
associated O +
with O +
significant O +
decrease O +
of O +
intracellular O +
PKC O +
substrate O +
phosphorylation O +
in O +
BPDE B-Chemical +
treated O +
cells O -
. O +

Non O -
- O -
specific O +
PKC O +
inhibitors O +
staurosporine B-Chemical +
and O +
bisindolylmaleimide B-Chemical +
II I-Chemical +
as O +
well O +
as O +
inhibitors O +
specific O +
to O +
conventional O +
PKCs O +
( O -
Go6976 B-Chemical -
) O +
and O +
PKC O -
- O -
delta O +
( O -
rottlerin B-Chemical -
) O +
attenuated O +
NF O -
- O -
kappaB O +
activation O +
in O +
BPDE B-Chemical +
treated O +
cells O +
to O +
a O +
varying O +
degree O +
indicating O +
a O +
possible O +
link O +
between O +
PKC O +
down O -
- O -
regulation O +
and O +
the O +
attenuation O +
of O +
NF O -
- O -
kappaB O +
activity O +
by O +
TSC B-Chemical +
phenolic I-Chemical +
fraction I-Chemical -
. O +

Treatment O +
of O +
cells O +
with O +
PKC O +
inhibitors O +
also O +
potentiated O +
anchorage O -
- O -
independent O +
growth O +
of O +
BPDE B-Chemical +
treated O +
cells O +
on O +
soft O +
agar O -
. O +

Our O +
data O +
suggest O +
a O +
possible O +
role O +
of O +
PKC O +
down O -
- O -
regulation O +
in O +
potentiation O +
of O +
BPDE B-Chemical -
- O -
induced O +
tumorogenicity O +
by O +
TSC B-Chemical +
phenolic I-Chemical +
fraction I-Chemical -
. O +

The O +
role O +
of O +
p53 O +
in O +
glucose B-Chemical +
metabolism O -
. O +

The O +
p53 O +
protein O +
functions O +
to O +
prevent O +
tumour O +
development O +
by O +
inhibiting O +
the O +
outgrowth O +
of O +
stressed O +
or O +
damaged O +
cells O -
. O +

In O +
addition O +
to O +
well O +
established O +
functions O +
to O +
block O +
cell O +
proliferation O -
, O +
recent O +
studies O +
have O +
revealed O +
a O +
role O +
for O +
p53 O +
in O +
the O +
regulation O +
of O +
pathways O +
involved O +
in O +
glucose B-Chemical +
metabolism O -
. O +

The O +
metabolic O +
functions O +
of O +
p53 O +
resist O +
the O +
shift O +
to O +
glycolysis O +
that O +
is O +
characteristically O +
seen O +
in O +
cancers O -
, O +
and O +
also O +
help O +
cells O +
adapt O +
to O +
and O +
survive O +
limited O +
periods O +
of O +
metabolic O +
stress O -
. O +

Such O +
activities O +
of O +
p53 O +
would O +
not O +
only O +
help O +
to O +
prevent O +
cancer O +
development O -
, O +
but O +
might O +
also O +
contribute O +
to O +
non O -
- O -
tumour O +
related O +
roles O +
for O +
p53 O -
, O +
such O +
as O +
in O +
the O +
regulation O +
of O +
longevity O -
. O +

These O +
new O +
functions O +
of O +
p53 O +
are O +
providing O +
interesting O +
possibilities O +
for O +
the O +
development O +
of O +
novel O +
therapies O -
. O +

14 O -
- O -
3 O -
- O -
3zeta O +
Overexpression O +
and O +
abnormal O +
beta O -
- O -
catenin O +
expression O +
are O +
associated O +
with O +
poor O +
differentiation O +
and O +
progression O +
in O +
stage O +
I O +
non O -
- O -
small O +
cell O +
lung O +
cancer O -
. O +

Recent O +
studies O +
have O +
shown O +
that O +
14 O -
- O -
3 O -
- O -
3zeta O +
interacted O +
with O +
other O +
key O +
cellular O +
proteins O +
involved O +
in O +
the O +
tumor O +
development O +
and O +
progression O -
. O +

Knowledge O +
of O +
14 O -
- O -
3 O -
- O -
3zeta O +
and O +
beta O -
- O -
catenin O +
expression O +
and O +
clinical O +
significance O +
in O +
the O +
same O +
tumor O +
tissues O +
is O +
limited O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
expression O +
and O +
significance O +
of O +
14 O -
- O -
3 O -
- O -
3zeta O +
and O +
beta O -
- O -
catenin O +
in O +
stage O +
I O +
non O -
- O -
small O -
- O -
cell O +
lung O +
cancer O +
( O -
NSCLC O -
) O -
. O +

Specimens O +
of O +
NSCLC O +
and O +
adjacent O +
normal O +
lung O +
tissues O +
were O +
collected O +
from O +
110 O +
patients O -
. O +

The O +
expressions O +
of O +
14 O -
- O -
3 O -
- O -
3zeta O +
and O +
beta O -
- O -
catenin O +
were O +
detected O +
by O +
western O +
blotting O -
, O +
double O +
labeling O +
immunofluorescence O -
, O +
confocal O +
laser O +
scanning O +
microscopy O +
and O +
immunohistochemistry O -
. O +

The O +
expression O +
of O +
14 O -
- O -
3 O -
- O -
3zeta O +
was O +
upregulated O +
in O +
stage O +
I O +
NSCLC O -
. O +

Further O -
, O +
the O +
overexpression O +
of O +
14 O -
- O -
3 O -
- O -
3zeta O +
correlated O +
with O +
histological O +
grades O -
, O +
lymph O +
node O +
metastasis O +
and O +
poor O +
clinical O +
outcome O -
. O +

Abnormal O +
expression O +
of O +
beta O -
- O -
catenin O +
was O +
significantly O +
correlated O +
with O +
poor O +
differentiation O +
and O +
lymph O +
node O +
metastasis O -
. O +

Abnormal O +
beta O -
- O -
catenin O +
expression O +
was O +
associated O +
significantly O +
with O +
positive O +
14 O -
- O -
3 O -
- O -
3zeta O +
expression O -
. O +

In O +
conclusion O -
, O +
14 O -
- O -
3 O -
- O -
3zeta O +
and O +
beta O -
- O -
catenin O +
might O +
have O +
an O +
important O +
role O +
in O +
development O -
, O +
progression O +
and O +
metastatic O +
process O +
of O +
NSCLC O -
. O +

14 O -
- O -
3 O -
- O -
3zeta O +
might O +
be O +
used O +
as O +
prognostic O +
biomarkers O +
for O +
NSCLC O -
. O +

Killing O +
tumor O +
cells O +
through O +
their O +
surface O +
beta O -
( O -
2 O -
) O -
-microglobulin O +
or O +
major O +
histocompatibility O +
complex O +
class O +
I O +
molecules O -
. O +

Targeted O +
antibody O -
- O -
based O +
therapy O +
has O +
been O +
used O +
successfully O +
to O +
treat O +
cancers O -
. O +

Recent O +
studies O +
have O +
demonstrated O +
that O +
tumor O +
cells O +
treated O +
with O +
antibodies O +
specific O +
for O +
beta O -
( O -
2 O -
) O -
-microglobulin O +
( O -
beta O -
( O -
2 O -
) O -
M O -
) O +
or O +
major O +
histocompatibility O +
complex O +
( O -
MHC O -
) O +
class O +
I O +
molecules O +
undergo O +
apoptosis O +
in O +
vitro O +
and O +
in O +
vivo O +
( O -
mouse O +
models O -
) O -
. O +

Antibodies O +
against O +
beta O -
( O -
2 O -
) O -
M O +
or O +
MHC O +
class O +
I O +
induce O +
tumor O +
cell O +
apoptosis O +
by O +
1 O -
) O +
recruiting O +
MHC O +
class O +
I O +
molecules O +
to O +
lipid O +
rafts O +
and O +
activating O +
LYN O +
kinase O +
and O +
the O +
signal O -
- O -
transducing O +
enzyme O +
phospholipase O +
C O -
- O -
gamma2-dependent O +
c O -
- O -
Jun O +
N O -
- O -
terminal O +
kinase O +
signaling O +
pathway O +
and O +
2 O -
) O +
expelling O +
interleukin O +
6 O +
and O +
insulin O -
- O -
like O +
growth O +
factor O +
1 O +
receptors O +
out O +
of O +
lipid O +
rafts O +
and O +
inhibiting O +
the O +
growth O +
and O +
survival O +
factor O -
- O -
induced O +
activation O +
of O +
the O +
phosphatidylinositol O +
3-kinase O -
/ O -
Akt O +
and O +
extracellular O +
signal O -
- O -
related O +
kinase O +
pathways O -
. O +

Consequently O -
, O +
mitochondrial O +
integrity O +
is O +
compromised O -
, O +
and O +
the O +
caspase-9-dependent O +
cascade O +
is O +
activated O +
in O +
treated O +
tumor O +
cells O -
. O +

However O -
, O +
although O +
beta O -
( O -
2 O -
) O -
M O +
and O +
MHC O +
class O +
I O +
are O +
expressed O +
on O +
normal O +
hematopoietic O +
cells O -
, O +
which O +
is O +
a O +
potential O +
safety O +
concern O -
, O +
the O +
monoclonal O +
antibodies O +
were O +
selective O +
to O +
tumor O +
cells O +
and O +
did O +
not O +
damage O +
normal O +
cells O +
in O +
vitro O +
or O +
in O +
human O -
- O -
like O +
mouse O +
models O -
. O +

These O +
findings O +
suggest O +
that O +
targeting O +
beta O -
( O -
2 O -
) O -
M O +
or O +
MHC O +
class O +
I O +
by O +
using O +
antibodies O +
or O +
other O +
agents O +
offers O +
a O +
potential O +
therapeutic O +
approach O +
for O +
beta O -
( O -
2 O -
) O -
M O -
/ O -
MHC O +
class O +
I O -
- O -
expressing O +
malignancies O -
. O +

Cancer O +
2010 O -
. O +

( O -
c O -
) O +
2010 O +
American O +
Cancer O +
Society O -
. O +

p24 O +
family O +
type O +
1 O +
transmembrane O +
proteins O +
are O +
required O +
for O +
insulin O +
biosynthesis O +
and O +
secretion O +
in O +
pancreatic O +
beta O -
- O -
cells O -
. O +

The O +
p24 O +
protein O +
family O +
have O +
multiple O +
functions O +
in O +
protein O +
transport O +
in O +
the O +
early O +
secretory O +
pathway O -
. O +

In O +
this O +
study O +
we O +
examined O +
the O +
role O +
of O +
p24 O +
proteins O +
in O +
insulin O +
transport O -
. O +

Several O +
members O +
were O +
detected O +
in O +
insulinoma O +
cell O +
lines O +
and O +
rat O +
islets O +
and O +
expression O +
levels O +
positively O +
correlated O +
with O +
insulin O +
abundance O -
, O +
particularly O +
for O +
p24delta1 O +
and O +
p24beta1 O -
. O +

Knocking O +
down O +
p24delta1 O +
in O +
insulinoma O +
cell O +
lines O -
, O +
which O +
also O +
resulted O +
in O +
the O +
concomitant O +
knock O -
- O -
down O +
of O +
other O +
family O +
members O -
, O +
impaired O +
glucose B-Chemical -
- O -
stimulated O +
insulin O +
secretion O -
, O +
decreased O +
total O +
cellular O +
insulin O +
content O +
and O +
reduced O +
proinsulin O +
biosynthesis O -
. O +

There O +
was O +
no O +
effect O +
on O +
overall O +
protein O +
biosynthesis O +
or O +
ER O +
stress O -
. O +

These O +
results O +
suggest O +
that O +
p24delta1 O +
and O +
possibly O +
other O +
p24 O +
family O +
proteins O +
are O +
required O +
for O +
normal O +
insulin O +
biosynthesis O +
and O +
subsequent O +
secretion O +
in O +
pancreatic O +
beta O -
- O -
cells O -
. O +

Lactate O -
- O -
dehydrogenase O +
5 O +
is O +
overexpressed O +
in O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
and O +
correlates O +
with O +
the O +
expression O +
of O +
the O +
transketolase O -
- O -
like O +
protein O +
1 O -
. O +

AIMS O -
: O +
As O +
one O +
of O +
the O +
five O +
lactate O +
dehydrogenase O +
( O -
LDH O -
) O +
isoenzymes O -
, O +
LDH5 O +
has O +
the O +
highest O +
efficiency O +
to O +
catalyze O +
pyruvate B-Chemical +
transformation O +
to O +
lactate B-Chemical -
. O +

LDH5 O +
overexpression O +
in O +
cancer O +
cells O +
induces O +
an O +
upregulated O +
glycolytic O +
metabolism O +
and O +
reduced O +
dependence O +
on O +
the O +
presence O +
of O +
oxygen B-Chemical -
. O +

Here O +
we O +
analyzed O +
LDH5 O +
protein O +
expression O +
in O +
a O +
well O +
characterized O +
large O +
cohort O +
of O +
primary O +
lung O +
cancers O +
in O +
correlation O +
to O +
clinico O -
- O -
pathological O +
data O +
and O +
its O +
possible O +
impact O +
on O +
patient O +
survival O -
. O +

METHODS O -
: O +
Primary O +
lung O +
cancers O +
( O -
n O +
= O +
269 O -
) O +
and O +
non O +
neoplastic O +
lung O +
tissue O +
( O -
n O +
= O +
35 O -
) O +
were O +
tested O +
for O +
LDH5 O +
expression O +
by O +
immunohistochemistry O +
using O +
a O +
polyclonal O +
LDH5 O +
antibody O +
( O -
ab53010 O -
) O -
. O +

The O +
results O +
of O +
LDH5 O +
expression O +
were O +
correlated O +
to O +
clinico O -
- O -
pathological O +
data O +
as O +
well O +
as O +
to O +
patient O -
's O +
survival O -
. O +

In O +
addition O -
, O +
the O +
results O +
of O +
the O +
previously O +
tested O +
transketolase O +
like O +
1 O +
protein O +
( O -
TKTL1 O -
) O +
expression O +
were O +
correlated O +
to O +
LDH5 O +
expression O -
. O +

RESULTS O -
: O +
89.5 O -
% O +
( O -
n O +
= O +
238 O -
) O +
of O +
NSCLC O +
revealed O +
LDH5 O +
expression O +
whereas O +
LDH5 O +
expression O +
was O +
not O +
detected O +
in O +
non O +
neoplastic O +
lung O +
tissues O +
( O -
n O +
= O +
34 O -
) O +
( O -
p O +
< O +
0.0001 O -
) O -
. O +

LDH5 O +
overexpression O +
was O +
associated O +
with O +
histological O +
type O +
( O -
adenocarcinoma O +
= O +
57 O -
% O -
, O +
squamous O +
cell O +
carcinoma O +
= O +
45 O -
% O -
, O +
large O +
cell O +
carcinoma O +
= O +
46 O -
% O -
, O +
p O +
= O +
0.006 O -
) O -
. O +

No O +
significant O +
correlation O +
could O +
be O +
detected O +
with O +
regard O +
to O +
TNM O -
- O -
stage O -
, O +
grading O +
or O +
survival O -
. O +

A O +
two O +
sided O +
correlation O +
between O +
the O +
expression O +
of O +
TKTL1 O +
and O +
LDH5 O +
could O +
be O +
shown O +
( O -
p O +
= O +
0.002 O -
) O +
within O +
the O +
overall O +
cohort O +
as O +
well O +
as O +
for O +
each O +
grading O +
and O +
pN O +
group O -
. O +

A O +
significant O +
correlation O +
between O +
LDH5 O +
and O +
TKTL1 O +
within O +
each O +
histologic O +
tumortype O +
could O +
not O +
be O +
revealed O -
. O +

CONCLUSIONS O -
: O +
LDH5 O +
is O +
overexpressed O +
in O +
NSCLC O +
and O +
could O +
hence O +
serve O +
as O +
an O +
additional O +
marker O +
for O +
malignancy O -
. O +

Furthermore O -
, O +
LDH5 O +
correlates O +
positively O +
with O +
the O +
prognostic O +
marker O +
TKTL1 O -
. O +

Our O +
results O +
confirm O +
a O +
close O +
link O +
between O +
the O +
two O +
metabolic O +
enzymes O +
and O +
indicate O +
an O +
alteration O +
in O +
the O +
glucose B-Chemical +
metabolism O +
in O +
the O +
process O +
of O +
malignant O +
transformation O -
. O +

Expression O +
of O +
KISS1 O +
and O +
MMP-9 O +
in O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
and O +
their O +
relations O +
to O +
metastasis O +
and O +
survival O -
. O +

KISS1 O +
and O +
matrix O +
metalloproteinase-9 O +
( O -
MMP-9 O -
) O +
may O +
play O +
important O +
roles O +
as O +
metastasis O +
suppressor O +
and O +
metastasis O +
promoter O +
genes O -
, O +
respectively O -
, O +
in O +
a O +
variety O +
of O +
malignancies O -
. O +

However O -
, O +
there O +
is O +
little O +
information O +
about O +
their O +
possible O +
roles O +
in O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
( O -
NSCLC O -
) O -
. O +

The O +
goals O +
of O +
this O +
study O +
were O +
to O +
determine O +
the O +
mRNA O +
and O +
protein O +
expressions O +
of O +
KISS1 O +
and O +
MMP-9 O +
in O +
NSCLC O +
and O +
their O +
relations O +
to O +
metastasis O +
and O +
prognosis O -
. O +

The O +
mRNA O +
and O +
protein O +
expressions O +
of O +
KISS1 O +
and O +
of O +
MMP-9 O +
protein O +
were O +
detected O +
by O +
in O +
situ O +
hybridization O +
and O +
immunohistochemistry O +
respectively O +
in O +
85 O +
cases O +
of O +
NSCLC O -
, O +
and O +
their O +
matched O +
lymph O +
node O +
metastases O -
. O +

Expressions O +
of O +
KISS1 O +
mRNA O +
and O +
protein O +
were O +
significantly O +
higher O +
in O +
low O +
TNM O +
stages O +
of O +
NSCLC O +
( O -
I O -
- O -
II O -
) O +
compared O +
to O +
more O +
advanced O +
stages O +
( O -
III O -
- O -
IV O -
) O +
( O -
p<0.05 O -
) O -
. O +

Moreover O -
, O +
in O +
advanced O +
TNM O +
stages O -
, O +
cases O +
without O +
metastasis O +
had O +
higher O +
KISS1 O +
gene O +
expression O +
compared O +
to O +
those O +
with O +
lymph O +
node O +
metastasis O +
( O -
p<0.05 O -
) O -
. O +

In O +
contrast O -
, O +
MMP-9 O +
expression O +
was O +
higher O +
in O +
stage O +
III O -
- O -
IV O +
NSCLC O +
cases O +
compared O +
to O +
stage O +
I O -
- O -
II O +
tumors O +
( O -
p<0.05 O -
) O +
and O +
higher O +
in O +
NSCLC O +
cases O +
with O +
metastasis O +
than O +
those O +
without O +
metastasis O +
( O -
p<0.05 O -
) O -
. O +

There O +
was O +
negative O +
correction O +
between O +
KISS1 O +
and O +
MMP-9 O +
protein O +
expression O +
( O -
p<0.01 O -
) O -
. O +

The O +
5-year O +
survival O +
rate O +
in O +
cases O +
with O +
higher O +
KISS1 O +
protein O +
expression O +
was O +
significantly O +
higher O +
than O +
in O +
those O +
with O +
low O +
expression O +
( O -
20.9 O +
vs. O +
2.4 O -
% O -
, O +
p<0.01 O -
) O -
. O +

However O -
, O +
the O +
5-year O +
survival O +
rate O +
of O +
patients O +
with O +
high O +
MMP-9 O +
protein O +
expression O +
were O +
lower O +
than O +
those O +
with O +
low O +
expression O +
( O -
19 O +
vs. O +
4.7 O -
% O -
, O +
p<0.05 O -
) O -
. O +

Our O +
data O +
suggest O +
that O +
KISS1 O +
and O +
MMP-9 O +
may O +
serve O +
as O +
potential O +
prognostic O +
and O +
therapeutic O +
markers O +
in O +
lung O +
cancer O -
. O +

Loss O +
of O +
CDC4 O -
/ O -
FBXW7 O +
in O +
gastric O +
carcinoma O -
. O +

BACKGROUND O -
: O +
CDC4 O -
/ O -
FBXW7 O -
, O +
encoding O +
a O +
ubiquitin O +
ligase O -
, O +
maps O +
to O +
4q32 O +
and O +
has O +
been O +
implicated O +
as O +
a O +
tumor O +
suppressor O +
gene O +
and O +
therapeutic O +
target O +
in O +
many O +
tumor O +
types O -
. O +

Mutations O +
in O +
colonic O +
adenomas O -
, O +
and O +
the O +
frequent O +
losses O +
on O +
4q O +
described O +
in O +
gastric O +
cancer O +
prompt O +
speculation O +
about O +
the O +
role O +
of O +
CDC4 O -
/ O -
FBXW7 O +
in O +
gastric O +
carcinogenesis O -
. O +

METHODS O -
: O +
We O +
assessed O +
the O +
role O +
of O +
CDC4 O -
/ O -
FBXW7 O +
in O +
gastric O +
cancer O -
, O +
through O +
loss O +
of O +
heterozygosity O +
( O -
LOH O -
) O +
and O +
multiplex O +
ligation O -
- O -
dependent O +
probe O +
amplification O +
( O -
MLPA O -
) O +
on O +
47 O +
flow O -
- O -
sorted O +
gastric O +
carcinomas O +
including O +
early O -
- O -
onset O +
gastric O +
cancers O +
( O -
EOGC O -
) O +
and O +
xenografted O +
conventional O +
gastric O +
carcinomas O -
. O +

Ploidy O +
analysis O +
was O +
carried O +
out O +
on O +
39 O +
EOGCs O +
and O +
immunohistochemistry O +
of O +
CDC4 O -
/ O -
FBXW7 O +
and O +
its O +
substrates O +
c O -
- O -
myc O -
, O +
c O -
- O -
jun O -
, O +
Notch O +
and O +
cyclin O +
E O +
was O +
performed O +
on O +
204 O +
gastric O +
carcinomas O +
using O +
tissue O +
microarrays O +
( O -
TMAs O -
) O -
. O +

Sequence O +
analysis O +
of O +
CDC4 O -
/ O -
FBXW7 O +
was O +
carried O +
out O +
on O +
gastric O +
carcinoma O +
cell O +
lines O +
and O +
xenografts O -
. O +

RESULTS O -
: O +
Loss O +
of O +
heterozygosity O +
of O +
CDC4 O -
/ O -
FBXW7 O +
occurred O +
in O +
32 O -
% O +
of O +
EOGCs O -
, O +
and O +
correlated O +
with O +
loss O +
of O +
expression O +
in O +
26 O -
% O -
. O +

Loss O +
of O +
expression O +
was O +
frequent O +
in O +
both O +
EOGC O +
and O +
conventional O +
gastric O +
cancers O -
. O +

No O +
CDC4 O -
/ O -
FBXW7 O +
mutations O +
were O +
found O +
and O +
loss O +
of O +
CDC4 O -
/ O -
FBXW7 O +
did O +
not O +
correlate O +
with O +
ploidy O +
status O -
. O +

There O +
was O +
a O +
significant O +
correlation O +
between O +
loss O +
of O +
CDC4 O -
/ O -
FBXW7 O +
expression O +
and O +
upregulation O +
of O +
c O -
- O -
myc O -
. O +

CONCLUSION O -
: O +
Loss O +
of O +
CDC4 O -
/ O -
FBXW7 O +
appears O +
to O +
play O +
a O +
role O +
in O +
both O +
EOGC O +
and O +
conventional O +
gastric O +
carcinogenesis O -
, O +
and O +
c O -
- O -
myc O +
overexpression O +
is O +
likely O +
to O +
be O +
an O +
important O +
oncogenic O +
consequence O +
of O +
CDC4 O -
/ O -
FBXW7 O +
loss O -
. O +

Angiogenesis O +
inhibitors O -
: O +
current O +
strategies O +
and O +
future O +
prospects O -
. O +

Angiogenesis O +
has O +
become O +
an O +
attractive O +
target O +
for O +
drug O +
therapy O +
because O +
of O +
its O +
key O +
role O +
in O +
tumor O +
growth O -
. O +

An O +
extensive O +
array O +
of O +
compounds O +
is O +
currently O +
in O +
preclinical O +
development O -
, O +
with O +
many O +
now O +
entering O +
the O +
clinic O +
and/or O +
achieving O +
approval O +
from O +
the O +
US O +
Food O +
and O +
Drug O +
Administration O -
. O +

Several O +
regulatory O +
and O +
signaling O +
molecules O +
governing O +
angiogenesis O +
are O +
of O +
interest O -
, O +
including O +
growth O +
factors O +
( O -
eg O -
, O +
vascular O +
endothelial O +
growth O +
factor O -
, O +
platelet O -
- O -
derived O +
growth O +
factor O -
, O +
fibroblast O +
growth O +
factor O -
, O +
and O +
epidermal O +
growth O +
factor O -
) O -
, O +
receptor O +
tyrosine O +
kinases O -
, O +
and O +
transcription O +
factors O +
such O +
as O +
hypoxia O +
inducible O +
factor O -
, O +
as O +
well O +
as O +
molecules O +
involved O +
in O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
and O +
phosphoinositide O +
3-kinase O +
( O -
PI3 O -
K O -
) O +
signaling O -
. O +

Pharmacologic O +
agents O +
have O +
been O +
identified O +
that O +
target O +
these O +
pathways O -
, O +
yet O +
for O +
some O +
agents O +
( O -
notably O +
thalidomide B-Chemical -
) O -
, O +
an O +
understanding O +
of O +
the O +
specific O +
mechanisms O +
of O +
antitumor O +
action O +
has O +
proved O +
elusive O -
. O +

The O +
following O +
review O +
describes O +
key O +
molecular O +
mechanisms O +
and O +
novel O +
therapies O +
that O +
are O +
on O +
the O +
horizon O +
for O +
antiangiogenic O +
tumor O +
therapy O -
. O +

Betulin B-Chemical +
induces O +
mitochondrial O +
cytochrome O +
c O +
release O +
associated O +
apoptosis O +
in O +
human O +
cancer O +
cells O -
. O +

We O +
examined O +
whether O +
betulin B-Chemical -
, O +
a O +
naturally O +
abundant O +
compound O -
, O +
has O +
anticancer O +
functions O +
in O +
human O +
cancer O +
cells O -
. O +

The O +
results O +
showed O +
that O +
betulin B-Chemical +
significantly O +
inhibited O +
cell O +
viability O +
in O +
cervix O +
carcinoma O +
HeLa O +
cells O -
, O +
hepatoma O +
HepG2 O +
cells O -
, O +
lung O +
adenocarcinoma O +
A549 O +
cells O -
, O +
and O +
breast O +
cancer O +
MCF-7 O +
cells O +
with O +
IC O -
( O -
50 O -
) O +
values O +
ranging O +
from O +
10 O +
to O +
15 O +
microg O -
/ O -
mL. O +
While O +
betulin B-Chemical +
exhibited O +
only O +
moderate O +
anticancer O +
activity O +
in O +
other O +
human O +
cancer O +
cells O +
such O +
as O +
hepatoma O +
SK O -
- O -
HEP-1 O +
cells O -
, O +
prostate O +
carcinoma O +
PC-3 O -
, O +
and O +
lung O +
carcinoma O +
NCI O -
- O -
H460 O -
, O +
with O +
IC O -
( O -
50 O -
) O +
values O +
ranging O +
from O +
20 O +
to O +
60 O +
microg O -
/ O -
mL O -
, O +
it O +
showed O +
minor O +
growth O +
inhibition O +
in O +
human O +
erythroleukemia O +
K562 O +
cells O +
( O -
IC O -
( O -
50 O -
) O +
> O +
100 O +
microg O -
/ O -
mL O -
) O -
. O +

We O +
further O +
investigated O +
the O +
mechanism O +
of O +
anticancer O +
activity O +
by O +
betulin B-Chemical -
, O +
using O +
HeLa O +
cells O +
as O +
an O +
experimental O +
model O -
. O +

Betulin B-Chemical +
( O -
10 O +
microg O -
/ O -
mL O -
) O +
induces O +
apoptotic O +
cell O +
death O -
, O +
as O +
evidenced O +
by O +
morphological O +
characteristics O +
such O +
as O +
membrane O +
phosphatidylserine O +
translocation O -
, O +
nuclear O +
condensation O -
/ O -
fragmentation O -
, O +
and O +
apoptotic O +
body O +
formation O -
. O +

A O +
kinetics O +
analysis O +
showed O +
that O +
the O +
depolarization O +
of O +
mitochondrial O +
membrane O +
potential O +
and O +
the O +
release O +
of O +
mitochondrial O +
cytochrome O +
c O +
occurred O +
as O +
early O +
as O +
30 O +
min O +
after O +
treatment O +
with O +
betulin B-Chemical -
. O +

Betulin B-Chemical -
, O +
unlike O +
its O +
chemical O +
derivative O +
betulinic B-Chemical +
acid I-Chemical -
, O +
did O +
not O +
directly O +
trigger O +
mitochondrial O +
cytochrome O +
c O +
release O +
in O +
isolated O +
mitochondria O -
. O +

Importantly O -
, O +
Bax O +
and O +
Bak O +
were O +
rapidly O +
translocated O +
to O +
the O +
mitochondria O +
30 O +
min O +
after O +
betulin B-Chemical +
treatment O -
. O +

The O +
sequential O +
activation O +
of O +
caspase-9 O +
and O +
caspase-3 O -
/ O -
-7 O +
and O +
the O +
cleavage O +
of O +
poly O -
( O -
ADP O -
- O -
ribose O -
) O +
polymerase O +
( O -
PARP O -
) O +
were O +
observed O +
behind O +
those O +
mitochondrial O +
events O -
. O +

Furthermore O -
, O +
specific O +
downregulation O +
of O +
either O +
caspase-9 O -
, O +
Bax O -
, O +
or O +
Bak O +
by O +
siRNA O +
effectively O +
reduced O +
PARP O +
cleavage O +
and O +
caspase-3 O +
activation O -
. O +

Taken O +
together O -
, O +
the O +
lines O +
of O +
evidence O +
demonstrate O +
that O +
betulin B-Chemical +
triggers O +
apoptosis O +
of O +
human O +
cancer O +
cells O +
through O +
the O +
intrinsic O +
apoptotic O +
pathway O -
. O +

Overexpression O +
of O +
Bax O +
inhibitor-1 O +
( O -
BI-1 O -
) O +
induces O +
cell O +
transformation O +
in O +
NIH3T3 O +
cells O -
. O +

BI-1 O +
( O -
Bax O +
inhibitor-1 O -
) O -
, O +
an O +
apoptosis O -
- O -
inhibiting O +
gene O +
belonging O +
to O +
the O +
Bcl-2 O +
protein O +
family O -
, O +
plays O +
an O +
important O +
role O +
in O +
mitochondrial O +
apoptosis O +
pathway O +
to O +
suppress O +
Bax O -
- O -
induced O +
apoptosis O -
. O +

To O +
investigate O +
the O +
potential O +
role O +
of O +
BI-1 O +
in O +
promoting O +
cell O +
growth O +
and O +
tumorigenesis O -
, O +
in O +
the O +
present O +
study O +
we O +
overexpressed O +
the O +
BI-1 O +
gene O +
in O +
NIH3T3 O +
cells O +
using O +
the O +
lentivirus O -
- O -
mediated O +
gene O +
expression O +
system O -
. O +

Our O +
in O +
vitro O +
studies O +
showed O +
that O +
NIH3T3 O +
cells O +
overexpressing O +
BI-1 O +
displayed O +
a O +
significantly O +
higher O +
growth O +
rate O +
and O +
formed O +
more O +
and O +
larger O +
colonies O +
than O +
the O +
control O +
cells O -
. O +

In O +
addition O -
, O +
our O +
in O +
vivo O +
studies O +
indicated O +
that O +
the O +
lenti O -
- O -
BI-1-infected O +
cells O +
formed O +
obvious O +
tumours O -
, O +
while O +
no O +
tumours O +
were O +
formed O +
by O +
the O +
control O +
cells O +
after O +
subcutaneously O +
injected O +
into O +
nude O +
mice O -
. O +

These O +
results O +
strongly O +
suggested O +
that O +
the O +
BI-1 O +
gene O +
might O +
play O +
a O +
crucial O +
role O +
in O +
neoplastic O +
genesis O +
and O +
development O -
. O +

Anti O -
- O -
metastasis O +
effects O +
of O +
gallic B-Chemical +
acid I-Chemical +
on O +
gastric O +
cancer O +
cells O +
involves O +
inhibition O +
of O +
NF O -
- O -
kappaB O +
activity O +
and O +
downregulation O +
of O +
PI3K O -
/ O -
AKT O -
/ O -
small O +
GTPase O +
signals O -
. O +

Polyphenols B-Chemical +
are O +
natural O +
antioxidants O +
that O +
are O +
thought O +
to O +
contribute O +
to O +
prevention O +
of O +
cardiovascular O +
disease O +
and O +
malignancy O -
. O +

Although O +
many O +
studies O +
have O +
been O +
carried O +
out O +
to O +
investigate O +
the O +
chemopreventive O +
role O +
of O +
flavonoids B-Chemical -
, O +
less O +
attention O +
has O +
been O +
focused O +
on O +
phenolic B-Chemical +
acids I-Chemical -
. O +

In O +
this O +
study O -
, O +
the O +
aim O +
was O +
to O +
investigate O +
the O +
effect O +
of O +
phenolic B-Chemical +
acids I-Chemical +
found O +
abundantly O +
in O +
vegetables O -
, O +
i.e. O +
gallic B-Chemical +
acid I-Chemical +
( O -
GA B-Chemical -
) O -
, O +
caffeic B-Chemical +
acid I-Chemical +
( O -
CA B-Chemical -
) O +
and O +
protocatechuic B-Chemical +
acid I-Chemical +
( O -
PCA B-Chemical -
) O -
, O +
on O +
the O +
inhibition O +
of O +
gastric O +
adenocarcinoma O +
( O -
AGS O -
) O +
cell O +
metastasis O -
. O +

The O +
results O +
showed O +
0.01 O +
mM O +
GA B-Chemical +
induced O +
the O +
same O +
level O +
of O +
cell O +
toxicity O +
as O +
4.0mM O +
PCA B-Chemical -
. O +

Using O +
wound O -
- O -
healing O +
assay O +
and O +
Boyden O +
chamber O +
assay O -
, O +
GA B-Chemical +
had O +
potent O +
inhibitory O +
effects O +
on O +
AGS O +
cell O +
migration O -
. O +

The O +
expression O +
of O +
MMP-2 O -
/ O -
9 O +
of O +
AGS O +
cells O +
was O +
inhibited O +
by O +
2.0 O +
microM O +
of O +
GA B-Chemical -
. O +

It O +
is O +
possible O +
that O +
the O +
suppressive O +
effect O +
of O +
GA B-Chemical +
on O +
MMP-2 O -
/ O -
9 O +
might O +
involve O +
the O +
inhibition O +
of O +
NF O -
- O -
kappaB O +
activity O -
. O +

Multiple O +
proteins O +
involved O +
in O +
metastasis O +
and O +
the O +
cytoskeletal O +
reorganization O +
signal O +
pathway O -
, O +
including O +
Ras O -
, O +
Cdc42 O -
, O +
Rac1 O -
, O +
RhoA O -
, O +
RhoB O -
, O +
PI3 O -
K O +
and O +
p38MAPK O -
, O +
were O +
also O +
inhibited O +
by O +
GA B-Chemical -
. O +

Furthermore O -
, O +
immunoreactivity O +
assay O +
of O +
cytoskeletal O +
F O -
- O -
actin O +
demonstrated O +
a O +
significant O +
inhibitory O +
effect O +
of O +
GA B-Chemical +
treatment O -
. O +

In O +
conclusion O -
, O +
GA B-Chemical +
may O +
have O +
the O +
potential O +
to O +
be O +
an O +
effective O +
agent O +
for O +
prevention O +
and O +
treatment O +
of O +
gastric O +
cancer O +
metastasis O -
. O +

Adenovirus O +
5 O +
E1A O +
enhances O +
histone O +
deacetylase O +
inhibitors O -
- O -
induced O +
apoptosis O +
through O +
Egr-1-mediated O +
Bim O +
upregulation O -
. O +

Histone O +
deacetylase O +
inhibitors O +
( O -
HDACi O -
) O +
are O +
potent O +
anti O -
- O -
cancer O +
agents O +
for O +
variety O +
of O +
cancer O +
types O -
. O +

Suberoylanilide B-Chemical +
hydroxamic I-Chemical +
acid I-Chemical +
( O -
SAHA B-Chemical -
) O +
has O +
been O +
approved O +
as O +
a O +
drug O +
to O +
treat O +
cutaneous O +
T O +
cell O +
lymphoma O -
, O +
and O +
the O +
combination O +
of O +
HDACi O +
and O +
other O +
agents O +
have O +
been O +
actively O +
tested O +
in O +
many O +
clinical O +
trials O -
. O +

Adenovirus O +
5 O +
early O +
region O +
1A O +
( O -
E1A O -
) O +
has O +
been O +
shown O +
to O +
exhibit O +
high O +
tumor O +
suppressor O +
activity O -
, O +
and O +
gene O +
therapy O +
using O +
E1A O +
has O +
been O +
tested O +
in O +
clinical O +
trials O -
. O +

Here O -
, O +
we O +
showed O +
that O +
proapoptotic O +
activity O +
of O +
HDACi O +
was O +
robustly O +
enhanced O +
by O +
E1A O +
in O +
multiple O +
cancer O +
cells O -
, O +
but O +
not O +
in O +
normal O +
cells O -
. O +

Moreover O -
, O +
we O +
showed O +
that O +
combination O +
of O +
E1A O +
gene O +
therapy O +
and O +
SAHA B-Chemical +
showed O +
high O +
therapeutic O +
efficacy O +
with O +
low O +
toxicity O +
in O +
vivo O +
ovarian O +
and O +
breast O +
xenograft O +
models O -
. O +

SAHA B-Chemical +
downregulated O +
Bcl O -
- O -
XL O +
and O +
upregulated O +
proapoptotic O +
BH3-only O +
protein O +
Bim O -
, O +
whose O +
expression O +
was O +
further O +
enhanced O +
by O +
E1A O +
in O +
cancer O +
cells O -
. O +

These O +
alterations O +
of O +
Bcl-2 O +
family O +
proteins O +
were O +
critical O +
for O +
apoptosis O +
induced O +
by O +
the O +
combination O +
in O +
cancer O +
cells O -
. O +

SAHA B-Chemical +
enhanced O +
acetylation O +
of O +
histone O +
H3 O +
in O +
Bim O +
promoter O +
region O -
, O +
while O +
E1A O +
upregulated O +
Egr-1 O -
, O +
which O +
was O +
directly O +
involved O +
in O +
Bim O +
transactivation O -
. O +

Together O -
, O +
our O +
results O +
provide O +
not O +
only O +
a O +
novel O +
insight O +
into O +
the O +
mechanisms O +
underlying O +
anti O -
- O -
tumor O +
activity O +
of O +
E1A O -
, O +
but O +
also O +
a O +
rationale O +
for O +
the O +
combined O +
HDACi O +
and O +
E1A O +
gene O +
therapy O +
in O +
future O +
clinical O +
trials O -
. O +

Sanguinarine B-Chemical +
induces O +
apoptosis O +
of O +
human O +
osteosarcoma O +
cells O +
through O +
the O +
extrinsic O +
and O +
intrinsic O +
pathways O -
. O +

The O +
quaternary O +
benzo B-Chemical -
[ I-Chemical -
c I-Chemical -
] I-Chemical -
phenanthridine I-Chemical +
alkaloid I-Chemical +
sanguinarine B-Chemical +
inhibits O +
the O +
proliferation O +
of O +
cancerous O +
cells O +
from O +
different O +
origins O -
, O +
including O +
lung O -
, O +
breast O -
, O +
pancreatic O +
and O +
colon O -
, O +
but O +
nothing O +
is O +
known O +
of O +
its O +
effects O +
on O +
osteosarcoma O -
, O +
a O +
primary O +
malignant O +
bone O +
tumour O -
. O +

We O +
have O +
found O +
that O +
sanguinarine B-Chemical +
alters O +
the O +
morphology O +
and O +
reduces O +
the O +
viability O +
of O +
MG-63 O +
and O +
SaOS-2 O +
human O +
osteosarcoma O +
cell O +
lines O +
in O +
concentration- O +
and O +
time O -
- O -
dependent O +
manner O -
. O +

Incubation O +
with O +
1 O +
micromol O -
/ O -
L O +
sanguinarine B-Chemical +
for O +
4 O +
and O +
24h O +
killed O +
more O +
efficiently O +
MG-63 O +
cells O +
than O +
SaOS-2 O +
cells O -
, O +
while O +
incubation O +
with O +
5 O +
micromol O -
/ O -
L O +
sanguinarine B-Chemical +
killed O +
almost O +
100 O -
% O +
of O +
both O +
cell O +
populations O +
within O +
24h O -
. O +

This O +
treatment O +
also O +
changed O +
the O +
mitochondrial O +
membrane O +
potential O +
in O +
both O +
MG-63 O +
and O +
SaOS-2 O +
cells O +
within O +
1h O -
, O +
caused O +
chromatin O +
condensation O +
and O +
the O +
formation O +
of O +
apoptotic O +
bodies O -
. O +

It O +
activated O +
multicaspases O -
, O +
and O +
increased O +
the O +
activities O +
of O +
caspase-8 O +
and O +
caspase-9 O +
in O +
both O +
MG-63 O +
and O +
SaOS-2 O +
cells O -
. O +

These O +
data O +
highlight O +
sanguinarine B-Chemical +
as O +
a O +
novel O +
potential O +
agent O +
for O +
bone O +
cancer O +
therapy O -
. O +

The O +
neural O +
stem O +
cell O +
fate O +
determinant O +
TLX O +
promotes O +
tumorigenesis O +
and O +
genesis O +
of O +
cells O +
resembling O +
glioma O +
stem O +
cells O -
. O +

A O +
growing O +
body O +
of O +
evidence O +
indicates O +
that O +
deregulation O +
of O +
stem O +
cell O +
fate O +
determinants O +
is O +
a O +
hallmark O +
of O +
many O +
types O +
of O +
malignancies O -
. O +

The O +
neural O +
stem O +
cell O +
fate O +
determinant O +
TLX O +
plays O +
a O +
pivotal O +
role O +
in O +
neurogenesis O +
in O +
the O +
adult O +
brain O +
by O +
maintaining O +
neural O +
stem O +
cells O -
. O +

Here O -
, O +
we O +
report O +
a O +
tumorigenic O +
role O +
of O +
TLX O +
in O +
brain O +
tumor O +
initiation O +
and O +
progression O -
. O +

Increased O +
TLX O +
expression O +
was O +
observed O +
in O +
a O +
number O +
of O +
glioma O +
cells O +
and O +
glioma O +
stem O +
cells O -
, O +
and O +
correlated O +
with O +
poor O +
survival O +
of O +
patients O +
with O +
gliomas O -
. O +

Ectopic O +
expression O +
of O +
TLX O +
in O +
the O +
U87MG O +
glioma O +
cell O +
line O +
and O +
Ink4a O -
/ O -
Arf O -
- O -
deficient O +
mouse O +
astrocytes O +
( O -
Ink4a O -
/ O -
Arf O -
( O -
- O -
/ O -
- O -
) O +
astrocytes O -
) O +
induced O +
cell O +
proliferation O +
with O +
a O +
concomitant O +
increase O +
in O +
cyclin O +
D O +
expression O -
, O +
and O +
accelerated O +
foci O +
formation O +
in O +
soft O +
agar O +
and O +
tumor O +
formation O +
in O +
in O +
vivo O +
transplantation O +
assays O -
. O +

Furthermore O -
, O +
overexpression O +
of O +
TLX O +
in O +
Ink4a O -
/ O -
Arf O -
( O -
- O -
/ O -
- O -
) O +
astrocytes O +
inhibited O +
cell O +
migration O +
and O +
invasion O +
and O +
promoted O +
neurosphere O +
formation O +
and O +
Nestin O +
expression O -
, O +
which O +
are O +
hallmark O +
characteristics O +
of O +
glioma O +
stem O +
cells O -
, O +
under O +
stem O +
cell O +
culture O +
conditions O -
. O +

Our O +
results O +
indicate O +
that O +
TLX O +
is O +
involved O +
in O +
glioma O +
stem O +
cell O +
genesis O +
and O +
represents O +
a O +
potential O +
therapeutic O +
target O +
for O +
this O +
type O +
of O +
malignancy O -
. O +

Actin O -
- O -
sequestering O +
protein O -
, O +
thymosin O +
beta-4 O -
, O +
is O +
a O +
novel O +
hypoxia O +
responsive O +
regulator O -
. O +

Angiogenesis O +
is O +
induced O +
by O +
soluble O +
factors O +
such O +
as O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
released O +
from O +
tumor O +
cells O +
in O +
hypoxia O -
. O +

It O +
enhances O +
solid O +
tumor O +
growth O +
and O +
provides O +
an O +
ability O +
to O +
establish O +
metastasis O +
at O +
peripheral O +
sites O +
by O +
tumor O +
cell O +
migration O -
. O +

Thymosin O +
beta-4 O +
( O -
TB4 O -
) O +
is O +
an O +
actin O -
- O -
sequestering O +
protein O +
to O +
control O +
cytoskeletal O +
reorganization O -
. O +

Here O -
, O +
we O +
investigated O +
whether O +
angiogenesis O +
and O +
tumor O +
metastasis O +
are O +
dependent O +
on O +
hypoxia O +
conditioning O -
- O -
induced O +
TB4 O +
expression O +
in O +
B16F10 O +
melanoma O +
cells O -
. O +

TB4 O +
expression O +
in O +
B16F10 O +
cells O +
was O +
increased O +
by O +
hypoxia O +
conditioning O +
in O +
a O +
time O -
- O -
dependent O +
manner O -
. O +

In O +
addition O -
, O +
we O +
found O +
an O +
increase O +
of O +
angiogenesis O +
and O +
HIF-1alpha O +
expression O +
in O +
TB4-transgenic O +
( O -
Tg O -
) O +
mice O +
as O +
compared O +
to O +
wildtype O +
mice O -
. O +

When O +
wound O +
healing O +
assay O +
was O +
used O +
to O +
assess O +
in O +
vitro O +
tumor O +
cell O +
migration O -
, O +
hypoxia O +
conditioning O +
for O +
1 O +
h O +
enhanced O +
B16F10 O +
cell O +
migration O -
. O +

When O +
TB4 O +
expression O +
in O +
B16F10 O +
cells O +
was O +
inhibited O +
by O +
the O +
infection O +
with O +
small O +
hairpin O +
( O -
sh O -
) O +
RNA O +
of O +
TB4 O +
cloned O +
in O +
lentiviral O +
vector O -
, O +
tumor O +
cell O +
migration O +
was O +
retarded O -
. O +

In O +
addition O -
, O +
hypoxia O +
conditioning O -
- O -
induced O +
tumor O +
cell O +
migration O +
was O +
reduced O +
by O +
the O +
infection O +
of O +
lentiviral O +
shRNA O +
of O +
TB4 O -
. O +

HIF-1alpha O +
stabilization O +
and O +
the O +
expression O +
of O +
VEGF O +
isoform O +
165 O +
and O +
121 O +
in O +
hypoxia O +
were O +
also O +
reduced O +
by O +
the O +
infection O +
of O +
lentiviral O +
shRNA O +
of O +
TB4 O +
in O +
B16F10 O +
cells O -
. O +

We O +
also O +
found O +
an O +
increase O +
of O +
tumor O +
growth O +
and O +
lung O +
metastasis O +
count O +
in O +
TB4-Tg O +
mice O +
as O +
compared O +
to O +
wildtype O +
mice O -
. O +

Collectively O -
, O +
hypoxia O +
conditioning O +
induced O +
tumor O +
cell O +
migration O +
by O +
TB4 O +
expression O -
- O -
dependent O +
HIF-1alpha O +
stabilization O -
. O +

It O +
suggests O +
that O +
TB4 O +
could O +
be O +
a O +
hypoxia O +
responsive O +
regulator O +
to O +
control O +
tumor O +
cell O +
migration O +
in O +
angiogenesis O +
and O +
tumor O +
metastasis O -
. O +

Skin O +
deep O +
and O +
deeper O -
: O +
multiple O +
pathways O +
in O +
basal O +
cell O +
carcinogenesis O -
. O +

This O +
perspective O +
places O +
the O +
report O +
by O +
Villani O +
et O +
al. O +
that O +
appears O +
in O +
this O +
issue O +
of O +
the O +
journal O +
( O -
beginning O +
on O +
page O +
1222 O -
) O +
in O +
the O +
context O +
of O +
recent O +
work O +
showing O +
an O +
intersection O +
between O +
two O +
important O +
developmental O +
pathways O +
implicated O +
in O +
oncogenesis O -
: O +
the O +
hedgehog O +
and O +
insulin O -
- O -
like O +
growth O +
factor O +
( O -
IGF O -
) O +
pathways O -
. O +

Villani O +
et O +
al. O +
define O +
a O +
key O +
role O +
for O +
the O +
IGF O +
regulatory O +
protein O +
Igfbp2 O +
in O +
a O +
genetic O +
model O +
of O +
basal O +
cell O +
carcinogenesis O +
driven O +
by O +
targeted O +
constitutive O +
activation O +
of O +
hedgehog O +
signaling O -
. O +

Placed O +
in O +
the O +
framework O +
of O +
other O +
recently O +
published O +
work O -
, O +
the O +
observations O +
of O +
Villani O +
et O +
al. O +
both O +
raise O +
questions O +
about O +
the O +
cell O +
of O +
origin O +
for O +
basal O +
cell O +
cancers O +
and O +
define O +
additional O +
putative O +
therapeutic O +
and O +
preventive O +
targets O +
for O +
this O +
disease O -
. O +

Brick1 O +
is O +
an O +
essential O +
regulator O +
of O +
actin O +
cytoskeleton O +
required O +
for O +
embryonic O +
development O +
and O +
cell O +
transformation O -
. O +

Brick1 O +
( O -
Brk1 O -
) O +
is O +
the O +
less O -
- O -
studied O +
component O +
of O +
the O +
Wave O -
/ O -
Scar O +
pathway O +
involved O +
in O +
the O +
branched O +
nucleation O +
of O +
actin O +
fibers O -
. O +

The O +
clinical O +
relevance O +
of O +
Brk1 O +
is O +
emphasized O +
by O +
correlative O +
data O +
showing O +
that O +
Von O +
Hippel O -
- O -
Lindau O +
( O -
VHL O -
) O +
patients O +
that O +
also O +
lose O +
the O +
BRK1 O +
gene O +
are O +
protected O +
against O +
the O +
development O +
of O +
tumors O -
. O +

This O +
contrasts O +
with O +
recent O +
evidence O +
suggesting O +
that O +
the O +
Wave O +
complex O +
may O +
function O +
as O +
an O +
invasion O +
suppressor O +
in O +
epithelial O +
cancers O -
. O +

Here O -
, O +
we O +
show O +
that O +
the O +
downregulation O +
of O +
Brk1 O +
results O +
in O +
abnormal O +
actin O +
stress O +
fiber O +
formation O +
and O +
vinculin O +
distribution O +
and O +
loss O +
of O +
Arp2 O -
/ O -
3 O +
and O +
Wave O +
proteins O +
at O +
the O +
cellular O +
protrusions O -
. O +

Brk1 O +
is O +
required O +
for O +
cell O +
proliferation O +
and O +
cell O +
transformation O +
by O +
oncogenes O -
. O +

In O +
addition O -
, O +
Brk1 O +
downregulation O +
results O +
in O +
defective O +
directional O +
migration O +
and O +
invasive O +
growth O +
in O +
renal O +
cell O +
carcinoma O +
cells O +
as O +
well O +
as O +
in O +
other O +
tumor O +
cell O +
types O -
. O +

Finally O -
, O +
genetic O +
ablation O +
of O +
Brk1 O +
results O +
in O +
dramatic O +
defects O +
in O +
embryo O +
compaction O +
and O +
development O -
, O +
suggesting O +
an O +
essential O +
role O +
for O +
this O +
protein O +
in O +
actin O +
dynamics O -
. O +

Thus O -
, O +
genetic O +
loss O +
or O +
inhibition O +
of O +
BRK1 O +
is O +
likely O +
to O +
be O +
protective O +
against O +
tumor O +
development O +
due O +
to O +
proliferation O +
and O +
motility O +
defects O +
in O +
affected O +
cells O -
. O +

Ras O -
- O -
association O +
domain O +
family O +
1C O +
protein O +
promotes O +
breast O +
cancer O +
cell O +
migration O +
and O +
attenuates O +
apoptosis O -
. O +

BACKGROUND O -
: O +
The O +
Ras O +
association O +
domain O +
family O +
1 O +
( O -
RASSF1 O -
) O +
gene O +
is O +
a O +
Ras O +
effector O +
encoding O +
two O +
major O +
mRNA O +
forms O -
, O +
RASSF1A O +
and O +
RASSF1C O -
, O +
derived O +
by O +
alternative O +
promoter O +
selection O +
and O +
alternative O +
mRNA O +
splicing O -
. O +

RASSF1A O +
is O +
a O +
tumor O +
suppressor O +
gene O -
. O +

However O -
, O +
very O +
little O +
is O +
known O +
about O +
the O +
function O +
of O +
RASSF1C O +
both O +
in O +
normal O +
and O +
transformed O +
cells O -
. O +

METHODS O -
: O +
Gene O +
silencing O +
and O +
over O -
- O -
expression O +
techniques O +
were O +
used O +
to O +
modulate O +
RASSF1C O +
expression O +
in O +
human O +
breast O +
cancer O +
cells O -
. O +

Affymetrix O -
- O -
microarray O +
analysis O +
was O +
performed O +
using O +
T47D O +
cells O +
over O -
- O -
expressing O +
RASSF1C O +
to O +
identify O +
RASSF1C O +
target O +
genes O -
. O +

RT O -
- O -
PCR O +
and O +
western O +
blot O +
techniques O +
were O +
used O +
to O +
validate O +
target O +
gene O +
expression O -
. O +

Cell O +
invasion O +
and O +
apoptosis O +
assays O +
were O +
also O +
performed O -
. O +

RESULTS O -
: O +
In O +
this O +
article O -
, O +
we O +
report O +
the O +
effects O +
of O +
altering O +
RASSF1C O +
expression O +
in O +
human O +
breast O +
cancer O +
cells O -
. O +

We O +
found O +
that O +
silencing O +
RASSF1C O +
mRNA O +
in O +
breast O +
cancer O +
cell O +
lines O +
( O -
MDA O -
- O -
MB231 O +
and O +
T47D O -
) O +
caused O +
a O +
small O +
but O +
significant O +
decrease O +
in O +
cell O +
proliferation O -
. O +

Conversely O -
, O +
inducible O +
over O -
- O -
expression O +
of O +
RASSF1C O +
in O +
breast O +
cancer O +
cells O +
( O -
MDA O -
- O -
MB231 O +
and O +
T47D O -
) O +
resulted O +
in O +
a O +
small O +
increase O +
in O +
cell O +
proliferation O -
. O +

We O +
also O +
report O +
on O +
the O +
identification O +
of O +
novel O +
RASSF1C O +
target O +
genes O -
. O +

RASSF1C O +
down O -
- O -
regulates O +
several O +
pro O -
- O -
apoptotic O +
and O +
tumor O +
suppressor O +
genes O +
and O +
up O -
- O -
regulates O +
several O +
growth O +
promoting O +
genes O +
in O +
breast O +
cancer O +
cells O -
. O +

We O +
further O +
show O +
that O +
down O -
- O -
regulation O +
of O +
caspase O +
3 O +
via O +
overexpression O +
of O +
RASSF1C O +
reduces O +
breast O +
cancer O +
cells O -
' O +
sensitivity O +
to O +
the O +
apoptosis O +
inducing O +
agent O -
, O +
etoposide B-Chemical -
. O +

Furthermore O -
, O +
we O +
found O +
that O +
RASSF1C O +
over O -
- O -
expression O +
enhances O +
T47D O +
cell O +
invasion O -
/ O -
migration O +
in O +
vitro O -
. O +

CONCLUSION O -
: O +
Together O -
, O +
our O +
findings O +
suggest O +
that O +
RASSF1C O -
, O +
unlike O +
RASSF1A O -
, O +
is O +
not O +
a O +
tumor O +
suppressor O -
, O +
but O +
instead O +
may O +
play O +
a O +
role O +
in O +
stimulating O +
metastasis O +
and O +
survival O +
in O +
breast O +
cancer O +
cells O -
. O +

Expression O +
profiling O +
in O +
progressive O +
stages O +
of O +
fumarate O -
- O -
hydratase O +
deficiency O -
: O +
the O +
contribution O +
of O +
metabolic O +
changes O +
to O +
tumorigenesis O -
. O +

Hereditary O +
leiomyomatosis O +
and O +
renal O +
cell O +
carcinoma O +
( O -
HLRCC O -
) O +
is O +
caused O +
by O +
mutations O +
in O +
the O +
Krebs O +
cycle O +
enzyme O +
fumarate O +
hydratase O +
( O -
FH O -
) O -
. O +

It O +
has O +
been O +
proposed O +
that O +
" O -
pseudohypoxic O -
" O +
stabilization O +
of O +
hypoxia O -
- O -
inducible O +
factor O -
- O -
alpha O +
( O -
HIF O -
- O -
alpha O -
) O +
by O +
fumarate B-Chemical +
accumulation O +
contributes O +
to O +
tumorigenesis O +
in O +
HLRCC O -
. O +

We O +
hypothesized O +
that O +
an O +
additional O +
direct O +
consequence O +
of O +
FH O +
deficiency O +
is O +
the O +
establishment O +
of O +
a O +
biosynthetic O +
milieu O -
. O +

To O +
investigate O +
this O +
hypothesis O -
, O +
we O +
isolated O +
primary O +
mouse O +
embryonic O +
fibroblast O +
( O -
MEF O -
) O +
lines O +
from O +
Fh1-deficient O +
mice O -
. O +

As O +
predicted O -
, O +
these O +
MEFs O +
upregulated O +
Hif-1alpha O +
and O +
HIF O +
target O +
genes O +
directly O +
as O +
a O +
result O +
of O +
FH O +
deficiency O -
. O +

In O +
addition O -
, O +
detailed O +
metabolic O +
assessment O +
of O +
these O +
MEFs O +
confirmed O +
their O +
dependence O +
on O +
glycolysis O -
, O +
and O +
an O +
elevated O +
rate O +
of O +
lactate B-Chemical +
efflux O -
, O +
associated O +
with O +
the O +
upregulation O +
of O +
glycolytic O +
enzymes O +
known O +
to O +
be O +
associated O +
with O +
tumorigenesis O -
. O +

Correspondingly O -
, O +
Fh1-deficient O +
benign O +
murine O +
renal O +
cysts O +
and O +
an O +
advanced O +
human O +
HLRCC O -
- O -
related O +
renal O +
cell O +
carcinoma O +
manifested O +
a O +
prominent O +
and O +
progressive O +
increase O +
in O +
the O +
expression O +
of O +
HIF O -
- O -
alpha O +
target O +
genes O +
and O +
in O +
genes O +
known O +
to O +
be O +
relevant O +
to O +
tumorigenesis O +
and O +
metastasis O -
. O +

In O +
accord O +
with O +
our O +
hypothesis O -
, O +
in O +
a O +
variety O +
of O +
different O +
FH O -
- O -
deficient O +
tissues O -
, O +
including O +
a O +
novel O +
murine O +
model O +
of O +
Fh1-deficient O +
smooth O +
muscle O -
, O +
we O +
show O +
a O +
striking O +
and O +
progressive O +
upregulation O +
of O +
a O +
tumorigenic O +
metabolic O +
profile O -
, O +
as O +
manifested O +
by O +
increased O +
PKM2 O +
and O +
LDHA O +
protein O -
. O +

Based O +
on O +
the O +
models O +
assessed O +
herein B-Chemical -
, O +
we O +
infer O +
that O +
that O +
FH O +
deficiency O +
compels O +
cells O +
to O +
adopt O +
an O +
early O -
, O +
reversible O -
, O +
and O +
progressive O +
protumorigenic O +
metabolic O +
milieu O +
that O +
is O +
reminiscent O +
of O +
that O +
driving O +
the O +
Warburg O +
effect O -
. O +

Targets O +
identified O +
in O +
these O +
novel O +
and O +
diverse O +
FH O -
- O -
deficient O +
models O +
represent O +
excellent O +
potential O +
candidates O +
for O +
further O +
mechanistic O +
investigation O +
and O +
therapeutic O +
metabolic O +
manipulation O +
in O +
tumors O -
. O +

Role O +
of O +
stromal O +
myofibroblasts O +
in O +
invasive O +
breast O +
cancer O -
: O +
stromal O +
expression O +
of O +
alpha O -
- O -
smooth O +
muscle O +
actin O +
correlates O +
with O +
worse O +
clinical O +
outcome O -
. O +

BACKGROUND O -
: O +
Recently O -
, O +
the O +
desmoplastic O +
reaction O +
has O +
been O +
implicated O +
as O +
having O +
an O +
important O +
function O +
in O +
epithelial O +
solid O +
tumor O +
biology O -
. O +

There O +
have O +
been O +
no O +
reports O +
showing O +
the O +
relativity O +
of O +
invasive O +
breast O +
cancer O +
and O +
the O +
desmoplastic O +
reaction O +
by O +
a O +
quantitative O +
analysis O +
of O +
the O +
myofibroblasts O +
that O +
were O +
an O +
important O +
player O +
in O +
the O +
desmoplastic O +
reaction O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
immunohistochemically O +
investigate O +
the O +
correlation O +
between O +
the O +
desmoplastic O +
reaction O +
and O +
the O +
clinicopathology O +
of O +
invasive O +
breast O +
cancer O -
. O +

METHODS O -
: O +
The O +
study O +
included O +
60 O +
patients O +
with O +
a O +
known O +
prognosis O +
of O +
invasive O +
breast O +
cancer O -
. O +

We O +
quantified O +
the O +
expression O +
of O +
alpha O -
- O -
SMA O +
as O +
a O +
marker O +
of O +
myofibroblasts O +
in O +
the O +
invasive O +
breast O +
cancer O -
. O +

After O +
staining O +
samples O +
for O +
alpha O -
- O -
SMA O -
, O +
their O +
expression O +
was O +
extracted O +
and O +
quantified O +
as O +
a O +
relative O +
percentage O +
by O +
computer O -
- O -
assisted O +
image O +
analysis O -
. O +

RESULTS O -
: O +
There O +
was O +
relatively O +
wide O +
variation O +
in O +
the O +
expression O +
of O +
alpha O -
- O -
SMA O +
with O +
the O +
percentage O +
of O +
the O +
area O +
from O +
0.68 O +
to O +
28.15 O -
% O +
( O -
mean O +
8.48 O +
+ O -
/- O +

5.40 O -
% O -
) O -
. O +

The O +
metastasis O +
group O +
showed O +
significantly O +
higher O +
alpha O -
- O -
SMA O +
expression O +
compared O +
with O +
the O +
no O +
metastasis O +
group O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

When O +
the O +
patients O +
were O +
divided O +
into O +
two O +
groups O +
according O +
to O +
their O +
alpha O -
- O -
SMA O +
expression O +
using O +
a O +
cutoff O +
point O +
at O +
the O +
mean O +
value O +
of O +
8.48 O -
% O -
, O +
the O +
high O +
alpha O -
- O -
SMA O +
group O +
had O +
a O +
significantly O +
poorer O +
overall O +
survival O +
rate O +
( O -
p O +
< O +
0.001 O -
) O -
. O +

Multivariate O +
analysis O +
demonstrated O +
that O +
alpha O -
- O -
SMA O +
and O +
lymph O +
node O +
metastasis O +
were O +
identified O +
as O +
independent O +
predictive O +
factors O +
of O +
metastasis O -
. O +

CONCLUSION O -
: O +
Myofibroblasts O +
represent O +
an O +
important O +
prognostic O +
factor O +
for O +
invasive O +
growth O +
that O +
is O +
translated O +
into O +
a O +
poor O +
clinical O +
prognosis O +
for O +
patients O +
with O +
invasive O +
breast O +
cancer O -
. O +

A O +
STAT3-mediated O +
metabolic O +
switch O +
is O +
involved O +
in O +
tumour O +
transformation O +
and O +
STAT3 O +
addiction O -
. O +

The O +
pro O -
- O -
oncogenic O +
transcription O +
factor O +
STAT3 O +
is O +
constitutively O +
activated O +
in O +
a O +
wide O +
variety O +
of O +
tumours O +
that O +
often O +
become O +
addicted O +
to O +
its O +
activity O -
, O +
but O +
no O +
unifying O +
view O +
of O +
a O +
core O +
function O +
determining O +
this O +
widespread O +
STAT3-dependence O +
has O +
yet O +
emerged O -
. O +

We O +
show O +
here O +
that O +
constitutively O +
active O +
STAT3 O +
acts O +
as O +
a O +
master O +
regulator O +
of O +
cell O +
metabolism O -
, O +
inducing O +
aerobic O +
glycolysis O +
and O +
down O -
- O -
regulating O +
mitochondrial O +
activity O +
both O +
in O +
primary O +
fibroblasts O +
and O +
in O +
STAT3-dependent O +
tumour O +
cell O +
lines O -
. O +

As O +
a O +
result O -
, O +
cells O +
are O +
protected O +
from O +
apoptosis O +
and O +
senescence O +
while O +
becoming O +
highly O +
sensitive O +
to O +
glucose B-Chemical +
deprivation O -
. O +

We O +
show O +
that O +
enhanced O +
glycolysis O +
is O +
dependent O +
on O +
HIF-1alpha O +
up O -
- O -
regulation O -
, O +
while O +
reduced O +
mitochondrial O +
activity O +
is O +
HIF-1alpha O -
- O -
independent O +
and O +
likely O +
caused O +
by O +
STAT3-mediated O +
down O -
- O -
regulation O +
of O +
mitochondrial O +
proteins O -
. O +

The O +
induction O +
of O +
aerobic O +
glycolysis O +
is O +
an O +
important O +
component O +
of O +
STAT3 O +
pro O -
- O -
oncogenic O +
activities O -
, O +
since O +
inhibition O +
of O +
STAT3 O +
tyrosine O +
phosphorylation O +
in O +
the O +
tumour O +
cell O +
lines O +
down O -
- O -
regulates O +
glycolysis O +
prior O +
to O +
leading O +
to O +
growth O +
arrest O +
and O +
cell O +
death O -
, O +
both O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

We O +
propose O +
that O +
this O +
novel O -
, O +
central O +
metabolic O +
role O +
is O +
at O +
the O +
core O +
of O +
the O +
addiction O +
for O +
STAT3 O +
shown O +
by O +
so O +
many O +
biologically O +
different O +
tumours O -
. O +

The O +
disintegrin O -
- O -
like O +
and O +
cysteine O -
- O -
rich O +
domains O +
of O +
ADAM-9 O +
mediate O +
interactions O +
between O +
melanoma O +
cells O +
and O +
fibroblasts O -
. O +

A O +
characteristic O +
of O +
malignant O +
cells O +
is O +
their O +
capacity O +
to O +
invade O +
their O +
surrounding O +
and O +
to O +
metastasize O +
to O +
distant O +
organs O -
. O +

During O +
these O +
processes O -
, O +
proteolytic O +
activities O +
of O +
tumor O +
and O +
stromal O +
cells O +
modify O +
the O +
extracellular O +
matrix O +
to O +
produce O +
a O +
microenvironment O +
suitable O +
for O +
their O +
growth O +
and O +
migration O -
. O +

In O +
recent O +
years O +
the O +
family O +
of O +
ADAM O +
proteases O +
has O +
been O +
ascribed O +
important O +
roles O +
in O +
these O +
processes O -
. O +

ADAM-9 O +
is O +
expressed O +
in O +
human O +
melanoma O +
at O +
the O +
tumor O -
- O -
stroma O +
border O +
where O +
direct O +
or O +
indirect O +
interactions O +
between O +
tumor O +
cells O +
and O +
fibroblasts O +
occur O -
. O +

To O +
analyze O +
the O +
role O +
of O +
ADAM-9 O +
for O +
the O +
interaction O +
between O +
melanoma O +
cells O +
and O +
stromal O +
fibroblasts O -
, O +
we O +
produced O +
the O +
recombinant O +
disintegrin O -
- O -
like O +
and O +
cysteine O -
- O -
rich O +
domain O +
of O +
ADAM-9 O +
( O -
DC-9 O -
) O -
. O +

Melanoma O +
cells O +
and O +
human O +
fibroblasts O +
adhered O +
to O +
immobilized O +
DC-9 O +
in O +
a O +
Mn B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
-dependent O +
fashion O +
suggesting O +
an O +
integrin O -
- O -
mediated O +
process O -
. O +

Inhibition O +
studies O +
showed O +
that O +
adhesion O +
of O +
fibroblasts O +
was O +
mediated O +
by O +
several O +
beta1 O +
integrin O +
receptors O +
independent O +
of O +
the O +
RGD O +
and O +
ECD O +
recognition O +
motif O -
. O +

Furthermore O -
, O +
interaction O +
of O +
fibroblasts O +
and O +
high O +
invasive O +
melanoma O +
cells O +
with O +
soluble O +
recombinant O +
DC-9 O +
resulted O +
in O +
enhanced O +
expression O +
of O +
MMP-1 O +
and O +
MMP-2 O -
. O +

Silencing O +
of O +
ADAM-9 O +
in O +
melanoma O +
cells O +
significantly O +
reduced O +
cell O +
adhesion O +
to O +
fibroblasts O -
. O +

Ablation O +
of O +
ADAM-9 O +
in O +
fibroblasts O +
almost O +
completely O +
abolished O +
these O +
cellular O +
interactions O +
and O +
melanoma O +
cell O +
invasion O +
in O +
vitro O -
. O +

In O +
summary O -
, O +
these O +
results O +
suggest O +
that O +
ADAM-9 O +
expression O +
plays O +
an O +
important O +
role O +
in O +
mediating O +
cell O -
- O -
cell O +
contacts O +
between O +
fibroblasts O +
and O +
melanoma O +
cells O +
and O +
that O +
these O +
interactions O +
contribute O +
to O +
proteolytic O +
activities O +
required O +
during O +
invasion O +
of O +
melanoma O +
cells O -
. O +

Emerging O +
metabolic O +
targets O +
in O +
cancer O +
therapy O -
. O +

Cancer O +
cells O +
are O +
different O +
from O +
normal O +
cells O +
in O +
their O +
metabolic O +
properties O -
. O +

Normal O +
cells O +
mostly O +
rely O +
on O +
mitochondrial O +
oxidative O +
phosphorylation O +
to O +
produce O +
energy O -
. O +

In O +
contrast O -
, O +
cancer O +
cells O +
depend O +
mostly O +
on O +
glycolysis O -
, O +
the O +
aerobic O +
breakdown O +
of O +
glucose B-Chemical +
into O +
ATP B-Chemical -
. O +

This O +
altered O +
energy O +
dependency O +
is O +
known O +
as O +
the O +
" O -
Warburg O +
effect O -
" O +
and O +
is O +
a O +
hallmark O +
of O +
cancer O +
cells O -
. O +

In O +
recent O +
years O -
, O +
investigating O +
the O +
metabolic O +
changes O +
within O +
cancer O +
cells O +
has O +
been O +
a O +
rapidly O +
growing O +
area O -
. O +

Emerging O +
evidence O +
shows O +
that O +
oncogenes O +
that O +
drive O +
the O +
cancer O -
- O -
promoting O +
signals O +
also O +
drive O +
the O +
altered O +
metabolism O -
. O +

Although O +
the O +
exact O +
mechanisms O +
underlying O +
the O +
Warburg O +
effect O +
are O +
unclear O -
, O +
the O +
existing O +
evidence O +
suggests O +
that O +
increased O +
glycolysis O +
plays O +
an O +
important O +
role O +
in O +
support O +
malignant O +
behavior O +
of O +
cancer O +
cells O -
. O +

A O +
thorough O +
understanding O +
of O +
the O +
unique O +
metabolism O +
of O +
cancer O +
cells O +
will O +
help O +
to O +
design O +
of O +
more O +
effective O +
drugs O +
targeting O +
metabolic O +
pathways O -
, O +
which O +
will O +
greatly O +
impact O +
the O +
capacity O +
to O +
effectively O +
treat O +
cancer O +
patients O -
. O +

Here O +
we O +
provide O +
an O +
overview O +
of O +
the O +
current O +
understanding O +
of O +
the O +
Warburg O +
effect O +
upon O +
tumor O +
cell O +
growth O +
and O +
survival O -
, O +
and O +
discussion O +
on O +
the O +
potential O +
metabolic O +
targets O +
for O +
cancer O +
therapy O -
. O +

MTSS1 O -
: O +
a O +
multifunctional O +
protein O +
and O +
its O +
role O +
in O +
cancer O +
invasion O +
and O +
metastasis O -
. O +

MTSS1 O +
( O -
metastasis O +
suppressor-1 O -
) O +
was O +
first O +
identified O +
as O +
a O +
metastasis O +
suppressor O +
missing O +
in O +
metastatic O +
bladder O +
carcinoma O +
cell O +
lines O -
. O +

The O +
down O -
- O -
regulation O +
of O +
MTSS1 O +
that O +
may O +
be O +
caused O +
by O +
DNA O +
methylation O +
was O +
also O +
observed O +
in O +
many O +
other O +
types O +
of O +
cancer O -
. O +

While O +
accumlating O +
evidence O +
for O +
the O +
function O +
of O +
MTSS1 O +
support O +
the O +
concept O +
that O +
it O +
is O +
unlikely O +
to O +
be O +
a O +
metastasis O +
suppressor O -
, O +
but O +
actually O +
acts O +
as O +
a O +
scaffold O +
protein O +
that O +
interacts O +
with O +
multiple O +
partners O +
to O +
regulate O +
actin O +
dynamics O -
. O +

It O +
has O +
also O +
been O +
demonstrated O +
that O +
MTSS1 O +
is O +
involved O +
in O +
the O +
Shh O +
signaling O +
pathway O +
in O +
the O +
developing O +
hair O +
follicle O +
and O +
in O +
basal O +
cell O +
carcinomas O +
of O +
the O +
skin O -
. O +

Such O +
evidence O +
indicates O +
that O +
MTSS1 O +
as O +
a O +
multiple O +
functional O +
molecular O +
player O +
and O +
has O +
an O +
important O +
role O +
in O +
development O -
, O +
carcinogenesis O +
and O +
metastasis O -
. O +

However O -
, O +
the O +
biochemical O +
mechanisms O +
by O +
which O +
MTSS1 O +
functions O +
in O +
cells O +
and O +
the O +
physiological O +
role O +
of O +
this O +
protein O +
in O +
animals O +
remain O +
largely O +
unknown O -
. O +

In O +
this O +
review O -
, O +
we O +
will O +
discuss O +
the O +
current O +
knowledge O +
of O +
MTSS1 O -
's O +
role O +
in O +
cancer O +
metastasis O -
, O +
carcinogenesis O -
, O +
and O +
development O -
. O +

The O +
clinical O +
significance O +
of O +
MTSS1 O +
will O +
also O +
be O +
discussed O -
. O +

Serum O +
soluble O +
vascular O +
adhesion O +
protein-1 O +
is O +
a O +
valuable O +
prognostic O +
marker O +
in O +
gastric O +
cancer O -
. O +

BACKGROUND O -
: O +
Vascular O +
adhesion O +
protein-1 O +
( O -
VAP-1 O -
) O +
regulates O +
leukocyte O +
tissue O +
infiltration O -
. O +

Elevated O +
serum O +
soluble O +
VAP-1 O +
( O -
sVAP-1 O -
) O +
levels O +
occur O +
in O +
certain O +
diseases O +
having O +
an O +
inflammatory O +
component O -
. O +

We O +
previously O +
showed O +
in O +
colorectal O +
cancer O +
that O +
sVAP-1 O +
expression O +
is O +
significantly O +
higher O +
relative O +
to O +
controls O -
, O +
and O +
this O +
decreased O +
expression O +
is O +
associated O +
with O +
poor O +
prognosis O +
and O +
lymph O +
node O +
and O +
liver O +
metastasis O -
. O +

However O -
, O +
sVAP-1 O +
expression O +
has O +
not O +
been O +
described O +
for O +
gastric O +
cancer O -
. O +

This O +
study O +
determines O +
the O +
relationship O +
between O +
preoperative O +
serum O +
sVAP-1 O +
levels O +
and O +
clinicopathological O +
features O +
and O +
prognosis O +
in O +
gastric O +
cancer O -
. O +

METHODS O -
: O +
Preoperative O +
serum O +
was O +
collected O +
from O +
107 O +
gastric O +
cancer O +
patients O +
and O +
33 O +
normal O +
controls O -
. O +

sVAP-1 O +
levels O +
were O +
assayed O +
by O +
enzyme O -
- O -
linked O +
immunosorbent O +
assay O -
. O +

RESULTS O -
: O +
The O +
mean O +
sVAP-1 O +
level O +
for O +
cancer O +
patients O +
was O +
significantly O +
higher O +
relative O +
to O +
controls O -
, O +
and O +
decreased O +
with O +
disease O +
progression O -
. O +

Tumor O +
size O -
, O +
serosal O +
invasion O -
, O +
lymph O +
node O +
metastasis O -
, O +
peritoneal O +
dissemination O -
, O +
and O +
TNM O +
classification O +
was O +
significantly O +
correlated O +
with O +
sVAP-1 O +
level O -
. O +

sVAP-1 O +
is O +
also O +
an O +
independent O +
predictive O +
marker O +
for O +
lymph O +
node O +
metastasis O -
. O +

Patients O +
having O +
low O +
sVAP-1 O +
levels O +
had O +
significantly O +
poorer O +
prognosis O +
relative O +
to O +
patients O +
having O +
elevated O +
sVAP-1 O +
in O +
all O +
or O +
stages O +
I O -
- O -
III O +
gastric O +
cancer O +
patients O -
, O +
respectively O -
. O +

CONCLUSIONS O -
: O +
Low O +
sVAP-1 O +
levels O +
are O +
associated O +
with O +
poor O +
prognosis O +
in O +
gastric O +
cancer O -
. O +

Determining O +
sVAP-1 O +
levels O +
may O +
be O +
valuable O +
for O +
predicting O +
prognosis O +
and O +
lymph O +
node O +
metastasis O -
. O +

Diallyl B-Chemical +
trisulfide I-Chemical +
( O -
DATS B-Chemical -
) O +
inhibits O +
mouse O +
colon O +
tumor O +
in O +
mouse O +
CT-26 O +
cells O +
allograft O +
model O +
in O +
vivo O -
. O +

Our O +
earlier O +
studies O +
showed O +
that O +
DATS B-Chemical +
induced O +
apoptosis O +
in O +
human O +
colon O +
cancer O +
HT29 O +
and O +
colo O +
205 O +
cell O +
lines O +
in O +
vitro O -
. O +

However O -
, O +
there O +
is O +
no O +
report O +
to O +
show O +
that O +
DATS B-Chemical +
induced O +
apoptosis O +
in O +
vitro O +
and O +
inhibited O +
CT26 O +
cancer O +
cells O +
in O +
vivo O +
on O +
a O +
murine O +
allograft O +
animal O +
model O -
. O +

In O +
vitro O +
studies O -
, O +
the O +
results O +
indicated O +
that O +
DATS B-Chemical +
induced O +
morphological O +
changes O +
and O +
induction O +
of O +
apoptosis O +
in O +
CT26 O +
cells O -
. O +

In O +
vivo O +
studies O -
, O +
CT26 O +
cancer O +
cells O +
were O +
implanted O +
into O +
BALB O -
/ O -
c O +
mice O +
and O +
groups O +
of O +
mice O +
were O +
treated O +
with O +
vehicle O -
, O +
DATS B-Chemical +
( O -
10 O +
and O +
50 O +
mg O -
/ O -
kg O +
of O +
body O +
weight O -
) O -
. O +

DATS B-Chemical +
were O +
injected O +
once O +
per O +
four O +
days O +
intraperitoneally O +
( O -
i.p O -
. O -
) O -
, O +
with O +
treatment O +
starting O +
4 O +
weeks O +
prior O +
to O +
cells O +
inoculation O -
. O +

Treatment O +
with O +
vehicle O +
or O +
with O +
10 O +
and O +
50 O +
mg O -
/ O -
kg O +
of O +
DATS B-Chemical +
resulted O +
in O +
a O +
reduction O +
in O +
tumor O +
volume O +
and O +
weight O -
. O +

Tumor O +
volume O +
and O +
total O +
hemoglobin O +
in O +
allograft O +
mice O +
treated O +
with O +
50 O +
mg O -
/ O -
kg O +
DATS B-Chemical +
were O +
significantly O +
smaller O +
than O +
that O +
in O +
the O +
control O +
group O -
. O +

These O +
findings O +
indicated O +
that O +
DATS B-Chemical +
inhibits O +
tumor O +
growth O +
in O +
an O +
allograft O +
animal O +
model O -
. O +

Thus O -
, O +
DATS B-Chemical +
may O +
represent O +
a O +
colon O +
cancer O +
preventive O +
agent O +
and O +
can O +
be O +
used O +
in O +
the O +
future O -
. O +

Metabolic O +
regulation O +
by O +
p53 O -
. O +

We O +
are O +
increasingly O +
aware O +
that O +
cellular O +
metabolism O +
plays O +
a O +
vital O +
role O +
in O +
diseases O +
such O +
as O +
cancer O -
, O +
and O +
that O +
p53 O +
is O +
an O +
important O +
regulator O +
of O +
metabolic O +
pathways O -
. O +

By O +
transcriptional O +
activation O +
and O +
other O +
means O -
, O +
p53 O +
is O +
able O +
to O +
contribute O +
to O +
the O +
regulation O +
of O +
glycolysis O -
, O +
oxidative O +
phosphorylation O -
, O +
glutaminolysis O -
, O +
insulin O +
sensitivity O -
, O +
nucleotide B-Chemical +
biosynthesis O -
, O +
mitochondrial O +
integrity O -
, O +
fatty B-Chemical +
acid I-Chemical +
oxidation O -
, O +
antioxidant B-Chemical +
response O -
, O +
autophagy O +
and O +
mTOR O +
signalling O -
. O +

The O +
ability O +
to O +
positively O +
and O +
negatively O +
regulate O +
many O +
of O +
these O +
pathways O -
, O +
combined O +
with O +
feedback O +
signalling O +
from O +
these O +
pathways O +
to O +
p53 O -
, O +
demonstrates O +
the O +
reciprocal O +
and O +
flexible O +
nature O +
of O +
the O +
regulation O -
, O +
facilitating O +
a O +
diverse O +
range O +
of O +
responses O +
to O +
metabolic O +
stress O -
. O +

Intriguingly O -
, O +
metabolic O +
stress O +
triggers O +
primarily O +
an O +
adaptive O +
( O -
rather O +
than O +
pro O -
- O -
apoptotic O -
) O +
p53 O +
response O -
, O +
and O +
p53 O +
is O +
emerging O +
as O +
an O +
important O +
regulator O +
of O +
metabolic O +
homeostasis O -
. O +

A O +
better O +
understanding O +
of O +
how O +
p53 O +
coordinates O +
metabolic O +
adaptation O +
will O +
facilitate O +
the O +
identification O +
of O +
novel O +
therapeutic O +
targets O +
and O +
will O +
also O +
illuminate O +
the O +
wider O +
role O +
of O +
p53 O +
in O +
human O +
biology O -
. O +

Use O +
of O +
DNA O +
microarray O +
and O +
small O +
animal O +
positron O +
emission O +
tomography O +
in O +
preclinical O +
drug O +
evaluation O +
of O +
RAF265 B-Chemical -
, O +
a O +
novel O +
B O -
- O -
Raf O -
/ O -
VEGFR-2 O +
inhibitor O -
. O +

Positron O +
emission O +
tomography O +
( O -
PET O -
) O +
imaging O +
has O +
become O +
a O +
useful O +
tool O +
for O +
assessing O +
early O +
biologic O +
response O +
to O +
cancer O +
therapy O +
and O +
may O +
be O +
particularly O +
useful O +
in O +
the O +
development O +
of O +
new O +
cancer O +
therapeutics O -
. O +

RAF265 B-Chemical -
, O +
a O +
novel O +
B O -
- O -
Raf O -
/ O -
vascular O +
endothelial O +
growth O +
factor O +
receptor-2 O +
inhibitor O -
, O +
was O +
evaluated O +
in O +
the O +
preclinical O +
setting O +
for O +
its O +
ability O +
to O +
inhibit O +
the O +
uptake O +
of O +
PET O +
tracers O +
in O +
the O +
A375M O -
( O -
B O -
- O -
Raf O -
( O -
V600E O -
) O -
) O +
human O +
melanoma O +
cell O +
line O -
. O +

RAF265 B-Chemical +
inhibited O +
2-deoxy-2- B-Chemical -
[ I-Chemical -
( I-Chemical -
18 I-Chemical -
) I-Chemical -
F I-Chemical -
] I-Chemical -
fluoro I-Chemical -
- I-Chemical -
d I-Chemical -
- I-Chemical -
glucose I-Chemical +
( O -
FDG B-Chemical -
) O +
accumulation O +
in O +
cell O +
culture O +
at O +
28 O +
hours O +
in O +
a O +
dose O -
- O -
dependent O +
manner O -
. O +

RAF265 B-Chemical +
also O +
inhibited O +
FDG B-Chemical +
accumulation O +
in O +
tumor O +
xenografts O +
after O +
1 O +
day O +
of O +
drug O +
treatment O -
. O +

This O +
decrease O +
persisted O +
for O +
the O +
remaining O +
2 O +
weeks O +
of O +
treatment O -
. O +

DNA O +
microarray O +
analysis O +
of O +
treated O +
tumor O +
xenografts O +
revealed O +
significantly O +
decreased O +
expression O +
of O +
genes O +
regulating O +
glucose B-Chemical +
and O +
thymidine B-Chemical +
metabolism O +
and O +
revealed O +
changes O +
in O +
apoptotic O +
genes O -
, O +
suggesting O +
that O +
the O +
imaging O +
tracers O +
FDG B-Chemical -
, O +
3-deoxy-3- B-Chemical -
[ I-Chemical -
( I-Chemical -
18 I-Chemical -
) I-Chemical -
F I-Chemical -
] I-Chemical -
fluorothymidine I-Chemical -
, O +
and O +
annexin O +
V O +
could O +
serve O +
as O +
potential O +
imaging O +
biomarkers O +
for O +
RAF265 B-Chemical +
therapy O +
monitoring O -
. O +

We O +
concluded O +
that O +
RAF265 B-Chemical +
is O +
highly O +
efficacious O +
in O +
this O +
xenograft O +
model O +
of O +
human O +
melanoma O +
and O +
decreases O +
glucose B-Chemical +
metabolism O +
as O +
measured O +
by O +
DNA O +
microarray O +
analysis O -
, O +
cell O +
culture O +
assays O -
, O +
and O +
small O +
animal O +
FDG B-Chemical +
PET O +
scans O +
as O +
early O +
as O +
1 O +
day O +
after O +
treatment O -
. O +

Our O +
results O +
support O +
the O +
use O +
of O +
FDG B-Chemical +
PET O +
in O +
clinical O +
trials O +
with O +
RAF265 B-Chemical +
to O +
assess O +
early O +
tumor O +
response O -
. O +

DNA O +
microarray O +
analysis O +
and O +
small O +
animal O +
PET O +
studies O +
may O +
be O +
used O +
as O +
complementary O +
technologies O +
in O +
drug O +
development O -
. O +

DNA O +
microarray O +
analysis O +
allows O +
for O +
analysis O +
of O +
drug O +
effects O +
on O +
multiple O +
pathways O +
linked O +
to O +
cancer O +
and O +
can O +
suggest O +
corresponding O +
imaging O +
tracers O +
for O +
further O +
analysis O +
as O +
biomarkers O +
of O +
tumor O +
response O -
. O +

Systematic O +
proteomic O +
analysis O +
of O +
human O +
hepotacellular O +
carcinoma O +
cells O +
reveals O +
molecular O +
pathways O +
and O +
networks O +
involved O +
in O +
metastasis O -
. O +

Systematic O +
proteomic O +
studying O +
of O +
the O +
mechanism O +
of O +
hepatocellular O +
carcinoma O +
( O -
HCC O -
) O +
metastasis O +
remains O +
challenging O -
. O +

We O +
performed O +
comparative O +
proteomic O +
and O +
pathway O +
analysis O +
of O +
four O +
human O +
metastatic O +
HCC O +
cell O +
lines O +
to O +
identify O +
metastasis O -
- O -
associated O +
proteins O -
. O +

These O +
HCC O +
cell O +
lines O +
had O +
a O +
similar O +
genetic O +
background O +
but O +
with O +
an O +
increasing O +
potential O +
of O +
metastasis O -
. O +

Using O +
a O +
combination O +
of O +
two O +
dimensional O +
electrophoresis O +
( O -
2-DE O -
) O +
and O +
MALDI O -
- O -
TOF O +
mass O +
spectrometry O -
, O +
a O +
total O +
of O +
125 O +
proteins O +
and O +
their O +
post O -
- O -
translational O +
modification O +
forms O +
or O +
isoforms O +
were O +
found O +
to O +
be O +
differentially O +
expressed O +
in O +
the O +
cell O +
lines O -
. O +

Among O +
them O -
, O +
29 O +
were O +
gradually O +
up O -
- O -
regulated O +
whereas O +
17 O +
were O +
down O -
- O -
regulated O +
with O +
increasing O +
metastatic O +
potential O -
. O +

Instead O +
of O +
a O +
traditional O +
single O -
- O -
gene O +
readout O -
, O +
global O +
bioinformatics O +
analysis O +
was O +
carried O +
out O -
, O +
which O +
revealed O +
that O +
the O +
glycolysis O +
pathway O +
was O +
the O +
most O +
significantly O +
enriched O +
pathway O -
. O +

The O +
heat O +
shock O +
proteins O +
( O -
HSPs O -
) O +
centered O +
and O +
NF O -
- O -
kappaB O +
centered O +
networks O +
were O +
also O +
enriched O +
in O +
the O +
result O -
, O +
which O +
may O +
imply O +
the O +
key O +
function O +
of O +
inflaming O +
on O +
metastasis O -
. O +

Meanwhile O -
, O +
knockdown O +
of O +
HDGF O -
, O +
an O +
up O -
- O -
regulated O +
protein O +
and O +
a O +
target O +
of O +
NF O -
- O -
kappaB O -
, O +
induced O +
cell O +
apoptosis O +
in O +
the O +
metastatic O +
HCC O +
cells O -
. O +

This O +
work O +
provides O +
a O +
demonstration O +
that O +
a O +
combination O +
of O +
bioinformatics O +
and O +
comparative O +
proteomics O +
can O +
help O +
in O +
finding O +
out O +
potential O +
biomarkers O +
associated O +
with O +
HCC O +
metastasis O +
on O +
the O +
level O +
of O +
pathways O -
. O +

Roles O +
of O +
brca2 O +
( O -
fancd1 O -
) O +
in O +
oocyte O +
nuclear O +
architecture O -
, O +
gametogenesis O -
, O +
gonad O +
tumors O -
, O +
and O +
genome O +
stability O +
in O +
zebrafish O -
. O +

Mild O +
mutations O +
in O +
BRCA2 O +
( O -
FANCD1 O -
) O +
cause O +
Fanconi O +
anemia O +
( O -
FA O -
) O +
when O +
homozygous O -
, O +
while O +
severe O +
mutations O +
cause O +
common O +
cancers O +
including O +
breast O -
, O +
ovarian O -
, O +
and O +
prostate O +
cancers O +
when O +
heterozygous O -
. O +

Here O +
we O +
report O +
a O +
zebrafish O +
brca2 O +
insertional O +
mutant O +
that O +
shares O +
phenotypes O +
with O +
human O +
patients O +
and O +
identifies O +
a O +
novel O +
brca2 O +
function O +
in O +
oogenesis O -
. O +

Experiments O +
showed O +
that O +
mutant O +
embryos O +
and O +
mutant O +
cells O +
in O +
culture O +
experienced O +
genome O +
instability O -
, O +
as O +
do O +
cells O +
in O +
FA O +
patients O -
. O +

In O +
wild O -
- O -
type O +
zebrafish O -
, O +
meiotic O +
cells O +
expressed O +
brca2 O -
; O +
and O -
, O +
unexpectedly O -
, O +
transcripts O +
in O +
oocytes O +
localized O +
asymmetrically O +
to O +
the O +
animal O +
pole O -
. O +

In O +
juvenile O +
brca2 O +
mutants O -
, O +
oocytes O +
failed O +
to O +
progress O +
through O +
meiosis O -
, O +
leading O +
to O +
female O -
- O -
to O -
- O -
male O +
sex O +
reversal O -
. O +

Adult O +
mutants O +
became O +
sterile O +
males O +
due O +
to O +
the O +
meiotic O +
arrest O +
of O +
spermatocytes O -
, O +
which O +
then O +
died O +
by O +
apoptosis O -
, O +
followed O +
by O +
neoplastic O +
proliferation O +
of O +
gonad O +
somatic O +
cells O +
that O +
was O +
similar O +
to O +
neoplasia O +
observed O +
in O +
ageing O +
dead O +
end O +
( O -
dnd O -
) O -
-knockdown O +
males O -
, O +
which O +
lack O +
germ O +
cells O -
. O +

The O +
construction O +
of O +
animals O +
doubly O +
mutant O +
for O +
brca2 O +
and O +
the O +
apoptotic O +
gene O +
tp53 O +
( O -
p53 O -
) O +
rescued O +
brca2-dependent O +
sex O +
reversal O -
. O +

Double O +
mutants O +
developed O +
oocytes O +
and O +
became O +
sterile O +
females O +
that O +
produced O +
only O +
aberrant O +
embryos O +
and O +
showed O +
elevated O +
risk O +
for O +
invasive O +
ovarian O +
tumors O -
. O +

Oocytes O +
in O +
double O -
- O -
mutant O +
females O +
showed O +
normal O +
localization O +
of O +
brca2 O +
and O +
pou5f1 O +
transcripts O +
to O +
the O +
animal O +
pole O +
and O +
vasa O +
transcripts O +
to O +
the O +
vegetal O +
pole O -
, O +
but O +
had O +
a O +
polarized O +
rather O +
than O +
symmetrical O +
nucleus O +
with O +
the O +
distribution O +
of O +
nucleoli O +
and O +
chromosomes O +
to O +
opposite O +
nuclear O +
poles O -
; O +
this O +
result O +
revealed O +
a O +
novel O +
role O +
for O +
Brca2 O +
in O +
establishing O +
or O +
maintaining O +
oocyte O +
nuclear O +
architecture O -
. O +

Mutating O +
tp53 O +
did O +
not O +
rescue O +
the O +
infertility O +
phenotype O +
in O +
brca2 O +
mutant O +
males O -
, O +
suggesting O +
that O +
brca2 O +
plays O +
an O +
essential O +
role O +
in O +
zebrafish O +
spermatogenesis O -
. O +

Overall O -
, O +
this O +
work O +
verified O +
zebrafish O +
as O +
a O +
model O +
for O +
the O +
role O +
of O +
Brca2 O +
in O +
human O +
disease O +
and O +
uncovered O +
a O +
novel O +
function O +
of O +
Brca2 O +
in O +
vertebrate O +
oocyte O +
nuclear O +
architecture O -
. O +

Induction O +
of O +
Id-1 O +
by O +
FGF-2 O +
involves O +
activity O +
of O +
EGR-1 O +
and O +
sensitizes O +
neuroblastoma O +
cells O +
to O +
cell O +
death O -
. O +

Inhibitor O +
of O +
differentiation-1 O +
( O -
Id-1 O -
) O +
is O +
a O +
member O +
of O +
helix O -
- O -
loop O -
- O -
helix O +
( O -
HLH O -
) O +
family O +
of O +
proteins O +
that O +
regulate O +
gene O +
transcription O +
through O +
their O +
inhibitory O +
binding O +
to O +
basic O -
- O -
HLH O +
transcription O +
factors O -
. O +

Similarly O +
to O +
other O +
members O +
of O +
this O +
family O -
, O +
Id-1 O +
is O +
involved O +
in O +
the O +
repression O +
of O +
cell O +
differentiation O +
and O +
activation O +
of O +
cell O +
growth O -
. O +

The O +
dual O +
function O +
of O +
Id-1 O -
, O +
inhibition O +
of O +
differentiation O -
, O +
and O +
stimulation O +
of O +
cell O +
proliferation O -
, O +
might O +
be O +
interdependent O -
, O +
as O +
cell O +
differentiation O +
is O +
generally O +
coupled O +
with O +
the O +
exit O +
from O +
the O +
cell O +
cycle O -
. O +

Fibroblast O +
growth O +
factor-2 O +
( O -
FGF-2 O -
) O +
has O +
been O +
reported O +
to O +
play O +
multiple O +
roles O +
in O +
different O +
biological O +
processes O +
during O +
development O +
of O +
the O +
central O +
nervous O +
system O +
( O -
CNS O -
) O -
. O +

In O +
addition O -
, O +
FGF-2 O +
has O +
been O +
described O +
to O +
induce O +
" O -
neuronal O -
- O -
like O -
" O +
differentiation O +
and O +
trigger O +
apoptosis O +
in O +
neuroblastoma O +
SK O -
- O -
N O -
- O -
MC O +
cells O -
. O +

Although O +
regulation O +
of O +
Id-1 O +
protein O +
by O +
several O +
mitogenic O +
factors O +
is O +
well O -
- O -
established O -
, O +
little O +
is O +
known O +
about O +
the O +
role O +
of O +
FGF-2 O +
in O +
the O +
regulation O +
of O +
Id-1 O -
. O +

Using O +
human O +
neuroblastoma O +
cell O +
line O -
, O +
SK O -
- O -
N O -
- O -
MC O -
, O +
we O +
found O +
that O +
treatment O +
of O +
these O +
cells O +
with O +
FGF-2 O +
resulted O +
in O +
early O +
induction O +
of O +
both O +
Id-1 O +
mRNA O +
and O +
protein O -
. O +

The O +
induction O +
occurs O +
within O +
1 O +
h O +
from O +
FGF-2 O +
treatment O +
and O +
is O +
mediated O +
by O +
ERK1 O -
/ O -
2 O +
pathway O -
, O +
which O +
in O +
turn O +
stimulates O +
expression O +
of O +
the O +
early O +
growth O +
response-1 O +
( O -
Egr-1 O -
) O +
transcription O +
factor O -
. O +

We O +
also O +
demonstrate O +
direct O +
interaction O +
of O +
Egr-1 O +
with O +
Id-1 O +
promoter O +
in O +
vitro O +
and O +
in O +
cell O +
culture O -
. O +

Finally O -
, O +
inhibition O +
of O +
Id-1 O +
expression O +
results O +
in O +
G O -
( O -
2 O -
) O +
/M O +
accumulation O +
of O +
FGF-2-treated O +
cells O +
and O +
delayed O +
cell O +
death O -
. O +

Vimentin O +
is O +
preferentially O +
expressed O +
in O +
human O +
breast O +
carcinomas O +
with O +
low O +
estrogen O +
receptor O +
and O +
high O +
Ki-67 O +
growth O +
fraction O -
. O +

Vimentin O +
expression O -
, O +
growth O +
fractions O +
( O -
GF O -
) O -
, O +
and O +
estrogen O +
receptor O +
( O -
ER O -
) O +
levels O +
were O +
determined O +
for O +
90 O +
untreated O +
primary O +
breast O +
carcinomas O -
. O +

Coexpression O +
of O +
keratin O +
and O +
vimentin O +
was O +
found O +
in O +
approximately O +
20 O -
% O +
of O +
the O +
tumors O +
regardless O +
of O +
menopausal O +
status O -
. O +

Vimentin O +
was O +
expressed O +
preferentially O +
in O +
tumor O +
cells O +
of O +
high O -
- O -
grade O +
ductal O +
breast O +
carcinomas O +
( O -
15 O +
of O +
28 O +
histologic O +
grade O +
3 O +
vs. O +
0 O +
of O +
40 O +
grades O +
1 O +
and O +
2 O -
) O -
. O +

Vimentin O +
expression O +
was O +
found O +
preferentially O +
in O +
tumors O +
with O +
high O +
GF O +
( O -
greater O +
than O +
15 O -
% O +
Ki-67 O +
positive O +
by O +
immunoperoxidase O +
staining O -
) O +
and O +
low O +
ER O +
levels O +
( O -
less O +
than O +
60 O +
fmols O -
/ O -
mg O +
protein O +
by O +
a O +
monoclonal O +
enzyme O +
immunoassay O -
) O -
. O +

Sixty O -
- O -
eight O +
percent O +
of O +
tumors O +
in O +
this O +
group O +
were O +
vimentin O +
positive O +
and O +
88 O -
% O +
of O +
all O +
vimentin O -
- O -
positive O +
tumors O +
fell O +
into O +
this O +
category O -
. O +

More O +
than O +
50 O -
% O +
of O +
the O +
tumor O +
cells O +
coexpressed O +
vimentin O +
and O +
keratin O -
. O +

Thus O -
, O +
vimentin O +
expression O +
may O +
be O +
helpful O +
in O +
identifying O +
a O +
substantial O +
subset O +
of O +
ER O -
- O -
independent O +
breast O +
carcinomas O +
with O +
poor O +
prognostic O +
indicators O -
. O +

Inhibition O +
of O +
autophagy O +
potentiates O +
the O +
antitumor O +
effect O +
of O +
the O +
multikinase O +
inhibitor O +
sorafenib B-Chemical +
in O +
hepatocellular O +
carcinoma O -
. O +

Multikinase O +
inhibitor O +
sorafenib B-Chemical +
inhibits O +
proliferation O +
and O +
angiogenesis O +
of O +
tumors O +
by O +
suppressing O +
the O +
Raf O -
/ O -
MEK O -
/ O -
ERK O +
signaling O +
pathway O +
and O +
VEGF O +
receptor O +
tyrosine O +
kinase O -
. O +

It O +
significantly O +
prolongs O +
median O +
survival O +
of O +
patients O +
with O +
advanced O +
hepatocellular O +
carcinoma O +
( O -
HCC O -
) O +
but O +
the O +
response O +
is O +
disease O -
- O -
stabilizing O +
and O +
cytostatic O +
rather O +
than O +
one O +
of O +
tumor O +
regression O -
. O +

To O +
examine O +
the O +
mechanisms O +
underlying O +
the O +
relative O +
resistance O +
in O +
HCC O -
, O +
we O +
investigated O +
the O +
role O +
of O +
autophagy O -
, O +
an O +
evolutionarily O +
conserved O +
self O -
- O -
digestion O +
pathway O -
, O +
in O +
hepatoma O +
cells O +
in O +
vitro O +
and O +
in O +
vivo O -
. O +

Sorafenib B-Chemical +
treatment O +
led O +
to O +
accumulation O +
of O +
autophagosomes O +
as O +
evidenced O +
by O +
conversion O +
from O +
LC3-I O +
to O +
LC3-II O +
observed O +
by O +
immunoblot O +
in O +
Huh7 O -
, O +
HLF O +
and O +
PLC O -
/ O -
PRF O -
/ O -
5 O +
cells O -
. O +

This O +
induction O +
was O +
due O +
to O +
activation O +
of O +
autophagic O +
flux O -
, O +
as O +
there O +
was O +
further O +
increase O +
in O +
LC3-II O +
expression O +
upon O +
treatment O +
with O +
lysosomal O +
inhibitors O -
, O +
clear O +
decline O +
of O +
the O +
autophagy O +
substrate O +
p62 O -
, O +
and O +
an O +
mRFP O -
- O -
GFP O -
- O -
LC3 O +
fluorescence O +
change O +
in O +
sorafenib B-Chemical -
- O -
treated O +
hepatoma O +
cells O -
. O +

Sorafenib B-Chemical +
inhibited O +
the O +
mammalian O +
target O +
of O +
rapamycin O +
complex O +
1 O +
and O +
its O +
inhibition O +
led O +
to O +
accumulation O +
of O +
LC3-II O -
. O +

Pharmacological O +
inhibition O +
of O +
autophagic O +
flux O +
by O +
chloroquine B-Chemical +
increased O +
apoptosis O +
and O +
decreased O +
cell O +
viability O +
in O +
hepatoma O +
cells O -
. O +

siRNA O -
- O -
mediated O +
knockdown O +
of O +
the O +
ATG7 O +
gene O +
also O +
sensitized O +
hepatoma O +
cells O +
to O +
sorafenib B-Chemical -
. O +

Finally O -
, O +
sorafenib B-Chemical +
induced O +
autophagy O +
in O +
Huh7 O +
xenograft O +
tumors O +
in O +
nude O +
mice O +
and O +
coadministration O +
with O +
chloroquine B-Chemical +
significantly O +
suppressed O +
tumor O +
growth O +
compared O +
with O +
sorafenib B-Chemical +
alone O -
. O +

In O +
conclusion O -
, O +
sorafenib B-Chemical +
administration O +
induced O +
autophagosome O +
formation O +
and O +
enhanced O +
autophagic O +
activity O -
, O +
which O +
conferred O +
a O +
survival O +
advantage O +
to O +
hepatoma O +
cells O -
. O +

Concomitant O +
inhibition O +
of O +
autophagy O +
may O +
be O +
an O +
attractive O +
strategy O +
for O +
unlocking O +
the O +
antitumor O +
potential O +
of O +
sorafenib B-Chemical +
in O +
HCC O -
. O +

Desensitization O +
of O +
prostaglandin B-Chemical +
F2 I-Chemical +
alpha I-Chemical -
- O -
stimulated O +
inositol B-Chemical +
phosphate I-Chemical +
generation O +
in O +
NIH-3T3 O +
fibroblasts O +
transformed O +
by O +
overexpression O +
of O +
normal O +
c O -
- O -
Ha O -
- O -
ras-1 O -
, O +
c O -
- O -
Ki O -
- O -
ras-2 O +
and O +
c O -
- O -
N O -
- O -
ras O +
genes O -
. O +

The O +
stimulation O +
of O +
inositol B-Chemical +
phosphate I-Chemical +
generation O +
in O +
control O +
and O +
ras O -
- O -
gene O -
- O -
transformed O +
NIH-3T3 O +
cells O +
by O +
prostaglandin B-Chemical +
F2 I-Chemical +
alpha I-Chemical +
( O -
PGF2 B-Chemical +
alpha I-Chemical -
) O +
was O +
investigated O -
. O +

Compared O +
with O +
the O +
control O +
cells O -
, O +
a O +
desensitization O +
of O +
the O +
response O +
was O +
observed O +
in O +
cells O +
transformed O +
by O +
the O +
overexpression O +
of O +
N- O -
, O +
Ha- O -
, O +
or O +
Ki O -
- O -
ras O +
genes O -
. O +

This O +
desensitization O +
was O +
without O +
effect O +
upon O +
the O +
concentration O +
causing O +
half O -
- O -
maximal O +
effect O +
( O -
EC50 O -
) O -
, O +
dissociation O +
constant O +
( O -
Kd O -
) O +
or O +
number O +
of O +
PGF2 O +
alpha O +
receptors O -
. O +

Inhibition O +
of O +
PG B-Chemical +
synthesis O +
was O +
without O +
effect O +
upon O +
desensitization O -
, O +
demonstrating O +
that O +
the O +
effect O +
was O +
not O +
agonist O -
- O -
induced O -
. O +

Desensitization O +
could O +
be O +
induced O +
in O +
NIH-3T3 O +
cells O +
by O +
culturing O +
under O +
conditions O +
where O +
the O +
cells O +
were O +
all O +
in O +
the O +
exponential O +
growth O +
phase O -
, O +
or O +
by O +
a O +
12 O +
h O +
exposure O +
to O +
a O +
C O -
- O -
kinase O -
- O -
activating O +
phorbol B-Chemical +
ester I-Chemical -
. O +

These O +
results O +
suggest O +
that O +
desensitization O +
of O +
certain O +
agonist O -
- O -
induced O +
inositol B-Chemical +
phospholipid I-Chemical +
responses O +
in O +
ras O -
- O -
transformed O +
cells O +
is O +
a O +
consequence O +
of O +
increased O +
cell O +
proliferation O +
and O +
associated O +
amplification O +
in O +
C O -
- O -
kinase O +
activity O +
and O +
is O +
an O +
indirect O +
consequence O +
of O +
transformation O +
by O +
ras O -
. O +

Expression O +
of O +
thymidylate O +
synthase O +
and O +
dihydropyrimidine O +
dehydrogenase O +
in O +
primary O +
oral O +
squamous O +
cell O +
carcinoma O +
and O +
corresponding O +
metastases O +
in O +
cervical O +
lymph O +
nodes O -
: O +
association O +
with O +
the O +
metastasis O +
suppressor O +
CD82 O -
. O +

Thymidylate O +
synthase O +
( O -
TS O -
) O +
and O +
dihydropyrimidine O +
dehydrogenase O +
( O -
DPD O -
) O +
are O +
5-fluorouracil B-Chemical +
( O -
5-FU B-Chemical -
) O +
metabolizing O +
enzymes O +
and O +
are O +
involved O +
in O +
the O +
sensitivity O +
of O +
carcinoma O +
patients O +
to O +
5-FU B-Chemical -
. O +

Although O +
5-FU B-Chemical +
is O +
often O +
used O +
for O +
the O +
treatment O +
of O +
oral O +
carcinoma O -
, O +
there O +
has O +
not O +
been O +
any O +
investigation O +
into O +
the O +
expression O +
of O +
these O +
enzymes O +
in O +
metastatic O +
lymph O +
nodes O +
or O +
of O +
their O +
roles O +
in O +
the O +
effectiveness O +
of O +
5-FU B-Chemical +
in O +
treating O +
lymph O +
node O -
- O -
metastatic O +
cancer O -
. O +

Oral O +
squamous O +
cell O +
carcinoma O +
( O -
OSCC O -
) O +
often O +
metastasizes O +
to O +
the O +
lymph O +
nodes O -
, O +
and O +
these O +
enzymes O +
may O +
be O +
significant O +
in O +
the O +
survival O +
of O +
patients O +
with O +
this O +
disease O -
. O +

This O +
study O +
investigated O +
the O +
expression O +
of O +
TS O +
and O +
DPD O +
in O +
cervical O +
lymph O +
node O +
metastases O +
and O +
its O +
relationship O +
with O +
primary O +
OSCC O -
, O +
as O +
well O +
as O +
the O +
interaction O +
between O +
these O +
enzymes O +
and O +
Kangai O +
1 O -
( O -
KAI1 O -
/ O -
CD82 O -
) O +
which O +
is O +
a O +
metastasis O +
suppressor O +
protein O -
. O +

Surgical O +
specimens O +
from O +
20 O +
cases O +
of O +
OSCC O +
with O +
lymph O +
node O +
metastasis O -
, O +
20 O +
cases O +
of O +
OSCC O +
without O +
lymph O +
node O +
metastasis O -
, O +
and O +
10 O +
cases O +
of O +
normal O +
mucosa O +
were O +
examined O +
by O +
immunohistochemistry O -
. O +

The O +
relationship O +
between O +
TS O +
and O +
DPD O +
expression O +
and O +
clinicopathological O +
data O +
was O +
analyzed O -
. O +

TS O +
and O +
DPD O +
proteins O +
were O +
overexpressed O +
in O +
primary O +
OSCC O +
compared O +
to O +
that O +
in O +
normal O +
mucosa O -
. O +

TS O +
expression O +
of O +
the O +
primary O +
oral O +
cancer O +
cells O +
in O +
the O +
group O +
with O +
lymph O +
node O +
metastasis O +
was O +
higher O +
than O +
that O +
of O +
those O +
without O -
. O +

DPD O +
expression O +
did O +
not O +
significantly O +
correlate O +
with O +
the O +
occurrence O +
of O +
lymph O +
node O +
metastasis O -
, O +
nor O +
was O +
it O +
different O +
between O +
primary O +
oral O +
cancer O +
cells O +
and O +
cervical O +
metastases O -
. O +

CD82 O +
expression O +
was O +
significantly O +
reduced O +
in O +
lymph O +
node O +
metastases O -
. O +

These O +
findings O +
indicate O +
that O +
TS O +
and O +
CD82 O +
may O +
be O +
of O +
great O +
value O +
in O +
assessing O +
lymph O +
node O +
metastasis O +
of O +
OSCC O -
, O +
and O +
could O +
be O +
taken O +
as O +
new O +
targets O +
for O +
therapy O +
of O +
metastatic O +
OSCC O -
. O +

Aquaporins O +
in O +
human O +
breast O +
cancer O -
: O +
identification O +
and O +
involvement O +
in O +
carcinogenesis O +
of O +
breast O +
cancer O -
. O +

BACKGROUND O +
AND O +
OBJECTIVES O -
: O +
Aquaporins O +
( O -
AQPs O -
) O +
play O +
important O +
roles O +
in O +
water B-Chemical +
and O +
glycerol B-Chemical +
transport O -
. O +

Recently O -
, O +
the O +
role O +
of O +
AQPs O +
in O +
human O +
carcinogenesis O +
has O +
become O +
an O +
area O +
of O +
great O +
interest O -
. O +

However O -
, O +
little O +
is O +
known O +
about O +
the O +
function O +
of O +
AQPs O +
in O +
human O +
breast O +
cancer O -
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
expression O +
profile O +
of O +
AQPs O +
in O +
human O +
breast O +
cancer O +
and O +
its O +
significance O -
. O +

METHODS O -
: O +
In O +
this O +
study O -
, O +
we O +
screened O +
the O +
expression O +
profile O +
of O +
AQP0 O -
- O -
12 O +
in O +
breast O +
cancer O +
tissues O +
and O +
corresponding O +
normal O +
tissues O +
by O +
RT O -
- O -
PCR O -
, O +
Western O +
blotting O +
and O +
immunohistochemistry O -
. O +

RESULTS O -
: O +
AQP1 O -
, O +
3 O -
- O -
5 O -
, O +
and O +
10 O -
- O -
12 O +
were O +
expressed O +
in O +
human O +
breast O +
cancer O +
and/or O +
normal O +
breast O +
tissues O -
, O +
and O +
AQP1 O +
and O +
3 O -
- O -
5 O +
exhibited O +
differential O +
expression O -
. O +

AQP1 O +
was O +
expressed O +
in O +
cell O +
membranes O +
and O +
its O +
expression O +
was O +
higher O +
in O +
cancer O +
than O +
that O +
in O +
normal O +
tissues O -
. O +

AQP4 O +
was O +
expressed O +
in O +
the O +
cell O +
membrane O +
and O +
cytoplasm O +
and O +
was O +
detected O +
markedly O +
stronger O +
in O +
normal O +
than O +
in O +
cancer O +
tissues O -
. O +

AQP5 O +
was O +
expressed O +
mainly O +
in O +
cell O +
membranes O +
in O +
carcinoma O +
tissues O -
, O +
but O +
was O +
almost O +
absent O +
in O +
normal O +
breast O +
tissues O -
. O +

Expression O +
of O +
AQP5 O +
was O +
associated O +
with O +
cellular O +
differentiation O -
, O +
lymph O +
node O +
invasion O -
, O +
and O +
clinicopathological O +
staging O -
. O +

CONCLUSIONS O -
: O +
These O +
observations O +
suggested O +
that O +
several O +
subtypes O +
of O +
the O +
AQP O +
family O +
play O +
a O +
role O +
in O +
human O +
breast O +
carcinogenesis O -
. O +

Relationship O +
between O +
of O +
blood O +
flow O -
, O +
glucose B-Chemical +
metabolism O -
, O +
protein O +
synthesis O -
, O +
glucose B-Chemical +
and O +
ATP B-Chemical +
content O +
in O +
experimentally O -
- O -
induced O +
glioma O +
( O -
RG1 O +
2.2 O -
) O +
of O +
rat O +
brain O -
. O +

In O +
experimental O +
RG1 O +
2.2 O +
glioma O +
of O +
rat O +
brain O -
, O +
local O +
blood O +
flow O -
, O +
glucose B-Chemical +
utilization O -
, O +
protein O +
synthesis O -
, O +
glucose B-Chemical +
and O +
ATP B-Chemical +
content O +
were O +
measured O +
by O +
means O +
of O +
triple O +
tracer O +
autoradiography O +
and O +
bioluminescence O +
technique O -
, O +
respectively O -
, O +
to O +
determine O +
hemodynamic O +
and O +
metabolic O +
thresholds O +
for O +
local O +
tumor O +
energy O +
failure O -
. O +

Perfusion O +
thresholds O +
were O +
estimated O +
at O +
tumor O +
blood O +
flow O +
values O +
of O +
69.0 O +
+ O -
/- O +

0.1 O +
ml O -
/ O -
100 O +
g O -
/ O -
min O +
( O -
estimate O +
+ O -
/- O +

standard O +
error O -
) O +
and O +
of O +
69 O +
+ O -
/- O +

7.1 O +
ml O -
/ O -
100 O +
g O -
/ O -
min O +
for O +
the O +
beginning O +
of O +
the O +
decline O +
in O +
regional O +
ATP B-Chemical +
and O +
glucose B-Chemical +
content O -
, O +
respectively O -
. O +

Metabolic O +
thresholds O +
were O +
derived O +
at O +
tumor O +
glucose B-Chemical +
utilization O +
values O +
of O +
70.6 O +
+ O -
/- O +

8.3 O +
mumol O -
/ O -
100 O +
g O -
/ O -
min O +
for O +
reduced O +
protein O +
synthesis O -
, O +
of O +
55.0 O +
+ O -
/- O +

0.2 O +
mumol O -
/ O -
100 O +
g O -
/ O -
min O +
for O +
the O +
decrease O +
in O +
glucose B-Chemical +
content O -
, O +
and O +
34.7 O +
+ O -
/- O +

4.7 O +
mumol O -
/ O -
100 O +
g O -
/ O -
min O +
for O +
decline O +
in O +
ATP B-Chemical +
content O -
. O +

Our O +
results O +
suggest O +
that O +
blood O +
flow O +
limits O +
glucose B-Chemical +
supply O +
to O +
tumor O +
tissue O +
at O +
much O +
higher O +
flow O +
rates O +
than O +
in O +
normal O +
brain O +
which O -
, O +
in O +
turn O -
, O +
is O +
associated O +
with O +
a O +
decrease O +
in O +
tumor O +
glucose B-Chemical +
utilization O -
. O +

A O +
reduction O +
and O +
not O +
an O +
increase O +
in O +
tumor O +
glucose B-Chemical +
availability O +
could O +
be O +
a O +
more O +
appropriate O +
strategy O +
for O +
the O +
induction O +
of O +
energy O +
failure O +
in O +
tumors O -
. O +

Selective O +
inhibition O +
of O +
nuclear O +
factor O -
- O -
kappaB O +
by O +
nuclear B-Chemical +
factor I-Chemical -
- I-Chemical -
kappaB I-Chemical +
essential I-Chemical +
modulator I-Chemical -
- I-Chemical -
binding I-Chemical +
domain I-Chemical +
peptide I-Chemical +
suppresses O +
the O +
metastasis O +
of O +
highly O +
metastatic O +
oral O +
squamous O +
cell O +
carcinoma O -
. O +

Nuclear O +
factor O -
- O -
kappaB O +
( O -
NF O -
- O -
kappaB O -
) O +
activation O +
contributes O +
to O +
the O +
development O +
of O +
metastasis O -
, O +
thus O +
leading O +
to O +
a O +
poor O +
prognosis O +
in O +
many O +
cancers O -
, O +
including O +
OSCC O -
. O +

However O -
, O +
little O +
in O +
vivo O +
experimental O +
data O +
are O +
available O +
about O +
the O +
effects O +
of O +
NF O -
- O -
kappaB O +
inhibition O +
on O +
OSCC O +
metastasis O -
. O +

OSCC O +
sublines O +
were O +
established O +
from O +
a O +
GFP O -
- O -
expressing O +
parental O +
cell O +
line O -
, O +
GSAS O -
, O +
and O +
designated O +
GSAS O -
/ O -
N3 O +
and O +
N5 O +
according O +
to O +
the O +
in O +
vivo O +
passage O +
number O +
after O +
cervical O +
lymph O +
node O +
metastasis O +
by O +
a O +
serial O +
orthotopic O +
transplantation O +
model O -
. O +

In O +
vitro O +
migration O +
and O +
invasion O +
were O +
assessed O +
in O +
these O +
cells O -
, O +
and O +
the O +
NF O -
- O -
kappaB O +
activities O +
and O +
expression O +
of O +
NF O -
- O -
kappaB O -
- O -
regulated O +
metastasis O -
- O -
related O +
molecules O +
were O +
also O +
examined O -
. O +

In O +
in O +
vivo O +
experiments O -
, O +
the O +
metastasis O +
and O +
survival O +
of O +
tumor O -
- O -
engrafted O +
mice O +
were O +
monitored O -
. O +

Furthermore O -
, O +
the O +
effects O +
of O +
a O +
selective O +
NF O -
- O -
kappaB O +
inhibitor O -
, O +
NEMO B-Chemical -
- I-Chemical -
binding I-Chemical +
domain I-Chemical +
( I-Chemical -
NBD I-Chemical -
) I-Chemical +
peptide I-Chemical -
, O +
on O +
metastasis O +
in O +
GSAS O -
/ O -
N5-engrafted O +
mice O +
were O +
assessed O -
, O +
and O +
engrafted O +
tongue O +
tumors O +
were O +
immunohistochemically O +
examined O -
. O +

Highly O +
metastatic O +
GSAS O -
/ O -
N3 O +
and O +
N5 O +
cells O +
showed O +
an O +
enhanced O +
NF O -
- O -
kappaB O +
activity O -
, O +
thus O +
contributing O +
to O +
increased O +
migration O -
, O +
invasion O -
, O +
and O +
a O +
poor O +
prognosis O +
compared O +
with O +
the O +
parent O +
cells O -
. O +

Furthermore O -
, O +
the O +
expression O +
levels O +
of O +
NF O -
- O -
kappaB O -
- O -
regulated O +
metastasis O -
- O -
related O +
molecules O -
, O +
such O +
as O +
fibronectin O -
, O +
beta1 O +
integrin O -
, O +
MMP-1 O -
, O +
-2 O -
, O +
-9 O -
, O +
and O +
-14 O -
, O +
and O +
VEGF O -
- O -
C O -
, O +
were O +
upregulated O +
in O +
the O +
highly O +
metastatic O +
cells O -
. O +

The O +
NBD B-Chemical +
peptide I-Chemical +
suppressed O +
metastasis O +
and O +
tongue O +
tumor O +
growth O +
in O +
GSAS O -
/ O -
N5-inoculated O +
mice O -
, O +
and O +
was O +
accompanied O +
by O +
the O +
downregulation O +
of O +
the O +
NF O -
- O -
kappaB O -
- O -
regulated O +
metastasis O -
- O -
related O +
molecules O +
in O +
engrafted O +
tongue O +
tumors O -
. O +

Our O +
results O +
suggest O +
that O +
the O +
selective O +
inhibition O +
of O +
NF O -
- O -
kappaB O +
activation O +
by O +
NBD B-Chemical +
peptide I-Chemical +
may O +
provide O +
an O +
effective O +
approach O +
for O +
the O +
treatment O +
of O +
highly O +
metastatic O +
OSCC O -
. O +

beta O -
- O -
catenin O +
signaling O +
controls O +
metastasis O +
in O +
Braf O -
- O -
activated O +
Pten O -
- O -
deficient O +
melanomas O -
. O +

Malignant O +
melanoma O +
is O +
characterized O +
by O +
frequent O +
metastasis O -
, O +
however O -
, O +
specific O +
changes O +
that O +
regulate O +
this O +
process O +
have O +
not O +
been O +
clearly O +
delineated O -
. O +

Although O +
it O +
is O +
well O +
known O +
that O +
Wnt O +
signaling O +
is O +
frequently O +
dysregulated O +
in O +
melanoma O -
, O +
the O +
functional O +
implications O +
of O +
this O +
observation O +
are O +
unclear O -
. O +

By O +
modulating O +
beta O -
- O -
catenin O +
levels O +
in O +
a O +
mouse O +
model O +
of O +
melanoma O +
that O +
is O +
based O +
on O +
melanocyte O -
- O -
specific O +
Pten O +
loss O +
and O +
Braf O -
( O -
V600E O -
) O +
mutation O -
, O +
we O +
demonstrate O +
that O +
beta O -
- O -
catenin O +
is O +
a O +
central O +
mediator O +
of O +
melanoma O +
metastasis O +
to O +
the O +
lymph O +
nodes O +
and O +
lungs O -
. O +

In O +
addition O +
to O +
altering O +
metastasis O -
, O +
beta O -
- O -
catenin O +
levels O +
control O +
tumor O +
differentiation O +
and O +
regulate O +
both O +
MAPK O -
/ O -
Erk O +
and O +
PI3K O -
/ O -
Akt O +
signaling O -
. O +

Highly O +
metastatic O +
tumors O +
with O +
beta O -
- O -
catenin O +
stabilization O +
are O +
very O +
similar O +
to O +
a O +
subset O +
of O +
human O +
melanomas O -
. O +

Together O +
these O +
findings O +
establish O +
Wnt O +
signaling O +
as O +
a O +
metastasis O +
regulator O +
in O +
melanoma O -
. O +

Impaired O +
CK1 O +
delta O +
activity O +
attenuates O +
SV40-induced O +
cellular O +
transformation O +
in O +
vitro O +
and O +
mouse O +
mammary O +
carcinogenesis O +
in O +
vivo O -
. O +

Simian O +
virus O +
40 O +
( O -
SV40 O -
) O +
is O +
a O +
powerful O +
tool O +
to O +
study O +
cellular O +
transformation O +
in O +
vitro O -
, O +
as O +
well O +
as O +
tumor O +
development O +
and O +
progression O +
in O +
vivo O -
. O +

Various O +
cellular O +
kinases O -
, O +
among O +
them O +
members O +
of O +
the O +
CK1 O +
family O -
, O +
play O +
an O +
important O +
role O +
in O +
modulating O +
the O +
transforming O +
activity O +
of O +
SV40 O -
, O +
including O +
the O +
transforming O +
activity O +
of O +
T O -
- O -
Ag O -
, O +
the O +
major O +
transforming O +
protein O +
of O +
SV40 O -
, O +
itself O -
. O +

Here O +
we O +
characterized O +
the O +
effects O +
of O +
mutant O +
CK1delta O +
variants O +
with O +
impaired O +
kinase O +
activity O +
on O +
SV40-induced O +
cell O +
transformation O +
in O +
vitro O -
, O +
and O +
on O +
SV40-induced O +
mammary O +
carcinogenesis O +
in O +
vivo O +
in O +
a O +
transgenic O -
/ O -
bi O -
- O -
transgenic O +
mouse O +
model O -
. O +

CK1delta O +
mutants O +
exhibited O +
a O +
reduced O +
kinase O +
activity O +
compared O +
to O +
wtCK1delta O +
in O +
in O +
vitro O +
kinase O +
assays O -
. O +

Molecular O +
modeling O +
studies O +
suggested O +
that O +
mutation O +
N172D O -
, O +
located O +
within O +
the O +
substrate O +
binding O +
region O -
, O +
is O +
mainly O +
responsible O +
for O +
impaired O +
mutCK1delta O +
activity O -
. O +

When O +
stably O +
over O -
- O -
expressed O +
in O +
maximal O +
transformed O +
SV-52 O +
cells O -
, O +
CK1delta O +
mutants O +
induced O +
reversion O +
to O +
a O +
minimal O +
transformed O +
phenotype O +
by O +
dominant O -
- O -
negative O +
interference O +
with O +
endogenous O +
wtCK1delta O -
. O +

To O +
characterize O +
the O +
effects O +
of O +
CK1delta O +
on O +
SV40-induced O +
mammary O +
carcinogenesis O -
, O +
we O +
generated O +
transgenic O +
mice O +
expressing O +
mutant O +
CK1delta O +
under O +
the O +
control O +
of O +
the O +
whey O +
acidic O +
protein O +
( O -
WAP O -
) O +
gene O +
promoter O -
, O +
and O +
crossed O +
them O +
with O +
SV40 O +
transgenic O +
WAP O -
- O -
T O -
- O -
antigen O +
( O -
WAP O -
- O -
T O -
) O +
mice O -
. O +

Both O +
WAP O -
- O -
T O +
mice O +
as O +
well O +
as O +
WAP O -
- O -
mutCK1delta O -
/ O -
WAP O -
- O -
T O +
bi O -
- O -
transgenic O +
mice O +
developed O +
breast O +
cancer O -
. O +

However O -
, O +
tumor O +
incidence O +
was O +
lower O +
and O +
life O +
span O +
was O +
significantly O +
longer O +
in O +
WAP O -
- O -
mutCK1delta O -
/ O -
WAP O -
- O -
T O +
bi O -
- O -
transgenic O +
animals O -
. O +

The O +
reduced O +
CK1delta O +
activity O +
did O +
not O +
affect O +
early O +
lesion O +
formation O +
during O +
tumorigenesis O -
, O +
suggesting O +
that O +
impaired O +
CK1delta O +
activity O +
reduces O +
the O +
probability O +
for O +
outgrowth O +
of O +
in O +
situ O +
carcinomas O +
to O +
invasive O +
carcinomas O -
. O +

The O +
different O +
tumorigenic O +
potential O +
of O +
SV40 O +
in O +
WAP O -
- O -
T O +
and O +
WAP O -
- O -
mutCK1delta O -
/ O -
WAP O -
- O -
T O +
tumors O +
was O +
also O +
reflected O +
by O +
a O +
significantly O +
different O +
expression O +
of O +
various O +
genes O +
known O +
to O +
be O +
involved O +
in O +
tumor O +
progression O -
, O +
specifically O +
of O +
those O +
involved O +
in O +
wnt O -
- O -
signaling O +
and O +
DNA O +
repair O -
. O +

Our O +
data O +
show O +
that O +
inactivating O +
mutations O +
in O +
CK1delta O +
impair O +
SV40-induced O +
cellular O +
transformation O +
in O +
vitro O +
and O +
mouse O +
mammary O +
carcinogenesis O +
in O +
vivo O -
. O +

Mitochondrial O +
apoptosis O +
and O +
FAK O +
signaling O +
disruption O +
by O +
a O +
novel O +
histone O +
deacetylase O +
inhibitor O -
, O +
HTPB B-Chemical -
, O +
in O +
antitumor O +
and O +
antimetastatic O +
mouse O +
models O -
. O +

BACKGROUND O -
: O +
Compound O +
targeting O +
histone O +
deacetylase O +
( O -
HDAC O -
) O +
represents O +
a O +
new O +
era O +
in O +
molecular O +
cancer O +
therapeutics O -
. O +

However O -
, O +
effective O +
HDAC O +
inhibitors O +
for O +
the O +
treatment O +
of O +
solid O +
tumors O +
remain O +
to O +
be O +
developed O -
. O +

METHODOLOGY O -
/ O -
PRINCIPAL O +
FINDINGS O -
: O +
Here O -
, O +
we O +
propose O +
a O +
novel O +
HDAC O +
inhibitor O -
, O +
N B-Chemical -
- I-Chemical -
Hydroxy-4- I-Chemical -
( I-Chemical -
4-phenylbutyryl I-Chemical -
- I-Chemical -
amino I-Chemical -
) I-Chemical +
benzamide I-Chemical +
( O -
HTPB B-Chemical -
) O -
, O +
as O +
a O +
potential O +
chemotherapeutic O +
drug O +
for O +
solid O +
tumors O -
. O +

The O +
HDAC O +
inhibition O +
of O +
HTPB B-Chemical +
was O +
confirmed O +
using O +
HDAC O +
activity O +
assay O -
. O +

The O +
antiproliferative O +
and O +
anti O -
- O -
migratory O +
mechanisms O +
of O +
HTPB B-Chemical +
were O +
investigated O +
by O +
cell O +
proliferation O -
, O +
flow O +
cytometry O -
, O +
DNA O +
ladder O -
, O +
caspase O +
activity O -
, O +
Rho O +
activity O -
, O +
F O -
- O -
actin O +
polymerization O -
, O +
and O +
gelatin O -
- O -
zymography O +
for O +
matrix O +
metalloproteinases O +
( O -
MMPs O -
) O -
. O +

Mice O +
with O +
tumor O +
xenograft O +
and O +
experimental O +
metastasis O +
model O +
were O +
used O +
to O +
evaluate O +
effects O +
on O +
tumor O +
growth O +
and O +
metastasis O -
. O +

Our O +
results O +
indicated O +
that O +
HTPB B-Chemical +
was O +
a O +
pan O -
- O -
HDAC O +
inhibitor O +
in O +
suppressing O +
cell O +
viability O +
specifically O +
of O +
lung O +
cancer O +
cells O +
but O +
not O +
of O +
the O +
normal O +
lung O +
cells O -
. O +

Upon O +
HTPB B-Chemical +
treatment O -
, O +
cell O +
cycle O +
arrest O +
was O +
induced O +
and O +
subsequently O +
led O +
to O +
mitochondria O -
- O -
mediated O +
apoptosis O -
. O +

HTPB B-Chemical +
disrupted O +
F O -
- O -
actin O +
dynamics O +
via O +
downregulating O +
RhoA O +
activity O -
. O +

Moreover O -
, O +
HTPB B-Chemical +
inhibited O +
activity O +
of O +
MMP2 O +
and O +
MMP9 O -
, O +
reduced O +
integrin O -
- O -
beta1 O -
/ O -
focal O +
adhesion O +
complex O +
formation O +
and O +
decreased O +
pericellular O +
poly O -
- O -
fibronectin O +
assemblies O -
. O +

Finally O -
, O +
intraperitoneal O +
injection O +
or O +
oral O +
administration O +
of O +
HTPB B-Chemical +
efficiently O +
inhibited O +
A549 O +
xenograft O +
tumor O +
growth O +
in O +
vivo O +
without O +
side O +
effects O -
. O +

HTPB B-Chemical +
delayed O +
lung O +
metastasis O +
of O +
4T1 O +
mouse O +
breast O +
cancer O +
cells O -
. O +

Acetylation O +
of O +
histone O +
and O +
non O -
- O -
histone O +
proteins O -
, O +
induction O +
of O +
apoptotic O -
- O -
related O +
proteins O +
and O +
de O -
- O -
phosphorylation O +
of O +
focal O +
adhesion O +
kinase O +
were O +
confirmed O +
in O +
treated O +
mice O -
. O +

CONCLUSIONS O -
/ O -
SIGNIFICANCE O -
: O +
These O +
results O +
suggested O +
that O +
intrinsic O +
apoptotic O +
pathway O +
may O +
involve O +
in O +
anti O -
- O -
tumor O +
growth O +
effects O +
of O +
HTPB B-Chemical +
in O +
lung O +
cancer O +
cells O -
. O +

HTPB B-Chemical +
significantly O +
suppresses O +
tumor O +
metastasis O +
partly O +
through O +
inhibition O +
of O +
integrin O -
- O -
beta1 O -
/ O -
FAK O -
/ O -
MMP O -
/ O -
RhoA O -
/ O -
F O -
- O -
actin O +
pathways O -
. O +

We O +
have O +
provided O +
convincing O +
preclinical O +
evidence O +
that O +
HTPB B-Chemical +
is O +
a O +
potent O +
HDAC O +
targeted O +
inhibitor O +
and O +
is O +
thus O +
a O +
promising O +
candidate O +
for O +
lung O +
cancer O +
chemotherapy O -
. O +

Inactivation O +
of O +
androgen B-Chemical -
- O -
induced O +
regulator O +
ARD1 O +
inhibits O +
androgen O +
receptor O +
acetylation O +
and O +
prostate O +
tumorigenesis O -
. O +

Androgen B-Chemical +
signaling O +
through O +
androgen O +
receptor O +
( O -
AR O -
) O +
is O +
critical O +
for O +
prostate O +
tumorigenesis O -
. O +

Given O +
that O +
AR O -
- O -
mediated O +
gene O +
regulation O +
is O +
enhanced O +
by O +
AR O +
coregulators O -
, O +
inactivation O +
of O +
those O +
coregulators O +
is O +
emerging O +
as O +
a O +
promising O +
therapy O +
for O +
prostate O +
cancer O +
( O -
PCa O -
) O -
. O +

Here O -
, O +
we O +
show O +
that O +
the O +
N O -
- O -
acetyltransferase O +
arrest O -
- O -
defect O +
1 O +
protein O +
( O -
ARD1 O -
) O +
functions O +
as O +
a O +
unique O +
AR O +
regulator O +
in O +
PCa O +
cells O -
. O +

ARD1 O +
is O +
up O -
- O -
regulated O +
in O +
human O +
PCa O +
cell O +
lines O +
and O +
primary O +
tumor O +
biopsies O -
. O +

The O +
expression O +
of O +
ARD1 O +
was O +
augmented O +
by O +
treatment O +
with O +
synthetic O +
androgen B-Chemical +
( O -
R1881 B-Chemical -
) O +
unless O +
AR O +
is O +
deficient O +
or O +
is O +
inhibited O +
by O +
AR O -
- O -
specific O +
siRNA O +
or O +
androgen B-Chemical +
inhibitor O +
bicalutamide B-Chemical +
( O -
Casodex B-Chemical -
) O -
. O +

Depletion O +
of O +
ARD1 O +
by O +
shRNA O +
suppressed O +
PCa O +
cell O +
proliferation O -
, O +
anchorage O -
- O -
independent O +
growth O -
, O +
and O +
xenograft O +
tumor O +
formation O +
in O +
SCID O +
mice O -
, O +
suggesting O +
that O +
AR O -
- O -
dependent O +
ARD1 O +
expression O +
is O +
biologically O +
germane O -
. O +

Notably O -
, O +
ARD1 O +
was O +
critical O +
for O +
transcriptionally O +
regulating O +
a O +
number O +
of O +
AR O +
target O +
genes O +
that O +
are O +
involved O +
in O +
prostate O +
tumorigenesis O -
. O +

Furthermore O -
, O +
ARD1 O +
interacted O +
physically O +
with O +
and O +
acetylated O +
the O +
AR O +
protein O +
in O +
vivo O +
and O +
in O +
vitro O -
. O +

Because O +
AR O -
- O -
ARD1 O +
interaction O +
facilitated O +
the O +
AR O +
binding O +
to O +
its O +
targeted O +
promoters O +
for O +
gene O +
transcription O -
, O +
we O +
propose O +
that O +
ARD1 O +
functions O +
as O +
a O +
unique O +
AR O +
regulator O +
and O +
forms O +
a O +
positive O +
feedback O +
loop O +
for O +
AR O -
- O -
dependent O +
prostate O +
tumorigenesis O -
. O +

Disruption O +
of O +
AR O -
- O -
ARD1 O +
interactions O +
may O +
be O +
a O +
potent O +
intervention O +
for O +
androgen O -
- O -
dependent O +
PCa O +
therapy O -
. O +

The O +
role O +
of O +
He O -
s O +
genes O +
in O +
intestinal O +
development O -
, O +
homeostasis O +
and O +
tumor O +
formation O -
. O +

Notch O +
signaling O +
regulates O +
intestinal O +
development O -
, O +
homeostasis O +
and O +
tumorigenesis O -
, O +
but O +
its O +
precise O +
downstream O +
mechanism O +
remains O +
largely O +
unknown O -
. O +

Here O +
we O +
found O +
that O +
inactivation O +
of O +
the O +
Notch O +
effectors O +
Hes1 O -
, O +
Hes3 O +
and O +
Hes5 O -
, O +
but O +
not O +
Hes1 O +
alone O -
, O +
led O +
to O +
reduced O +
cell O +
proliferation O -
, O +
increased O +
secretory O +
cell O +
formation O +
and O +
altered O +
intestinal O +
structures O +
in O +
adult O +
mice O -
. O +

However O -
, O +
in O +
Apc O +
mutation O -
- O -
induced O +
intestinal O +
tumors O -
, O +
inactivation O +
of O +
Hes1 O +
alone O +
was O +
sufficient O +
for O +
reducing O +
tumor O +
cell O +
proliferation O +
and O +
inducing O +
differentiation O +
of O +
tumor O +
cells O +
into O +
all O +
types O +
of O +
intestinal O +
epithelial O +
cells O -
, O +
but O +
without O +
affecting O +
the O +
homeostasis O +
of O +
normal O +
crypts O +
owing O +
to O +
genetic O +
redundancy O -
. O +

These O +
results O +
indicated O +
that O +
He O -
s O +
genes O +
cooperatively O +
regulate O +
intestinal O +
development O +
and O +
homeostasis O +
and O +
raised O +
the O +
possibility O +
that O +
Hes1 O +
is O +
a O +
promising O +
target O +
to O +
induce O +
the O +
differentiation O +
of O +
tumor O +
cells O -
. O +

Activation O -
- O -
induced O +
cytidine O +
deaminase O +
in O +
antibody O +
diversification O +
and O +
chromosome O +
translocation O -
. O +

DNA O +
damage O -
, O +
rearrangement O -
, O +
and O +
mutation O +
of O +
the O +
human O +
genome O +
are O +
the O +
basis O +
of O +
carcinogenesis O +
and O +
thought O +
to O +
be O +
avoided O +
at O +
all O +
costs O -
. O +

An O +
exception O +
is O +
the O +
adaptive O +
immune O +
system O +
where O +
lymphocytes O +
utilize O +
programmed O +
DNA O +
damage O +
to O +
effect O +
antigen O +
receptor O +
diversification O -
. O +

Both O +
B O +
and O +
T O +
lymphocytes O +
diversify O +
their O +
antigen O +
receptors O +
through O +
RAG1 O -
/ O -
2 O +
mediated O +
recombination O -
, O +
but O +
B O +
cells O +
undergo O +
two O +
additional O +
processes O -
-- O -
somatic O +
hypermutation O +
( O -
SHM O -
) O +
and O +
class O -
- O -
switch O +
recombination O +
( O -
CSR O -
) O -
, O +
both O +
initiated O +
by O +
activation O -
- O -
induced O +
cytidine O +
deaminase O +
( O -
AID O -
) O -
. O +

AID O +
deaminates O +
cytidines B-Chemical +
in O +
DNA O +
resulting O +
in O +
U O -
: O -
G O +
mismatches O +
that O +
are O +
processed O +
into O +
point O +
mutations O +
in O +
SHM O +
or O +
double O -
- O -
strand O +
breaks O +
in O +
CSR O -
. O +

Although O +
AID O +
activity O +
is O +
focused O +
at O +
Immunoglobulin O +
( O -
Ig O -
) O +
gene O +
loci O -
, O +
it O +
also O +
targets O +
a O +
wide O +
array O +
of O +
non O -
- O -
Ig O +
genes O +
including O +
oncogenes O +
associated O +
with O +
lymphomas O -
. O +

Here O -
, O +
we O +
review O +
the O +
molecular O +
basis O +
of O +
AID O +
regulation O -
, O +
targeting O -
, O +
and O +
initiation O +
of O +
CSR O +
and O +
SHM O -
, O +
as O +
well O +
as O +
AID O -
's O +
role O +
in O +
generating O +
chromosome O +
translocations O +
that O +
contribute O +
to O +
lymphomagenesis O -
. O +

Expression O +
of O +
HER2 O +
and O +
bradykinin O +
B1 O +
receptors O +
in O +
precursor O +
lesions O +
of O +
gallbladder O +
carcinoma O -
. O +

AIM O -
: O +
To O +
determine O +
the O +
expression O +
of O +
HER2 O +
and O +
bradykinin O +
B O -
( O -
1 O -
) O +
receptors O +
( O -
B O -
( O -
1 O -
) O -
R O -
) O +
in O +
the O +
two O +
pathogenic O +
models O +
of O +
gallbladder O +
cancer O -
: O +
the O +
metaplasia O -
- O -
dysplasia O -
- O -
carcinoma O +
and O +
the O +
adenoma O -
- O -
carcinoma O +
pathways O -
. O +

METHODS O -
: O +
Receptor O +
proteins O +
were O +
visualized O +
by O +
immunohistochemistry O +
on O +
5-mum O +
sections O +
of O +
paraffin O -
- O -
embedded O +
tissue O -
. O +

Expression O +
of O +
both O +
receptors O +
was O +
studied O +
in O +
biopsy O +
samples O +
from O +
92 O +
patients O +
( O -
6 O +
males O +
and O +
86 O +
females O -
; O +
age O +
ranging O +
from O +
28 O +
to O +
86 O +
years O -
, O +
mean O +
56 O +
years O -
) O -
. O +

High O +
HER2 O +
expression O +
in O +
specimens O +
was O +
additionally O +
investigated O +
by O +
fluorescence O +
in O +
situ O +
hybridization O -
. O +

Cell O +
proliferation O +
in O +
each O +
sample O +
was O +
assessed O +
by O +
using O +
the O +
Ki-67 O +
proliferation O +
marker O -
. O +

RESULTS O -
: O +
HER2 O +
receptor O +
protein O +
was O +
absent O +
in O +
adenomas O +
and O +
in O +
normal O +
gallbladder O +
epithelium O -
. O +

On O +
the O +
contrary O -
, O +
there O +
was O +
intense O +
staining O +
for O +
HER2 O +
on O +
the O +
basolateral O +
membrane O +
of O +
epithelial O +
cells O +
of O +
intestinal O +
metaplasia O +
( O -
22 O -
/ O -
24 O -
; O +
91.7 O -
% O -
) O +
and O +
carcinoma O +
in O +
situ O +
( O -
9 O -
/ O -
10 O -
; O +
90 O -
% O -
) O -
, O +
the O +
lesions O +
that O +
displayed O +
a O +
significantly O +
high O +
proliferation O +
index O -
. O +

Protein O +
up O -
- O -
regulation O +
of O +
HER2 O +
in O +
the O +
epithelium O +
with O +
metaplasia O +
or O +
carcinoma O +
in O +
situ O +
was O +
not O +
accompanied O +
by O +
HER2 O +
gene O +
amplification O -
. O +

A O +
similar O +
result O +
was O +
observed O +
in O +
invasive O +
carcinomas O +
( O -
0 O -
/ O -
12 O -
) O -
. O +

The O +
B O -
( O -
1 O -
) O -
R O +
distribution O +
pattern O +
mirrored O +
that O +
of O +
HER2 O +
except O +
that O +
B O -
( O -
1 O -
) O -
R O +
was O +
additionally O +
observed O +
in O +
the O +
adenomas O -
. O +

The O +
B O -
( O -
1 O -
) O -
R O +
appeared O +
either O +
as O +
cytoplasmic O +
dots O +
or O +
labeling O +
on O +
the O +
apical O +
cell O +
membrane O +
of O +
the O +
cells O +
composing O +
the O +
epithelia O +
with O +
intestinal O +
metaplasia O +
( O -
24 O -
/ O -
24 O -
; O +
100 O -
% O -
) O +
and O +
carcinoma O +
in O +
situ O +
( O -
10 O -
/ O -
10 O -
; O +
100 O -
% O -
) O +
and O +
in O +
the O +
epithelial O +
cells O +
of O +
adenomas O -
. O +

In O +
contrast O -
, O +
both O +
HER2 O +
( O -
4 O -
/ O -
12 O -
; O +
33 O -
% O -
) O +
and O +
B O -
( O -
1 O -
) O -
R O +
( O -
1 O -
/ O -
12 O -
; O +
8.3 O -
% O -
) O +
showed O +
a O +
low O +
expression O +
in O +
invasive O +
gallbladder O +
carcinomas O -
. O +

CONCLUSION O -
: O +
The O +
up O -
- O -
regulation O +
of O +
HER2 O +
and O +
B O -
( O -
1 O -
) O -
R O +
in O +
precursor O +
lesions O +
of O +
gallbladder O +
carcinoma O +
suggests O +
cross O -
- O -
talk O +
between O +
these O +
two O +
receptors O +
that O +
may O +
be O +
of O +
importance O +
in O +
the O +
modulation O +
of O +
cell O +
proliferation O +
in O +
gallbladder O +
carcinogenesis O -
. O +

Expression O +
of O +
basic O +
fibroblast O +
growth O +
factor O +
in O +
normal O +
human O +
tissues O -
. O +

The O +
distribution O +
of O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
) O +
was O +
studied O +
immunohistochemically O +
in O +
fresh O +
frozen O +
sections O +
of O +
normal O +
human O +
tissues O -
. O +

Immunodetection O +
was O +
performed O +
with O +
a O +
specific O +
anti O -
- O -
bFGF O +
mouse O +
monoclonal O +
antibody O +
that O +
was O +
found O +
to O +
react O +
with O +
recombinant O +
human O +
bFGF O +
in O +
Western O +
blot O +
analysis O -
, O +
and O +
to O +
specifically O +
neutralize O +
the O +
mitogenic O +
activity O +
of O +
bFGF O +
on O +
bovine O +
vascular O +
endothelial O +
cells O -
. O +

Expression O +
of O +
bFGF O +
on O +
normal O +
human O +
tissues O +
was O +
ubiquitously O +
detected O +
in O +
the O +
basement O +
membranes O +
of O +
all O +
size O +
blood O +
vessels O -
, O +
but O +
was O +
not O +
found O +
in O +
epidermal O +
or O +
epithelial O +
basement O +
membranes O +
of O +
a O +
variety O +
of O +
tissues O +
tested O -
. O +

Intensity O +
and O +
patterns O +
of O +
localization O +
in O +
blood O +
vessels O +
was O +
consistent O +
in O +
various O +
tissues O -
, O +
but O +
varied O +
among O +
different O +
regions O +
of O +
the O +
vascular O +
bed O -
. O +

Whereas O +
homogeneous O +
and O +
intense O +
immunoreactivity O +
were O +
observed O +
in O +
large O +
and O +
intermediate O +
size O +
blood O +
vessels O -
, O +
heterogeneity O +
of O +
expression O +
was O +
found O +
in O +
capillaries O -
. O +

The O +
most O +
intense O +
immunoreactivity O +
was O +
observed O +
in O +
branching O +
capillaries O -
. O +

Endothelial O +
cell O +
staining O +
was O +
heterogeneous O +
and O +
varied O +
in O +
different O +
regions O -
. O +

Strong O +
staining O +
for O +
bFGF O +
was O +
also O +
found O +
in O +
cardiac O +
muscle O +
fibers O -
, O +
smooth O +
muscle O +
cells O +
of O +
mid O -
- O -
size O +
blood O +
vessels O -
, O +
the O +
gut O +
and O +
the O +
myometrium O -
, O +
in O +
central O +
nervous O +
system O +
neurons O +
and O +
cerebellar O +
Purkinje O +
cells O -
, O +
and O +
on O +
epithelial O +
cells O +
of O +
the O +
bronchi O -
, O +
colon O -
, O +
endometrium O -
, O +
and O +
sweat O +
gland O +
ducts O +
of O +
the O +
skin O -
. O +

The O +
presence O +
of O +
bFGF O +
in O +
the O +
extracellular O +
compartment O +
of O +
a O +
diverse O +
variety O +
of O +
organs O +
may O +
play O +
a O +
role O +
in O +
angiogenesis O -
. O +

However O -
, O +
the O +
function O +
of O +
bFGF O +
in O +
parenchymal O +
cells O +
remains O +
to O +
be O +
determined O -
. O +

Members O +
of O +
the O +
src O +
and O +
ras O +
oncogene O +
families O +
supplant O +
the O +
epidermal O +
growth O +
factor O +
requirement O +
of O +
BALB O -
/ O -
MK-2 O +
keratinocytes O +
and O +
induce O +
distinct O +
alterations O +
in O +
their O +
terminal O +
differentiation O +
program O -
. O +

BALB- O -
/ O -
MK-2 O +
mouse O +
epidermal O +
keratinocytes O +
required O +
epidermal O +
growth O +
factor O +
for O +
proliferation O +
and O +
terminally O +
differentiated O +
in O +
response O +
to O +
high O +
Ca2 B-Chemical -
+ O +
concentration O -
. O +

Infection O +
with O +
retroviruses O +
containing O +
transforming O +
genes O +
of O +
the O +
src O +
and O +
ras O +
oncogene O +
families O +
led O +
to O +
rapid O +
loss O +
of O +
epidermal O +
growth O +
factor O +
dependence O -
, O +
in O +
some O +
cases O -
, O +
accompanied O +
by O +
alterations O +
in O +
cellular O +
morphology O -
. O +

The O +
virus O -
- O -
altered O +
cells O +
continued O +
to O +
proliferate O +
in O +
the O +
presence O +
of O +
high O +
levels O +
of O +
extracellular O +
calcium B-Chemical +
but O +
exhibited O +
alterations O +
in O +
normal O +
keratinocyte O +
terminal O +
differentiation O +
that O +
appear O +
to O +
be O +
specific O +
to O +
the O +
particular O +
oncogene O -
. O +

These O +
alterations O +
bore O +
similarities O +
to O +
abnormalities O +
in O +
differentiation O +
observed O +
in O +
naturally O +
occurring O +
squamous O +
epithelial O +
malignancies O -
. O +

Experimental O +
drug O +
therapy O +
of O +
peritumoral O +
brain O +
edema O -
. O +

Four O +
drugs O +
with O +
potential O +
anti O -
- O -
peritumoral O +
brain O +
edema O +
activity O +
were O +
studied O +
using O +
the O +
VX2 O +
rabbit O +
brain O +
tumor O +
model O -
. O +

Meclofenamate B-Chemical +
and O +
indomethacin B-Chemical +
were O +
tested O +
in O +
an O +
attempt O +
to O +
confirm O +
recent O +
reports O +
of O +
anti O -
- O -
edema O +
activity O +
in O +
non B-Chemical +
steroidal I-Chemical +
anti I-Chemical -
- I-Chemical -
inflammatory I-Chemical +
drugs I-Chemical +
( O -
NSAID B-Chemical -
's I-Chemical -
) O -
. O +

The O +
' O -
angiostatic O -
' O +
steroids O +
17 B-Chemical +
hydroxyprogesterone I-Chemical +
and O +
epicortisol B-Chemical +
were O +
tested O +
because O +
of O +
their O +
lack O +
of O +
glucocorticoid B-Chemical +
and O +
mineralocorticoid B-Chemical +
effects O +
and O +
their O +
structural O +
similarity O +
to O +
glucocorticoids B-Chemical -
. O +

The O +
protein O +
and O +
water O +
component O +
of O +
brain O +
edema O +
were O +
indirectly O +
quantitated O -
. O +

None O +
of O +
the O +
test O +
drugs O +
demonstrated O +
significant O +
anti O -
- O -
edema O +
activity O -
. O +

This O +
work O +
does O +
not O +
confirm O +
reports O +
that O +
NSAID B-Chemical -
's O +
have O +
anti O -
- O -
edema O +
activity O +
and O +
suggests O +
that O +
there O +
may O +
be O +
no O +
correlation O +
between O +
' O -
angiostatic O -
' O +
and O +
anti O -
- O -
edema O +
activity O +
in O +
certain O +
steroid B-Chemical +
compounds I-Chemical -
. O +

Energy O +
supply O +
of O +
the O +
mitotic O +
cell O +
cycle O +
and O +
the O +
Na+ B-Chemical -
/ O -
H+-antiport B-Chemical +
in O +
ascites O +
tumors O -
. O +

The O +
activation O +
of O +
Na+ B-Chemical +
transport O +
is O +
due O +
to O +
the O +
exchange O +
of O +
protons B-Chemical +
formed O +
via O +
glucose B-Chemical +
conversion O +
into O +
lactate B-Chemical +
for O +
Na+ B-Chemical -
, O +
i.e. O -
, O +
to O +
the O +
stimulation O +
of O +
the O +
Na+ B-Chemical -
/ O -
H+-antiport B-Chemical -
. O +

Experimental O +
results O +
and O +
theoretical O +
calculations O +
suggest O +
that O +
in O +
glucose B-Chemical -
- O -
containing O +
medium O +
the O +
Na+ B-Chemical +
transport O +
increases O +
from O +
0.75 O +
to O +
1.78 O +
pmol O -
/ O -
hour O +
per O +
cell O -
. O +

The O +
permeability O +
of O +
plasma O +
membranes O +
for O +
K+ B-Chemical +
increases O +
2.75 O +
fold O -
, O +
while O +
the O +
passive O +
flux O +
of O +
Na+ B-Chemical +
diminishes O -
. O +

The O +
intensity O +
of O +
O2 B-Chemical +
adsorption O +
by O +
ascites O +
tumor O +
cells O +
does O +
not O +
practically O +
depend O +
on O +
the O +
monovalent O +
cation B-Chemical +
concentration O +
gradient O +
between O +
the O +
cells O +
and O +
the O +
culture O +
medium O -
, O +
whereas O +
the O +
rate O +
of O +
glycolysis O +
decreases O +
simultaneously O +
with O +
the O +
diminution O +
of O +
the O +
concentration O +
gradient O -
. O +

In O +
synchronized O +
cultures O +
at O +
the O +
beginning O +
of O +
the O +
mitotic O +
cycle O -
, O +
the O +
bulk O +
of O +
ATP B-Chemical +
resynthesized O +
via O +
glycolysis O +
is O +
utilized O +
for O +
the O +
synthesis O +
of O +
biopolymers O -
, O +
whereas O +
that O +
at O +
the O +
end O +
of O +
the O +
S O -
- O -
phase O +
and O +
in O +
the O +
G2-phase O +
is O +
utilized O +
for O +
cation B-Chemical +
transport O +
across O +
plasma O +
membranes O -
. O +

From O +
35 O +
to O +
100 O -
% O +
of O +
the O +
whole O +
amount O +
of O +
ATP B-Chemical +
resynthesized O +
via O +
glycolysis O +
is O +
utilized O +
for O +
transport O +
purposes O -
. O +

It O +
is O +
concluded O +
that O +
the O +
observed O +
increase O +
in O +
the O +
Na+ B-Chemical -
/ O -
K+ B-Chemical +
ratio O +
in O +
ascites O +
tumor O +
cells O +
is O +
connected O +
with O +
their O +
enhanced O +
ability O +
to O +
synthesize O +
lactic B-Chemical +
acid I-Chemical -
. O +

Presumably O -
, O +
glycolysis O +
is O +
one O +
of O +
the O +
regulatory O +
mechanisms O +
of O +
intracellular O +
ratios O +
of O +
monovalent O +
cations B-Chemical -
. O +

Osteonectin O +
transcript O +
and O +
metastatic O +
behavior O +
in O +
v O -
- O -
Ki O -
- O -
ras O +
transformed O +
fibroblasts O -
. O +

Osteonectin O +
is O +
one O +
of O +
the O +
major O +
non O -
- O -
collagenous O +
proteins O +
of O +
bone O -
. O +

However O -
, O +
its O +
transcript O +
has O +
been O +
found O +
in O +
many O +
soft O -
, O +
extracellular O +
matrix O -
- O -
producing O +
tissues O -
; O +
an O +
osteonectin O -
- O -
related O +
protein O +
was O +
detected O +
in O +
tumor O +
basement O +
membrane O -
. O +

We O +
have O +
investigated O +
the O +
expression O +
of O +
osteonectin O +
gene O +
in O +
fresh O +
BALB O -
/ O -
c O +
fibroblasts O +
transformed O +
by O +
v O -
- O -
Ki O -
- O -
ras O -
. O +

Transformed O +
cells O +
exhibited O +
lower O +
levels O +
of O +
RNA O +
as O +
compared O +
with O +
normal O +
fibroblasts O -
. O +

The O +
transformed O +
cells O +
were O +
cloned O +
after O +
in O +
vivo O +
tumorigenic O +
assay O -
, O +
and O +
4 O +
clones O +
were O +
analyzed O +
for O +
osteonectin O +
expression O +
by O +
Northern O +
blots O -
. O +

Two O +
of O +
them O +
were O +
selected O +
for O +
high O +
or O +
low O +
osteonectin O +
expression O +
and O +
tested O +
in O +
vivo O +
in O +
spontaneous O +
and O +
artificial O +
metastasis O +
assays O -
. O +

High O +
osteonectin O +
expression O +
was O +
correlated O +
with O +
high O +
lung O +
colonization O -
. O +

When O +
10 O -
( O -
5 O -
) O +
cells O +
were O +
injected O +
i.v O -
. O -
, O +
median O +
colony O +
value O +
was O +
55 O +
and O +
20 O +
in O +
higher O +
expressor O +
vs. O +
lower O +
expressor O +
respectively O +
( O -
p O +
less O +
than O +
0.005 O -
) O -
. O +

Spontaneous O +
metastasis O +
indicates O +
a O +
possible O +
reverse O +
correlation O -
. O +

Our O +
data O +
align O +
osteonectin O +
with O +
other O +
matrix O -
- O -
components O +
and O +
adhesion O +
molecules O +
in O +
affecting O +
potential O +
metastatic O +
spreading O +
of O +
transformed O +
cells O -
. O +

[ O -
Tumor O +
metastasis O +
and O +
the O +
fibrinolytic O +
system O -
] O -
. O +

Metastatic O +
spread O +
of O +
malignant O +
tumor O +
appears O +
to O +
correlate O +
with O +
activation O +
of O +
the O +
fibrolytic O +
system O -
. O +

The O +
role O +
of O +
fibrinolysis O +
in O +
growth O +
and O +
metastasis O +
was O +
examined O +
in O +
Lewis O +
lung O +
carcinoma O +
of O +
mice O -
. O +

The O +
inhibition O +
of O +
fibrinolysis O +
or O +
proteases O +
decreased O +
the O +
primary O +
tumor O +
growth O +
and O +
pulmonary O +
metastasis O -
, O +
whereas O +
the O +
activation O +
of O +
fibrinolysis O +
or O +
proteases O +
increased O +
the O +
number O +
of O +
metastatic O +
foci O +
in O +
the O +
lung O -
. O +

Electronmicroscopically O -
, O +
thrombus O +
formation O +
in O +
the O +
primary O +
site O +
prevented O +
tumor O +
invasion O +
and O +
metastasis O +
formation O -
. O +

Plasminogen O +
activator O +
( O -
PA O -
) O +
content O +
of O +
excised O +
tumors O +
was O +
determined O +
by O +
SDS O -
- O -
PAGE O -
, O +
and O +
major O +
PA O +
was O +
found O +
to O +
be O +
urokinase O +
( O -
UK O -
) O +
type O -
. O +

Immunohistochemical O +
study O +
with O +
specific O +
antisera O +
was O +
done O -
. O +

When O +
tumor O +
cells O +
possessed O +
a O +
high O +
level O +
of O +
UK O -
, O +
laminin O +
and O +
type O +
IV O +
collagen O -
, O +
components O +
of O +
the O +
basement O +
membrane O -
, O +
disappeared O +
from O +
tumor O +
tissues O -
. O +

These O +
findings O +
suggest O +
that O +
PA O +
through O +
protease O +
cascade O +
plays O +
a O +
role O +
in O +
tumor O +
invasion O +
and O +
metastasis O -
. O +

Clinically O -
, O +
patients O +
with O +
advanced O +
cancer O +
are O +
usually O +
in O +
a O +
hypercoagulable O +
state O +
with O +
elevated O +
fibrinogen O -
, O +
and O +
fibrin O +
deposition O +
around O +
tumor O +
mass O +
is O +
a O +
serious O +
problem O +
in O +
cancer O +
chemotherapy O -
. O +

UK O +
infusion O +
prior O +
to O +
5-fluorouracil B-Chemical +
increased O +
tissue O +
concentration O +
of O +
antitumor O +
agent O -
. O +

However O -
, O +
development O +
of O +
consumption O +
coagulopathy O +
characterized O +
by O +
progression O +
from O +
hypercoagulable O +
state O +
to O +
disseminated O +
intravascular O +
coagulation O +
has O +
also O +
been O +
found O +
in O +
several O +
cases O -
. O +

[ O -
Intraepithelial O +
neoplasm O +
of O +
the O +
uterine O +
cervix O +
and O +
angiogenesis O -
: O +
morphologic O +
study O -
] O +
Thirty O +
uterine O +
cervix O +
specimens O +
sampled O +
following O +
conization O +
or O +
total O +
hysterectomy O +
were O +
studied O +
using O +
histology O -
, O +
histoenzymology O +
( O -
vessel O +
phosphatase O +
alkaline O +
activity O -
) O -
, O +
and O +
immunohistochemistry O +
( O -
demonstration O +
of O +
laminin O +
and O +
type O +
IV O +
collagen O +
in O +
epithelium O +
and O +
vessel O +
basement O +
membranes O -
) O -
. O +

Pathologic O +
conditions O +
included O +
dystrophia O -
, O +
moderate O +
dysplasia O -
, O +
severe O +
dysplasia O -
, O +
and O +
intraepithelial O +
carcinoma O -
. O +

Results O +
were O +
compared O +
to O +
findings O +
in O +
a O +
control O +
group O -
. O +

We O +
found O +
that O +
the O +
severity O +
of O +
vascular O +
abnormalities O +
correlated O +
positively O +
with O +
the O +
severity O +
of O +
histologic O +
epithelial O +
lesions O -
; O +
this O +
finding O +
is O +
consistent O +
with O +
colposcopic O +
results O -
. O +

Anarchic O +
angiogenesis O +
with O +
large O -
, O +
moniliform O -
, O +
tortuous O +
vessels O +
was O +
seen O +
in O +
severe O +
dysplasias O +
and O +
carcinomas O -
. O +

The O +
vascular O +
anomalies O +
seem O +
to O +
precede O +
the O +
development O +
of O +
histologic O +
lesions O +
in O +
some O +
instances O -
. O +

Histogenesis O +
of O +
the O +
abnormal O +
vessels O +
may O +
involve O +
production O +
of O +
an O +
angiogenic O +
factor O +
by O +
the O +
cancerized O +
epithelia O -
. O +

Glycolysis O +
and O +
glutaminolysis O +
in O +
perifused O +
Ehrlich O +
ascites O +
tumour O +
cells O -
. O +

A O +
perifusion O +
system O +
was O +
designed O +
in O +
order O +
to O +
study O +
glucose B-Chemical +
and O +
glutamine O +
metabolism O +
by O +
freshly O +
harvested O +
Ehrlich O +
ascites O +
tumour O +
cells O +
in O +
steady O +
state O +
conditions O -
. O +

Cells O +
were O +
perifused O +
in O +
the O +
presence O +
of O +
5 O +
mM O +
glucose B-Chemical -
, O +
0.5 O +
mM O +
glutamine O +
or O +
5 O +
mM O +
glucose B-Chemical +
and O +
0.5 O +
mM O +
glutamine O -
. O +

The O +
results O +
in O +
steady O +
state O +
reveal O +
that O +
both O +
substrates O +
glucose B-Chemical +
and O +
glutamine O +
are O +
continuously O +
wasted O +
by O +
tumour O +
cells O -
, O +
excreting O +
two O +
moles O +
of O +
lactate B-Chemical +
per O +
mol O +
of O +
glucose B-Chemical +
and O +
one O +
mol O +
of O +
glutamate O +
and O +
ammonia B-Chemical +
per O +
mol O +
of O +
glutamine O +
consumed O +
into O +
the O +
medium O -
. O +

Glutamine O +
consumption O +
in O +
the O +
presence O +
of O +
glucose B-Chemical +
was O +
higher O +
than O +
with O +
glutamine O +
alone O -
. O +

On O +
the O +
mechanism O +
of O +
glycolysis O +
stimulation O +
by O +
neutral O +
detergents O +
in O +
3T3 O +
and O +
Ehrlich O +
ascites O +
tumor O +
cells O -
. O +

Glycolysis O +
of O +
3T3 O +
and O +
Ehrlich O +
ascites O +
tumor O +
cells O +
was O +
greatly O +
enhanced O +
by O +
Nonidet B-Chemical +
P-40 I-Chemical +
or O +
Triton B-Chemical +
X-100 I-Chemical +
at O +
about O +
100 O +
micrograms O -
/ O -
mg O +
cell O +
protein O -
. O +

This O +
enhanced O +
glycolysis O +
was O +
partly O +
sensitive O +
to O +
rutamycin B-Chemical +
and O +
partly O +
sensitive O +
to O +
ouabain B-Chemical -
, O +
suggesting O +
that O +
the O +
detergent O +
released O +
the O +
control O +
of O +
the O +
ATPase O +
of O +
the O +
mitochondria O +
and O +
of O +
the O +
plasma O +
membrane O +
Na+K+-ATPase O -
. O +

Nonidet B-Chemical +
P-40 I-Chemical +
had O +
no O +
effect O +
on O +
glycolysis O +
in O +
cell O -
- O -
free O +
extracts O +
from O +
Ehrlich O +
ascites O +
tumor O +
cells O +
to O +
which O +
soluble O +
mitochondrial O +
ATPase O +
was O +
added O -
. O +

Measuring O +
ouabain B-Chemical -
- O -
sensitive O +
22Na O +
efflux O +
and O +
using O +
ouabain B-Chemical -
- O -
sensitive O +
lactate B-Chemical +
production O +
as O +
a O +
measure O +
of O +
ATP B-Chemical +
hydrolysis O +
by O +
the O +
Na+K+ O +
pump O -
, O +
it O +
was O +
shown O +
that O +
Nonidet B-Chemical +
P-40 I-Chemical +
greatly O +
decreased O +
the O +
efficiency O +
of O +
the O +
Na+K+ O +
pump O -
. O +

Quercetin B-Chemical +
increased O +
the O +
efficiency O +
of O +
pumping O +
in O +
EAT O +
cells O +
both O +
in O +
the O +
absence O +
and O +
presence O +
of O +
the O +
detergent O -
. O +

Epidermal O +
growth O +
factor O +
and O +
its O +
receptor O -
. O +

Epidermal O +
growth O +
factor O +
( O -
EGF O -
) O +
binds O +
with O +
high O +
affinity O +
and O +
specificity O +
to O +
a O +
single O +
site O +
on O +
the O +
external O +
domain O +
of O +
its O +
transmembrane O +
receptor O +
to O +
activate O +
the O +
tyrosine O +
protein O +
kinase O +
activity O +
of O +
its O +
cytoplasmic O +
portion O -
. O +

The O +
EGF O +
receptor O +
gene O +
is O +
amplified O +
and O +
over O -
- O -
expressed O +
in O +
several O +
human O +
tumors O -
, O +
suggesting O +
that O +
increased O +
concentrations O +
of O +
the O +
proto O -
- O -
oncogene O +
leads O +
to O +
constitutive O +
activity O +
similar O +
to O +
that O +
seen O +
with O +
oncogene O +
erb O +
B. O +
Synthesis O +
and O +
degradation O +
of O +
the O +
EGF O +
receptor O +
are O +
regulated O -
, O +
in O +
addition O -
, O +
covalent O +
modification O +
by O +
phosphorylation O +
regulates O +
activity O +
of O +
the O +
receptor O +
protein O -
. O +

Intramolecular O +
self O -
- O -
phosphorylation O +
of O +
Tyr1173 O +
removes O +
a O +
competitive O +
inhibitory O +
constraint O +
to O +
enhance O +
phosphorylation O +
of O +
substrates O -
. O +

Phosphorylation O +
of O +
Thr654 O +
by O +
protein O +
kinase O +
C O +
decreases O +
high O +
affinity O +
EGF O +
binding O +
and O +
EGF O -
- O -
stimulated O +
tyrosine O +
protein O +
kinase O +
activity O -
, O +
providing O +
a O +
mechanism O +
for O +
heterologous O +
regulation O +
of O +
the O +
EGF O +
receptor O +
by O +
tumor O +
promoters O +
and O +
other O +
ligand O +
X O +
receptor O +
complexes O -
. O +

Extensive O +
regulation O +
contributes O +
to O +
normal O +
growth O +
control O -
, O +
abrogation O +
of O +
regulatory O +
controls O +
contributes O +
to O +
uncontrolled O +
growth O +
as O +
seen O +
with O +
erb O +
B O +
transformation O +
and O +
EGF O +
receptor O +
gene O +
amplification O +
in O +
human O +
tumors O -
. O +

Multi O -
- O -
step O +
neoplastic O +
transformation O +
of O +
normal O +
human O +
fibroblasts O +
by O +
Co-60 B-Chemical +
gamma O +
rays O +
and O +
Ha O -
- O -
ras O +
oncogenes O -
. O +

As O +
reported O +
previously O +
( O -
Namba O +
et O +
al. O -
, O +
1985 O -
; O +
Namba O -
, O +
1985 O -
) O -
, O +
normal O +
human O +
fibroblasts O +
were O +
transformed O +
into O +
immortal O +
cells O +
with O +
abnormal O +
karyotypes O +
by O +
Co-60 B-Chemical +
gamma O -
- O -
ray O +
irradiation O -
. O +

These O +
immortally O +
transformed O +
cells O +
( O -
KMST-6 O -
) O +
showed O +
no O +
clonability O +
in O +
soft O +
agar O +
and O +
were O +
not O +
tumorigenic O -
. O +

However O -
, O +
by O +
treatment O +
with O +
Ha O -
- O -
ras O +
oncogenes O +
derived O +
from O +
a O +
human O +
lung O +
carcinoma O +
or O +
Harvey O +
murine O +
sarcoma O +
virus O -
, O +
the O +
KMST-6 O +
cells O +
acquired O +
elevated O +
clonability O +
in O +
soft O +
agar O +
and O +
transplantability O +
in O +
nude O +
mice O -
. O +

All O +
the O +
tumors O +
produced O +
grew O +
progressively O +
without O +
showing O +
regression O +
and O +
killed O +
the O +
mice O -
. O +

The O +
tumors O +
were O +
also O +
serially O +
transplantable O +
into O +
other O +
mice O -
. O +

The O +
Ha O -
- O -
ras O +
oncogene O +
alone O +
did O +
not O +
convert O +
normal O +
human O +
fibroblasts O +
into O +
either O +
immortal O +
or O +
tumorigenic O +
cells O -
. O +

Our O +
current O +
data O +
suggest O +
that O +
gamma O +
rays O +
worked O +
as O +
an O +
initiator O +
of O +
carcinogenesis O +
in O +
normal O +
human O +
cells O -
, O +
giving O +
rise O +
to O +
chromosome O +
aberrations O +
and O +
immortality O -
, O +
and O +
the O +
Ha O -
- O -
ras O +
oncogene O +
played O +
a O +
role O +
in O +
the O +
progression O +
of O +
the O +
immortally O +
transformed O +
cell O +
population O +
to O +
a O +
neoplastic O +
one O +
showing O +
enhanced O +
colony O +
formation O +
in O +
soft O +
agar O +
and O +
tumorigenicity O +
in O +
nude O +
mice O -
. O +

Glutamine O +
and O +
glucose B-Chemical +
as O +
energy O +
substrates O +
for O +
Ehrlich O +
ascites O +
tumour O +
cells O -
. O +

Energy O +
metabolism O +
of O +
freshly O +
harvested O +
Ehrlich O +
ascites O +
tumour O +
cells O +
in O +
the O +
presence O +
of O +
5 O +
mM O +
glucose B-Chemical +
and/or O +
0.5 O +
mM O +
glutamine O +
was O +
studied O -
. O +

The O +
rate O +
of O +
oxygen B-Chemical +
utilization O +
was O +
not O +
altered O +
by O +
the O +
addition O +
of O +
0.5 O +
mM O +
glutamine O -
; O +
5 O +
mM O +
glucose B-Chemical +
induced O +
an O +
inhibition O +
of O +
respiration O -
. O +

In O +
the O +
presence O +
of O +
both O +
glucose B-Chemical +
and O +
glutamine O -
, O +
the O +
Crabtree O +
effect O +
decreased O -
. O +

In O +
these O +
conditions O -
, O +
the O +
rates O +
of O +
oxygen B-Chemical +
uptake O -
, O +
the O +
CO2 B-Chemical +
evolution O +
and O +
the O +
changes O +
in O +
the O +
redox O +
states O +
of O +
cytochromes O +
indicate O +
that O +
glucose B-Chemical +
is O +
preferred O +
by O +
Ehrlich O +
ascites O +
tumour O +
cells O +
as O +
energy O +
substrate O -
. O +

Glucose B-Chemical +
decreased O +
the O +
rate O +
of O +
glutamine O +
utilization O +
by O +
34 O -
% O -
. O +

On O +
the O +
other O +
hand O -
, O +
glutaminolysis O +
did O +
not O +
inhibit O +
glycolysis O -
. O +

Growth O +
state O -
- O -
dependent O +
regulation O +
of O +
protein O +
kinase O +
C O +
in O +
normal O +
and O +
transformed O +
murine O +
cells O -
. O +

We O +
determined O +
whether O +
growth O +
state O +
can O +
influence O +
the O +
action O +
of O +
protein O +
kinase O +
C O +
by O +
measuring O +
protein O +
kinase O +
C O +
activity O +
in O +
growing O +
and O +
stationary O +
cultures O +
of O +
normal O +
and O +
transformed O +
cells O -
. O +

Two O +
approaches O +
were O +
used O +
to O +
measure O +
protein O +
kinase O +
C O -
: O +
assay O +
of O +
intact O +
cells O +
for O +
inhibition O +
of O +
epidermal O +
growth O +
factor O +
( O -
EGF O -
) O +
binding O +
in O +
response O +
to O +
phorbol B-Chemical +
dibutyrate I-Chemical +
( O -
PDBu B-Chemical -
) O -
; O +
and O +
assay O +
of O +
detergent O +
extracts O +
for O +
total O +
calcium B-Chemical -
, O +
phospholipid B-Chemical -
- O -
dependent O +
kinase O +
activity O -
. O +

In O +
extracts O +
of O +
growing O +
and O +
stationary O +
Swiss O +
3T3 O +
cells O -
, O +
the O +
total O +
amount O +
of O +
protein O +
kinase O +
C O +
activity O +
was O +
similar O -
, O +
indicating O +
that O +
growth O +
state O +
does O +
not O +
alter O +
the O +
level O +
of O +
enzyme O +
in O +
the O +
cell O -
. O +

The O +
short O -
- O -
term O +
response O +
of O +
Swiss O +
3T3 O +
cells O +
to O +
an O +
activator O +
of O +
protein O +
kinase O +
C O +
also O +
appeared O +
to O +
be O +
independent O +
of O +
growth O +
state O -
, O +
since O +
the O +
50 O -
% O +
effective O +
dose O +
for O +
PDBu B-Chemical +
inhibition O +
of O +
EGF O +
binding O +
to O +
its O +
receptor O +
was O +
approximately O +
7 O +
nM O +
for O +
both O +
growth O +
conditions O -
. O +

In O +
contrast O -
, O +
the O +
response O +
of O +
cells O +
to O +
long O -
- O -
term O +
treatment O +
with O +
PDBu B-Chemical +
was O +
significantly O +
different O +
depending O +
upon O +
the O +
initial O +
growth O +
state O +
of O +
the O +
cells O -
. O +

In O +
both O +
growth O +
states O -
, O +
PDBu B-Chemical +
caused O +
loss O +
of O +
protein O +
kinase O +
C O +
activity O -
, O +
which O +
reflected O +
a O +
loss O +
in O +
protein O +
mass O +
as O +
determined O +
by O +
immunoblotting O +
with O +
antiserum O +
to O +
protein O +
kinase O +
C. O +
However O -
, O +
the O +
maximum O +
decrease O +
approached O +
100 O -
% O +
in O +
stationary O +
cultures O +
versus O +
approximately O +
75 O -
% O +
in O +
growing O +
cells O -
. O +

Protein O +
kinase O +
C O +
levels O +
in O +
several O +
transformed O +
cell O +
lines O +
were O +
subject O +
to O +
down O +
modulation O +
in O +
a O +
similar O +
growth O +
state O -
- O -
dependent O +
manner O -
. O +

Further O -
, O +
the O +
inhibition O +
of O +
EGF O +
binding O +
by O +
tumor O +
promoters O +
following O +
long O -
- O -
term O +
treatment O +
of O +
Swiss O +
3T3 O +
cells O +
with O +
PDBu B-Chemical +
also O +
varied O +
with O +
growth O +
state O -
. O +

In O +
down O +
modulated O +
growing O +
cells O -
, O +
PDBu B-Chemical +
caused O +
almost O +
complete O +
inhibition O +
of O +
EGF O +
binding O -
, O +
whereas O +
in O +
down O +
modulated O +
stationary O +
cells O -
, O +
minimal O +
inhibition O +
of O +
EGF O +
binding O +
by O +
PDBu B-Chemical +
was O +
observed O -
. O +

These O +
results O +
suggest O +
that O +
prolonged O +
treatment O +
with O +
tumor O +
promoters O +
alters O +
the O +
sensitivity O +
of O +
cells O +
to O +
activators O +
of O +
protein O +
kinase O +
C O +
in O +
a O +
growth O +
state O -
- O -
dependent O +
manner O -
. O +

Suppression O +
and O +
re O -
- O -
expression O +
of O +
transformed O +
phenotype O +
in O +
hybrids O +
of O +
HA O -
- O -
ras-1-transformed O +
rat-1 O +
cells O +
and O +
early O -
- O -
passage O +
rat O +
embryonic O +
fibroblasts O -
. O +

Rat-1 O +
cells O +
which O +
had O +
been O +
transformed O +
with O +
the O +
activated O +
Ha O -
- O -
ras-1 O +
gene O +
from O +
human O +
EJ O +
bladder O +
carcinoma O +
cells O +
were O +
fused O +
with O +
diploid O +
embryonic O +
rat O +
fibroblasts O -
. O +

Four O +
selected O +
cell O +
hybrids O +
expressed O +
the O +
human O +
transforming O +
gene O +
product O +
p21 O +
at O +
levels O +
of O +
10 O +
to O +
30 O -
% O +
compared O +
to O +
100 O -
% O +
in O +
the O +
transformed O +
parental O +
cells O -
. O +

The O +
hybrid O +
cells O -
, O +
however O -
, O +
exhibited O +
normal O +
morphology O -
, O +
anchorage O +
requirement O +
for O +
proliferation O -
, O +
and O +
largely O +
extended O +
latency O +
periods O +
of O +
tumorigenicity O +
in O +
newborn O +
rats O -
. O +

Tumorigenic O +
hybrid O +
derivatives O +
contained O +
lower O +
numbers O +
of O +
chromosomes O +
than O +
the O +
tetraploid O +
parental O +
hybrids O -
. O +

DNA O +
of O +
the O +
non O -
- O -
tumorigenic O +
cell O +
hybrids O +
transformed O +
Rat-1 O +
cells O +
to O +
anchorage O -
- O -
independent O +
proliferation O +
as O +
expected O +
for O +
the O +
transforming O +
human O +
Ha O -
- O -
ras O +
gene O +
present O +
in O +
the O +
donor O +
DNA O -
. O +

We O +
conclude O +
that O +
the O +
transforming O +
properties O +
of O +
the O +
activated O +
Ha O -
- O -
ras O +
gene O +
in O +
Rat-1 O +
cells O +
can O +
be O +
suppressed O +
at O +
the O +
post O -
- O -
translational O +
level O +
by O +
the O +
presence O +
of O +
the O +
genome O +
from O +
diploid O +
embryonic O +
rat O +
fibroblasts O +
but O +
additional O +
controls O +
of O +
expression O +
of O +
the O +
transforming O +
gene O +
are O +
likely O +
to O +
exist O -
. O +

Normal O +
cells O +
contain O +
suppressor O +
gene O -
( O -
s O -
) O +
which O +
safeguard O +
these O +
cells O +
against O +
transformation O +
by O +
the O +
product O +
of O +
the O +
transforming O +
Ha O -
- O -
ras-1 O +
oncogene O -
. O +

Identification O +
of O +
the O +
putative O +
transforming O +
protein O +
of O +
the O +
human O +
T O -
- O -
cell O +
leukemia O +
viruses O +
HTLV O -
- O -
I O +
and O +
HTLV O -
- O -
II O -
. O +

The O +
human O +
T O -
- O -
cell O +
leukemia O +
viruses O +
HTLV O -
- O -
I O +
and O +
HTLV O -
- O -
II O +
are O +
unique O +
among O +
the O +
transforming O +
retroviruses O +
of O +
vertebrates O +
in O +
their O +
ability O +
to O +
transform O +
human O +
T O +
cells O +
in O +
vitro O +
and O +
in O +
their O +
close O +
association O +
with O +
human O +
malignancies O +
( O -
T O -
- O -
cell O +
lymphomas O +
and O +
leukemia O -
) O -
. O +

Their O +
genomes O +
are O +
relatively O +
simple O -
, O +
containing O +
the O +
genes O +
gag O -
, O +
pol O -
, O +
env O -
, O +
and O +
a O +
3 O -
' O +
region O +
termed O +
" O -
X. O -
" O +
This O +
3 O -
' O +
region O +
may O +
be O +
responsible O +
for O +
the O +
transforming O +
potential O +
of O +
the O +
viruses O -
. O +

The O +
existence O +
of O +
proteins O +
encoded O +
by O +
the O +
3 O -
' O +
region O +
has O +
been O +
postulated O +
on O +
the O +
basis O +
of O +
multiple O +
open O +
reading O +
frames O -
. O +

In O +
the O +
present O +
study O +
this O +
region O +
is O +
shown O +
to O +
contain O +
a O +
gene O +
encoding O +
a O +
protein O +
of O +
40 O +
kilodaltons O +
in O +
HTLV O -
- O -
I O +
and O +
37 O +
kilodaltons O +
in O +
HTLV O -
- O -
II O -
. O +

It O +
is O +
proposed O +
that O +
these O +
proteins O +
be O +
called O -
, O +
respectively O -
, O +
p40xI O +
and O +
p37xII O -
. O +

Protection O +
from O +
experimental O +
ocular O +
herpetic O +
keratitis O +
by O +
a O +
heat O -
- O -
killed O +
virus O +
vaccine O -
. O +

New O +
Zealand O +
white O +
rabbits O +
were O +
given O +
limbal O +
inoculations O +
of O +
a O +
heat O -
- O -
killed O +
suspension O +
of O +
herpes O +
simplex O +
virus O +
( O -
HSV O -
) O +
in O +
a O +
lysate O +
of O +
human O +
embryonic O +
kidney O +
cells O -
. O +

At O +
intervals O +
of O +
four O +
to O +
14 O +
days O -
, O +
the O +
animals O +
were O +
challenged O +
by O +
intrastromal O +
inoculation O +
with O +
10,000 O +
plaque O -
- O -
forming O +
units O +
of O +
viable O +
HSV O -
. O +

Epithelial O +
keratitis O -
, O +
disciform O +
edema O -
, O +
and O +
necrotizing O +
keratitis O +
with O +
neovascularization O +
of O +
the O +
cornea O +
developed O +
in O +
control O +
animals O -
. O +

Epithelial O +
keratitis O +
and O +
corneal O +
edema O +
also O +
developed O +
in O +
the O +
immunized O +
animals O +
during O +
the O +
first O +
week O +
after O +
virus O +
challenge O -
, O +
but O +
these O +
symptoms O +
rapidly O +
resolved O +
during O +
the O +
following O +
weeks O -
. O +

The O +
absence O +
of O +
iritis O -
, O +
neovascularization O -
, O +
and O +
necrotizing O +
keratitis O +
in O +
the O +
corneas O +
of O +
the O +
immunized O +
animals O +
was O +
particularly O +
striking O -
. O +

The O +
genetics O +
of O +
transformation O +
by O +
SV O +
40 O -
. O +

Experiments O +
using O +
the O +
tsA O +
58 O +
allele O +
of O +
the O +
SV O +
40-A O +
gene O +
have O +
demonstrated O +
that O +
the O +
SV O +
40 O +
large O +
T O -
- O -
antigen O +
is O +
strictly O +
required O +
both O +
for O +
immortalization O +
and O +
induction O +
anchorage O +
independence O +
of O +
cells O -
. O +

It O +
has O +
been O +
suggested O +
that O +
the O +
immortalized O +
phenotype O +
is O +
mediated O +
by O +
an O +
extra O +
cellular O +
factor O -
. O +

The O +
synthesis O +
and/or O +
the O +
excretion O +
of O +
this O +
factor O +
in O +
a O +
medium O +
is O +
controlled O +
by O +
the O +
A O +
gene O -
. O +

Protein O +
kinase O +
activities O +
in O +
immune O +
complexes O +
of O +
simian O +
virus O +
40 O +
large O +
T O -
- O -
antigen O +
and O +
transformation O -
- O -
associated O +
cellular O +
p53 O +
protein O -
. O +

Immune O +
complex O +
kinase O +
assays O +
in O +
the O +
simian O +
virus O +
40 O +
system O +
were O +
performed O +
by O +
incubation O +
of O +
immunoprecipitates O +
containing O +
tumor O +
antigens O +
with O +
[ B-Chemical -
gamma-32P I-Chemical -
] I-Chemical -
ATP I-Chemical -
, O +
followed O +
by O +
analysis O +
of O +
any O +
phosphoacceptor O +
proteins O -
. O +

These O +
assays O +
yielded O +
mainly O +
the O +
viral O +
large O +
T O -
- O -
antigen O +
and O -
, O +
in O +
particular O -
, O +
the O +
associated O +
cellular O +
p53 O +
as O +
endogenous O +
substrates O -
. O +

The O +
nature O +
of O +
these O +
substrates O +
was O +
confirmed O +
by O +
proteolysis O +
techniques O -
. O +

Under O +
specific O +
conditions O -
, O +
casein O +
could O +
be O +
used O +
as O +
an O +
exogenous O +
substrate O +
as O +
well O -
. O +

The O +
kinase O +
reactions O +
showed O +
preference O +
for O +
ATP B-Chemical +
and O +
MgCl2 B-Chemical +
instead O +
of O +
GTP B-Chemical +
or O +
MnCl2 B-Chemical -
. O +

Both O +
phosphoserine O +
and O +
phosphothreonine O -
, O +
but O +
in O +
no O +
case O +
phosphotyrosine O -
, O +
were O +
detected O +
after O +
an O +
immune O +
complex O +
kinase O +
reaction O -
. O +

Apparently O -
, O +
several O +
in O +
vivo O +
phosphorylation O +
sites O +
were O +
recognized O +
in O +
vitro O +
in O +
both O +
large O +
T O -
- O -
antigen O +
and O +
p53 O -
, O +
but O +
the O +
presence O +
of O +
some O +
artifactual O +
sites O +
could O +
not O +
be O +
completely O +
excluded O -
. O +

Although O +
contaminating O +
kinases O +
were O +
detectable O +
in O +
the O +
immune O +
complexes O -
, O +
at O +
least O +
the O +
p53 O +
molecules O +
were O +
phosphorylated O +
in O +
vitro O +
in O +
a O +
more O +
specific O +
way O -
. O +

This O +
followed O +
from O +
several O +
characteristics O +
of O +
the O +
immune O +
complex O +
kinase O +
reactions O +
and O +
especially O +
from O +
the O +
strong O +
inhibition O +
of O +
p53 O +
phosphorylation O +
by O +
two O +
anti O -
- O -
large O -
- O -
T O +
monoclonal O +
antibodies O -
. O +

It O +
was O +
shown O +
that O +
large O +
T O -
- O -
antigen O +
showed O +
associated O +
kinase O +
activity O -
, O +
although O +
none O +
of O +
our O +
results O +
could O +
unambiguously O +
demonstrate O +
an O +
intrinsic O +
kinase O +
activity O +
of O +
this O +
protein O -
. O +

Finally O -
, O +
anti O -
- O -
p53 O +
monoclonal O +
antibodies O +
only O +
slightly O +
affected O +
in O +
vitro O +
phosphorylation O +
reactions O -
, O +
whereas O +
a O +
p53 O +
molecule O +
from O +
a O +
simian O +
virus O +
40-free O -
, O +
chemically O +
transformed O +
human O +
cell O +
line O +
was O +
not O +
phosphorylated O +
in O +
vitro O +
under O +
any O +
condition O +
tested O -
. O +

Thus O -
, O +
it O +
is O +
highly O +
unlikely O +
that O +
the O +
p53 O +
molecule O +
per O +
se O +
carries O +
intrinsic O +
or O +
even O +
associated O +
kinase O +
activities O -
. O +

DNA O +
methylation O +
and O +
expression O +
of O +
HLA O -
- O -
DR O +
alpha O -
. O +

B O -
- O -
cell O +
lines O +
established O +
from O +
two O +
individuals O +
with O +
T O -
- O -
cell O +
acute O +
lymphocytic O +
leukemia O +
( O -
T O -
- O -
ALL O -
) O +
express O +
HLA O -
- O -
DR O +
antigens O -
, O +
whereas O +
the O +
isogenic O +
T O -
- O -
cells O +
do O +
not O -
. O +

The O +
lack O +
of O +
expression O +
correlates O +
with O +
a O +
lack O +
of O +
detectable O +
HLA O -
- O -
DR O +
mRNA O -
. O +

All O +
of O +
the O +
DR O +
alpha O +
DNA O +
sequences O +
detected O +
by O +
a O +
cloned O +
DR O +
alpha O +
cDNA O +
probe O +
are O +
contained O +
in O +
a O +
BglII O +
fragment O +
which O +
varies O +
slightly O +
in O +
size O +
( O -
4.0 O +
to O +
4.8 O +
kilobases O -
) O +
from O +
one O +
individual O +
to O +
another O -
. O +

In O +
DNA O +
from O +
the O +
T O -
- O -
cells O +
not O +
expressing O +
DR O +
alpha O +
mRNA O -
, O +
all O +
of O +
the O +
potential O +
HpaII O +
sites O +
within O +
the O +
BglII O +
fragment O +
appeared O +
to O +
be O +
methylated O -
. O +

In O +
contrast O -
, O +
at O +
least O +
some O +
of O +
these O +
sites O +
were O +
not O +
methylated O +
in O +
DNA O +
from O +
the O +
B O -
- O -
cells O +
expressing O +
high O +
levels O +
of O +
DR O +
alpha O +
mRNA O -
. O +

Treatment O +
of O +
these O +
T O -
- O -
cells O +
with O +
5-azacytidine B-Chemical +
resulted O +
in O +
the O +
induction O +
of O +
DR O +
surface O +
antigen O +
expression O -
, O +
the O +
appearance O +
of O +
DR O +
alpha O +
mRNA O -
, O +
and O +
the O +
partial O +
demethylation O +
of O +
the O +
DR O +
alpha O +
DNA O +
sequences O -
. O +

T O -
- O -
cell O +
lines O +
established O +
from O +
human O +
T O -
- O -
cell O +
leukemia O -
- O -
lymphoma O +
virus O +
associated O +
T O -
- O -
cell O +
neoplasias O -
, O +
in O +
contrast O +
to O +
the O +
T O -
- O -
cell O +
acute O +
lymphocytic O +
leukemia O +
cell O +
lines O -
, O +
expressed O +
both O +
DR O +
antigens O +
and O +
DR O +
alpha O +
mRNA O -
; O +
the O +
HpaII O +
sites O +
within O +
the O +
BglII O +
fragment O +
of O +
DR O +
alpha O +
DNA O +
of O +
these O +
human O +
T O -
- O -
cell O +
leukemia O -
- O -
lymphoma O +
virus O -
- O -
positive O +
T O -
- O -
cell O +
lines O +
were O +
in O +
all O +
cases O +
at O +
least O +
partially O +
unmethylated O -
. O +

Uncultured O +
peripheral O +
blood O +
T O -
- O -
cells O +
from O +
human O +
T O -
- O -
cell O +
leukemia O -
- O -
lymphoma O +
virus O -
- O -
infected O +
individuals O +
expressed O +
DR O +
antigens O +
at O +
a O +
low O +
level O -
, O +
and O +
the O +
DR O +
alpha O +
locus O +
was O +
partially O +
unmethylated O -
. O +

After O +
48 O +
h O +
in O +
culture O -
, O +
DR O +
antigen O +
expression O +
was O +
substantially O +
increased O -
, O +
but O +
no O +
significant O +
changes O +
were O +
observed O +
in O +
methylation O +
of O +
the O +
DR O +
alpha O +
locus O +
or O +
in O +
the O +
amount O +
of O +
DR O +
mRNA O +
which O +
was O +
present O -
. O +

This O +
suggests O +
that O +
expression O +
of O +
DR O +
antigens O +
also O +
can O +
be O +
modulated O +
post O -
- O -
transcriptionally O -
. O +

The O +
effect O +
of O +
translocations O +
on O +
the O +
cellular O +
myc O +
gene O +
in O +
Burkitt O +
lymphomas O -
. O +

Chromosomal O +
translocations O +
are O +
found O +
to O +
be O +
a O +
characteristic O +
feature O +
of O +
Burkitt O +
lymphomas O -
. O +

Similar O +
translocations O +
are O +
found O +
in O +
mouse O +
plasmacytomas O +
and O +
both O +
diseases O +
involve O +
interchanges O +
between O +
one O +
of O +
the O +
immunoglobulin O +
loci O +
and O +
DNA O +
in O +
the O +
vicinity O +
of O +
the O +
myc O +
gene O -
. O +

The O +
structure O +
of O +
the O +
myc O +
gene O +
has O +
been O +
elucidated O +
from O +
studies O +
on O +
translocated O +
versions O +
of O +
the O +
gene O -
. O +

Activation O +
of O +
the O +
myc O +
gene O +
may O +
play O +
a O +
role O +
in O +
transformation O +
by O +
promoting O +
growth O +
of O +
the O +
cells O +
bearing O +
the O +
rearranged O +
chromosomes O -
. O +

Metabolic O +
alterations O +
in O +
a O +
noncachectic O +
animal O +
tumor O +
system O -
. O +

The O +
increased O +
energy O +
expended O +
by O +
the O +
host O +
to O +
synthesize O +
substrate O -
, O +
which O +
is O +
utilized O +
by O +
the O +
tumor O -
, O +
is O +
a O +
potential O +
cause O +
of O +
cancer O +
cachexia O -
. O +

In O +
vivo O +
glucose B-Chemical +
and O +
alanine O +
kinetics O +
were O +
examined O +
by O +
tracer O +
methodology O +
in O +
a O +
sarcoma O -
- O -
bearing O +
rat O +
model O -
. O +

The O +
effects O +
of O +
3-mercaptopicolinic B-Chemical +
acid I-Chemical -
, O +
a O +
potent O +
inhibitor O +
of O +
gluconeogenesis O -
, O +
was O +
also O +
examined O +
on O +
this O +
model O -
. O +

Both O +
tumor O -
- O -
bearing O +
( O -
TB O -
) O +
and O +
nontumor O +
bearing O +
( O -
NTB O -
) O +
animals O +
were O +
gaining O +
weight O +
prior O +
to O +
study O +
and O +
the O +
tumors O +
were O +
relatively O +
small O -
. O +

The O +
TB O +
animals O +
had O +
significantly O +
lower O +
plasma O +
glucose B-Chemical +
and O +
higher O +
blood O +
lactic B-Chemical +
acid I-Chemical +
levels O +
compared O +
with O +
NTB O +
animals O -
. O +

After O +
inhibition O +
of O +
gluconeogenesis O -
, O +
the O +
plasma O +
glucose B-Chemical +
decreased O +
and O +
the O +
blood O +
lactate B-Chemical +
increased O +
significantly O +
more O +
in O +
TB O +
than O +
NTB O +
animals O -
. O +

The O +
glucose B-Chemical +
turnover O +
rate O +
was O +
significantly O +
greater O +
in O +
TB O +
compared O +
with O +
NTB O +
animals O -
, O +
as O +
was O +
the O +
rate O +
of O +
glucose B-Chemical +
recycling O +
and O +
the O +
rate O +
of O +
gluconeogenesis O +
( O -
alanine O +
leads O +
to O +
glucose B-Chemical -
) O -
, O +
both O +
energy O +
demanding O +
processes O -
. O +

These O +
results O +
suggest O +
that O +
the O +
tumor O -
- O -
bearing O +
animal O -
, O +
even O +
prior O +
to O +
significant O +
cachexia O -
, O +
has O +
an O +
excess O +
demand O +
for O +
energy O -
, O +
the O +
provision O +
of O +
which O +
may O +
be O +
a O +
significant O +
factor O +
in O +
malignant O +
cachexia O -
. O +

Mast O +
cell O +
heparin B-Chemical +
stimulates O +
migration O +
of O +
capillary O +
endothelial O +
cells O +
in O +
vitro O -
. O +

Migration O +
of O +
capillary O +
endothelial O +
cells O +
is O +
an O +
important O +
component O +
of O +
angiogenesis O +
in O +
vivo O -
. O +

Increased O +
numbers O +
of O +
mast O +
cells O +
have O +
been O +
associated O +
with O +
several O +
types O +
of O +
angiogenesis O -
. O +

We O +
have O +
used O +
a O +
quantitative O +
assay O +
in O +
vitro O +
to O +
demonstrate O +
that O +
mast O +
cells O +
release O +
a O +
factor O +
that O +
significantly O +
increases O +
bovine O +
capillary O +
endothelial O +
cell O +
migration O -
. O +

The O +
factor O +
is O +
present O +
in O +
medium O +
conditioned O +
by O +
mast O +
cells O +
as O +
well O +
as O +
lysates O +
of O +
mast O +
cells O -
. O +

The O +
stimulatory O +
effect O +
of O +
mast O +
cells O +
on O +
migration O +
is O +
specific O +
for O +
capillary O +
endothelial O +
cells O -
. O +

Furthermore O -
, O +
mast O +
cells O +
have O +
no O +
mitogenic O +
activity O +
for O +
capillary O +
endothelial O +
cells O -
. O +

Of O +
all O +
the O +
secretory O +
products O +
of O +
mast O +
cells O +
tested O -
, O +
only O +
heparin B-Chemical +
stimulated O +
capillary O +
endothelial O +
cell O +
migration O +
in O +
vitro O -
. O +

Heparin B-Chemical +
preparations O +
from O +
a O +
variety O +
of O +
sources O +
stimulated O +
capillary O +
endothelial O +
cell O +
migration O +
to O +
the O +
same O +
degree O +
but O +
did O +
not O +
stimulate O +
migration O +
of O +
several O +
other O +
cell O +
types O -
. O +

The O +
migration O +
activity O +
of O +
heparin B-Chemical +
and O +
mast O +
cell O +
conditioned O +
medium O +
was O +
blocked O +
by O +
specific O +
antagonists O +
of O +
heparin B-Chemical +
( O -
protamine O +
and O +
heparinase O -
) O -
, O +
but O +
not O +
by O +
chondroitinase O +
ABC O -
. O +

The O +
migration O +
activity O +
of O +
mast O +
cell O +
conditioned O +
medium O +
was O +
resistant O +
to O +
heat O +
( O -
100 O +
degrees O +
C O -
) O +
and O +
incubation O +
with O +
proteolytic O +
enzymes O -
. O +

These O +
results O +
suggest O +
that O +
the O +
role O +
of O +
mast O +
cells O +
in O +
angiogenesis O +
may O +
be O +
to O +
enhance O +
migration O +
of O +
the O +
endothelial O +
cells O +
of O +
growing O +
capillaries O -
. O +

The O +
inhibition O +
of O +
cultured O +
myoblast O +
differentiation O +
by O +
the O +
simian O +
virus O +
40 O +
large O +
T O +
antigen O +
occurs O +
after O +
myogenin O +
expression O +
and O +
Rb O +
up O -
- O -
regulation O +
and O +
is O +
not O +
exerted O +
by O +
transformation O -
- O -
competent O +
cytoplasmic O +
mutants O -
. O +

We O +
have O +
investigated O +
the O +
mechanism O +
by O +
which O +
the O +
simian O +
virus O +
40 O +
large O +
T O +
antigen O +
( O -
SVLT O -
) O +
interferes O +
with O +
the O +
differentiation O +
of O +
C2 O +
myoblasts O -
. O +

SVLT O +
mutants O -
, O +
defective O +
either O +
in O +
the O +
Rb O +
binding O +
site O -
, O +
near O +
the O +
N O -
- O -
terminal O +
end O -
, O +
in O +
a O +
region O +
that O +
affects O +
binding O +
to O +
p53 O -
, O +
or O +
in O +
the O +
nuclear O +
transport O +
signal O -
, O +
were O +
also O +
employed O +
to O +
determine O +
whether O +
the O +
interference O +
was O +
especially O +
dependent O +
on O +
these O +
functional O +
domains O -
. O +

It O +
was O +
found O +
that O +
wild O -
- O -
type O +
( O -
wt O -
) O +
SVLT O +
strongly O +
inhibited O +
the O +
terminal O +
differentiation O +
of O +
mouse O +
C2 O +
myoblasts O -
, O +
but O +
this O +
arrest O +
occurred O +
only O +
after O +
the O +
synthesis O +
of O +
myogenin O -
, O +
an O +
initial O +
step O +
in O +
biochemical O +
differentiation O -
. O +

Neither O +
the O +
synthesis O +
nor O +
some O +
basic O +
activities O +
of O +
MyoD O +
appeared O +
to O +
be O +
affected O +
by O +
wt O +
SVLT O -
. O +

In O +
these O +
transformants O -
, O +
mitogen O +
depletion O +
elicited O +
an O +
increase O +
in O +
the O +
Rb O +
level O +
comparable O +
to O +
that O +
in O +
normal O +
C2 O +
cells O -
; O +
wt O +
SVLT O -
, O +
however O -
, O +
promoted O +
the O +
phosphorylation O +
of O +
a O +
large O +
part O +
of O +
the O +
induced O +
Rb O -
. O +

Mutations O +
affecting O +
nuclear O +
transport O +
were O +
far O +
more O +
critical O +
for O +
the O +
ability O +
to O +
interfere O +
with O +
myogenic O +
differentiation O +
than O +
were O +
those O +
affecting O +
the O +
transforming O +
potential O -
; O +
cytoplasmic O +
SVLT O +
expression O +
was O +
fully O +
compatible O +
with O +
the O +
terminal O +
differentiation O +
of O +
C2 O +
cells O -
, O +
despite O +
enabling O +
them O +
to O +
grow O +
in O +
semisolid O +
medium O -
, O +
thus O +
showing O +
that O +
the O +
myogenesis O -
- O -
inhibiting O +
property O +
can O +
be O +
dissociated O +
from O +
transforming O +
competence O -
. O +

The O +
remaining O +
SVLT O +
mutants O +
presented O +
different O +
degrees O +
of O +
ability O +
to O +
inhibit O +
differentiation O +
( O -
as O +
shown O +
by O +
the O +
expression O +
of O +
tissue O -
- O -
specific O +
markers O +
in O +
transformants O -
) O -
. O +

The O +
inhibiting O +
mutants O -
, O +
including O +
the O +
Rb O +
binding O +
site O +
mutant O -
, O +
were O +
able O +
to O +
promote O +
a O +
higher O +
state O +
of O +
Rb O +
phosphorylation O +
than O +
that O +
observed O +
in O +
either O +
normal O +
cells O +
or O +
cytoplasmic O -
- O -
SVLT O +
transformants O -
. O +

Cancer O +
progression O +
and O +
p53 O -
. O +

In O +
a O +
complex O +
organism O -
, O +
somatic O +
cells O +
are O +
under O +
intermittent O +
selection O +
pressure O +
for O +
the O +
emergence O +
of O +
mutants O +
that O +
can O +
survive O +
environmental O +
insults O +
and O +
that O +
can O +
grow O +
autonomously O +
despite O +
adverse O +
conditions O -
. O +

Repeated O +
rounds O +
of O +
mutation O -
, O +
selection O -
, O +
and O +
proliferation O +
may O +
lead O +
to O +
cancer O -
. O +

The O +
organism O +
prevents O +
malignant O +
transformation O +
by O +
assuring O +
accurate O +
DNA O +
repair O +
before O +
cell O +
division O -
, O +
by O +
forcing O +
the O +
death O +
of O +
cells O +
with O +
excessive O +
DNA O +
damage O -
, O +
and O +
by O +
placing O +
limits O +
on O +
the O +
replicative O +
lifespans O +
of O +
most O +
somatic O +
cells O -
. O +

The O +
p53 O +
gene O +
is O +
a O +
" O -
guardian O +
of O +
the O +
genome O -
"-- O -
it O +
regulates O +
multiple O +
components O +
of O +
the O +
DNA O +
damage O +
control O +
response O +
and O +
promotes O +
cellular O +
senescence O -
. O +

Disabling O +
mutations O +
and O +
deletions O +
of O +
p53 O +
occur O +
in O +
50 O -
% O +
of O +
human O +
tumours O -
. O +

p53-deficient O +
cancers O +
are O +
often O +
unstable O -
, O +
aggressive O -
, O +
and O +
resistant O +
to O +
therapy O -
. O +

Anti O -
- O -
transforming O +
growth O +
factor O +
( O -
TGF O -
) O -
-beta O +
antibodies O +
inhibit O +
breast O +
cancer O +
cell O +
tumorigenicity O +
and O +
increase O +
mouse O +
spleen O +
natural O +
killer O +
cell O +
activity O -
. O +

Implications O +
for O +
a O +
possible O +
role O +
of O +
tumor O +
cell O -
/ O -
host O +
TGF O -
- O -
beta O +
interactions O +
in O +
human O +
breast O +
cancer O +
progression O -
. O +

TGF O -
- O -
beta O +
effects O +
on O +
angiogenesis O -
, O +
stroma O +
formation O -
, O +
and O +
immune O +
function O +
suggest O +
its O +
possible O +
involvement O +
in O +
tumor O +
progression O -
. O +

This O +
hypothesis O +
was O +
tested O +
using O +
the O +
2G7 O +
IgG2b O -
, O +
which O +
neutralizes O +
TGF O -
- O -
beta O +
1 O -
, O +
-beta O +
2 O -
, O +
and O +
-beta O +
3 O -
, O +
and O +
the O +
MDA-231 O +
human O +
breast O +
cancer O +
cell O +
line O -
. O +

Inoculation O +
of O +
these O +
cells O +
in O +
athymic O +
mice O +
decreases O +
mouse O +
spleen O +
natural O +
killer O +
( O -
NK O -
) O +
cell O +
activity O -
. O +

Intraperitoneal O +
injections O +
of O +
2G7 O +
starting O +
1 O +
d O +
after O +
intraperitoneal O +
inoculation O +
of O +
tumor O +
cells O +
suppressed O +
intraabdominal O +
tumor O +
and O +
lung O +
metastases O -
, O +
whereas O +
the O +
nonneutralizing O +
anti O -
- O -
TGF O -
- O -
beta O +
12H5 O +
IgG2a O +
had O +
no O +
effect O -
. O +

2G7 O +
transiently O +
inhibited O +
growth O +
of O +
established O +
MDA-231 O +
subcutaneous O +
tumors O -
. O +

Histologically O -
, O +
both O +
2G7-treated O +
and O +
control O +
tumors O +
were O +
identical O -
. O +

Intraperitoneal O +
administration O +
of O +
2G7 O +
resulted O +
in O +
a O +
marked O +
increase O +
in O +
mouse O +
spleen O +
NK O +
cell O +
activity O -
. O +

2G7 O +
did O +
not O +
inhibit O +
MDA-231 O +
primary O +
tumor O +
or O +
metastases O +
formation O -
, O +
nor O +
did O +
it O +
stimulate O +
NK O +
cell O -
- O -
mediated O +
cytotoxicity O +
in O +
beige O +
NK O -
- O -
deficient O +
nude O +
mice O -
. O +

Finally O -
, O +
serum O -
- O -
free O +
conditioned O +
medium O +
from O +
MDA-231 O +
cells O +
inhibited O +
the O +
NK O +
cell O +
activity O +
of O +
human O +
blood O +
lymphocytes O -
. O +

This O +
inhibition O +
was O +
blocked O +
by O +
the O +
neutralizing O +
anti O -
- O -
TGF O -
- O -
beta O +
2G7 O +
antibody O +
but O +
not O +
by O +
a O +
nonspecific O +
IgG2 O -
. O +

These O +
data O +
support O +
a O +
possible O +
role O +
for O +
tumor O +
cell O +
TGF O -
- O -
beta O +
in O +
the O +
progression O +
of O +
mammary O +
carcinomas O +
by O +
suppressing O +
host O +
immune O +
surveillance O -
. O +

The O +
Met O +
proto O -
- O -
oncogene O +
mesenchymal O +
to O +
epithelial O +
cell O +
conversion O -
. O +

Coexpression O +
of O +
the O +
human O +
Met O +
receptor O +
and O +
its O +
ligand O -
, O +
hepatocyte O +
growth O +
factor O -
/ O -
scatter O +
factor O +
( O -
HGF O -
/ O -
SF O -
) O -
, O +
in O +
NIH O +
3T3 O +
fibroblasts O +
causes O +
the O +
cells O +
to O +
become O +
tumorigenic O +
in O +
nude O +
mice O -
. O +

The O +
resultant O +
tumors O +
display O +
lumen O -
- O -
like O +
morphology O -
, O +
contain O +
carcinoma O -
- O -
like O +
focal O +
areas O +
with O +
intercellular O +
junctions O +
resembling O +
desmosomes O -
, O +
and O +
coexpress O +
epithelial O +
( O -
cytokeratin O -
) O +
and O +
mesenchymal O +
( O -
vimentin O -
) O +
cytoskeletal O +
markers O -
. O +

The O +
tumor O +
cells O +
also O +
display O +
enhanced O +
expression O +
of O +
desmosomal O +
and O +
tight O -
- O -
junction O +
proteins O -
. O +

The O +
apparent O +
mesenchymal O +
to O +
epithelial O +
conversion O +
of O +
the O +
tumor O +
cells O +
mimics O +
the O +
conversion O +
that O +
occurs O +
during O +
embryonic O +
kidney O +
development O -
, O +
suggesting O +
that O +
Met O -
- O -
HGF O -
/ O -
SF O +
signaling O +
plays O +
a O +
role O +
in O +
this O +
process O +
as O +
well O +
as O +
in O +
tumors O +
that O +
express O +
both O +
epithelial O +
and O +
mesenchymal O +
markers O -
. O +

Molecular O +
mediators O +
of O +
interactions O +
with O +
extracellular O +
matrix O +
components O +
in O +
metastasis O +
and O +
angiogenesis O -
. O +

Metastasis O +
and O +
tumor O +
angiogenesis O +
are O +
invasive O +
phenomena O +
and O +
share O +
many O +
common O +
properties O +
at O +
the O +
physiological O +
level O +
and O +
some O +
similarities O +
at O +
the O +
molecular O +
level O -
. O +

Each O +
consists O +
of O +
repetitive O +
cycles O +
of O +
interaction O +
with O +
adjacent O +
extracellular O +
matrix O +
components O +
by O +
mediating O +
cellular O +
adhesion O -
, O +
matrix O +
dissolution O -
, O +
and O +
cellular O +
motility O +
to O +
achieve O +
metastasis O +
of O +
cancer O +
cells O +
or O +
neovascularization O +
of O +
tumors O -
. O +

Molecular O +
factors O +
which O +
implement O +
this O +
triad O +
of O +
events O +
are O +
reviewed O -
, O +
as O +
are O +
several O +
signal O +
transduction O +
components O +
which O +
may O +
regulate O +
them O -
. O +

Some O +
potentially O +
promising O +
prognostic O -
, O +
diagnostic O -
, O +
and O +
therapeutic O +
modalities O +
for O +
tumor O +
angiogenesis O +
and O +
metastatic O +
disease O +
are O +
also O +
discussed O -
. O +

Enhanced O +
DNA O -
- O -
binding O +
activity O +
of O +
a O +
Stat3-related O +
protein O +
in O +
cells O +
transformed O +
by O +
the O +
Src O +
oncoprotein O -
. O +

Cytokines O +
and O +
growth O +
factors O +
induce O +
tyrosine O +
phosphorylation O +
of O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O -
STATs O -
) O +
that O +
directly O +
activate O +
gene O +
expression O -
. O +

Cells O +
stably O +
transformed O +
by O +
the O +
Src O +
oncogene O +
tyrosine O +
kinase O +
were O +
examined O +
for O +
STAT O +
protein O +
activation O -
. O +

Assays O +
of O +
electrophoretic O +
mobility O -
, O +
DNA O -
- O -
binding O +
specificity O -
, O +
and O +
antigenicity O +
indicated O +
that O +
Stat3 O +
or O +
a O +
closely O +
related O +
STAT O +
family O +
member O +
was O +
constitutively O +
activated O +
by O +
the O +
Src O +
oncoprotein O -
. O +

Induction O +
of O +
this O +
DNA O -
- O -
binding O +
activity O +
was O +
accompanied O +
by O +
tyrosine O +
phosphorylation O +
of O +
Stat3 O +
and O +
correlated O +
with O +
Src O +
transformation O -
. O +

These O +
findings O +
demonstrate O +
that O +
Src O +
can O +
activate O +
STAT O +
signaling O +
pathways O +
and O +
raise O +
the O +
possibility O +
that O +
Stat3 O +
contributes O +
to O +
oncogenesis O +
by O +
Src O -
. O +

Bicistronic O +
retroviral O +
vector O +
reveals O +
capacity O +
of O +
v O -
- O -
erbA O +
to O +
induce O +
erythroleukemia O +
and O +
to O +
co O -
- O -
operate O +
with O +
v O -
- O -
myb O -
. O +

Previous O +
studies O +
have O +
shown O +
that O +
v O -
- O -
erbA O +
and O +
v O -
- O -
myb O +
can O +
induce O +
the O +
proliferation O +
of O +
avian O +
erythroid O +
cells O +
in O +
culture O -
. O +

To O +
study O +
the O +
combined O +
effects O +
of O +
v O -
- O -
erbA O +
and O +
v O -
- O -
myb O -
, O +
the O +
two O +
oncogenes O +
were O +
engineered O +
into O +
a O +
retrovirus O +
bicistronic O +
vector O +
with O +
an O +
internal O +
ribosomal O +
entry O +
site O +
( O -
IRES O -
) O +
or O +
into O +
a O +
vector O +
with O +
a O +
splice O +
acceptor O +
( O -
SPL O -
) O -
. O +

This O +
allowed O +
coexpression O +
of O +
the O +
two O +
proteins O +
and O +
a O +
comparison O +
with O +
the O +
same O +
vector O +
containing O +
either O +
v O -
- O -
erbA O +
or O +
v O -
- O -
myb O +
only O -
. O +

Both O +
the O +
erbA O +
IRES O +
and O +
the O +
erbA O -
/ O -
myb O +
IRES O +
virus O +
constructs O +
transformed O +
erythroid O +
cells O +
after O +
infection O +
of O +
bone O +
marrow O +
or O +
blastoderm O +
cultures O -
. O +

The O +
erbA O -
/ O -
myb O +
IRES O +
virus O +
exhibited O +
a O +
5 O -
- O -
10-fold O +
higher O +
transformed O +
colony O +
forming O +
efficiency O +
than O +
the O +
erbA O +
IRES O +
virus O +
in O +
the O +
blastoderm O +
assay O -
. O +

Surprisingly O -
, O +
when O +
injected O +
into O +
chicken O +
embryos O +
in O +
the O +
presence O +
of O +
helper O +
virus O -
, O +
both O +
viruses O +
induced O +
an O +
erythroleukemia O +
in O +
about O +
half O +
of O +
the O +
animals O -
. O +

In O +
contrast O -
, O +
no O +
leukemia O +
was O +
observed O +
with O +
a O +
myb O +
IRES O +
virus O -
, O +
with O +
spliced O +
vectors O +
containing O +
v O -
- O -
erbA O +
alone O +
or O +
v O -
- O -
erbA O +
in O +
combination O +
with O +
v O -
- O -
myb O -
, O +
nor O +
with O +
erbA O +
IRES O +
and O +
erbA O -
/ O -
myb O +
IRES O +
viruses O +
produced O +
in O +
the O +
absence O +
of O +
helper O +
virus O -
. O +

The O +
average O +
latency O +
of O +
leukemia O +
induction O +
was O +
shorter O +
for O +
the O +
erbA O -
/ O -
myb O +
IRES O +
virus O +
( O -
3.5 O +
weeks O -
) O +
than O +
for O +
the O +
erbA O +
IRES O +
virus O +
( O -
5 O +
weeks O -
) O -
. O +

Nevertheless O -
, O +
for O +
both O +
viruses O +
the O +
leukemic O +
blasts O +
retained O +
full O +
factor O +
dependence O +
for O +
growth O -
. O +

These O +
results O +
show O +
that O +
v O -
- O -
erbA O +
is O +
capable O +
of O +
inducing O +
an O +
erythroleukemia O +
when O +
expressed O +
by O +
a O +
high O +
titer O +
bicistronic O +
retrovirus O +
under O +
conditions O +
of O +
virus O +
spreading O +
and O +
that O +
its O +
in O +
vitro O +
and O +
in O +
vivo O +
transforming O +
potential O +
can O +
be O +
enhanced O +
by O +
v O -
- O -
myb O -
. O +

VEGF165 O +
expressed O +
by O +
a O +
replication O -
- O -
deficient O +
recombinant O +
adenovirus O +
vector O +
induces O +
angiogenesis O +
in O +
vivo O -
. O +

To O +
evaluate O +
the O +
concept O +
that O +
localized O +
delivery O +
of O +
angiogenic O +
factors O +
via O +
virus O -
- O -
mediated O +
gene O +
transfer O +
may O +
be O +
useful O +
in O +
the O +
treatment O +
of O +
ischemic O +
disorders O -
, O +
the O +
replication O -
- O -
deficient O +
adenovirus O +
( O -
Ad O -
) O +
vector O +
AdCMV.VEGF165 O +
( O -
where O +
CMV O +
is O +
cytomegalovirus O +
and O +
VEGF O +
is O +
vascular O +
endothelial O +
growth O +
factor O -
) O +
containing O +
the O +
cDNA O +
for O +
human O +
VEGF165 O -
, O +
a O +
secreted O +
endothelial O +
cell O -
- O -
specific O +
angiogenic O +
growth O +
factor O -
, O +
was O +
constructed O -
. O +

Human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O -
HUVECs O -
) O +
and O +
rat O +
aorta O +
smooth O +
muscle O +
cells O +
( O -
RASMCs O -
) O +
infected O +
with O +
AdCMV.VEGF165 O +
( O -
5 O +
and O +
20 O +
plaque O -
- O -
forming O +
units O +
[ O -
pfu O -
] O +
per O +
cell O -
) O +
demonstrated O +
VEGF O +
mRNA O +
expression O +
and O +
protein O +
secretion O +
into O +
the O +
supernatant O -
. O +

Furthermore O -
, O +
the O +
conditioned O +
medium O +
from O +
these O +
cells O +
enhanced O +
vascular O +
permeability O +
in O +
vivo O -
. O +

In O +
contrast O -
, O +
neither O +
VEGF O +
mRNA O +
nor O +
secreted O +
protein O +
was O +
found O +
in O +
uninfected O +
HUVECs O +
or O +
RASMCs O +
or O +
in O +
cells O +
infected O +
with O +
the O +
control O +
vector O +
AdCMV.beta O +
gal O +
( O -
where O +
beta O +
gal O +
is O +
beta O -
- O -
galactosidase O -
) O -
. O +

Assessment O +
of O +
starved O +
HUVECs O +
at O +
14 O +
days O +
demonstrated O +
sixfold O +
more O +
cells O +
for O +
AdCMV.VEGF165-infected O +
HUVECs O +
( O -
20 O +
pfu O +
per O +
cell O -
) O +
than O +
for O +
either O +
infected O +
or O +
uninfected O +
control O +
cells O -
. O +

RASMC O +
proliferation O +
was O +
unaffected O +
by O +
infection O +
with O +
AdCMV.VEGF165 O -
. O +

When O +
plated O +
in O +
2 O -
% O +
serum O +
on O +
dishes O +
precoated O +
with O +
reconstituted O +
basement O +
membrane O +
( O -
Matrigel O -
) O -
, O +
HUVECs O +
infected O +
with O +
AdCMV.VEGF165 O +
( O -
20 O +
pfu O +
per O +
cell O -
) O +
differentiated O +
into O +
capillary O -
- O -
like O +
structures O -
. O +

Under O +
similar O +
conditions O -
, O +
both O +
uninfected O +
HUVECs O +
and O +
HUVECs O +
infected O +
with O +
AdCMV.beta O +
gal O +
did O +
not O +
differentiate O -
. O +

To O +
evaluate O +
the O +
ability O +
of O +
AdCMV.VEGF165 O +
to O +
function O +
in O +
vivo O -
, O +
either O +
AdCMV O -
. O +

VEGF165 O +
or O +
AdCMV.beta O +
gal O +
( O -
2 O +
x O +
10 O -
( O -
10 O -
) O +
pfu O -
) O +
was O +
resuspended O +
in O +
0.5 O +
mL O +
Matrigel O +
and O +
injected O +
subcutaneously O +
into O +
mice O -
. O +

Immunohistochemical O +
staining O +
demonstrated O +
VEGF O +
in O +
the O +
tissues O +
surrounding O +
the O +
Matrigel O +
plugs O +
containing O +
AdCMV.VEGF165 O +
up O +
to O +
3 O +
weeks O +
after O +
injection O -
, O +
whereas O +
no O +
VEGF O +
was O +
found O +
in O +
the O +
control O +
plugs O +
with O +
AdCMV.beta O +
gal O -
. O +

Two O +
weeks O +
after O +
injection O -
, O +
there O +
was O +
histological O +
evidence O +
of O +
neovascularization O +
in O +
the O +
tissues O +
surrounding O +
the O +
Matrigel O +
containing O +
AdCMV.VEGF165 O -
, O +
whereas O +
no O +
significant O +
angiogenesis O +
was O +
observed O +
in O +
response O +
to O +
AdCMV.beta O +
gal O -
. O +

Furthermore O -
, O +
the O +
Matrigel O +
plugs O +
with O +
AdCMV.VEGF165 O +
demonstrated O +
hemoglobin O +
content O +
fourfold O +
higher O +
than O +
the O +
plugs O +
with O +
AdCMV.beta O +
gal O -
. O +

Together O -
, O +
these O +
in O +
vitro O +
and O +
in O +
vivo O +
studies O +
are O +
consistent O +
with O +
the O +
concept O +
that O +
Ad O +
vectors O +
may O +
provide O +
a O +
useful O +
strategy O +
for O +
efficient O +
local O +
delivery O +
of O +
VEGF165 O +
in O +
the O +
treatment O +
of O +
ischemic O +
diseases O -
. O +

Metastatic O +
NIH O +
3T3 O +
x O +
LTA O +
cell O +
hybrids O +
express O +
72 O +
kDa O +
type O +
IV O +
collagenase O -
. O +

We O +
previously O +
reported O +
that O +
the O +
murine O +
fibroblast O +
cell O +
line O +
LTA O +
is O +
tumorigenic O +
but O +
non O -
- O -
metastatic O -
, O +
and O +
is O +
non O -
- O -
responsive O +
to O +
a O +
transfected O +
H O -
- O -
ras O +
oncogene O -
. O +

In O +
contrast O -
, O +
NIH O +
3T3 O +
cells O +
are O +
non O -
- O -
tumorigenic O +
but O +
are O +
ras O -
- O -
responsive O +
and O +
become O +
metastatic O +
when O +
transfected O +
with O +
ras O -
. O +

Somatic O +
cell O +
hybrids O +
between O +
LTA O +
and O +
NIH O +
3T3 O +
cells O +
are O +
tumorigenic O -
, O +
metastatic O +
and O +
ras O -
- O -
responsive O -
. O +

Here O +
we O +
examined O +
expression O +
of O +
type O +
IV O +
collagenases O +
in O +
parental O +
LTA O +
and O +
NIH O +
3T3 O +
cells O +
( O -
with O +
and O +
without O +
ras O -
) O +
and O +
four O +
metastatic O +
LTA O +
x O +
NIH O +
3T3 O +
hybrids O +
( O -
also O +
with O +
and O +
without O +
ras O -
) O -
. O +

Parental O +
NIH O +
3T3-derived O +
cells O +
had O +
both O +
72 O +
kDa O +
and O +
92 O +
kDa O +
gelatinase O +
activities O -
, O +
and O +
LTA O -
- O -
derived O +
cells O +
had O +
either O +
aberrantly O +
sized O +
approximately O +
90 O +
kDa O +
activity O +
alone O +
or O +
neither O +
enzyme O +
activity O -
. O +

All O +
four O +
metastatic O +
hybrids O +
expressed O +
60 O -
- O -
72 O +
kDa O +
gelatinase O +
activity O -
, O +
while O +
three O +
of O +
them O +
also O +
had O +
92 O +
kDa O +
activity O +
and O +
one O +
had O +
only O +
minimal O +
92 O +
kDa O +
activity O -
. O +

Thus O +
the O +
metastatic O +
phenotype O +
of O +
the O +
hybrids O +
was O +
associated O +
with O +
expression O +
of O +
72 O +
kDa O +
gelatinase O -
. O +

Levels O +
of O +
RNA O +
for O +
tissue O +
inhibitors O +
of O +
metalloproteinases O +
( O -
TIMP-1 O -
, O +
TIMP-2 O -
) O +
were O +
relatively O +
constant O -
, O +
suggesting O +
independent O +
regulation O +
of O +
type O +
IV O +
collagenases O +
and O +
their O +
inhibitors O -
. O +

Southern O +
blotting O +
and O +
probing O +
with O +
PCR O -
- O -
synthesized O +
cDNA O +
fragments O +
of O +
the O +
mouse O +
72 O +
kDa O +
type O +
IV O +
collagenase O +
gene O +
showed O +
that O +
this O +
gene O +
was O +
present O +
in O +
all O +
cells O +
although O +
the O +
structure O +
of O +
this O +
gene O +
in O +
one O +
of O +
the O +
three O +
LTA O +
cell O +
lines O +
differed O +
from O +
that O +
of O +
the O +
other O +
cells O -
. O +

Our O +
results O +
suggest O +
that O +
a O +
key O +
change O +
in O +
the O +
metastatic O +
hybrids O -
, O +
relative O +
to O +
non O -
- O -
metastatic O +
parental O +
LTA O +
cells O -
, O +
is O +
induction O +
of O +
expression O +
of O +
72 O +
kDa O +
type O +
IV O +
collagenase O -
. O +

Neoplastic O +
progression O +
of O +
human O +
colorectal O +
cancer O +
is O +
associated O +
with O +
overexpression O +
of O +
the O +
stromelysin-3 O +
and O +
BM-40 O -
/ O -
SPARC O +
genes O -
. O +

The O +
interaction O +
of O +
neoplastic O +
cells O +
with O +
the O +
extracellular O +
matrix O +
is O +
a O +
critical O +
event O +
for O +
the O +
initiation O +
of O +
cancer O +
invasion O +
and O +
metastasis O -
. O +

This O +
study O +
was O +
designed O +
to O +
evaluate O +
the O +
potential O +
implication O +
of O +
stromelysin-3 O +
( O -
ST3 O -
) O -
, O +
a O +
newly O +
identified O +
member O +
of O +
the O +
matrix O -
- O -
degrading O +
metalloproteinase O +
family O -
, O +
and O +
of O +
BM-40 O -
/ O -
SPARC O -
, O +
a O +
glycoprotein O +
associated O +
with O +
the O +
extracellular O +
matrix O -
, O +
during O +
the O +
progression O +
of O +
human O +
colorectal O +
cancers O -
. O +

We O +
analyzed O +
the O +
relative O +
abundance O +
of O +
ST3 O +
and O +
BM-40 O -
/ O -
SPARC O +
transcripts O +
by O +
Northern O +
blot O -
, O +
and O +
their O +
distribution O +
by O +
in O +
situ O +
hybridization O -
, O +
in O +
normal O +
mucosa O -
, O +
benign O +
adenomas O -
, O +
and O +
primary O +
colorectal O +
adenocarcinomas O +
and O +
their O +
liver O +
metastases O -
. O +

The O +
ST3 O +
and O +
BM-40 O -
/ O -
SPARC O +
transcripts O +
were O +
overexpressed O +
in O +
primary O +
colorectal O +
cancers O +
and O +
their O +
liver O +
metastases O +
compared O +
to O +
non O -
- O -
neoplastic O +
mucosa O -
. O +

These O +
transcripts O +
were O +
localized O +
in O +
stromal O +
fibroblasts O +
adjacent O +
to O +
the O +
neoplastic O +
foci O -
. O +

Overexpression O +
of O +
ST3 O +
correlated O +
with O +
the O +
progression O +
of O +
human O +
colorectal O +
tumors O +
toward O +
local O +
invasion O +
and O +
liver O +
metastasis O -
. O +

Induction O +
of O +
these O +
genes O +
also O +
occurred O +
in O +
diverticulitis O +
and O +
digestive O +
neoplasms O +
such O +
as O +
gastric O +
and O +
esophageal O +
carcinomas O -
. O +

Selenoperoxidase O -
- O -
dependent O +
glutathione B-Chemical +
cycle O +
activity O +
in O +
peroxide B-Chemical -
- O -
challenged O +
leukemia O +
cells O -
. O +

Murine O +
leukemia O +
L1210 O +
cells O +
rendered O +
deficient O +
in O +
glutathione O +
peroxidase O +
( O -
GPX O -
) O +
and O +
phospholipid O +
hydroperoxide O +
glutathione O +
peroxidase O +
( O -
PHGPX O -
) O +
by O +
Se B-Chemical +
deprivation O +
( O -
L.Se O -
( O -
- O -
) O +
cells O -
) O +
were O +
found O +
to O +
be O +
more O +
sensitive O +
to O +
tert B-Chemical -
- I-Chemical -
butyl I-Chemical +
hydroperoxide I-Chemical +
( O -
t B-Chemical -
- I-Chemical -
BuOOH I-Chemical -
) O +
cytotoxicity O +
than O +
Se B-Chemical -
- O -
replete O +
controls O +
( O -
L.Se O -
( O -
+ O -
) O +
cells O -
) O -
. O +

Human O +
K562 O +
cells O -
, O +
which O +
express O +
PHGPX O -
, O +
but O +
not O +
GPX O -
, O +
were O +
also O +
more O +
sensitive O +
to O +
t B-Chemical -
- I-Chemical -
BuOOH I-Chemical +
in O +
the O +
Se B-Chemical -
- O -
deficient O +
( O -
K.Se O -
( O -
- O -
) O -
) O +
than O +
Se B-Chemical -
- O -
satisfied O +
( O -
K.Se O -
( O -
+ O -
) O -
) O +
condition O -
. O +

In O +
examining O +
the O +
metabolic O +
basis O +
for O +
selenoperoxidase O -
- O -
dependent O +
resistance O -
, O +
we O +
found O +
that O +
glucose B-Chemical -
- O -
replete O +
Se O -
( O -
- O -
) O +
cells O +
reduce O +
t B-Chemical -
- I-Chemical -
BuOOH I-Chemical +
to O +
t B-Chemical -
- I-Chemical -
butanol I-Chemical +
far O +
more O +
slowly O +
than O +
Se O -
( O -
+ O -
) O +
cells O -
, O +
the O +
ratio O +
of O +
the O +
first O -
- O -
order O +
rate O +
constants O +
approximating O +
that O +
of O +
the O +
GPX O +
activities O +
( O -
L1210 O +
cells O -
) O +
or O +
PHGPX O +
activities O +
( O -
K562 O +
cells O -
) O -
. O +

Monitoring O +
peroxide B-Chemical -
- O -
induced O +
changes O +
in O +
GSH B-Chemical +
and O +
GSSG B-Chemical +
gave O +
consistent O +
results O -
; O +
e.g. O -
, O +
glucose B-Chemical -
- O -
depleted O +
L.Se O -
( O -
+ O -
) O +
cells O +
exhibited O +
a O +
first O +
order O +
loss O +
of O +
GSH B-Chemical +
that O +
was O +
substantially O +
faster O +
than O +
that O +
of O +
glucose B-Chemical -
- O -
depleted O +
L.Se O -
( O -
- O -
) O +
cells O -
. O +

Under O +
the O +
conditions O +
used O -
, O +
peroxide B-Chemical -
- O -
induced O +
conversion O +
of O +
GSH B-Chemical +
to O +
GSSG B-Chemical +
could O +
be O +
stoichiometrically O +
reversed O +
by O +
resupplying O +
D B-Chemical -
- I-Chemical -
glucose I-Chemical -
, O +
indicating O +
that O +
no O +
significant O +
lysis O +
or O +
GSSG B-Chemical +
efflux O +
and/or O +
interchange O +
had O +
taken O +
place O -
. O +

The O +
apparent O +
first O -
- O -
order O +
rate O +
constant O +
for O +
GSH B-Chemical +
decay O +
increased O +
progressively O +
for O +
L1210 O +
cells O +
expressing O +
a O +
range O +
of O +
GPX O +
activities O +
from O +
approximately O +
5 O -
% O +
to O +
100 O -
% O -
, O +
demonstrating O +
that O +
peroxide B-Chemical +
detoxification O +
is O +
strictly O +
dependent O +
on O +
enzyme O +
content O -
. O +

The O +
initial O +
rate O +
of O +
14CO2 B-Chemical +
release O +
from O +
D- B-Chemical -
[ I-Chemical -
1 I-Chemical -
- I-Chemical -
14C I-Chemical -
] I-Chemical -
glucose I-Chemical +
supplied O +
in O +
the O +
medium O +
was O +
much O +
greater O +
for O +
L.Se O -
( O -
+ O -
) O +
or O +
K.Se O -
( O -
+ O -
) O +
cells O +
than O +
for O +
their O +
respective O +
Se O -
( O -
- O -
) O +
counterparts O -
, O +
consistent O +
with O +
greater O +
hexose B-Chemical +
monophosphate I-Chemical +
shunt O +
activity O +
in O +
the O +
former O -
. O +

These O +
results O +
highlight O +
the O +
importance O +
of O +
selenoperoxidase O +
action O +
in O +
the O +
glutathione B-Chemical +
cycle O +
as O +
a O +
means O +
by O +
which O +
tumor O +
cells O +
cope O +
with O +
hydroperoxide B-Chemical +
stress O -
. O +

Differential O +
expression O +
and O +
mutation O +
of O +
NME O +
genes O +
in O +
autologous O +
cultured O +
human O +
melanoma O +
cells O +
with O +
different O +
metastatic O +
potentials O -
. O +

The O +
putative O +
metastasis O +
suppressor O +
genes O -
, O +
NME1 O -
( O -
nm23 O -
- O -
1 O -
) O +
and O +
NME2 O -
( O -
nm23 O -
- O -
2 O -
) O -
, O +
were O +
examined O +
in O +
a O +
model O +
system O +
we O +
developed O +
to O +
approximate O +
the O +
dissemination O +
of O +
melanoma O +
from O +
a O +
primary O +
skin O +
tumor O -
. O +

We O +
utilized O +
two O +
autologous O +
human O +
melanoma O +
cell O +
lines O -
, O +
IV O +
Cl O +
1 O +
and O +
IV O +
Cl O +
3 O -
, O +
which O +
displayed O +
qualitatively O +
different O +
metastatic O +
phenotypes O +
following O +
subdermal O +
inoculation O +
into O +
nude O +
mice O -
. O +

Highly O +
metastatic O +
IV O +
Cl O +
1 O +
cells O +
expressed O +
approximately O +
5 O +
fold O +
lower O +
levels O +
of O +
protein O +
encoded O +
by O +
NME O +
genes O +
than O +
non O -
- O -
metastatic O +
IV O +
Cl O +
3 O +
cells O -
. O +

Similar O +
differences O +
in O +
NME O +
protein O +
levels O +
were O +
observed O +
in O +
tumors O +
induced O +
by O +
the O +
two O +
cell O +
lines O +
in O +
nude O +
mice O -
. O +

There O +
were O +
no O +
differences O +
in O +
NME O +
mRNA O +
levels O +
between O +
these O +
two O +
cell O +
lines O -
, O +
suggesting O +
that O +
expression O +
of O +
these O +
proteins O +
is O +
regulated O +
at O +
a O +
post O -
- O -
transcriptional O +
level O -
. O +

We O +
found O +
a O +
ser122-pro O +
mutation O +
in O +
the O +
NME2 O +
gene O +
of O +
metastatic O +
IV O +
Cl O +
1 O +
cells O -
. O +

A O +
similar O +
ser120-gly O +
mutation O +
in O +
NME1 O +
has O +
been O +
found O +
in O +
human O +
neuroblastoma O -
, O +
suggesting O +
that O +
mutation O +
in O +
this O +
region O +
may O +
be O +
a O +
general O +
phenomenon O +
related O +
to O +
tumor O +
progression O -
. O +

These O +
mutations O +
may O +
have O +
functional O +
consequences O +
since O +
they O +
eliminate O +
potential O +
phosphorylation O +
sites O +
and O +
may O +
affect O +
the O +
tertiary O +
structure O +
of O +
mature O +
protein O +
complexes O -
. O +

Comparative O +
NMR O +
study O +
of O +
a O +
differentiated O +
rat O +
hepatoma O +
and O +
its O +
dedifferentiated O +
subclone O +
cultured O +
as O +
spheroids O +
and O +
as O +
implanted O +
tumors O -
. O +

H4IIEC3 O +
( O -
H4 O -
) O -
, O +
a O +
differentiated O +
rat O +
hepatoma O +
line O +
and O +
H5 O -
, O +
its O +
dedifferentiated O +
subclone O -
, O +
were O +
investigated O +
as O +
proliferating O +
spheroids O +
and O +
as O +
implanted O +
subcutaneous O +
tumors O +
in O +
juvenile O +
rats O -
. O +

H4 O +
cells O +
formed O +
tight O -
, O +
round O +
spheroids O +
whereas O +
H5 O +
cells O +
formed O +
loose O -
, O +
grape O -
- O -
like O +
structures O -
. O +

31P B-Chemical +
MR O +
spectra O +
showed O +
that O +
phosphocreatine B-Chemical +
was O +
present O +
in O +
H5 O +
spheroids O +
but O +
not O +
in O +
H4 O +
spheroids O +
or O +
tumors O -
. O +

[ B-Chemical -
13C I-Chemical -
] I-Chemical -
Lactate I-Chemical +
production O +
from O +
[ B-Chemical -
13C I-Chemical -
] I-Chemical -
glucose I-Chemical -
, O +
with O +
no O +
detectable O +
uptake O +
of O +
[ B-Chemical -
13C I-Chemical -
] I-Chemical -
alanine I-Chemical -
, O +
indicated O +
that O +
energy O +
production O +
in O +
H5 O +
spheroids O +
was O +
primarily O +
via O +
glycolysis O -
. O +

No O +
[ B-Chemical -
13C I-Chemical -
] I-Chemical -
glucose I-Chemical +
utilization O +
was O +
detected O +
in O +
H4 O +
spheroids O -
, O +
but O +
uptake O +
of O +
alanine O +
and O +
accumulation O +
of O +
labeled O +
lactate B-Chemical -
, O +
glutamate O +
and O +
glutamine O +
indicated O +
oxidation O +
via O +
the O +
tricarboxylic B-Chemical +
acid I-Chemical +
( O -
TCA B-Chemical -
) O +
cycle O -
. O +

Tumors O +
of O +
H4 O +
cells O +
were O +
well O +
perfused O -
, O +
unlike O +
tumors O +
of O +
H5 O +
cells O +
which O +
were O +
highly O +
necrotic O -
. O +

Following O +
i.v O -
. O +

infusion O +
with O +
[ B-Chemical -
13C I-Chemical -
] I-Chemical -
alanine I-Chemical -
, O +
[ B-Chemical -
13C I-Chemical -
] I-Chemical -
lactate I-Chemical +
and O +
glutamate O -
, O +
evidence O +
of O +
oxidation O +
via O +
the O +
TCA B-Chemical +
cycle O -
, O +
were O +
observed O +
in O +
H4 O +
tumors O -
. O +

Thus O +
the O +
results O +
obtained O +
by O +
31P B-Chemical +
and O +
13C B-Chemical +
MRS O +
correlated O +
with O +
the O +
differentiation O +
state O +
of O +
H4 O +
and O +
H5 O +
spheroids O +
and O +
tumors O -
. O +

Effects O +
of O +
doxycycline B-Chemical +
on O +
in O +
vitro O +
growth O -
, O +
migration O -
, O +
and O +
gelatinase O +
activity O +
of O +
breast O +
carcinoma O +
cells O -
. O +

Metastatic O +
disease O +
is O +
one O +
of O +
the O +
major O +
causes O +
of O +
death O +
from O +
cancer O +
in O +
human O +
beings O -
. O +

Several O +
enzyme O +
systems O +
have O +
been O +
implicated O +
in O +
the O +
metastatic O +
process O -
, O +
but O +
the O +
metalloproteinases O +
( O -
MPs O -
) O +
appear O +
to O +
be O +
the O +
major O +
group O +
involved O +
in O +
most O +
instances O +
of O +
neoplastic O +
invasion O -
. O +

Increased O +
MP O +
activity O +
has O +
been O +
correlated O +
with O +
the O +
metastatic O +
potential O +
of O +
many O +
cancers O -
, O +
including O +
breast O +
cancer O -
. O +

MPs O +
also O +
play O +
a O +
role O +
in O +
tumor O +
angiogenesis O -
. O +

Tetracyclines B-Chemical +
are O +
antimicrobial O +
agents O +
that O +
can O +
suppress O +
MP O +
activity O +
in O +
a O +
variety O +
of O +
tissues O -
, O +
including O +
gingiva O -
, O +
bone O -
, O +
and O +
cartilage O -
. O +

Several O +
reports O +
have O +
indicated O +
that O +
tetracyclines B-Chemical +
can O +
suppress O +
tumor O +
MPs O +
as O +
well O -
. O +

A O +
synthetic O +
tetracycline B-Chemical -
, O +
doxycycline B-Chemical -
, O +
inhibits O +
migration O +
of O +
human O +
MDA O -
- O -
MB-435 O +
breast O +
adenocarcinoma O +
cells O +
through O +
a O +
reconstituted O +
basement O +
membrane O +
( O -
Matrigel O -
) O -
, O +
an O +
assay O +
used O +
as O +
an O +
in O +
vitro O +
surrogate O +
for O +
the O +
in O +
vivo O +
process O +
of O +
tumor O +
invasion O +
through O +
basement O +
membranes O -
. O +

Additionally O -
, O +
doxycycline B-Chemical +
diminishes O +
the O +
proliferation O +
of O +
this O +
breast O +
cancer O +
cell O +
line O +
and O +
also O +
decreases O +
its O +
gelatinolytic O +
activity O -
, O +
as O +
determined O +
by O +
gel O +
zymography O -
. O +

Human O +
cytomegalovirus O +
elevates O +
levels O +
of O +
the O +
cellular O +
protein O +
p53 O +
in O +
infected O +
fibroblasts O -
. O +

Human O +
cytomegalovirus O +
( O -
HCMV O -
) O -
, O +
like O +
other O +
DNA O +
tumor O +
viruses O -
, O +
induces O +
morphological O +
transformation O +
of O +
cells O +
in O +
vitro O +
and O +
stimulates O +
host O +
cell O +
macromolecular O +
synthesis O +
in O +
infected O +
cells O -
. O +

Since O +
other O +
DNA O +
tumor O +
viruses O -
, O +
such O +
as O +
simian O +
virus O +
40 O +
and O +
adenovirus O -
, O +
have O +
previously O +
been O +
shown O +
to O +
interact O +
with O +
cellular O +
protein O +
p53 O -
, O +
we O +
investigated O +
whether O +
infection O +
of O +
cells O +
by O +
HCMV O +
would O +
modulate O +
cellular O +
p53 O +
levels O -
. O +

Our O +
results O +
indicate O +
that O +
HCMV O +
elevates O +
cellular O +
p53 O +
levels O +
on O +
the O +
order O +
of O +
10- O +
to O +
20-fold O +
in O +
infected O +
fibroblasts O -
. O +

The O +
induction O +
of O +
elevated O +
p53 O +
levels O +
was O +
dependent O +
upon O +
the O +
presence O +
of O +
active O +
virus O +
and O +
was O +
prevented O +
by O +
neutralizing O +
antibody O -
. O +

The O +
induction O +
of O +
elevated O +
p53 O +
levels O +
was O +
determined O +
not O +
to O +
be O +
due O +
to O +
virus O -
- O -
receptor O +
interactions O +
or O +
HCMV O +
late O +
events O -
. O +

The O +
induction O +
of O +
elevated O +
p53 O +
levels O +
commenced O +
at O +
immediate O -
- O -
early O +
times O +
of O +
the O +
HCMV O +
multiplication O +
cycle O +
( O -
6 O +
h O +
postinfection O -
) O +
and O +
reached O +
maximal O +
levels O +
by O +
24 O +
h O +
postinfection O -
, O +
before O +
most O +
of O +
the O +
HCMV O +
DNA O +
synthesis O +
was O +
initiated O -
. O +

HCMV O +
immediate O -
- O -
early O +
proteins O +
were O +
clearly O +
shown O +
to O +
be O +
responsible O +
for O +
elevating O +
p53 O +
levels O +
in O +
infected O +
fibroblasts O -
; O +
expression O +
of O +
HCMV O +
immediate O -
- O -
early O +
region O +
1 O +
and O +
2 O +
proteins O +
resulted O +
in O +
elevation O +
of O +
p53 O +
levels O +
in O +
transfected O +
human O +
fibroblasts O -
. O +

This O +
is O +
the O +
first O +
report O +
of O +
increased O +
p53 O +
levels O +
caused O +
by O +
HCMV O +
in O +
infected O +
fibroblasts O -
. O +

Cyclin O +
D1 O -
/ O -
bcl-1 O +
cooperates O +
with O +
myc O +
genes O +
in O +
the O +
generation O +
of O +
B O -
- O -
cell O +
lymphoma O +
in O +
transgenic O +
mice O -
. O +

The O +
chromosomal O +
translocation O +
t O -
( O -
11:14 O -
) O +
is O +
associated O +
with O +
human O +
lymphoid O +
neoplasia O +
affecting O +
centrocytic O +
B O -
- O -
cells O +
of O +
intermediate O +
differentiation O -
. O +

As O +
a O +
consequence O +
the O +
cyclin O +
D1 O +
( O -
bcl-1 O -
) O +
gene O +
is O +
juxtaposed O +
to O +
the O +
immunoglobulin O +
heavy O +
chain O +
enhancer O +
E O +
mu O -
. O +

To O +
show O +
that O +
transcriptional O +
activation O +
of O +
cyclin O +
D1 O +
is O +
causally O +
involved O +
in O +
the O +
generation O +
of O +
B O -
- O -
cell O +
neoplasia O +
we O +
have O +
generated O +
transgenic O +
mice O +
that O +
carry O +
a O +
cyclin O +
D1 O +
gene O +
under O +
the O +
transcriptional O +
control O +
of O +
the O +
E O +
mu O +
element O -
. O +

E O +
mu O +
cyclin O +
D1 O +
transgenic O +
mice O +
show O +
only O +
very O +
subtle O +
alterations O +
in O +
the O +
cycling O +
behaviour O +
of O +
B O -
- O -
cell O +
populations O +
in O +
the O +
bone O +
marrow O +
compared O +
with O +
normal O +
mice O +
and O +
do O +
not O +
develop O +
lymphoid O +
tumours O -
. O +

However O -
, O +
E O +
mu O -
- O -
directed O +
coexpression O +
of O +
cyclin O +
D1 O +
and O +
N O -
- O -
MYC O +
or O +
L O -
- O -
MYC O +
in O +
double O +
transgenic O +
mice O +
reveals O +
a O +
strong O +
cooperative O +
effect O +
between O +
MYC O +
and O +
cyclin O +
D1 O +
provoking O +
the O +
rapid O +
development O +
of O +
clonal O +
pre O -
- O -
B O +
and O +
B O -
- O -
cell O +
lymphomas O -
. O +

Interestingly O -
, O +
crossing O +
of O +
cyclin O +
D1 O +
transgenic O +
mice O +
with O +
E O +
mu O +
L O -
- O -
myc O +
transgenics O +
that O +
express O +
their O +
transgene O +
in O +
both O +
B- O +
and O +
T O -
- O -
cells O +
but O +
predominantly O +
develop O +
T O -
- O -
cell O +
tumours O +
leads O +
in O +
double O +
transgenics O +
exclusively O +
to O +
B O -
- O -
cell O +
neoplasia O -
. O +

The O +
data O +
presented O +
here O +
demonstrate O +
that O +
transcriptional O +
activation O +
of O +
cyclin O +
D1 O +
can O +
oncogenically O +
transform O +
B O -
- O -
cells O +
in O +
concert O +
with O +
a O +
myc O +
gene O -
. O +

They O +
establish O +
cyclin O +
D1 O +
as O +
a O +
proto O -
- O -
oncogene O +
whose O +
activity O +
appears O +
to O +
depend O +
on O +
a O +
specific O +
cell O +
type O +
as O +
well O +
as O +
on O +
a O +
specific O +
cooperating O +
partner O +
and O +
link O +
disturbances O +
in O +
the O +
regulation O +
of O +
cell O +
cycle O +
progression O +
to O +
the O +
development O +
of O +
human O +
malignancies O -
. O +

Identification O +
of O +
latency O -
- O -
associated O +
transcripts O +
that O +
map O +
antisense O +
to O +
the O +
ICP4 O +
homolog O +
gene O +
of O +
Marek O -
's O +
disease O +
virus O -
. O +

Two O +
small O +
RNAs O +
( O -
0.9 O +
and O +
0.75 O +
kb O -
) O -
, O +
named O +
Marek O -
's O +
disease O +
virus O +
( O -
MDV O -
) O +
small O +
RNAs O +
( O -
MSRs O -
) O +
and O +
a O +
10-kb O +
RNA O -
, O +
all O +
of O +
which O +
map O +
antisense O +
to O +
the O +
MDV O +
ICP4 O +
homolog O +
gene O -
, O +
have O +
been O +
readily O +
detected O +
in O +
MDCC O -
- O -
MSB1 O +
MDV O -
- O -
transformed O +
T O -
- O -
lymphoblastoid O +
cells O -
. O +

These O +
RNAs O +
were O +
not O +
detectable O +
in O +
reticuloendotheliosis O +
virus O -
- O -
transformed O +
T O +
cells O -
. O +

When O +
MDV O +
was O +
reactivated O +
by O +
treatment O +
of O +
lymphoblastoid O +
cells O +
with O +
25 O +
micrograms O +
of O +
iododeoxyuridine B-Chemical +
per O +
ml O -
, O +
the O +
relative O +
levels O +
of O +
the O +
transcripts O +
decreased O -
. O +

These O +
RNAs O +
were O +
not O +
detected O +
by O +
Northern O +
( O -
RNA O -
) O +
hybridization O +
in O +
productively O +
infected O +
chicken O +
embryo O +
fibroblasts O +
48 O +
h O +
postinfection O -
; O +
however O -
, O +
they O +
were O +
apparent O +
140 O +
h O +
postinfection O -
. O +

By O +
using O +
Northern O +
hybridization O -
, O +
RNase O +
protection O +
assays O -
, O +
and O +
primer O +
extension O +
analysis O -
, O +
the O +
MSRs O +
were O +
determined O +
to O +
map O +
antisense O +
to O +
the O +
predicted O +
translational O +
start O +
site O +
of O +
the O +
ICP4 O +
homolog O +
gene O -
. O +

The O +
conclusion O +
most O +
consistent O +
with O +
the O +
data O +
is O +
that O +
the O +
two O +
MSRs O +
are O +
overlapping O -
, O +
spliced O +
RNAs O -
. O +

Both O +
small O +
RNAs O +
contain O +
a O +
latency O +
promoter O +
binding O +
factor O +
consensus O +
recognition O +
sequence O +
located O +
toward O +
their O +
5 O -
' O +
ends O +
as O +
well O +
as O +
two O +
potential O +
ICP4 O +
recognition O +
consensus O +
sequences O -
, O +
one O +
in O +
each O +
orientation O -
. O +

The O +
region O +
contains O +
a O +
number O +
of O +
small O +
open O +
reading O +
frames O +
on O +
each O +
side O +
and O +
within O +
the O +
MSRs O -
. O +

Although O +
the O +
exact O +
endpoints O +
are O +
unknown O -
, O +
the O +
large O +
10-kb O +
species O +
spans O +
the O +
entire O +
ICP4 O +
homolog O +
region O -
. O +

We O +
believe O +
that O +
this O +
group O +
of O +
RNAs O -
, O +
which O +
map O +
antisense O +
to O +
the O +
ICP4 O +
homolog O +
gene O -
, O +
are O +
latency O -
- O -
associated O +
transcripts O +
of O +
MDV O -
. O +

Increased O +
expression O +
of O +
specific O +
protein O +
tyrosine O +
phosphatases O +
in O +
human O +
breast O +
epithelial O +
cells O +
neoplastically O +
transformed O +
by O +
the O +
neu O +
oncogene O -
. O +

Protein O +
tyrosine O +
phosphorylation O -
/ O -
dephosphorylation O +
is O +
a O +
fundamental O +
mechanism O +
in O +
the O +
regulation O +
of O +
cell O +
proliferation O +
and O +
neoplastic O +
transformation O -
; O +
this O +
metabolic O +
process O +
is O +
modulated O +
by O +
the O +
opposing O +
activities O +
of O +
protein O +
tyrosine O +
kinases O +
and O +
protein O +
tyrosine O +
phosphatases O +
( O -
PTPases O -
) O -
. O +

While O +
the O +
role O +
of O +
protein O +
tyrosine O +
kinases O +
has O +
been O +
examined O +
extensively O +
in O +
human O +
breast O +
tumorigenesis O -
, O +
the O +
role O +
of O +
PTPases O +
in O +
this O +
process O +
is O +
virtually O +
unknown O -
. O +

To O +
address O +
this O +
issue O -
, O +
an O +
activated O +
neu O +
oncogene O +
was O +
introduced O +
into O +
an O +
immortalized O +
nontumorigenic O +
human O +
breast O +
epithelial O +
cell O +
line O +
( O -
184B5 O -
) O -
. O +

This O +
resulted O +
in O +
a O +
substantial O +
increase O +
in O +
P185neu O +
expression O -
, O +
which O +
led O +
to O +
the O +
formation O +
of O +
progressively O +
growing O +
carcinomas O +
after O +
such O +
cells O +
were O +
inoculated O +
into O +
athymic O +
nude O +
mice O -
. O +

Importantly O -
, O +
a O +
striking O +
increase O +
in O +
the O +
expression O +
of O +
specific O +
PTPases O -
, O +
LAR O +
and O +
PTP1B O -
, O +
was O +
observed O +
in O +
3 O +
independently O +
neu O +
transformed O +
cell O +
lines O +
and O +
their O +
derived O +
tumors O -
. O +

This O +
elevation O +
was O +
verified O +
at O +
both O +
the O +
mRNA O +
and O +
protein O +
levels O -
. O +

TC O -
- O -
PTP O +
PTPase O +
expression O +
was O +
only O +
slightly O +
increased O +
in O +
these O +
neu O +
transformed O +
cells O -
, O +
and O +
no O +
expression O +
of O +
CD45 O +
PTPase O +
was O +
observed O -
. O +

The O +
level O +
of O +
neu O +
expression O -
, O +
as O +
well O +
as O +
the O +
differential O +
expression O +
between O +
P185neu O +
and O +
LAR O -
/ O -
PTP1B O -
, O +
directly O +
correlated O +
with O +
tumorigenicity O -
. O +

Furthermore O -
, O +
rat O +
mammary O +
carcinomas O +
with O +
elevated O +
neu O +
expression O +
( O -
neu O -
- O -
induced O -
) O +
also O +
had O +
sharply O +
elevated O +
LAR O -
- O -
PTPase O +
expression O +
when O +
compared O +
to O +
rat O +
mammary O +
carcinomas O +
with O +
little O +
or O +
no O +
neu O +
expression O +
( O -
7,12-dimethylbenzanthracene B-Chemical +
induced O -
) O -
; O +
the O +
level O +
of O +
expression O +
of O +
LAR O +
PTPase O +
was O +
directly O +
correlated O +
with O +
the O +
level O +
of O +
neu O +
expression O -
. O +

Thus O -
, O +
our O +
results O +
provide O +
the O +
first O +
evidence O +
that O -
, O +
in O +
human O +
breast O +
carcinoma O +
cells O +
and O +
in O +
rat O +
mammary O +
carcinomas O +
that O +
have O +
an O +
induced O +
increase O +
in O +
neu O +
expression O -
, O +
a O +
consistent O +
and O +
substantial O +
increase O +
in O +
the O +
expression O +
of O +
specific O +
PTPases O +
occurs O -
. O +

The O +
relationship O +
between O +
P185neu O -
- O -
protein O +
tyrosine O +
kinase O +
expression O +
and O +
specific O +
PTPase O +
expression O +
may O +
play O +
a O +
critical O +
role O +
in O +
human O +
breast O +
tumorigenesis O -
. O +

In O +
vivo O +
effects O +
of O +
insulin O +
on O +
tumor O +
and O +
skeletal O +
muscle O +
glucose B-Chemical +
metabolism O +
in O +
patients O +
with O +
lymphoma O -
. O +

BACKGROUND O -
: O +
The O +
anabolic O +
properties O +
of O +
insulin O +
have O +
been O +
suggested O +
for O +
use O +
to O +
reverse O +
malnutrition O +
associated O +
with O +
cancer O -
. O +

The O +
host O +
and O +
tumor O +
sensitivities O +
to O +
insulin O +
are O +
critical O +
for O +
such O +
treatments O -
, O +
which O +
aim O +
to O +
improve O +
patient O +
nutrition O -
. O +

The O +
authors O +
studied O +
insulin O +
effects O +
on O +
tumor O +
and O +
skeletal O +
muscle O +
metabolism O +
with O +
2- B-Chemical -
[ I-Chemical -
18F I-Chemical -
] I-Chemical -
-fluoro-2-deoxy I-Chemical -
- I-Chemical -
D I-Chemical -
- I-Chemical -
glucose I-Chemical +
( O -
[ B-Chemical -
18F I-Chemical -
] I-Chemical -
FDG I-Chemical -
) O +
and O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O -
. O +

METHODS O -
: O +
Six O +
patients O +
with O +
lymphoma O +
twice O +
underwent O +
[ B-Chemical -
18F I-Chemical -
] I-Chemical -
FDG I-Chemical -
- O -
PET O +
imaging O -
: O +
once O +
after O +
fasting O +
overnight O +
and O +
once O +
during O +
euglycemic O +
hyperinsulinemic O +
clamp O -
. O +

The O +
dynamic O +
uptake O +
of O +
the O +
glucose B-Chemical +
analogue O +
[ B-Chemical -
18F I-Chemical -
] I-Chemical -
FDG I-Chemical +
was O +
measured O +
in O +
diseased O +
nodes O +
and O +
upper O +
arm O +
skeletal O +
muscle O +
in O +
both O +
metabolic O +
states O -
. O +

The O +
[ B-Chemical -
18F I-Chemical -
] I-Chemical -
FDG I-Chemical +
uptake O +
in O +
muscle O +
and O +
the O +
whole O +
body O +
glucose B-Chemical +
use O +
during O +
euglycemic O +
hyperinsulinemic O +
clamp O +
were O +
compared O +
with O +
those O +
of O +
weight O -
- O -
matched O +
healthy O +
subjects O +
studied O +
under O +
similar O +
circumstances O -
. O +

RESULTS O -
: O +
In O +
lymphomatous O +
tissue O -
, O +
[ B-Chemical -
18F I-Chemical -
] I-Chemical -
FDG I-Chemical +
uptake O +
rates O +
were O +
similar O +
in O +
overnight O +
fasting O +
and O +
euglycemic O +
hyperinsulinemic O +
clamp O +
( O -
38 O +
+ O -
/- O +
10 O +
versus O +
41 O +
+ O -
/- O +

9 O +
mumol O -
/ O -
100 O +
g O -
/ O -
minute O -
, O +
not O +
significant O -
) O -
, O +
whereas O +
glucose B-Chemical +
uptake O +
in O +
skeletal O +
muscle O +
was O +
increased O +
by O +
insulin O +
( O -
1.7 O +
+ O -
/- O +

0.2 O +
versus O +
3.8 O +
+ O -
/- O +

0.5 O +
mumol O -
/ O -
100 O +
g O -
/ O -
minute O -
, O +
P O +
= O +
0.012 O -
) O -
. O +

Both O +
basal O +
( O -
2.3 O +
+ O -
/- O +

0.2 O +
mumol O -
/ O -
100 O +
g O -
/ O -
minute O -
, O +
P O +
= O +
0.061 O -
) O +
and O +
insulin O -
- O -
stimulated O +
( O -
8.5 O +
+ O -
/- O +

1.9 O +
mumol O -
/ O -
100 O +
g O -
/ O -
minute O -
, O +
P O +
= O +
0.055 O -
) O +
skeletal O +
arm O +
muscle O +
glucose B-Chemical +
uptake O +
rates O +
were O +
higher O +
in O +
control O +
subjects O +
than O +
in O +
patients O -
. O +

Whole O +
body O +
glucose B-Chemical +
use O +
was O +
55 O -
% O +
lower O +
in O +
patients O +
than O +
in O +
control O +
subjects O +
( O -
17 O +
+ O -
/- O +

3 O +
mumol O -
/ O -
kg O -
/ O -
minute O +
versus O +
38 O +
+ O -
/- O +

3 O +
mumol O -
/ O -
kg O -
/ O -
minute O -
, O +
P O +
= O +
0.002 O -
) O -
, O +
consistent O +
with O +
insulin O +
resistance O +
in O +
cancer O -
. O +

CONCLUSIONS O -
: O +
We O +
found O +
that O +
insulin O +
does O +
not O +
induce O +
major O +
changes O +
in O +
glucose B-Chemical +
uptake O +
of O +
lymphomatous O +
tissue O -
. O +

Although O +
insulin O +
sensitivity O +
of O +
skeletal O +
muscle O +
was O +
also O +
reduced O +
in O +
patients O +
with O +
lymphoma O -
, O +
the O +
net O +
insulin O +
effect O +
may O +
counteract O +
imbalance O +
between O +
glucose B-Chemical +
uptake O +
of O +
tumor O +
and O +
muscle O -
, O +
offering O +
a O +
potential O +
means O +
to O +
circumvent O +
at O +
least O +
some O +
metabolic O +
abnormalities O +
found O +
in O +
cancer O -
. O +

Effect O +
of O +
1-alkylpyrrolidine B-Chemical +
N I-Chemical -
- I-Chemical -
oxides I-Chemical +
on O +
energy O +
metabolism O +
of O +
cancer O +
cells O -
. O +

The O +
main O +
purpose O +
of O +
the O +
present O +
investigation O +
was O +
to O +
study O +
the O +
effect O +
of O +
a O +
homologous O +
series O +
of O +
1-alkylpyrrolidine B-Chemical +
N I-Chemical -
- I-Chemical -
oxides I-Chemical +
on O +
ATP B-Chemical -
- O -
producing O +
processes O +
in O +
Ehrlich O +
ascites O +
and O +
L1210 O +
murine O +
leukemia O +
cells O -
. O +

The O +
effect O +
on O +
aerobic O +
glucose B-Chemical +
consumption O -
, O +
lactic B-Chemical +
acid I-Chemical +
formation O -
, O +
content O +
of O +
total O +
( O -
T O -
- O -
SH O -
) O +
and O +
non O -
- O -
protein O +
thiol O +
groups O +
( O -
NP O -
- O -
SH O -
) O -
, O +
endogenous O +
respiration O +
and O +
the O +
level O +
of O +
ATP B-Chemical +
in O +
tumor O +
cells O +
incubated O +
in O +
vitro O +
was O +
investigated O -
. O +

1-Tetradecylpyrrolidine B-Chemical +
N I-Chemical -
- I-Chemical -
oxide I-Chemical +
( O -
TPNO B-Chemical -
) O -
, O +
one O +
of O +
the O +
most O +
active O +
compounds O -
, O +
immediately O +
after O +
addition O +
to O +
the O +
suspension O +
of O +
Ehrlich O +
cells O +
in O +
an O +
ice O +
bath O -
, O +
decreased O +
the O +
level O +
of O +
ATP B-Chemical +
to O +
the O +
same O +
extent O +
over O +
the O +
whole O +
concentration O +
range O -
. O +

After O +
2 O +
h O +
incubation O +
at O +
37 O +
degrees O +
C O +
the O +
drop O +
in O +
the O +
ATP B-Chemical +
level O +
was O +
lower O -
. O +

The O +
decrease O +
in O +
ATP B-Chemical +
level O +
might O +
be O +
explained O +
through O +
the O +
interaction O +
of O +
the O +
amine B-Chemical +
oxide I-Chemical +
with O +
the O +
cell O +
membrane O +
integrity O -
. O +

High O +
density O +
of O +
somatostatin O +
receptors O +
in O +
veins O +
surrounding O +
human O +
cancer O +
tissue O -
: O +
role O +
in O +
tumor O -
- O -
host O +
interaction O -
? O +

Somatostatin O +
receptors O +
were O +
detected O +
in O +
peritumoral O +
veins O +
of O +
various O +
human O +
cancer O +
tissue O +
specimens O -
. O +

Vascular O +
and O +
neoplastic O +
tissue O +
from O +
14 O +
colonic O +
adenocarcinomas O -
, O +
13 O +
carcinoids O -
, O +
6 O +
renal O -
- O -
cell O +
carcinomas O +
and O +
7 O +
malignant O +
lymphomas O +
were O +
analyzed O +
for O +
somatostatin O +
receptors O +
by O +
use O +
of O +
quantitative O +
receptor O +
autoradiography O -
. O +

In O +
colonic O +
carcinoma O +
specimens O -
, O +
the O +
peritumoral O +
vessels O +
expressed O +
a O +
high O +
density O +
of O +
somatostatin O +
receptors O -
, O +
whereas O +
the O +
neoplastic O +
tissue O +
itself O +
was O +
receptor O -
- O -
negative O +
in O +
many O +
cases O -
. O +

In O +
contrast O -
, O +
the O +
incidence O +
and O +
density O +
of O +
somatostatin O +
receptors O +
in O +
peritumoral O +
vessels O +
was O +
low O +
in O +
well O -
- O -
differentiated O +
gastrointestinal O +
and O +
bronchial O +
carcinoids O -
, O +
in O +
contrast O +
to O +
the O +
high O +
density O +
of O +
such O +
receptors O +
in O +
the O +
carcinoid O +
tumor O +
tissue O -
. O +

Autochthonous O +
vessels O +
surrounding O +
other O +
tumors O +
such O +
as O +
renal O -
- O -
cell O +
carcinomas O +
or O +
malignant O +
lymphomas O +
also O +
frequently O +
expressed O +
somatostatin O +
receptors O -
. O +

In O +
all O +
cases O -
, O +
the O +
somatostatin O +
receptors O +
were O +
localized O +
in O +
veins O -
, O +
particularly O +
in O +
the O +
smooth O -
- O -
muscle O +
cell O +
layer O -
. O +

They O +
exhibited O +
specific O +
and O +
high O -
- O -
affinity O +
binding O +
of O +
somatostatin-14 O -
, O +
somatostatin-28 O +
and O +
octreotide B-Chemical -
, O +
suggesting O +
a O +
preferential O +
expression O +
of O +
the O +
SSTR2 O +
receptor O +
subtype O -
. O +

Since O +
the O +
vessels O +
of O +
normal O +
non O -
- O -
neoplastic O +
human O +
tissues O -
, O +
e.g. O +
of O +
intestine O +
or O +
lymphatic O +
organs O -
, O +
have O +
few O +
somatostatin O +
receptors O -
, O +
the O +
increased O +
somatostatin O +
receptor O +
expression O +
in O +
peritumoral O +
vessels O +
observed O +
in O +
this O +
study O +
may O +
be O +
linked O +
to O +
the O +
neoplastic O +
process O +
itself O -
. O +

The O +
results O +
suggest O +
that O +
somatostatin O +
and O +
somatostatin O +
receptors O +
may O +
play O +
a O +
regulatory O +
role O +
for O +
hemodynamic O +
tumor O -
- O -
host O +
interactions O -
, O +
possibly O +
involving O +
tumor O +
stroma O +
generation O -
, O +
tumor O +
environment O -
, O +
angiogenesis O +
and O -
, O +
particularly O -
, O +
vascular O +
drainage O +
of O +
poorly O +
differentiated O +
neoplasms O -
. O +

[ O -
Treatment O +
of O +
the O +
diabetic O +
foot O +
by O +
hyperbaric B-Chemical +
oxygen I-Chemical -
] O +
Diabetic O +
foot O +
wounds O +
are O +
consequences O +
of O +
the O +
neuropathy O +
and O +
the O +
small O +
and O +
large O +
vessel O +
disease O +
that O +
complicate O +
diabetes O -
. O +

At O +
the O +
cellular O +
level O -
, O +
the O +
result O +
is O +
hypoxia O +
which O +
impairs O +
wound O +
healing O -
. O +

Hyperbaric O +
oxygenation O +
( O -
HBO O -
) O +
may O +
be O +
a O +
useful O +
adjuvant O +
to O +
wound O +
care O -
. O +

It O +
leads O +
to O +
enhanced O +
oxygenation O +
of O +
the O +
affected O +
tissues O -
, O +
has O +
an O +
antiseptic O +
effect O -
, O +
reduces O +
edema O -
, O +
and O +
accelerates O +
collagen O +
production O +
and O +
angiogenesis O -
, O +
thus O +
enhancing O +
tissue O +
repair O -
. O +

14 O +
diabetics O +
with O +
chronic O +
nonhealing O +
wounds O +
which O +
did O +
not O +
respond O +
to O +
treatment O +
for O +
at O +
least O +
3 O +
months O +
were O +
treated O +
by O +
HBO O -
. O +

All O +
had O +
palpable O +
pedal O +
pulses O -
. O +

Transcutaneous O +
measurements O +
of O +
tissue O +
pO2 O +
showed O +
elevation O +
from O +
20 O +
+ O -
/- O +

10 O +
mm O +
Hg O +
during O +
air O +
breathing O +
to O +
643 O +
+ O -
/- O +

242 O +
mm O +
Hg O +
while O +
breathing O +
pure O +
oxygen B-Chemical +
at O +
2.5 O +
ATA O -
. O +

They O +
were O +
treated O +
with O +
HBO O +
in O +
56 O +
+ O -
/- O +

10 O +
consecutive O +
HBO O +
sessions O -
. O +

In O +
11 O +
there O +
was O +
complete O +
wound O +
healing O -
, O +
while O +
in O +
1 O +
there O +
was O +
partial O +
response O -
, O +
in O +
1 O +
minimal O +
response O -
, O +
and O +
in O +
1 O +
a O +
transient O +
response O -
. O +

HBO O +
is O +
useful O +
in O +
chronic O +
nonhealing O +
wounds O +
of O +
the O +
diabetic O +
foot O +
and O +
of O +
the O +
diabetic O +
foot O +
with O +
impending O +
amputation O -
. O +

It O +
is O +
a O +
safe O +
mode O +
of O +
therapy O -
, O +
but O +
further O +
studies O +
are O +
required O +
to O +
establish O +
its O +
efficacy O +
and O +
to O +
ascertain O +
which O +
diabetic O +
patients O +
and O +
wounds O +
will O +
benefit O +
the O +
most O +
from O +
it O -
. O +

Vitamins B-Chemical +
regulate O +
gene O +
expression O +
and O +
induce O +
differentiation O +
and O +
growth O +
inhibition O +
in O +
cancer O +
cells O -
. O +

Their O +
relevance O +
in O +
cancer O +
prevention O -
. O +

Although O +
several O +
hypotheses O +
for O +
human O +
carcinogenesis O +
have O +
been O +
proposed O -
, O +
the O +
specific O +
genetic O +
changes O +
that O +
cause O +
normal O +
cells O +
to O +
become O +
cancer O +
cells O +
have O +
not O +
been O +
identified O -
. O +

In O +
spite O +
of O +
uncertainties O +
regarding O +
the O +
mechanisms O +
of O +
carcinogenesis O -
, O +
several O +
vitamins B-Chemical +
such O +
as O +
beta B-Chemical -
- I-Chemical -
carotene I-Chemical +
and O +
vitamins B-Chemical +
A I-Chemical -
, O +
C B-Chemical -
, O +
and O +
E B-Chemical -
, O +
which O +
can O +
reduce O +
the O +
risk O +
of O +
cancer O -
, O +
have O +
been O +
identified O -
, O +
using O +
animal O +
and O +
in O +
vitro O +
models O +
of O +
carcinogenesis O -
. O +

These O +
studies O +
have O +
led O +
to O +
a O +
hypothesis O +
that O +
the O +
supplemental O +
intake O +
of O +
these O +
vitamins B-Chemical +
may O +
reduce O +
the O +
risk O +
of O +
cancer O -
. O +

This O +
hypothesis O +
in O +
humans O +
can O +
be O +
tested O +
only O +
by O +
intervention O +
trials O +
that O +
are O +
in O +
progress O -
. O +

Prospective O +
and O +
retrospective O +
case O -
- O -
controlled O +
experimental O +
designs O +
are O +
not O +
suitable O +
for O +
testing O +
the O +
above O +
hypothesis O -
. O +

The O +
fact O +
that O +
some O +
vitamins B-Chemical +
induce O +
cell O +
differentiation O +
and/or O +
growth O +
inhibition O +
in O +
tumor O +
cells O +
in O +
culture O +
suggests O +
that O +
the O +
use O +
of O +
these O +
vitamins B-Chemical +
in O +
cancer O +
prevention O +
has O +
a O +
cellular O +
basis O -
. O +

In O +
addition O +
to O +
having O +
a O +
direct O +
effect O +
on O +
tumor O +
cells O -
, O +
vitamins B-Chemical +
such O +
as O +
alpha B-Chemical -
- I-Chemical -
tocopheryl I-Chemical +
succinate I-Chemical +
and O +
beta B-Chemical -
- I-Chemical -
carotene I-Chemical +
enhance O +
the O +
effect O +
of O +
other O +
agents O +
that O +
induce O +
differentiation O +
in O +
tumor O +
cells O -
. O +

Some O +
vitamins B-Chemical +
like O +
beta B-Chemical -
- I-Chemical -
carotene I-Chemical -
, O +
retinoic B-Chemical +
acid I-Chemical -
, O +
alpha B-Chemical -
- I-Chemical -
tocopheryl I-Chemical +
succinate I-Chemical -
, O +
and O +
vitamin B-Chemical +
D I-Chemical +
also O +
regulate O +
the O +
expressions O +
of O +
certain O +
oncogenes O +
and O +
cellular O +
genes O -
. O +

These O +
are O +
exciting O +
new O +
functions O +
of O +
vitamins B-Chemical +
that O +
nobody O +
could O +
have O +
predicted O +
only O +
a O +
few O +
years O +
ago O -
. O +

Increased O +
nm23-H1 O +
and O +
nm23-H2 O +
messenger O +
RNA O +
expression O +
and O +
absence O +
of O +
mutations O +
in O +
colon O +
carcinomas O +
of O +
low O +
and O +
high O +
metastatic O +
potential O -
. O +

BACKGROUND O -
: O +
The O +
murine O +
nm23 O +
gene O +
suppresses O +
the O +
metastatic O +
behavior O +
of O +
malignant O +
rodent O +
tumor O +
lines O -
, O +
and O +
reduced O +
nm23 O +
expression O +
correlates O +
with O +
increased O +
likelihood O +
of O +
lymph O +
node O +
metastases O +
in O +
human O +
breast O +
cancers O -
. O +

More O +
recent O +
data O +
have O +
demonstrated O +
the O +
existence O +
of O +
two O +
human O +
nm23 O +
gene O +
homologues O -
, O +
nm23-H1 O +
and O +
nm23-H2 O -
, O +
and O +
have O +
shown O +
that O +
deletion O +
of O +
nm23-H1 O +
alleles O +
occurs O +
in O +
some O +
colon O +
carcinomas O +
associated O +
with O +
poor O +
prognosis O -
. O +

These O +
findings O +
suggest O +
that O +
nm23-H1 O +
encodes O +
for O +
suppression O +
of O +
colon O +
carcinoma O +
metastasis O -
. O +

In O +
contrast O -
, O +
we O +
have O +
previously O +
reported O +
that O +
total O +
nm23 O +
messenger O +
RNA O +
( O -
mRNA O -
) O +
expression O +
is O +
increased O +
to O +
similar O +
levels O +
in O +
colon O +
tumors O +
of O +
both O +
high O +
and O +
low O +
metastatic O +
potential O -
. O +

PURPOSE O -
: O +
This O +
study O +
was O +
designed O +
to O +
reconcile O +
our O +
previous O +
findings O +
with O +
the O +
recent O +
report O +
of O +
nm23-H1 O +
allelic O +
deletion O +
in O +
human O +
colon O +
cancers O +
associated O +
with O +
poor O +
prognosis O -
. O +

Our O +
purpose O +
was O +
to O +
examine O +
human O +
colon O +
cancers O +
for O +
inactivation O +
of O +
two O +
candidate O +
metastasis O +
suppressor O +
genes O -
, O +
nm23-H1 O +
and O +
nm23-H2 O -
, O +
either O +
by O +
mutation O +
or O +
by O +
loss O +
of O +
gene O +
transcription O -
. O +

METHODS O -
: O +
We O +
used O +
ribonuclease O +
protection O +
assays O +
to O +
analyze O +
human O +
colon O +
tumors O +
for O +
the O +
level O +
of O +
nm23-H1 O +
( O -
43 O +
samples O -
) O +
and O +
nm23-H2 O +
( O -
41 O +
samples O -
) O +
transcript O +
( O -
mRNA O -
) O +
expression O +
and O +
the O +
presence O +
of O +
mutations O +
that O +
could O +
inactivate O +
potential O +
suppressor O +
function O -
. O +

RESULTS O -
: O +
We O +
detected O +
only O +
wild O -
- O -
type O +
nm23-H1 O +
and O +
nm23-H2 O +
mRNA O -
. O +

Expression O +
of O +
nm23-H1 O +
mRNA O +
increased O +
in O +
33 O +
of O +
41 O +
colon O +
tumors O -
, O +
and O +
expression O +
of O +
nm23-H2 O +
mRNA O +
was O +
elevated O +
in O +
28 O +
of O +
41 O +
colon O +
tumors O +
relative O +
to O +
that O +
in O +
matched O +
normal O +
mucosa O -
. O +

Increases O +
in O +
these O +
mRNA O +
levels O +
were O +
similar O +
in O +
tumors O +
of O +
both O +
low O +
and O +
high O +
metastatic O +
potential O -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
suggest O +
that O -
, O +
despite O +
correlation O +
of O +
nm23-H1 O +
allelic O +
deletions O +
with O +
colon O +
cancers O +
associated O +
with O +
poor O +
prognosis O -
, O +
nm23-H1 O +
and O +
nm23-H2 O +
alleles O +
do O +
not O +
directly O +
mediate O +
metastasis O +
suppression O +
in O +
colon O +
carcinoma O -
. O +

Our O +
results O +
leave O +
unexplained O +
the O +
observation O +
that O +
nm23-H1 O +
allelic O +
deletion O +
correlates O +
with O +
metastatic O +
potential O +
of O +
colon O +
carcinomas O -
. O +

IMPLICATIONS O -
: O +
These O +
findings O +
also O +
contrast O +
with O +
the O +
demonstration O +
of O +
nm23 O +
metastasis O +
suppressor O +
activity O +
in O +
murine O +
melanoma O +
and O +
with O +
the O +
correlation O +
of O +
loss O +
of O +
nm23 O +
expression O +
in O +
breast O +
cancer O +
with O +
poor O +
prognosis O -
. O +

It O +
may O +
be O +
that O +
metastasis O +
suppression O +
by O +
the O +
nm23 O +
gene O +
is O +
a O +
tissue O -
- O -
specific O +
phenomenon O -
. O +

E O +
mu O -
- O -
bcl-2 O +
transgene O +
facilitates O +
spontaneous O +
transformation O +
of O +
early O +
pre O -
- O -
B O +
and O +
immunoglobulin O -
- O -
secreting O +
cells O +
but O +
not O +
T O +
cells O -
. O +

To O +
assess O +
the O +
lymphoid O +
tumorigenic O +
potential O +
of O +
bcl-2 O -
, O +
mice O +
of O +
five O +
independent O +
strains O +
expressing O +
a O +
bcl-2 O +
transgene O +
in O +
B O +
and/or O +
T O +
cells O +
were O +
monitored O +
for O +
disease O +
up O +
to O +
12 O +
months O +
of O +
age O -
. O +

Lymphoma O +
prevalence O +
was O +
minimal O +
in O +
the O +
T O +
lineage O +
but O +
significant O -
, O +
although O +
low O +
( O -
3 O -
- O -
15 O -
% O -
) O -
, O +
in O +
the O +
B O +
lineage O -
. O +

The O +
principal O +
types O +
of O +
tumors O +
were O +
plasmacytomas O +
secreting O +
immunoglobulin O +
and O +
novel O +
lymphomas O +
that O +
expressed O +
markers O +
such O +
as O +
Sca-1 O -
, O +
CD4 O -
, O +
Thy-1 O -
, O +
CD34 O +
and O +
CD45 O -
( O -
B220 O -
) O -
, O +
consistent O +
with O +
an O +
origin O +
very O +
early O +
in O +
B O -
- O -
lymphoid O +
development O -
. O +

Rearrangement O +
of O +
the O +
c O -
- O -
myc O +
gene O +
was O +
common O +
in O +
the O +
plasmacytomas O -
, O +
implying O +
a O +
synergistic O +
role O +
for O +
myc O +
and O +
bcl-2 O +
in O +
their O +
etiology O -
, O +
but O +
was O +
not O +
detected O +
in O +
the O +
lymphomas O -
. O +

Tumorigenic O +
activity O +
of O +
rho O +
genes O +
from O +
Aplysia O +
californica O -
. O +

rho O +
genes O +
have O +
been O +
found O +
in O +
both O +
lower O +
and O +
higher O +
eucaryotes O -
. O +

They O +
code O +
for O +
proteins O +
of O +
21 O +
kDa O -
, O +
highly O +
conserved O +
in O +
evolution O -
, O +
which O +
belong O +
to O +
the O +
superfamily O +
of O +
ras O +
GTPases O -
. O +

Among O +
the O +
members O +
of O +
this O +
superfamily O +
there O +
are O +
proteins O +
with O +
a O +
regulatory O +
function O -
, O +
such O +
as O +
ras O -
, O +
and O +
proteins O +
involved O +
in O +
vesicular O +
trafficking O -
, O +
such O +
as O +
the O +
family O +
of O +
rab O +
proteins O -
. O +

We O +
have O +
investigated O +
the O +
putative O +
role O +
of O +
rho O +
proteins O +
from O +
Aplysia O +
californica O +
as O +
transforming O +
GTPases O +
utilizing O +
the O +
wild O -
- O -
type O +
and O +
a O +
Val-14 O +
mutant O -
, O +
equivalent O +
to O +
the O +
oncogenic O +
Val-12 O +
mutation O +
of O +
ras O +
genes O +
found O +
in O +
animal O +
and O +
human O +
tumors O -
. O +

Over O -
- O -
expression O +
of O +
either O +
rho O +
gene O +
was O +
sufficient O +
to O +
confer O +
anchorage- O +
and O +
serum O -
- O -
independent O +
growth O -
. O +

Moreover O -
, O +
when O +
introduced O +
into O +
nude O +
mice O -
, O +
selected O +
clones O +
generated O +
from O +
either O +
gene O +
were O +
able O +
to O +
induce O +
tumors O -
, O +
although O +
those O +
carrying O +
the O +
mutated O +
version O +
were O +
more O +
efficient O -
. O +

Pathological O +
analysis O +
indicated O +
that O +
generated O +
tumors O +
corresponded O +
to O +
well O -
- O -
differentiated O +
fibrosarcomas O +
with O +
distinct O +
and O +
intersecting O +
bundles O +
and O +
spindle O +
cells O -
. O +

By O +
contrast O -
, O +
ras O -
- O -
induced O +
tumors O +
were O +
poorly O +
differentiated O +
fibrosarcomas O -
. O +

Thus O -
, O +
our O +
results O +
indicate O +
that O +
under O +
appropriate O +
conditions O +
rho O +
genes O +
function O +
as O +
oncogenes O +
and O +
may O +
have O +
a O +
role O +
in O +
the O +
regulation O +
of O +
proliferation O +
in O +
fibroblast O +
cells O -
. O +

Immune O +
consequences O +
of O +
burn O +
injury O -
. O +

The O +
purpose O +
of O +
the O +
immune O +
system O +
is O +
to O +
protect O +
cells O +
from O +
invasion O +
by O +
microorganisms O -
. O +

The O +
body O +
has O +
three O +
equally O +
important O +
interactive O +
immune O +
defense O +
systems O -
, O +
all O +
of O +
which O +
are O +
profoundly O +
disrupted O +
with O +
major O +
burn O +
injury O -
. O +

The O +
immune O +
response O +
to O +
burn O +
injury O +
is O +
immediate O -
, O +
prolonged O -
, O +
and O +
severe O -
. O +

The O +
end O +
result O +
in O +
individuals O +
surviving O +
burn O +
shock O +
is O +
immunosuppression O -
, O +
with O +
increased O +
susceptibility O +
to O +
potentially O +
fatal O +
systemic O +
burn O +
wound O +
or O +
pulmonary O +
sepsis O -
. O +

Nursing O +
actions O +
to O +
support O +
the O +
humoral O +
and O +
cell O -
- O -
mediated O +
immune O +
system O +
of O +
the O +
burned O +
patient O +
include O +
providing O +
nutritional O +
support O +
to O +
maintain O +
serum O +
protein O +
levels O +
at O +
optimal O +
levels O -
; O +
measures O +
to O +
decrease O +
edema O +
and O +
promote O +
angiogenesis O +
in O +
areas O +
of O +
partial O -
- O -
thickness O +
injury O -
; O +
meticulous O +
treatment O +
of O +
the O +
wound O +
to O +
prevent O +
infection O +
and O +
promote O +
healing O -
; O +
monitoring O +
of O +
antibiotic O +
use O -
; O +
conservative O +
use O +
of O +
invasive O +
techniques O -
, O +
including O +
intubation O +
and O +
vascular O +
access O +
devices O -
; O +
maintenance O +
of O +
fluid O +
and O +
electrolyte O +
balance O +
and O +
body O +
temperature O -
; O +
and O +
energy O +
conservation O +
measures O -
. O +

Application O +
of O +
clonal O +
analysis O -
. O +

Differential O +
diagnosis O +
for O +
synchronous O +
primary O +
ovarian O +
and O +
endometrial O +
cancers O +
and O +
metastatic O +
cancer O -
. O +

Simultaneous O +
involvement O +
of O +
the O +
endometrium O +
and O +
the O +
ovary O +
by O +
carcinoma O +
is O +
a O +
familiar O +
problem O +
in O +
the O +
routine O +
practice O +
of O +
surgical O +
pathology O -
. O +

Such O +
cases O +
may O +
be O +
considered O +
either O +
examples O +
of O +
a O +
single O +
primary O +
carcinoma O +
with O +
metastasis O +
or O +
as O +
synchronous O +
primary O +
neoplasms O -
. O +

The O +
distinction O +
between O +
these O +
two O +
possibilities O +
is O +
made O +
based O +
on O +
clinicopathologic O +
observations O -
, O +
and O +
therefore O +
may O +
not O +
be O +
definitive O -
. O +

In O +
the O +
present O +
study O -
, O +
the O +
authors O +
used O +
molecular O +
techniques O +
to O +
analyze O +
the O +
clonal O +
composition O +
of O +
five O +
cases O +
of O +
concurrent O +
adenocarcinomas O +
of O +
the O +
endometrium O +
and O +
ovary O +
that O +
were O +
clinicopathologically O +
diagnosed O +
as O +
synchronous O +
primary O +
tumors O -
. O +

Patterns O +
of O +
X O -
- O -
chromosome O +
inactivation O -
, O +
mutations O +
in O +
the O +
K O -
- O -
ras O +
gene O -
, O +
mutations O +
or O +
allelic O +
loss O +
of O +
the O +
p53 O +
gene O -
, O +
or O +
human O +
papillomavirus O +
detection O +
were O +
identical O +
in O +
both O +
endometrial O +
and O +
ovarian O +
lesions O +
in O +
three O +
of O +
the O +
cases O +
suggesting O +
that O +
those O +
three O +
cases O +
represented O +
single O +
primary O +
tumors O +
with O +
metastases O -
. O +

In O +
both O +
of O +
the O +
other O +
two O +
cases O -
, O +
the O +
patterns O +
of O +
X O -
- O -
chromosome O +
inactivation O +
clearly O +
demonstrated O +
the O +
presence O +
of O +
independent O +
primary O +
tumors O -
. O +

The O +
application O +
of O +
molecular O +
technology O +
may O +
play O +
an O +
important O +
role O +
for O +
the O +
differential O +
diagnosis O +
between O +
synchronous O +
primary O +
carcinomas O +
and O +
a O +
single O +
carcinoma O +
with O +
metastasis O -
. O +

Pancreatic O +
somatostatin O -
- O -
secreting O +
gangliocytic O +
paraganglioma O +
with O +
lymph O +
node O +
metastases O -
. O +

Gangliocytic O +
paraganglioma O +
( O -
GPG O -
) O +
with O +
local O +
lymph O +
node O +
metastasis O +
was O +
found O +
in O +
the O +
pancreas O +
of O +
a O +
74-yr O -
- O -
old O +
female O +
who O +
presented O +
with O +
diarrhea O -
, O +
steatorrhea O -
, O +
vomiting O -
, O +
nausea O -
, O +
and O +
abdominal O +
pain O -
. O +

A O +
Whipple O +
procedure O +
led O +
to O +
a O +
complete O +
resolution O +
of O +
these O +
symptoms O +
and O +
a O +
return O +
of O +
an O +
elevated O +
stomatostatin O +
level O +
to O +
normal O -
. O +

This O +
is O +
the O +
first O +
description O +
of O +
GPG O +
in O +
this O +
location O +
and O +
the O +
first O +
endocrinologically O +
active O +
GPG O -
. O +

The O +
effects O +
of O +
radiation O +
on O +
neovascularization O +
in O +
a O +
rat O +
model O -
. O +

It O +
is O +
thought O +
that O +
radiation O +
treatment O +
inhibits O +
neovascularization O +
of O +
recipient O +
and/or O +
graft O +
tissues O -
, O +
and O +
this O +
may O +
account O +
in O +
part O +
for O +
abnormalities O +
in O +
wound O +
healing O +
associated O +
with O +
radiation O +
therapy O -
. O +

We O +
have O +
examined O +
this O +
hypothesis O +
using O +
a O +
model O +
that O +
measures O +
the O +
neovascularization O +
of O +
an O +
implanted O +
foreign O +
material O -
. O +

Expanded O +
polytetrafluoroethylene B-Chemical +
( O -
PTFE B-Chemical -
) O +
sheets O +
were O +
implanted O +
adjacent O +
to O +
both O +
superficial O +
epigastric O +
vascular O +
pedicles O +
of O +
63 O +
rats O +
distributed O +
into O +
7 O +
groups O +
( O -
n O +
= O +
7 O -
) O +
that O +
differed O +
with O +
respect O +
to O +
dose O +
and O +
timing O +
of O +
irradiation O -
. O +

Zero O +
to O +
10 O +
daily O +
fractions O +
of O +
electron O -
- O -
beam O +
radiation O +
( O -
300 O +
cGy O +
each O -
) O +
were O +
delivered O +
to O +
the O +
implant O +
in O +
the O +
right O +
groin O -
, O +
while O +
the O +
implant O +
in O +
the O +
left O +
groin O +
served O +
as O +
a O +
nonirradiated O +
internal O +
control O -
. O +

Unirradiated O +
animals O +
showed O +
equal O +
neovascularization O +
of O +
both O +
implants O -
. O +

Rats O +
that O +
were O +
irradiated O +
twice O +
( O -
single O +
fractions O +
at O +
0 O +
and O +
24 O +
hours O +
after O +
implantation O -
) O +
did O +
not O +
show O +
a O +
significant O +
decrease O +
in O +
the O +
neovascularization O +
of O +
the O +
irradiated O +
implant O +
compared O +
with O +
the O +
contralateral O +
control O +
implant O -
. O +

In O +
contrast O -
, O +
the O +
implants O +
that O +
were O +
irradiated O +
three O +
times O +
( O -
single O +
fractions O +
at O +
0 O -
, O +
24 O -
, O +
and O +
48 O +
hours O +
after O +
implantation O -
) O +
demonstrated O +
significantly O +
diminished O +
( O +
greater O +
than O +
25 O +
percent O -
, O +
p O +
less O +
than O +
0.05 O -
) O +
neovascularization O +
beyond O +
day O +
7 O -
, O +
whereas O +
implants O +
irradiated O +
only O +
at O +
48 O +
hours O +
after O +
implantation O +
did O +
not O -
. O +

Interestingly O -
, O +
neovascularization O +
of O +
the O +
implants O +
irradiated O +
with O +
10 O +
fractions O +
( O -
3000 O +
cGy O -
) O +
was O +
not O +
significantly O +
decreased O +
compared O +
with O +
irradiation O +
with O +
three O +
fractions O +
( O -
900 O +
cGy O -
) O -
. O +

Irradiation O +
delivered O +
before O +
implantation O +
( O -
900 O +
cGy O -
) O +
inhibited O +
neovascularization O +
significantly O +
less O +
than O +
the O +
same O +
dose O +
administered O +
after O +
implantation O -
. O +

The O +
results O +
of O +
this O +
study O +
suggest O +
that O +
a O +
subclinical O +
cumulative O +
dose O +
of O +
900 O +
cGy O +
is O +
the O +
threshold O +
for O +
impaired O +
tissue O +
revascularization O +
provided O +
that O +
treatment O +
is O +
delivered O +
immediately O +
after O +
implantation O +
over O +
a O +
48-hour O +
interval O -
. O +

Vitamin B-Chemical +
E I-Chemical +
inhibits O +
experimental O +
carcinogenesis O +
and O +
tumour O +
angiogenesis O -
. O +

In O +
an O +
experiment O +
in O +
which O +
vitamin B-Chemical +
E I-Chemical +
inhibited O +
carcinogenesis O -
, O +
it O +
was O +
found O +
that O +
tumour O +
angiogenesis O +
and O +
tumour O +
growth O -
- O -
factor O +
alpha O +
( O -
TGF O +
alpha O -
) O +
expression O +
were O +
also O +
inhibited O -
. O +

Forty O +
male O +
golden O +
hamsters O +
were O +
divided O +
into O +
four O +
equal O +
groups O -
. O +

Group O +
1 O +
animals O +
had O +
the O +
left O +
buccal O +
pouches O +
painted O +
three O +
times O +
weekly O +
with O +
7,12-dimethylbenz B-Chemical -
( I-Chemical -
a I-Chemical -
) I-Chemical -
anthracene I-Chemical +
( O -
DMBA B-Chemical -
) O +
for O +
14 O +
weeks O -
. O +

Group O +
2 O +
animals O +
had O +
the O +
same O +
procedure O +
of O +
DMBA B-Chemical +
applications O +
but O +
also O +
received O +
alpha B-Chemical +
tocopherol I-Chemical -
. O +

Groups O +
3 O +
and O +
4 O +
were O +
vitamin B-Chemical +
E I-Chemical +
and O +
untreated O +
controls O -
. O +

Angiogenesis O +
was O +
studied O +
with O +
factor O +
8-related O +
antigen O +
( O -
F8-RA O -
) O +
which O +
identifies O +
endothelial O +
cells O -
. O +

TGF O +
alpha O +
was O +
studied O +
with O +
the O +
appropriate O +
antibody O -
. O +

Staining O +
was O +
effected O +
by O +
the O +
standard O +
avidin O -
- O -
biotin B-Chemical +
horseradish O +
peroxidase O +
system O -
. O +

Mean O +
tumour O +
volume O +
was O +
significantly O +
lower O +
in O +
the O +
DMBA B-Chemical -
- O -
vitamin B-Chemical +
E I-Chemical +
group O +
compared O +
to O +
the O +
tumour O +
control O +
group O -
. O +

Angiogenesis O +
was O +
significantly O +
inhibited O +
in O +
the O +
DMBA B-Chemical -
- O -
vitamin B-Chemical +
E I-Chemical +
group O +
and O +
TGF O +
alpha O +
expression O +
was O +
also O +
inhibited O -
. O +

It O +
is O +
suggested O +
that O +
inhibition O +
of O +
tumour O +
angiogenesis O +
by O +
vitamin B-Chemical +
E I-Chemical +
may O +
be O +
an O +
additional O +
mechanism O +
for O +
the O +
anticancer O +
action O +
of O +
vitamin B-Chemical +
E. I-Chemical +

c O -
- O -
erb O +
B2 O +
overexpression O +
decreases O +
the O +
benefit O +
of O +
adjuvant O +
tamoxifen B-Chemical +
in O +
early O -
- O -
stage O +
breast O +
cancer O +
without O +
axillary O +
lymph O +
node O +
metastases O -
. O +

PURPOSE O -
: O +
We O +
studied O +
retrospectively O +
the O +
interaction O +
between O +
c O -
- O -
erbB2 O +
overexpression O +
and O +
adjuvant O +
tomoxifen B-Chemical +
in O +
node O -
- O -
negative O +
breast O +
cancer O +
patients O +
enrolled O +
in O +
the O +
Gruppo O +
Universitario O +
Napoletano O +
1 O +
( O -
GUN-1 O -
) O +
trial O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
c O -
- O -
erbB2 O -
, O +
evaluated O +
by O +
immunohistochemistry O +
in O +
145 O +
of O +
173 O +
patients O +
randomly O +
assigned O +
to O +
2-year O +
adjuvant O +
tamoxifen B-Chemical +
or O +
no O +
further O +
therapy O -
, O +
was O +
considered O +
overexpressed O +
if O +
greater O +
than O +
10 O -
% O +
of O +
the O +
cells O +
showed O +
specific O +
membrane O +
staining O -
. O +

The O +
role O +
of O +
each O +
prognostic O +
variable O +
and O +
their O +
independent O +
effect O +
were O +
studied O +
using O +
the O +
Cox O +
model O -
. O +

Disease O -
- O -
free O +
( O -
DFS O -
) O +
and O +
overall O +
( O -
OAS O -
) O +
survival O +
curves O +
were O +
estimated O +
by O +
the O +
Kaplan O -
- O -
Meier O +
method O -
. O +

RESULTS O -
: O +
As O +
of O +
November O +
30 O -
, O +
1994 O -
, O +
the O +
median O +
follow O -
- O -
up O +
period O +
was O +
12 O +
years O -
. O +

c O -
- O -
erbB2 O +
was O +
overexpressed O +
in O +
43 O +
of O +
145 O +
patients O +
( O -
29.7 O -
% O -
) O -
, O +
which O +
directly O +
correlated O +
with O +
tumor O +
size O +
and O +
inversely O +
with O +
estrogen O +
receptor O +
( O -
ER O -
) O +
level O -
. O +

At O +
univariate O +
analysis O -
, O +
overexpression O +
of O +
c O -
- O -
erbB2 O +
did O +
not O +
affect O +
either O +
DFS O +
or O +
OAS O -
; O +
tamoxifen B-Chemical +
had O +
a O +
greater O +
effect O +
on O +
reducing O +
the O +
risk O +
of O +
recurrence O +
than O +
of O +
death O -
. O +

Addition O +
of O +
c O -
- O -
erbB2 O +
to O +
a O +
multivariate O +
Cox O +
model O +
that O +
contained O +
menopausal O +
status O -
, O +
tumor O +
size O -
, O +
nuclear O +
grade O -
, O +
and O +
treatment O +
as O +
covariates O +
did O +
not O +
affect O +
the O +
significance O +
of O +
the O +
model O +
for O +
DSF O +
or O +
OAS O -
, O +
whereas O +
addition O +
of O +
the O +
first O -
- O -
order O +
interaction O +
between O +
c O -
- O -
erbB2 O +
and O +
tamoxifen B-Chemical +
was O +
statistically O +
significant O +
both O +
for O +
DFS O +
and O +
OAS O -
. O +

The O +
same O +
result O +
was O +
obtained O +
when O +
the O +
model O +
contained O +
ER O +
status O +
and O +
ER O -
- O -
tamoxifen B-Chemical +
interaction O -
. O +

Indeed O -
, O +
adjuvant O +
tamoxifen B-Chemical +
significantly O +
prolonged O +
DFS O +
and O +
OAS O +
in O +
c O -
- O -
erbB2-negative O +
cases O -
, O +
whereas O +
it O +
had O +
no O +
effect O +
on O +
DFS O +
and O +
OAS O +
in O +
c O -
- O -
erbB2-positive O +
patients O -
. O +

CONCLUSION O -
: O +
In O +
early O -
- O -
stage O +
breast O +
cancer O +
patients O -
, O +
overexpression O +
of O +
c O -
- O -
erbB2 O +
is O +
a O +
marker O +
of O +
lack O +
of O +
efficacy O +
of O +
adjuvant O +
tamoxifen B-Chemical -
. O +

Fas O -
- O -
signaling O +
and O +
effects O +
on O +
receptor O +
tyrosine O +
kinase O +
signal O +
transduction O +
in O +
human O +
breast O +
epithelial O +
cells O -
. O +

Fas O -
- O -
mediated O +
cell O +
death O +
was O +
examined O +
in O +
MCF-10AT O +
preneoplastic O +
human O +
breast O +
epithelial O +
cells O -
. O +

Treatment O +
with O +
anti O -
- O -
Fas O +
for O +
48 O +
h O +
induced O +
apoptosis O +
with O +
cells O +
exhibiting O +
typical O +
apoptotic O +
features O +
including O +
loss O +
of O +
cell O +
contact O -
, O +
condensation O +
of O +
chromatin O -
, O +
and O +
increased O +
staining O +
of O +
the O +
nuclear O +
membrane O -
. O +

DNA O +
fragmentation O +
occurred O +
in O +
response O +
to O +
anti O -
- O -
Fas O +
treatment O -
. O +

Anti O -
- O -
Fas O +
treatment O +
resulted O +
in O +
decreased O +
p53 O +
protein O +
levels O -
, O +
while O +
bcl-2 O +
and O +
bax O +
protein O +
levels O +
remained O +
unaffected O -
. O +

Cells O +
treated O +
with O +
anti O -
- O -
Fas O +
also O +
exhibited O +
increased O +
tyrosine O +
phosphorylation O +
of O +
the O +
c O -
- O -
met O +
growth O +
factor O +
receptor O +
tyrosine O +
kinase O -
. O +

Immunoprecipitation O +
experiments O +
demonstrated O +
that O +
Fas O +
associated O +
with O +
c O -
- O -
erbB2 O +
and O +
c O -
- O -
met O +
in O +
untreated O +
cells O -
. O +

Treatment O +
with O +
anti O -
- O -
Fas O -
, O +
however O -
, O +
significantly O +
decreased O +
Fas O -
- O -
c O -
- O -
erbB2 O +
and O +
Fas O -
- O -
c O -
- O -
met O +
association O -
. O +

Anti O -
- O -
Fas O +
treatment O +
of O +
these O +
cells O +
caused O +
a O +
significant O +
decrease O +
in O +
p120-GAP O +
levels O -
, O +
ERK-1 O +
levels O -
, O +
and O +
phosphorylation O -
, O +
as O +
well O +
as O +
Grb2-Sosl O +
and O +
MEK-1-ERK-1 O +
association O -
. O +

These O +
results O +
show O +
that O +
Fas O -
- O -
signaling O +
exerted O +
a O +
suppressive O +
effect O +
on O +
p53 O +
levels O +
and O +
on O +
downstream O +
effectors O +
of O +
receptor O +
tyrosine O +
kinase O +
signal O +
transduction O -
, O +
thereby O +
ensuring O +
cell O +
death O -
. O +

[ O -
Effects O +
of O +
carcinostatic O +
agents O +
in O +
the O +
hematogenous O +
metastasis O +
of O +
cancer O -
] O -
. O +

The O +
experimental O +
studies O +
in O +
vitro O +
and O +
in O +
vivo O +
were O +
performed O +
to O +
investigate O +
the O +
effects O +
of O +
carcinostatic O +
agents O +
in O +
the O +
adhesion O +
of O +
cancer O +
cells O +
to O +
endothelial O +
cells O -
. O +

Certain O +
carcinostatic O +
agents O +
induce O +
the O +
expression O +
of O +
E O -
- O -
selectin O +
on O +
endothelial O +
cells O +
and O +
enhance O +
the O +
expression O +
of O +
carbohydrate B-Chemical +
ligands O +
on O +
cancer O +
cells O -
. O +

Consequently O -
, O +
increased O +
adhesion O +
of O +
cancer O +
cells O +
to O +
endothelial O +
cells O +
was O +
observed O +
by O +
the O +
treatment O +
of O +
carcinostatic O +
agents O -
. O +

In O +
the O +
trans O -
- O -
splenic O +
hepatic O +
metastasis O +
model O +
using O +
nude O +
mice O -
, O +
the O +
augmentation O +
of O +
cancer O +
metastasis O +
was O +
observed O +
by O +
the O +
treatment O +
of O +
carcinostatic O +
agents O -
. O +

From O +
the O +
above O -
, O +
we O +
concluded O +
that O +
carcinostatic O +
agents O +
may O +
increase O +
the O +
metastatic O +
ability O +
of O +
cancer O +
cells O +
in O +
patients O +
with O +
cancer O -
. O +

Regulation O +
of O +
p53-dependent O +
apoptosis O -
, O +
transcriptional O +
repression O -
, O +
and O +
cell O +
transformation O +
by O +
phosphorylation O +
of O +
the O +
55-kilodalton O +
E1B O +
protein O +
of O +
human O +
adenovirus O +
type O +
5 O -
. O +

The O +
adenovirus O +
type O +
5 O +
55-kDa O +
E1B O +
protein O +
( O -
E1B-55kDa O -
) O +
cooperates O +
with O +
E1A O +
gene O +
products O +
to O +
induce O +
cell O +
transformation O -
. O +

E1A O +
proteins O +
stimulate O +
DNA O +
synthesis O +
and O +
cell O +
proliferation O -
; O +
however O -
, O +
they O +
also O +
cause O +
rapid O +
cell O +
death O +
by O +
p53-dependent O +
and O +
p53-independent O +
apoptosis O -
. O +

It O +
is O +
believed O +
that O +
the O +
role O +
of O +
the O +
E1B-55kDa O +
protein O +
in O +
transformation O +
is O +
to O +
protect O +
against O +
p53-dependent O +
apoptosis O +
by O +
binding O +
to O +
and O +
inactivating O +
p53 O -
. O +

It O +
has O +
been O +
shown O +
previously O +
that O +
the O +
55-kDa O +
polypeptide O +
abrogates O +
p53-mediated O +
transactivation O +
and O +
that O +
mutants O +
defective O +
in O +
p53 O +
binding O +
are O +
unable O +
to O +
cooperate O +
with O +
E1A O +
in O +
transformation O -
. O +

We O +
have O +
previously O +
mapped O +
phosphorylation O +
sites O +
near O +
the O +
carboxy O +
terminus O +
of O +
the O +
E1B-55kDa O +
protein O +
at O +
Ser-490 O +
and O +
Ser-491 O -
, O +
which O +
lie O +
within O +
casein O +
kinase O +
II O +
consensus O +
sequences O -
. O +

Conversion O +
of O +
these O +
sites O +
to O +
alanine O +
residues O +
greatly O +
reduced O +
transforming O +
activity O -
, O +
and O +
although O +
the O +
mutant O +
55-kDa O +
protein O +
was O +
found O +
to O +
interact O +
with O +
p53 O +
at O +
normal O +
levels O -
, O +
it O +
was O +
somewhat O +
defective O +
for O +
suppression O +
of O +
p53 O +
transactivation O +
activity O -
. O +

We O +
now O +
report O +
that O +
a O +
nearby O +
residue O -
, O +
Thr-495 O -
, O +
also O +
appears O +
to O +
be O +
phosphorylated O -
. O +

We O +
demonstrate O +
directly O +
that O +
the O +
wild O -
- O -
type O +
55-kDa O +
protein O +
is O +
able O +
to O +
block O +
E1A O -
- O -
induced O +
p53-dependent O +
apoptosis O -
, O +
whereas O +
cells O +
infected O +
by O +
mutant O +
pm490 O -
/ O -
1 O -
/ O -
5A O -
, O +
which O +
contains O +
alanine O +
residues O +
at O +
all O +
three O +
phosphorylation O +
sites O -
, O +
exhibited O +
extensive O +
DNA O +
fragmentation O +
and O +
classic O +
apoptotic O +
cell O +
death O -
. O +

The O +
E1B-55kDa O +
product O +
has O +
been O +
shown O +
to O +
exhibit O +
intrinsic O +
transcriptional O +
repression O +
activity O +
when O +
localized O +
to O +
promoters O -
, O +
such O +
as O +
by O +
fusion O +
with O +
the O +
GAL4 O +
DNA O -
- O -
binding O +
domain O -
, O +
even O +
in O +
the O +
absence O +
of O +
p53 O -
. O +

Such O +
repression O +
activity O +
was O +
totally O +
absent O +
with O +
mutant O +
pm490 O -
/ O -
1 O -
/ O -
5A O -
. O +

These O +
data O +
suggested O +
that O +
inhibition O +
of O +
p53-dependent O +
apoptosis O +
may O +
depend O +
on O +
the O +
transcriptional O +
repression O +
function O +
of O +
the O +
55-kDa O +
protein O -
, O +
which O +
appears O +
to O +
be O +
regulated O +
be O +
phosphorylation O +
at O +
the O +
carboxy O +
terminus O -
. O +

Non O -
- O -
invasive O +
grading O +
of O +
primary O +
brain O +
tumours O -
: O +
results O +
of O +
a O +
comparative O +
study O +
between O +
SPET O +
with O +
123I B-Chemical -
- I-Chemical -
alpha I-Chemical -
- I-Chemical -
methyl I-Chemical +
tyrosine I-Chemical +
and O +
PET O +
with O +
18F B-Chemical -
- I-Chemical -
deoxyglucose I-Chemical -
. O +

Use O +
of O +
iodine-123-alpha B-Chemical -
- I-Chemical -
methyl I-Chemical +
tyrosine I-Chemical +
( O -
123I B-Chemical -
- I-Chemical -
IMT I-Chemical -
) O +
allows O +
investigation O +
of O +
the O +
amino O +
acid O +
transport O +
rate O +
in O +
gliomas O -
. O +

It O +
was O +
the O +
aim O +
of O +
this O +
study O +
to O +
compare O +
the O +
value O +
of O +
measurement O +
of O +
glucose B-Chemical +
metabolism O +
with O +
that O +
of O +
measurement O +
of O +
123I B-Chemical -
- I-Chemical -
IMT I-Chemical +
uptake O +
for O +
the O +
non O -
- O -
invasive O +
grading O +
of O +
brain O +
tumours O -
. O +

The O +
study O +
population O +
comprised O +
23 O +
patients O +
with O +
histopathologically O +
proven O +
primary O +
brain O +
tumours O -
; O +
14 O +
had O +
high O -
- O -
grade O +
gliomas O -
, O +
and O +
nine O +
low O -
- O -
grade O +
brain O +
neoplasms O -
. O +

Glucose B-Chemical +
metabolism O +
was O +
studied O +
using O +
an O +
ECAT O +
EXACT O +
47 O +
positron O +
emission O +
tomography O +
( O -
PET O -
) O +
camera O +
and O +
fluorine-18 B-Chemical +
fluorodeoxyglucose I-Chemical +
( O -
18F B-Chemical -
- I-Chemical -
FDG I-Chemical -
) O -
; O +
123I B-Chemical -
- I-Chemical -
IMT I-Chemical +
uptake O +
was O +
measured O +
with O +
the O +
triple O -
- O -
headed O +
single O -
- O -
photon O +
emission O +
tomography O +
( O -
SPET O -
) O +
camera O -
, O +
MULTISPECT O +
3 O -
. O +

18F B-Chemical -
- I-Chemical -
FDG I-Chemical +
and O +
123I B-Chemical -
- I-Chemical -
IMT I-Chemical +
uptake O +
was O +
quantified O +
as O +
ratios O +
between O +
the O +
uptake O +
by O +
the O +
tumour O +
and O +
contralateral O +
regions O +
of O +
reference O -
. O +

Glucose B-Chemical +
metabolism O +
and O +
amino O +
acid O +
uptake O +
of O +
the O +
brain O +
tumours O +
correlated O +
significantly O +
( O -
r=0.71 O -
, O +
P O +
< O -
0.001 O -
) O -
. O +

Assuming O +
discrimination O +
thresholds O +
between O +
high O -
- O -
grade O +
and O +
low O -
- O -
grade O +
tumours O +
of O +
0.8 O +
for O +
18F B-Chemical -
- I-Chemical -
FDG I-Chemical +
uptake O +
and O +
1.8 O +
for O +
123I B-Chemical -
- I-Chemical -
IMT I-Chemical +
uptake O -
, O +
the O +
accuracy O +
values O +
of O +
18F B-Chemical -
- I-Chemical -
FDG I-Chemical +
PET O +
and O +
123I B-Chemical -
- I-Chemical -
IMT I-Chemical +
SPET O +
for O +
differentiating O +
between O +
high O -
- O -
grade O +
and O +
low O -
- O -
grade O +
tumours O +
were O +
21 O -
/ O -
23 O +
( O -
91 O -
% O -
) O +
and O +
19 O -
/ O -
23 O +
( O -
83 O -
% O -
) O -
, O +
respectively O -
. O +

The O +
difference O +
in O +
diagnostic O +
performance O +
was O +
not O +
significant O +
on O +
receiver O +
operating O +
characteristic O +
analysis O +
( O -
P O +
> O -
0.4 O -
) O -
. O +

It O +
is O +
concluded O +
that O +
there O +
is O +
no O +
major O +
difference O +
between O +
the O +
PET O +
investigation O +
of O +
glucose B-Chemical +
metabolism O +
and O +
the O +
less O +
expensive O +
SPET O +
measurement O +
of O +
amino O +
acid O +
uptake O +
in O +
terms O +
of O +
their O +
accuracy O +
in O +
evaluating O +
the O +
malignancy O +
grade O +
of O +
primary O +
brain O +
tumours O -
. O +

This O +
encourages O +
the O +
performance O +
of O +
further O +
studies O +
to O +
analyse O +
the O +
potential O +
impact O +
of O +
123I B-Chemical -
- I-Chemical -
IMT I-Chemical +
SPET O +
on O +
the O +
therapeutic O +
management O +
of O +
patients O +
with O +
brain O +
tumours O -
. O +

[ O -
Expression O +
of O +
metastasis O +
suppressor O +
gene O +
nm23 O +
in O +
human O +
hepatocellular O +
carcinoma O -
] O -
. O +

For O +
the O +
purpose O +
of O +
investigating O +
the O +
relationship O +
between O +
the O +
metastatic O +
potential O +
of O +
the O +
tumor O +
as O +
well O +
as O +
the O +
expression O +
of O +
nm23-H1 O +
mRNA O -
, O +
and O +
for O +
determing O +
the O +
location O +
of O +
the O +
positive O +
sites O +
in O +
the O +
cells O -
, O +
tumor O +
metastasis O +
suppressor O +
gene O +
nm23-H1 O +
in O +
human O +
hepatocellular O +
carcinoma O +
( O -
and O +
the O +
nonneoplastic O +
area O +
surrounding O +
the O +
tumor O -
) O +
was O +
detected O +
by O +
in O +
situ O +
hybridization O +
using O +
digoxiginin B-Chemical -
- O -
labeled O +
nm23-H1 O +
antisense O +
complementary O +
RNA O +
probe O -
. O +

The O +
primary O +
results O +
indicated O +
( O -
i O -
) O +
positive O +
results O +
of O +
in O +
situ O +
hybridization O +
are O +
presence O +
of O +
granules O +
or O +
masses O +
in O +
the O +
cytoplasm O -
; O +
( O -
ii O -
) O +
the O +
less O +
expression O +
of O +
nm23-H1 O +
mRNA O -
, O +
the O +
higher O +
metastatic O +
rate O +
of O +
the O +
human O +
hepatocellular O +
carcinoma O +
( O -
P O +
< O +
0.05 O -
) O -
; O +
( O -
iii O -
) O +
expression O +
of O +
nm23-H1 O +
mRNA O +
dose O +
not O +
correlate O +
with O +
some O +
other O +
factors O +
such O +
as O +
tumor O +
size O +
and O +
the O +
background O +
of O +
other O +
liver O +
diseases O -
. O +

Suppression O +
of O +
tumor O +
growth O +
by O +
the O +
3 O -
' O +
untranslated O +
region O +
of O +
mel-18 O +
in O +
3Y1 O +
cells O +
transformed O +
by O +
the O +
E6 O +
and O +
E7 O +
genes O +
of O +
human O +
papillomavirus O +
type O +
18 O -
. O +

By O +
introducing O +
a O +
cDNA O +
library O +
derived O +
from O +
rat O +
embryonic O +
fibroblast O +
cells O -
, O +
we O +
isolated O +
several O +
morphologically O +
flat O +
revertants O +
of O +
rat O +
3Y1 O +
cells O +
transformed O +
by O +
the O +
E6 O +
and O +
E7 O +
genes O +
of O +
human O +
papillomavirus O +
type O +
18 O +
( O -
HPV18 O -
) O -
. O +

From O +
one O +
of O +
the O +
revertants O -
, O +
we O +
recovered O +
a O +
0.2-kb O +
cDNA O -
, O +
N56 O -
, O +
that O +
suppresses O +
the O +
tumor O +
growth O +
of O +
the O +
transformed O +
3Y1 O +
cells O +
irrespective O +
of O +
the O +
expression O +
of O +
the O +
E6 O +
and O +
E7 O +
genes O -
. O +

The O +
nucleotide O +
sequence O +
of O +
the O +
cDNA O +
was O +
shown O +
to O +
be O +
identical O +
to O +
that O +
of O +
the O +
3 O -
' O +
untranslated O +
region O +
of O +
a O +
putative O +
mammalian O +
polycomb O +
group O +
gene O -
, O +
mel-18 O -
. O +

Prognostic O +
value O +
of O +
HLA O -
- O -
DR O +
expression O +
and O +
dendritic O +
cell O +
infiltration O +
in O +
gastric O +
cancer O -
. O +

We O +
attempted O +
to O +
correlate O +
the O +
expression O +
of O +
human O +
leukocyte O +
antigen O +
DR O +
( O -
HLA O -
- O -
DR O -
) O +
and O +
tumor O +
infiltration O +
by O +
S-100-protein O -
- O -
positive O +
dendritic O +
cells O +
with O +
clinicopathologic O +
features O +
in O +
165 O +
patients O +
with O +
gastric O +
cancer O -
. O +

The O +
expression O +
of O +
HLA O -
- O -
DR O +
was O +
correlated O +
with O +
the O +
histologic O +
type O -
. O +

Infiltration O +
of O +
dendritic O +
cells O +
correlated O +
negatively O +
with O +
distant O +
lymph O +
node O +
metastases O -
, O +
clinical O +
stage O -
, O +
and O +
peritoneal O +
invasion O -
. O +

There O +
was O +
no O +
correlation O +
between O +
the O +
expression O +
of O +
HLA O -
- O -
DR O +
and O +
infiltration O +
by O +
dendritic O +
cells O -
. O +

In O +
patients O +
with O +
resectable O +
gastric O +
cancer O -
, O +
the O +
grade O +
of O +
infiltrating O +
dendritic O +
cells O +
may O +
be O +
a O +
suitable O +
predictor O +
of O +
prognosis O -
. O +

Integrin O +
alphavbeta3 O +
requirement O +
for O +
sustained O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
activity O +
during O +
angiogenesis O -
. O +

Angiogenesis O +
depends O +
on O +
growth O +
factors O +
and O +
vascular O +
cell O +
adhesion O +
events O -
. O +

Integrins O +
and O +
growth O +
factors O +
are O +
capable O +
of O +
activating O +
the O +
ras O -
/ O -
MAP O +
kinase O +
pathway O +
in O +
vitro O -
, O +
yet O +
how O +
these O +
signals O +
influence O +
endothelial O +
cells O +
during O +
angiogenesis O +
is O +
unknown O -
. O +

Upon O +
initiation O +
of O +
angiogenesis O +
with O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
) O +
on O +
the O +
chick O +
chorioallantoic O +
membrane O +
( O -
CAM O -
) O -
, O +
endothelial O +
cell O +
mitogen O -
- O -
activated O +
protein O +
( O -
MAP O -
) O +
kinase O +
( O -
ERK O -
) O +
activity O +
was O +
detected O +
as O +
early O +
as O +
5 O +
min O +
yet O +
was O +
sustained O +
for O +
at O +
least O +
20 O +
h. O +
The O +
initial O +
wave O +
of O +
ERK O +
activity O +
( O -
5 O -
- O -
120 O +
min O -
) O +
was O +
refractory O +
to O +
integrin B-Chemical +
antagonists I-Chemical -
, O +
whereas O +
the O +
sustained O +
activity O +
( O -
4 O -
- O -
20 O +
h O -
) O +
depended O +
on O +
integrin O +
alphavbeta3 O -
, O +
but O +
not O +
beta1 O +
integrins O -
. O +

Inhibition O +
of O +
MAP O +
kinase O +
kinase O +
( O -
MEK O -
) O +
during O +
this O +
sustained O +
alphavbeta3-dependent O +
ERK O +
signal O +
blocked O +
the O +
formation O +
of O +
new O +
blood O +
vessels O +
while O +
not O +
influencing O +
preexisting O +
blood O +
vessels O +
on O +
the O +
CAM O -
. O +

Inhibition O +
of O +
MEK O +
also O +
blocked O +
growth O +
factor O +
induced O +
migration O +
but O +
not O +
adhesion O +
of O +
endothelial O +
cells O +
in O +
vitro O -
. O +

Therefore O -
, O +
angiogenesis O +
depends O +
on O +
sustained O +
ERK O +
activity O +
regulated O +
by O +
the O +
ligation O +
state O +
of O +
both O +
a O +
growth O +
factor O +
receptor O +
and O +
integrin O +
alphavbeta3 O -
. O +

Basic O +
fibroblast O +
growth O +
factor O -
: O +
a O +
missing O +
link O +
between O +
collagen O +
VII O -
, O +
increased O +
collagenase O -
, O +
and O +
squamous O +
cell O +
carcinoma O +
in O +
recessive O +
dystrophic O +
epidermolysis O +
bullosa O -
. O +

BACKGROUND O -
: O +
Patients O +
with O +
recessive O +
dystrophic O +
epidermolysis O +
bullosa O +
( O -
RDEB O -
) O +
have O +
deficiencies O +
of O +
collagen O +
type O +
VII O +
and O +
have O +
elevated O +
levels O +
of O +
fibroblast O +
collagenase O -
, O +
and O +
a O +
greatly O +
increased O +
risk O +
of O +
cutaneous O +
squamous O +
cell O +
carcinoma O -
. O +

Patients O +
with O +
other O +
genetic O +
blistering O +
disorders O +
do O +
not O +
have O +
elevated O +
collagenase O +
or O +
an O +
increased O +
risk O +
of O +
squamous O +
cell O +
carcinoma O -
, O +
despite O +
chronic O +
wounding O -
. O +

The O +
connection O +
between O +
collagen O +
type O +
VII O +
deficiency O -
, O +
increased O +
collagenase O -
, O +
and O +
squamous O +
cell O +
carcinoma O +
is O +
not O +
understood O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
Urine O +
from O +
81 O +
patients O +
with O +
RDEB O +
( O -
39 O +
patients O -
) O -
, O +
junctional O +
epidermolysis O +
bullosa O +
( O -
JEB O -
; O +
12 O +
patients O -
) O -
, O +
and O +
epidermolysis O +
bullosa O +
simplex O +
( O -
EBS O -
; O +
30 O +
patients O -
) O -
, O +
as O +
well O +
as O +
unaffected O +
family O +
members O +
of O +
RDEB O +
patients O +
( O -
33 O +
patients O -
) O -
, O +
was O +
tested O +
for O +
the O +
presence O +
of O +
basic O +
fibroblast O +
growth O +
factor O +
( O -
bFGF O -
) O +
using O +
a O +
sensitive O +
radioimmunoassay O -
. O +

These O +
patients O +
included O +
many O +
who O +
were O +
enrolled O +
in O +
the O +
Epidermolysis O +
Bullosa O +
Registry O +
and O +
others O +
who O +
were O +
referred O +
by O +
their O +
physicians O -
. O +

RESULTS O -
: O +
Fifty O -
- O -
one O +
percent O +
of O +
patients O +
with O +
RDEB O +
had O +
elevated O +
levels O +
( O +
greater O +
than O +
5000 O +
pg O -
/ O -
g O -
) O +
of O +
urinary O +
bFGF O -
. O +

In O +
contrast O -
, O +
none O +
of O +
the O +
patients O +
with O +
JEB O +
had O +
elevated O +
levels O +
of O +
bFGF O -
. O +

Twenty O -
- O -
one O +
percent O +
of O +
clinically O +
unaffected O +
family O +
members O +
had O +
elevated O +
levels O +
of O +
bFGF O -
, O +
and O +
13 O -
% O +
of O +
patients O +
with O +
EBS O +
had O +
elevated O +
levels O +
of O +
bFGF O -
. O +

The O +
frequency O +
of O +
elevated O +
bFGF O +
values O +
among O +
all O +
groups O +
was O +
statistically O +
significant O +
( O -
p O +
= O +
0.002 O -
) O -
, O +
and O +
the O +
levels O +
of O +
bFGF O +
in O +
RDEB O +
patients O +
were O +
significantly O +
elevated O +
compared O +
with O +
those O +
of O +
other O +
groups O +
( O -
p O +
less O +
than O +
0.05 O -
) O -
. O +

CONCLUSIONS O -
: O +
We O +
have O +
found O +
that O +
patients O +
with O +
RDEB O +
have O +
elevated O +
levels O +
of O +
bFGF O -
, O +
which O +
may O +
contribute O +
to O +
increased O +
fibroblast O +
collagenase O +
and O +
the O +
development O +
of O +
squamous O +
cell O +
carcinoma O -
. O +

These O +
results O +
suggest O +
a O +
novel O +
treatment O +
for O +
RDEB O -
, O +
namely O -
, O +
angiogenesis O +
inhibitors O -
, O +
which O +
may O +
antagonize O +
the O +
effects O +
of O +
bFGF O +
in O +
this O +
disorder O -
. O +

There O +
are O +
currently O +
no O +
other O +
means O +
of O +
treatment O +
for O +
this O +
disorder O -
, O +
which O +
has O +
a O +
high O +
morbidity O +
and O +
mortality O +
rate O -
. O +

Induction O +
of O +
Ets-1 O +
in O +
endothelial O +
cells O +
during O +
reendothelialization O +
after O +
denuding O +
injury O -
. O +

Ets-1 O -
, O +
a O +
transcription O +
factor O -
, O +
is O +
induced O +
in O +
endothelial O +
cells O +
( O -
ECs O -
) O +
during O +
angiogenesis O -
. O +

Here O -
, O +
we O +
investigated O +
the O +
expression O +
of O +
Ets-1 O +
during O +
reendothelialization O -
. O +

When O +
a O +
confluent O +
monolayer O +
of O +
human O +
umbilical O +
vein O +
endothelial O +
cell O +
line O -
, O +
ECV304 O -
, O +
was O +
denuded O -
, O +
ECV304 O +
at O +
the O +
wound O +
edge O +
expressed O +
Ets-1 O -
. O +

An O +
immunohistochemical O +
analysis O +
revealed O +
that O +
Ets-1 O +
accumulated O +
in O +
migrating O +
cells O +
at O +
the O +
wound O +
edge O +
and O +
returned O +
to O +
basal O +
level O +
when O +
reendothelialization O +
was O +
accomplished O -
. O +

This O +
induction O +
of O +
Ets-1 O +
could O +
be O +
reproduced O +
in O +
in O +
vivo O +
denudation O +
of O +
rat O +
aortic O +
endothelium O +
by O +
a O +
balloon O +
catheter O -
. O +

The O +
induction O +
of O +
Ets-1 O +
in O +
ECs O +
after O +
denudation O +
was O +
regulated O +
transcriptionally O -
, O +
and O +
humeral O +
factors O +
released O +
from O +
injured O +
ECs O +
might O +
not O +
be O +
responsible O -
. O +

Mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
activities O +
were O +
investigated O +
to O +
explore O +
the O +
mechanism O +
of O +
this O +
induction O -
. O +

Although O +
extracellular O +
signal O -
- O -
regulated O +
protein O +
kinase O +
1 O -
/ O -
2 O +
( O -
ERK1 O -
/ O -
2 O -
) O -
, O +
c O -
- O -
Jun O +
N O -
- O -
terminal O +
kinase O +
1 O +
( O -
JNK1 O -
) O -
, O +
and O +
p38 O +
were O +
activated O +
after O +
denudation O -
, O +
the O +
activation O +
of O +
ERK1 O +
and O +
p38 O +
was O +
more O +
rapid O +
and O +
prominent O -
. O +

PD98059 B-Chemical -
, O +
a O +
specific O +
MAPK O -
/ O -
ERK O +
kinase O +
( O -
MEK O -
) O +
1 O +
inhibitor O -
, O +
did O +
not O +
affect O +
the O +
induction O +
of O +
ets-1 O +
mRNA O -
, O +
whereas O +
SB203580 B-Chemical -
, O +
a O +
specific O +
p38 O +
inhibitor O -
, O +
almost O +
completely O +
abrogated O +
its O +
induction O -
. O +

These O +
results O +
indicate O +
that O +
Ets-1 O +
is O +
induced O +
in O +
ECs O +
after O +
denudation O +
through O +
activation O +
of O +
p38 O -
. O +

This O +
induction O +
of O +
Ets-1 O +
may O +
be O +
relevant O +
for O +
reendothelialization O +
by O +
regulating O +
the O +
expression O +
of O +
certain O +
genes O -
. O +

SV40 O +
Tag O +
transformation O +
of O +
the O +
normal O +
invasive O +
trophoblast O +
results O +
in O +
a O +
premalignant O +
phenotype O -
. O +

I. O +
Mechanisms O +
responsible O +
for O +
hyperinvasiveness O +
and O +
resistance O +
to O +
anti O -
- O -
invasive O +
action O +
of O +
TGFbeta O -
. O +

Invasion O +
of O +
the O +
uterus O +
by O +
first O +
trimester O +
human O +
placental O +
extravillous O +
trophoblast O +
( O -
EVT O -
) O +
cells O +
depends O +
on O +
mechanisms O +
shared O +
by O +
malignant O +
cells O -
. O +

However O -
, O +
unlike O +
tumor O +
invasion O -
, O +
trophoblast O +
invasion O +
of O +
the O +
uterus O +
is O +
stringently O +
controlled O +
in O +
situ O +
by O +
local O +
molecules O +
such O +
as O +
transforming O +
growth O +
factor O +
( O -
TGF O -
) O -
beta O -
. O +

Since O +
EVT O +
cells O +
possess O +
active O +
invasion O -
- O -
associated O +
genes O +
but O +
are O +
nontumorigenic O -
, O +
our O +
objective O +
was O +
to O +
induce O +
premalignant O +
and O +
then O +
malignant O +
phenotype O +
into O +
a O +
normal O +
EVT O +
cell O +
line O +
in O +
order O +
to O +
identify O +
the O +
molecular O +
basis O +
of O +
tumor O +
progression O -
. O +

Simian O +
virus O +
40 O +
large O +
T O +
antigen O +
( O -
SV40 O +
Tag O -
) O +
was O +
introduced O +
into O +
a O +
normal O +
human O +
first O +
trimester O +
invasive O +
EVT O +
cell O +
line O -
, O +
HTR8 O -
, O +
established O +
in O +
our O +
laboratory O -
. O +

Since O +
the O +
HTR8 O +
line O +
has O +
a O +
limited O +
in O +
vitro O +
lifespan O +
of O +
12 O -
- O -
15 O +
passages O -
, O +
SV40 O +
Tag O -
- O -
transformed O +
cells O +
were O +
selected O +
on O +
the O +
basis O +
of O +
extended O +
lifespan O -
. O +

A O +
long O -
- O -
lived O +
line O -
, O +
RSVT-2 O -
, O +
was O +
produced O +
and O +
an O +
immortalized O +
subclone O -
, O +
RSVT2 O -
/ O -
C O -
, O +
was O +
further O +
derived O +
under O +
a O +
forced O +
crisis O +
regimen O -
. O +

We O +
examined O +
transformation O -
- O -
induced O +
alterations O +
in O +
proliferative O +
and O +
invasive O +
abilities O -
, O +
responses O +
to O +
the O +
invasion O +
and O +
proliferation O -
- O -
regulating O +
growth O +
factor O +
TGFbeta O +
and O +
changes O +
in O +
gene O +
expression O +
for O +
invasion O -
- O -
associated O +
enzymes O +
or O +
enzyme O +
inhibitors O -
. O +

RSVT-2 O +
and O +
RSVT2 O -
/ O -
C O +
cell O +
lines O +
were O +
hyperproliferative O +
and O +
hyperinvasive O +
when O +
compared O +
with O +
the O +
parental O +
HTR8 O +
cell O +
line O -
. O +

They O +
were O +
also O +
variably O +
resistant O +
to O +
the O +
anti O -
- O -
proliferative O +
and O +
anti O -
- O -
invasive O +
signals O +
from O +
TGFbeta O -
. O +

Since O +
both O +
cell O +
lines O +
remained O +
non O -
- O -
tumorigenic O +
in O +
nude O +
mice O -
, O +
these O +
properties O +
indicate O +
that O +
they O +
attained O +
a O +
premalignant O +
phenotype O -
. O +

Both O +
cell O +
lines O +
showed O +
reduced O +
expression O +
of O +
tissue O +
inhibitor O +
of O +
metalloproteases O +
( O -
TIMP O -
) O -
-1 O -
, O +
while O +
TIMP-2 O +
and O +
plasminogen O +
activator O +
inhibitor O +
( O -
PAI O -
) O -
-I O +
expression O +
was O +
was O +
also O +
reduced O +
in O +
RSVT2 O -
/ O -
C O +
cells O -
, O +
thus O +
contributing O +
to O +
their O +
hyperinvasiveness O -
. O +

Their O +
resistance O +
to O +
the O +
anti O -
- O -
invasive O +
action O +
of O +
TGFbeta O +
was O +
explained O +
by O +
the O +
failure O +
of O +
TGFbeta O +
to O +
upregulate O +
TIMPs O +
and O +
PAI O -
- O -
I O -
, O +
in O +
contrast O +
to O +
the O +
TGFbeta O -
- O -
induced O +
upregulation O +
noted O +
in O +
parental O +
HTR8 O +
cells O -
. O +

Expression O +
of O +
two O +
type O +
II O -
- O -
like O +
tumor O +
hexokinase O +
RNA O +
transcripts O +
in O +
cancer O +
cell O +
lines O -
. O +

To O +
maintain O +
an O +
elevated O +
glycolytic O +
rate O -
, O +
cancerous O +
or O +
proliferating O +
cells O +
alter O +
the O +
expression O +
pattern O +
of O +
rate O +
limiting O +
glycolytic O +
enzymes O -
. O +

Since O +
glucose B-Chemical +
phosphorylation O +
is O +
the O +
first O +
step O +
in O +
glycolysis O -
, O +
hexokinase O +
( O -
HK O -
) O -
, O +
the O +
first O +
rate O +
limiting O +
glycolytic O +
enzyme O -
, O +
can O +
play O +
a O +
key O +
regulatory O +
role O +
in O +
this O +
process O -
. O +

A O +
low O -
- O -
Km O -
, O +
mitochondrial O +
type O +
II O -
- O -
like O +
tumor O +
HK O +
is O +
described O +
as O +
the O +
predominant O +
form O +
in O +
hepatomas O -
. O +

However O -
, O +
recent O +
identification O +
of O +
a O +
high O -
- O -
Km O +
glucose B-Chemical +
phosphorylating O +
activity O +
in O +
a O +
range O +
of O +
cancer O +
cells O +
prompted O +
us O +
to O +
characterize O +
glucose B-Chemical +
phosphorylating O +
enzymes O +
of O +
cancer O +
cells O +
at O +
the O +
molecular O +
level O -
. O +

Highly O +
sensitive O +
reverse O -
- O -
transcription O +
polymerase O +
chain O +
reaction O +
identifies O +
an O +
induction O +
and O +
overexpression O +
of O +
a O +
type O +
II O -
- O -
like O +
tumor O +
HK O +
RNA O +
in O +
a O +
range O +
of O +
cancer O +
cell O +
lines O +
irrespective O +
of O +
tissue O +
origin O -
. O +

In O +
addition O -
, O +
we O +
report O +
here O +
the O +
identification O +
of O +
two O +
RNA O +
transcripts O +
of O +
type O +
II O -
- O -
like O +
tumor O +
HK O +
of O +
approximately O +
5.5 O +
and O +
approximately O +
4.0 O +
kb O +
in O +
these O +
cancer O +
cells O +
lines O -
, O +
including O +
muscle O -
- O -
derived O +
L6 O +
myoblast O +
cells O -
. O +

Interestingly O -
, O +
under O +
normal O +
conditions O +
muscle O +
cells O +
express O +
only O +
a O +
approximately O +
5.5-kb O +
type O +
II O +
HK O +
RNA O +
transcript O -
. O +

A O +
significant O +
amount O +
of O +
type O +
I O +
HK O +
RNA O +
was O +
also O +
found O +
expressed O +
in O +
cancer O +
cell O +
lines O -
. O +

RNA O +
encoding O +
glucokinase O +
( O -
GK O -
) O -
, O +
the O +
high O -
- O -
Km O +
HK O +
isozyme O -
, O +
was O +
found O +
only O +
in O +
cancer O +
cells O +
originating O +
from O +
liver O +
and O +
pancreas O -
, O +
which O +
express O +
GK O +
under O +
normal O +
conditions O -
. O +

Homeobox O +
genes O +
in O +
hematopoiesis O +
and O +
leukemogenesis O -
. O +

Homeobox O +
genes O +
have O +
a O +
strikingly O +
conserved O +
61-amino O +
acid O +
sequence O -
, O +
encoding O +
DNA O -
- O -
binding O +
domain O -
. O +

Some O +
homeobox O +
genes O -
, O +
located O +
in O +
four O +
clusters O +
are O +
designated O +
HOX O +
A O +
through O +
D O -
, O +
while O +
others O +
are O +
known O +
as O +
divergent O +
homeobox O +
genes O -
. O +

Many O +
researchers O +
have O +
demonstrated O +
that O +
hematopoietic O +
cells O +
express O +
many O +
homeobox O +
genes O -
. O +

Induced O +
over- O +
and O +
under O -
- O -
expression O +
of O +
these O +
genes O +
has O +
been O +
used O +
to O +
demonstrate O +
their O +
affect O +
on O +
some O +
aspects O +
of O +
hematopoiesis O +
and O +
leukemogenesis O -
. O +

Recently O -
, O +
knock O -
- O -
out O +
mice O +
of O +
homeobox O +
genes O +
by O +
targeted O +
disruption O +
have O +
also O +
been O +
used O +
to O +
examine O +
their O +
hematological O +
effect O -
. O +

There O +
are O +
examples O +
of O +
the O +
aberrant O +
expression O +
of O +
a O +
homeobox O +
gene O +
causing O +
leukemias O +
in O +
humans O -
. O +

In O +
pre O -
- O -
B O +
acute O +
lymphoblastic O +
leukemia O +
( O -
ALL O -
) O +
with O +
t O -
( O -
1;19 O -
) O +
translocation O -
, O +
a O +
fusion O +
protein O +
is O +
created O +
between O +
E2A O +
and O +
a O +
homeobox O +
gene O +
PBX O -
. O +

In O +
T O -
- O -
cell O +
ALL O +
with O +
t O -
( O -
10;14 O -
) O +
translocation O -
, O +
the O +
HOX O +
11 O +
gene O +
is O +
deregulated O -
. O +

In O +
acute O +
myeloid O +
leukemia O +
( O -
AML O -
) O +
with O +
t O -
( O -
7;11 O -
) O +
translocation O -
, O +
the O +
HOX O +
A9 O +
gene O +
is O +
rearranged O -
. O +

In O +
this O +
review O +
article O -
, O +
many O +
functions O +
of O +
homeobox O +
genes O +
both O +
at O +
the O +
early O +
stem O +
cell O +
level O +
as O +
well O +
as O +
at O +
the O +
later O +
stages O +
of O +
hematopoietic O +
differentiation O -
, O +
and O +
the O +
leukemogenic O +
effect O +
of O +
altered O +
homeobox O +
genes O +
are O +
discussed O -
. O +

The O +
myoadipose O +
flap O -
: O +
a O +
new O +
composite O -
. O +

A O +
prefabricated O +
composite O +
fat O +
flap O +
consisting O +
of O +
muscle O +
woven O +
into O +
an O +
anatomically O +
distinct O +
fat O +
pad O +
was O +
studied O +
in O +
a O +
rabbit O +
model O -
. O +

In O +
17 O +
rabbits O -
, O +
a O +
2-cm O +
strip O +
of O +
latissimus O +
dorsi O +
was O +
woven O +
into O +
the O +
parascapular O +
fat O +
pad O +
on O +
one O +
side O -
, O +
with O +
the O +
contralateral O +
fat O +
pad O +
serving O +
as O +
a O +
control O -
. O +

At O +
3 O +
weeks O -
, O +
the O +
endogenous O +
blood O +
supply O +
of O +
both O +
the O +
control O +
and O +
the O +
experimental O +
fat O +
pads O +
was O +
isolated O +
and O +
ligated O -
, O +
and O +
the O +
composite O +
fat O -
/ O -
muscle O +
flap O +
was O +
transferred O +
to O +
the O +
chest O +
wall O -
. O +

At O +
6 O +
weeks O -
, O +
animals O +
were O +
killed O -
, O +
and O +
flaps O +
were O +
analyzed O +
for O +
length O -
, O +
width O -
, O +
and O +
weight O -
; O +
perfused O +
with O +
fluorescein B-Chemical +
or O +
lead B-Chemical +
oxide I-Chemical -
; O +
and O +
examined O +
histologically O -
. O +

Significant O +
differences O +
were O +
found O +
between O +
the O +
control O +
and O +
experimental O +
fat O +
pads O +
with O +
regard O +
to O +
weight O +
and O +
length O -
. O +

Experimental O +
flaps O +
were O +
found O +
to O +
be O +
perfused O +
fully O +
with O +
fluorescein B-Chemical +
and O +
lead B-Chemical +
oxide I-Chemical -
; O +
control O +
fat O +
pads O +
were O +
found O +
not O +
to O +
be O +
perfused O -
. O +

The O +
lead B-Chemical +
oxide I-Chemical +
group O +
revealed O +
extensive O +
growth O +
of O +
blood O +
vessels O +
from O +
the O +
latissimus O +
graft O +
into O +
the O +
experimental O +
fat O +
pad O -
. O +

No O +
vessels O +
were O +
visualized O +
in O +
the O +
controls O -
. O +

Finally O -
, O +
sections O +
of O +
the O +
control O +
and O +
experimental O +
flaps O +
were O +
analyzed O +
histologically O -
. O +

A O +
preponderance O +
of O +
viable O +
fat O -
, O +
with O +
evidence O +
of O +
neovascularization O -
, O +
was O +
found O +
in O +
experimental O +
flaps O -
, O +
compared O +
with O +
the O +
necrotic O +
fat O +
that O +
characterized O +
the O +
controls O -
. O +

We O +
conclude O +
that O +
prefabrication O +
of O +
a O +
fat O +
flap O +
is O +
possible O +
and O +
may O +
have O +
extensive O +
application O +
in O +
various O +
areas O +
of O +
plastic O +
surgery O -
. O +

Gene O +
therapy O +
for O +
gliomas O -
: O +
p53 O +
and O +
E2F-1 O +
proteins O +
and O +
the O +
target O +
of O +
apoptosis O -
. O +

Current O +
therapy O +
for O +
glioma O +
is O +
suboptimal O -
. O +

The O +
transfer O +
of O +
apoptosis O +
genes O +
to O +
tumors O +
constitutes O +
one O +
of O +
the O +
most O +
promising O +
strategies O +
for O +
cancer O +
gene O +
therapy O -
. O +

We O +
have O +
previously O +
shown O +
that O +
massive O +
apoptosis O +
occurs O +
when O +
wild O -
- O -
type O +
p53 O +
or O +
E2F-1 O +
expression O +
is O +
induced O +
in O +
glioma O -
. O +

However O -
, O +
the O +
mechanism O +
of O +
action O +
and O +
the O +
efficiency O +
in O +
inducing O +
apoptosis O +
of O +
these O +
two O +
proteins O +
are O +
not O +
similar O -
. O +

Adenovirus O -
- O -
mediated O +
p53 O +
gene O +
transfer O +
is O +
ineffective O +
in O +
causing O +
apoptosis O +
in O +
glioma O +
cells O +
that O +
retain O +
wild O -
- O -
type O +
p53 O +
genotype O +
or O +
overexpress O +
the O +
p21 O +
protein O -
. O +

The O +
p16 O -
/ O -
Rb O -
/ O -
E2F O +
pathway O +
is O +
the O +
most O +
frequent O +
target O +
of O +
genetic O +
alterations O +
in O +
gliomas O -
, O +
and O +
therefore O +
constitutes O +
a O +
suitable O +
target O +
for O +
gene O +
therapy O +
strategies O -
. O +

However O -
, O +
the O +
transfer O +
of O +
either O +
the O +
p16 O +
or O +
Rb O +
gene O +
to O +
glioma O +
cells O +
results O +
in O +
cytostatic O +
effect O -
. O +

The O +
E2F-1 O +
protein O +
is O +
able O +
to O +
induce O +
generalized O +
apoptosis O +
in O +
gliomas O +
independently O +
of O +
the O +
p53 O -
, O +
p16 O +
or O +
Rb O +
status O -
. O +

In O +
addition O -
, O +
p21- O +
or O +
p16-mediated O +
growth O +
arrest O +
did O +
not O +
protect O +
glioma O +
cells O +
from O +
E2F-1-mediated O +
apoptosis O -
. O +

The O +
apoptotic O +
molecule O +
bax O +
is O +
induced O +
in O +
p53-mediated O +
apoptosis O -
, O +
but O +
bax O +
is O +
not O +
induced O +
in O +
E2F-1-mediated O +
apoptosis O +
in O +
glioma O +
cells O -
. O +

Careful O +
selection O +
of O +
patients O +
may O +
be O +
necessary O +
before O +
designing O +
therapeutic O +
strategies O +
using O +
either O +
p53 O +
or O +
E2F-1 O +
as O +
a O +
therapeutic O +
tools O +
for O +
glioma O +
patients O -
. O +

Protective O +
function O +
of O +
von O +
Hippel O -
- O -
Lindau O +
protein O +
against O +
impaired O +
protein O +
processing O +
in O +
renal O +
carcinoma O +
cells O -
. O +

The O +
absence O +
of O +
functional O +
von O +
Hippel O -
- O -
Lindau O +
( O -
VHL O -
) O +
tumor O +
suppressor O +
gene O +
leads O +
to O +
the O +
development O +
of O +
neoplasias O +
characteristic O +
of O +
VHL O +
disease O -
, O +
including O +
renal O +
cell O +
carcinoma O +
( O -
RCC O -
) O -
. O +

Here O -
, O +
we O +
compared O +
the O +
sensitivity O +
of O +
RCC O +
cells O +
lacking O +
VHL O +
gene O +
function O +
with O +
that O +
of O +
RCC O +
cells O +
expressing O +
the O +
wild O -
- O -
type O +
VHL O +
gene O +
( O -
wtVHL O -
) O +
after O +
exposure O +
to O +
various O +
stresses O -
. O +

While O +
the O +
response O +
to O +
most O +
treatments O +
was O +
not O +
affected O +
by O +
the O +
VHL O +
gene O +
status O -
, O +
glucose B-Chemical +
deprivation O +
was O +
found O +
to O +
be O +
much O +
more O +
cytotoxic O +
for O +
RCC O +
cells O +
lacking O +
VHL O +
gene O +
function O +
than O +
for O +
wtVHL O -
- O -
expressing O +
cells O -
. O +

The O +
heightened O +
sensitivity O +
of O +
VHL O -
- O -
deficient O +
cells O +
was O +
not O +
attributed O +
to O +
dissimilar O +
energy O +
requirements O +
or O +
to O +
differences O +
in O +
glucose B-Chemical +
uptake O -
, O +
but O +
more O +
likely O +
reflects O +
a O +
lesser O +
ability O +
of O +
VHL O -
- O -
deficient O +
cells O +
to O +
handle O +
abnormally O +
processed O +
proteins O +
arising O +
from O +
impaired O +
glycosylation O -
. O +

In O +
support O +
of O +
this O +
hypothesis O -
, O +
other O +
treatments O +
which O +
act O +
through O +
different O +
mechanisms O +
to O +
interfere O +
with O +
protein O +
processing O +
( O -
i.e. O -
, O +
tunicamycin B-Chemical -
, O +
brefeldin B-Chemical +
A I-Chemical -
, O +
and O +
azetidine B-Chemical -
) O +
were O +
also O +
found O +
to O +
be O +
much O +
more O +
toxic O +
for O +
VHL O -
- O -
deficient O +
cells O -
. O +

Furthermore O -
, O +
ubiquitination O +
of O +
cellular O +
proteins O +
was O +
elevated O +
in O +
VHL O -
- O -
deficient O +
cells O -
, O +
particularly O +
after O +
glucose B-Chemical +
deprivation O -
, O +
supporting O +
a O +
role O +
for O +
the O +
VHL O +
gene O +
in O +
ubiquitin O -
- O -
mediated O +
proteolysis O -
. O +

Accordingly O -
, O +
the O +
rate O +
of O +
elimination O +
of O +
abnormal O +
proteins O +
was O +
lower O +
in O +
cells O +
lacking O +
a O +
functional O +
VHL O +
gene O +
than O +
in O +
wtVHL O -
- O -
expressing O +
cells O -
. O +

Thus O -
, O +
pVHL O +
appears O +
to O +
participate O +
in O +
the O +
elimination O +
of O +
misprocessed O +
proteins O -
, O +
such O +
as O +
those O +
arising O +
in O +
the O +
cell O +
due O +
to O +
the O +
unavailability O +
of O +
glucose B-Chemical +
or O +
to O +
other O +
stresses O -
. O +

Effect O +
of O +
U-995 O -
, O +
a O +
potent O +
shark O +
cartilage O -
- O -
derived O +
angiogenesis O +
inhibitor O -
, O +
on O +
anti O -
- O -
angiogenesis O +
and O +
anti O -
- O -
tumor O +
activities O -
. O +

BACKGROUND O -
: O +
A O +
potent O +
angiogenesis O +
inhibitor O -
, O +
U-995 O -
, O +
has O +
been O +
purified O +
from O +
the O +
cartilage O +
of O +
the O +
blue O +
shark O +
( O -
Prionace O +
glauca O -
) O -
. O +

U-995 O +
is O +
composed O +
of O +
two O +
single O +
peptides O +
with O +
molecular O +
mass O +
of O +
10 O +
and O +
14 O +
kDa O -
, O +
respectively O -
. O +

MATERIALS O +
AND O +
METHODS O -
: O +
U-995 O +
was O +
designed O +
to O +
study O +
human O +
umbilical O +
vein O +
endothelial O +
cell O +
( O -
HUVEC O -
) O +
migration O +
and O +
proliferation O +
in O +
vitro O +
and O +
angiogenesis O +
induced O +
by O +
TNF O +
alpha O +
in O +
chicken O +
chorioallantoic O +
membrane O +
( O -
CAM O -
) O -
. O +

Furthermore O -
, O +
we O +
determined O +
the O +
ability O +
of O +
U-995 O +
to O +
inhibiting O +
tumor O +
cell O +
growth O +
and O +
metastasis O -
. O +

RESULTS O -
: O +
U-995 O +
( O -
15 O +
and O +
30 O +
micrograms O -
/ O -
ml O -
) O +
markedly O +
inhibited O +
HUVEC O +
migration O +
and O -
, O +
at O +
15 O -
- O -
50 O +
micrograms O -
/ O -
ml O +
produced O +
a O +
dose O -
- O -
dependent O +
decline O +
in O +
[ O -
3H O -
] O -
-thymidine O +
incorporation O -
. O +

30 O +
and O +
50 O +
micrograms O -
/ O -
ml O +
of O +
U-995 O -
, O +
when O +
added O +
to O +
TNF O +
alpha O -
- O -
induced O +
angiogenesis O +
caused O +
discontinuous O +
and O +
disrupted O +
blood O +
vessels O -
. O +

Moreover O -
, O +
U-995 O +
( O -
30 O +
micrograms O -
/ O -
ml O -
) O +
markedly O +
prevented O +
collagenase O -
- O -
induced O +
collagenolysis O -
. O +

In O +
addition O -
, O +
when O +
200 O +
micrograms O +
U-995 O +
was O +
injected O +
i.p O -
. O +

into O +
mice O +
it O +
suppressed O +
sarcoma-180 O +
cell O +
growth O +
and O +
B16-F10 O +
mouse O +
melanoma O +
cell O +
metastasis O +
in O +
vivo O -
. O +

CONCLUSIONS O -
: O +
These O +
results O +
suggest O +
that O +
the O +
anti O -
- O -
angiogenic O +
effects O +
of O +
U-995 O +
may O +
be O +
be O +
due O +
to O +
interference O +
with O +
the O +
proliferation O +
and O +
migration O +
of O +
HUVECs O +
as O +
well O +
as O +
inhibition O +
of O +
collagenolysis O -
, O +
thereby O +
leading O +
to O +
inhibition O +
of O +
both O +
angiogenesis O +
and O +
tumor O +
cell O +
growth O -
. O +

